{"question_id": "55031181e9bde69634000014", "question": "Is Hirschsprung disease a mendelian or a multifactorial disorder?", "retrieved_chunks": [{"doc_id": "15829955", "chunk_id": "15829955_1", "score": 9.81470012664795, "text": "Hirschsprung disease (HSCR) is a multifactorial, non-mendelian disorder in which rare high-penetrance coding sequence mutations in the receptor tyrosine kinase RET contribute to risk in combination with mutations at other genes."}, {"doc_id": "15829955", "chunk_id": "15829955_0", "score": 9.639654159545898, "text": "Hirschsprung disease (HSCR) is a multifactorial, non-mendelian disorder in which rare high-penetrance coding sequence mutations in the receptor tyrosine kinase RET contribute to risk in combination with mutations at other genes"}, {"doc_id": "15617541", "chunk_id": "15617541_0", "score": 5.455429553985596, "text": "In this study, we review the identification of genes and loci involved in the non-syndromic common form and syndromic Mendelian forms of Hirschsprung's disease. The majority of the identified genes are related to Mendelian syndromic forms of Hirschsprung's disease. The non-Mendelian inheritance of sporadic non-syndromic Hirschsprung's disease proved to be complex; involvement of multiple loci was demonstrated in a multiplicative model"}], "context": "[15829955:15829955_1] Hirschsprung disease (HSCR) is a multifactorial, non-mendelian disorder in which rare high-penetrance coding sequence mutations in the receptor tyrosine kinase RET contribute to risk in combination with mutations at other genes.\n[15829955:15829955_0] Hirschsprung disease (HSCR) is a multifactorial, non-mendelian disorder in which rare high-penetrance coding sequence mutations in the receptor tyrosine kinase RET contribute to risk in combination with mutations at other genes\n[15617541:15617541_0] In this study, we review the identification of genes and loci involved in the non-syndromic common form and syndromic Mendelian forms of Hirschsprung's disease. The majority of the identified genes are related to Mendelian syndromic forms of Hirschsprung's disease. The non-Mendelian inheritance of sporadic non-syndromic Hirschsprung's disease proved to be complex; involvement of multiple loci was demonstrated in a multiplicative model", "answer": "<think> Okay, let's tackle this question about Hirschsprung disease being Mendelian or multifactorial. The user provided three evidence snippets. First, looking at the evidence from [15829955:15829955_1] and [15829955:15617541_0], both mention that Hirschsprung disease is a multifactorial, non-mendelian disorder. They talk about rare mutations in the RET gene contributing to risk along with other genes. That suggests multiple factors are involved, so it's multifactorial. Then there's [15617541:15617541_0], which says that the non-syndromic form is non-Mendelian and complex, involving multiple loci in a multiplicative model. This also points towards a multifactorial cause. However, they do mention Mendelian syndromic forms, but the question is about the general case. The key here is that the answer should be based on the majority of the evidence. The first two documents clearly state", "citations": [{"doc_id": "15829955", "chunk_id": "15829955_1"}, {"doc_id": "15829955", "chunk_id": "15617541_0"}, {"doc_id": "15617541", "chunk_id": "15617541_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question about Hirschsprung disease being Mendelian or multifactorial. The user provided three evidence snippets. First, looking at the evidence from [15829955:15829955_1] and [15829955:15617541_0], both mention that Hirschsprung disease is a multifactorial, non-mendelian disorder. They talk about rare mutations in the RET gene contributing to risk along with other genes. That suggests multiple factors are involved, so it's multifactorial. Then there's [15617541:15617541_0], which says that the non-syndromic form is non-Mendelian and complex, involving multiple loci in a multiplicative model. This also points towards a multifactorial cause. However, they do mention Mendelian syndromic forms, but the question is about the general case. The key here is that the answer should be based on the majority of the evidence. The first two documents clearly state", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question about whether Hirschsprung disease is Mendelian or multifactorial. The user provided some evidence, so I need to parse that carefully. First, looking at the evidence: the first two chunks from 15829955 mention that HSCR is a multifactorial, non-mendelian disorder. They talk about rare mutations in the RET gene contributing to risk along with other genes. That seems to point towards a multifactorial cause because it involves multiple genetic factors. Then there's the third chunk from 15617541 which says that the majority of identified genes are related to Mendelian syndromic forms, but the non-Mendelian inheritance of sporadic cases is complex, involving multiple loci in a multiplicative model. So this suggests that while some forms (syndromic) might be Mendelian, the common, non-syndromic form is multifactorial. The question is asking if it's Mendelian or multifactorial. The answer needs to be concise with citations. The key here is that the disease can have both aspects, but the main point", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question about Hirschsprung disease being Mendelian or multifactorial. The user wants a strict JSON answer with the answer and base confidence. First, I need to look at the evidence provided. There are three documents here. Let me check each one. Document 15829955 has two chunks. Both say that HSCR is a multifactorial, non-mendelian disorder. They mention mutations in RET and other genes contributing to risk. So that's clear—multifactorial and non-Mendelian. Then there's document 15617541 which talks about genes and loci in Hirschsprung disease. It says the majority are related to Mendelian syndromic forms, but the non-Mendelian inheritance of sporadic cases is complex with multiple loci. So this supports that non-syndromic is multifactorial. Putting it together: The answer should be that it's a multifactorial, non-mendelian disorder. The confidence is high because two sources mention this. However, one document mentions Mendelian forms but the question is about Hirsch", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["12239580", "15617541", "15829955", "15858239", "20598273", "21995290", "23001136", "6650562", "8896569"], "ideal_answer": "Coding sequence mutations in RET, GDNF, EDNRB, EDN3, and SOX10 are involved in the development of Hirschsprung disease. The majority of these genes was shown to be related to Mendelian syndromic forms of Hirschsprung's disease, whereas the non-Mendelian inheritance of sporadic non-syndromic Hirschsprung disease proved to be complex; involvement of multiple loci was demonstrated in a multiplicative model."}
{"question_id": "55046d5ff8aee20f27000007", "question": "List signaling molecules (ligands) that interact with the receptor EGFR?", "retrieved_chunks": [{"doc_id": "23399900", "chunk_id": "23399900_0", "score": 6.7815752029418945, "text": "the 7 known EGFR ligands (EGF, betacellulin, epiregulin, heparin-binding EGF, transforming growth factor-α [TGF-α], amphiregulin, and epigen)"}, {"doc_id": "24323361", "chunk_id": "24323361_0", "score": 6.202628135681152, "text": "the epidermal growth factor receptor (EGFR) ligands, such as epidermal growth factor (EGF) and amphiregulin (AREG)"}, {"doc_id": "32533590", "chunk_id": "32533590_0", "score": 6.164878845214844, "text": "Gene ontology data showed the upregulation of genes related to EGFR signaling, and we identified that FGFR4 overexpression secretes EGFR ligands such as amphiregulin (AREG) with consequent activation of EGFR and ErbB3."}], "context": "[23399900:23399900_0] the 7 known EGFR ligands (EGF, betacellulin, epiregulin, heparin-binding EGF, transforming growth factor-α [TGF-α], amphiregulin, and epigen)\n[24323361:24323361_0] the epidermal growth factor receptor (EGFR) ligands, such as epidermal growth factor (EGF) and amphiregulin (AREG)\n[32533590:32533590_0] Gene ontology data showed the upregulation of genes related to EGFR signaling, and we identified that FGFR4 overexpression secretes EGFR ligands such as amphiregulin (AREG) with consequent activation of EGFR and ErbB3.", "answer": "<think> Okay, let's tackle this question. The user is asking for signaling molecules, specifically ligands, that interact with the EGFR receptor. I need to look at the provided evidence to find the answer. Looking at the first piece of evidence, document 23399900:23399900_0 lists seven known EGFR ligands: EGF, betacellulin, epiregulin, heparin-binding EGF, TGF-α, amphiregulin, and epigen. That's a comprehensive list. The second evidence, 24323361:24323361_0, mentions EGF and amphiregulin again. The third one, 32533590:32533597_0, talks about FGFR4 overexpression secreting AREG, which is another name for amphiregulin. So combining these, the main ligands are EGF, amphiregulin (AREG), and others listed in the first evidence. The answer should include all seven from the", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking for signaling molecules, specifically ligands, that interact with the EGFR receptor. I need to look at the provided evidence to find the answer. Looking at the first piece of evidence, document 23399900:23399900_0 lists seven known EGFR ligands: EGF, betacellulin, epiregulin, heparin-binding EGF, TGF-α, amphiregulin, and epigen. That's a comprehensive list. The second evidence, 24323361:24323361_0, mentions EGF and amphiregulin again. The third one, 32533590:32533597_0, talks about FGFR4 overexpression secreting AREG, which is another name for amphiregulin. So combining these, the main ligands are EGF, amphiregulin (AREG), and others listed in the first evidence. The answer should include all seven from the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, so the user is asking for signaling molecules, or ligands, that interact with the EGFR receptor. Let me look at the evidence provided. First, there's a document [23399900:23399900_0] which lists seven known EGFR ligands: EGF, betacellulin, epiregulin, heparin-binding EGF, TGF-α, amphiregulin, and epigen. That seems comprehensive. Then [24323361:24323361_0] mentions EGF and amphiregulin (AREG) as examples. The third document [32533590:32533590_0] talks about FGFR4 overexpression secreting AREG, which is also an EGFR ligand. So the answer should include all the ligands from the first source, but I need to check if there's any conflicting information. The second and third documents mention some of them again, like EGF and AREG. The first document lists more,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking for signaling molecules, specifically ligands, that interact with the EGFR receptor. I need to look at the provided evidence to find the answer. First, I'll check each piece of evidence. The first document [23399900:23399900_0] lists seven known EGFR ligands: EGF, betacellulin, epiregulin, heparin-binding EGF, TGF-α, amphiregulin, and epigen. That's a comprehensive list. The second document [24323361:24323361_0] mentions EGF and amphiregulin (AREG) as examples. The third document [32533590:32533590_0] talks about FGFR4 overexpression secreting AREG, which is also an EGFR ligand. So, combining these, the main ligands are EGF, amphiregulin (AREG), betacellulin, epiregulin", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["21514161", "22247333", "22260327", "23089711", "23099994", "23212918", "23382875", "23399900", "23729230", "23787814", "23821377", "23888072", "23959273", "24124521", "24204699", "24323361"], "ideal_answer": "The 7 known EGFR ligands are: epidermal growth factor (EGF), betacellulin (BTC), epiregulin (EPR), heparin-binding EGF (HB-EGF), transforming growth factor-α [TGF-α], amphiregulin (AREG) and epigen (EPG)."}
{"question_id": "54e25eaaae9738404b000017", "question": "Is the protein Papilin secreted?", "retrieved_chunks": [{"doc_id": "7515725", "chunk_id": "7515725_0", "score": 5.666638374328613, "text": "Collagen IV, laminin, glutactin, papilin, and other extracellular matrix proteins were made primarily by hemocytes and were secreted into the medium."}, {"doc_id": "21784067", "chunk_id": "21784067_0", "score": 3.164663791656494, "text": "Using expression analysis, we identify three genes that are transcriptionally regulated by HLH-2: the protocadherin cdh-3, and two genes encoding secreted extracellular matrix proteins, mig-6/papilin and him-4/hemicentin."}, {"doc_id": "11076767", "chunk_id": "11076767_0", "score": -0.5660957098007202, "text": "Papilin is an extracellular matrix glycoprotein"}], "context": "[7515725:7515725_0] Collagen IV, laminin, glutactin, papilin, and other extracellular matrix proteins were made primarily by hemocytes and were secreted into the medium.\n[21784067:21784067_0] Using expression analysis, we identify three genes that are transcriptionally regulated by HLH-2: the protocadherin cdh-3, and two genes encoding secreted extracellular matrix proteins, mig-6/papilin and him-4/hemicentin.\n[11076767:11076767_0] Papilin is an extracellular matrix glycoprotein", "answer": "<think> Okay, let's tackle this question. The user is asking if the protein Papilin is secreted. I need to look at the evidence provided to determine that. First, looking at the evidence documents. The first one says that collagen IV, laminin, glutactin, papilin, and other ECM proteins are made by hemocytes and secreted into the medium. So that directly mentions papilin is secreted. That's a strong point. The second document talks about genes regulated by HLH-2, including mig-6/papilin and him-4/hemicentin. It specifies that these are secreted extracellular matrix proteins. So this also supports that papilin is secreted. The third document states that papilin is an ECM glycoprotein. While it doesn't explicitly mention secretion, being an extracellular matrix protein often implies it's secreted. But I need to be careful here. The first two documents clearly state that it's secreted, so maybe the third is just additional info confirming its role in ECM. So combining the first two documents, there's clear evidence that papilin is secreted. The", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if the protein Papilin is secreted. I need to look at the evidence provided to determine that. First, looking at the evidence documents. The first one says that collagen IV, laminin, glutactin, papilin, and other ECM proteins are made by hemocytes and secreted into the medium. So that directly mentions papilin is secreted. That's a strong point. The second document talks about genes regulated by HLH-2, including mig-6/papilin and him-4/hemicentin. It specifies that these are secreted extracellular matrix proteins. So this also supports that papilin is secreted. The third document states that papilin is an ECM glycoprotein. While it doesn't explicitly mention secretion, being an extracellular matrix protein often implies it's secreted. But I need to be careful here. The first two documents clearly state that it's secreted, so maybe the third is just additional info confirming its role in ECM. So combining the first two documents, there's clear evidence that papilin is secreted. The", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user wants to know if the protein Papilin is secreted. I need to look at the evidence provided. First, evidence from [7515725:7515725_0] says that collagen IV, laminin, glutactin, papilin, and other ECM proteins are made by hemocytes and secreted into the medium. So that's a direct mention of papilin being secreted. Then, [21784067:21784067_0] mentions that mig-6/papilin is a secreted extracellular matrix protein. That's another citation pointing to secretion. The third evidence, [11076767:11076767_0], states that papilin is an ECM glycoprotein. While it doesn't explicitly say secreted, ECM proteins are usually secreted, but I need to be careful here. However, the other two sources clearly state secretion, so maybe this one is just confirming its nature without directly addressing secretion. So combining", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user wants to know if the protein Papilin is secreted. I need to check the provided evidence. First, looking at the evidence documents. The first one says that collagen IV, laminin, glutactin, papilin, and other ECM proteins are made by hemocytes and secreted into the medium. So that directly mentions papilin being secreted. That's a strong citation. The second document talks about genes regulated by HLH-2, including mig-6/papilin and him-4/hemicentin. It specifies that these are secreted extracellular matrix proteins. So this also supports that papilin is secreted. The third document states that papilin is an ECM glycoprotein. While it doesn't explicitly mention secretion, being an extracellular matrix protein often implies it's secreted. However, the first two documents clearly state secretion, so that's more direct evidence. Combining these, the answer should be yes, Papilin is secreted. The confidence would be high because multiple sources confirm this. The base_confidence can be 1.0 since all", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["11076767", "12666201", "15094110", "15094122", "19297413", "19724244", "20805556", "21784067", "3320045", "7515725"], "ideal_answer": "Yes, papilin is a secreted protein"}
{"question_id": "535d292a9a4572de6f000003", "question": "Are long non coding RNAs spliced?", "retrieved_chunks": [{"doc_id": "26649774", "chunk_id": "26649774_0", "score": 5.515077114105225, "text": "Circular RNAs (circRNAs) are long, non-coding RNAs that result from the non-canonical splicing of linear pre-mRNAs."}, {"doc_id": "25994219", "chunk_id": "25994219_0", "score": 4.214262962341309, "text": "Long non-coding RNAs (lncRNAs) are emerging as key molecules in cancers, yet their potential molecular mechanisms are not well understood."}, {"doc_id": "25404134", "chunk_id": "25404134_0", "score": 3.977782726287842, "text": "Recent studies have disclosed the function of enhancer RNAs (eRNAs), which are long non-coding RNAs transcribed from gene enhancer regions, in transcriptional regulation."}], "context": "[26649774:26649774_0] Circular RNAs (circRNAs) are long, non-coding RNAs that result from the non-canonical splicing of linear pre-mRNAs.\n[25994219:25994219_0] Long non-coding RNAs (lncRNAs) are emerging as key molecules in cancers, yet their potential molecular mechanisms are not well understood.\n[25404134:25404134_0] Recent studies have disclosed the function of enhancer RNAs (eRNAs), which are long non-coding RNAs transcribed from gene enhancer regions, in transcriptional regulation.", "answer": "<think> Okay, let's tackle this question. The user is asking if long non-coding RNAs (lncRNAs) are spliced. The evidence provided has three documents. First, looking at document [26649774:26649774_0], it mentions circular RNAs (circRNAs) which are long non-coding RNAs resulting from non-canonical splicing of pre-mRNAs. So this suggests that some lncRNAs, specifically circRNAs, can be spliced. But the question is about all lncRNAs or in general. Next, document [25994219:25994219_0] talks about lncRNAs in cancers but doesn't mention splicing. The third document [25404134:25404134_0] discusses enhancer RNAs (eRNAs), which are a type of lncRNA, and their role in transcriptional regulation. Again, no mention of splicing here. So the only direct evidence is from the first document about", "citations": [{"doc_id": "26649774", "chunk_id": "26649774_0"}, {"doc_id": "25994219", "chunk_id": "25994219_0"}, {"doc_id": "25404134", "chunk_id": "25404134_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if long non-coding RNAs (lncRNAs) are spliced. The evidence provided has three documents. First, looking at document [26649774:26649774_0], it mentions circular RNAs (circRNAs) which are long non-coding RNAs resulting from non-canonical splicing of pre-mRNAs. So this suggests that some lncRNAs, specifically circRNAs, can be spliced. But the question is about all lncRNAs or in general. Next, document [25994219:25994219_0] talks about lncRNAs in cancers but doesn't mention splicing. The third document [25404134:25404134_0] discusses enhancer RNAs (eRNAs), which are a type of lncRNA, and their role in transcriptional regulation. Again, no mention of splicing here. So the only direct evidence is from the first document about", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if long non-coding RNAs (lncRNAs) are spliced. The evidence provided has three chunks. First, looking at the first evidence: [26649774:26649774_0] mentions circular RNAs (circRNAs) which are long non-coding RNAs resulting from non-canonical splicing of pre-mRNAs. So this suggests that some lncRNAs, specifically circRNAs, are spliced. But the question is about all lncRNAs or in general. The second chunk [25994219:25994219_0] talks about lncRNAs in cancers but doesn't mention splicing. The third chunk [25404134:25404134_0] discusses enhancer RNAs (eRNAs), which are lncRNAs, and their role in transcriptional regulation. Again, no mention of splicing here. So the only direct evidence is the first chunk about circRN", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if long non coding RNAs (lncRNAs) are spliced. The evidence provided has three chunks. First, looking at chunk [26649774:26649771_0], it mentions circular RNAs (circRNAs) which are long non-coding RNAs resulting from non-canonical splicing of pre-mRNAs. So this directly talks about splicing in the context of lncRNAs. That's a clear mention of splicing. Then, chunk [25994219:25994219_0] discusses lncRNAs in cancers but doesn't mention splicing. It's about their role and mechanisms, not splicing. So this doesn't answer the question. The third chunk [25404134:25404134_0] talks about enhancer RNAs (eRNAs), which are lncRNAs, and their function in transcriptional regulation. Again, no mention of splicing here. So the only", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["21622663", "22707570", "22955974", "22955988", "24106460", "24285305"], "ideal_answer": "Long non coding RNAs appear to be spliced through the same pathway as the mRNAs"}
{"question_id": "55262a9787ecba3764000009", "question": "Is RANKL secreted from the cells?", "retrieved_chunks": [{"doc_id": "23698708", "chunk_id": "23698708_0", "score": 7.07332181930542, "text": "Activated human T cells express alternative mRNA transcripts encoding a secreted form of RANKL."}, {"doc_id": "22901753", "chunk_id": "22901753_0", "score": 5.878667831420898, "text": "Although B. abortus-activated T cells actively secreted the pro-osteoclastogenic cytokines RANKL and IL-17, osteoclastogenesis depended on IL-17, because osteoclast generation induced by Brucella-activated T cells was completely abrogated when these cells were cultured with BMMs from IL-17 receptor knockout mice."}, {"doc_id": "23632157", "chunk_id": "23632157_0", "score": 5.340981483459473, "text": "OPG, on the other hand, is secreted by osteoblast as a decoy receptor for RANKL, prevents RANKL from binding to RANK and thus prevents bone resorption"}], "context": "[23698708:23698708_0] Activated human T cells express alternative mRNA transcripts encoding a secreted form of RANKL.\n[22901753:22901753_0] Although B. abortus-activated T cells actively secreted the pro-osteoclastogenic cytokines RANKL and IL-17, osteoclastogenesis depended on IL-17, because osteoclast generation induced by Brucella-activated T cells was completely abrogated when these cells were cultured with BMMs from IL-17 receptor knockout mice.\n[23632157:23632157_0] OPG, on the other hand, is secreted by osteoblast as a decoy receptor for RANKL, prevents RANKL from binding to RANK and thus prevents bone resorption", "answer": "<think> Okay, let's tackle this question. The user is asking if RANKL is secreted from cells. I need to look at the evidence provided. First, evidence document [23698708:23698708_0] says that activated human T cells express alternative mRNA transcripts encoding a secreted form of RANKL. So this directly mentions that RANKL is secreted by T cells. That's a strong point. Then, document [22901753:22901753_0] talks about B. abortus-activated T cells secreting RANKL and IL-17. Again, this supports that RANKL is secreted by these cells. The third evidence, [23632157:23632155_0], mentions OPG being secreted by osteoblasts as a decoy for RANKL. While this talks about OPG, it implies that RANKL is secreted since it's acting as a decoy. But the main point here is about OPG", "citations": [{"doc_id": "23698708", "chunk_id": "23698708_0"}, {"doc_id": "22901753", "chunk_id": "22901753_0"}, {"doc_id": "23632157", "chunk_id": "23632155_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if RANKL is secreted from cells. I need to look at the evidence provided. First, evidence document [23698708:23698708_0] says that activated human T cells express alternative mRNA transcripts encoding a secreted form of RANKL. So this directly mentions that RANKL is secreted by T cells. That's a strong point. Then, document [22901753:22901753_0] talks about B. abortus-activated T cells secreting RANKL and IL-17. Again, this supports that RANKL is secreted by these cells. The third evidence, [23632157:23632155_0], mentions OPG being secreted by osteoblasts as a decoy for RANKL. While this talks about OPG, it implies that RANKL is secreted since it's acting as a decoy. But the main point here is about OPG", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if RANKL is secreted from cells. I need to look at the evidence provided. First evidence: [23698708:23698708_0] says activated human T cells express alternative mRNA transcripts encoding a secreted form of RANKL. So this directly mentions that RANKL is secreted by T cells. That's a strong point. Second evidence: [22901753:22901753_0] talks about B. abortus-activated T cells secreting RANKL and IL-17. Again, this confirms that RANKL is secreted by these T cells. Third evidence: [23632157:23632157_0] mentions OPG being secreted by osteoblasts as a decoy for RANKL. This shows that RANKL is indeed secreted because OPG is acting as a decoy. But this evidence is about OPG, not directly about RANKL's secretion", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if RANKL is secreted from cells. I need to look at the evidence provided. First, check the evidence documents. The first one says that activated human T cells express alternative mRNA transcripts encoding a secreted form of RANKL. So that directly mentions secretion. The second document talks about B. abortus-activated T cells secreting RANKL and IL-17, which also supports secretion. The third document mentions OPG being secreted by osteoblasts as a decoy for RANKL, but that's about OPG, not RANKL itself. So the answer should be yes, based on the first two documents. The confidence is high because two different sources mention secretion of RANKL. The third document doesn't contradict but also doesn't directly address RANKL secretion. So base_confidence would be 1.0 since there's clear evidence from two separate studies. </think> { \"answer\": \"Yes, RANKL is secreted from cells. Activated human T cells express a secreted form of RANKL [2369", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["21618594", "22867712", "22901753", "22948539", "23632157", "23698708", "23827649", "23835909", "24265865", "24267510"], "ideal_answer": "Receptor activator of nuclear factor κB ligand (RANKL) is a cytokine predominantly secreted by osteoblasts."}
{"question_id": "51406e6223fec90375000009", "question": "Does metformin interfere thyroxine absorption?", "retrieved_chunks": [{"doc_id": "26191653", "chunk_id": "26191653_0", "score": 6.750408172607422, "text": "It has been hypothesized that metformin may suppress serum thyrotropin (TSH) concentrations by enhancing LT4 absorption or by directly affecting the hypothalamic-pituitary axis."}, {"doc_id": "8835050", "chunk_id": "8835050_0", "score": 3.851344585418701, "text": "Metformin decreases absorption of vitamin B12 and folic acid, although reported cases of megaloblastic anemia are rare."}, {"doc_id": "26191653", "chunk_id": "26191653_1", "score": 2.08963680267334, "text": "LT4 absorption is unchanged by concomitant metformin ingestion."}], "context": "[26191653:26191653_0] It has been hypothesized that metformin may suppress serum thyrotropin (TSH) concentrations by enhancing LT4 absorption or by directly affecting the hypothalamic-pituitary axis.\n[8835050:8835050_0] Metformin decreases absorption of vitamin B12 and folic acid, although reported cases of megaloblastic anemia are rare.\n[26191653:26191653_1] LT4 absorption is unchanged by concomitant metformin ingestion.", "answer": "<think> Okay, let's tackle this question. The user is asking if metformin interferes with thyroxine (T4) absorption. I need to look at the provided evidence to find the answer. First, evidence document [26191653:26191653_0] mentions that metformin might suppress TSH by enhancing LT4 absorption or affecting the hypothalamic-pituitary axis. But then, in [26191653:26191653_1], it states that LT4 absorption isn't changed by metformin. So there's a contradiction here. The first part suggests metformin might enhance absorption, but the second part says it doesn't affect it. The other evidence, [8835050:8835050_0], talks about B12 and folic acid absorption, which isn't related to thyroxine. So that's probably not relevant here. The key is that the two documents from the same ID (26191653) have conflicting info.", "citations": [{"doc_id": "26191653", "chunk_id": "26191653_0"}, {"doc_id": "26191653", "chunk_id": "26191653_1"}, {"doc_id": "8835050", "chunk_id": "8835050_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if metformin interferes with thyroxine (T4) absorption. I need to look at the provided evidence to find the answer. First, evidence document [26191653:26191653_0] mentions that metformin might suppress TSH by enhancing LT4 absorption or affecting the hypothalamic-pituitary axis. But then, in [26191653:26191653_1], it states that LT4 absorption isn't changed by metformin. So there's a contradiction here. The first part suggests metformin might enhance absorption, but the second part says it doesn't affect it. The other evidence, [8835050:8835050_0], talks about B12 and folic acid absorption, which isn't related to thyroxine. So that's probably not relevant here. The key is that the two documents from the same ID (26191653) have conflicting info.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if metformin interferes with thyroxine (T4) absorption. I need to look at the provided evidence to find the answer. First, looking at the evidence documents. The first one, 26191653:26191653_0, says that metformin might suppress TSH by enhancing LT4 absorption or affecting the hypothalamic-pituitary axis. Wait, that's a bit confusing. It mentions \"enhancing\" LT4 absorption, which would mean it's helping the absorption, not interfering with it. But then the next chunk from the same document, 26191653:26191653_1, says that LT4 absorption is unchanged when metformin is taken together. So there's a contradiction here. The first part suggests that metformin might enhance absorption, but the second part says it doesn't change absorption. Then there's another document, 8835050:8835057_0, which talks about", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if metformin interferes with thyroxine (T4) absorption. I need to look at the provided evidence to find the answer. First, evidence document [26191653:26191653_0] mentions that metformin might suppress TSH by enhancing LT4 absorption or affecting the hypothalamic-pituitary axis. But then, in [26191653:26191653_1], it states that LT4 absorption isn't changed by metformin. So there's a contradiction here. The first chunk suggests metformin could enhance absorption, the second says it doesn't change it. Another evidence point [8835050:8835050_0] talks about B12 and folic acid absorption, which isn't directly related to thyroxine. So that's probably not relevant here. The key is to resolve the conflicting info. The second chunk from the same doc (26191653) directly", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["26191653"], "ideal_answer": "No. There are not reported data indicating that metformin reduce with thyroxine absorption."}
{"question_id": "553fa78b1d53b76422000007", "question": "Which miRNAs could be used as potential biomarkers for epithelial ovarian cancer?", "retrieved_chunks": [{"doc_id": "23542579", "chunk_id": "23542579_2", "score": 8.470380783081055, "text": "Serum miR-132, miR-26a, let-7b, and miR-145 could be considered as potential candidates as novel biomarkers in serous ovarian cancer."}, {"doc_id": "23542579", "chunk_id": "23542579_1", "score": 8.27552604675293, "text": "Serum miR-132, miR-26a, let-7b, and miR-145 could be considered as potential candidates as novel biomarkers in serous ovarian cancer"}, {"doc_id": "21971665", "chunk_id": "21971665_0", "score": 5.796660423278809, "text": "Taken together, miR-152 and miR-148a may be involved in the carcinogenesis of ovarian cancer through deregulation of cell proliferation. They may be novel biomarkers for early detection or therapeutic targets of ovarian cancer"}], "context": "[23542579:23542579_2] Serum miR-132, miR-26a, let-7b, and miR-145 could be considered as potential candidates as novel biomarkers in serous ovarian cancer.\n[23542579:23542579_1] Serum miR-132, miR-26a, let-7b, and miR-145 could be considered as potential candidates as novel biomarkers in serous ovarian cancer\n[21971665:21971665_0] Taken together, miR-152 and miR-148a may be involved in the carcinogenesis of ovarian cancer through deregulation of cell proliferation. They may be novel biomarkers for early detection or therapeutic targets of ovarian cancer", "answer": "<think> Okay, let's see. The user is asking which miRNAs could be used as potential biomarkers for epithelial ovarian cancer. The evidence provided has three entries. First, the two entries with ID 23542579 mention serum miR-132, miR-26a, let-7b, and miR-145 as potential biomarkers in serous ovarian cancer. Then there's another entry with ID 21971665 talking about miR-152 and miR-148a being involved in carcinogenesis and possibly novel biomarkers. So the question is about epithelial ovarian cancer, but the evidence mentions \"serous ovarian cancer\" and \"ovarian cancer\" generally. I need to check if these miRNAs are specifically for epithelial ovarian cancer or if they're applicable. Since the user's question is about epithelial ovarian cancer, which is a type of ovarian cancer, maybe the serous type is a subset. The answer should include both sets of miRNAs mentioned in the evidence. But wait, the first two entries are duplicates, so I", "citations": [], "candidates": [{"answer": "<think> Okay, let's see. The user is asking which miRNAs could be used as potential biomarkers for epithelial ovarian cancer. The evidence provided has three entries. First, the two entries with ID 23542579 mention serum miR-132, miR-26a, let-7b, and miR-145 as potential biomarkers in serous ovarian cancer. Then there's another entry with ID 21971665 talking about miR-152 and miR-148a being involved in carcinogenesis and possibly novel biomarkers. So the question is about epithelial ovarian cancer, but the evidence mentions \"serous ovarian cancer\" and \"ovarian cancer\" generally. I need to check if these miRNAs are specifically for epithelial ovarian cancer or if they're applicable. Since the user's question is about epithelial ovarian cancer, which is a type of ovarian cancer, maybe the serous type is a subset. The answer should include both sets of miRNAs mentioned in the evidence. But wait, the first two entries are duplicates, so I", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user wants to know which miRNAs could be potential biomarkers for epithelial ovarian cancer based on the provided evidence. First, I need to look at the evidence given. There are three documents mentioned. The first two documents (23542579:23542579_1 and 23542579:23542579_2) both mention serum miR-132, miR-26a, let-7b, and miR-145 as potential biomarkers in serous ovarian cancer. The third document (21971665:21971665_0) talks about miR-152 and miR-ight8a possibly involved in carcinogenesis and being novel biomarkers. The question is about epithelial ovarian cancer, which is a type of ovarian cancer. The evidence from the first two documents specifically mentions \"serous ovarian cancer,\" which is a subtype of epithelial ovarian cancer. So those miRNAs (132,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which miRNAs could be potential biomarkers for epithelial ovarian cancer. The evidence provided has three entries. First, I need to look at each piece of evidence. The first two entries are the same, citing [23542579:23542579_2] and [23542579:23542579_1], both stating that miR-132, miR-26a, let-7b, and miR-145 are potential biomarkers in serous ovarian cancer. The third entry, [21971665:21971665_0], mentions miR-152 and miR-148a being involved in carcinogenesis and possibly as novel biomarkers. Now, the question is about epithelial ovarian cancer. The first two references mention \"serous ovarian cancer,\" which is a subtype of epithelial ovarian cancer. So those miRNAs are relevant here. The third reference talks about miR", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["18954897", "19074899", "20035894", "21345725", "21571355", "21971665", "22246341", "23272653", "23542579", "23621186", "23836287", "23888941", "23918241", "23978303"], "ideal_answer": "miR-200a, miR-100, miR-141, miR-200b, miR-200c, miR-203, miR-510, miR-509-5p, miR-132, miR-26a, let-7b, miR-145, miR-182, miR-152, miR-148a, let-7a, let-7i, miR-21, miR-92 and miR-93 could be used as potential biomarkers for epithelial ovarian cancer."}
{"question_id": "5149199dd24251bc05000040", "question": "Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis?", "retrieved_chunks": [{"doc_id": "20663605", "chunk_id": "20663605_0", "score": 9.341995239257812, "text": "For more than 50 years the acetylcholinesterase inhibitor pyridostigmine bromide has been the drug of choice in the symptomatic therapy for myasthenia gravis."}, {"doc_id": "15610702", "chunk_id": "15610702_0", "score": 8.536487579345703, "text": "Acetylcholinesterase inhibitors provide temporary, symptomatic treatment for all forms of myasthenia gravis."}, {"doc_id": "29655452", "chunk_id": "29655452_0", "score": 8.516647338867188, "text": "The 2 exceptions are acetylcholinesterase inhibitors and complement inhibition with eculizumab, which was recently approved by the US Food and Drug Administration for myasthenia gravis."}], "context": "[20663605:20663605_0] For more than 50 years the acetylcholinesterase inhibitor pyridostigmine bromide has been the drug of choice in the symptomatic therapy for myasthenia gravis.\n[15610702:15610702_0] Acetylcholinesterase inhibitors provide temporary, symptomatic treatment for all forms of myasthenia gravis.\n[29655452:29655452_0] The 2 exceptions are acetylcholinesterase inhibitors and complement inhibition with eculizumab, which was recently approved by the US Food and Drug Administration for myasthenia gravis.", "answer": "<think> Okay, let's tackle this question. The user is asking which acetylcholinesterase inhibitors are used for treating myasthenia gravis. The evidence provided has three chunks. First chunk (20663605:20663605_0) says that pyridostigmine bromide has been the drug of choice for over 50 years. So that's one inhibitor. Second chunk (15610702:15610702_0) mentions that acetylcholinesterase inhibitors in general provide temporary symptomatic treatment, but it doesn't name any specific ones. Third chunk (29655452:29655452_0) states that the exceptions are acetylcholinesterase inhibitors and eculizumab. Wait, that's a bit confusing. The question is about which inhibitors are used, but this chunk says they are exceptions. Maybe it's referring to other treatments? Or perhaps it's saying that despite being exceptions, they are still used? Hmm. Wait, the third chunk", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which acetylcholinesterase inhibitors are used for treating myasthenia gravis. The evidence provided has three chunks. First chunk (20663605:20663605_0) says that pyridostigmine bromide has been the drug of choice for over 50 years. So that's one inhibitor. Second chunk (15610702:15610702_0) mentions that acetylcholinesterase inhibitors in general provide temporary symptomatic treatment, but it doesn't name any specific ones. Third chunk (29655452:29655452_0) states that the exceptions are acetylcholinesterase inhibitors and eculizumab. Wait, that's a bit confusing. The question is about which inhibitors are used, but this chunk says they are exceptions. Maybe it's referring to other treatments? Or perhaps it's saying that despite being exceptions, they are still used? Hmm. Wait, the third chunk", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which acetylcholinesterase inhibitors are used for treating myasthenia gravis. The evidence provided has three documents. First, document 20663605:20663605_0 says that pyridostigmine bromide has been the drug of choice for over 50 years. That's a clear mention of a specific inhibitor. Then document 15610702:15610702_0 states that acetylcholinesterase inhibitors in general provide temporary, symptomatic treatment. But this is more of a general statement, not specifying which ones. The third document, 29655452:29655452_0, mentions that the exceptions are acetylcholinesterase inhibitors and eculizumab. Wait, that's a bit confusing. The sentence says \"the 2 exceptions are...\" which might mean that these two categories are not used, but that seems contradictory because the question is about which ones *are* used", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which acetylcholinesterase inhibitors are used for treating myasthenia gravis. The evidence provided has three chunks. First chunk says that pyridostigmine bromide has been the drug of choice for over 50 years. So that's definitely one inhibitor. The second chunk mentions that acetylcholinesterase inhibitors in general provide temporary symptomatic treatment, but it doesn't name any specific ones. The third chunk lists two exceptions: acetylcholinesterase inhibitors and eculizumab. Wait, eculizumab is a complement inhibitor, not an acetylcholinesterase inhibitor. So the third chunk might be saying that except for these two categories, others are used. But since the question is about inhibitors, the first chunk's pyridostigmine is the main one. The second chunk is general, but the third chunk mentions that the exceptions include acetylcholinesterase inhibitors, which might mean that they are used, but the answer should focus on the specific ones mentioned. So the only specific inhibitor in the evidence is pyridostigmine", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["15610702", "20663605", "21133188", "21328290", "21815707", "21845054"], "ideal_answer": "Pyridostigmine and neostygmine are acetylcholinesterase inhibitors that are used as first-line therapy for symptomatic treatment of myasthenia gravis. Pyridostigmine is the most widely used acetylcholinesterase inhibitor. Extended release pyridotsygmine and novel acetylcholinesterase inhibitors inhibitors with oral antisense oligonucleotides are being studied."}
{"question_id": "52bf1db603868f1b06000011", "question": "Has Denosumab (Prolia) been approved by FDA?", "retrieved_chunks": [{"doc_id": "21170699", "chunk_id": "21170699_0", "score": 10.686975479125977, "text": "The fully human monoclonal antibody denosumab (Prolia(®)) has been recently approved by the European Medical Agency (EMEA) and the Food and Drug Administration (FDA) for the treatment of postmenopausal osteoporosis."}, {"doc_id": "24126422", "chunk_id": "24126422_0", "score": 9.701005935668945, "text": "Denosumab (Prolia®) is a fully human monoclonal antibody for RANKL, which selectively inhibits osteoclastogenesis, being recently approved for the treatment of postmenopausal osteoporosis in women at a high or increased risk of fracture by the FDA in the United Sates and by the European Medicines Agency in Europe since June 2010."}, {"doc_id": "24316116", "chunk_id": "24316116_0", "score": 8.695709228515625, "text": "Denosumab is a RANK-ligand antibody that was approved by the FDA in 2010 for the prevention of skeletal fractures in patients with bone metastases from solid tumors."}], "context": "[21170699:21170699_0] The fully human monoclonal antibody denosumab (Prolia(®)) has been recently approved by the European Medical Agency (EMEA) and the Food and Drug Administration (FDA) for the treatment of postmenopausal osteoporosis.\n[24126422:24126422_0] Denosumab (Prolia®) is a fully human monoclonal antibody for RANKL, which selectively inhibits osteoclastogenesis, being recently approved for the treatment of postmenopausal osteoporosis in women at a high or increased risk of fracture by the FDA in the United Sates and by the European Medicines Agency in Europe since June 2010.\n[24316116:24316116_0] Denosumab is a RANK-ligand antibody that was approved by the FDA in 2010 for the prevention of skeletal fractures in patients with bone metastases from solid tumors.", "answer": "<think> Okay, let's tackle this question. The user wants to know if Denosumab (Prolia) has been approved by the FDA. I need to check the evidence provided. Looking at the first evidence snippet [21170699:21170699_0], it says that denosumab was approved by both EMEA and FDA for postmenopausal osteoporosis. That's a direct mention of FDA approval. The second snippet [24126422:24316116_0] also states that the FDA approved it in the US for postmenopausal osteoporosis. The third snippet [24316116:24316116_0] mentions FDA approval in 2010 for preventing fractures in bone metastases. So all three sources mention FDA approval, but the dates vary. The first one says \"recently\" which might be relative to when the evidence was written, but the third one gives a specific year, 2010. The answer needs to be concise", "citations": [{"doc_id": "21170699", "chunk_id": "21170699_0"}, {"doc_id": "24126422", "chunk_id": "24316116_0"}, {"doc_id": "24316116", "chunk_id": "24316116_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user wants to know if Denosumab (Prolia) has been approved by the FDA. I need to check the evidence provided. Looking at the first evidence snippet [21170699:21170699_0], it says that denosumab was approved by both EMEA and FDA for postmenopausal osteoporosis. That's a direct mention of FDA approval. The second snippet [24126422:24316116_0] also states that the FDA approved it in the US for postmenopausal osteoporosis. The third snippet [24316116:24316116_0] mentions FDA approval in 2010 for preventing fractures in bone metastases. So all three sources mention FDA approval, but the dates vary. The first one says \"recently\" which might be relative to when the evidence was written, but the third one gives a specific year, 2010. The answer needs to be concise", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if Denosumab (Prolia) has been approved by the FDA. I need to check the evidence provided. Looking at the evidence, there are three documents. The first one says it was approved by both EMEA and FDA for postmenopausal osteoporosis. The second mentions FDA approval in the US for postmenopausal osteoporosis in high-risk women, and the third states FDA approval in 2010 for preventing fractures in patients with bone metastases. So all three documents confirm FDA approval. The first document mentions 2010, but the third also says 2010. Wait, the second document says \"since June 2010\" which might be when it was approved. The third one also says 2010. So the answer should be yes, and the confidence is high because all three sources agree. The base confidence can be 1.0 since all evidence points to FDA approval. </think> { \"answer\": \"Yes, Denosumab (Prolia®) has been approved by the FDA.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's see. The user is asking if Denosumab (Prolia) has been approved by the FDA. I need to check the evidence provided. Looking at the first evidence snippet: It mentions that Denosumab was approved by both EMEA and FDA for postmenopausal osteoporosis. So that's a direct answer. The second snippet says it was approved by the FDA in the US and EMA in Europe since June 2010. The third one states it was approved by FDA in 2010 for preventing fractures in bone metastases. All three sources confirm FDA approval. The first two mention the specific date, June 2010, and the third mentions 2010 as well. So the answer is yes. The confidence should be high since all three documents agree. I need to pick one citation. Let's use the first one because it directly states FDA approval. But wait, the first snippet says \"recently approved\" but the other ones have specific dates. Maybe the first one is a bit vague, but since all three confirm FDA approval, it's safe to say yes.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["20811384", "21113693", "21129866", "21170699", "21208140", "21470540", "21785279", "21942303", "22074657", "22540167", "22716221", "22826702", "23367751", "23652187", "23757624", "23759273", "23956508", "24114694", "24126422", "24308016", "24316116"], "ideal_answer": "Yes, Denosumab was approved by the FDA in 2010."}
{"question_id": "5709e4b2cf1c32585100001c", "question": "List the human genes encoding for the dishevelled proteins?", "retrieved_chunks": [{"doc_id": "19618470", "chunk_id": "19618470_0", "score": 5.572644233703613, "text": "Dishevelled (Dvl) proteins are key transducers of Wnt signaling encoded by members of a multi-gene family in vertebrates. We report here the divergent, tissue-specific expression patterns for all three Dvl genes in Xenopus embryos, which contrast dramatically with their expression patterns in mice."}, {"doc_id": "8856345", "chunk_id": "8856345_0", "score": 5.32364559173584, "text": "We report here that the mouse Dishevelled-1 (Dvl-1) and Dishevelled-2 genes encode proteins that are differentially localized in Wnt-overexpressing PC12 cell lines (PC12/Wnt)."}, {"doc_id": "7958461", "chunk_id": "7958461_0", "score": 2.8897006511688232, "text": "In the Drosophila embryo dishevelled (dsh) function is required by target cells in order to respond to wingless (wg, the homolog of Wnt-1), demonstrating a role for dsh in Wnt signal transduction. We have isolated a mouse homolog of the Drosophila dsh segment polarity gene. The 695-amino-acid protein encoded by the mouse dishevelled gene (Dvl-1) shares 50% identity (65% similarity) with dsh."}], "context": "[19618470:19618470_0] Dishevelled (Dvl) proteins are key transducers of Wnt signaling encoded by members of a multi-gene family in vertebrates. We report here the divergent, tissue-specific expression patterns for all three Dvl genes in Xenopus embryos, which contrast dramatically with their expression patterns in mice.\n[8856345:8856345_0] We report here that the mouse Dishevelled-1 (Dvl-1) and Dishevelled-2 genes encode proteins that are differentially localized in Wnt-overexpressing PC12 cell lines (PC12/Wnt).\n[7958461:7958461_0] In the Drosophila embryo dishevelled (dsh) function is required by target cells in order to respond to wingless (wg, the homolog of Wnt-1), demonstrating a role for dsh in Wnt signal transduction. We have isolated a mouse homolog of the Drosophila dsh segment polarity gene. The 695-amino-acid protein encoded by the mouse dishevelled gene (Dvl-1) shares 50% identity (65% similarity) with dsh.", "answer": "<think> Okay, let's tackle this question. The user is asking for the human genes that encode the dishevelled proteins. I need to look at the evidence provided to find the answer. Looking at the first piece of evidence, it mentions that Dishevelled (Dvl) proteins are encoded by members of a multi-gene family in vertebrates, and specifically points out three Dvl genes in Xenopus embryos. But since the question is about humans, I need to check if any of these references mention human genes. The second evidence talks about mouse Dishevelled-1 (Dvl-1) and Dishevelled-2 genes. However, the question is about human genes, so this might not directly answer it, but maybe there's a connection. The third evidence mentions a mouse homolog of Drosophila dsh, which is Dvl-1 in mice. But again, that's mouse, not human. Wait, the first reference says \"all three Dvl genes in Xenopus embryos,\" but Xenopus is an animal, not humans. However, the question is about human genes. The evidence might not explicitly list human gene names", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking for the human genes that encode the dishevelled proteins. I need to look at the evidence provided to find the answer. Looking at the first piece of evidence, it mentions that Dishevelled (Dvl) proteins are encoded by members of a multi-gene family in vertebrates, and specifically points out three Dvl genes in Xenopus embryos. But since the question is about humans, I need to check if any of these references mention human genes. The second evidence talks about mouse Dishevelled-1 (Dvl-1) and Dishevelled-2 genes. However, the question is about human genes, so this might not directly answer it, but maybe there's a connection. The third evidence mentions a mouse homolog of Drosophila dsh, which is Dvl-1 in mice. But again, that's mouse, not human. Wait, the first reference says \"all three Dvl genes in Xenopus embryos,\" but Xenopus is an animal, not humans. However, the question is about human genes. The evidence might not explicitly list human gene names", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user wants a list of human genes encoding dishevelled proteins. Looking at the evidence provided, there are three documents. First, document [19618470:19618470_0] mentions that Dishevelled (Dvl) proteins are encoded by members of a multi-gene family in vertebrates, and specifically talks about three Dvl genes in Xenopus embryos. But the question is about humans, so I need to check if this document mentions human genes. It doesn't explicitly state that, but it's part of the evidence. Next, [8856345:8856345_0] refers to mouse Dishevelled-1 (Dvl-1) and Dvl-2 genes. Since the question is about humans, this might be relevant if there's a homolog. However, the document is about mice, not humans. But maybe the human genes are similar. The third document [7958461:7958461_0] talks about a mouse hom", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking for the human genes that encode the dishevelled proteins. I need to look at the evidence provided to find the answer. First, looking at the first evidence snippet [19618470:19618470_0], it mentions that Dishevelled (Dvl) proteins are encoded by members of a multi-gene family in vertebrates. It also refers to three Dvl genes in Xenopus embryos, but the question is about humans. However, this snippet doesn't specify human genes, so maybe it's a starting point. Next, [8856345:8856345_0] talks about mouse Dishevelled-1 (Dvl-1) and Dishevelled-2 genes. Since the question is about humans, this might not directly answer it, but it's possible that human genes are similar. However, the snippet doesn't mention human genes explicitly. Then there's [7958461:7958461_ity] which mentions a mouse", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["12883684", "16457155", "19618470", "23836490", "24040443", "7958461", "8149913", "8817329", "8856345"], "ideal_answer": "DVL-1 DVL-2 DVL-3"}
{"question_id": "56bc751eac7ad10019000013", "question": "Name synonym of Acrokeratosis paraneoplastica.", "retrieved_chunks": [{"doc_id": "8949310", "chunk_id": "8949310_0", "score": 6.799607276916504, "text": "Acrokeratosis paraneoplastica: Bazex syndrome."}, {"doc_id": "6225397", "chunk_id": "6225397_0", "score": 6.467101097106934, "text": "Acrokeratosis paraneoplastica (Bazex&apos; syndrome) is a rare but clinically distinctive dermatosis that has been associated in all reported cases, to our knowledge, with either a primary malignant neoplasm of the upper aerodigestive tract or metastatic cancer to the lymph nodes of the neck. Acrokeratosis paraneoplastica was found in a 53-year-old black man with squamous cell carcinoma of the tonsil."}, {"doc_id": "17097409", "chunk_id": "17097409_0", "score": 6.454122543334961, "text": "Acrokeratosis paraneoplastica (Bazex's syndrome): association with liposarcoma."}], "context": "[8949310:8949310_0] Acrokeratosis paraneoplastica: Bazex syndrome.\n[6225397:6225397_0] Acrokeratosis paraneoplastica (Bazex&apos; syndrome) is a rare but clinically distinctive dermatosis that has been associated in all reported cases, to our knowledge, with either a primary malignant neoplasm of the upper aerodigestive tract or metastatic cancer to the lymph nodes of the neck. Acrokeratosis paraneoplastica was found in a 53-year-old black man with squamous cell carcinoma of the tonsil.\n[17097409:17097409_0] Acrokeratosis paraneoplastica (Bazex's syndrome): association with liposarcoma.", "answer": "Bazex syndrome [8949310:8949310_0]", "citations": [{"doc_id": "8949310", "chunk_id": "8949310_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking for a synonym of \"Acrokeratosis paraneoplastica.\" Looking at the evidence provided, the first document mentions \"Bazex syndrome\" in relation to Acrokeratosis paraneoplastica. The second document also refers to it as Bazex syndrome. The third one uses \"Bazex's syndrome.\" So, \"Bazex syndrome\" seems to be the synonym here. I need to check if all the documents cite the same thing. The first evidence says \"Acrokeratosis paraneoplastica: Bazex syndrome.\" The second one says \"Acokeratosis paraneoplastica (Bazex's syndrome)\" and the third mentions \"Bazex's syndrome.\" So, the synonym is consistently called Bazex syndrome across all three documents. The answer should be concise, so just \"Bazex syndrome\" with the citation from the first document. The confidence level is high because all sources agree on this synonym. So base_confidence would be 1.0. </think> { \"answer\": \"Bazex syndrome [8949310:", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "Bazex syndrome [8949310:8949310_0]", "base_prob": 1.0, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 1.0}, {"answer": "<think> Okay, let's tackle this question. The user is asking for a synonym of \"Acrokeratosis paraneoplastica.\" Looking at the evidence provided, there are three references. First, reference [8949310:8949310_0] mentions \"Bazex syndrome\" in relation to Acrokeratosis paraneoplastica. That seems like a direct synonym. Then, the second reference also uses \"Bazex's syndrome\" in the same context. The third reference again refers to it as Bazex's syndrome. So all three sources connect Acrokeratosis paraneoplastica with Bazex syndrome. I need to make sure that \"Bazex syndrome\" is indeed a synonym here. The term \"Bazex's syndrome\" is used in all three documents, so that's a strong indication. The answer should be concise, citing the first document since it's the earliest mention. The confidence level is high because all three sources agree on this synonym. So the answer is Bazex syndrome, with the citation from the first document. The base confidence would be 1.0 as there's consistent", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 1.0, "gold_docs": ["1433123", "1521479", "16435144", "17097409", "17374318", "18672707", "18775590", "22146896", "22252191", "22470801", "3819049", "6225397", "7640201", "7796616", "8949310"], "ideal_answer": "Acrokeratosis paraneoplastic (Bazex syndrome) is a rare, but distinctive paraneoplastic dermatosis characterized by erythematosquamous lesions located at the acral sites and is most commonly associated with carcinomas of the upper aerodigestive tract."}
{"question_id": "54d4e03a3706e89528000001", "question": "Which are the classes of anti-arrhythmic drugs according to Vaughan-Williams classification?", "retrieved_chunks": [{"doc_id": "9803978", "chunk_id": "9803978_0", "score": 9.344623565673828, "text": "Antiarrhythmic agents are traditionally classified according to Vaughan Williams into four classes of action. Class I antiarrhythmic agents include most of the drugs traditionally thought of as antiarrhythmics, and have as a common action, blockade of the fast-inward sodium channel on myocardium."}, {"doc_id": "11564050", "chunk_id": "11564050_0", "score": 9.344623565673828, "text": "Antiarrhythmic agents are traditionally classified according to Vaughan Williams into four classes of action. Class I antiarrhythmic agents include most of the drugs traditionally thought of as antiarrhythmics, and have as a common action, blockade of the fast-inward sodium channel on myocardium."}, {"doc_id": "10810787", "chunk_id": "10810787_1", "score": 9.307180404663086, "text": "Antiarrhythmic drugs can be divided into four Vaughan Williams classes (I-IV) according to defined electrophysiological effects on the myocardium."}], "context": "[9803978:9803978_0] Antiarrhythmic agents are traditionally classified according to Vaughan Williams into four classes of action. Class I antiarrhythmic agents include most of the drugs traditionally thought of as antiarrhythmics, and have as a common action, blockade of the fast-inward sodium channel on myocardium.\n[11564050:11564050_0] Antiarrhythmic agents are traditionally classified according to Vaughan Williams into four classes of action. Class I antiarrhythmic agents include most of the drugs traditionally thought of as antiarrhythmics, and have as a common action, blockade of the fast-inward sodium channel on myocardium.\n[10810787:10810787_1] Antiarrhythmic drugs can be divided into four Vaughan Williams classes (I-IV) according to defined electrophysiological effects on the myocardium.", "answer": "<think> Okay, so the user is asking about the classes of anti-arrhythmic drugs according to the Vaughan-Williams classification. Let me check the evidence provided. Looking at the evidence, there are three documents mentioned. The first two both say that antiarrhythmic agents are classified into four classes by Vaughan Williams, with Class I involving sodium channel blockade. The third document also mentions four classes (I-IV) based on electrophysiological effects. Wait, but the question is about the classes themselves. The answer needs to list the classes. However, the evidence doesn't explicitly name all four classes beyond Class I. The first two documents mention Class I, but don't go into Classes II, III, and IV. The third document just refers to them as I-IV without details. Hmm, so the user is asking for the classes, but the provided evidence only mentions that there are four classes (I-IV) and describes Class I. Since the answer needs to be based on the given evidence, maybe the answer should state that there are four classes (I-IV) as per Vaughan-Williams classification, even though the specific names of each class aren't", "citations": [], "candidates": [{"answer": "<think> Okay, so the user is asking about the classes of anti-arrhythmic drugs according to the Vaughan-Williams classification. Let me check the evidence provided. Looking at the evidence, there are three documents mentioned. The first two both say that antiarrhythmic agents are classified into four classes by Vaughan Williams, with Class I involving sodium channel blockade. The third document also mentions four classes (I-IV) based on electrophysiological effects. Wait, but the question is about the classes themselves. The answer needs to list the classes. However, the evidence doesn't explicitly name all four classes beyond Class I. The first two documents mention Class I, but don't go into Classes II, III, and IV. The third document just refers to them as I-IV without details. Hmm, so the user is asking for the classes, but the provided evidence only mentions that there are four classes (I-IV) and describes Class I. Since the answer needs to be based on the given evidence, maybe the answer should state that there are four classes (I-IV) as per Vaughan-Williams classification, even though the specific names of each class aren't", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the classes of anti-arrhythmic drugs according to the Vaughan-Williams classification. I need to generate a concise answer with citations and a confidence score. First, looking at the evidence provided. There are three documents mentioned. Documents 9803978 and 11564050 both mention four classes, with Class I agents blocking sodium channels. Document 10810787 also states four classes (I-IV) based on electrophysiological effects. So the answer should state that there are four classes (I-IV) as per Vaughan Williams. The first two documents mention Class I, but the third one refers to classes I-IV without specifying each class. However, the question is about the classes themselves, not the details of each. The key point is that there are four classes. The citations can be from any of the documents, but since multiple sources agree on the four classes, I can use one of them. The answer should be concise: \"Four classes (I-IV) according to Vaughan Williams classification [980", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the classes of anti-arrhythmic drugs according to the Vaughan-Williams classification. I need to generate a concise answer with citations and a confidence score. First, I'll check the evidence provided. There are three documents here. Documents 9803978 and 11564050 both mention four classes (Class I, II, III, IV), but they only detail Class I agents. The third document says they're divided into four Vaughan Williams classes (I-IV) based on electrophysiological effects. However, the first two documents don't mention Classes II, III, and IV specifically. Wait, the user is asking for all the classes. But the evidence here only explicitly mentions Class I. The third document says four classes but doesn't list them. So maybe the answer should state that there are four classes (I-IV) as per Vaughan-Williams, even though the evidence doesn't detail each class beyond Class I. But the user might expect the answer to mention all four classes. However, the provided evidence only talks about Class I in", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["10810787", "11564050", "1290288", "7875632", "9803978"], "ideal_answer": "Antiarrhythmic drugs can be divided into four Vaughan Williams classes (I-IV). Class I antiarrhythmic agents have as a common action, blockade of the sodium channels. Class II agents are antisympathetic drugs, particularly the beta-adrenoceptor blockers. Class-III antiarrhythmics have as a common action the potassium-channel blockade. Class IV antiarrhythmic drugs are calcium channel blockers."}
{"question_id": "55072c803b8a5dc045000001", "question": "Which are the different isoforms of the mammalian Notch receptor?", "retrieved_chunks": [{"doc_id": "22842086", "chunk_id": "22842086_0", "score": 3.7455735206604004, "text": "There are four different mammalian Notch receptors that can be activated by five cell surface ligands"}, {"doc_id": "11532344", "chunk_id": "11532344_0", "score": 3.0279664993286133, "text": "There are four mammalian Notch receptors that have only partially overlapping functions despite sharing similar structures and ligands."}, {"doc_id": "23028706", "chunk_id": "23028706_0", "score": 2.4647395610809326, "text": "Here, we investigate protein interactions between NOTCH3 and other vascular Notch isoforms and characterize the effects of elevated NOTCH3 on smooth muscle gene regulation. We demonstrate that NOTCH3 forms heterodimers with NOTCH1, NOTCH3, and NOTCH4."}], "context": "[22842086:22842086_0] There are four different mammalian Notch receptors that can be activated by five cell surface ligands\n[11532344:11532344_0] There are four mammalian Notch receptors that have only partially overlapping functions despite sharing similar structures and ligands.\n[23028706:23028706_0] Here, we investigate protein interactions between NOTCH3 and other vascular Notch isoforms and characterize the effects of elevated NOTCH3 on smooth muscle gene regulation. We demonstrate that NOTCH3 forms heterodimers with NOTCH1, NOTCH3, and NOTCH4.", "answer": "<think> Okay, let's tackle this question. The user is asking about the different isoforms of the mammalian Notch receptor. First, I need to look at the evidence provided. Looking at the first evidence snippet [22842086:22842086_0], it mentions four different mammalian Notch receptors that can be activated by five ligands. So that's a key point. Then the second snippet [11532344:11532344_0] also states there are four Notch receptors with partially overlapping functions. The third one [23028706:23028706_0] talks about NOTCH3 interacting with other isoforms like NOTCH1, NOTCH3, and NOTCH4. Wait, that seems a bit confusing because it lists NOTCH3 forming heterodimers with itself and others. Hmm, but the question is about isoforms, not just the number of receptors. The first two snippets mention four receptors, but the third one refers to Notch3 interacting with other isoforms. However", "citations": [{"doc_id": "22842086", "chunk_id": "22842086_0"}, {"doc_id": "11532344", "chunk_id": "11532344_0"}, {"doc_id": "23028706", "chunk_id": "23028706_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking about the different isoforms of the mammalian Notch receptor. First, I need to look at the evidence provided. Looking at the first evidence snippet [22842086:22842086_0], it mentions four different mammalian Notch receptors that can be activated by five ligands. So that's a key point. Then the second snippet [11532344:11532344_0] also states there are four Notch receptors with partially overlapping functions. The third one [23028706:23028706_0] talks about NOTCH3 interacting with other isoforms like NOTCH1, NOTCH3, and NOTCH4. Wait, that seems a bit confusing because it lists NOTCH3 forming heterodimers with itself and others. Hmm, but the question is about isoforms, not just the number of receptors. The first two snippets mention four receptors, but the third one refers to Notch3 interacting with other isoforms. However", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question about the different isoforms of the mammalian Notch receptor. The user provided three evidence snippets, so I need to parse those carefully. First, looking at the evidence: 1. [22842086:22842086_0] says there are four different mammalian Notch receptors activated by five ligands. But wait, the question is about isoforms, not just the number of receptors. However, this might be a starting point. 2. [11532344:11532344_0] mentions four Notch receptors with partially overlapping functions. Again, this talks about four receptors but doesn't specify isoforms. But maybe \"isoforms\" here refer to the different receptors? 3. [23028706:23028706_0] discusses NOTCH3 interacting with NOTCH1, NOTCH3, and NOTCH4. This suggests that there are at least four isoforms: NOTCH1, NOTCH2, NOTCH3, NOTCH4. Wait", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question about the different isoforms of the mammalian Notch receptor. The user provided three evidence snippets, so I need to parse those carefully. First, looking at the evidence: 1. [22842086:22842086_0] says there are four different mammalian Notch receptors activated by five ligands. Wait, the question is about isoforms, not the number of receptors. But maybe this is referring to the same thing? Or perhaps the four receptors are the isoforms? But then [11532344:11532344_0] states there are four Notch receptors with partially overlapping functions. So that's consistent with the first snippet. The third evidence [23028706:23028706_0] talks about NOTCH3 forming heterodimers with NOTCH1, NOTCH3, and NOTCH4. Wait, that seems a bit confusing. If NOTCH3 is part of the heterodimers, maybe this indicates different isoforms? But the snippet", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["11532344", "11732008", "16307184", "21356309", "21639801", "22842086", "23028706"], "ideal_answer": "Notch signaling is an evolutionarily conserved mechanism, used to regulate cell fate decisions. Four Notch receptors have been identified in man: Notch-1, Notch-2, Notch-3 and Notch-4."}
{"question_id": "53061af558348c0f52000002", "question": "Which are the major characteristics of cellular senescence?", "retrieved_chunks": [{"doc_id": "18976161", "chunk_id": "18976161_0", "score": 7.492673873901367, "text": "Cellular senescence is recognized as a critical cellular response to prolonged rounds of replication and environmental stresses. Its defining characteristics are arrested cell-cycle progression and the development of aberrant gene expression with proinflammatory behavior."}, {"doc_id": "23422284", "chunk_id": "23422284_0", "score": 2.602902412414551, "text": "utophagy and senescence share a number of characteristics, which suggests that both responses could serve to collaterally protect the cell from the toxicity of external stress such as radiation and chemotherapy and internal forms of stress such as telomere shortening and oncogene activation"}, {"doc_id": "17664422", "chunk_id": "17664422_0", "score": 2.471251964569092, "text": "Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation"}], "context": "[18976161:18976161_0] Cellular senescence is recognized as a critical cellular response to prolonged rounds of replication and environmental stresses. Its defining characteristics are arrested cell-cycle progression and the development of aberrant gene expression with proinflammatory behavior.\n[23422284:23422284_0] utophagy and senescence share a number of characteristics, which suggests that both responses could serve to collaterally protect the cell from the toxicity of external stress such as radiation and chemotherapy and internal forms of stress such as telomere shortening and oncogene activation\n[17664422:17664422_0] Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation", "answer": "<think> Okay, let's tackle this question. The user wants the major characteristics of cellular senescence based on the provided evidence. First, I need to look at the evidence given. The first document says that cellular senescence is a response to replication and stress, with arrested cell-cycle progression and aberrant gene expression leading to proinflammatory behavior. That seems like a key point. The second document mentions autophagy and senescence sharing characteristics, but that's more about their shared functions rather than the defining features of senescence itself. The third document talks about tumor regression when c-Myc is inactivated, which is a consequence rather than a characteristic. So the main answer should focus on the first document's points: arrested cell-cycle progression and proinflammatory gene expression. Those are the defining characteristics. The confidence here is high because that's directly stated. The other documents don't provide more relevant info for the question. Need to make sure the answer is concise and cites the correct chunk. Base confidence would be 1.0 since the evidence clearly states those points. </think> { \"answer\": \"Arrested cell-c", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user wants the major characteristics of cellular senescence based on the provided evidence. First, I need to look at the evidence given. The first document says that cellular senescence is a response to replication and stress, with arrested cell-cycle progression and aberrant gene expression leading to proinflammatory behavior. That seems like a key point. The second document mentions autophagy and senescence sharing characteristics, but that's more about their shared functions rather than the defining features of senescence itself. The third document talks about tumor regression when c-Myc is inactivated, which is a consequence rather than a characteristic. So the main answer should focus on the first document's points: arrested cell-cycle progression and proinflammatory gene expression. Those are the defining characteristics. The confidence here is high because that's directly stated. The other documents don't provide more relevant info for the question. Need to make sure the answer is concise and cites the correct chunk. Base confidence would be 1.0 since the evidence clearly states those points. </think> { \"answer\": \"Arrested cell-c", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to generate a candidate biomedical answer based on the given evidence. The question is about the major characteristics of cellular senescence. First, let me look at the evidence provided. The first document says that cellular senescence is a response to replication and stress, with arrested cell-cycle progression and aberrant gene expression leading to proinflammatory behavior. That seems like key points. The second document mentions that autophagy and senescence share characteristics, both protecting cells from stress, but that might not be a major characteristic of senescence itself. The third document talks about tumor regression when c-Myc is inactivated, which is more about the role in cancer rather than characteristics. So the main characteristics should be from the first evidence: arrested cell-cycle progression and proinflammatory gene expression. The second part about autophagy might not be a primary characteristic but a related process. The third point is about tumor regression, which is an effect rather than a characteristic. I need to make sure the answer is concise and cites the correct document. The first evidence is from 18976161:18976161_", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user wants the major characteristics of cellular senescence based on the provided evidence. First, I need to look at the evidence given. There are three documents here. Let me go through each one. The first document says that cellular senescence is a response to replication and stress, with defining features being arrested cell-cycle progression and aberrant gene expression leading to proinflammatory behavior. That seems like a key point. The second document talks about autophagy and senescence sharing characteristics, but the question is about senescence itself, so maybe that's not directly relevant. The third document mentions tumor regression upon c-Myc inactivation, which is more about the role in tumors rather than characteristics. So the main characteristics from the first document are arrested cell-cycle progression and proinflammatory gene expression. The second document might mention some shared traits with autophagy, but since the question is about senescence's own features, I should focus on the first document. The third document isn't about characteristics but about a function in tumors. Therefore, the answer should be the t", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["18976161", "8824885", "9624027"], "ideal_answer": "The defining characteristics of cellular senescence are altered morphology, arrested cell-cycle progression, development of aberrant gene expression with proinflammatory behavior, and telomere shortening."}
{"question_id": "56c1f01def6e394741000045", "question": "Orteronel was developed for treatment of which cancer?", "retrieved_chunks": [{"doc_id": "25264242", "chunk_id": "25264242_1", "score": 7.942438125610352, "text": "Orteronel is a nonsteroidal, selective inhibitor of 17,20-lyase that was recently in phase 3 clinical development as a treatment for castration-resistant prostate cancer."}, {"doc_id": "24799061", "chunk_id": "24799061_2", "score": 7.376224517822266, "text": "Orteronel for the treatment of prostate cancer."}, {"doc_id": "21978946", "chunk_id": "21978946_0", "score": 7.288248538970947, "text": "Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer."}], "context": "[25264242:25264242_1] Orteronel is a nonsteroidal, selective inhibitor of 17,20-lyase that was recently in phase 3 clinical development as a treatment for castration-resistant prostate cancer.\n[24799061:24799061_2] Orteronel for the treatment of prostate cancer.\n[21978946:21978946_0] Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer.", "answer": "<think> Okay, let's tackle this question. The user is asking which cancer Orteronel was developed for treatment. The evidence provided has three chunks. First chunk (25264242:25264242_1) says it's a inhibitor of 17,20-lyase for castration-resistant prostate cancer. Second chunk (24799061:24799061_2) directly mentions prostate cancer. Third chunk (21978946:21978946_0) talks about potential utility in prostate cancer treatment. So, the answer should be prostate cancer. The first chunk specifies castration-resistant prostate cancer, but the other chunks just say prostate cancer. The question is about which cancer it's developed for, so the most specific and direct mention is from the second chunk. However, the first chunk also mentions castration-resistant, which is a type of prostate cancer. But the answer should be concise. The second chunk says \"prostate cancer\" without qualifiers, so that's the primary answer. The confidence can be high", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which cancer Orteronel was developed for treatment. The evidence provided has three chunks. First chunk (25264242:25264242_1) says it's a inhibitor of 17,20-lyase for castration-resistant prostate cancer. Second chunk (24799061:24799061_2) directly mentions prostate cancer. Third chunk (21978946:21978946_0) talks about potential utility in prostate cancer treatment. So, the answer should be prostate cancer. The first chunk specifies castration-resistant prostate cancer, but the other chunks just say prostate cancer. The question is about which cancer it's developed for, so the most specific and direct mention is from the second chunk. However, the first chunk also mentions castration-resistant, which is a type of prostate cancer. But the answer should be concise. The second chunk says \"prostate cancer\" without qualifiers, so that's the primary answer. The confidence can be high", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which cancer Orteronel was developed for treatment. The evidence provided has three chunks. First chunk (25264242:25264242_1) says it's a selective inhibitor of 17,20-lyase for castration-resistant prostate cancer. Second chunk (24799061:24799061_2) mentions Orteronel for prostate cancer. Third chunk (21978946:21978946_0) talks about discovering it as a 17,20-lyase inhibitor with potential in prostate cancer. So the answer should be prostate cancer. The first chunk specifically mentions castration-resistant prostate cancer, which is a type of prostate cancer. The other chunks also point to prostate cancer. The confidence can be high since multiple sources mention prostate cancer. But one source specifies \"castration-resistant,\" but the question just asks for the cancer type. So the answer is prostate cancer. The base confidence would be 1.0 because", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which cancer Orteronel was developed for treatment. The evidence provided has three chunks. First chunk (25264242:25264242_1) says it's a inhibitor of 17,20-lyase for castration-resistant prostate cancer. Second chunk (24799061:24799061_2) mentions Orteronel for prostate cancer. Third chunk (21978946:21978946_0) talks about discovering it as a 17,20-lyase inhibitor with potential in prostate cancer. So the answer should be prostate cancer. The first chunk specifically mentions castration-resistant prostate cancer, but the others are more general. However, the question is about the cancer type, so prostate cancer is the main answer. The confidence would be high since multiple sources mention prostate cancer. But the first chunk adds \"castration-resistant,\" which is a specific type. However, the question doesn't specify if it's castration-resistant", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["21978946", "24100689", "24418642", "24799061", "25264242", "25537627", "25624429", "25701170", "26150028"], "ideal_answer": "Orteronel was developed for treatment of castration-resistant prostate cancer."}
{"question_id": "5313b049e3eabad021000013", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "retrieved_chunks": [{"doc_id": "12422054", "chunk_id": "12422054_0", "score": 6.673473834991455, "text": "Herceptin (trastuzumab), an anti-HER2 monoclonal antibody, is the first oncogene-targeted therapy to be developed for the treatment of metastatic breast cancer."}, {"doc_id": "19593441", "chunk_id": "19593441_1", "score": 6.55655574798584, "text": "Herceptin (trastuzumab) is a humanized monoclonal antibody that is approved for the treatment of metastatic breast cancer patients whose tumors overexpress Her2 (erbB2/neu)."}, {"doc_id": "25377592", "chunk_id": "25377592_0", "score": 6.241744041442871, "text": "BACKGROUND Trastuzumab (Herceptin(®)) is a humanized monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2) and is used in the treatment of HER2-overexpressing breast and gastric cancer."}], "context": "[12422054:12422054_0] Herceptin (trastuzumab), an anti-HER2 monoclonal antibody, is the first oncogene-targeted therapy to be developed for the treatment of metastatic breast cancer.\n[19593441:19593441_1] Herceptin (trastuzumab) is a humanized monoclonal antibody that is approved for the treatment of metastatic breast cancer patients whose tumors overexpress Her2 (erbB2/neu).\n[25377592:25377592_0] BACKGROUND Trastuzumab (Herceptin(®)) is a humanized monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2) and is used in the treatment of HER2-overexpressing breast and gastric cancer.", "answer": "<think> Okay, let's tackle this question. The user is asking if Trastuzumab (Herceptin) has potential use in treating prostate cancer. The evidence provided mentions that Herceptin is used for metastatic breast cancer and HER2-overexpressing breast and gastric cancers. First, I need to check if there's any mention of prostate cancer in the evidence. Looking at the three documents: 1. Document 12422054 talks about metastatic breast cancer. 2. Document 19593441 also mentions metastatic breast cancer and Her2 overexpression. 3. Document 25377592 refers to breast and gastric cancers, not prostate. None of the evidence directly states that Trastuzumab is used for prostate cancer. The documents all focus on breast and gastric cancers. Since the question is about prostate cancer, and there's no evidence supporting its use there, the answer should be no. The confidence level would be low because the evidence doesn't mention prostate cancer at all. The model can't infer anything beyond what's stated. So base_confidence might be 0.", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if Trastuzumab (Herceptin) has potential use in treating prostate cancer. The evidence provided mentions that Herceptin is used for metastatic breast cancer and HER2-overexpressing breast and gastric cancers. First, I need to check if there's any mention of prostate cancer in the evidence. Looking at the three documents: 1. Document 12422054 talks about metastatic breast cancer. 2. Document 19593441 also mentions metastatic breast cancer and Her2 overexpression. 3. Document 25377592 refers to breast and gastric cancers, not prostate. None of the evidence directly states that Trastuzumab is used for prostate cancer. The documents all focus on breast and gastric cancers. Since the question is about prostate cancer, and there's no evidence supporting its use there, the answer should be no. The confidence level would be low because the evidence doesn't mention prostate cancer at all. The model can't infer anything beyond what's stated. So base_confidence might be 0.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if Trastuzumab (Herceptin) is potentially useful in treating prostate cancer. The evidence provided mentions that Herceptin is used for breast and gastric cancers, specifically those overexpressing HER2. First, I need to check if there's any mention of prostate cancer in the evidence. Looking at the three references: all of them talk about breast cancer and gastric cancer. There's no reference to prostate cancer here. The answer should be based on the given evidence. Since the evidence doesn't mention prostate cancer, the correct approach is to state that there's no evidence supporting its use for prostate cancer. The confidence level would be low because the information provided doesn't address prostate cancer at all. So the answer would be no, and the confidence might be 0.2 or something like that. But wait, maybe the model is confident in the absence of evidence? Hmm, but the user wants a factual answer based on the given evidence. Since the evidence only mentions breast and gastric cancers, the answer should reflect that there's no mention of prostate cancer. Therefore, the answer is no, and the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if Trastuzumab (Herceptin) is potentially useful in treating prostate cancer. The evidence provided mentions that Herceptin is used for breast and gastric cancers, specifically targeting HER2. First, I need to check if there's any mention of prostate cancer in the evidence. Looking at the three references: all of them talk about breast cancer and gastric cancer. There's no reference to prostate cancer here. So, the answer would be that based on the given evidence, there's no indication that Herceptin is used for prostate cancer. The confidence level would be low because the evidence doesn't address prostate cancer at all. The model can't infer anything beyond what's provided. Therefore, the answer should state that the evidence doesn't support its use in prostate cancer, with a confidence of 0.2 or something similar, since there's no direct information. </think> { \"answer\": \"No, Trastuzumab (Herceptin) is not indicated for prostate cancer treatment based on the provided evidence. The evidence supports its use in metastatic breast cancer and HER2-overexpress", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["10473102", "10519379", "11236029", "11331475", "11502465", "11685722", "11685733", "11786427", "11920466", "12173324", "12677892", "15036648", "15046685", "15139054", "15264245", "15571968", "15919200", "16163160", "17142577", "17210707", "17211467", "18038879", "18071949", "19373278", "20716957", "21254978", "21326934", "21364123", "21844010", "22137850", "22322558", "22505344", "22977535", "23255921", "23294030"], "ideal_answer": "Although is still controversial, Trastuzumab (Herceptin) can be of potential use in the treatment of prostate cancer overexpressing HER2, either alone or in combination with other drugs."}
{"question_id": "53137541e3eabad021000010", "question": "Which are the Yamanaka factors?", "retrieved_chunks": [{"doc_id": "21761058", "chunk_id": "21761058_1", "score": 8.523773193359375, "text": "Yamanaka factors, namely Sox2, Oct3/4 (Pou5f1), Klf4, and c-Myc"}, {"doc_id": "22357549", "chunk_id": "22357549_0", "score": 8.07437801361084, "text": "Yamanaka factors (Pou5f1, Myc, Klf4, and Sox2)"}, {"doc_id": "21761058", "chunk_id": "21761058_0", "score": 7.866320610046387, "text": "These protein sets have been called the Yamanaka factors, namely Sox2, Oct3/4 (Pou5f1), Klf4, and c-Myc, and the Thomson factors, namely Sox2, Oct3, Lin28, and Nanog"}], "context": "[21761058:21761058_1] Yamanaka factors, namely Sox2, Oct3/4 (Pou5f1), Klf4, and c-Myc\n[22357549:22357549_0] Yamanaka factors (Pou5f1, Myc, Klf4, and Sox2)\n[21761058:21761058_0] These protein sets have been called the Yamanaka factors, namely Sox2, Oct3/4 (Pou5f1), Klf4, and c-Myc, and the Thomson factors, namely Sox2, Oct3, Lin28, and Nanog", "answer": "<think> Okay, let's tackle this question. The user is asking about the Yamanaka factors. From the evidence provided, there are a few documents mentioning this. First, document [21761058:21761058_1] lists Sox2, Oct3/4 (Pou5f1), Klf4, and c-Myc as the Yamanaka factors. Then, document [22357549:22357549_0] also mentions Pou5f1, Myc, Klf4, and Sox2. Wait, that's the same set but with different names for Oct3/4 (Pou5f1 vs Pou5f1). Also, document [21761058:21761058_0] refers to the same factors again, adding that they're also called Thomson factors. So, the main point is that the Yamanaka factors are Sox2, Oct3/4 (which is Pou5f1), Klf4, and c-Myc. The other document", "citations": [{"doc_id": "21761058", "chunk_id": "21761058_1"}, {"doc_id": "22357549", "chunk_id": "22357549_0"}, {"doc_id": "21761058", "chunk_id": "21761058_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking about the Yamanaka factors. From the evidence provided, there are a few documents mentioning this. First, document [21761058:21761058_1] lists Sox2, Oct3/4 (Pou5f1), Klf4, and c-Myc as the Yamanaka factors. Then, document [22357549:22357549_0] also mentions Pou5f1, Myc, Klf4, and Sox2. Wait, that's the same set but with different names for Oct3/4 (Pou5f1 vs Pou5f1). Also, document [21761058:21761058_0] refers to the same factors again, adding that they're also called Thomson factors. So, the main point is that the Yamanaka factors are Sox2, Oct3/4 (which is Pou5f1), Klf4, and c-Myc. The other document", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the Yamanaka factors. From the evidence provided, there are a few documents mentioning this. First, document [21761058:21761058_1] lists Sox2, Oct3/4 (Pou5f1), Klf4, and c-Myc as the Yamanaka factors. Another document [22357549:22357549_0] also mentions Pou5f1, Myc, Klf4, and Sox2. Wait, that's the same set but with different names for Oct3/4 (Pou5f1 vs Pou5f1). Then there's another entry [21761058:2176105.58_0] which again lists the same factors but also mentions Thomson factors. So, looking at all the evidence, the main components are Sox2, Pou5f1 (which is Oct3/4), Klf4, and c-Myc. The second document uses \"", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, so the user is asking about the Yamanaka factors. Let me look at the evidence provided. First, there's a document [21761058:21761058_1] that lists Sox2, Oct3/4 (Pou5f1), Klf4, and c-Myc as the Yamanaka factors. Another one [22357549:22357549_0] mentions Pou5f1, Myc, Klf4, and Sox2. Wait, that's the same set but with different names for Oct3/4 (Pou5f1 vs Pou5f1). Then there's [21761058:21761058_0] which also lists the same factors, adding that they're called Thomson factors too. So all the documents agree on the four factors: Sox2, Oct3/4 (which is Pou5f1), Klf4, and c-Myc. The second document uses \"Myc\" instead of \"c-Myc", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["19030024", "20144262", "21249204", "21640101", "21761058", "21839145", "22075965", "22357549", "22449255", "23166588", "23527808", "23612755", "23658991", "23704989", "23939864", "24150221"], "ideal_answer": "The Yamanaka factors are the OCT4, SOX2, MYC, and KLF4 transcription factors"}
{"question_id": "515aa0abd24251bc050000a8", "question": "What is the aim of the Human Chromosome-centric Proteome Project (C-HPP)?", "retrieved_chunks": [{"doc_id": "22443261", "chunk_id": "22443261_0", "score": 10.71954345703125, "text": "The objective of the international Chromosome-Centric Human Proteome Project (C-HPP) is to map and annotate all proteins encoded by the genes on each human chromosome. The C-HPP consortium was established to organize a collaborative network among the research teams responsible for protein mapping of individual chromosomes and to identify compelling biological and genetic mechanisms influencing colocated genes and their protein products. The C-HPP aims to foster the development of proteome analysis and integration of the findings from related molecular -omics technology platforms through collaborations among universities, industries, and private research groups."}, {"doc_id": "23253012", "chunk_id": "23253012_0", "score": 10.111676216125488, "text": "The Chromosome-centric Human Proteome Project (C-HPP) aims to systematically map the entire human proteome with the intent to enhance our understanding of human biology at the cellular level."}, {"doc_id": "23153008", "chunk_id": "23153008_1", "score": 9.85740852355957, "text": "The Chromosome-centric Human Proteome Project (C-HPP) aims to define all proteins encoded in each chromosome and especially to identify proteins that currently lack evidence by mass spectrometry."}], "context": "[22443261:22443261_0] The objective of the international Chromosome-Centric Human Proteome Project (C-HPP) is to map and annotate all proteins encoded by the genes on each human chromosome. The C-HPP consortium was established to organize a collaborative network among the research teams responsible for protein mapping of individual chromosomes and to identify compelling biological and genetic mechanisms influencing colocated genes and their protein products. The C-HPP aims to foster the development of proteome analysis and integration of the findings from related molecular -omics technology platforms through collaborations among universities, industries, and private research groups.\n[23253012:23253012_0] The Chromosome-centric Human Proteome Project (C-HPP) aims to systematically map the entire human proteome with the intent to enhance our understanding of human biology at the cellular level.\n[23153008:23153008_1] The Chromosome-centric Human Proteome Project (C-HPP) aims to define all proteins encoded in each chromosome and especially to identify proteins that currently lack evidence by mass spectrometry.", "answer": "<think> Okay, let's tackle this query. The user is asking about the aim of the Human Chromosome-centric Proteome Project (C-HPP). I need to generate a concise answer from the provided evidence and return it in strict JSON format. First, I'll look at the evidence documents. Document 22443261:22443261_0 mentions that the C-HPP's objective is to map and annotate all proteins encoded by genes on each human chromosome. It also talks about identifying biological mechanisms influencing colocated genes and fostering collaborations. Then, document 23253012:23253012_0 states the aim is to systematically map the entire proteome to enhance understanding of human biology at the cellular level. The third document, 23153008:23153008_1, says the project aims to define all proteins in each chromosome and identify those lacking evidence via mass spectrometry. I need to combine these points into a single answer. The main goals seem to be mapping proteins on each chromosome, annotating them, and", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this query. The user is asking about the aim of the Human Chromosome-centric Proteome Project (C-HPP). I need to generate a concise answer from the provided evidence and return it in strict JSON format. First, I'll look at the evidence documents. Document 22443261:22443261_0 mentions that the C-HPP's objective is to map and annotate all proteins encoded by genes on each human chromosome. It also talks about identifying biological mechanisms influencing colocated genes and fostering collaborations. Then, document 23253012:23253012_0 states the aim is to systematically map the entire proteome to enhance understanding of human biology at the cellular level. The third document, 23153008:23153008_1, says the project aims to define all proteins in each chromosome and identify those lacking evidence via mass spectrometry. I need to combine these points into a single answer. The main goals seem to be mapping proteins on each chromosome, annotating them, and", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to generate a candidate biomedical answer based on the provided evidence. Let me start by understanding the question: What is the aim of the Human Chromosome-centric Proteome Project (C-HPP)? Looking at the evidence, there are three documents. The first one says the C-HPP's objective is to map and annotate all proteins encoded by genes on each human chromosome. It also mentions organizing a collaborative network and identifying biological mechanisms influencing colocated genes. Additionally, it talks about fostering proteome analysis and collaborations. The second document states that the aim is to systematically map the entire human proteome to enhance understanding of human biology at the cellular level. The third one says the goal is to define all proteins in each chromosome, especially those lacking evidence from mass spectrometry. I need to combine these points into a concise answer with citations. The main aims seem to be mapping proteins on each chromosome, annotating them, and identifying proteins that are not yet evidenced. Also, enhancing understanding of human biology and collaboration among different groups. The confidence level should be high since", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. Let me start by understanding the question: What is the aim of the Human Chromosome-centric Proteome Project (C-HPP)? Looking at the evidence provided, there are three documents. The first one says the objective is to map and annotate all proteins encoded by genes on each human chromosome. It also mentions organizing a collaborative network and identifying biological mechanisms affecting colocated genes. The second document states the aim is to systematically map the entire human proteome to enhance understanding of human biology at the cellular level. The third document adds that it aims to define all proteins in each chromosome, especially those lacking evidence from mass spectrometry. I need to combine these points into a concise answer with citations. The main aims seem to be mapping proteins on each chromosome, annotating them, and enhancing understanding of human biology. Also, identifying proteins without evidence is part of it. The answer should mention mapping and annotating proteins, the collaboration aspect, and the goal of enhancing cellular-level understanding. The confidence level: all three d", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["21742803", "22443261", "22966780", "23153008", "23205526", "23214983", "23227862", "23234512", "23249167", "23252913", "23253012", "23259496", "23276153", "23308364", "23312004"], "ideal_answer": "The chromosome-centric human proteome project aims to systematically map all human proteins, chromosome by chromosome, in a gene-centric manner through dedicated efforts from national and international teams The Chromosome-Centric Human Proteome Project (C-HPP) is an international effort for creating an annotated proteomic catalog for each chromosome. (PMID: 23312004) The chromosome-centric human proteome project aims to systematically map all human proteins, chromosome by chromosome, in a gene-centric manner through dedicated efforts from national and international teams. (PMID: 23308364) The Chromosome-centric Human Proteome Project (C-HPP) aims to systematically map the entire human proteome with the intent to enhance our understanding of human biology at the cellular level. (PMID: 23253012)"}
{"question_id": "56af9f130a360a5e45000015", "question": "Where is the protein Pannexin1 located?", "retrieved_chunks": [{"doc_id": "24194896", "chunk_id": "24194896_0", "score": 4.8776750564575195, "text": "In mammals, a single pannexin1 gene (Panx1) is widely expressed in the CNS including the inner and outer retinae, forming large-pore voltage-gated membrane channels, which are involved in calcium and ATP signaling."}, {"doc_id": "17064878", "chunk_id": "17064878_0", "score": 4.2120819091796875, "text": "pannexin1, a vertebrate homolog of invertebrate gap junction proteins."}, {"doc_id": "25007779", "chunk_id": "25007779_1", "score": 2.516667127609253, "text": "Pannexin1 (Panx1) is a newly discovered extracellular ATP release channel with a wide tissue distribution and diverse biological functions in mammals."}], "context": "[24194896:24194896_0] In mammals, a single pannexin1 gene (Panx1) is widely expressed in the CNS including the inner and outer retinae, forming large-pore voltage-gated membrane channels, which are involved in calcium and ATP signaling.\n[17064878:17064878_0] pannexin1, a vertebrate homolog of invertebrate gap junction proteins.\n[25007779:25007779_1] Pannexin1 (Panx1) is a newly discovered extracellular ATP release channel with a wide tissue distribution and diverse biological functions in mammals.", "answer": "<think> Okay, let's tackle this question. The user is asking where the protein Pannexin1 is located. The evidence provided has three documents. First, looking at document [24194896:24194896_0], it says that Panx1 is widely expressed in the CNS, including inner and outer retinae. That's a specific location. Then, document [25007779:25007779_1] mentions a wide tissue distribution, so it's not just the CNS. The third document [17064878:17064878_0] is about the vertebrate homolog, but doesn't specify location. So the answer needs to combine the CNS and retinae from the first document with the wide tissue distribution from the third. But the question is about where it's located. The first evidence is more specific, mentioning CNS and retinae. The other documents support that it's widespread. However, the user wants a concise answer with citations. So the main locations are CNS, inner and outer retinae", "citations": [{"doc_id": "24194896", "chunk_id": "24194896_0"}, {"doc_id": "25007779", "chunk_id": "25007779_1"}, {"doc_id": "17064878", "chunk_id": "17064878_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking where the protein Pannexin1 is located. The evidence provided has three documents. First, looking at document [24194896:24194896_0], it says that Panx1 is widely expressed in the CNS, including inner and outer retinae. That's a specific location. Then, document [25007779:25007779_1] mentions a wide tissue distribution, so it's not just the CNS. The third document [17064878:17064878_0] is about the vertebrate homolog, but doesn't specify location. So the answer needs to combine the CNS and retinae from the first document with the wide tissue distribution from the third. But the question is about where it's located. The first evidence is more specific, mentioning CNS and retinae. The other documents support that it's widespread. However, the user wants a concise answer with citations. So the main locations are CNS, inner and outer retinae", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, the user is asking where the protein Pannexin1 is located. Let me look at the evidence provided. First, document [24194896:24194896_0] says that Panx1 is widely expressed in the CNS, including inner and outer retinae. That's a specific location. Then, [25007779:25007779_1] mentions it's found in various tissues, but doesn't specify locations. The other document is more about its function as an ATP release channel. So the most specific answer comes from the first evidence. It mentions CNS and retinae. I need to make sure that's the primary location. The confidence here would be high because it's directly stated. The other documents don't provide more precise locations, so the answer should focus on the CNS and retinae. Let me structure the JSON with that info and a confidence level. Since the first source is explicit, I'll set base_confidence to 0.95 or something like that. </think> { \"answer\": \"Pannexin", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question about where the protein Pannexin1 is located. The user wants a concise answer with citations and a confidence score. First, I need to look at the evidence provided. There are three references here. Let me go through each one. The first evidence [24194896:24194896_0] says that Panx1 is widely expressed in the CNS, including the inner and outer retinae. So that's a specific location: central nervous system and retinae. The second reference [17064878:1706487质] mentions that Pannexin1 is a vertebrate homolog of gap junction proteins. But this doesn't specify location, just its classification. So maybe not directly relevant to the question. Third evidence [25007779:25007779_1] states that Panx1 has a wide tissue distribution and diverse functions. So it's present in many tissues, but the first reference gives more specific locations. The answer needs to be concise. The", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["17064878", "19409451", "24194896", "24642372", "24694658", "24782784", "25007779", "25056878", "25698922", "26100513"], "ideal_answer": "The protein Pannexin1 is localized to the plasma membranes."}
{"question_id": "5718bbb37de986d80d00000b", "question": "Which currently known mitochondrial diseases have been attributed to POLG mutations?", "retrieved_chunks": [{"doc_id": "20927567", "chunk_id": "20927567_0", "score": 7.503829002380371, "text": "About 150 mutations in the human POLG have been identified in patients with mitochondrial diseases such as Alpers syndrome, progressive external ophthalmoplegia, and ataxia-neuropathy syndromes."}, {"doc_id": "15351195", "chunk_id": "15351195_0", "score": 6.311924934387207, "text": "Mutations in the gene encoding mitochondrial DNA polymerase gamma (POLG), the enzyme that synthesises mitochondrial DNA (mtDNA), have been associated with a mitochondrial disease-autosomal dominant or recessive progressive external ophthalmoplegia-and multiple deletions of mtDNA."}, {"doc_id": "18546365", "chunk_id": "18546365_0", "score": 5.579039096832275, "text": "Mutations in the POLG gene have emerged as one of the most common causes of inherited mitochondrial disease in children and adults. They are responsible for a heterogeneous group of at least 6 major phenotypes of neurodegenerative disease that include: 1) childhood Myocerebrohepatopathy Spectrum disorders (MCHS), 2) Alpers syndrome, 3) Ataxia Neuropathy Spectrum (ANS) disorders, 4) Myoclonus Epilepsy Myopathy Sensory Ataxia (MEMSA), 5) autosomal recessive Progressive External Ophthalmoplegia (arPEO), and 6) autosomal dominant Progressive External Ophthalmoplegia (adPEO)"}], "context": "[20927567:20927567_0] About 150 mutations in the human POLG have been identified in patients with mitochondrial diseases such as Alpers syndrome, progressive external ophthalmoplegia, and ataxia-neuropathy syndromes.\n[15351195:15351195_0] Mutations in the gene encoding mitochondrial DNA polymerase gamma (POLG), the enzyme that synthesises mitochondrial DNA (mtDNA), have been associated with a mitochondrial disease-autosomal dominant or recessive progressive external ophthalmoplegia-and multiple deletions of mtDNA.\n[18546365:18546365_0] Mutations in the POLG gene have emerged as one of the most common causes of inherited mitochondrial disease in children and adults. They are responsible for a heterogeneous group of at least 6 major phenotypes of neurodegenerative disease that include: 1) childhood Myocerebrohepatopathy Spectrum disorders (MCHS), 2) Alpers syndrome, 3) Ataxia Neuropathy Spectrum (ANS) disorders, 4) Myoclonus Epilepsy Myopathy Sensory Ataxia (MEMSA), 5) autosomal recessive Progressive External Ophthalmoplegia (arPEO), and 6) autosomal dominant Progressive External Ophthalmoplegia (adPEO)", "answer": "<think> Okay, let's tackle this question. The user is asking which known mitochondrial diseases are associated with POLG mutations. First, I need to look at the evidence provided. There are three documents here. Let me go through each one. Document 20927567 mentions that about 150 mutations in POLG are linked to diseases like Alpers syndrome, progressive external ophthalmoplegia, and ataxia-neuropathy syndromes. So that's a list of three conditions. Then document 15351195 talks about mutations in POLG being associated with mitochondrial disease, specifically autosomal dominant or recessive progressive external ophthalmoplegia, and multiple mtDNA deletions. So here, it's PEO (progressive external ophthalmoplegia) again, but specifies both dominant and recessive forms. Document 18546365 is more detailed, listing six major phenotypes. These include childhood Myocerebrohepatopathy Spectrum (MCHS), Alpers syndrome, Ataxia Neuropathy Spectrum (ANS) disorders, Myoclonus Epilepsy Myopathy", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which known mitochondrial diseases are associated with POLG mutations. First, I need to look at the evidence provided. There are three documents here. Let me go through each one. Document 20927567 mentions that about 150 mutations in POLG are linked to diseases like Alpers syndrome, progressive external ophthalmoplegia, and ataxia-neuropathy syndromes. So that's a list of three conditions. Then document 15351195 talks about mutations in POLG being associated with mitochondrial disease, specifically autosomal dominant or recessive progressive external ophthalmoplegia, and multiple mtDNA deletions. So here, it's PEO (progressive external ophthalmoplegia) again, but specifies both dominant and recessive forms. Document 18546365 is more detailed, listing six major phenotypes. These include childhood Myocerebrohepatopathy Spectrum (MCHS), Alpers syndrome, Ataxia Neuropathy Spectrum (ANS) disorders, Myoclonus Epilepsy Myopathy", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which known mitochondrial diseases are attributed to POLG mutations. First, I need to look at the evidence provided. There are three documents mentioned. Let me go through each one. Document 20927567 mentions that about 150 mutations in POLG are linked to diseases like Alpers syndrome, progressive external ophthalmoplegia, and ataxia-neuropathy syndromes. So that's a list of three conditions. Document 15351195 talks about mutations in POLG associated with mitochondrial disease, specifically autosomal dominant or recessive progressive external ophthalmoplegia, and multiple mtDNA deletions. So here, progressive external ophthalmoplegia is mentioned again, along with possible multiple deletions. Document 18546365 lists six major phenotypes: MCHS, Alpers syndrome, ANS disorders, MEMSA, arPEO, and adPEO. These are more specific diagnoses. Now, I need to combine these. The question is about currently known diseases. The answer should include all the mentioned", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which known mitochondrial diseases are associated with POLG mutations. I need to look at the evidence provided. First, looking at the first evidence snippet: it mentions Alpers syndrome, progressive external ophthalmoplegia, and ataxia-neuropathy syndromes. The second snippet adds that mutations in POLG are linked to mitochondrial disease, specifically autosomal dominant or recessive progressive external ophthalmoplegia, and multiple mtDNA deletions. The third snippet is more detailed, listing six major phenotypes. It includes childhood Myocerebrohepatopathy Spectrum (MCHS), Alpers syndrome, Ataxia Neuropathy Spectrum (ANS) disorders, MEMSA, arPEO, and adPEO. So the answer needs to compile all these diseases mentioned across the evidence. The key is to make sure I include all the ones listed in the third snippet because that's the most comprehensive. Alpers syndrome is mentioned in the first two, and the third adds more specific types like MCHS, ANS, MEMSA, arPEO, adPEO. Also, progressive external o", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["12825077", "15351195", "18546365", "20927567", "22647225"], "ideal_answer": "Mutations in the POLG gene have emerged as one of the most common causes of inherited mitochondrial disease in children and adults. They are responsible for a heterogeneous group of at least 6 major phenotypes of neurodegenerative disease that include: 1) childhood Myocerebrohepatopathy Spectrum disorders (MCHS), 2) Alpers syndrome, 3) Ataxia Neuropathy Spectrum (ANS) disorders, 4) Myoclonus Epilepsy Myopathy Sensory Ataxia (MEMSA), 5) autosomal recessive Progressive External Ophthalmoplegia (arPEO), and 6) autosomal dominant Progressive External Ophthalmoplegia (adPEO). Mutations in the POLG gene have emerged as one of the most common causes of inherited mitochondrial disease in children and adults. They are responsible for a heterogeneous group of at least 6 major phenotypes of neurodegenerative disease that include: 1) childhood Myocerebrohepatopathy Spectrum disorders (MCHS), 2) Alpers syndrome, 3) Ataxia Neuropathy Spectrum (ANS) disorders, 4) Myoclonus Epilepsy Myopathy Sensory Ataxia (MEMSA), 5) autosomal recessive Progressive External Ophthalmoplegia (arPEO), and 6) autosomal dominant Progressive External Ophthalmoplegia (adPEO)"}
{"question_id": "532f062ad6d3ac6a34000027", "question": "What is the effect of ivabradine in heart failure after myocardial infarction?", "retrieved_chunks": [{"doc_id": "21878041", "chunk_id": "21878041_0", "score": 7.201775550842285, "text": "Indeed, heart rate reduction with ivabradine, a selective and specific I(f) inhibitor, reduces myocardial oxygen demand, increases diastolic perfusion time and improves energetics in ischemic myocardium. Ivabradine protects the myocardium during ischemia, improves left ventricular function in heart failure and reduces remodeling following myocardial infarction. It improves prognosis in patients with coronary artery disease, left ventricular dysfunction and heart rate ≥70 beats per minute, as well as in patients with heart failure and left ventricular dysfunction."}, {"doc_id": "23096376", "chunk_id": "23096376_0", "score": 5.771203517913818, "text": "The most significant results were obtained in the subgroup of patients with life-limiting exertional angina. In this group, ivabradine significantly reduced the primary endpoint, a composite of cardiovascular death, hospitalization for fatal and nonfatal acute myocardial infarction (AMI) or heart failure, by 24%, and hospitalizations for AMI by 42%. In the subgroup of patients with baseline heart rate >70 bpm, hospitalizations for AMI and revascularization were reduced by 73% and 59%, respectively"}, {"doc_id": "19514618", "chunk_id": "19514618_0", "score": 5.532497882843018, "text": "Ivabradine did not significantly affect the combined primary endpoint. Significant reduction by 36% (p = 0.001) in myocardial infarction and by 30% (p = 0.016) in coronary revascularization was observed in the pre-defined subgroup of patients with heart rate > or = 70/min."}], "context": "[21878041:21878041_0] Indeed, heart rate reduction with ivabradine, a selective and specific I(f) inhibitor, reduces myocardial oxygen demand, increases diastolic perfusion time and improves energetics in ischemic myocardium. Ivabradine protects the myocardium during ischemia, improves left ventricular function in heart failure and reduces remodeling following myocardial infarction. It improves prognosis in patients with coronary artery disease, left ventricular dysfunction and heart rate ≥70 beats per minute, as well as in patients with heart failure and left ventricular dysfunction.\n[23096376:23096376_0] The most significant results were obtained in the subgroup of patients with life-limiting exertional angina. In this group, ivabradine significantly reduced the primary endpoint, a composite of cardiovascular death, hospitalization for fatal and nonfatal acute myocardial infarction (AMI) or heart failure, by 24%, and hospitalizations for AMI by 42%. In the subgroup of patients with baseline heart rate >70 bpm, hospitalizations for AMI and revascularization were reduced by 73% and 59%, respectively\n[19514618:19514618_0] Ivabradine did not significantly affect the combined primary endpoint. Significant reduction by 36% (p = 0.001) in myocardial infarction and by 30% (p = 0.016) in coronary revascularization was observed in the pre-defined subgroup of patients with heart rate > or = 70/min.", "answer": "<think> Okay, let's tackle this question about ivabradine's effect on heart failure after myocardial infarction. First, I need to look at the evidence provided. The user provided three documents. Let me go through each one. Document 21878041: This says that ivabradine reduces heart rate, which lowers myocardial oxygen demand. It also improves diastolic perfusion and energetics in ischemic hearts. It protects the myocardium during ischemia, improves left ventricular function in heart failure, and reduces remodeling after MI. Also mentions better prognosis in certain patients with CAD, LV dysfunction, and heart rate ≥70 bpm, as well as those with HF and LV dysfunction. Document 23096376: Talks about a subgroup with life-limiting exertional angina. Ivabradine reduced the primary endpoint (cardiovascular death, hospitalization for AMI or heart failure) by 24%, and hospitalizations for AMI by 42%. Also, in those with baseline HR >70 bpm, hospitalizations for AMI and revascularization were down by", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question about ivabradine's effect on heart failure after myocardial infarction. First, I need to look at the evidence provided. The user provided three documents. Let me go through each one. Document 21878041: This says that ivabradine reduces heart rate, which lowers myocardial oxygen demand. It also improves diastolic perfusion and energetics in ischemic hearts. It protects the myocardium during ischemia, improves left ventricular function in heart failure, and reduces remodeling after MI. Also mentions better prognosis in certain patients with CAD, LV dysfunction, and heart rate ≥70 bpm, as well as those with HF and LV dysfunction. Document 23096376: Talks about a subgroup with life-limiting exertional angina. Ivabradine reduced the primary endpoint (cardiovascular death, hospitalization for AMI or heart failure) by 24%, and hospitalizations for AMI by 42%. Also, in those with baseline HR >70 bpm, hospitalizations for AMI and revascularization were down by", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question about ivabradine's effect in heart failure after myocardial infarction. The user wants a concise answer with citations and a confidence score. First, I need to look at the evidence provided. There are three documents. Let me go through each one. Document 21878041: This says that ivabradine reduces heart rate, which lowers myocardial oxygen demand, improves diastolic perfusion, and enhances energetics in ischemic hearts. It protects the myocardium during ischemia, improves left ventricular function in heart failure, and reduces remodeling after MI. Also mentions it's beneficial for patients with CAD, LV dysfunction, and heart rate ≥70 bpm, as well as those with HF and LV dysfunction. Document 23096376: Talks about a subgroup with life-limiting exertional angina. Ivabradine reduced the primary endpoint (composite of cardiovascular death, hospitalization for AMI or heart failure) by 24%, and hospitalizations for AMI by 42%. In those with baseline HR >70, reductions in AMI", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, so I need to generate a biomedical answer about the effect of ivabradine in heart failure after myocardial infarction based on the provided evidence. Let me start by reading through the evidence carefully. First, document [21878041:21878041_0] says that ivabradine reduces heart rate, which lowers myocardial oxygen demand and improves diastolic perfusion. It also protects the myocardium during ischemia, improves left ventricular function in heart failure, and reduces remodeling after MI. This seems to directly address the question about heart failure post-MI. Then there's [23096376:23096376_0], which mentions that in patients with life-limiting exertional angina (which might be related to heart failure), ivabradine reduced primary endpoints like cardiovascular death, hospitalization for AMI or heart failure by 24%, and AMI hospitalizations by 42%. Also, in those with baseline HR >70 bpm, there were reductions in AMI and revascularization. This suggests a benefit", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["14981003", "18310678", "18621770", "18757088", "19074674", "19129742", "19411283", "19514618", "19664404", "20000882", "20028694", "21838751", "21878041", "22416440", "23067195", "23096376", "23394554", "23536611"], "ideal_answer": "Ιvabradine decreases heart rate and reduces myocardial oxygen demand, increases diastolic perfusion time and improves energetics in ischemic myocardium. Ivabradine protects the myocardium during ischemia, improves left ventricular function in heart failure and reduces remodeling following myocardial infarction. It improves prognosis in patients with coronary artery disease, left ventricular dysfunction and heart rate ≥70 beats per minute, as well as in patients with heart failure and left ventricular dysfunction. The beneficial effects of ivabradine may be due to the reversal of electrophysiological cardiac remodelling in post-MI rats by reduction of functional overexpression of HCN channels. Furthermore, the improvement of cardiac function is related not only to the HR reduction per se but also to modifications in the extracellular matrix."}
{"question_id": "52bf1b0a03868f1b06000009", "question": "What is the mode of inheritance of Wilson's disease?", "retrieved_chunks": [{"doc_id": "22610954", "chunk_id": "22610954_0", "score": 5.54994010925293, "text": "Wilson's disease (WD), or hepatolenticular degeneration, is an autosomal recessive inheritance disorder of copper metabolism caused by ATP7B gene mutation."}, {"doc_id": "2724779", "chunk_id": "2724779_0", "score": 4.603377819061279, "text": "Wilson's disease is a rare genetic disorder of copper metabolism with autosomal recessive inheritance."}, {"doc_id": "30271060", "chunk_id": "30271060_0", "score": 3.657937526702881, "text": "Wilson's disease is an autosomal recessive disease of abnormal copper metabolism."}], "context": "[22610954:22610954_0] Wilson's disease (WD), or hepatolenticular degeneration, is an autosomal recessive inheritance disorder of copper metabolism caused by ATP7B gene mutation.\n[2724779:2724779_0] Wilson's disease is a rare genetic disorder of copper metabolism with autosomal recessive inheritance.\n[30271060:30271060_0] Wilson's disease is an autosomal recessive disease of abnormal copper metabolism.", "answer": "<think> Okay, the user is asking about the mode of inheritance of Wilson's disease. Let me check the evidence provided. Looking at the evidence, there are three references. All of them mention that Wilson's disease is an autosomal recessive disorder. The first one says it's caused by a mutation in the ATP7B gene. The second and third also confirm autosomal recessive inheritance. So the answer should be that it's autosomal recessive. I need to cite the documents. The first evidence is from 22610954:22610954_0, the second from 2724779:2724779_0, and the third from 30271060:30271060_0. But since the question is about the mode of inheritance, any of these can be used. Maybe pick the first one as it's the first mention. The base confidence is high because all three sources agree. So set base_confidence to 1.0. Make sure the answer is concise and includes the citation. Alright", "citations": [], "candidates": [{"answer": "<think> Okay, the user is asking about the mode of inheritance of Wilson's disease. Let me check the evidence provided. Looking at the evidence, there are three references. All of them mention that Wilson's disease is an autosomal recessive disorder. The first one says it's caused by a mutation in the ATP7B gene. The second and third also confirm autosomal recessive inheritance. So the answer should be that it's autosomal recessive. I need to cite the documents. The first evidence is from 22610954:22610954_0, the second from 2724779:2724779_0, and the third from 30271060:30271060_0. But since the question is about the mode of inheritance, any of these can be used. Maybe pick the first one as it's the first mention. The base confidence is high because all three sources agree. So set base_confidence to 1.0. Make sure the answer is concise and includes the citation. Alright", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, the user is asking about the mode of inheritance of Wilson's disease. Let me check the evidence provided. Looking at the evidence, there are three references. All of them mention that Wilson's disease is an autosomal recessive disorder. The first one says it's caused by a mutation in the ATP7B gene. The second and third also confirm autosomal recessive inheritance. So the answer should be that it's autosomal recessive. I need to cite the documents. The first document is 22610954:22610954_0, the second is 2724779:2724779_0, and the third is 30271060:30271060_0. But the answer should be concise with citations. Maybe pick one of them? Wait, the user said to return strict JSON with answer and base_confidence. The answer needs to include the citations as [doc_id:chunk_id]. So the answer is \"autosomal recessive\" with citations from all three documents. But how", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, the user is asking about the mode of inheritance of Wilson's disease. Let me look at the evidence provided. The first document says it's an autosomal recessive disorder caused by a mutation in the ATP7B gene. The second one mentions it's a rare genetic disorder with autosomal recessive inheritance. The third also states it's an autosomal recessive disease of abnormal copper metabolism. All three sources agree on autosomal recessive inheritance. I need to make sure there's no conflicting information. All three chunks point to the same conclusion. So the answer should be that Wilson's disease is inherited in an autosomal recessive manner, citing all three documents. The confidence level should be high since all evidence supports this. Let me structure the JSON with the answer and the base confidence as 1.0. </think> { \"answer\": \"Wilson's disease is inherited in an autosomal recessive manner [22610954:22610954_0, 2724779:2724779_0, 30271060:", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["12152840", "1248830", "14580665", "16932613", "1940586", "20662462", "22610954", "2724779", "6109943", "6620327", "759736", "8186659", "838566", "8615372"], "ideal_answer": "Wilson's disease (WD) is an autosomal recessive disorder."}
{"question_id": "517395b98ed59a060a00001a", "question": "Are transcription and splicing connected?", "retrieved_chunks": [{"doc_id": "19823040", "chunk_id": "19823040_1", "score": 7.05962610244751, "text": "transcription and splicing are functionally intertwined, and that modified nucleosomes with trimethylation of lysine 36 in histone subunit 3 (H3K36me3) are enriched at internal exons and the downstream flanking intronic regions of highly expressed genes"}, {"doc_id": "23074139", "chunk_id": "23074139_2", "score": 5.875174522399902, "text": "Moreover, splicing was found to be necessary for the proper 'writing' of particular chromatin signatures, giving further mechanistic support to functional interconnections between splicing, transcription and chromatin structure."}, {"doc_id": "22955974", "chunk_id": "22955974_3", "score": 4.883185386657715, "text": "We show that in the human genome, splicing occurs predominantly during transcription."}], "context": "[19823040:19823040_1] transcription and splicing are functionally intertwined, and that modified nucleosomes with trimethylation of lysine 36 in histone subunit 3 (H3K36me3) are enriched at internal exons and the downstream flanking intronic regions of highly expressed genes\n[23074139:23074139_2] Moreover, splicing was found to be necessary for the proper 'writing' of particular chromatin signatures, giving further mechanistic support to functional interconnections between splicing, transcription and chromatin structure.\n[22955974:22955974_3] We show that in the human genome, splicing occurs predominantly during transcription.", "answer": "<think> Okay, I need to answer whether transcription and splicing are connected based on the given evidence. Let me look at the three references provided. First, reference [19823040:19823040_1] says that transcription and splicing are functionally intertwined. It also mentions something about nucleosomes and H3K36me3 being enriched in certain regions. That seems to indicate a connection between the two processes. Then, [23074139:23074139_2] talks about splicing being necessary for chromatin signatures, which further supports the functional interconnections between splicing, transcription, and chromatin structure. So this also suggests they're connected. The third reference [22955974:22955974_3] states that splicing occurs predominantly during transcription. This directly links the timing of splicing with the transcription process, implying a connection. All three pieces of evidence point to a functional relationship between transcription and splicing. The first one mentions they are intertwined, the second adds about chromatin signatures,", "citations": [{"doc_id": "19823040", "chunk_id": "19823040_1"}, {"doc_id": "23074139", "chunk_id": "23074139_2"}, {"doc_id": "22955974", "chunk_id": "22955974_3"}], "candidates": [{"answer": "<think> Okay, I need to answer whether transcription and splicing are connected based on the given evidence. Let me look at the three references provided. First, reference [19823040:19823040_1] says that transcription and splicing are functionally intertwined. It also mentions something about nucleosomes and H3K36me3 being enriched in certain regions. That seems to indicate a connection between the two processes. Then, [23074139:23074139_2] talks about splicing being necessary for chromatin signatures, which further supports the functional interconnections between splicing, transcription, and chromatin structure. So this also suggests they're connected. The third reference [22955974:22955974_3] states that splicing occurs predominantly during transcription. This directly links the timing of splicing with the transcription process, implying a connection. All three pieces of evidence point to a functional relationship between transcription and splicing. The first one mentions they are intertwined, the second adds about chromatin signatures,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if transcription and splicing are connected. I need to look at the provided evidence to form a biomedical answer. First, I'll go through each of the evidence points. The first piece [19823040:19823040_1] mentions that transcription and splicing are functionally intertwined. It also talks about modified nucleosomes and H3K36me3 being enriched in certain regions, which might relate to how transcription and splicing interact. So this supports a connection. The second evidence [23074139:23074139_2] states that splicing is necessary for proper chromatin signatures, further supporting the functional interconnections between splicing, transcription, and chromatin structure. This seems like another strong point. Third, [22955974:22955974_3] says splicing occurs predominantly during transcription. That directly links the timing of splicing with transcription, implying they are connected processes. Putting this together, all three pieces of evidence", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if transcription and splicing are connected. I need to look at the provided evidence to form a concise answer with citations and a confidence level. First, looking at the evidence: 1. The first document says that transcription and splicing are functionally intertwined. It also mentions something about H3K36me3 being enriched in certain regions. But the main point here is the functional connection between transcription and splicing. 2. The second document states that splicing is necessary for proper chromatin signatures, which supports the idea that there's a mechanistic link between splicing, transcription, and chromatin structure. This reinforces the connection. 3. The third document mentions that splicing occurs predominantly during transcription. That directly links the timing of splicing with transcription, suggesting they are connected processes happening during transcription. So all three pieces of evidence point to a connection between transcription and splicing. The answer should state that they are connected, citing these documents. The confidence level should be high since all three sources support this. I need ", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["15383674", "15870275", "15905409", "16172632", "16769980", "16921380", "17189193", "20808788", "21095588", "21964334", "22156210", "22479188", "22975042", "23074139", "23097425", "23209445"], "ideal_answer": "Yes. There is strong evidence that splicing and transcription are intimately coupled in metazoans, with genome wide surveys show that most splicing occurs during transcription. Chromatin structure, RNA polymerase dynamics, and recruitment of splicing factors through the transcriptional machinery are factors that explain a role for transcription in the regulation of splicing."}
{"question_id": "52bf19c503868f1b06000001", "question": "What is the mode of inheritance of Facioscapulohumeral muscular dystrophy (FSHD)?", "retrieved_chunks": [{"doc_id": "22551571", "chunk_id": "22551571_0", "score": 8.945333480834961, "text": "Facioscapulohumeral muscular dystrophy (FSHD) is a neuromuscular disease, characterized by an autosomal dominant mode of inheritance, facial involvement, and selectivity and asymmetry of muscle involvement."}, {"doc_id": "15307599", "chunk_id": "15307599_0", "score": 7.493689060211182, "text": "Facioscapulohumeral muscular dystrophy (FSHD) is a primary muscle disorder with autosomal dominant inheritance."}, {"doc_id": "10969520", "chunk_id": "10969520_0", "score": 7.443556308746338, "text": "Facioscapulohumeral muscular dystrophy (FSHD) is a slowly progressive myopathy with autosomal dominant inheritance remarkable for its early involvement of facial musculature."}], "context": "[22551571:22551571_0] Facioscapulohumeral muscular dystrophy (FSHD) is a neuromuscular disease, characterized by an autosomal dominant mode of inheritance, facial involvement, and selectivity and asymmetry of muscle involvement.\n[15307599:15307599_0] Facioscapulohumeral muscular dystrophy (FSHD) is a primary muscle disorder with autosomal dominant inheritance.\n[10969520:10969520_0] Facioscapulohumeral muscular dystrophy (FSHD) is a slowly progressive myopathy with autosomal dominant inheritance remarkable for its early involvement of facial musculature.", "answer": "<think> Okay, let's tackle this question about the mode of inheritance of FSHD. The user wants a concise answer from the provided evidence, in JSON format with citations and a confidence score. First, I need to look at the evidence given. There are three chunks here. All three mention autosomal dominant inheritance. The first one says \"autosomal dominant mode of inheritance,\" the second mentions \"autosomal dominant inheritance,\" and the third also states \"autosomal dominant inheritance.\" So all three sources agree on the same point. The answer should be straightforward: autosomal dominant. The citations would be all three documents since they all support this. But the user might expect each citation to be included. However, in JSON, I need to list them as [doc_id:chunk_id]. So each of the three chunks is a source. Wait, but the question is about the mode of inheritance. The answer is clear from all three sources. The confidence should be high since all three pieces of evidence agree. So base_confidence would be 1.0 because there's no conflicting information. I need to make sure that the answer is concise. The answer is \"autosomal", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question about the mode of inheritance of FSHD. The user wants a concise answer from the provided evidence, in JSON format with citations and a confidence score. First, I need to look at the evidence given. There are three chunks here. All three mention autosomal dominant inheritance. The first one says \"autosomal dominant mode of inheritance,\" the second mentions \"autosomal dominant inheritance,\" and the third also states \"autosomal dominant inheritance.\" So all three sources agree on the same point. The answer should be straightforward: autosomal dominant. The citations would be all three documents since they all support this. But the user might expect each citation to be included. However, in JSON, I need to list them as [doc_id:chunk_id]. So each of the three chunks is a source. Wait, but the question is about the mode of inheritance. The answer is clear from all three sources. The confidence should be high since all three pieces of evidence agree. So base_confidence would be 1.0 because there's no conflicting information. I need to make sure that the answer is concise. The answer is \"autosomal", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, the user is asking about the mode of inheritance of Facioscapulohumeral muscular dystrophy (FSHD). Let me look at the evidence provided. First, I see three documents cited. The first one says FSHD has an autosomal dominant mode of inheritance. The second and third also mention autosomal dominant inheritance. All three are from different sources but agree on the same point. I need to make sure that all the citations support the answer. Each of the chunks in the evidence points to autosomal dominant. So the answer should be clear. The model's confidence here is pretty high since all three sources consistently state the same thing. The answer should be concise, so just stating \"autosomal dominant\" with the citations. The base_confidence can be 1.0 because there's no conflicting information. I need to format it into JSON as specified, making sure the keys are correct and the confidence is a float. </think> { \"answer\": \"Autosomal dominant [22551571:22551571_0][15307599:153", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, the user is asking about the mode of inheritance of Facioscapulohumeral muscular dystrophy (FSHD). Let me look at the evidence provided. The first document says FSHD has an autosomal dominant mode of inheritance. The second one also mentions autosomal dominant inheritance. The third evidence chunk confirms it again, stating autosomal dominant inheritance. All three sources are consistent in saying that the inheritance pattern is autosomal dominant. I need to make sure there's no conflicting information. All three citations point to the same answer, so the confidence level should be high. The answer should be concise, mentioning autosomal dominant and citing the documents. The base_confidence can be 1.0 since all evidence supports this. Let me structure the JSON accordingly. </think> { \"answer\": \"Facioscapulohumeral muscular dystrophy (FSHD) exhibits an autosomal dominant mode of inheritance [22551571:22551571_0, 15307599:15307599_0, 1096952", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["10487912", "10864616", "10969520", "15307599", "19248726", "21795275", "22525183", "22551571", "23143600", "23573591", "7739631"], "ideal_answer": "Facioscapulohumeral muscular dystrophy has an autosomal dominant inheritance pattern."}
{"question_id": "54db1d580f63c58e6e000005", "question": "Is Alu hypomethylation associated with breast cancer?", "retrieved_chunks": [{"doc_id": "24971511", "chunk_id": "24971511_0", "score": 9.603660583496094, "text": "Alu and LINE-1 hypomethylation is associated with HER2 enriched subtype of breast cancer"}, {"doc_id": "24971511", "chunk_id": "24971511_1", "score": 8.644245147705078, "text": "Alu hypomethylation is probably a late event during breast cancer progression"}, {"doc_id": "31383000", "chunk_id": "31383000_1", "score": 3.7526326179504395, "text": "In addition, hypomethylation of TBC1D16 was observed in multiple tumours, including a breast cancer primary/metastasis pair, and to a lesser degree in melanoma, although again not all tumours or cancer primary/metastasis pairs exhibited altered patterns of methylation."}], "context": "[24971511:24971511_0] Alu and LINE-1 hypomethylation is associated with HER2 enriched subtype of breast cancer\n[24971511:24971511_1] Alu hypomethylation is probably a late event during breast cancer progression\n[31383000:31383000_1] In addition, hypomethylation of TBC1D16 was observed in multiple tumours, including a breast cancer primary/metastasis pair, and to a lesser degree in melanoma, although again not all tumours or cancer primary/metastasis pairs exhibited altered patterns of methylation.", "answer": "<think> Okay, the user is asking if Alu hypomethylation is associated with breast cancer. Let me look at the evidence provided. First evidence document 24971511:24971511_0 says that Alu and LINE-1 hypomethylation is linked to the HER2 enriched subtype of breast cancer. That directly connects Alu hypomethylation to a specific type of breast cancer. So that's a strong point. Then there's another chunk from the same document, 24971511:24971511_1, which states that Alu hypomethylation is probably a late event during breast cancer progression. This suggests it's involved in the development of breast cancer, though maybe not the initial stages. The third evidence is from document 31383000:313830-than, which mentions hypomethylation of TBC1D16 in multiple tumors including a breast cancer primary/metastasis pair. While this is about TBC1D16, it does mention breast cancer, so it's", "citations": [], "candidates": [{"answer": "<think> Okay, the user is asking if Alu hypomethylation is associated with breast cancer. Let me look at the evidence provided. First evidence document 24971511:24971511_0 says that Alu and LINE-1 hypomethylation is linked to the HER2 enriched subtype of breast cancer. That directly connects Alu hypomethylation to a specific type of breast cancer. So that's a strong point. Then there's another chunk from the same document, 24971511:24971511_1, which states that Alu hypomethylation is probably a late event during breast cancer progression. This suggests it's involved in the development of breast cancer, though maybe not the initial stages. The third evidence is from document 31383000:313830-than, which mentions hypomethylation of TBC1D16 in multiple tumors including a breast cancer primary/metastasis pair. While this is about TBC1D16, it does mention breast cancer, so it's", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, the user is asking if Alu hypomethylation is associated with breast cancer. Let me look at the evidence provided. First, there's a document (24971511:24971511_0) that says Alu and LINE-1 hypomethylation is linked to the HER2 enriched subtype of breast cancer. That directly connects Alu hypomethylation to breast cancer, specifically a subtype. So that's a strong point. Another piece (24971511:24971511_1) mentions that Alu hypomethylation is probably a late event during breast cancer progression. This suggests it's related to the development of breast cancer, even if it's later in the process. That supports the association. The third evidence (31383000:313830 where TBC1D16 hypomethylation is observed in multiple tumors, including a breast cancer primary/metastasis pair) also mentions breast cancer. However, it's about TBC1D16, not Alu. But", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if Alu hypomethylation is associated with breast cancer. I need to look at the provided evidence to form an answer. First, looking at the evidence documents. The first one, 24971511:24971511_0, says that Alu and LINE-1 hypomethylation is linked to the HER2 enriched subtype of breast cancer. That directly connects Alu hypomethylation to a specific type of breast cancer. So that's a strong point. The second document, 24971511:24971511_1, mentions that Alu hypomethylation is probably a late event during breast cancer progression. This suggests that it's related to the development of breast cancer, even if it's a later stage. So this supports the association. The third document, 31383000:3138309_1, talks about hypomethylation of TBC1D16 in multiple tumors, including a breast cancer primary/metast", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["20682973", "24971511"], "ideal_answer": "Yes, Alu elements were found to be hypomethylated in breast cancer, especially in the HER2-enriched subtype. Furthermore, Alu hypomethylation was identified as a late event during breast cancer progression, and in invasive breast cancer, tended to be associated with negative estrogen receptor status and poor disease-free survival of the patients. Alu and LINE-1 hypomethylation is associated with HER2 enriched subtype of breast cancer"}
{"question_id": "54f9d3eedd3fc62544000004", "question": "Which proteins participate in the formation of the ryanodine receptor quaternary macromolecular complex?", "retrieved_chunks": [{"doc_id": "18206802", "chunk_id": "18206802_2", "score": 7.118478775024414, "text": "Junctin (JCN), a 26-kd sarcoplasmic reticulum (SR) transmembrane protein, forms a quaternary protein complex with the ryanodine receptor, calsequestrin, and triadin in the SR lumen of cardiac muscle. Within this complex, calsequestrin, triadin, and JCN appear to be critical for normal regulation of ryanodine receptor-mediated calcium (Ca) release."}, {"doc_id": "14638677", "chunk_id": "14638677_0", "score": 6.793920516967773, "text": "In mammalian striated muscles, ryanodine receptor (RyR), triadin, junctin, and calsequestrin form a quaternary complex in the lumen of sarcoplasmic reticulum. Such intermolecular interactions contribute not only to the passive buffering of sarcoplasmic reticulum luminal Ca2+, but also to the active Ca2+ release process during excitation-contraction coupling."}, {"doc_id": "22025663", "chunk_id": "22025663_1", "score": 6.719632148742676, "text": "Junctin, a 26 kDa intra-sarcoplasmic reticulum (SR) protein, forms a quaternary complex with triadin, calsequestrin and the ryanodine receptor (RyR) at the junctional SR membrane."}], "context": "[18206802:18206802_2] Junctin (JCN), a 26-kd sarcoplasmic reticulum (SR) transmembrane protein, forms a quaternary protein complex with the ryanodine receptor, calsequestrin, and triadin in the SR lumen of cardiac muscle. Within this complex, calsequestrin, triadin, and JCN appear to be critical for normal regulation of ryanodine receptor-mediated calcium (Ca) release.\n[14638677:14638677_0] In mammalian striated muscles, ryanodine receptor (RyR), triadin, junctin, and calsequestrin form a quaternary complex in the lumen of sarcoplasmic reticulum. Such intermolecular interactions contribute not only to the passive buffering of sarcoplasmic reticulum luminal Ca2+, but also to the active Ca2+ release process during excitation-contraction coupling.\n[22025663:22025663_1] Junctin, a 26 kDa intra-sarcoplasmic reticulum (SR) protein, forms a quaternary complex with triadin, calsequestrin and the ryanodine receptor (RyR) at the junctional SR membrane.", "answer": "<think> Okay, let's tackle this question. The user is asking which proteins are part of the ryanodine receptor quaternary complex. Looking at the evidence provided, there are three references. First, reference 18206802 mentions Junctin (JCN), Ryanodine receptor, calsequestrin, and triadin. Then, 14638677 also lists RyR, triadin, junctin, and calsequestrin. The third one, 22025663, again mentions Junctin, triadin, calsequestrin, and RyR. All three sources agree on the four proteins: Junctin, Triadin, Calsequestrin, and Ryanodine receptor. I need to make sure there's no conflicting information. All three documents list these four proteins. The answer should include all four. The confidence is high since all sources are consistent. So the answer is those four proteins with citations from the documents. The base confidence can be 1.0 as there's no contradictory info. </think> { \"answer", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which proteins are part of the ryanodine receptor quaternary complex. Looking at the evidence provided, there are three references. First, reference 18206802 mentions Junctin (JCN), Ryanodine receptor, calsequestrin, and triadin. Then, 14638677 also lists RyR, triadin, junctin, and calsequestrin. The third one, 22025663, again mentions Junctin, triadin, calsequestrin, and RyR. All three sources agree on the four proteins: Junctin, Triadin, Calsequestrin, and Ryanodine receptor. I need to make sure there's no conflicting information. All three documents list these four proteins. The answer should include all four. The confidence is high since all sources are consistent. So the answer is those four proteins with citations from the documents. The base confidence can be 1.0 as there's no contradictory info. </think> { \"answer", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which proteins are part of the ryanodine receptor quaternary macromolecular complex. I need to look at the evidence provided and extract the relevant proteins mentioned. First, looking at the first evidence snippet [18206802:18206802_2], it mentions Junctin (JCN), ryanodine receptor, calsequestrin, and triadin. So that's four proteins. The second snippet [14638677:14638677_0] also lists RyR, triadin, junctin, and calsequestrin. That's the same set. The third one [22025663:22025663_1] again mentions Junctin, triadin, calsequestrin, and Ryanodine receptor. So all three sources agree on the same four proteins: Junctin, Triadin, Calsequestrin, and Ryanodine Receptor. I need to make sure there", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's see. The user is asking which proteins are part of the ryanodine receptor quaternary complex. I need to look at the evidence provided. First, evidence [18206802:18206802_2] mentions Junctin (JCN), ryanodine receptor, calsequestrin, and triadin forming the complex. Then [14638677:14638676_0] says RyR, triadin, junctin, and calsequestrin form the quaternary complex. The third evidence [22025663:22025663_1] also lists Junctin, triadin, calsequestrin, and RyR as part of the complex. So all three sources agree on the four proteins: Junctin, triadin, calsequestrin, and ryanodine receptor. The answer should list these four. The confidence is high since all three documents mention the same set. So base_confidence would be", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["11069905", "12909320", "14638677", "15205169", "15731387", "16289269", "18206802", "18620751", "22025663", "22298808", "22427521", "9287354"], "ideal_answer": "Junctin is a major transmembrane protein in cardiac junctional sarcoplasmic reticulum, which forms a quaternary complex with the ryanodine receptor (Ca(2+) release channel), triadin, and calsequestrin. Calsequestrin (CSQ) is a Ca(2+) storage protein that interacts with triadin (TRN), the ryanodine receptor (RyR), and junctin (JUN) to form a macromolecular tetrameric Ca(2+) signaling complex in the cardiac junctional sarcoplasmic reticulum (SR). Junctin, calsequestrin, triadin, and the ryanodine receptor form a quaternary complex that may be required for normal operation of Ca2+ release."}
{"question_id": "5505edac8e1671127b000005", "question": "What kind of chromatography is HILIC?", "retrieved_chunks": [{"doc_id": "23073287", "chunk_id": "23073287_0", "score": 7.970343589782715, "text": "Hydrophilic-interaction liquid chromatography (HILIC) is a widely used technique for small polar molecule analysis"}, {"doc_id": "21316059", "chunk_id": "21316059_0", "score": 7.010393142700195, "text": "Hydrophilic Interaction Chromatography (HILIC)"}, {"doc_id": "21737084", "chunk_id": "21737084_0", "score": 5.63319206237793, "text": "A hydrophilic interaction liquid chromatography-tandem mass spectrometry (HILIC LC-MS/MS) method"}], "context": "[23073287:23073287_0] Hydrophilic-interaction liquid chromatography (HILIC) is a widely used technique for small polar molecule analysis\n[21316059:21316059_0] Hydrophilic Interaction Chromatography (HILIC)\n[21737084:21737084_0] A hydrophilic interaction liquid chromatography-tandem mass spectrometry (HILIC LC-MS/MS) method", "answer": "<think> Okay, let's tackle this question. The user is asking what kind of chromatography HILIC is. The evidence provided has three chunks. First, I need to understand what HILIC stands for. From the evidence, the first chunk says \"Hydrophilic-interaction liquid chromatography (HILIC)\" which directly defines it. The second chunk just repeats the name, and the third mentions HILIC LC-MS/MS, which is an application method. So the answer should be that HILIC is a type of liquid chromatography. The first chunk explicitly states that, so the citation would be [23073287:23073287_0]. The confidence is high because it's a direct definition. The other chunks support this but don't add new information. The model can be confident here since the definition is clear and repeated in the evidence. </think> { \"answer\": \"Hydrophilic-interaction liquid chromatography (HILIC) is a type of liquid chromatography [23073287:23073287_0].", "citations": [{"doc_id": "23073287", "chunk_id": "23073287_0"}, {"doc_id": "23073287", "chunk_id": "23073287_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking what kind of chromatography HILIC is. The evidence provided has three chunks. First, I need to understand what HILIC stands for. From the evidence, the first chunk says \"Hydrophilic-interaction liquid chromatography (HILIC)\" which directly defines it. The second chunk just repeats the name, and the third mentions HILIC LC-MS/MS, which is an application method. So the answer should be that HILIC is a type of liquid chromatography. The first chunk explicitly states that, so the citation would be [23073287:23073287_0]. The confidence is high because it's a direct definition. The other chunks support this but don't add new information. The model can be confident here since the definition is clear and repeated in the evidence. </think> { \"answer\": \"Hydrophilic-interaction liquid chromatography (HILIC) is a type of liquid chromatography [23073287:23073287_0].", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, the user is asking what kind of chromatography HILIC is. Let me look at the evidence provided. First, the evidence has three chunks. The first one says HILIC is a technique for small polar molecule analysis. The second mentions Hydrophilic Interaction Chromatography (HILIC) without additional details. The third talks about HILIC LC-MS/MS, which seems like an application method. So, the answer needs to be concise. The term \"Hydrophilic-interaction liquid chromatography\" is mentioned in the first chunk. The second chunk just repeats the name. The third chunk refers to it as part of a method. The key here is to identify that HILIC is a type of liquid chromatography. The first chunk explicitly states it's a technique, and the others support that. The confidence level should be high because all sources agree on the name and its classification. I need to make sure the answer is accurate. The correct term is Hydrophilic-interaction liquid chromatography, which is a type of liquid chromatography. The citations are from different chunks, but the main one is the first one.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to figure out what kind of chromatography HILIC is based on the given evidence. Let me look at the evidence provided. The first document says that HILIC is a technique for small polar molecule analysis. The second one just mentions Hydrophilic Interaction Chromatography (HILIC). The third one refers to HILIC LC-MS/MS, which seems like an application of HILIC. So, the question is asking what kind of chromatography HILIC is. From the evidence, all the references point to HILIC being a type of liquid chromatography. The term \"hydrophilic-interaction liquid chromatography\" is used in the first document, which directly states it's a chromatography technique. The other documents mention variations like HILIC LC-MS/MS, but the core method is still HILIC as a liquid chromatography technique. I should check if there's any conflicting information, but all sources agree that HILIC is a type of liquid chromatography. The answer needs to be concise and include citations. The confidence level should be high since all evidence points to the same conclusion. So", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["21238772", "21316059", "21737084", "22946920", "23073287", "23217321"], "ideal_answer": "Hydrophilic Interaction Chromatography (HILIC)"}
{"question_id": "5160193d298dcd4e51000039", "question": "What is the effect of TRH on myocardial contractility?", "retrieved_chunks": [{"doc_id": "1611701", "chunk_id": "1611701_1", "score": 6.403558731079102, "text": "Thus, TRH improves cardiac contractility, cardiac output, and hemodynamics during hemorrhagic shock."}, {"doc_id": "9088928", "chunk_id": "9088928_0", "score": 6.24492073059082, "text": "TRH in the range of 0.1-10 mumol/l was found to exert a positive inotropic effect on cardiac contractility"}, {"doc_id": "1611701", "chunk_id": "1611701_0", "score": 5.802417755126953, "text": "TRH improves cardiac contractility, cardiac output, and hemodynamics"}], "context": "[1611701:1611701_1] Thus, TRH improves cardiac contractility, cardiac output, and hemodynamics during hemorrhagic shock.\n[9088928:9088928_0] TRH in the range of 0.1-10 mumol/l was found to exert a positive inotropic effect on cardiac contractility\n[1611701:1611701_0] TRH improves cardiac contractility, cardiac output, and hemodynamics", "answer": "<think> Okay, let's tackle this question. The user is asking about the effect of TRH on myocardial contractility. I need to look at the provided evidence to form a concise answer with citations and a confidence level. First, I'll check each piece of evidence. The first document [1611701:1611701_1] says TRH improves cardiac contractility, cardiac output, and hemodynamics during hemorrhagic shock. That's directly related to myocardial contractility. The second evidence [9088928:9088928_0] mentions that TRH in a certain range has a positive inotropic effect on cardiac contractility. The third piece [1611701:1611701_0] repeats the first point about improving cardiac contractility and hemodynamics. So, all three sources support the idea that TRH enhances myocardial contractility. The answer should combine these points. The user wants a concise answer with citations. I need to make sure to include at least one citation. The confidence level is based on the fact that multiple documents", "citations": [{"doc_id": "1611701", "chunk_id": "1611701_1"}, {"doc_id": "9088928", "chunk_id": "9088928_0"}, {"doc_id": "1611701", "chunk_id": "1611701_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking about the effect of TRH on myocardial contractility. I need to look at the provided evidence to form a concise answer with citations and a confidence level. First, I'll check each piece of evidence. The first document [1611701:1611701_1] says TRH improves cardiac contractility, cardiac output, and hemodynamics during hemorrhagic shock. That's directly related to myocardial contractility. The second evidence [9088928:9088928_0] mentions that TRH in a certain range has a positive inotropic effect on cardiac contractility. The third piece [1611701:1611701_0] repeats the first point about improving cardiac contractility and hemodynamics. So, all three sources support the idea that TRH enhances myocardial contractility. The answer should combine these points. The user wants a concise answer with citations. I need to make sure to include at least one citation. The confidence level is based on the fact that multiple documents", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to generate a JSON answer based on the evidence provided. The question is about the effect of TRH on myocardial contractility. First, looking at the evidence: - Document 1611701:1611701_1 says TRH improves cardiac contractility, cardiac output, and hemodynamics during hemorrhagic shock. - Document 9088928:9088928_0 mentions that TRH in the range of 0.1-10 μmol/l has a positive inotropic effect on cardiac contractility. - Document 1611701:1611701_0 states TRH improves cardiac contractility, cardiac output, and hemodynamics. So all three documents support that TRH enhances cardiac contractility. The first and third are from the same doc ID, maybe different chunks. The second one provides a specific concentration range. The answer should be concise, citing the relevant documents. The answer needs to mention that TRH has a positive effect on myocardial contractility, possibly including the concentration range from the second evidence.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, the user is asking about the effect of TRH on myocardial contractility. Let me look at the evidence provided. First, there are three citations. The first one from 1611701:1611701_1 says TRH improves cardiac contractility, cardiac output, and hemodynamics during hemorrhagic shock. The second citation, 9088928:9088928_0, mentions that TRH in the range of 0.1-10 μmol/l has a positive inotropic effect on cardiac contractility. The third one, 1611701:1611701_0, repeats that TRH improves cardiac contractility and cardiac output. So all three sources agree that TRH enhances myocardial contractility. The first two mention it specifically, and the third reiterates the same point. The second citation also adds the concentration range, which is a bit more specific. However, the question is about the effect, not the concentration. The answer needs to be concise with citations. The main points are that TR", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["15096458", "1611701", "1979356", "2848686", "9088928", "9225129"], "ideal_answer": "TRH improves myocardial contractility"}
{"question_id": "51593dc8d24251bc05000099", "question": "Proteomic analyses need prior knowledge of the organism complete genome. Is the complete genome of the bacteria of the genus Arthrobacter available?", "retrieved_chunks": [{"doc_id": "21677849", "chunk_id": "21677849_0", "score": 0.8053627610206604, "text": "Complete genome sequence of Arthrobacter phenanthrenivorans type strain (Sphe3)."}, {"doc_id": "15246528", "chunk_id": "15246528_0", "score": 0.24066407978534698, "text": "Comparative genomic analysis of the malaria causative agent, Plasmodium falciparum, with other eukaryotes for which the complete genome is available, revealed that the genome from P. falciparum was more similar to the genome of a plant, Arabidopsis thaliana, than to other non-apicomplexan taxa."}, {"doc_id": "23039946", "chunk_id": "23039946_0", "score": -0.14639154076576233, "text": "Complete genome sequence and metabolic potential of the quinaldine-degrading bacterium Arthrobacter sp. Rue61a."}], "context": "[21677849:21677849_0] Complete genome sequence of Arthrobacter phenanthrenivorans type strain (Sphe3).\n[15246528:15246528_0] Comparative genomic analysis of the malaria causative agent, Plasmodium falciparum, with other eukaryotes for which the complete genome is available, revealed that the genome from P. falciparum was more similar to the genome of a plant, Arabidopsis thaliana, than to other non-apicomplexan taxa.\n[23039946:23039946_0] Complete genome sequence and metabolic potential of the quinaldine-degrading bacterium Arthrobacter sp. Rue61a.", "answer": "<think> Okay, let's tackle this question. The user is asking if the complete genome of bacteria in the genus Arthrobacter is available. The evidence given includes three references. First, looking at the evidence, the first document [21677849:21677849_0] mentions the complete genome sequence of Arthrobacter phenanthrenivorans type strain (Sphe3). That's a specific species within the genus Arthrobacter, so that shows that at least one member has its genome sequenced. The third document [23039946:23039946_0] talks about the complete genome sequence of Arthrobacter sp. Rue61a. Again, this is another species in the same genus, so that's another example of a complete genome being available. The second document [15246528:15246528_0] discusses Plasmodium falciparum, which is a different organism, so it's not relevant to Arthrobacter. So from", "citations": [{"doc_id": "21677849", "chunk_id": "21677849_0"}, {"doc_id": "23039946", "chunk_id": "23039946_0"}, {"doc_id": "15246528", "chunk_id": "15246528_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if the complete genome of bacteria in the genus Arthrobacter is available. The evidence given includes three references. First, looking at the evidence, the first document [21677849:21677849_0] mentions the complete genome sequence of Arthrobacter phenanthrenivorans type strain (Sphe3). That's a specific species within the genus Arthrobacter, so that shows that at least one member has its genome sequenced. The third document [23039946:23039946_0] talks about the complete genome sequence of Arthrobacter sp. Rue61a. Again, this is another species in the same genus, so that's another example of a complete genome being available. The second document [15246528:15246528_0] discusses Plasmodium falciparum, which is a different organism, so it's not relevant to Arthrobacter. So from", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if the complete genome of bacteria in the genus Arthrobacter is available. The evidence given has three documents. First, I need to check each document to see if they mention the availability of complete genomes for Arthrobacter species. Looking at the first evidence: [21677849:21677849_0] talks about the complete genome sequence of Arthrobacter phenanthrenivorans type strain (Sphe3). So that's a specific strain, but it's a complete genome. The second evidence is about Plasmodium falciparum compared to Arabidopsis, which isn't relevant to Arthrobacter. Third evidence: [23039946:23039946_0] mentions the complete genome sequence of Arthrobacter sp. Rue61a. Another strain, but again, a complete genome. So from the evidence, there are at least two examples of complete genomes for different strains in the genus Arthrobacter. The question is", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if the complete genome of bacteria in the genus Arthrobacter is available. The evidence given has three references. First, looking at the evidence, there are two mentions of Arthrobacter. The first one is [21677849:21677849_0] which talks about the complete genome sequence of Arthrobacter phenanthrenivorans type strain (Sphe3). That's a specific strain, so that's a complete genome available for that particular species. Then there's [23039946:23039946_0] which mentions the complete genome sequence of Arthrobacter sp. Rue61a. Again, this is another strain within the genus. So both references indicate that at least two different strains of Arthrobacter have their complete genomes sequenced. The third reference [15246528:15246528_0] is about Plasmodium falciparum, which isn't related to Arthrob", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["21677849", "23039946", "28138355", "28315371", "28450506", "28642378", "28904741"], "ideal_answer": "Yes, the complete genome sequence of Arthrobacter (two strains) is deposited in GenBank."}
{"question_id": "56e2cec751531f7e33000015", "question": "What is the structural fold of bromodomain proteins?", "retrieved_chunks": [{"doc_id": "17694091", "chunk_id": "17694091_0", "score": 6.534749984741211, "text": "These new studies also support the notion that functional diversity of a conserved bromodomain structural fold is achieved by evolutionary changes of structurally flexible amino-acid sequences in the ligand binding site such as the ZA and BC loops."}, {"doc_id": "17274598", "chunk_id": "17274598_0", "score": 2.550708293914795, "text": "The Brg1 bromodomain conserves the left-handed, four-helix bundle topology found in other bromodomain structures. However, the alphaZ helix of Brg1 bromodomain is about 4 residues shorter relative to previously published bromodomain structures."}, {"doc_id": "17148447", "chunk_id": "17148447_0", "score": 1.9005732536315918, "text": "Here, we report the crystal structure of the N-terminal bromodomain (BD1, residues 74-194) of human BRD2."}], "context": "[17694091:17694091_0] These new studies also support the notion that functional diversity of a conserved bromodomain structural fold is achieved by evolutionary changes of structurally flexible amino-acid sequences in the ligand binding site such as the ZA and BC loops.\n[17274598:17274598_0] The Brg1 bromodomain conserves the left-handed, four-helix bundle topology found in other bromodomain structures. However, the alphaZ helix of Brg1 bromodomain is about 4 residues shorter relative to previously published bromodomain structures.\n[17148447:17148447_0] Here, we report the crystal structure of the N-terminal bromodomain (BD1, residues 74-194) of human BRD2.", "answer": "<think> Okay, let's tackle this question about the structural fold of bromodomain proteins. The user wants a concise answer with citations and a confidence level. First, I need to look at the evidence provided. There are three references here. Let me go through each one. The first one says that bromodomain structural fold is conserved but varies functionally due to changes in flexible regions like ZA and BC loops. So it's talking about the overall structure being similar but with variations in certain areas. The second reference mentions Brg1 bromodomain having a left-handed, four-helix bundle topology, which is common in other bromodomains. However, the alphaZ helix is shorter by 4 residues. This suggests that while the basic fold is maintained, there are some differences in specific parts. The third reference talks about the crystal structure of BRD2's N-terminal BD1, but it doesn't specify the structural fold, just that they reported the structure. So maybe this supports the idea that the structure is a four-helix bundle, but I need to check if that's mentioned here. Wait, the second reference does mention the four-helix bundle topology", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question about the structural fold of bromodomain proteins. The user wants a concise answer with citations and a confidence level. First, I need to look at the evidence provided. There are three references here. Let me go through each one. The first one says that bromodomain structural fold is conserved but varies functionally due to changes in flexible regions like ZA and BC loops. So it's talking about the overall structure being similar but with variations in certain areas. The second reference mentions Brg1 bromodomain having a left-handed, four-helix bundle topology, which is common in other bromodomains. However, the alphaZ helix is shorter by 4 residues. This suggests that while the basic fold is maintained, there are some differences in specific parts. The third reference talks about the crystal structure of BRD2's N-terminal BD1, but it doesn't specify the structural fold, just that they reported the structure. So maybe this supports the idea that the structure is a four-helix bundle, but I need to check if that's mentioned here. Wait, the second reference does mention the four-helix bundle topology", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question about the structural fold of bromodomain proteins. The user wants a concise answer with citations and a confidence level. First, I need to look at the evidence provided. There are three references here. Let me go through each one. The first evidence [17694091:17694091_0] talks about the structural fold being conserved but with variations in certain loops like ZA and BC. It mentions that the functional diversity comes from changes in these flexible regions. So this suggests that the basic structure is maintained, but there are variations in specific areas. The second evidence [17274598:17274598_0] states that Brg1's bromodomain has a left-handed four-helix bundle topology, which is similar to other bromodomains. However, the alphaZ helix is shorter by 4 residues compared to previous structures. This indicates that while the overall fold is conserved, there are specific modifications. The third evidence [17148447:17148447", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to generate a candidate biomedical answer about the structural fold of bromodomain proteins based on the provided evidence. Let me start by understanding the question and the given evidence. The user is asking for the structural fold of bromodomain proteins. The evidence has three chunks from different studies. First chunk (17694091:17694091_0) talks about the functional diversity of the conserved bromodomain structural fold being achieved by evolutionary changes in flexible amino-acid sequences, specifically the ZA and BC loops. This suggests that while the overall structure is conserved, certain regions can vary. Second chunk (17274598:17274598_0) mentions that Brg1 bromodomain conserves the left-handed, four-helix bundle topology, which is common in other bromodomain structures. However, the alphaZ helix is 4 residues shorter. So the main structural fold is a four-helix bundle, but there's a variation in one of the helices. Third chunk (17148447:1", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["10365964", "10827952", "11090279", "17148447", "17274598", "17498659", "17582821", "17694091", "17848202"], "ideal_answer": "The structure fold of the bromodomains is an all-alpha-helical fold, which includes a left-handed four-helix bundle topology, with two short additional helices in a long connecting loop."}
{"question_id": "515deafd298dcd4e51000025", "question": "List the endoscopic diagnoses that have been reported in children with autism", "retrieved_chunks": [{"doc_id": "11007230", "chunk_id": "11007230_5", "score": 5.366944313049316, "text": "This study describes some of the endoscopic and pathological characteristics in a group of children with developmental disorders (affected children) that are associated with behavioral regression and bowel symptoms, and compares them with pediatric controls. METHODS: Ileocolonoscopy and biopsy were performed on 60 affected children (median age 6 yr, range 3-16; 53 male). Developmental diagnoses were autism (50 patients), Asperger's syndrome (five), disintegrative disorder (two), attention deficit hyperactivity disorder (ADHD) (one), schizophrenia (one), and dyslexia (one)."}, {"doc_id": "12846385", "chunk_id": "12846385_0", "score": 0.0751354768872261, "text": "In a sample of 137 children, age 24-96 months, classified as having autism or ASD by the Autism Diagnostic Observation Schedule-Generic, 24 percent had a history of at least one chronic gastrointestinal symptom. The most common symptom was diarrhea, which occurred in 17 percent."}, {"doc_id": "16003132", "chunk_id": "16003132_2", "score": 0.0657196119427681, "text": "Intestinal mucosal pathology, characterized by ileo-colonic lymphoid nodular hyperplasia (LNH) and mild acute and chronic inflammation of the colorectum, small bowel and stomach, has been reported in children with autistic spectrum disorder (ASD)"}], "context": "[11007230:11007230_5] This study describes some of the endoscopic and pathological characteristics in a group of children with developmental disorders (affected children) that are associated with behavioral regression and bowel symptoms, and compares them with pediatric controls. METHODS: Ileocolonoscopy and biopsy were performed on 60 affected children (median age 6 yr, range 3-16; 53 male). Developmental diagnoses were autism (50 patients), Asperger's syndrome (five), disintegrative disorder (two), attention deficit hyperactivity disorder (ADHD) (one), schizophrenia (one), and dyslexia (one).\n[12846385:12846385_0] In a sample of 137 children, age 24-96 months, classified as having autism or ASD by the Autism Diagnostic Observation Schedule-Generic, 24 percent had a history of at least one chronic gastrointestinal symptom. The most common symptom was diarrhea, which occurred in 17 percent.\n[16003132:16003132_2] Intestinal mucosal pathology, characterized by ileo-colonic lymphoid nodular hyperplasia (LNH) and mild acute and chronic inflammation of the colorectum, small bowel and stomach, has been reported in children with autistic spectrum disorder (ASD)", "answer": "<think> Okay, let's tackle this query. The user is asking for endoscopic diagnoses reported in children with autism. I need to look through the provided evidence to find relevant information. First, looking at evidence [11007230:11007230_5], it mentions that 60 affected children with developmental disorders (including autism) underwent ileocolonoscopy and biopsy. The study notes endoscopic and pathological characteristics. So, this might include findings like ileo-colonic lymphoid nodular hyperplasia, which is mentioned in another evidence point. Then, [12846385:12846385_0] talks about 24% of autistic children having chronic gastrointestinal symptoms, with diarrhea being common. However, this is more about symptoms rather than specific endoscopic diagnoses. The mention of \"history of at least one chronic gastrointestinal symptom\" might not directly point to an endoscopic diagnosis but could be related. The third evidence [16003132:16003132_2] explicitly states that intestinal mucosal pathology, including", "citations": [{"doc_id": "11007230", "chunk_id": "11007230_5"}, {"doc_id": "12846385", "chunk_id": "12846385_0"}, {"doc_id": "16003132", "chunk_id": "16003132_2"}], "candidates": [{"answer": "<think> Okay, let's tackle this query. The user is asking for endoscopic diagnoses reported in children with autism. I need to look through the provided evidence to find relevant information. First, looking at evidence [11007230:11007230_5], it mentions that 60 affected children with developmental disorders (including autism) underwent ileocolonoscopy and biopsy. The study notes endoscopic and pathological characteristics. So, this might include findings like ileo-colonic lymphoid nodular hyperplasia, which is mentioned in another evidence point. Then, [12846385:12846385_0] talks about 24% of autistic children having chronic gastrointestinal symptoms, with diarrhea being common. However, this is more about symptoms rather than specific endoscopic diagnoses. The mention of \"history of at least one chronic gastrointestinal symptom\" might not directly point to an endoscopic diagnosis but could be related. The third evidence [16003132:16003132_2] explicitly states that intestinal mucosal pathology, including", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user wants a list of endoscopic diagnoses in children with autism based on the provided evidence. First, I need to look at each evidence snippet. The first study (11007230:11007230_5) mentions ileocolonoscopy and biopsy in children with developmental disorders, including autism. They found characteristics like lymphoid nodular hyperplasia and inflammation. So that's an endoscopic finding. The second study (12846385:12846385_0) talks about gastrointestinal symptoms like diarrhea, but it's more about symptoms than specific endoscopic diagnoses. However, the third study (16003132:16003132_2) explicitly mentions intestinal mucosal pathology with ileo-colonic lymphoid nodular hyperplasia and inflammation. That seems to be a direct endoscopic diagnosis. So combining these, the main endoscopic diagnoses are ileocolonic lymphoid nodular hyperplasia and mild acute/chronic inflammation in the colorectum, small bowel", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user wants a list of endoscopic diagnoses in children with autism based on the provided evidence. First, I need to look at each evidence snippet. The first document [11007230:11007230_5] mentions ileocolonoscopy and biopsy in 60 children with developmental disorders, including autism. They found some endoscopic and pathological characteristics. The specific findings here are ileo-colonic lymphoid nodular hyperplasia (LNH) and mild acute/chronic inflammation of the colorectum, small bowel, and stomach. But this is from a study on developmental disorders, not specifically autism. However, since autism is mentioned as one of the diagnoses, maybe this applies. The second document [12846385:12846385_0] talks about 24% of autistic children having chronic GI symptoms, with diarrhea being the most common. But it doesn't mention specific endoscopic diagnoses, just symptoms. The third document [16003132:16003", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["10547242", "11007230", "12907332", "16003132", "22607127", "9585670"], "ideal_answer": "Endoscopic examinations in autistic children have been reported to show : I or II reflux esophagitis, Achalasia, chronic gastritis and chronic duodenitis, mild acute and chronic inflammation of the small bowel and colorectum and Ileo-colonic lymphoid nodular hyperplasia (LNH). The number of Paneth's cells in the duodenal crypts was found to be significantly elevated in autistic children compared with non-autistic control subjects. Low intestinal carbohydrate digestive enzyme activity was reported although there was no abnormality found in pancreatic function. Autistic children have ben reported to have an increased pancreatico-biliary fluid output after intravenous secretin administration."}
{"question_id": "532624ae600967d132000005", "question": "What are the outcomes of Renal sympathetic denervation?", "retrieved_chunks": [{"doc_id": "23890950", "chunk_id": "23890950_0", "score": 8.073639869689941, "text": "Renal sympathetic denervation delivers not only a decrease in blood pressure levels but also renal as well as systemic sympathetic nerve activity. The reduction in blood pressure appears to be sustained over 3 years after the procedure, which implies no counterregulatory mechanism or re-innervation of afferent renal sympathetic nerve so far."}, {"doc_id": "23819768", "chunk_id": "23819768_0", "score": 7.7841081619262695, "text": "Renal sympathetic denervation not only reduces blood pressure but also renal as well as systemic sympathetic nerve activity in such patients. The reduction in blood pressure appears to be sustained over 3 years after the procedure, which suggests absence of re-innervation of renal sympathetic nerves. Safety appears to be adequate."}, {"doc_id": "23774592", "chunk_id": "23774592_0", "score": 7.633447647094727, "text": "Clinical trials of renal sympathetic denervation have shown significant reductions in blood pressure in these patients. Renal sympathetic denervation also reduces heart rate, which is a surrogate marker of cardiovascular risk."}], "context": "[23890950:23890950_0] Renal sympathetic denervation delivers not only a decrease in blood pressure levels but also renal as well as systemic sympathetic nerve activity. The reduction in blood pressure appears to be sustained over 3 years after the procedure, which implies no counterregulatory mechanism or re-innervation of afferent renal sympathetic nerve so far.\n[23819768:23819768_0] Renal sympathetic denervation not only reduces blood pressure but also renal as well as systemic sympathetic nerve activity in such patients. The reduction in blood pressure appears to be sustained over 3 years after the procedure, which suggests absence of re-innervation of renal sympathetic nerves. Safety appears to be adequate.\n[23774592:23774592_0] Clinical trials of renal sympathetic denervation have shown significant reductions in blood pressure in these patients. Renal sympathetic denervation also reduces heart rate, which is a surrogate marker of cardiovascular risk.", "answer": "<think> Okay, so the user is asking about the outcomes of Renal sympathetic denervation. Let me look at the evidence provided. First, there are three documents. All of them mention that the procedure leads to a decrease in blood pressure. The first two documents also talk about reductions in renal and systemic sympathetic nerve activity. The third one adds that heart rate is reduced, which is a cardiovascular risk marker. The key outcomes here are the blood pressure reduction, decreased sympathetic activity, and maybe the sustained effect over three years. Also, the safety aspect is mentioned in the second document. But the question is about outcomes, so focusing on the effects rather than safety. I need to condense this into a concise answer with citations. The answer should mention blood pressure decrease, renal and systemic sympathetic nerve activity reduction, and the sustained effect. The confidence level should be high since all three sources agree on these points. The base_confidence would be 1.0 because all evidence supports the same outcomes without conflicting information. </think> { \"answer\": \"Renal sympathetic denervation leads to significant reductions in blood pressur", "citations": [], "candidates": [{"answer": "<think> Okay, so the user is asking about the outcomes of Renal sympathetic denervation. Let me look at the evidence provided. First, there are three documents. All of them mention that the procedure leads to a decrease in blood pressure. The first two documents also talk about reductions in renal and systemic sympathetic nerve activity. The third one adds that heart rate is reduced, which is a cardiovascular risk marker. The key outcomes here are the blood pressure reduction, decreased sympathetic activity, and maybe the sustained effect over three years. Also, the safety aspect is mentioned in the second document. But the question is about outcomes, so focusing on the effects rather than safety. I need to condense this into a concise answer with citations. The answer should mention blood pressure decrease, renal and systemic sympathetic nerve activity reduction, and the sustained effect. The confidence level should be high since all three sources agree on these points. The base_confidence would be 1.0 because all evidence supports the same outcomes without conflicting information. </think> { \"answer\": \"Renal sympathetic denervation leads to significant reductions in blood pressur", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to generate a JSON answer based on the evidence provided. Let me start by understanding the question: What are the outcomes of Renal sympathetic denervation? Looking at the evidence, there are three documents. All of them mention that renal sympathetic denervation leads to reduced blood pressure. Document 23890950 and . Also, they mention reductions in renal and systemic sympathetic nerve activity. The first two documents also note that the blood pressure reduction is sustained for three years, suggesting no re-innervation. The third document adds that there's a reduction in heart rate, which is a cardiovascular risk marker. So the main outcomes are decreased blood pressure, reduced sympathetic nerve activity (both renal and systemic), and sustained effects over 3 years. Also, the third document mentions a decrease in heart rate. I need to combine these points into a concise answer with citations. The answer should be brief but include the key outcomes. Now, for the base_confidence. All three documents agree on the blood pressure reduction and the duration. The third one adds heart rate as a surrogate marker. Since all sources are consistent, the confidence sho", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this query. The user wants a JSON answer with the outcomes of Renal sympathetic denervation, citing the evidence provided. First, I need to look at the evidence snippets. All three documents mention that renal sympathetic denervation reduces blood pressure. Document 23890950 and restriction 23819768 both say the reduction is sustained for 3 years, implying no re-innervation. Also, document 23774592 adds that it reduces heart rate, which is a cardiovascular risk marker. So the main outcomes are decreased blood pressure and reduced heart rate. The sustainability over 3 years is important. I should mention that the blood pressure reduction is long-lasting, and there's no re-innervation observed. Also, the heart rate reduction is a key point. Now, check if all three documents support this. Yes, all three mention BP reduction, and two mention the 3-year sustainability. The third adds heart rate as a surrogate marker. So combining these, the answer should include BP decrease, sustained over 3 years, and reduced heart rate. Confidence level:", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["21247927", "22573363", "23176687", "23514712", "23541665", "23774592", "23819768", "23890950", "24029963"], "ideal_answer": "Significant decreases and progressively higher reductions of systolic and diastolic blood pressure were observed after RSD. The complication rate was minimal. Renal sympathetic denervation also reduces heart rate, which is a surrogate marker of cardiovascular risk."}
{"question_id": "5518e7da622b194345000004", "question": "Which MAP kinase phosphorylates the transcription factor c-jun?", "retrieved_chunks": [{"doc_id": "8607977", "chunk_id": "8607977_1", "score": 9.816341400146484, "text": "A candidate for this extended family of MAP kinases is the c-Jun NH2-terminal kinase (Jnk), which binds to and phosphorylates the transcription factor c-Jun at the activating sites Ser-63 and Ser-73."}, {"doc_id": "8607977", "chunk_id": "8607977_0", "score": 9.730976104736328, "text": "A candidate for this extended family of MAP kinases is the c-Jun NH2-terminal kinase (Jnk), which binds to and phosphorylates the transcription factor c-Jun at the activating sites Ser-63 and Ser-73"}, {"doc_id": "23028407", "chunk_id": "23028407_0", "score": 5.489477634429932, "text": "JNK phosphorylates and regulates the activity of transcription factors other than c-Jun, including ATF2, Elk-1, p53 and c-Myc and non-transcription factors, such as members of the Bcl-2 family."}], "context": "[8607977:8607977_1] A candidate for this extended family of MAP kinases is the c-Jun NH2-terminal kinase (Jnk), which binds to and phosphorylates the transcription factor c-Jun at the activating sites Ser-63 and Ser-73.\n[8607977:8607977_0] A candidate for this extended family of MAP kinases is the c-Jun NH2-terminal kinase (Jnk), which binds to and phosphorylates the transcription factor c-Jun at the activating sites Ser-63 and Ser-73\n[23028407:23028407_0] JNK phosphorylates and regulates the activity of transcription factors other than c-Jun, including ATF2, Elk-1, p53 and c-Myc and non-transcription factors, such as members of the Bcl-2 family.", "answer": "<think> Okay, let's tackle this question. The user is asking which MAP kinase phosphorylates the transcription factor c-jun. Looking at the evidence provided, there are three chunks. First, chunk 8607977_1 and oint 8607977_0 both mention Jnk (c-Jun NH2-terminal kinase) phosphorylating c-Jun at Ser-63 and Ser-73. The third chunk talks about JNK regulating other transcription factors like ATF2, Elk-1, p53, and c-Myc, but also mentions non-transcription factors. However, the key point here is that the first two chunks directly state that Jnk phosphorylates c-Jun. The third chunk confirms JNK's role in regulating transcription factors, including c-Jun, but it's more general. So the answer should be Jnk, citing the first two chunks. The confidence is high because two separate chunks mention this exact relationship. The third chunk supports that JNK is involved in transcription factors, which includes c-jun, but the direct evidence is from the first two. So base_confidence would be 1.0", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which MAP kinase phosphorylates the transcription factor c-jun. Looking at the evidence provided, there are three chunks. First, chunk 8607977_1 and oint 8607977_0 both mention Jnk (c-Jun NH2-terminal kinase) phosphorylating c-Jun at Ser-63 and Ser-73. The third chunk talks about JNK regulating other transcription factors like ATF2, Elk-1, p53, and c-Myc, but also mentions non-transcription factors. However, the key point here is that the first two chunks directly state that Jnk phosphorylates c-Jun. The third chunk confirms JNK's role in regulating transcription factors, including c-Jun, but it's more general. So the answer should be Jnk, citing the first two chunks. The confidence is high because two separate chunks mention this exact relationship. The third chunk supports that JNK is involved in transcription factors, which includes c-jun, but the direct evidence is from the first two. So base_confidence would be 1.0", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which MAP kinase phosphorylates the transcription factor c-jun. Looking at the evidence provided, there are three chunks. First, chunk 8607977_1 and 些 other mention Jnk (c-Jun NH2-terminal kinase) phosphorylating c-Jun at Ser-63 and Ser-73. The second chunk is a duplicate of the first, so that's redundant. The third chunk says JNK also phosphorylates other factors like ATF2, Elk-1, p53, c-Myc, etc., but the question is specifically about c-jun. So the answer should be Jnk, citing the first two chunks. The confidence is high because the evidence directly states that Jnk phosphorylates c-Jun. The third chunk doesn't contradict but adds more info about other targets, which doesn't affect the answer here. So base_confidence would be 1.0 since the evidence clearly points to Jnk. </think> { \"answer\": \"The c-Jun NH2-terminal kinase (Jnk) phosphorylates the transcription factor c-jun [8607", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which MAP kinase phosphorylates the transcription factor c-jun. Looking at the evidence provided, there are three chunks. First, chunk 8607977_1 and 8607977_0 both mention that Jnk binds to and phosphorylates c-Jun at Ser-63 and Ser-73. So that's a direct answer. The other chunk, 23028407_0, talks about JNK phosphorylating other factors like ATF2, Elk-1, p53, and c-Myc, but also mentions non-transcription factors. However, the question specifically asks about c-jun, which is a transcription factor. The key here is that the first two chunks clearly state that Jnk is responsible for phosphorylating c-Jun. The third chunk confirms JNK's role in general but doesn't specify c-jun. So the answer should be Jnk (c-Jun NH2-terminal kinase). The confidence is high because two separate chunks directly cite this, and the third supports the family of kinases but not specifically", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["15228586", "15637069", "15708845", "23028407", "23147205", "23385061", "24113186", "24139673", "24144051", "24252081", "24270002", "24272171", "24285252", "24291243", "24300195", "24321066", "24321566", "8607977"], "ideal_answer": "c-Jun is phosphorylated by c-Jun NH2-terminal kinase (JNK). An in vitro kinase assay revealed that c-Jun phosphorylation is primarily mediated via activated c-Jun N-terminal protein kinase (JNK)."}
{"question_id": "530a5117970c65fa6b000007", "question": "What is the meaning of the acronym \"TAILS\" used in protein N-terminomics?", "retrieved_chunks": [{"doc_id": "23667905", "chunk_id": "23667905_0", "score": 4.396615028381348, "text": "analysis of N- terminomics data generated by terminal amine isotopic labeling of substrates (TAILS) enables high confidence peptide to protein assignment, protein N-terminal characterization and annotation, and for protease analysis readily allows protease substrate discovery with high confidence."}, {"doc_id": "21604129", "chunk_id": "21604129_1", "score": 2.994138717651367, "text": "Identification of proteolytic products and natural protein N-termini by Terminal Amine Isotopic Labeling of Substrates (TAILS)."}, {"doc_id": "21604129", "chunk_id": "21604129_0", "score": 2.482731342315674, "text": "Here we present in detail the steps required to perform our recently described approach we call Terminal Amine Isotopic Labeling of Substrates (TAILS), a combined N-terminomics and protease substrate discovery degradomics platform for the simultaneous quantitative and global analysis of the N-terminome and proteolysis in one MS/MS experiment."}], "context": "[23667905:23667905_0] analysis of N- terminomics data generated by terminal amine isotopic labeling of substrates (TAILS) enables high confidence peptide to protein assignment, protein N-terminal characterization and annotation, and for protease analysis readily allows protease substrate discovery with high confidence.\n[21604129:21604129_1] Identification of proteolytic products and natural protein N-termini by Terminal Amine Isotopic Labeling of Substrates (TAILS).\n[21604129:21604129_0] Here we present in detail the steps required to perform our recently described approach we call Terminal Amine Isotopic Labeling of Substrates (TAILS), a combined N-terminomics and protease substrate discovery degradomics platform for the simultaneous quantitative and global analysis of the N-terminome and proteolysis in one MS/MS experiment.", "answer": "<think> Okay, I need to figure out what TAILS stands for in the context of protein N-terminomics. Let me look at the evidence provided. The first document says \"terminal amine isotopic labeling of substrates (TAILS)\" so that's a direct mention. The second one also refers to \"Terminal Amine Isotopic Labeling of Substrates (TAILS)\". The third document talks about the steps for TAILS, describing it as a method for N-terminomics and protease substrate discovery. So putting this together, TAILS is an acronym for Terminal Amine Isotopic Labeling of Substrates. The key here is to make sure that the answer is concise and includes the citations. The user wants the answer in JSON with the answer and base_confidence. The confidence should be high since all three documents consistently refer to TAILS as that full term. I should check if there's any conflicting information, but all sources agree. So the answer is clear and the confidence can be set to 1.0. </think> { \"answer\": \"TAILS stands for Terminal Amine Isotopic Labeling of Substrates", "citations": [], "candidates": [{"answer": "<think> Okay, I need to figure out what TAILS stands for in the context of protein N-terminomics. Let me look at the evidence provided. The first document says \"terminal amine isotopic labeling of substrates (TAILS)\" so that's a direct mention. The second one also refers to \"Terminal Amine Isotopic Labeling of Substrates (TAILS)\". The third document talks about the steps for TAILS, describing it as a method for N-terminomics and protease substrate discovery. So putting this together, TAILS is an acronym for Terminal Amine Isotopic Labeling of Substrates. The key here is to make sure that the answer is concise and includes the citations. The user wants the answer in JSON with the answer and base_confidence. The confidence should be high since all three documents consistently refer to TAILS as that full term. I should check if there's any conflicting information, but all sources agree. So the answer is clear and the confidence can be set to 1.0. </think> { \"answer\": \"TAILS stands for Terminal Amine Isotopic Labeling of Substrates", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to figure out what TAILS stands for in the context of protein N-terminomics. Let me look at the evidence provided. The first document mentions \"terminal amine isotopic labeling of substrates (TAILS)\" and explains that it's used for N-terminomics data analysis. The second document also refers to \"Terminal Amine Isotopic Labeling of Substrates (TAILS)\" in the context of identifying proteolytic products and natural N-termini. The third document talks about the steps for TAILS as a method combining N-terminomics and protease substrate discovery. So, putting that together, TAILS is an acronym for Terminal Amine Isotopic Labeling of Substrates. The key here is to check if all the references support this. All three documents mention TAILS in relation to labeling substrates with isotopes, so it's consistent. The answer should be straightforward. The confidence level is high because all sources agree on the acronym's meaning. I'll make sure to cite the relevant chunks from the evidence. </think> { \"answer\": \"TAILS stands for Terminal Amine Isotopic Label", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to figure out what TAILS stands for in the context of protein N-terminomics. Let me look at the evidence provided. The first document mentions \"terminal amine isotopic labeling of substrates (TAILS)\" and explains that it's used for N-terminomics data analysis. The second document also refers to \"Terminal Amine Isotopic Labeling of Substrates (TAILS)\" in the context of identifying proteolytic products and N-termini. The third document talks about the steps for TAILS as a method combining N-terminomics and protease substrate discovery. So, putting this together, TAILS is an acronym for Terminal Amine Isotopic Labeling of Substrates. The key here is to make sure that the answer is concise and includes the citations from the documents. The user wants the answer in JSON with the answer and base_confidence. The confidence should be high since all three documents consistently use TAILS in this context. I'll check if there's any conflicting information, but it seems consistent. So the answer should state the acronym expansion and cite the relevant chunks. </think> { \"answer\":", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["20305284", "21604127", "21604129", "22367194", "22577022", "23667905"], "ideal_answer": "TAILS stands for \"Terminal Amine Isotopic Labeling of Substrates\""}
{"question_id": "56bf365eef6e39474100000e", "question": "Do mutations of AKT1 occur in meningiomas?", "retrieved_chunks": [{"doc_id": "24096618", "chunk_id": "24096618_1", "score": 9.515704154968262, "text": "AKT1E17K mutations were exclusively seen in meningiomas and occurred in 65 of 958 of these tumors. A strong preponderance was seen in the variant of meningothelial meningioma WHO grade I of basal and spinal localization. In contrast, AKT1E17K mutations were rare in WHO grade II and absent in WHO grade III meningiomas."}, {"doc_id": "23475883", "chunk_id": "23475883_3", "score": 9.238105773925781, "text": "SMO and AKT1 mutations occur in non-NF2 meningiomas."}, {"doc_id": "23475883", "chunk_id": "23475883_2", "score": 9.040596008300781, "text": "SMO and AKT1 mutations occur in non-NF2 meningiomas"}], "context": "[24096618:24096618_1] AKT1E17K mutations were exclusively seen in meningiomas and occurred in 65 of 958 of these tumors. A strong preponderance was seen in the variant of meningothelial meningioma WHO grade I of basal and spinal localization. In contrast, AKT1E17K mutations were rare in WHO grade II and absent in WHO grade III meningiomas.\n[23475883:23475883_3] SMO and AKT1 mutations occur in non-NF2 meningiomas.\n[23475883:23475883_2] SMO and AKT1 mutations occur in non-NF2 meningiomas", "answer": "<think> Okay, let's tackle this question. The user is asking if mutations of AKT1 occur in meningiomas. I need to check the provided evidence to find answers. Looking at the first piece of evidence, doc ID 24096618:24096618_1 mentions that AKT1E17K mutations were exclusively seen in meningiomas, occurring in 65 out of 958 tumors. That's a clear indication that AKT1 mutations do occur in meningiomas. The confidence here is pretty high because it's a specific study with numbers. Then there are two other entries from doc ID 23475883:23475883_3 and 23475883_2, both stating that SMO and AKT1 mutations occur in non-NF2 meningiomas. This reinforces the idea that AKT1 mutations are present in some meningiomas, specifically non-NF2 types. So combining these pieces of evidence, it's clear that AKT1 mutations do occur in meningiomas.", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if mutations of AKT1 occur in meningiomas. I need to check the provided evidence to find answers. Looking at the first piece of evidence, doc ID 24096618:24096618_1 mentions that AKT1E17K mutations were exclusively seen in meningiomas, occurring in 65 out of 958 tumors. That's a clear indication that AKT1 mutations do occur in meningiomas. The confidence here is pretty high because it's a specific study with numbers. Then there are two other entries from doc ID 23475883:23475883_3 and 23475883_2, both stating that SMO and AKT1 mutations occur in non-NF2 meningiomas. This reinforces the idea that AKT1 mutations are present in some meningiomas, specifically non-NF2 types. So combining these pieces of evidence, it's clear that AKT1 mutations do occur in meningiomas.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if mutations of AKT1 occur in meningiomas. The evidence provided has three chunks. First chunk (24096618:24096618_1) says that AKT1E17K mutations are exclusively seen in meningiomas, specifically 65 out of 958 tumors. It also mentions a strong preponderance in certain grades and locations. So this directly answers the question with a high confidence. Second chunk (23475883:23475883_3) states that SMO and AKT1 mutations occur in non-NF2 meningiomas. Similarly, the third chunk is a repeat of the second. So both of these support that AKT1 mutations are present in meningiomas, but specifically in non-NF2 types. Now, I need to combine this information. The first source is more detailed, mentioning the exact mutation (E17K) and the frequency. The other two sources mention the presence of AKT1 mutations in non-NF2 mening", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if mutations of AKT1 occur in meningiomas. I need to check the provided evidence to find answers. Looking at the first piece of evidence, document 24096618:24096618_1 mentions that AKT1E17K mutations were exclusively seen in meningiomas, occurring in 65 out of 958 tumors. That's a clear indication that AKT1 mutations do occur in meningiomas. The confidence here is high because it's a specific study with numbers. The other two pieces of evidence from 23475883:23475883_3 and 23475883:23475883_2 both state that SMO and AKT1 mutations occur in non-NF2 meningiomas. This supports the presence of AKT1 mutations in meningiomas, but they don't specify the exact type. However, since the first evidence already confirms it, this adds to the confidence. So combining these,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["23334667", "23348505", "23475883", "24096618", "25146167", "25857641"], "ideal_answer": "Yes, AKT1 mutation occurs in meningiomas."}
{"question_id": "52bf202003868f1b06000018", "question": "What are the main indications of lacosamide?", "retrieved_chunks": [{"doc_id": "17433624", "chunk_id": "17433624_2", "score": 5.424102306365967, "text": "These results suggest that lacosamide may have the potential to be clinically useful for at least the treatment of generalized tonic-clonic and partial-onset epilepsies, and support ongoing clinical trials in these indications."}, {"doc_id": "17433624", "chunk_id": "17433624_0", "score": 2.210594415664673, "text": "Lacosamide was effective against sound-induced seizures in the genetically susceptible Frings mouse, against maximal electroshock test (MES)-induced seizures in rats and mice, in the rat hippocampal kindling model of partial seizures, and in the 6Hz model of psychomotor seizures in mice."}, {"doc_id": "20677583", "chunk_id": "20677583_2", "score": 1.9226142168045044, "text": "Lacosamide (LCM) is a newer antiepileptic drug with a dual mode of action."}], "context": "[17433624:17433624_2] These results suggest that lacosamide may have the potential to be clinically useful for at least the treatment of generalized tonic-clonic and partial-onset epilepsies, and support ongoing clinical trials in these indications.\n[17433624:17433624_0] Lacosamide was effective against sound-induced seizures in the genetically susceptible Frings mouse, against maximal electroshock test (MES)-induced seizures in rats and mice, in the rat hippocampal kindling model of partial seizures, and in the 6Hz model of psychomotor seizures in mice.\n[20677583:20677583_2] Lacosamide (LCM) is a newer antiepileptic drug with a dual mode of action.", "answer": "<think> Okay, let's tackle this question about the main indications of lacosamide. The user wants a concise answer with citations and a confidence score. First, I need to look at the evidence provided. The first document says that lacosamide may be useful for generalized tonic-clonic and partial-onset epilepsies, supporting clinical trials. That's a direct mention of indications. The second document talks about effectiveness in various animal models, but those are preclinical studies. The third mentions it's a newer drug with dual action, but that's more about mechanism than indications. The question is about main indications, so the first evidence is the most relevant. The answer should include both generalized tonic-clonic and partial-onset epilepsies, citing document 17433624:17433622. The confidence here is high because it's a direct statement from a study. But I need to check if there's any conflicting info. The other documents don't mention indications, so no conflict. So the answer is those two types of epilepsy, and the confidence is 0.95 or something like that. </think> { \"", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question about the main indications of lacosamide. The user wants a concise answer with citations and a confidence score. First, I need to look at the evidence provided. The first document says that lacosamide may be useful for generalized tonic-clonic and partial-onset epilepsies, supporting clinical trials. That's a direct mention of indications. The second document talks about effectiveness in various animal models, but those are preclinical studies. The third mentions it's a newer drug with dual action, but that's more about mechanism than indications. The question is about main indications, so the first evidence is the most relevant. The answer should include both generalized tonic-clonic and partial-onset epilepsies, citing document 17433624:17433622. The confidence here is high because it's a direct statement from a study. But I need to check if there's any conflicting info. The other documents don't mention indications, so no conflict. So the answer is those two types of epilepsy, and the confidence is 0.95 or something like that. </think> { \"", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question about the main indications of lacosamide. The user wants a concise answer with citations and a confidence score. First, I need to look at the evidence provided. There are three documents here. Let me go through each one. The first document (17433624:17433628_2) mentions that lacosamide may be useful for generalized tonic-clonic and partial-onset epilepsies, supporting clinical trials in these areas. That's a direct mention of indications. The second document (17433624:17433624_0) talks about effectiveness in various seizure models, like sound-induced seizures in mice, MES test in rats and mice, hippocampal kindling in rats, and 6Hz model in mice. But these are preclinical studies, so they support the indications but aren't the main clinical indications themselves. The third document (20677583:20677583_2) states that lacosamide is a newer antiepileptic drug with a dual mode", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this query. The user wants the main indications of lacosamide based on the provided evidence. First, I need to look at the evidence snippets. The first one mentions that lacosamide might be useful for generalized tonic-clonic and partial-onset epilepsies, with ongoing trials. The second snippet says it's effective in various seizure models, including sound-induced seizures, MES test, hippocampal kindling, and 6Hz model. The third snippet states it's a newer antiepileptic drug with dual action. The question is about main indications, so I should focus on the clinical uses. The first evidence directly mentions generalized tonic-clonic and partial-onset epilepsies. The other snippets talk about animal models, which support its efficacy but aren't direct clinical indications. The third snippet just describes it as a new drug with dual action, not specific indications. So the answer should highlight the two main indications from the first evidence. The confidence is moderate because the evidence mentions potential and ongoing trials, but doesn't have extensive clinical trial data. The base_confidence would be around 0.7 since there's some supporting evidence b", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["17433624", "17461888", "20677583", "21271304", "21301338", "21861814", "23288091", "23648276"], "ideal_answer": "Lacosamide is an anti-epileptic drug, licensed for refractory partial-onset seizures. In addition to this, it has demonstrated analgesic activity in various animal models. Apart from this, LCM has demonstrated potent effects in animal models for a variety of CNS disorders like schizophrenia and stress induced anxiety."}
{"question_id": "552fac4fbc4f83e828000006", "question": "Which fusion protein is involved in the development of Ewing sarcoma?", "retrieved_chunks": [{"doc_id": "16697960", "chunk_id": "16697960_2", "score": 9.145721435546875, "text": "Our understanding of Ewing's sarcoma development mediated by the EWS/FLI fusion protein has been limited by a lack of knowledge regarding the tumor cell of origin"}, {"doc_id": "25432018", "chunk_id": "25432018_0", "score": 8.639945030212402, "text": "EWS-FLI1 is an oncogenic fusion protein implicated in the development of Ewing's sarcoma family tumors (ESFT)"}, {"doc_id": "16697960", "chunk_id": "16697960_3", "score": 8.251150131225586, "text": "Thus, we developed a highly validated transcriptional profile for the EWS/FLI fusion protein and identified a critical target gene in Ewing's sarcoma development."}], "context": "[16697960:16697960_2] Our understanding of Ewing's sarcoma development mediated by the EWS/FLI fusion protein has been limited by a lack of knowledge regarding the tumor cell of origin\n[25432018:25432018_0] EWS-FLI1 is an oncogenic fusion protein implicated in the development of Ewing's sarcoma family tumors (ESFT)\n[16697960:16697960_3] Thus, we developed a highly validated transcriptional profile for the EWS/FLI fusion protein and identified a critical target gene in Ewing's sarcoma development.", "answer": "<think> Okay, let's tackle this question. The user is asking which fusion protein is involved in the development of Ewing sarcoma. The evidence provided has three entries. First, looking at the evidence documents. The first one (16697960:16697960_2) mentions EWS/FLI fusion protein but says our understanding is limited. The second document (25432018:25432018_0) explicitly states that EWS-FLI1 is an oncogenic fusion protein implicated in Ewing's sarcoma. The third document (16697960:16697960_3) again refers to EWS/FLI fusion protein. So, the key here is to identify the correct fusion protein name. The second evidence document clearly states \"EWS-FLI1\" as the fusion protein. The others mention \"EWS/FLI\", which might be a different notation but the main point is that the fusion protein is EWS-FLI1. The answer should be EWS-", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which fusion protein is involved in the development of Ewing sarcoma. The evidence provided has three entries. First, looking at the evidence documents. The first one (16697960:16697960_2) mentions EWS/FLI fusion protein but says our understanding is limited. The second document (25432018:25432018_0) explicitly states that EWS-FLI1 is an oncogenic fusion protein implicated in Ewing's sarcoma. The third document (16697960:16697960_3) again refers to EWS/FLI fusion protein. So, the key here is to identify the correct fusion protein name. The second evidence document clearly states \"EWS-FLI1\" as the fusion protein. The others mention \"EWS/FLI\", which might be a different notation but the main point is that the fusion protein is EWS-FLI1. The answer should be EWS-", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let me try to work through this. The user is asking which fusion protein is involved in the development of Ewing sarcoma. The evidence provided has three chunks. First chunk [16697960:16697960_2] mentions EWS/FLI fusion protein but says our understanding is limited. The second chunk [25432018:25432018_0] explicitly states that EWS-FLI1 is an oncogenic fusion protein implicated in Ewing's sarcoma. The third chunk [16697960:16697960_3] again refers to EWS/FLI fusion protein. So the key here is to identify the correct fusion protein name. The second evidence chunk clearly states \"EWS-FLI1\", which seems to be the specific fusion protein. The first and third chunks use \"EWS/FLI\" but the second one specifies FLI1. I need to check if there's a difference between EWS/FLI and EWS-FLI1.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which fusion protein is involved in the development of Ewing sarcoma. Looking at the evidence provided, there are three references. First, reference [16697960:16697960_2] mentions the EWS/FLI fusion protein but states that our understanding is limited. Then, [25432018:25432018_0] explicitly says EWS-FLI1 is an oncogenic fusion protein implicated in Ewing's sarcoma. The third reference again talks about EWS/FLI, but it's more about the transcriptional profile. So, the key here is to identify the specific fusion protein. The second evidence document clearly states \"EWS-FLI1\" as the fusion protein. The other references mention \"EWS/FLI\" but the first and third are more about the study of this protein rather than specifying the exact name. Since the question asks for the fusion protein, the correct answer should be EWS-FLI1. The confidence level is high because the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["16206264", "16697960", "17250957", "17453169", "18256529", "18485618", "19718047", "20691659", "21680731", "21979944", "22241085", "22723308", "23750284", "23894528", "24481407", "25162919", "25401475", "25432018", "25483190"], "ideal_answer": "Ewing sarcoma is the second most common bone malignancy in children and young adults. In almost 95% of the cases, it is driven by oncogenic fusion protein EWS/FLI1, which acts as an aberrant transcription factor, that upregulates or downregulates target genes, leading to cellular transformation."}
{"question_id": "56be0da3ef6e394741000007", "question": "List Hemolytic Uremic Syndrome Triad.", "retrieved_chunks": [{"doc_id": "24161037", "chunk_id": "24161037_0", "score": 8.726425170898438, "text": "Hemolytic uremic syndrome (HUS) is a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure."}, {"doc_id": "17705684", "chunk_id": "17705684_0", "score": 8.694110870361328, "text": "Hemolytic uremic syndrome is a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure"}, {"doc_id": "16387683", "chunk_id": "16387683_0", "score": 8.663264274597168, "text": "Hemolytic uremic syndrome (HUS) is a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure"}], "context": "[24161037:24161037_0] Hemolytic uremic syndrome (HUS) is a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure.\n[17705684:17705684_0] Hemolytic uremic syndrome is a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure\n[16387683:16387683_0] Hemolytic uremic syndrome (HUS) is a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure", "answer": "<think> Okay, let's tackle this query. The user wants the triad for HUS, and there are three evidence snippets provided. First, I need to check if all the sources agree. Looking at the evidence, each of the three chunks says the same thing: microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. So the answer is consistent across all references. Now, the answer should be concise, listing the triad with citations. The user specified to use [doc_id:chunk_id] format. Each chunk is from a different document but same content. So I can pick one citation, maybe the first one, but since they're all correct, perhaps list all three? Wait, the example in the problem shows using one citation. But the question says \"citations\" plural. However, in the evidence, all three chunks are the same. Maybe it's acceptable to cite one, but the user might expect all three. Hmm. Wait, looking back at the user's example: in their own message, they have [24161037:24161037_0", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this query. The user wants the triad for HUS, and there are three evidence snippets provided. First, I need to check if all the sources agree. Looking at the evidence, each of the three chunks says the same thing: microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. So the answer is consistent across all references. Now, the answer should be concise, listing the triad with citations. The user specified to use [doc_id:chunk_id] format. Each chunk is from a different document but same content. So I can pick one citation, maybe the first one, but since they're all correct, perhaps list all three? Wait, the example in the problem shows using one citation. But the question says \"citations\" plural. However, in the evidence, all three chunks are the same. Maybe it's acceptable to cite one, but the user might expect all three. Hmm. Wait, looking back at the user's example: in their own message, they have [24161037:24161037_0", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this query. The user wants the triad of Hemolytic Uremic Syndrome (HUS) from the provided evidence. Looking at the evidence, there are three documents mentioned. Each of them states that HUS is a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. The document IDs are 24161037, 17705684, and 16387683. All three chunks (0) in each document mention the same triad. The answer needs to be concise, listing the three components. Since all sources agree, the confidence should be high. The base_confidence can be set to 1.0 because all evidence points to the same triad without conflicting information. I need to make sure the answer includes the three elements and cite one of the documents. Let's pick the first one as the citation. </think> { \"answer\": \"Microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure [241610", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, the user is asking for the triad of Hemolytic Uremic Syndrome (HUS). Let me check the evidence provided. Looking at the three documents, each one mentions the same three components: microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. All three sources are consistent here. The answer seems straightforward. I need to make sure I'm citing correctly. The user wants the answer in a JSON object with the answer and base_confidence. Since all three documents agree, the confidence should be high. Maybe 1.0 since all evidence points to the same triad. Wait, but sometimes even if multiple sources say the same thing, there might be slight variations. But here, all three are identical. So the answer is definitely correct. The answer should list the three components with citations from any of the documents. Let me pick one citation, like the first one, but since they're all the same, maybe just use one. So the answer is the triad as stated in the evidence. Base confidence is 1.0 because all sources confirm it. </think> { \"", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["16006690", "16387683", "17705684", "19227723", "19625716", "20209841", "20499172", "20865638", "22956028", "23380391", "24161037", "24516709", "24548192", "25011592", "25280590", "25345382", "25765799", "26265890", "2831711", "7487540", "8589282"], "ideal_answer": "Hemolytic uremic syndrome (HUS) is a clinical syndrome characterized by the triad of anaemia, thrombocytopenia, renal failure."}
{"question_id": "5158644cd24251bc0500008e", "question": "Does physical activity influence gut hormones?", "retrieved_chunks": [{"doc_id": "21554896", "chunk_id": "21554896_0", "score": 6.420056343078613, "text": "ur data suggest that the control of spontaneous physical activity by gut hormones or their neuropeptide targets may represent an important mechanistic component of energy balance regulation"}, {"doc_id": "11321513", "chunk_id": "11321513_0", "score": 3.98300838470459, "text": "We conclude that strenuous physical exercise; 1) fails to affect plasma leptin level but when performed after meal but not after blood withdrawal it results in an increase and fall in plasma leptin, and 2) the release of gut hormones (gastrin, CCK and PP) and stress hormones (norepinephrine, cortisol, GH) increase immediately after exercise independently of feeding or blood donation"}, {"doc_id": "36369926", "chunk_id": "36369926_0", "score": 1.4696956872940063, "text": "Physical activity is associated with reduced risks of colorectal cancer (CRC) incidence, recurrence and mortality. While these findings are consistent, the mechanism/s underlying this association remain unclear. Growing evidence supports the many ways in which differing characteristics of the gut microbiota can be tumourigenic or protective against CRC. CRC is characterised by significant dysbiosis including reduced short chain fatty acid-producing bacteria. Recent findings suggest that exercise can modify the gut microbiota, and these changes are inverse to the changes seen with CRC; however, this exercise-microbiota interaction is currently understudied in CRC. This review summarises parallel areas of research that are rapidly developing: The exercise-gut microbiota research and cancer-gut microbiota research and highlights the salient similarities. Preliminary evidence suggests that these areas are linked, with exercise mediating changes that promote the antitumorigenic characteristics of the gut microbiota."}], "context": "[21554896:21554896_0] ur data suggest that the control of spontaneous physical activity by gut hormones or their neuropeptide targets may represent an important mechanistic component of energy balance regulation\n[11321513:11321513_0] We conclude that strenuous physical exercise; 1) fails to affect plasma leptin level but when performed after meal but not after blood withdrawal it results in an increase and fall in plasma leptin, and 2) the release of gut hormones (gastrin, CCK and PP) and stress hormones (norepinephrine, cortisol, GH) increase immediately after exercise independently of feeding or blood donation\n[36369926:36369926_0] Physical activity is associated with reduced risks of colorectal cancer (CRC) incidence, recurrence and mortality. While these findings are consistent, the mechanism/s underlying this association remain unclear. Growing evidence supports the many ways in which differing characteristics of the gut microbiota can be tumourigenic or protective against CRC. CRC is characterised by significant dysbiosis including reduced short chain fatty acid-producing bacteria. Recent findings suggest that exercise can modify the gut microbiota, and these changes are inverse to the changes seen with CRC; however, this exercise-microbiota interaction is currently understudied in CRC. This review summarises parallel areas of research that are rapidly developing: The exercise-gut microbiota research and cancer-gut microbiota research and highlights the salient similarities. Preliminary evidence suggests that these areas are linked, with exercise mediating changes that promote the antitumorigenic characteristics of the gut microbiota.", "answer": "<think> Okay, let's tackle this question. The user is asking if physical activity influences gut hormones. I need to look at the provided evidence to find answers. First evidence: [21554896:21554896_0] mentions that gut hormones or their neuropeptide targets control spontaneous physical activity, which is part of energy balance regulation. So this suggests a bidirectional relationship, but the question is about whether physical activity influences gut hormones. This evidence points to gut hormones controlling activity, not sure if it's one-way. Second evidence: [11321513:11321513_0] says that strenuous exercise doesn't affect plasma leptin levels but when done after a meal, there's an increase and fall. Also, gut hormones like gastrin, CCK, PP are released immediately after exercise, regardless of feeding or blood donation. This directly shows that physical activity (exercise) leads to the release of gut hormones. So this is a clear example of physical activity influencing gut hormones. Third evidence: [36369926:3636", "citations": [{"doc_id": "21554896", "chunk_id": "21554896_0"}, {"doc_id": "11321513", "chunk_id": "11321513_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if physical activity influences gut hormones. I need to look at the provided evidence to find answers. First evidence: [21554896:21554896_0] mentions that gut hormones or their neuropeptide targets control spontaneous physical activity, which is part of energy balance regulation. So this suggests a bidirectional relationship, but the question is about whether physical activity influences gut hormones. This evidence points to gut hormones controlling activity, not sure if it's one-way. Second evidence: [11321513:11321513_0] says that strenuous exercise doesn't affect plasma leptin levels but when done after a meal, there's an increase and fall. Also, gut hormones like gastrin, CCK, PP are released immediately after exercise, regardless of feeding or blood donation. This directly shows that physical activity (exercise) leads to the release of gut hormones. So this is a clear example of physical activity influencing gut hormones. Third evidence: [36369926:3636", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if physical activity influences gut hormones. I need to look at the provided evidence and see which parts support that. First, looking at the first evidence snippet: [21554896:21554896_0] mentions that gut hormones or their neuropeptide targets control spontaneous physical activity, suggesting a bidirectional relationship. That's relevant because it shows that gut hormones can affect physical activity, but does it mean physical activity affects gut hormones? Maybe, but the wording is about control, so maybe it's two-way. Next, [11321513:11321513_0] states that strenuous exercise doesn't affect plasma leptin levels but when done after a meal, there's an increase and fall. Also, gut hormones like gastrin, CCK, PP are released immediately after exercise, regardless of feeding or blood donation. This directly shows that physical activity (exercise) leads to the release of gut hormones. So this is a clear example where physical activity does influence gut hormones. The third snippet [363", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if physical activity influences gut hormones. I need to look at the provided evidence and see which parts support that. First, looking at the first evidence snippet: it mentions that control of spontaneous physical activity by gut hormones or their neuropeptide targets is a component of energy balance regulation. That suggests there's an interaction between physical activity and gut hormones. So that's a point in favor. Next, the second snippet says that strenuous exercise doesn't affect plasma leptin levels but when done after a meal, it does. Also, it mentions that gut hormones like gastrin, CCK, and PP are released immediately after exercise, regardless of feeding or blood donation. This directly shows that physical activity leads to changes in gut hormone release. That's strong evidence. The third snippet talks about physical activity reducing CRC risks and how the gut microbiota is involved. It mentions that exercise can modify the gut microbiota, which might relate to gut hormones indirectly. However, this part is more about the microbiota rather than the hormones themselves. But it does connect exercise to changes ", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["11321513", "15795476", "16942616", "17470516", "18987287", "19158129", "19737911", "20061436", "20690071", "21554896", "21615652", "21927572", "22619704", "23111564", "23402716", "2888163"], "ideal_answer": "Yes."}
{"question_id": "515a7ffdd24251bc050000a5", "question": "What are the effects of depleting protein km23-1 (DYNLRB1) in a cell?", "retrieved_chunks": [{"doc_id": "23079622", "chunk_id": "23079622_0", "score": 6.48902702331543, "text": "Finally, our results demonstrated for the first time that depletion of km23-1 inhibited cell migration of human colon carcinoma cells (HCCCs) in wound-healing assays. Overall, our findings demonstrate that km23-1 regulates RhoA and motility-associated actin modulating proteins, suggesting that km23-1 may represent a novel target for anti-metastatic therapy."}, {"doc_id": "17420258", "chunk_id": "17420258_0", "score": 1.4518711566925049, "text": "Blockade of km23-1 using a small interfering RNA approach resulted in a reduction in both total intracellular Smad2 levels and in nuclear levels of phosphorylated Smad2 after TGFbeta treatment."}, {"doc_id": "15925487", "chunk_id": "15925487_0", "score": 0.9520411491394043, "text": "Blockade of km23 using small interfering RNAs significantly decreased key TGFbeta responses, including induction of fibronectin expression and inhibition of cell growth."}], "context": "[23079622:23079622_0] Finally, our results demonstrated for the first time that depletion of km23-1 inhibited cell migration of human colon carcinoma cells (HCCCs) in wound-healing assays. Overall, our findings demonstrate that km23-1 regulates RhoA and motility-associated actin modulating proteins, suggesting that km23-1 may represent a novel target for anti-metastatic therapy.\n[17420258:17420258_0] Blockade of km23-1 using a small interfering RNA approach resulted in a reduction in both total intracellular Smad2 levels and in nuclear levels of phosphorylated Smad2 after TGFbeta treatment.\n[15925487:15925487_0] Blockade of km23 using small interfering RNAs significantly decreased key TGFbeta responses, including induction of fibronectin expression and inhibition of cell growth.", "answer": "<think> Okay, I need to generate a biomedical answer about the effects of depleting protein km23-1 (DYNLRB1) based on the provided evidence. Let me start by reading through the question and the evidence carefully. The question is asking for the effects of depleting this protein. The evidence has three chunks. Let me parse each one: First chunk (23079622:23079622_0) says that depletion of km23-1 inhibited cell migration in HCCCs using wound-healing assays. It also mentions that km23-1 regulates RhoA and motility-associated actin modulating proteins, suggesting it's a target for anti-metastatic therapy. Second chunk (17420258:17420258_0) states that blocking km23-1 with siRNA reduced total intracellular Smad2 levels and nuclear phosphorylated Smad2 after TGFbeta treatment. So this relates to Smad2 and TGFbeta signaling. Third chunk (15925487:15", "citations": [], "candidates": [{"answer": "<think> Okay, I need to generate a biomedical answer about the effects of depleting protein km23-1 (DYNLRB1) based on the provided evidence. Let me start by reading through the question and the evidence carefully. The question is asking for the effects of depleting this protein. The evidence has three chunks. Let me parse each one: First chunk (23079622:23079622_0) says that depletion of km23-1 inhibited cell migration in HCCCs using wound-healing assays. It also mentions that km23-1 regulates RhoA and motility-associated actin modulating proteins, suggesting it's a target for anti-metastatic therapy. Second chunk (17420258:17420258_0) states that blocking km23-1 with siRNA reduced total intracellular Smad2 levels and nuclear phosphorylated Smad2 after TGFbeta treatment. So this relates to Smad2 and TGFbeta signaling. Third chunk (15925487:15", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the effects of depleting protein km23-1 (DYNLRB1) in a cell. I need to look at the provided evidence to form an answer. First, I'll go through each evidence chunk. The first one (23079622:23079622_0) says that depletion of km23-1 inhibited cell migration in HCCCs using wound-healing assays. It also mentions that km23-1 regulates RhoA and motility-associated actin modulating proteins, suggesting it's a target for anti-metastatic therapy. So this points to effects on cell migration and possibly metastasis. The second chunk (17420258:17420258_0) talks about using siRNA to block km23-1 leading to reduced Smad2 levels, both total intracellular and phosphorylated in the nucleus after TGFbeta treatment. This indicates effects on TGFbeta signaling pathways, specifically Smad2 regulation. The third chunk (15", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the effects of depleting protein km23-1 (DYNLRB1) in a cell. I need to look at the provided evidence to find relevant information. First, looking at the evidence documents: Document 23079622: It says that depletion of km23-1 inhibited cell migration in HCCCs using wound-healing assays. Also, it mentions that km23-1 regulates RhoA and motility-associated actin modulating proteins, suggesting it's a target for anti-metastatic therapy. Document 17420258: Blockade of km23-1 with siRNA reduced total intracellular Smad2 levels and nuclear phosphorylated Smad2 after TGFbeta treatment. So this relates to Smad2 regulation via TGFbeta signaling. Document 15925487: Blocking km23-1 with siRNA decreased TGFbeta responses like fibronectin expression and inhibited cell growth. So, combining these, depleting km23-1 leads to reduced", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["15925487", "16778097", "17420258", "19571232", "19711352", "22637579", "23079622"], "ideal_answer": "The knockdown of km23-1 results in numerous effects at the cellular level, such as decreased cell migration. Additionaly, km23-1 is involved in signalling pathways and its knockdown results in decreased RhoA activation, inhibition of TGFβ-mediated activation of ERK and JNK, phosphorylation of c-Jun, transactivation of the c-Jun promoter and decreased TGFbeta responses."}
{"question_id": "54cf7051f693c3b16b000013", "question": "Treatment of which disease was investigated in the MR CLEAN study?", "retrieved_chunks": [{"doc_id": "25179366", "chunk_id": "25179366_0", "score": 5.3612213134765625, "text": "MR CLEAN, a multicenter randomized clinical trial of endovascular treatment for acute ischemic stroke in the Netherlands: study protocol for a randomized controlled trial."}, {"doc_id": "25432979", "chunk_id": "25432979_0", "score": 4.060359954833984, "text": "INTRODUCTION: A recent randomized controlled trial (RCT), the Multicenter Randomized CLinical trial of Endovascular treatment for Acute ischemic stroke in the Netherlands (MR CLEAN), demonstrated better outcomes with endovascular treatment compared with medical therapy for acute ischemic stroke (AIS)."}, {"doc_id": "25517348", "chunk_id": "25517348_0", "score": 0.9853619337081909, "text": "CONCLUSIONS: In patients with acute ischemic stroke caused by a proximal intracranial occlusion of the anterior circulation, intraarterial treatment administered within 6 hours after stroke onset was effective and safe. (Funded by the Dutch Heart Foundation and others; MR CLEAN Netherlands Trial Registry number, NTR1804, and Current Controlled Trials number, ISRCTN10888758.)."}], "context": "[25179366:25179366_0] MR CLEAN, a multicenter randomized clinical trial of endovascular treatment for acute ischemic stroke in the Netherlands: study protocol for a randomized controlled trial.\n[25432979:25432979_0] INTRODUCTION: A recent randomized controlled trial (RCT), the Multicenter Randomized CLinical trial of Endovascular treatment for Acute ischemic stroke in the Netherlands (MR CLEAN), demonstrated better outcomes with endovascular treatment compared with medical therapy for acute ischemic stroke (AIS).\n[25517348:25517348_0] CONCLUSIONS: In patients with acute ischemic stroke caused by a proximal intracranial occlusion of the anterior circulation, intraarterial treatment administered within 6 hours after stroke onset was effective and safe. (Funded by the Dutch Heart Foundation and others; MR CLEAN Netherlands Trial Registry number, NTR1804, and Current Controlled Trials number, ISRCTN10888758.).", "answer": "Acute ischemic stroke [25432979:25432979_0]", "citations": [{"doc_id": "25432979", "chunk_id": "25432979_0"}], "candidates": [{"answer": "Acute ischemic stroke [25432979:25432979_0]", "base_prob": 1.0, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 1.0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which disease's treatment was investigated in the MR CLEAN study. The evidence provided has three documents. First, I need to look at each document to find the answer. The first document's title mentions \"endovascular treatment for acute ischemic stroke,\" which seems relevant. The second document's introduction says the MR CLEAN study compared endovascular treatment with medical therapy for acute ischemic stroke (AIS). The third conclusion also mentions acute ischemic stroke caused by a proximal intracranial occlusion of the anterior circulation. So, all three documents point to acute ischemic stroke as the disease under investigation. The answer should be \"acute ischemic stroke,\" and the citations would be from the second document (25432979:25432979_0) and possibly the first one. But since the question is about the disease, the main citation is the second document's introduction. The confidence level should be high because all sources consistently mention AIS. So base_confidence would be 1.0. </think> { \"answer\": \"acute ischemic stroke [", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to figure out which disease was investigated in the MR CLEAN study based on the provided evidence. Let me look at the evidence again. The first document mentions \"MR CLEAN, a multicenter randomized clinical trial of endovascular treatment for acute ischemic stroke in the Netherlands: study protocol for a randomized controlled trial.\" So that's a direct statement about the disease being studied. The second document says \"A recent RCT... demonstrated better outcomes with endovascular treatment compared with medical therapy for acute ischemic stroke (AIS).\" Here, AIS is acute ischemic stroke. The third document's conclusion states that the study was about patients with acute ischemic stroke caused by a proximal intracranial occlusion of the anterior circulation. So all three documents point to acute ischemic stroke as the disease under investigation. The answer should be acute ischemic stroke, and the citations are from the first two documents. The confidence is high because multiple sources confirm this. I'll structure the JSON with the answer and base_confidence. </think> { \"answer\": \"acute ischemic stroke [25432979:254", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 1.0, "gold_docs": ["24330796", "25179366", "25432979", "25517348"], "ideal_answer": "Multicenter Randomized CLinical trial of Endovascular treatment for Acute ischemic stroke in the Netherlands (MR CLEAN) study investigated endovascular treatment for acute ischemic stroke."}
{"question_id": "56a92be0a17756b72f000009", "question": "Which factors activate zygotic gene expression during the maternal-to-zygotic transition in zebrafish?", "retrieved_chunks": [{"doc_id": "24056933", "chunk_id": "24056933_1", "score": 8.03262996673584, "text": "Here we show that Nanog, Pou5f1 (also called Oct4) and SoxB1 regulate zygotic gene activation in zebrafish. We identified several hundred genes directly activated by maternal factors, constituting the first wave of zygotic transcription."}, {"doc_id": "24056933", "chunk_id": "24056933_2", "score": 5.883466720581055, "text": "Nanog, Pou5f1 and SoxB1 activate zygotic gene expression during the maternal-to-zygotic transition."}, {"doc_id": "23891688", "chunk_id": "23891688_0", "score": 5.523184776306152, "text": "The transcription factor Zelda plays a pivotal role in promoting the maternal to zygotic transition during embryogenesis in Drosophila melanogaster."}], "context": "[24056933:24056933_1] Here we show that Nanog, Pou5f1 (also called Oct4) and SoxB1 regulate zygotic gene activation in zebrafish. We identified several hundred genes directly activated by maternal factors, constituting the first wave of zygotic transcription.\n[24056933:24056933_2] Nanog, Pou5f1 and SoxB1 activate zygotic gene expression during the maternal-to-zygotic transition.\n[23891688:23891688_0] The transcription factor Zelda plays a pivotal role in promoting the maternal to zygotic transition during embryogenesis in Drosophila melanogaster.", "answer": "<think> Okay, let's tackle this question. The user is asking which factors activate zygotic gene expression during the maternal-to-zygotic transition in zebrafish. First, I need to look at the evidence provided. There are three documents here. The first two, 24056933, mention Nanog, Pou5f1 (Oct4), and SoxB1 as regulators of zygotic gene activation in zebrafish. Specifically, document 24056933_1 says these genes regulate zygotic gene activation, and document 24056933_2 states they activate zygotic gene expression during the transition. The third document, 23891688, talks about Zelda in Drosophila, but the question is about zebrafish, so that might not be relevant here. So the key point is that the factors mentioned in the first two documents are specific to zebrafish. The answer should include Nanog, Pou5f1 (Oct4), and SoxB1. The confidence level would be high because these are", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which factors activate zygotic gene expression during the maternal-to-zygotic transition in zebrafish. First, I need to look at the evidence provided. There are three documents here. The first two, 24056933, mention Nanog, Pou5f1 (Oct4), and SoxB1 as regulators of zygotic gene activation in zebrafish. Specifically, document 24056933_1 says these genes regulate zygotic gene activation, and document 24056933_2 states they activate zygotic gene expression during the transition. The third document, 23891688, talks about Zelda in Drosophila, but the question is about zebrafish, so that might not be relevant here. So the key point is that the factors mentioned in the first two documents are specific to zebrafish. The answer should include Nanog, Pou5f1 (Oct4), and SoxB1. The confidence level would be high because these are", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which factors activate zygotic gene expression during the maternal-to-zygotic transition in zebrafish. First, I need to look at the evidence provided. There are three documents here. The first two, 24056933, mention Nanog, Pou5f1 (Oct4), and SoxB1 as regulators of zygotic gene activation in zebrafish. Specifically, chunk 24056933_2 states that these three factors activate zygotic gene expression during the transition. The third document, 23891688, talks about Zelda in Drosophila, but the question is about zebrafish, so that might not be relevant here. So the answer should focus on the factors mentioned in the zebrafish evidence. The key points are Nanog, Pou5f1 (Oct4), and SoxB1. The confidence here is high because two chunks from the same study (24056933) directly state this. The third document is about a different organism", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which factors activate zygotic gene expression during the maternal-to-zygotic transition in zebrafish. First, I need to look at the evidence provided. There are three pieces of evidence here. The first two are from the same study (24056933) and mention Nanog, Pou5f1 (Oct4), and SoxB1 as regulators of zygotic gene activation in zebrafish. The third piece (23891688) talks about Zelda in Drosophila, which is a different species, so that might not be relevant here. The question specifically mentions zebrafish, so I should focus on the evidence related to zebrafish. The first two chunks from 24056933 directly mention these three factors: Nanog, Pou5f1, and SoxB1. They state that these genes regulate zygotic gene activation during the transition. The third chunk is about Zelda in flies, which isn't zebrafish, so I can ignore that. So the answer should", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["24056933"], "ideal_answer": "Nanog, Pou5f1 and SoxB1 activate zygotic gene expression during the maternal-to-zygotic transition. Maternal Nanog, Pou5f1 and SoxB1 are required to initiate the zygotic developmental program and induce clearance of the maternal program by activating miR-430 expression."}
{"question_id": "54f08d4a94afd61504000016", "question": "Is irritable bowel syndrome more common in women with endometriosis?", "retrieved_chunks": [{"doc_id": "21527837", "chunk_id": "21527837_2", "score": 8.362399101257324, "text": "Similarly, women with a history of irritable bowel syndrome were twice as likely to develop endometriosis [AOR=1.9, 95% CI (1.03-3.87)]."}, {"doc_id": "21527837", "chunk_id": "21527837_1", "score": 7.711513519287109, "text": "Similarly, women with a history of irritable bowel syndrome were twice as likely to develop endometriosis [AOR=1."}, {"doc_id": "19694698", "chunk_id": "19694698_0", "score": 6.986379623413086, "text": "Seventy-six women (21.4%) had previously been diagnosed with irritable bowel syndrome and 79% of them had endometriosis confirmed."}], "context": "[21527837:21527837_2] Similarly, women with a history of irritable bowel syndrome were twice as likely to develop endometriosis [AOR=1.9, 95% CI (1.03-3.87)].\n[21527837:21527837_1] Similarly, women with a history of irritable bowel syndrome were twice as likely to develop endometriosis [AOR=1.\n[19694698:19694698_0] Seventy-six women (21.4%) had previously been diagnosed with irritable bowel syndrome and 79% of them had endometriosis confirmed.", "answer": "<think> Okay, let's tackle this question. The user is asking if irritable bowel syndrome (IBS) is more common in women with endometriosis. The evidence provided has three chunks. First, chunk [21527837:21527837_2] says that women with a history of IBS are twice as likely to develop endometriosis, with an AOR of 1.9. That suggests a link between IBS and endometriosis, but it's about the likelihood of developing endometriosis if you have IBS, not the prevalence of IBS in women with endometriosis. Then chunk [21527837:21527837_1] seems to repeat the same point, so maybe a typo or duplicate. The third chunk [19694698:19694698_0] states that 76 women (21.4%) had IBS, and 79% of them had endometriosis confirmed. Wait, that's a bit confusing.", "citations": [{"doc_id": "21527837", "chunk_id": "21527837_2"}, {"doc_id": "21527837", "chunk_id": "21527837_1"}, {"doc_id": "19694698", "chunk_id": "19694698_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if irritable bowel syndrome (IBS) is more common in women with endometriosis. The evidence provided has three chunks. First, chunk [21527837:21527837_2] says that women with a history of IBS are twice as likely to develop endometriosis, with an AOR of 1.9. That suggests a link between IBS and endometriosis, but it's about the likelihood of developing endometriosis if you have IBS, not the prevalence of IBS in women with endometriosis. Then chunk [21527837:21527837_1] seems to repeat the same point, so maybe a typo or duplicate. The third chunk [19694698:19694698_0] states that 76 women (21.4%) had IBS, and 79% of them had endometriosis confirmed. Wait, that's a bit confusing.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if irritable bowel syndrome (IBS) is more common in women with endometriosis. The evidence provided has three chunks. First, chunk [21527837:21527837_2] says that women with a history of IBS are twice as likely to develop endometriosis, with an AOR of 1.9. That suggests a link between IBS and endometriosis, but it's about the likelihood of developing endometriosis after having IBS, not the prevalence of IBS in women with endometriosis. Then chunk [21527837:21527837_1] seems to repeat the same point as the first one. Maybe a formatting error, but the key info is still the AOR=1.9. Chunk [19694698:19694698_0] states that 76 out of 356 women (21.4%) had IBS, and", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if IBS is more common in women with endometriosis. The evidence given has three chunks. First, chunk 21527837_2 says that women with a history of IBS are twice as likely to develop endometriosis, with an AOR of 1.9. That suggests a link between IBS and endometriosis, but it's about the likelihood of developing endometriosis after having IBS, not the prevalence of IBS in those with endometriosis. Then chunk 21527837_1 is similar to the first one, so maybe a repetition. The third chunk, 19694698_0, states that 76 out of 100 women (21.4%) had IBS, and 79% of them had endometriosis confirmed. Wait, that seems like a high percentage. But the wording is \"had previously been diagnosed with IBS and 79% of them had endometriosis.\" So, among those with", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["14501624", "15341718", "15605531", "15894210", "17493437", "17635599", "17701798", "18478547", "18646315", "18715239", "18715240", "19694698", "19832874", "21527837", "21868492", "22096721", "22134016", "23507008"], "ideal_answer": "Yes, irritable bowel syndrome (IBS) is more common in women with endometriosis. It has been shown that 15% of the patients with endometriosis also had IBS. Women with endometriosis are more likely to have received a diagnosis of IBS. Endometriosis may coexist with or be misdiagnosed as IBS."}
{"question_id": "54f49995d0d681a040000002", "question": "What is evaluated using the EORTC QLQ – INFO25 questionnaire?", "retrieved_chunks": [{"doc_id": "22638756", "chunk_id": "22638756_1", "score": 7.85402774810791, "text": "The EORTC QLQ-INFO25 was used to evaluate the perceived level of and satisfaction with information."}, {"doc_id": "22638756", "chunk_id": "22638756_0", "score": 7.789133071899414, "text": "The EORTC QLQ-INFO25 was used to evaluate the perceived level of and satisfaction with information"}, {"doc_id": "21680301", "chunk_id": "21680301_1", "score": 7.475852966308594, "text": "The EORTC QLQ-INFO25 evaluates the information received by cancer patients"}], "context": "[22638756:22638756_1] The EORTC QLQ-INFO25 was used to evaluate the perceived level of and satisfaction with information.\n[22638756:22638756_0] The EORTC QLQ-INFO25 was used to evaluate the perceived level of and satisfaction with information\n[21680301:21680301_1] The EORTC QLQ-INFO25 evaluates the information received by cancer patients", "answer": "<think> Okay, let's tackle this question. The user is asking what the EORTC QLQ – INFO25 questionnaire evaluates. I need to look at the provided evidence to find the answer. Looking at the evidence, there are three chunks. The first two chunks from 22638756 mention that the questionnaire is used to evaluate the perceived level of and satisfaction with information. The third chunk from 21680301 says it evaluates the information received by cancer patients. So, the answer should combine these points. The main thing is that it's about evaluating how much information patients perceive and their satisfaction with it. The third chunk adds that it's specifically for cancer patients. But the question is about what is evaluated, so the key elements are perceived level and satisfaction with information. I need to make sure the answer is concise and includes citations. The base confidence should be high since all three chunks support the idea of evaluating information perception and satisfaction. Maybe a confidence of 0.95 or something. Let me check if there's any conflicting info, but all three seem to align. So the answer would be that it", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking what the EORTC QLQ – INFO25 questionnaire evaluates. I need to look at the provided evidence to find the answer. Looking at the evidence, there are three chunks. The first two chunks from 22638756 mention that the questionnaire is used to evaluate the perceived level of and satisfaction with information. The third chunk from 21680301 says it evaluates the information received by cancer patients. So, the answer should combine these points. The main thing is that it's about evaluating how much information patients perceive and their satisfaction with it. The third chunk adds that it's specifically for cancer patients. But the question is about what is evaluated, so the key elements are perceived level and satisfaction with information. I need to make sure the answer is concise and includes citations. The base confidence should be high since all three chunks support the idea of evaluating information perception and satisfaction. Maybe a confidence of 0.95 or something. Let me check if there's any conflicting info, but all three seem to align. So the answer would be that it", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking what the EORTC QLQ – INFO25 questionnaire evaluates. The evidence provided has three chunks. First, I need to parse each chunk. The first two chunks from 22638756 say that the questionnaire is used to evaluate the perceived level of and satisfaction with information. The third chunk from 21680301 states that it evaluates the information received by cancer patients. So, the answer should be that it's about evaluating the perceived level and satisfaction with information, as mentioned in the first two chunks. The third chunk supports that it's related to information received by patients. But the main point is the perceived level and satisfaction. Now, checking for confidence. Since two of the three sources mention the same thing, and the third is more general, I can be fairly confident. The base confidence would be high, maybe 0.95. But need to make sure there's no conflicting info. All chunks seem to align. So the answer is about perceived level and satisfaction with information, citing the first two chunks. The third chunk is a bit more", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking what the EORTC QLQ – INFO25 questionnaire evaluates. The evidence provided has three chunks. First, I need to parse each chunk. The first two chunks from 22638756 say that the questionnaire is used to evaluate the perceived level of and satisfaction with information. The third chunk from 21680301 states that it evaluates the information received by cancer patients. So, the answer needs to be concise. The key points are \"perceived level of and satisfaction with information\" and \"information received by cancer patients.\" But the question is about what is evaluated. The first two chunks mention satisfaction and perceived level, while the third mentions the information received. However, the third chunk's wording is slightly different. Wait, the first two chunks say \"perceived level of and satisfaction with information,\" which seems to be the main point. The third chunk says it evaluates the information received by cancer patients. But maybe that's a bit more specific. However, the first two chunks are more direct in stating the purpose. The answer should combine these points.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["20674333", "21671697", "21680301", "22052786", "22638756", "24834120", "25475735"], "ideal_answer": "The European Organisation for Research and Treatment of Cancer Quality of Life Group information questionnaire (EORTC QLQ-INFO 25) evaluates the level of information patients have received in different areas of their disease, treatment and care, and evaluates qualitative aspects together with satisfaction with information."}
{"question_id": "531d2aa5267d7dd053000003", "question": "Does BNP increase after intensive exercise in athletes?", "retrieved_chunks": [{"doc_id": "16338248", "chunk_id": "16338248_0", "score": 8.8280029296875, "text": "Increases in NT-proBNP can be found in a major part of obviously healthy athletes after prolonged strenuous exercise. The release of BNP during and after exercise may not result from myocardial damage but may have cytoprotective and growth-regulating effects. The different nature of exercise-induced increases in BNP and cardiac troponins has to be elucidated in the future."}, {"doc_id": "11320362", "chunk_id": "11320362_0", "score": 4.886676788330078, "text": "Such exercise significantly increased ANP and BNP levels in healthy men, and the increases could be partially attributed to myocardial damage during the race."}, {"doc_id": "14523304", "chunk_id": "14523304_0", "score": 4.443329811096191, "text": "The rise in BNP in older athletes may reflect a reversible, mainly diastolic left ventricular dysfunction."}], "context": "[16338248:16338248_0] Increases in NT-proBNP can be found in a major part of obviously healthy athletes after prolonged strenuous exercise. The release of BNP during and after exercise may not result from myocardial damage but may have cytoprotective and growth-regulating effects. The different nature of exercise-induced increases in BNP and cardiac troponins has to be elucidated in the future.\n[11320362:11320362_0] Such exercise significantly increased ANP and BNP levels in healthy men, and the increases could be partially attributed to myocardial damage during the race.\n[14523304:14523304_0] The rise in BNP in older athletes may reflect a reversible, mainly diastolic left ventricular dysfunction.", "answer": "<think> Okay, let's tackle this question. The user is asking if BNP increases after intensive exercise in athletes. I need to look at the evidence provided. First, evidence from [16338248:16338248_0] says that NT-proBNP increases in healthy athletes after prolonged strenuous exercise. They mention that BNP release might not be from myocardial damage but could have cytoprotective effects. So this suggests BNP does increase, but the reason is different from damage. Then [11320362:11320362_0] states that intense exercise increases ANP and BNP in healthy men, with some attributed to myocardial damage. This directly supports that BNP levels go up during exercise, even if part of it is due to damage. The third evidence [14523304:14523304_0] talks about BNP rising in older athletes possibly indicating reversible diastolic dysfunction. This implies that even though there's an increase, it might be related to heart function issues, but the", "citations": [{"doc_id": "16338248", "chunk_id": "16338248_0"}, {"doc_id": "11320362", "chunk_id": "11320362_0"}, {"doc_id": "14523304", "chunk_id": "14523304_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if BNP increases after intensive exercise in athletes. I need to look at the evidence provided. First, evidence from [16338248:16338248_0] says that NT-proBNP increases in healthy athletes after prolonged strenuous exercise. They mention that BNP release might not be from myocardial damage but could have cytoprotective effects. So this suggests BNP does increase, but the reason is different from damage. Then [11320362:11320362_0] states that intense exercise increases ANP and BNP in healthy men, with some attributed to myocardial damage. This directly supports that BNP levels go up during exercise, even if part of it is due to damage. The third evidence [14523304:14523304_0] talks about BNP rising in older athletes possibly indicating reversible diastolic dysfunction. This implies that even though there's an increase, it might be related to heart function issues, but the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if BNP increases after intensive exercise in athletes. I need to look at the evidence provided. First, evidence document [16338248:16338248_0] says that NT-proBNP increases in healthy athletes after prolonged strenuous exercise. It mentions that BNP release during and after exercise might not be from myocardial damage but could have cytoprotective effects. So this suggests that BNP does increase, but the reason isn't just heart damage. Then there's [11320362:11320362_0], which states that intense exercise increased ANP and BNP levels in healthy men, with some attributed to myocardial damage. This directly supports that BNP increases during exercise, though part of it might be due to damage. The third document [14523304:14523304_0] talks about a rise in BNP in older athletes possibly indicating reversible diastolic dysfunction. This implies that even if there's some dysfunction, B", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if BNP increases after intensive exercise in athletes. I need to look at the provided evidence to form an answer. First, evidence document [16338248:16338248_0] says that NT-proBNP increases in healthy athletes after prolonged strenuous exercise. It mentions that BNP release might not be from myocardial damage but could have cytoprotective effects. So this suggests BNP does increase, but the reason is different from damage. Then document [11320362:11320362_0] states that exercise significantly increased ANP and BNP in healthy men, with partial attribution to myocardial damage. This directly supports that BNP increases during exercise, even if some of it is due to damage. The third document [14523304:14523304_0] talks about a rise in BNP in older athletes possibly indicating reversible diastolic dysfunction. This implies that BNP does increase, but the context here is older athletes,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["11320362", "12417808", "12890912", "14523304", "16125505", "16338248", "16446686", "16879068", "17289431", "17395308", "18076361", "18184752", "18248532", "18630737", "19092706", "19638823", "22653984", "23304255"], "ideal_answer": "BNP and NTproBNP increase early after exercise in healthy athletes performing different types of sports. It is unknown the reason of this increase. The transient increases in BNP, NT-pro-BNP and troponin T are more likely to reflect myocardial stunning than cardiomyocyte damage."}
{"question_id": "56bf3a79ef6e39474100000f", "question": "What is the association of estrogen replacement therapy and intracranial meningioma risk?", "retrieved_chunks": [{"doc_id": "24138870", "chunk_id": "24138870_0", "score": 7.877739906311035, "text": "Several studies indicate that use of hormone replacement therapy (HRT) is associated with an increased risk of intracranial meningioma, while associations between HRT use and risk of other brain tumors have been less explored."}, {"doc_id": "17580362", "chunk_id": "17580362_1", "score": 5.603789806365967, "text": "available data suggest an association between the use of hormone replacement therapy and increased meningioma risk."}, {"doc_id": "17580362", "chunk_id": "17580362_0", "score": 5.5330986976623535, "text": "Although not definitive, available data suggest an association between the use of hormone replacement therapy and increased meningioma risk."}], "context": "[24138870:24138870_0] Several studies indicate that use of hormone replacement therapy (HRT) is associated with an increased risk of intracranial meningioma, while associations between HRT use and risk of other brain tumors have been less explored.\n[17580362:17580362_1] available data suggest an association between the use of hormone replacement therapy and increased meningioma risk.\n[17580362:17580362_0] Although not definitive, available data suggest an association between the use of hormone replacement therapy and increased meningioma risk.", "answer": "<think> Okay, let's tackle this question. The user is asking about the association between estrogen replacement therapy and the risk of intracranial meningioma. First, I need to look at the provided evidence. There are three chunks here. Let me go through each one. The first chunk [24138870:24138870_0] says that several studies show HRT is linked to an increased risk of intracranial meningioma, but other brain tumors have less explored associations. So this directly mentions meningioma and HRT. The second chunk [17580362:17580362_1] states that available data suggest an association between HRT and increased meningioma risk. That's another citation pointing to the same conclusion. The third chunk [17580362:17580362_0] is similar, mentioning that although not definitive, data still suggest an association. So all three pieces of evidence point towards a possible increased risk, though one notes it's not definitive. Now, the question specifically", "citations": [{"doc_id": "24138870", "chunk_id": "24138870_0"}, {"doc_id": "17580362", "chunk_id": "17580362_1"}, {"doc_id": "17580362", "chunk_id": "17580362_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking about the association between estrogen replacement therapy and the risk of intracranial meningioma. First, I need to look at the provided evidence. There are three chunks here. Let me go through each one. The first chunk [24138870:24138870_0] says that several studies show HRT is linked to an increased risk of intracranial meningioma, but other brain tumors have less explored associations. So this directly mentions meningioma and HRT. The second chunk [17580362:17580362_1] states that available data suggest an association between HRT and increased meningioma risk. That's another citation pointing to the same conclusion. The third chunk [17580362:17580362_0] is similar, mentioning that although not definitive, data still suggest an association. So all three pieces of evidence point towards a possible increased risk, though one notes it's not definitive. Now, the question specifically", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the association between estrogen replacement therapy (ERT) and the risk of intracranial meningioma. First, I need to look at the provided evidence. There are three chunks here. Let me go through each one. The first chunk [24138870:24138873_0] says that several studies show HRT is linked to an increased risk of intracranial meningioma, but other brain tumors have less explored associations. So that's a direct mention of an association with meningioma. The second chunk [17580362:17580362_1] states that available data suggest an association between HRT and increased meningioma risk. That's another citation pointing to the same conclusion. The third chunk [17580362:17580362_0] is similar, mentioning that while not definitive, available data still suggest an association. So all three pieces of evidence point towards an increased risk, though some are more cautious about the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this query. The user is asking about the association between estrogen replacement therapy (ERT) and the risk of intracranial meningioma. First, I need to look at the provided evidence. There are three documents here. Let me go through each one. Document 24138870: This mentions that several studies show HRT is linked to increased risk of intracranial meningioma, but other brain tumors have less explored associations. So this suggests a positive association for meningiomas specifically. Then document 17580362 has two chunks. The first chunk (17580362_1) says available data suggest an association between HRT and increased meningioma risk. The second chunk (17580362_0) is similar, stating that although not definitive, the data still suggest an association. So both of these support the idea that there's a link, though maybe not conclusive. Now, the question is about estrogen replacement therapy. The evidence talks about hormone replacement therapy (HRT) in general. Since estrogen is a component of", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["15006250", "16570277", "16759391", "17580362", "20091865", "20730482", "20738039", "20802020", "21067422", "22287638", "23101448", "24138870", "25335165"], "ideal_answer": "The association between hormone replacement therapy and meningioma risk is controversial. Increased risk of meningioma was demonstrated in estrogen-only hormonal replacement therapy. However, other studies did not find an association between hormonal replacement therapy and meningioma risk."}
{"question_id": "54fefff26ad7dcbc1200000b", "question": "Are there web based self management strategies for chronic pain ?", "retrieved_chunks": [{"doc_id": "23538392", "chunk_id": "23538392_0", "score": 8.74492073059082, "text": "Web-based interventions may also be effective in enhancing self-management for individuals with chronic pain, but little is known about long-term effects. Research on Web-based interventions to support self-management following participation in pain management programs is limited. OBJECTIVE: The aim is to examine the long-term effects of a 4-week smartphone-intervention"}, {"doc_id": "23859438", "chunk_id": "23859438_0", "score": 7.57433557510376, "text": "Results suggest the potential value of self-management for chronic pain patients and the potential acceptability of web-based delivery of intervention content."}, {"doc_id": "21375412", "chunk_id": "21375412_0", "score": 3.698030471801758, "text": "therapy adaptation and the resultant specification for the SMART2 project-a technology-based self-management system for assisting long-term health conditions, including chronic pain"}], "context": "[23538392:23538392_0] Web-based interventions may also be effective in enhancing self-management for individuals with chronic pain, but little is known about long-term effects. Research on Web-based interventions to support self-management following participation in pain management programs is limited. OBJECTIVE: The aim is to examine the long-term effects of a 4-week smartphone-intervention\n[23859438:23859438_0] Results suggest the potential value of self-management for chronic pain patients and the potential acceptability of web-based delivery of intervention content.\n[21375412:21375412_0] therapy adaptation and the resultant specification for the SMART2 project-a technology-based self-management system for assisting long-term health conditions, including chronic pain", "answer": "<think> Okay, let's tackle this query. The user is asking if there are web-based self-management strategies for chronic pain. I need to look at the evidence provided to form an answer. First, looking at the evidence documents. The first one, 23538392:23538392_0, mentions that web-based interventions may help with self-management for chronic pain, but there's limited research on long-term effects. The second document, 23859438:23859438_0, says results show the potential value of self-management and acceptability of web-based delivery. The third one, 21375412:21375412_0, talks about a technology-based system called SMART2 for long-term conditions, including chronic pain. So combining these, there are web-based strategies. The first document mentions a smartphone intervention, the second supports web-based delivery, and the third provides a specific example (SMART2). However, the first document also notes that research is limited. So the answer should confirm that such strategies exist but", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this query. The user is asking if there are web-based self-management strategies for chronic pain. I need to look at the evidence provided to form an answer. First, looking at the evidence documents. The first one, 23538392:23538392_0, mentions that web-based interventions may help with self-management for chronic pain, but there's limited research on long-term effects. The second document, 23859438:23859438_0, says results show the potential value of self-management and acceptability of web-based delivery. The third one, 21375412:21375412_0, talks about a technology-based system called SMART2 for long-term conditions, including chronic pain. So combining these, there are web-based strategies. The first document mentions a smartphone intervention, the second supports web-based delivery, and the third provides a specific example (SMART2). However, the first document also notes that research is limited. So the answer should confirm that such strategies exist but", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this query. The user is asking if there are web-based self-management strategies for chronic pain. I need to look at the provided evidence to form an answer. First, evidence document 23538392 mentions web-based interventions that may help with self-management for chronic pain, but there's limited research on long-term effects. Then, 23859438 says results show potential value of self-management and acceptability of web-based delivery. The third document, 21375412, talks about a technology-based system called SMART2 for long-term conditions, including chronic pain. So combining these, the answer should state that yes, there are web-based strategies. The first document mentions interventions, the second supports their potential, and the third provides an example (SMART2). The confidence level should be moderate because while there's evidence, the first doc notes limited research. So base_confidence might be 0.7 or so. Need to make sure the answer is concise with citations. </think> { \"answer\": \"Yes, web-based self-management strategies exist for chronic pain, such as", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this query. The user is asking if there are web-based self-management strategies for chronic pain. I need to look at the evidence provided to form a concise answer with citations and a confidence level. First, I'll check each of the three evidence snippets. The first one (23538392:23538392_0) mentions that web-based interventions may be effective in enhancing self-management for chronic pain, but there's limited research on long-term effects. So this supports the existence of such strategies, though the evidence is about limited research. The second snippet (23859438:23859438_0) states that results suggest the potential value of self-management for chronic pain patients and that web-based delivery is acceptable. This also points to web-based strategies being used, with some acceptability. The third one (21375412:21375412_0) talks about a technology-based self-management system called SMART2 for long-term conditions, including chronic pain. This directly mentions a specific web-based strategy", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["23538392", "23768119", "23859438", "24067267", "24251273"], "ideal_answer": "Results suggest the potential value of self-management for chronic pain patients and the potential acceptability of web-based delivery of intervention content. Yes, there are successful web based self management strategies for chronic pain."}
{"question_id": "571f34ac0fd6f91b68000005", "question": "Is Weaver syndrome similar to Sotos?", "retrieved_chunks": [{"doc_id": "22287508", "chunk_id": "22287508_2", "score": 9.422014236450195, "text": "Weaver syndrome is closely related to Sotos syndrome,"}, {"doc_id": "22287508", "chunk_id": "22287508_1", "score": 9.268279075622559, "text": "Clinically, Weaver syndrome is closely related to Sotos syndrome, which is frequently caused by mutations in NSD1."}, {"doc_id": "22287508", "chunk_id": "22287508_0", "score": 9.163851737976074, "text": "Clinically, Weaver syndrome is closely related to Sotos syndrome, which is frequently caused by mutations in NSD1"}], "context": "[22287508:22287508_2] Weaver syndrome is closely related to Sotos syndrome,\n[22287508:22287508_1] Clinically, Weaver syndrome is closely related to Sotos syndrome, which is frequently caused by mutations in NSD1.\n[22287508:22287508_0] Clinically, Weaver syndrome is closely related to Sotos syndrome, which is frequently caused by mutations in NSD1", "answer": "Yes, Weaver syndrome is closely related to Sotos syndrome [22287508:22287508_2].", "citations": [{"doc_id": "22287508", "chunk_id": "22287508_2"}], "candidates": [{"answer": "Yes, Weaver syndrome is closely related to Sotos syndrome [22287508:22287508_2].", "base_prob": 1.0, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 1.0}, {"answer": "<think> Okay, let's tackle this question. The user wants to know if Weaver syndrome is similar to Sotos. Looking at the evidence provided, there are three chunks from the same source, all pointing to a close relationship between the two syndromes. First, I need to check if the answer is directly supported by the evidence. The first chunk says they're closely related. The others mention clinical similarities and that Sotos is often caused by NSD1 mutations. Wait, but the user is asking about similarity, not causation. However, the evidence does state that they are clinically similar. So the answer should be yes, they are similar, citing the relevant chunks. Now, the confidence level. The model seems pretty confident because all three chunks support the same point. But I need to make sure there's no conflicting information. Since all sources agree, the base_confidence can be high, maybe 0.95. But wait, the user said \"strict JSON\" and the example might have a confidence based on how much the evidence supports it. Since all three chunks are from the same source and reinforce each other, that's strong support. So 0.9", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if Weaver syndrome is similar to Sotos. The evidence provided has three chunks, all from the same document ID. Let me read through them. First chunk says Weaver is closely related to Sotos. The second and third mention that clinically, they are closely related, and Sotos is often caused by NSD1 mutations. Wait, but the user wants a biomedical answer. So I need to check if the evidence supports that they are similar. Looking at the chunks, all three point to a close relationship between the two syndromes. The key here is that the answer should be based on the evidence. The confidence level is important too. Since all the evidence directly states their closeness, the model can be confident. But I need to make sure the answer is concise and includes citations. The answer should mention the clinical similarity and the genetic cause for Sotos. Wait, but the question is about similarity, not the genetic cause. However, the evidence does link them closely. So the answer would be that they are similar, citing the document. The base confidence is high because all three chunks support this. So the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 1.0, "gold_docs": ["12464997", "12807965", "19011474", "22287508", "23592277", "24214728", "24852293", "9781911"], "ideal_answer": "Overgrowth conditions are a heterogeneous group of disorders characterised by increased growth and variable features, including macrocephaly, distinctive facial appearance and various degrees of learning difficulties and intellectual disability. Among them, Sotos and Weaver syndromes are clinically well defined and due to heterozygous mutations in NSD1 and EZH2, respectively. NSD1 and EZH2 are both histone-modifying enzymes Constitutional NSD1 and EZH2 mutations cause Sotos and Weaver syndromes respectively, overgrowth syndromes with considerable phenotypic overlap. NSD1 and EZH2 are SET domain-containing histone methyltransferases that play key roles in the regulation of transcription through histone modification and chromatin modeling."}
{"question_id": "54e0d1491388e8454a000014", "question": "Which enzyme is targeted by Evolocumab?", "retrieved_chunks": [{"doc_id": "24661068", "chunk_id": "24661068_0", "score": 6.792755126953125, "text": "AREAS COVERED: Evolocumab (AMG145) is a monoclonal antibody inhibiting the proprotein convertase subtilisin/kexin type 9 that binds to the liver LDL receptor and prevents it from normal recycling by targeting it for degradation."}, {"doc_id": "24961142", "chunk_id": "24961142_0", "score": 6.360899448394775, "text": "AREAS COVERED: Evolocumab and alirocumab are fully human monoclonal antibodies inhibiting the proprotein convertase subtilisin/kexin type 9 (PCSK9) that binds to hepatic LDL receptor and prevents it from normal recycling by targeting it for degradation."}, {"doc_id": "25282520", "chunk_id": "25282520_0", "score": 5.342667579650879, "text": "Evolocumab, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), reduced LDL cholesterol by 16% in a pilot study."}], "context": "[24661068:24661068_0] AREAS COVERED: Evolocumab (AMG145) is a monoclonal antibody inhibiting the proprotein convertase subtilisin/kexin type 9 that binds to the liver LDL receptor and prevents it from normal recycling by targeting it for degradation.\n[24961142:24961142_0] AREAS COVERED: Evolocumab and alirocumab are fully human monoclonal antibodies inhibiting the proprotein convertase subtilisin/kexin type 9 (PCSK9) that binds to hepatic LDL receptor and prevents it from normal recycling by targeting it for degradation.\n[25282520:25282520_0] Evolocumab, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), reduced LDL cholesterol by 16% in a pilot study.", "answer": "<think> Okay, let's tackle this question. The user is asking which enzyme is targeted by Evolocumab. I need to look at the evidence provided. First, looking at the evidence documents. The first one, 24661068:24661068_0, says Evolocumab is a monoclonal antibody that inhibits PCSK9 and binds to the liver LDL receptor. It mentions preventing normal recycling by targeting it for degradation. So PCSK9 is the enzyme here. The second document, 24961142:24961142_0, also states that Evolocumab and alirocumab inhibit PCSK9, which binds to the hepatic LDL receptor. This reinforces that PCSK9 is the target. The third document, 25282520:25282520_0, mentions Evolocumab targets PCSK9, reducing LDL cholesterol. This again points to PCSK9 as the enzyme. All three sources consistently mention PCSK9 as the target. The", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which enzyme is targeted by Evolocumab. I need to look at the evidence provided. First, looking at the evidence documents. The first one, 24661068:24661068_0, says Evolocumab is a monoclonal antibody that inhibits PCSK9 and binds to the liver LDL receptor. It mentions preventing normal recycling by targeting it for degradation. So PCSK9 is the enzyme here. The second document, 24961142:24961142_0, also states that Evolocumab and alirocumab inhibit PCSK9, which binds to the hepatic LDL receptor. This reinforces that PCSK9 is the target. The third document, 25282520:25282520_0, mentions Evolocumab targets PCSK9, reducing LDL cholesterol. This again points to PCSK9 as the enzyme. All three sources consistently mention PCSK9 as the target. The", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which enzyme is targeted by Evolocumab. I need to look at the evidence provided. First, looking at the evidence documents. The first one, 24661068:24661068_0, says Evolocumab is a monoclonal antibody that inhibits PCSK9 and binds to the liver LDL receptor. It mentions preventing normal recycling by targeting it for degradation. So PCSK9 is involved here. The second document, 24961142:24961142_0, also states that Evolocumab and alirocumab inhibit PCSK9, which binds to the hepatic LDL receptor. This reinforces that PCSK9 is the target. The third document, 25282520:25282520_0, directly mentions that Evolocumab is a monoclonal antibody to PCSK9. So this is another confirmation. All three sources point to PCSK9 as the enzyme targeted by Evol", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, so the user is asking which enzyme is targeted by Evolocumab. Let me look at the evidence provided. First, the first document says Evolocumab is a monoclonal antibody that inhibits PCSK9 and binds to the liver LDL receptor, preventing it from recycling by targeting degradation. The second document mentions that both Evolocumab and Alirocumab inhibit PCSK9, which binds to the hepatic LDL receptor. The third document states that Evolocumab targets PCSK9, reducing LDL cholesterol. So all three sources point to PCSK9 as the enzyme targeted by Evolocumab. The answer should be PCSK9. The confidence is high because all three pieces of evidence consistently state this. I need to make sure the citation is correct. The first document mentions PCSK9 in the context of Evolocumab, so the citation would be [24661068:24661068_0]. The base confidence can be 1.0 since all evidence supports this. </think> { \"answer\": \"Evolocumab", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["24255061", "24284914", "24373748", "24477778", "24481874", "24509273", "24598985", "24661068", "24662398", "24678979", "24691094", "24694531", "24825642", "24859266", "24953393", "24953396", "24961142", "25002170", "25052769", "25079474", "25282519", "25282520", "25410046", "25470376"], "ideal_answer": "Evolocumab (AMG145) is a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9) that demonstrated marked reductions in plasma low-density lipoprotein cholesterol concentrations in statin-intolerant patients."}
{"question_id": "553a8d78f321868558000003", "question": "Are ultraconserved elements often transcribed?", "retrieved_chunks": [{"doc_id": "23393190", "chunk_id": "23393190_5", "score": 6.222445487976074, "text": "The majority of these regions map onto ultraconserved elements and we demonstrate that they can act as functional enhancers within the organism of origin, as well as in cross-transgenesis experiments, and that they are transcribed in extant species of Olfactores. We refer to the elements as 'Olfactores conserved non-coding elements'"}, {"doc_id": "23393190", "chunk_id": "23393190_4", "score": 6.159970760345459, "text": "The majority of these regions map onto ultraconserved elements and we demonstrate that they can act as functional enhancers within the organism of origin, as well as in cross-transgenesis experiments, and that they are transcribed in extant species of Olfactores."}, {"doc_id": "23393190", "chunk_id": "23393190_3", "score": 5.898499488830566, "text": "The majority of these regions map onto ultraconserved elements and we demonstrate that they can act as functional enhancers within the organism of origin, as well as in cross-transgenesis experiments, and that they are transcribed in extant species of Olfactores"}], "context": "[23393190:23393190_5] The majority of these regions map onto ultraconserved elements and we demonstrate that they can act as functional enhancers within the organism of origin, as well as in cross-transgenesis experiments, and that they are transcribed in extant species of Olfactores. We refer to the elements as 'Olfactores conserved non-coding elements'\n[23393190:23393190_4] The majority of these regions map onto ultraconserved elements and we demonstrate that they can act as functional enhancers within the organism of origin, as well as in cross-transgenesis experiments, and that they are transcribed in extant species of Olfactores.\n[23393190:23393190_3] The majority of these regions map onto ultraconserved elements and we demonstrate that they can act as functional enhancers within the organism of origin, as well as in cross-transgenesis experiments, and that they are transcribed in extant species of Olfactores", "answer": "<think> Okay, let's tackle this. The user is asking if ultraconserved elements are often transcribed. The evidence provided has three chunks from the same document ID, all referencing the same study. Looking at the chunks, each mentions that \"they are transcribed in extant species of Olfactores.\" The key here is \"transcribed\" and \"extant species,\" which suggests that these elements are indeed transcribed. The term \"ultraconserved elements\" is mentioned in each chunk, so they're directly related to the question. I need to check if there's any conflicting information, but all three chunks agree on this point. The confidence level should be high since multiple chunks support the same conclusion. The answer should state that ultraconserved elements are transcribed, citing the document with the chunk IDs. The base confidence can be set to 1.0 because all evidence points to the same fact. </think> { \"answer\": \"Yes, ultraconserved elements are transcribed in extant species of Olfactores [23393190:23393190_3][23393", "citations": [{"doc_id": "23393190", "chunk_id": "23393190_3"}], "candidates": [{"answer": "<think> Okay, let's tackle this. The user is asking if ultraconserved elements are often transcribed. The evidence provided has three chunks from the same document ID, all referencing the same study. Looking at the chunks, each mentions that \"they are transcribed in extant species of Olfactores.\" The key here is \"transcribed\" and \"extant species,\" which suggests that these elements are indeed transcribed. The term \"ultraconserved elements\" is mentioned in each chunk, so they're directly related to the question. I need to check if there's any conflicting information, but all three chunks agree on this point. The confidence level should be high since multiple chunks support the same conclusion. The answer should state that ultraconserved elements are transcribed, citing the document with the chunk IDs. The base confidence can be set to 1.0 because all evidence points to the same fact. </think> { \"answer\": \"Yes, ultraconserved elements are transcribed in extant species of Olfactores [23393190:23393190_3][23393", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this query. The user is asking if ultraconserved elements are often transcribed. The evidence provided has three chunks from the same document ID, all referencing the same study. Looking at the evidence, each chunk says that the regions map onto ultraconserved elements and that they are transcribed in extant species of Olfactores. The key point here is that the elements are transcribed. The answer needs to be concise with citations. The base confidence should be high since all three chunks consistently state that they are transcribed. However, I need to check if there's any conflicting information. All three chunks are identical in content, so no conflicts. The confidence can be set to 1.0 as the evidence directly supports the statement. So the answer is yes, and the citation would be from the document ID and chunk IDs. Since all chunks are the same, I can use one of them. Let's pick chunk 3 for example. </think> { \"answer\": \"Yes, ultraconserved elements are transcribed in extant species of Olfactores [23393190:233", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this. The question is whether ultraconserved elements are often transcribed. The evidence provided has three chunks from the same document, all pointing to the fact that these regions (which map onto ultraconserved elements) are transcribed in extant species of Olfactores. First, I need to make sure I understand what ultraconserved elements are. From what I remember, ultraconserved elements are DNA sequences that are highly conserved across different species, meaning they haven't changed much over evolutionary time. They're often found in non-coding regions but can have functional roles. Looking at the evidence, each chunk says that the regions map onto ultraconserved elements and that they are transcribed in extant species of Olfactores. The key term here is \"transcribed,\" which directly answers the question. The chunks are repetitive, so the main point is consistent across all three. The answer should be a concise statement citing the relevant chunk. Since all three chunks are from the same document, I can pick one. Let's go with the first one: [23393190:23393", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["16705037", "19660540", "20202189", "21187392", "22094949", "22328099", "22617881", "23393190", "24037088", "24384562"], "ideal_answer": "Yes. Especially, a large fraction of non-exonic UCEs is transcribed across all developmental stages examined from only one DNA strand."}
{"question_id": "51404dd723fec90375000002", "question": "What is the methyl donor of DNA (cytosine-5)-methyltransferases?", "retrieved_chunks": [{"doc_id": "8065896", "chunk_id": "8065896_0", "score": 8.325078010559082, "text": "The DNA (cytosine-5)-methyltransferase (m5C-MTase) M.BspRI is able to accept the methyl group from the methyl donor S-adenosyl-L-methionine (AdoMet) in the absence of DNA. Transfer of the methyl group to the enzyme is a slow reaction relative to DNA methylation. S"}, {"doc_id": "8441637", "chunk_id": "8441637_0", "score": 6.531011581420898, "text": "All DNA (cytosine-5)-methyltransferases contain a single conserved cysteine. It has been proposed that this cysteine initiates catalysis by attacking the C6 of cytosine and thereby activating the normally inert C5 position."}, {"doc_id": "9576871", "chunk_id": "9576871_0", "score": 6.51622200012207, "text": "Most prokaryotic (cytosine-5)-DNA methyltransferases increase the frequency of deamination at the cytosine targeted for methylation in vitro in the absence of the cofactor S-adenosylmethionine (AdoMet) or the reaction product S-adenosylhomocysteine (AdoHcy)."}], "context": "[8065896:8065896_0] The DNA (cytosine-5)-methyltransferase (m5C-MTase) M.BspRI is able to accept the methyl group from the methyl donor S-adenosyl-L-methionine (AdoMet) in the absence of DNA. Transfer of the methyl group to the enzyme is a slow reaction relative to DNA methylation. S\n[8441637:8441637_0] All DNA (cytosine-5)-methyltransferases contain a single conserved cysteine. It has been proposed that this cysteine initiates catalysis by attacking the C6 of cytosine and thereby activating the normally inert C5 position.\n[9576871:9576871_0] Most prokaryotic (cytosine-5)-DNA methyltransferases increase the frequency of deamination at the cytosine targeted for methylation in vitro in the absence of the cofactor S-adenosylmethionine (AdoMet) or the reaction product S-adenosylhomocysteine (AdoHcy).", "answer": "<think> Okay, let's tackle this question. The user is asking about the methyl donor for DNA (cytosine-5)-methyltransferases. I need to look at the evidence provided to find the correct answer. First, looking at the evidence documents. The first one, 8065896:8065896_0, mentions that M.BspRI can accept the methyl group from S-adenosyl-L-methionine (AdoMet) in the absence of DNA. That seems directly relevant. The second document talks about a conserved cysteine in the enzyme but doesn't mention the methyl donor. The third one discusses prokaryotic enzymes and mentions AdoMet and AdoHcy as cofactors, but it's in the context of deamination frequency without the cofactor. The key here is that the first document explicitly states that AdoMet is the methyl donor for the enzyme M.BspRI. Even though the third document mentions AdoMet as a cofactor, the first one directly links it to the methyl group transfer. The second document doesn't mention the donor, so it", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking about the methyl donor for DNA (cytosine-5)-methyltransferases. I need to look at the evidence provided to find the correct answer. First, looking at the evidence documents. The first one, 8065896:8065896_0, mentions that M.BspRI can accept the methyl group from S-adenosyl-L-methionine (AdoMet) in the absence of DNA. That seems directly relevant. The second document talks about a conserved cysteine in the enzyme but doesn't mention the methyl donor. The third one discusses prokaryotic enzymes and mentions AdoMet and AdoHcy as cofactors, but it's in the context of deamination frequency without the cofactor. The key here is that the first document explicitly states that AdoMet is the methyl donor for the enzyme M.BspRI. Even though the third document mentions AdoMet as a cofactor, the first one directly links it to the methyl group transfer. The second document doesn't mention the donor, so it", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the methyl donor for DNA (cytosine-5)-methyltransferases. I need to look at the provided evidence to find the correct answer. First, looking at the evidence documents. The first one, 8065896:8065896_0, mentions that M.BspRI can accept a methyl group from S-adenosyl-L-methionine (AdoMet) in the absence of DNA. That seems directly relevant. The second document talks about a conserved cysteine in the enzyme but doesn't mention the methyl donor. The third one says that some DNA methyltransferases require AdoMet or AdoHcy, but it's in the context of the cofactor being absent. So the first document clearly states that AdoMet is the methyl donor for M.BspRI. Even though the other documents don't mention AdoMet, the first one directly cites it. The answer should be S-adenosyl-L-methionine (AdoMet), citing the first document. The confidence is high because", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the methyl donor for DNA (cytosine-5)-methyltransferases. I need to look at the evidence provided to find the correct answer. Looking at the first evidence snippet [8065896:8065896_0], it mentions that the enzyme M.BspRI can accept a methyl group from S-adenosyl-L-methionine (AdoMet) in the absence of DNA. The text says that transferring the methyl group to the enzyme is a slow reaction compared to DNA methylation. So AdoMet is mentioned here as the methyl donor. The second snippet [8441637:8441637_0] talks about a conserved cysteine in the enzyme, but it doesn't mention the methyl donor. It explains the mechanism of attack on cytosine's C6, which is part of the catalytic process, but not the donor. The third snippet [9576871:9576871_0] discusses prokaryotic enzymes", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["11208790", "15273274", "1584813", "7578083", "7607467", "8065896", "8441638"], "ideal_answer": "S-adenosyl-L-methionine (AdoMet, SAM) is the methyl donor of DNA (cytosine-5)-methyltransferases. DNA (cytosine-5)-methyltransferases catalyze the transfer of a methyl group from S-adenosyl-L-methionine to the C-5 position of cytosine residues in DNA."}
{"question_id": "552fa6f5bc4f83e828000002", "question": "Is peripheral neuroepithelioma related to Ewing sarcoma?", "retrieved_chunks": [{"doc_id": "7513503", "chunk_id": "7513503_1", "score": 9.991371154785156, "text": "Ewings sarcoma (ES) and peripheral neuroepithelioma (PN) are closely related tumors, and it can be difficult to distinguish them from other small-round-cell tumors (SRCTs)."}, {"doc_id": "1283315", "chunk_id": "1283315_1", "score": 9.887290954589844, "text": "Ewing's sarcoma (ES) and peripheral neuroepithelioma (PN) are related tumors, possibly of neural crest origin, which are cytogenetically characterized by the specific translocation t(11;22)(q24;q12)."}, {"doc_id": "7513503", "chunk_id": "7513503_0", "score": 9.874422073364258, "text": "Ewing's sarcoma (ES) and peripheral neuroepithelioma (PN) are closely related tumors, and it can be difficult to distinguish them from other small-round-cell tumors (SRCTs)"}], "context": "[7513503:7513503_1] Ewings sarcoma (ES) and peripheral neuroepithelioma (PN) are closely related tumors, and it can be difficult to distinguish them from other small-round-cell tumors (SRCTs).\n[1283315:1283315_1] Ewing's sarcoma (ES) and peripheral neuroepithelioma (PN) are related tumors, possibly of neural crest origin, which are cytogenetically characterized by the specific translocation t(11;22)(q24;q12).\n[7513503:7513503_0] Ewing's sarcoma (ES) and peripheral neuroepithelioma (PN) are closely related tumors, and it can be difficult to distinguish them from other small-round-cell tumors (SRCTs)", "answer": "<think> Okay, so the user is asking if peripheral neuroepithelioma is related to Ewing sarcoma. Let me look at the evidence provided. First, the evidence has three chunks. The first one says that Ewing's sarcoma (ES) and peripheral neuroepithelioma (PN) are closely related tumors, and it's hard to distinguish them from other small-round-cell tumors. The second chunk mentions they are related tumors possibly of neural crest origin with a specific translocation. The third chunk is the same as the first one, so that's redundant. So all three chunks say they are closely related. The answer should be yes, they are related. The citations are from document 7513503, chunks 1 and 0, and document 1283315 chunk 1. But the user wants one answer with citations. Maybe pick the first one. Also, the confidence is high because multiple sources confirm their relationship. So base_confidence should be 1.0 since all evidence points to them being related. </think> { \"answer\": \"Yes, peripheral neuroepithelioma (PN) and", "citations": [], "candidates": [{"answer": "<think> Okay, so the user is asking if peripheral neuroepithelioma is related to Ewing sarcoma. Let me look at the evidence provided. First, the evidence has three chunks. The first one says that Ewing's sarcoma (ES) and peripheral neuroepithelioma (PN) are closely related tumors, and it's hard to distinguish them from other small-round-cell tumors. The second chunk mentions they are related tumors possibly of neural crest origin with a specific translocation. The third chunk is the same as the first one, so that's redundant. So all three chunks say they are closely related. The answer should be yes, they are related. The citations are from document 7513503, chunks 1 and 0, and document 1283315 chunk 1. But the user wants one answer with citations. Maybe pick the first one. Also, the confidence is high because multiple sources confirm their relationship. So base_confidence should be 1.0 since all evidence points to them being related. </think> { \"answer\": \"Yes, peripheral neuroepithelioma (PN) and", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, so the user is asking if peripheral neuroepithelioma is related to Ewing sarcoma. Let me look at the evidence provided. The first document says that Ewing's sarcoma (ES) and peripheral neuroepithelioma (PN) are closely related tumors and it's hard to tell them apart from other SRCTs. The second one mentions they are related, possibly of neural crest origin, with the same translocation t(11;22)(q24;q12). The third document is similar to the first, repeating that they are closely related and difficult to distinguish. So all three sources clearly state that these two tumors are closely related. The key points here are the close relationship, possible shared origin, and similar genetic markers. The answer should confirm that they are related, citing the documents. The confidence level is high because multiple sources agree on this. I need to make sure the answer is concise and includes the correct citations. Also, the base_confidence should be 1.0 since all evidence points to a direct relationship. </think> { \"answer\": \"Yes, peripheral neuroepithelioma (PN)", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if peripheral neuroepithelioma is related to Ewing sarcoma. Looking at the evidence provided, there are three chunks. First chunk [7513503:7513503_1] says they're closely related and hard to distinguish from other SRCTs. The second chunk [1283315:1283315_1] mentions they're related, possibly of neural crest origin, with the same translocation t(11;22). The third chunk is a repeat of the first one. So all the evidence points to them being closely related tumors. The answer should state that they are related, citing the documents. The confidence is high since multiple sources back this up. I need to make sure the answer is concise and includes the correct citations. Also, the base_confidence should be 1.0 because the evidence clearly supports the relationship. </think> { \"answer\": \"Yes, peripheral neuroepithelioma (PN) and Ewing sarcoma (ES) are closely related tumors, often difficult", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["10968707", "1283315", "25303625", "3390826", "3760036", "7513503", "7595741", "7771924", "8204006", "8321753", "8644855", "9825003"], "ideal_answer": "Experimental data support the concept that Ewing sarcoma and peripheral neuroepithelioma are both peripheral primitive neuroectodermal neoplasms, differing only in the extent of neuroectodermal phenotype and morphological differentiation."}
{"question_id": "56d0451c3975bb303a00000e", "question": "Which signaling pathway does sonidegib inhibit?", "retrieved_chunks": [{"doc_id": "25981810", "chunk_id": "25981810_0", "score": 7.353166103363037, "text": "Hedgehog pathway signalling is aberrantly activated in around 95% of tumours. We assessed the antitumour activity of sonidegib, a Hedgehog signalling inhibitor, in patients with advanced basal cell carcinoma."}, {"doc_id": "25473003", "chunk_id": "25473003_1", "score": 5.5475172996521, "text": "The association between Hh activation status and tumor response to the Hh pathway inhibitor sonidegib (LDE225) was analyzed."}, {"doc_id": "24613036", "chunk_id": "24613036_0", "score": 5.544329643249512, "text": "Among such pathways, RAS/RAF/MEK/ERK, PI3K/AKT/mTOR, EGFR, and Notch are of particular interest because agents that selectively inhibit these pathways are available and can be readily combined with agents such as vismodegib, sonidegib (LDE225), and BMS-833923, which target smoothened-a key Hh pathway regulator."}], "context": "[25981810:25981810_0] Hedgehog pathway signalling is aberrantly activated in around 95% of tumours. We assessed the antitumour activity of sonidegib, a Hedgehog signalling inhibitor, in patients with advanced basal cell carcinoma.\n[25473003:25473003_1] The association between Hh activation status and tumor response to the Hh pathway inhibitor sonidegib (LDE225) was analyzed.\n[24613036:24613036_0] Among such pathways, RAS/RAF/MEK/ERK, PI3K/AKT/mTOR, EGFR, and Notch are of particular interest because agents that selectively inhibit these pathways are available and can be readily combined with agents such as vismodegib, sonidegib (LDE225), and BMS-833923, which target smoothened-a key Hh pathway regulator.", "answer": "<think> Okay, let's tackle this question. The user is asking which signaling pathway sonidegib inhibits. Looking at the evidence provided, there are three documents. First, document 25981810:25981810_0 mentions that sonidegib is a Hedgehog signalling inhibitor. That's pretty direct. Then, document 25473003:25473003_1 also talks about Hh activation and sonidegib as an Hh pathway inhibitor. The third document, 24613036:24613036_0, mentions that sonidegib targets smoothened, which is a key regulator of the Hedgehog pathway. So all three sources point to the Hedgehog pathway. The first two explicitly state that sonidegib inhibits the Hedgehog pathway. The third one, while not directly saying \"inhibits,\" refers to smoothened as a key component of the Hh pathway, which aligns with the other documents. I need to make sure there's", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which signaling pathway sonidegib inhibits. Looking at the evidence provided, there are three documents. First, document 25981810:25981810_0 mentions that sonidegib is a Hedgehog signalling inhibitor. That's pretty direct. Then, document 25473003:25473003_1 also talks about Hh activation and sonidegib as an Hh pathway inhibitor. The third document, 24613036:24613036_0, mentions that sonidegib targets smoothened, which is a key regulator of the Hedgehog pathway. So all three sources point to the Hedgehog pathway. The first two explicitly state that sonidegib inhibits the Hedgehog pathway. The third one, while not directly saying \"inhibits,\" refers to smoothened as a key component of the Hh pathway, which aligns with the other documents. I need to make sure there's", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which signaling pathway sonidegib inhibits. Looking at the evidence provided, there are three references. First, the document [25981810:25981810_0] mentions that sonidegib is a Hedgehog signalling inhibitor. That's pretty direct. Then, [25473003:25473003_1] talks about Hh activation status and sonidegib, reinforcing the Hedgehog pathway. The third document [24613036:24613036_0] lists sonidegib as targeting smoothened, which is a key component of the Hh pathway. So all three pieces of evidence point to the Hedgehog pathway. The confidence here is high because multiple sources consistently mention the Hedgehog pathway in relation to sonidegib. I should make sure the answer is concise and includes the citations. The base confidence can be set to 1.0 since all evidence aligns. </think> { \"answer\":", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's see. The user is asking which signaling pathway sonidegib inhibits. I need to look at the evidence provided. First, evidence document 25981810 mentions that sonidegib is a Hedgehog signalling inhibitor. That's pretty direct. Then another doc, 25473003, talks about Hh activation and sonidegib as an Hh pathway inhibitor. The third one, 24613036, mentions that sonidegib targets smoothened, which is a key regulator of the Hh pathway. So all three documents point to the Hedgehog (Hh) pathway. The answer should be the Hedgehog signaling pathway. The confidence is high because multiple sources confirm this. I'll check if there's any conflicting info, but none here. So base_confidence can be 1.0. </think> { \"answer\": \"Sonidegib inhibits the Hedgehog (Hh) signaling pathway [25981810:25981810_0][2547", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["24523439", "24598114", "24613036", "24817600", "24928708", "25473003", "25646180", "25981810"], "ideal_answer": "Sonidegib is a Hedghog signalling pathway inhibitor."}
{"question_id": "54ede8c594afd61504000009", "question": "In which phase of the cell cycle arrest is impaired in Fanconi anemia?", "retrieved_chunks": [{"doc_id": "11035915", "chunk_id": "11035915_1", "score": 8.095922470092773, "text": "Arrest of S-phase progression is impaired in Fanconi anemia cells."}, {"doc_id": "11035915", "chunk_id": "11035915_0", "score": 7.926003932952881, "text": "Arrest of S-phase progression is impaired in Fanconi anemia cells"}, {"doc_id": "11749045", "chunk_id": "11749045_0", "score": 6.368258953094482, "text": "The 4N cell cycle delay in Fanconi anemia reflects growth arrest in late S phase."}], "context": "[11035915:11035915_1] Arrest of S-phase progression is impaired in Fanconi anemia cells.\n[11035915:11035915_0] Arrest of S-phase progression is impaired in Fanconi anemia cells\n[11749045:11749045_0] The 4N cell cycle delay in Fanconi anemia reflects growth arrest in late S phase.", "answer": "<think> Okay, let's tackle this question. The user is asking which phase of the cell cycle is impaired in Fanconi anemia. The evidence provided has three chunks. First, I need to understand what each chunk says. The first two chunks (both from 11035915) mention that arrest of S-phase progression is impaired in Fanconi anemia cells. The third chunk (from 11749045) states that the 4N cell cycle delay in Fanconi anemia reflects growth arrest in late S phase. So, the key terms here are \"S-phase progression\" and \"late S phase.\" The question is about which phase of the cell cycle is impaired. The answer should be S-phase because both chunks mention S-phase. The third chunk adds that it's late S phase, but the main point is still S-phase. I need to check if there's any conflicting information. All three pieces of evidence point to S-phase. The first two are duplicates, and the third supports the same conclusion. So the answer should be S-phase. Now, the confidence level. Since all the evidence directly points to S", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which phase of the cell cycle is impaired in Fanconi anemia. The evidence provided has three chunks. First, I need to understand what each chunk says. The first two chunks (both from 11035915) mention that arrest of S-phase progression is impaired in Fanconi anemia cells. The third chunk (from 11749045) states that the 4N cell cycle delay in Fanconi anemia reflects growth arrest in late S phase. So, the key terms here are \"S-phase progression\" and \"late S phase.\" The question is about which phase of the cell cycle is impaired. The answer should be S-phase because both chunks mention S-phase. The third chunk adds that it's late S phase, but the main point is still S-phase. I need to check if there's any conflicting information. All three pieces of evidence point to S-phase. The first two are duplicates, and the third supports the same conclusion. So the answer should be S-phase. Now, the confidence level. Since all the evidence directly points to S", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which phase of the cell cycle is impaired in Fanconi anemia. The evidence provided has three chunks. First, I need to understand what each chunk says. The first two chunks (both from 11035915) mention that arrest of S-phase progression is impaired in Fanconi anemia cells. The third chunk (from 11749045) states that the 4N cell cycle delay in Fanconi anemia reflects growth arrest in late S phase. So, the key terms here are \"S-phase progression\" and \"late S phase.\" The first two chunks directly mention S-phase, while the third specifies \"late S phase.\" The question is about which phase is impaired. The answer should be S-phase, but the third chunk adds that it's specifically late S phase. However, the question doesn't specify whether it's early or late, just the phase. The answer needs to be concise with citations. The first two chunks are duplicates, so I can use one of them. The third chunk supports the same phase but with more detail. But since the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which phase of the cell cycle is impaired in Fanconi anemia. The evidence provided has three chunks. First, I need to understand what each chunk says. The first two chunks (11035915:11035915_1 and 0) both mention that arrest of S-phase progression is impaired in Fanconi anemia cells. So that's a direct citation pointing to S phase. The third chunk (11749045:11749045_0) says that the 4N cell cycle delay in Fanconi anemia reflects growth arrest in late S phase. Here, \"late S phase\" is mentioned. So this also points to S phase, but specifically late S phase. Now, the question is about which phase is impaired. The answer seems to be S-phase. Both chunks 1 and 3 reference S phase, with chunk 3 specifying \"late S phase\". However, the first two chunks just say \"S-phase progression is impaired\". The user wants a concise answer with citations. So I", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["11035915", "11749045", "14988723", "9414295", "9650445"], "ideal_answer": "In response to damage induced by DNA cross-linking agents, the S-phase checkpoint is inefficient in Fanconi anemia (FA) cells, leading to accumulation of secondary lesions, such as single- and double-strand breaks and gaps. The prolonged time in G2 phase seen in FA cells therefore exists in order to allow the cells to remove lesions which accumulated during the preceding abnormal S phase."}
{"question_id": "56c3327c50c68dd41600000c", "question": "Which DNA sequences are more prone for the formation of R-loops?", "retrieved_chunks": [{"doc_id": "24743386", "chunk_id": "24743386_1", "score": 7.385017395019531, "text": "Finally, non-denaturing bisulfite mapping of the displaced single-stranded DNA confirmed R-loop formation at the endogenous FMR1 locus and further indicated that R-loops formed over CGG repeats may be prone to structural complexities, including hairpin formation, not commonly associated with other R-loops."}, {"doc_id": "24743386", "chunk_id": "24743386_0", "score": 7.1751389503479, "text": "Finally, non-denaturing bisulfite mapping of the displaced single-stranded DNA confirmed R-loop formation at the endogenous FMR1 locus and further indicated that R-loops formed over CGG repeats may be prone to structural complexities, including hairpin formation, not commonly associated with other R-loops"}, {"doc_id": "22464440", "chunk_id": "22464440_0", "score": 4.766057968139648, "text": "Ginno et al. (2012) describe unusual sequence features at promoter CpG islands that can lead to formation of persistent RNA-DNA hybrids (R loops), which are proposed to prevent genomic DNA methylation"}], "context": "[24743386:24743386_1] Finally, non-denaturing bisulfite mapping of the displaced single-stranded DNA confirmed R-loop formation at the endogenous FMR1 locus and further indicated that R-loops formed over CGG repeats may be prone to structural complexities, including hairpin formation, not commonly associated with other R-loops.\n[24743386:24743386_0] Finally, non-denaturing bisulfite mapping of the displaced single-stranded DNA confirmed R-loop formation at the endogenous FMR1 locus and further indicated that R-loops formed over CGG repeats may be prone to structural complexities, including hairpin formation, not commonly associated with other R-loops\n[22464440:22464440_0] Ginno et al. (2012) describe unusual sequence features at promoter CpG islands that can lead to formation of persistent RNA-DNA hybrids (R loops), which are proposed to prevent genomic DNA methylation", "answer": "<think> Okay, I need to generate a biomedical answer based on the given evidence. The question is asking which DNA sequences are more prone to forming R-loops. Looking at the evidence provided, there are three documents. Let me check each one. First, document 24743386 has two chunks. Both mention that R-loops formed over CGG repeats are prone to structural complexities like hairpin formation. That's a direct statement about CGG repeats being more prone. The third document (22464440) talks about promoter CpG islands with unusual sequence features leading to persistent R-loops. However, it doesn't specify the exact sequences, just mentions \"unusual sequence features\" and \"CpG islands.\" But since the first two documents specifically mention CGG repeats, that's more concrete. So the answer should be CGG repeats, citing the first document. The confidence is high because the evidence directly states that R-loops over CGG repeats are prone to structural issues. The other document mentions CpG islands but doesn't specify sequences as clearly. So base_confidence would be 0.95 or so.", "citations": [], "candidates": [{"answer": "<think> Okay, I need to generate a biomedical answer based on the given evidence. The question is asking which DNA sequences are more prone to forming R-loops. Looking at the evidence provided, there are three documents. Let me check each one. First, document 24743386 has two chunks. Both mention that R-loops formed over CGG repeats are prone to structural complexities like hairpin formation. That's a direct statement about CGG repeats being more prone. The third document (22464440) talks about promoter CpG islands with unusual sequence features leading to persistent R-loops. However, it doesn't specify the exact sequences, just mentions \"unusual sequence features\" and \"CpG islands.\" But since the first two documents specifically mention CGG repeats, that's more concrete. So the answer should be CGG repeats, citing the first document. The confidence is high because the evidence directly states that R-loops over CGG repeats are prone to structural issues. The other document mentions CpG islands but doesn't specify sequences as clearly. So base_confidence would be 0.95 or so.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which DNA sequences are more prone to forming R-loops. The evidence provided has three chunks. First, looking at the first two chunks from 24743386: they mention that R-loops formed over CGG repeats may be prone to structural complexities like hairpin formation. That's a direct citation pointing to CGG repeats. The third chunk from 22464440 talks about promoter CpG islands having unusual sequence features leading to R-loop formation, but it doesn't specify the exact sequences. So the main evidence here is the CGG repeats in the first two chunks. The answer should be CGG repeats, citing those documents. The confidence level: since the first two chunks directly mention CGG repeats and their association with structural complexities, that's strong evidence. The third chunk is about CpG islands but doesn't specify sequences, so it's less relevant here. Therefore, base_confidence would be high, maybe 0.95. Need to make sure the answer is concise and includes the correct citations. </think> { \"answer\": \"CGG", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which DNA sequences are more prone to forming R-loops. The evidence provided has three chunks. First, looking at the first two chunks from 24743386: they mention that R-loops formed over CGG repeats are prone to structural complexities like hairpin formation. That seems directly relevant. The third chunk from 22464440 talks about promoter CpG islands having unusual sequences leading to R-loop formation, but it doesn't specify the exact sequences. So the main point here is that CGG repeats are mentioned in the first two chunks as being associated with structural issues that make R-loops more likely. The other chunk mentions CpG islands but doesn't name specific sequences. Therefore, the answer should focus on CGG repeats. The confidence level: the first two chunks directly cite CGG repeats, so that's a strong point. The third chunk is less specific, so maybe a moderate confidence. But since two sources mention CGG, I'll set the base_confidence to 0.95. Need to make sure the answer is concise and includes", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["15531884", "16793409", "18986989", "20080737", "22464440", "24743386", "24787137", "24843019", "25147206", "25296254", "25972891"], "ideal_answer": "R-loops, transcriptionally-induced RNA:DNA hybrids, occurring at repeat tracts (CTG)n, (CAG)n, (CGG)n, (CCG)n and (GAA)n, are associated with diseases including myotonic dystrophy, Huntington's disease, fragile X and Friedreich's ataxia. Physiological R-loop formation at CpG island promoters can contribute to DNA replication origin specification at these regions, the most efficient replication initiation sites in mammalian cells. R-loops may also possess beneficial effects, as their widespread formation has been detected over CpG island promoters in human genes. R-loops are particularly enriched over G-rich terminator elements."}
{"question_id": "551c23bc6b348bb82c00000b", "question": "Mutation of which gene is implicated in the familial isolated pituitary adenoma?", "retrieved_chunks": [{"doc_id": "23371967", "chunk_id": "23371967_0", "score": 8.3985013961792, "text": "Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene."}, {"doc_id": "22527616", "chunk_id": "22527616_1", "score": 8.271871566772461, "text": "Genetic analysis in a patient presenting with meningioma and familial isolated pituitary adenoma (FIPA) reveals selective involvement of the R81X mutation of the AIP gene in the pathogenesis of the pituitary tumor."}, {"doc_id": "24078436", "chunk_id": "24078436_0", "score": 8.087667465209961, "text": "Familial isolated pituitary adenoma caused by a Aip gene mutation not described before in a family context."}], "context": "[23371967:23371967_0] Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene.\n[22527616:22527616_1] Genetic analysis in a patient presenting with meningioma and familial isolated pituitary adenoma (FIPA) reveals selective involvement of the R81X mutation of the AIP gene in the pathogenesis of the pituitary tumor.\n[24078436:24078436_0] Familial isolated pituitary adenoma caused by a Aip gene mutation not described before in a family context.", "answer": "<think> Okay, let's tackle this question. The user is asking which gene mutation is implicated in familial isolated pituitary adenoma (FIPA). The evidence provided has three references. First, I need to look at each of the evidence points. The first one says that FIPA is linked to mutations in the AIP gene. The second mention also talks about the R81X mutation of the AIP gene being involved. The third reference mentions a new Aip gene mutation in a family context. So all three sources point to the AIP gene. The answer should be AIP. Now, checking the confidence. Since all three references consistently state AIP, the confidence is high. But I need to make sure there's no conflicting information. None of the evidence contradicts each other. So base_confidence should be 1.0. The citation would be from the first document, as it's the main one. So the answer is AIP gene with citation [23371967:23371967_0]. </think> { \"answer\": \"The AIP gene mutation is implicated in familial isolated pit", "citations": [{"doc_id": "23371967", "chunk_id": "23371967_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which gene mutation is implicated in familial isolated pituitary adenoma (FIPA). The evidence provided has three references. First, I need to look at each of the evidence points. The first one says that FIPA is linked to mutations in the AIP gene. The second mention also talks about the R81X mutation of the AIP gene being involved. The third reference mentions a new Aip gene mutation in a family context. So all three sources point to the AIP gene. The answer should be AIP. Now, checking the confidence. Since all three references consistently state AIP, the confidence is high. But I need to make sure there's no conflicting information. None of the evidence contradicts each other. So base_confidence should be 1.0. The citation would be from the first document, as it's the main one. So the answer is AIP gene with citation [23371967:23371967_0]. </think> { \"answer\": \"The AIP gene mutation is implicated in familial isolated pit", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which gene mutation is implicated in familial isolated pituitary adenoma (FIPA). The evidence provided has three references. First, I need to look at each of the evidence points. The first one says that FIPA is linked to mutations in the AIP gene. The second mention also talks about the AIP gene, specifically the R81X mutation. The third reference also points to the AIP gene being mutated in a familial context. So all three sources consistently cite the AIP gene. The answer should be AIP. Now, checking the confidence. Since all three pieces of evidence support AIP, the confidence is high. The model can be confident here. So base_confidence would be 1.0. </think> { \"answer\": \"The AIP gene mutation is implicated in familial isolated pituitary adenoma (FIPA) [23371967:23371967_0][22527616:22527616_1][24078436:", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, so the user is asking which gene's mutation is implicated in familial isolated pituitary adenoma (FIPA). Let me look at the evidence provided. The first document, 23371967, mentions that FIPA is associated with mutations in the AIP gene. The second one, 22527616, specifically talks about the R81X mutation of the AIP gene in a patient with meningioma and FIPA. The third document, 24078436, also points to the AIP gene mutation causing familial isolated pituitary adenoma. All three sources consistently cite the AIP gene. The answer should be AIP. The confidence is high because all three papers support this. I need to make sure the answer is concise and includes citations. The base_confidence can be 1.0 since all evidence points to AIP. </think> { \"answer\": \"The AIP gene [23371967:23371967_0][22527616:2252", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["17244780", "17893250", "17961654", "17993773", "19883897", "20457215", "20506337", "20570174", "20616498", "20616502", "20669561", "20833337", "21450940", "21454441", "21498161", "21778740", "22291433", "22527616", "22584704", "22915287", "23038625", "23286415", "23310926", "23371967", "23633209", "23652674", "23743763", "24050928", "24078436", "24366639", "24423289", "24789813", "24996936"], "ideal_answer": "Mutation of aryl hydrocarbon receptor interacting protein (AIP) gene was implicated in the familial isolated pituitary adenoma (FIPA) syndrome. About 20% of the families with FIPA harbor inactivating mutation in AIP gene."}
{"question_id": "5314a7a4dae131f847000003", "question": "which mutations of troponin C gene have been found to cause hypertrophic cardiomyopathy?", "retrieved_chunks": [{"doc_id": "18285522", "chunk_id": "18285522_0", "score": 8.698280334472656, "text": "The cardiac troponin C (cTnC) mutation, L29Q, has been found in a patient with familial hypertrophic cardiomyopathy."}, {"doc_id": "21262074", "chunk_id": "21262074_1", "score": 8.68394660949707, "text": "We report the first frameshift mutation (c.363dupG or p.Gln122AlafsX30) in Troponin C causing hypertrophic cardiomyopathy (and sudden cardiac death) in a 19-year-old male, and have demonstrated that the mutation segregates with hypertrophic cardiomyopathy within the family."}, {"doc_id": "22815480", "chunk_id": "22815480_0", "score": 8.005660057067871, "text": "A mutation in TNNC1-encoded cardiac troponin C, TNNC1-A31S, predisposes to hypertrophic cardiomyopathy and ventricular fibrillation."}], "context": "[18285522:18285522_0] The cardiac troponin C (cTnC) mutation, L29Q, has been found in a patient with familial hypertrophic cardiomyopathy.\n[21262074:21262074_1] We report the first frameshift mutation (c.363dupG or p.Gln122AlafsX30) in Troponin C causing hypertrophic cardiomyopathy (and sudden cardiac death) in a 19-year-old male, and have demonstrated that the mutation segregates with hypertrophic cardiomyopathy within the family.\n[22815480:22815480_0] A mutation in TNNC1-encoded cardiac troponin C, TNNC1-A31S, predisposes to hypertrophic cardiomyopathy and ventricular fibrillation.", "answer": "<think> Okay, the user is asking which mutations of the troponin C gene have been found to cause hypertrophic cardiomyopathy. Let me look at the evidence provided. First, there's the L29Q mutation mentioned in document 18285522. That's one example. Then, the frameshift mutation c.363dupG leading to p.Gln122AlafsX30 from 21262074. That's another one. The third piece of evidence is TNNC1-A31S from 22815480. So, I need to list these three mutations as the answer. Each has a citation. The user wants a concise answer with citations in the format [doc_id:chunk_id]. Then the base confidence should be a float between 0 and 1. Since all three are from different studies, I can be fairly confident. Maybe 0.95? But I need to check if there's any reason to doubt. The mutations are all specific and from different sources, so combining them is valid. So the answer would include all", "citations": [], "candidates": [{"answer": "<think> Okay, the user is asking which mutations of the troponin C gene have been found to cause hypertrophic cardiomyopathy. Let me look at the evidence provided. First, there's the L29Q mutation mentioned in document 18285522. That's one example. Then, the frameshift mutation c.363dupG leading to p.Gln122AlafsX30 from 21262074. That's another one. The third piece of evidence is TNNC1-A31S from 22815480. So, I need to list these three mutations as the answer. Each has a citation. The user wants a concise answer with citations in the format [doc_id:chunk_id]. Then the base confidence should be a float between 0 and 1. Since all three are from different studies, I can be fairly confident. Maybe 0.95? But I need to check if there's any reason to doubt. The mutations are all specific and from different sources, so combining them is valid. So the answer would include all", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, the user is asking which mutations in the troponin C gene cause hypertrophic cardiomyopathy. Let me look at the evidence provided. First, there's the L29Q mutation mentioned in document 18285522. That's one example. Then, the frameshift mutation c.363dupG leading to p.Gln122AlafsX30 from 21262074. That's another one. The third evidence is TNNC1-A31S from 22815480. So these three mutations are all in the TNNC1 gene, which encodes cardiac troponin C. I need to list them as the answer. Each has a citation. The confidence should be high since there are multiple examples. But wait, the user wants one candidate answer. Maybe pick one? Or list all three? The question says \"mutations\", plural, so probably include all three. But the example in the evidence shows each mutation as separate entries. So the answer should mention all three mutations with their respective citations. Wait, the user's instruction", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to generate a JSON answer based on the provided evidence. The question is about which mutations of the troponin C gene cause hypertrophic cardiomyopathy. Let me look at the evidence given. First, the evidence has three entries. The first one mentions L29Q mutation in cTnC causing familial HCM. The second talks about a frameshift mutation c.363dupG leading to p.Gln122AlafsX30, which causes HCM and sudden cardiac death. The third entry states TNNC1-A31S mutation in TNNC1 predisposes to HCM and ventricular fibrillation. So the answer should list these mutations. Each of them is a different mutation. The user wants a concise answer with citations. The base confidence is a float between 0 and 1. Since all three evidence points are from different studies, I can be confident that these mutations are indeed associated with HCM. But how confident am I? Well, each study is separate, so combining them would mean high confidence. Maybe 0.95 or something. Wait, the user said \"strict JSON", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["16302972", "18285522", "18572189", "19439414", "19506933", "20459070", "20566645", "21262074", "22489623", "22815480", "23425245", "24260207"], "ideal_answer": "The following mutations of troponin C gene have been found to cause hypertrophic cardiomyopathy: L29Q; A8V; A31S; E134D; c.363dupG; A23Q; D145E and C84Y"}
{"question_id": "535d78137d100faa09000005", "question": "What is known about the effect of acupuncture in smoking cessation ?", "retrieved_chunks": [{"doc_id": "15861492", "chunk_id": "15861492_0", "score": 5.501813888549805, "text": "auricular acupuncture in smoking cessation has some effect."}, {"doc_id": "18405159", "chunk_id": "18405159_0", "score": 5.015536308288574, "text": "Acupuncture combined with auricular point sticking and pressing has reliable therapeutic effect for smoking cessation"}, {"doc_id": "17264832", "chunk_id": "17264832_0", "score": 4.5480427742004395, "text": "Auricular acupuncture appears to be effective for smoking cessation, but the effect may not depend on point location."}], "context": "[15861492:15861492_0] auricular acupuncture in smoking cessation has some effect.\n[18405159:18405159_0] Acupuncture combined with auricular point sticking and pressing has reliable therapeutic effect for smoking cessation\n[17264832:17264832_0] Auricular acupuncture appears to be effective for smoking cessation, but the effect may not depend on point location.", "answer": "<think> Okay, let's tackle this query. The user is asking about the effect of acupuncture in smoking cessation. The evidence provided has three chunks. First, I need to check each chunk for relevant information. The first chunk says auricular acupuncture has some effect. The second mentions combining acupuncture with other methods like auricular point sticking and pressing has a reliable therapeutic effect. The third states that auricular acupuncture is effective but the effect might not depend on point location. I need to synthesize this into a concise answer. The key points are that auricular acupuncture is effective, and when combined with other techniques, it's reliable. Also, the effectiveness isn't dependent on specific points. Now, I should cite the relevant documents. The first chunk is from 15861492:15861492_0, the second from 18405159:18405159_0, and the third from 17264832:17264832_0. But the answer needs to be concise, so maybe mention auricular acupuncture's effectiveness and", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this query. The user is asking about the effect of acupuncture in smoking cessation. The evidence provided has three chunks. First, I need to check each chunk for relevant information. The first chunk says auricular acupuncture has some effect. The second mentions combining acupuncture with other methods like auricular point sticking and pressing has a reliable therapeutic effect. The third states that auricular acupuncture is effective but the effect might not depend on point location. I need to synthesize this into a concise answer. The key points are that auricular acupuncture is effective, and when combined with other techniques, it's reliable. Also, the effectiveness isn't dependent on specific points. Now, I should cite the relevant documents. The first chunk is from 15861492:15861492_0, the second from 18405159:18405159_0, and the third from 17264832:17264832_0. But the answer needs to be concise, so maybe mention auricular acupuncture's effectiveness and", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this query. The user is asking about the effect of acupuncture in smoking cessation. The evidence provided has three chunks. First, I need to parse each chunk. The first one says auricular acupuncture has some effect. The second mentions combining acupuncture with auricular point sticking and pressing has a reliable therapeutic effect. The third states that auricular acupuncture is effective but the effect might not depend on point location. So, all three chunks support the idea that acupuncture, particularly auricular acupuncture, is effective for smoking cessation. However, the second chunk adds that combining it with other methods (sticking and pressing) makes it more reliable. The third chunk adds a nuance that the effectiveness isn't dependent on specific points. The answer needs to be concise, citing the documents. The user wants a JSON object with 'answer' and 'base_confidence'. The confidence should be between 0 and 1. Since all three sources agree on the effectiveness but vary in details (like combination therapy and point location), I can say there's moderate confidence. Maybe 0.8? Because they all confirm effectiveness, but there's some variati", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this query. The user is asking about the effect of acupuncture in smoking cessation. The evidence provided has three chunks. First, I need to check each chunk to see what they say. The first one says auricular acupuncture has some effect. The second mentions combining acupuncture with auricular point sticking and pressing has a reliable therapeutic effect. The third states that auricular acupuncture is effective but the effect might not depend on point location. So, all three chunks support the idea that acupuncture, particularly auricular acupuncture, is effective for smoking cessation. However, the second chunk adds that combining it with other methods (sticking and pressing) makes it more reliable. The third chunk adds a nuance that the effectiveness isn't dependent on the specific points used. I need to synthesize this into a concise answer. The main point is that auricular acupuncture is effective, possibly when combined with other techniques. The confidence level should be high because multiple sources back this up. But I should note the variation in the second chunk about combining methods and the third chunk's point about location not mattering. W", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["10024707", "11154059", "12356614", "12416359", "15004442", "15861492", "16566674", "17264832", "17698433", "18405159", "22373002", "24030452"], "ideal_answer": "Ear acupressure (EAP) and ear acupuncture have been used for smoking cessation, and some positive results have been reported. Auricular (ear) acupressure has been purported to be beneficial in achieving smoking cessation in some studies, while in others has been deemed insignificant. The combined acupuncture-education group showing the greatest effect from treatment."}
{"question_id": "56c6dd275795f9a73e000008", "question": "Which post-translational histone modifications are characteristic of constitutive heterochromatin?", "retrieved_chunks": [{"doc_id": "12581305", "chunk_id": "12581305_0", "score": 4.429203033447266, "text": "Histone modifications in Arabidopsis- high methylation of H3 lysine 9 is dispensable for constitutive heterochromatin"}, {"doc_id": "17891782", "chunk_id": "17891782_0", "score": 4.23682165145874, "text": "Constitutive heterochromatin during mouse oogenesis: the pattern of histone H3 modifications and localization of HP1alpha and HP1beta proteins."}, {"doc_id": "18592385", "chunk_id": "18592385_0", "score": 3.8797664642333984, "text": "At the SUMO-1 labelled areas, the presence of HP1alpha protein, as well as of trimethylated H3-K9 and H4-K20 histone modifications, supports a role for SUMO-1 in constitutive heterochromatin organization."}], "context": "[12581305:12581305_0] Histone modifications in Arabidopsis- high methylation of H3 lysine 9 is dispensable for constitutive heterochromatin\n[17891782:17891782_0] Constitutive heterochromatin during mouse oogenesis: the pattern of histone H3 modifications and localization of HP1alpha and HP1beta proteins.\n[18592385:18592385_0] At the SUMO-1 labelled areas, the presence of HP1alpha protein, as well as of trimethylated H3-K9 and H4-K20 histone modifications, supports a role for SUMO-1 in constitutive heterochromatin organization.", "answer": "<think> Okay, let's tackle this question. The user is asking which post-translational histone modifications are characteristic of constitutive heterochromatin. The evidence given has three references. First, I need to look at each document to find the relevant information. The first reference (12581305) mentions that high methylation of H3 lysine 9 is dispensable for constitutive heterochromatin. So, this suggests that while H3K9 methylation is present, it's not essential here. But maybe other modifications are more important. The second reference (17891782) talks about histone H3 modifications during mouse oogenesis and the localization of HP1alpha and HP1beta. HP1 proteins are known to bind to heterochromatin, so this might indicate that certain H3 modifications are involved. But the exact modifications aren't specified here. The third reference (18592385) states that SUMO-1 labelled areas have HP1alpha, trimethylated H3-K9, and H4-K20. This seems directly relevant because it lists two", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which post-translational histone modifications are characteristic of constitutive heterochromatin. The evidence given has three references. First, I need to look at each document to find the relevant information. The first reference (12581305) mentions that high methylation of H3 lysine 9 is dispensable for constitutive heterochromatin. So, this suggests that while H3K9 methylation is present, it's not essential here. But maybe other modifications are more important. The second reference (17891782) talks about histone H3 modifications during mouse oogenesis and the localization of HP1alpha and HP1beta. HP1 proteins are known to bind to heterochromatin, so this might indicate that certain H3 modifications are involved. But the exact modifications aren't specified here. The third reference (18592385) states that SUMO-1 labelled areas have HP1alpha, trimethylated H3-K9, and H4-K20. This seems directly relevant because it lists two", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking about post-translational histone modifications characteristic of constitutive heterochromatin. The evidence provided has three documents. First, I need to recall what constitutive heterochromatin is. It's a type of heterochromatin that's present in all cell types, unlike facultative heterochromatin which is cell-type specific. Post-translational modifications include things like methylation, acetylation, ubiquitination, etc. Looking at the evidence: Document 12581305: It says high methylation of H3 lysine 9 is dispensable for constitutive heterochromatin. So this suggests that H3K9me3 might not be necessary, but maybe other modifications are involved. Document 17891782: Talks about histone H3 modifications during mouse oogenesis. It mentions the pattern of H3 modifications and localization of HP1alpha and beta. HP1 proteins bind to heterochromatin, so their presence might indicate certain modifications. But the specific modifications here aren't detailed. Document 18592", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking about post-translational histone modifications characteristic of constitutive heterochromatin. The evidence provided has three references. First, I need to recall what constitutive heterochromatin is. It's a type of heterochromatin that's present in all cells, not just specific cell types. Histone modifications are chemical changes to the histone proteins that affect chromatin structure and function. Looking at the evidence: 1. The first reference says high methylation of H3 lysine 9 (H3K9me3) is dispensable for constitutive heterochromatin in Arabidopsis. Wait, \"dispensable\" here might mean it's not required? But that seems conflicting because usually, H3K9me3 is associated with heterochromatin. Maybe the study found that while present, it's not essential for maintaining constitutive heterochromatin. Or maybe there's a nuance here. 2. The second reference talks about mouse oogenesis and mentions histone H3 modifications. It doesn't specify which ones, but the title suggests they're looking at patterns in", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["11356363", "11740497", "12581305", "17710556", "17891782", "18592385", "18987983", "20532208", "21541345", "21803857", "22319459", "22572731"], "ideal_answer": "H3K9me3 is the major marker of constitutive heterochromatin. Other histone methylation marks usually found in constitutive heterochromatin, are H4K20me3 and H3K79me3. Classical histone modifications associated with heterochromatin include H3K9me2, H3K27me1 and H3K27me2. Histone H3 trimethylation at lysine 36 is associated with constitutive and facultative heterochromatin. H3S10 phosphorylation marks constitutive heterochromatin during interphase in early mouse embryos until the 4-cell stage"}
{"question_id": "56c1f02cef6e39474100004c", "question": "GV1001 vaccine targets which enzyme?", "retrieved_chunks": [{"doc_id": "19388882", "chunk_id": "19388882_0", "score": 6.686008453369141, "text": "Human telomerase reverse transcriptase (hTERT), the rate-limiting subunit of the telomerase complex, is therefore an attractive target for cancer vaccination. The present review provides an update on the development of GV1001, a peptide vaccine representing a 16-aa hTERT sequence."}, {"doc_id": "24439482", "chunk_id": "24439482_0", "score": 5.650123596191406, "text": "GV1001 is a 16-amino-acid vaccine peptide derived from the human telomerase reverse transcriptase sequence."}, {"doc_id": "24815142", "chunk_id": "24815142_0", "score": 5.186768531799316, "text": "Peptide GV1001 is a peptide vaccine representing a 16-amino acid human telomerase reverse transcriptase sequence, which has been reported to possess potential antineoplastic and anti-inflammatory activity."}], "context": "[19388882:19388882_0] Human telomerase reverse transcriptase (hTERT), the rate-limiting subunit of the telomerase complex, is therefore an attractive target for cancer vaccination. The present review provides an update on the development of GV1001, a peptide vaccine representing a 16-aa hTERT sequence.\n[24439482:24439482_0] GV1001 is a 16-amino-acid vaccine peptide derived from the human telomerase reverse transcriptase sequence.\n[24815142:24815142_0] Peptide GV1001 is a peptide vaccine representing a 16-amino acid human telomerase reverse transcriptase sequence, which has been reported to possess potential antineoplastic and anti-inflammatory activity.", "answer": "<think> Okay, let's tackle this question. The user is asking which enzyme the GV1001 vaccine targets. The evidence provided has three documents. First, document [19388882:19388882_0] mentions human telomerase reverse transcriptase (hTERT) as the target. It states that hTERT is the rate-limiting subunit of the telomerase complex and is an attractive target for cancer vaccination. The GV1001 vaccine is a peptide based on a 16-aa hTERT sequence. Document [24439482:24439482_0] directly says that GV1001 is a 16-amino-acid peptide derived from the human telomerase reverse transcriptase sequence. This reinforces the previous point. Document [24815142:24815142_0] also confirms that GV1001 is a peptide vaccine representing the 16-aa hTERT sequence and mentions its potential antineoplastic activity, which ties", "citations": [{"doc_id": "19388882", "chunk_id": "19388882_0"}, {"doc_id": "24439482", "chunk_id": "24439482_0"}, {"doc_id": "24815142", "chunk_id": "24815142_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which enzyme the GV1001 vaccine targets. The evidence provided has three documents. First, document [19388882:19388882_0] mentions human telomerase reverse transcriptase (hTERT) as the target. It states that hTERT is the rate-limiting subunit of the telomerase complex and is an attractive target for cancer vaccination. The GV1001 vaccine is a peptide based on a 16-aa hTERT sequence. Document [24439482:24439482_0] directly says that GV1001 is a 16-amino-acid peptide derived from the human telomerase reverse transcriptase sequence. This reinforces the previous point. Document [24815142:24815142_0] also confirms that GV1001 is a peptide vaccine representing the 16-aa hTERT sequence and mentions its potential antineoplastic activity, which ties", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which enzyme the GV1001 vaccine targets. The evidence provided has three documents. First, I need to look at each document. Document 19388882:19388882_0 mentions human telomerase reverse transcriptase (hTERT) as the target. It says hTERT is the rate-limiting subunit of the telomerase complex and that GV1001 is a peptide vaccine based on a 16-aa hTERT sequence. That's a direct mention. Document 24439482:24439482_0 states that GV1001 is a 16-amino-acid peptide derived from the human telomerase reverse transcriptase sequence. So this reinforces the same information as the first document. Document 24815142:24815142_0 also mentions that GV1001 is a peptide vaccine representing a 16-amino acid hTERT sequence, with potential antine", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which enzyme the GV1001 vaccine targets. The evidence provided has three documents. First, looking at document [19388882:19388882_0], it mentions human telomerase reverse transcriptase (hTERT) as the target. It also states that GV1001 is a peptide vaccine based on a 16-aa hTERT sequence. That's a direct mention of hTERT. Document [24439482:24439482_0] confirms that GV1001 is derived from the hTERT sequence, reinforcing the same point. The third document [24815142:24815142_0] again refers to GV1001 as a peptide representing the hTERT sequence, and mentions its antineoplastic activity, which is related to targeting cancer cells, so it's consistent with the other documents. All three sources consistently point to hTERT as the enzyme targeted by GV", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["19072345", "19388882", "20822343", "21377838", "21586625", "22841437", "23827187", "24411674", "24439482", "24815142", "24919654", "24954781"], "ideal_answer": "GV1001 is a 16-amino-acid vaccine peptide derived from the human telomerase reverse transcriptase sequence. It has been developed as a vaccine against various cancers."}
{"question_id": "550af222c2af5d5b7000000b", "question": "Which is the E3 ubiquitin ligase which ubiquitinates IkB leading to its proteasomal degradation?", "retrieved_chunks": [{"doc_id": "12832479", "chunk_id": "12832479_0", "score": 6.744091987609863, "text": "MDM2 is an E3 ubiquitin ligase that targets p53 for proteasomal degradation. Recent studies have shown, however, that the ring-finger domain (RFD) of MDM2, where the ubiquitin E3 ligase activity resides, is necessary but not sufficient for p53 ubiquitination, suggesting that an additional activity of MDM2 might be required."}, {"doc_id": "22666487", "chunk_id": "22666487_1", "score": 6.625942707061768, "text": "The p53 transcription factor and tumor suppressor is regulated primarily by the E3 ubiquitin ligase Mdm2, which ubiquitinates p53 to target it for proteasomal degradation. Aside from its ubiquitin ligase function, Mdm2 has been believed to be capable of suppressing p53's transcriptional activity by binding with and masking the transactivation domain of p53."}, {"doc_id": "15013777", "chunk_id": "15013777_1", "score": 6.396766662597656, "text": "Mdm2 is a RING finger E3 ubiquitin ligase, which promotes ubiquitination and proteasomal degradation of the p53 tumor suppressor protein. Acetylation of p53 regulates p53's transcriptional activity and inhibits Mdm2-mediated p53 ubiquitination and degradation."}], "context": "[12832479:12832479_0] MDM2 is an E3 ubiquitin ligase that targets p53 for proteasomal degradation. Recent studies have shown, however, that the ring-finger domain (RFD) of MDM2, where the ubiquitin E3 ligase activity resides, is necessary but not sufficient for p53 ubiquitination, suggesting that an additional activity of MDM2 might be required.\n[22666487:22666487_1] The p53 transcription factor and tumor suppressor is regulated primarily by the E3 ubiquitin ligase Mdm2, which ubiquitinates p53 to target it for proteasomal degradation. Aside from its ubiquitin ligase function, Mdm2 has been believed to be capable of suppressing p53's transcriptional activity by binding with and masking the transactivation domain of p53.\n[15013777:15013777_1] Mdm2 is a RING finger E3 ubiquitin ligase, which promotes ubiquitination and proteasomal degradation of the p53 tumor suppressor protein. Acetylation of p53 regulates p53's transcriptional activity and inhibits Mdm2-mediated p53 ubiquitination and degradation.", "answer": "<think> Okay, let me try to figure this out. The question is asking which E3 ubiquitin ligase ubiquitinates IkB, leading to its proteasomal degradation. The evidence provided mentions MDM2 and Mdm2 in several chunks. Looking at the first chunk [12832479:12832479_0], it says MDM2 is an E3 ligase that targets p53, not IkB. Then [22666487:22666487_1] mentions Mdm2 ubiquitinates p53 for degradation. The third chunk [15013777:15013777_1] again talks about Mdm2 promoting p53 degradation. Wait, but the question is about IkB, not p53. The evidence given doesn't mention IkB at all. All the chunks talk about p53 and MDM2's role in ubiquitinating p53. Maybe there's a confusion here? Or perhaps the user made a mistake? But according to the provided", "citations": [{"doc_id": "12832479", "chunk_id": "12832479_0"}, {"doc_id": "22666487", "chunk_id": "22666487_1"}, {"doc_id": "15013777", "chunk_id": "15013777_1"}], "candidates": [{"answer": "<think> Okay, let me try to figure this out. The question is asking which E3 ubiquitin ligase ubiquitinates IkB, leading to its proteasomal degradation. The evidence provided mentions MDM2 and Mdm2 in several chunks. Looking at the first chunk [12832479:12832479_0], it says MDM2 is an E3 ligase that targets p53, not IkB. Then [22666487:22666487_1] mentions Mdm2 ubiquitinates p53 for degradation. The third chunk [15013777:15013777_1] again talks about Mdm2 promoting p53 degradation. Wait, but the question is about IkB, not p53. The evidence given doesn't mention IkB at all. All the chunks talk about p53 and MDM2's role in ubiquitinating p53. Maybe there's a confusion here? Or perhaps the user made a mistake? But according to the provided", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which E3 ubiquitin ligase ubiquitinates IkB, leading to its proteasomal degradation. The evidence provided mentions MDM2 and Mdm2 in several chunks. First, I need to check if any of the evidence directly mentions IkB. Looking at the evidence: Chunk 12832479_0 talks about MDM2 targeting p53, not IkB. Chunk 22666487_1 also mentions Mdm2 ubiquitinating p53. Chunk 15013777_1 again refers to Mdm2 ubiquitinating p53. None of these chunks mention IkB. Wait, the question is about IkB, but all the evidence provided is about p53. Maybe there's a confusion here. But the user might have intended to ask about p53, or maybe there's another E3 ligase mentioned in the evidence that I'm missing. Let me check again. The chunks only mention MDM2/Mdm2 as the E3 ligase for p53.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which E3 ubiquitin ligase ubiquitinates IkB, leading to its proteasomal degradation. The evidence provided mentions MDM2 and Mdm2 in several chunks. First, I need to check if any of the evidence directly mentions IkB. Looking at the evidence: Chunk 12832479_0 talks about MDM2 targeting p53, not IkB. Chunk 22666487_1 also mentions Mdm2 ubiquitinating p53. Chunk 15013777_1 again refers to Mdm2 and p53. None of these chunks mention IkB. Wait, maybe there's a confusion here. The question is about IkB, but the evidence all talks about p53. Is there a possibility that the user mixed up IkB and p53? Because in reality, I know that NEMO (NF-κB Essential Modulator) is an E3 ubiquitin ligase involved in IkB degradation. But according to the given evidence, there's no mention", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["10837071", "16778892", "17001349", "20028970", "22435548"], "ideal_answer": "IκB degradation involves ubiquitination mediated by a specific E3 ubiquitin ligase SCF(β-TrCP). SCF(β-TrCP) -mediated IκB ubiquitination and degradation is a very efficient process, often resulting in complete degradation of the key inhibitor IκBα within a few minutes of cell stimulation. IkappaB degradation is dependent upon its phosphorylation by the IkappaB kinase (IKK) complex and subsequent ubiquitination facilitated by beta-Trcp E3 ubiquitin ligase.Sequence comparison analysis showed sequence motif identity between CLU and beta-transducin repeat-containing protein (beta-TrCP), a main E3 ubiquitin ligase involved in IkappaB-alpha degradation. IkappaB degradation is dependent upon its phosphorylation by the IkappaB kinase (IKK) complex and subsequent ubiquitination facilitated by beta-Trcp E3 ubiquitin ligase. SCF(β-TrCP) -mediated IκB ubiquitination and degradation is a very efficient process, often resulting in complete degradation of the key inhibitor IκBα within a few minutes of cell stimulation."}
{"question_id": "5318a955b166e2b806000020", "question": "Is c-met involved in the activation of the Akt pathway?", "retrieved_chunks": [{"doc_id": "16278380", "chunk_id": "16278380_0", "score": 8.796241760253906, "text": "Activation of C-MET enhances XIAP through the Akt pathway."}, {"doc_id": "18262389", "chunk_id": "18262389_4", "score": 7.9973673820495605, "text": "These observations indicate that HGF and c-Met can regulate the early stages of dendrite maturation via activation of the Akt/GSK-3beta pathway."}, {"doc_id": "18234991", "chunk_id": "18234991_0", "score": 7.928978443145752, "text": "HGF was found to enhance cell migration, and that HGF-induced migration depends on PI3K/Akt pathway. The activation of PI3K/Akt pathway induced by the HGF/c-Met axis is involved in the downregulation of cell adhesion molecules E-cadherin and beta-catenin, contributing to the attenuation of cell-cell adhesion and promoting the enhanced motility and migration of uveal melanoma cells."}], "context": "[16278380:16278380_0] Activation of C-MET enhances XIAP through the Akt pathway.\n[18262389:18262389_4] These observations indicate that HGF and c-Met can regulate the early stages of dendrite maturation via activation of the Akt/GSK-3beta pathway.\n[18234991:18234991_0] HGF was found to enhance cell migration, and that HGF-induced migration depends on PI3K/Akt pathway. The activation of PI3K/Akt pathway induced by the HGF/c-Met axis is involved in the downregulation of cell adhesion molecules E-cadherin and beta-catenin, contributing to the attenuation of cell-cell adhesion and promoting the enhanced motility and migration of uveal melanoma cells.", "answer": "<think> Okay, let's tackle this question. The user is asking if c-met is involved in activating the Akt pathway. I need to look at the provided evidence to find answers. First, looking at the evidence: 1. [16278380:16278380_0] says activation of C-MET enhances XIAP through the Akt pathway. So here, c-met's activation is linked to the Akt pathway. That's a direct mention. 2. [18262389:18262389_4] mentions HGF and c-Met regulating dendrite maturation via Akt/GSK-3beta pathway. Again, c-Met is connected to Akt pathway activation. 3. [18234991:1823499ity_0] states that HGF-induced migration depends on PI3K/Akt pathway, and the HGF/c-Met axis activates this pathway. So here, c-met's role in activating Akt is also mentioned. All three pieces of evidence connect c-met to the Akt pathway. The", "citations": [{"doc_id": "16278380", "chunk_id": "16278380_0"}, {"doc_id": "18262389", "chunk_id": "18262389_4"}, {"doc_id": "18234991", "chunk_id": "1823499ity_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if c-met is involved in activating the Akt pathway. I need to look at the provided evidence to find answers. First, looking at the evidence: 1. [16278380:16278380_0] says activation of C-MET enhances XIAP through the Akt pathway. So here, c-met's activation is linked to the Akt pathway. That's a direct mention. 2. [18262389:18262389_4] mentions HGF and c-Met regulating dendrite maturation via Akt/GSK-3beta pathway. Again, c-Met is connected to Akt pathway activation. 3. [18234991:1823499ity_0] states that HGF-induced migration depends on PI3K/Akt pathway, and the HGF/c-Met axis activates this pathway. So here, c-met's role in activating Akt is also mentioned. All three pieces of evidence connect c-met to the Akt pathway. The", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if c-met is involved in activating the Akt pathway. I need to look at the provided evidence to find answers. First, looking at the evidence: 1. [16278380:16278380_0] says activation of C-MET enhances XIAP through the Akt pathway. So here, c-met is linked to the Akt pathway. That's a direct mention. 2. [18262389:18262389_4] mentions HGF and c-Met regulating dendrite maturation via Akt/GSK-3beta pathway. Again, c-Met is connected to Akt. 3. [18234991:18234991_0] states that HGF/c-Met axis activates PI3K/Akt pathway, which is involved in cell migration. This also shows c-met's role in Akt activation. So all three pieces of evidence connect c-met to the Akt pathway. The answer should confirm that c-met is indeed involved", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if c-met is involved in activating the Akt pathway. The evidence provided has three references. First, looking at the first piece of evidence: [16278380:16278380_0] says that activation of C-MET enhances XIAP through the Akt pathway. So this directly links c-Met to the Akt pathway. That's a clear mention. The second evidence: [18262389:18262389_4] mentions HGF and c-Met regulating dendrite maturation via Akt/GSK-3beta pathway. Again, this shows that c-Met is connected to the Akt pathway. Third evidence: [18234991:1823499Or_0] states that HGF-induced migration depends on PI3K/Akt pathway, and the HGF/c-Met axis activates this pathway. So here, c-Met is part of the pathway leading to Akt activation. All three pieces of evidence connect c-Met to the Akt pathway in", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["10714768", "11821397", "14570904", "15522281", "16278380", "17258200", "17464994", "17942284", "18234991", "18262389", "19850646", "20233866", "21536148", "21687953", "22789825", "22820099", "23229794", "23345546"], "ideal_answer": "HGF-induced activation of c-Met is playing a pivotal role in the stimulation of c-Src activation, resulting in induction of phosphatidylinositol 3-kinase complexes p85α/p110α and p85α/p110δ, which is required for Akt-mediated activation of mammalian target of rapamycin, with consequent inhibition of IκB kinase and nuclear factor-κB activation, resulting in enhanced cell survival."}
{"question_id": "531a3fe3b166e2b806000038", "question": "Is pregnancy an additional risk during during H1N1 infection?", "retrieved_chunks": [{"doc_id": "21252793", "chunk_id": "21252793_0", "score": 6.863368988037109, "text": "Emerging data suggest that pregnancy conveys high risk for severe complications from the 2009 pandemic influenza A virus (2009 H1N1) infection"}, {"doc_id": "19643469", "chunk_id": "19643469_0", "score": 6.651741027832031, "text": "Pregnant women might be at increased risk for complications from pandemic H1N1 virus infection."}, {"doc_id": "22782418", "chunk_id": "22782418_1", "score": 6.643764972686768, "text": "To investigate whether exposure to an adjuvanted influenza A(H1N1)pdm09 vaccine during pregnancy was associated with increased risk of adverse fetal outcomes."}], "context": "[21252793:21252793_0] Emerging data suggest that pregnancy conveys high risk for severe complications from the 2009 pandemic influenza A virus (2009 H1N1) infection\n[19643469:19643469_0] Pregnant women might be at increased risk for complications from pandemic H1N1 virus infection.\n[22782418:22782418_1] To investigate whether exposure to an adjuvanted influenza A(H1N1)pdm09 vaccine during pregnancy was associated with increased risk of adverse fetal outcomes.", "answer": "<think> Okay, let's tackle this question. The user is asking if pregnancy is an additional risk during H1N1 infection. I need to look at the evidence provided. First, evidence document [21252793:21252793_0] says that pregnancy conveys high risk for severe complications from 2009 H1N1. That's a direct statement linking pregnancy to increased risk. Then, [19643469:19643469_0] also mentions pregnant women might be at increased risk for complications from pandemic H1N1. Both of these support the idea that pregnancy is a risk factor. The third document [22782418:22782418_1] talks about a study on vaccines during pregnancy, but the question is about infection, not vaccination. So maybe this isn't directly relevant. But the other two documents are clear. So the answer should be yes, pregnancy is an additional risk. The confidence would be high because two different sources mention increased risk. The third document doesn't directly", "citations": [{"doc_id": "21252793", "chunk_id": "21252793_0"}, {"doc_id": "19643469", "chunk_id": "19643469_0"}, {"doc_id": "22782418", "chunk_id": "22782418_1"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if pregnancy is an additional risk during H1N1 infection. I need to look at the evidence provided. First, evidence document [21252793:21252793_0] says that pregnancy conveys high risk for severe complications from 2009 H1N1. That's a direct statement linking pregnancy to increased risk. Then, [19643469:19643469_0] also mentions pregnant women might be at increased risk for complications from pandemic H1N1. Both of these support the idea that pregnancy is a risk factor. The third document [22782418:22782418_1] talks about a study on vaccines during pregnancy, but the question is about infection, not vaccination. So maybe this isn't directly relevant. But the other two documents are clear. So the answer should be yes, pregnancy is an additional risk. The confidence would be high because two different sources mention increased risk. The third document doesn't directly", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, the user is asking if pregnancy is an additional risk during H1N1 infection. Let me look at the evidence provided. First, the evidence has three chunks. The first one says that pregnancy conveys high risk for severe complications from 2009 H1N1. The second chunk mentions pregnant women might be at increased risk for complications from pandemic H1N1. The third chunk is about a study investigating vaccine exposure during pregnancy and adverse fetal outcomes, but it's not directly about the infection itself. So, the first two chunks directly address the risk of H1Where is the answer? The question is whether pregnancy increases the risk during H1N1 infection. Both chunks 21252793 and 19643469 support that pregnant women are at higher risk. The third chunk is about a vaccine, not the infection, so maybe not relevant here. The answer should be concise, citing the relevant documents. The confidence level: since two out of three pieces of evidence support the claim, but the third isn't directly related. So base_confidence would be high, like 0.95.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, the user is asking if pregnancy is an additional risk during H1N1 infection. Let me look at the evidence provided. First, the evidence has three chunks. The first one says that pregnancy conveys high risk for severe complications from 2009 H1N1. The second chunk mentions pregnant women might be at increased risk for complications from pandemic H1N1. The third chunk is about a study investigating if the vaccine during pregnancy is linked to adverse outcomes, but that's about vaccination, not the infection itself. So the answer should focus on the first two chunks. Both indicate that pregnancy increases the risk of complications from H1N1. The third chunk isn't directly relevant because it's about疫苗 exposure, not the infection. The model's confidence should be high since two separate sources mention increased risk. But I need to check if there's any conflicting info. No, all three are supporting that pregnancy is a risk factor. Wait, the third chunk is a study, but the question is about infection, not vaccination. So the answer should be based on the first two. So the answer would be that yes, pregnancy is an additional", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["19643469", "20100064", "20148081", "20531946", "21252793", "21596080", "21756329", "21913391", "22030045", "22120858", "22272853", "22331165", "22411229", "22482974", "22515877", "22551713", "22564554", "22782418", "22851818", "22859826", "22901103", "23116790", "24051575"], "ideal_answer": "Pregnant women are at increased risk for complications from pandemic influenza H1N1 virus infection. Pregnant women, because of their altered immunity and physiological adaptations, are at higher risk of developing pulmonary complications, especially in the second and third trimesters. Pregnancy, particularly during the third trimester, increases the risk of complications and early antiviral treatment is associated with improved outcomes."}
{"question_id": "51757bbb8ed59a060a00002e", "question": "Are long non coding RNAs as conserved in sequence as protein coding genes?", "retrieved_chunks": [{"doc_id": "21619633", "chunk_id": "21619633_5", "score": 4.922537803649902, "text": "They are therefore functionally related to a number of key protein coding developmental genes, that form genomic regulatory blocks (GRBs) with arrays of highly conserved non-coding elements (HCNEs) functioning as long-range enhancers that collaboratively regulate the expression of their target genes."}, {"doc_id": "27990773", "chunk_id": "27990773_0", "score": 3.7512528896331787, "text": "p53 functions primarily as a sequence-specific transcription factor that controls the expression of hundreds of protein-coding genes and noncoding RNAs, including microRNAs (miRNAs) and long noncoding RNAs (lncRNAs)."}, {"doc_id": "36875647", "chunk_id": "36875647_0", "score": 3.514025926589966, "text": "Circular RNAs (circRNAs) are a novel category of covalently-closed non-coding RNAs mainly derived from the back-splicing of exons or introns of protein-coding genes."}], "context": "[21619633:21619633_5] They are therefore functionally related to a number of key protein coding developmental genes, that form genomic regulatory blocks (GRBs) with arrays of highly conserved non-coding elements (HCNEs) functioning as long-range enhancers that collaboratively regulate the expression of their target genes.\n[27990773:27990773_0] p53 functions primarily as a sequence-specific transcription factor that controls the expression of hundreds of protein-coding genes and noncoding RNAs, including microRNAs (miRNAs) and long noncoding RNAs (lncRNAs).\n[36875647:36875647_0] Circular RNAs (circRNAs) are a novel category of covalently-closed non-coding RNAs mainly derived from the back-splicing of exons or introns of protein-coding genes.", "answer": "<think> Okay, let's tackle this question. The user is asking if long non-coding RNAs (lncRNAs) are as conserved in sequence as protein-coding genes. I need to look at the provided evidence to find answers. First, looking at the evidence documents. The first one [21619633:21619633_5] mentions that lncRNAs are functionally related to key protein coding developmental genes and that there are genomic regulatory blocks (GRBs) with highly conserved non-coding elements (HCNEs) acting as enhancers. This suggests that some elements are conserved, but the document specifically talks about HCNEs, which are non-coding, not necessarily lncRNAs themselves. So maybe this indicates some conservation in regulatory regions, but not sure if it's directly about lncRNA sequence conservation. Next, [27990773:27990773_0] states that p53 controls expression of lncRNAs and other non-coding RNAs. This doesn't directly address conservation, but shows that l", "citations": [{"doc_id": "21619633", "chunk_id": "21619633_5"}, {"doc_id": "27990773", "chunk_id": "27990773_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if long non-coding RNAs (lncRNAs) are as conserved in sequence as protein-coding genes. I need to look at the provided evidence to find answers. First, looking at the evidence documents. The first one [21619633:21619633_5] mentions that lncRNAs are functionally related to key protein coding developmental genes and that there are genomic regulatory blocks (GRBs) with highly conserved non-coding elements (HCNEs) acting as enhancers. This suggests that some elements are conserved, but the document specifically talks about HCNEs, which are non-coding, not necessarily lncRNAs themselves. So maybe this indicates some conservation in regulatory regions, but not sure if it's directly about lncRNA sequence conservation. Next, [27990773:27990773_0] states that p53 controls expression of lncRNAs and other non-coding RNAs. This doesn't directly address conservation, but shows that l", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if long non-coding RNAs (lncRNAs) are as conserved in sequence as protein-coding genes. First, I need to look at the evidence provided. The first document mentions that lncRNAs are functionally related to key protein coding developmental genes and are part of genomic regulatory blocks with highly conserved non-coding elements. But this talks about functional conservation, not necessarily sequence conservation. The second document says p53 controls expression of lncRNAs and other noncoding RNAs. This doesn't directly address sequence conservation. The third document discusses circular RNAs (circRNAs) derived from protein-coding genes via back-splicing. However, the question is about lncRNAs, not circRNAs. So this might not be directly relevant. Wait, the first evidence mentions \"highly conserved non-coding elements (HCNEs)\" which are part of regulatory blocks with protein coding genes. But HCNEs are non-coding, so maybe they're conserved in sequence? However, the question is about lncRNAs specifically. The answer needs", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if long non-coding RNAs (lncRNAs) are as conserved in sequence as protein-coding genes. I need to look at the provided evidence to form an answer. First, I'll go through each of the evidence snippets. The first one [21619633:21619633_5] talks about lncRNAs being functionally related to protein coding genes and mentions genomic regulatory blocks (GRBs) with highly conserved non-coding elements (HCNEs) acting as enhancers. But this doesn't directly address sequence conservation, more about functional relationships. The second snippet [27990773:27990773_0] says p53 controls expression of lncRNAs and other non-coding RNAs. This indicates that lncRNAs are regulated, but again, not directly about sequence conservation. The third evidence [36875647:36875647_0] mentions circular RNAs (circRNAs)", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["20428234", "20587619", "20624288", "21112873", "21622663", "22707570", "22708672", "22844254", "22955988", "23028352", "23454638", "23463798", "23467124"], "ideal_answer": "No. Most long non coding RNAs (lncRNAs) are under lower sequence constraints than protein-coding genes."}
{"question_id": "56c1f03bef6e394741000053", "question": "Mutation of which gene is implicated in the Brain-lung-thyroid syndrome?", "retrieved_chunks": [{"doc_id": "26196025", "chunk_id": "26196025_0", "score": 8.195072174072266, "text": "The disorder is caused by mutations to the NKX2.1 (TITF1) gene and also forms part of the \"brain-lung-thyroid syndrome\", in which additional developmental abnormalities of lung and thyroid tissue are observed."}, {"doc_id": "23430038", "chunk_id": "23430038_0", "score": 8.14413833618164, "text": "Mutations in the gene encoding thyroid transcription factor, NKX2-1, result in neurologic abnormalities, hypothyroidism, and neonatal respiratory distress syndrome (RDS) that together are known as the brain-thyroid-lung syndrome."}, {"doc_id": "19336474", "chunk_id": "19336474_4", "score": 7.832055568695068, "text": "Thyroid transcription factor 1 (NKX2-1/TITF1) mutations cause brain-lung-thyroid syndrome, characterized by congenital hypothyroidism (CH), infant respiratory distress syndrome (IRDS) and benign hereditary chorea (BHC). The objectives of the present study were (i) detection of NKX2-1 mutations in patients with CH associated with pneumopathy and/or BHC, (ii) functional analysis of new mutations in vitro and (iii) description of the phenotypic spectrum of brain-lung-thyroid syndrome."}], "context": "[26196025:26196025_0] The disorder is caused by mutations to the NKX2.1 (TITF1) gene and also forms part of the \"brain-lung-thyroid syndrome\", in which additional developmental abnormalities of lung and thyroid tissue are observed.\n[23430038:23430038_0] Mutations in the gene encoding thyroid transcription factor, NKX2-1, result in neurologic abnormalities, hypothyroidism, and neonatal respiratory distress syndrome (RDS) that together are known as the brain-thyroid-lung syndrome.\n[19336474:19336474_4] Thyroid transcription factor 1 (NKX2-1/TITF1) mutations cause brain-lung-thyroid syndrome, characterized by congenital hypothyroidism (CH), infant respiratory distress syndrome (IRDS) and benign hereditary chorea (BHC). The objectives of the present study were (i) detection of NKX2-1 mutations in patients with CH associated with pneumopathy and/or BHC, (ii) functional analysis of new mutations in vitro and (iii) description of the phenotypic spectrum of brain-lung-thyroid syndrome.", "answer": "<think> Okay, let's tackle this question. The user is asking which gene mutation is implicated in Brain-lung-thyroid syndrome. I need to look at the evidence provided. First, I'll check each of the three documents. The first document (26196025:26196025_0) says the disorder is caused by mutations in the NKX2.1 gene, also known as TITF1, and that it's part of the brain-lung-thyroid syndrome. That seems like a direct answer. The second document (23430038:23430038_0) mentions mutations in the NKX2-1 gene leading to neurologic issues, hypothyroidism, and RDS, which are part of the brain-thyroid-lung syndrome. So that's another citation pointing to NKX2-1. The third document (19336474:19336474_4) states that mutations in thyroid transcription factor 1 (NKX2-1/TITF1) cause", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which gene mutation is implicated in Brain-lung-thyroid syndrome. I need to look at the evidence provided. First, I'll check each of the three documents. The first document (26196025:26196025_0) says the disorder is caused by mutations in the NKX2.1 gene, also known as TITF1, and that it's part of the brain-lung-thyroid syndrome. That seems like a direct answer. The second document (23430038:23430038_0) mentions mutations in the NKX2-1 gene leading to neurologic issues, hypothyroidism, and RDS, which are part of the brain-thyroid-lung syndrome. So that's another citation pointing to NKX2-1. The third document (19336474:19336474_4) states that mutations in thyroid transcription factor 1 (NKX2-1/TITF1) cause", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's see. The user is asking which gene mutation is implicated in Brain-lung-thyroid syndrome. I need to look at the evidence provided. First, checking the evidence documents. The first one, 26196025:26196025_0, says mutations in NKX2.1 (TITF1) gene cause the disorder and it's part of brain-lung-thyroid syndrome. The second document, 23430038:23430038_0, also mentions NKX2-1 gene mutations leading to similar symptoms. The third one, 19336474:19336474_4, again points to NKX2-1/TITF1 mutations causing the syndrome. All three sources consistently mention NKX2.1 (TITF1) as the gene involved. The answer should be NKX2.1, and the citations would be from all three documents. But since the user wants one candidate answer, I can pick one of them. However, the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which gene mutation is implicated in Brain-lung-thyroid syndrome. I need to look at the evidence provided. First, looking at the evidence documents. The first one, 26196025:26196025_0, says the disorder is caused by mutations in the NKX2.1 (TITF1) gene and is part of the brain-lung-thyroid syndrome. The second document, 23430038:23430038_0, also mentions mutations in the NKX2-1 gene leading to neurologic abnormalities, hypothyroidism, and RDS, which are part of the same syndrome. The third document, 19336474:193364774_4, again points to NKX2-1/TITF1 mutations causing the syndrome with congenital hypothyroidism, IRDS, and BHC. All three sources consistently mention NKX2.1 (TITF1) as the gene", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["19336474", "20020530", "21867529", "22166853", "22488412", "23430038", "24129101", "24171694", "25759798", "26196025"], "ideal_answer": "Brain-lung-thyroid syndrome (BLTS) characterized by congenital hypothyroidism, respiratory distress syndrome, and benign hereditary chorea is caused by thyroid transcription factor 1 (NKX2-1/TTF1) mutations."}
{"question_id": "52d946c798d023950500000a", "question": "What is clathrin?", "retrieved_chunks": [{"doc_id": "19793827", "chunk_id": "19793827_0", "score": 7.592948913574219, "text": "Clathrin is involved in the endocytosis and exocytosis of cellular proteins and the process of virus infection."}, {"doc_id": "26206992", "chunk_id": "26206992_0", "score": 6.641265869140625, "text": "Clathrin-independent endocytosis ( CIE ) is the process of cellular uptake of various particles , including pathogens , without the coat protein clathrin"}, {"doc_id": "28814502", "chunk_id": "28814502_0", "score": 6.349461555480957, "text": "Clathrin-mediated endocytosis is a major regulator of cell-surface protein internalization."}], "context": "[19793827:19793827_0] Clathrin is involved in the endocytosis and exocytosis of cellular proteins and the process of virus infection.\n[26206992:26206992_0] Clathrin-independent endocytosis ( CIE ) is the process of cellular uptake of various particles , including pathogens , without the coat protein clathrin\n[28814502:28814502_0] Clathrin-mediated endocytosis is a major regulator of cell-surface protein internalization.", "answer": "<think> Okay, I need to generate a JSON answer about what clathrin is based on the given evidence. Let me start by reading through the evidence provided. The first piece of evidence says that clathrin is involved in endocytosis and exocytosis of cellular proteins and virus infection. The second mentions clathrin-independent endocytosis, which doesn't use clathrin. The third talks about clathrin-mediated endocytosis being a major regulator for internalizing cell-surface proteins. So the question is asking for a definition of clathrin. From the evidence, the key points are that it's involved in endocytosis and exocytosis, and specifically mentions virus infection. Also, there's a mention of clathrin-mediated vs independent processes. But since the answer needs to be concise, I should focus on the main role. The answer should cite the first document because it directly states clathrin's involvement in endocytosis and exocytosis, and virus infection. The other documents talk about different types of endocytosis but maybe not the primary definition. So the base confidence would be high since the", "citations": [], "candidates": [{"answer": "<think> Okay, I need to generate a JSON answer about what clathrin is based on the given evidence. Let me start by reading through the evidence provided. The first piece of evidence says that clathrin is involved in endocytosis and exocytosis of cellular proteins and virus infection. The second mentions clathrin-independent endocytosis, which doesn't use clathrin. The third talks about clathrin-mediated endocytosis being a major regulator for internalizing cell-surface proteins. So the question is asking for a definition of clathrin. From the evidence, the key points are that it's involved in endocytosis and exocytosis, and specifically mentions virus infection. Also, there's a mention of clathrin-mediated vs independent processes. But since the answer needs to be concise, I should focus on the main role. The answer should cite the first document because it directly states clathrin's involvement in endocytosis and exocytosis, and virus infection. The other documents talk about different types of endocytosis but maybe not the primary definition. So the base confidence would be high since the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to generate a biomedical answer about clathrin based on the given evidence. Let me start by understanding the question: \"What is clathrin?\" The user wants a concise answer with citations and a confidence score. Looking at the evidence provided, there are three references. The first one says clathrin is involved in endocytosis, exocytosis, and virus infection. The second mentions clathrin-independent endocytosis, which doesn't use clathrin. The third talks about clathrin-mediated endocytosis being a major regulator of cell-surface protein internalization. So, the answer should define clathrin based on its role in these processes. The key points are endocytosis, exocytosis, and virus infection. The first reference directly states that, so I can cite that. Also, the third reference adds that it's a major regulator, which is important. But since the question is about what clathrin is, the primary definition comes from the first evidence. However, the third evidence provides additional context about its role in internalization. Wait, but the user wants one candidate answer", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to generate a candidate biomedical answer for the question \"What is clathrin?\" using the provided evidence. Let me start by understanding what the user is asking. The question is about clathrin, so I should look at the evidence given and extract relevant information. Looking at the evidence: 1. [19793827:19793827_0] says clathrin is involved in endocytosis, exocytosis of proteins, and virus infection. 2. [26206992:26206992_0] mentions clathrin-independent endocytosis, which doesn't use clathrin. 3. [28814502:28814502_0] states that clathrin-mediated endocytosis regulates cell-surface protein internalization. So, the answer should define clathrin based on its role in these processes. The key points are endocytosis, exocytosis, virus infection, and clathrin-mediated vs independent processes. But since the question", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["12952941", "19809570", "21445329", "22042622", "23093191", "24257253", "24263003", "24280271", "24299503", "24307937", "24322426"], "ideal_answer": "Clathrin helps build small vesicles in order to safely transport molecules within and between cells."}
{"question_id": "5322d9339b2d7acc7e000011", "question": "What are the main results of PRKAR1A Knockdown?", "retrieved_chunks": [{"doc_id": "22795129", "chunk_id": "22795129_1", "score": 3.5982704162597656, "text": "Like the other TSC-TBC components, TBC1D7 knockdown results in increased mTORC1 signaling, delayed induction of autophagy, and enhanced cell growth under poor growth conditions."}, {"doc_id": "23480756", "chunk_id": "23480756_0", "score": 0.1200663149356842, "text": "Suppression of protein kinase A regulatory subunit 1 alpha (PRKAR1A) has been proven to inhibit cholangiocarcinoma (CCA) cell growth and enhance apoptosis."}, {"doc_id": "22795129", "chunk_id": "22795129_2", "score": -0.7751121520996094, "text": "TBC1D7 knockdown decreases the association of TSC1 and TSC2 leading to decreased Rheb-GAP activity, without effects on the localization of TSC2 to the lysosome."}], "context": "[22795129:22795129_1] Like the other TSC-TBC components, TBC1D7 knockdown results in increased mTORC1 signaling, delayed induction of autophagy, and enhanced cell growth under poor growth conditions.\n[23480756:23480756_0] Suppression of protein kinase A regulatory subunit 1 alpha (PRKAR1A) has been proven to inhibit cholangiocarcinoma (CCA) cell growth and enhance apoptosis.\n[22795129:22795129_2] TBC1D7 knockdown decreases the association of TSC1 and TSC2 leading to decreased Rheb-GAP activity, without effects on the localization of TSC2 to the lysosome.", "answer": "<think> Okay, let's tackle this question. The user is asking about the main results of PRKAR1A Knockdown. First, I need to look at the provided evidence to find relevant information. Looking at the evidence, there are three chunks. The first one talks about TBC1D7 knockdown affecting mTORC1 signaling, autophagy, and cell growth. The second chunk mentions that suppressing PRKAR1A inhibits CCA cell growth and enhances apoptosis. The third chunk is about TBC1D7 affecting TSC1 and TSC2, but that's not directly related to PRKAR1A. So the key here is the second chunk, which directly mentions PRKAR1A. The answer should be based on that. The main results would be inhibiting CCA cell growth and enhancing apoptosis. The confidence level is high because it's a direct citation. I need to make sure the answer is concise and includes the correct citation. Also, check if there are any other mentions, but the other chunks don't relate to PRKAR1A. So the answer should be from the second evidence chunk. </think> {", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking about the main results of PRKAR1A Knockdown. First, I need to look at the provided evidence to find relevant information. Looking at the evidence, there are three chunks. The first one talks about TBC1D7 knockdown affecting mTORC1 signaling, autophagy, and cell growth. The second chunk mentions that suppressing PRKAR1A inhibits CCA cell growth and enhances apoptosis. The third chunk is about TBC1D7 affecting TSC1 and TSC2, but that's not directly related to PRKAR1A. So the key here is the second chunk, which directly mentions PRKAR1A. The answer should be based on that. The main results would be inhibiting CCA cell growth and enhancing apoptosis. The confidence level is high because it's a direct citation. I need to make sure the answer is concise and includes the correct citation. Also, check if there are any other mentions, but the other chunks don't relate to PRKAR1A. So the answer should be from the second evidence chunk. </think> {", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the main results of PRKAR1A knockdown. First, I need to look through the provided evidence to find any mentions of PRKAR1A. Looking at the evidence, there's a document [23480756:23480756_0] that says suppression of PRKAR1A inhibits cholangiocarcinoma cell growth and enhances apoptosis. That seems directly relevant. The other documents talk about TBC1D7 knockdown and its effects on mTORC1 signaling, but those aren't related to PRKAR1A. So the answer should be based on that one citation. The main results here are inhibited cell growth and enhanced apoptosis. The confidence level is medium because it's a single study, but since the question is specific and the evidence directly addresses PRKAR1A, I'll set the base_confidence to 0.7. I need to make sure the answer is concise and properly cites the document. No other evidence seems to apply here. Alright, that should be it. </think>", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the main results of PRKAR1A knockdown. First, I need to look through the provided evidence to find any mentions of PRKAR1A. Looking at the evidence, there's a document [23480756:23480756_0] that says suppression of PRKAR1A inhibits cholangiocarcinoma cell growth and enhances apoptosis. That seems directly relevant. The other documents talk about TBC1D7 knockdown and its effects on mTORC1 signaling, but that's not related to PRKAR1A. So the main result here is that knocking down PRKAR1A inhibits CCA cell growth and increases apoptosis. The confidence level should be high since it's a direct statement from the evidence. I need to make sure the answer is concise and includes the citation. Let me check if there are any other mentions, but I don't see any others. So the answer should be based on that one document. </think> { \"answer\": \"Suppression of PRKAR1", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["16937372", "20824711", "23480756", "24122441"], "ideal_answer": "Suppression of protein kinase A regulatory subunit 1 alpha (PRKAR1A) has been proven to inhibit cholangiocarcinoma (CCA) cell growth and enhance apoptosis. Also, Knockdown of the cAMP-dependent protein kinase (PKA) Type Ialpha regulatory subunit in mouse oocytes disrupts meiotic arrest and results in meiotic spindle defects."}
{"question_id": "535d75ab7d100faa09000004", "question": "Is TENS machine effective in pain?", "retrieved_chunks": [{"doc_id": "7644247", "chunk_id": "7644247_0", "score": 2.169318675994873, "text": "The results of this study have provided evidence of the hypoalgesic effects of TENS upon experimental ischaemic pain which were found to be frequency specific with the lower frequency used here (4 Hz) demonstrating the only significant effect"}, {"doc_id": "33664472", "chunk_id": "33664472_0", "score": -3.5784177780151367, "text": "All the methods analysed has shown to be effective in reducing pain"}, {"doc_id": "19818032", "chunk_id": "19818032_0", "score": -5.745018005371094, "text": "BoNT/A is an effective analgesic for chronic arthritis pain, but not for acute arthritis pain. Hi"}], "context": "[7644247:7644247_0] The results of this study have provided evidence of the hypoalgesic effects of TENS upon experimental ischaemic pain which were found to be frequency specific with the lower frequency used here (4 Hz) demonstrating the only significant effect\n[33664472:33664472_0] All the methods analysed has shown to be effective in reducing pain\n[19818032:19818032_0] BoNT/A is an effective analgesic for chronic arthritis pain, but not for acute arthritis pain. Hi", "answer": "<think> Okay, let's tackle this question about whether TENS machines are effective for pain. The user provided three evidence snippets. First, I need to look at each piece of evidence. The first one says that a study found TENS has hypoalgesic effects on experimental ischaemic pain, specifically mentioning lower frequency (4 Hz) was significant. So that's a direct mention of effectiveness in a specific type of pain. The second snippet states that all methods analyzed have shown effectiveness in reducing pain. But wait, the \"methods\" here aren't specified. However, since TENS is mentioned in the first snippet, maybe this is referring to TENS? But the chunk ID is 33664472_0, which isn't directly linked to TENS. The third snippet talks about BoNT/A being effective for chronic arthritis pain but not acute. That's about a different treatment, so probably not relevant here. So the main evidence pointing to TENS effectiveness is the first chunk. The second one is vague. The third is unrelated. Therefore, the answer should be based on the first evidence. The confidence would be high because there's a direct study", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question about whether TENS machines are effective for pain. The user provided three evidence snippets. First, I need to look at each piece of evidence. The first one says that a study found TENS has hypoalgesic effects on experimental ischaemic pain, specifically mentioning lower frequency (4 Hz) was significant. So that's a direct mention of effectiveness in a specific type of pain. The second snippet states that all methods analyzed have shown effectiveness in reducing pain. But wait, the \"methods\" here aren't specified. However, since TENS is mentioned in the first snippet, maybe this is referring to TENS? But the chunk ID is 33664472_0, which isn't directly linked to TENS. The third snippet talks about BoNT/A being effective for chronic arthritis pain but not acute. That's about a different treatment, so probably not relevant here. So the main evidence pointing to TENS effectiveness is the first chunk. The second one is vague. The third is unrelated. Therefore, the answer should be based on the first evidence. The confidence would be high because there's a direct study", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this query. The user is asking if TENS machines are effective in pain relief. The evidence provided has three documents. First, I need to check each document's relevance. The first one, 7644247:7644247_0, mentions that TENS has hypoalgesic effects on ischemic pain and that the effect is frequency-specific, with 4 Hz being significant. That seems directly relevant. The second document, 33664472:33664472_0, states that all methods analyzed were effective in reducing pain. But wait, it's a bit vague. It doesn't specify TENS, so I need to be careful here. Maybe the \"methods\" refer to various treatments, but the user is specifically asking about TENS. However, since the document says \"all the methods analysed has shown to be effective,\" maybe that includes TENS? But without more context, it's a bit unclear. However, given that the first document directly talks about TENS, perhaps this one is a broader statement. But I should note that", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, the user is asking if TENS machines are effective for pain. Let me look at the evidence provided. First evidence: [7644247:7644247_0] says that a study found TENS has hypoalgesic effects on experimental ischemic pain, specifically frequency-dependent, with 4 Hz being significant. So this supports effectiveness but in a specific context. Second evidence: [33664472:33664472_0] states all methods analyzed were effective in reducing pain. This seems broader, maybe referring to TENS as one of the methods. But I need to check if \"all the methods\" includes TENS. The wording is a bit vague, but since the question is about TENS, this could be relevant. Third evidence: [19818032:19818032_0] talks about BoNT/A for chronic arthritis pain, not directly about TENS. So probably not relevant here. So the answer should combine the first two pieces of evidence. The first one is specific to TENS and", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["17333874", "7644247"], "ideal_answer": "Transcutaneous electrical nerve stimulation is widely used in pain management"}
{"question_id": "56d1d14567f0cb3d66000003", "question": "Is there any algorithm for enhancer identification from chromatin state?", "retrieved_chunks": [{"doc_id": "23526891", "chunk_id": "23526891_2", "score": 9.26327896118164, "text": "RFECS: a random-forest based algorithm for enhancer identification from chromatin state."}, {"doc_id": "23526891", "chunk_id": "23526891_3", "score": 8.476518630981445, "text": "We developed a Random-Forest based algorithm, RFECS (Random Forest based Enhancer identification from Chromatin States) to integrate histone modification profiles for identification of enhancers, and used it to identify enhancers in a number of cell-types."}, {"doc_id": "23526891", "chunk_id": "23526891_0", "score": 6.6106672286987305, "text": "Here, we address this issue by exploring genome-wide profiles of 24 histone modifications in two distinct human cell types, embryonic stem cells and lung fibroblasts. We developed a Random-Forest based algorithm, RFECS (Random Forest based Enhancer identification from Chromatin States) to integrate histone modification profiles for identification of enhancers, and used it to identify enhancers in a number of cell-types."}], "context": "[23526891:23526891_2] RFECS: a random-forest based algorithm for enhancer identification from chromatin state.\n[23526891:23526891_3] We developed a Random-Forest based algorithm, RFECS (Random Forest based Enhancer identification from Chromatin States) to integrate histone modification profiles for identification of enhancers, and used it to identify enhancers in a number of cell-types.\n[23526891:23526891_0] Here, we address this issue by exploring genome-wide profiles of 24 histone modifications in two distinct human cell types, embryonic stem cells and lung fibroblasts. We developed a Random-Forest based algorithm, RFECS (Random Forest based Enhancer identification from Chromatin States) to integrate histone modification profiles for identification of enhancers, and used it to identify enhancers in a number of cell-types.", "answer": "<think> Okay, let's tackle this question. The user is asking if there's an algorithm for enhancer identification from chromatin state. Looking at the evidence provided, there's a mention of RFECS, which is a random-forest based algorithm. The documents all reference RFECS as the method developed to integrate histone modification profiles for identifying enhancers. The key points are that it's a Random Forest algorithm, uses chromatin states, and was applied to different cell types. I need to make sure the answer is concise and includes the citation. The document IDs are all from 23526891, with chunk IDs ranging from 0 to 3. The main citation would be [23526891:23526891_2], but also others mention it. However, the answer should reference the primary source. The confidence level is high because the evidence directly states that RFECS exists and is based on random forest. So base_confidence should be 1.0. </think> { \"answer\": \"Yes, RFECS (Random Forest based Enhancer identification from Chromatin States", "citations": [{"doc_id": "23526891", "chunk_id": "23526891_2"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if there's an algorithm for enhancer identification from chromatin state. Looking at the evidence provided, there's a mention of RFECS, which is a random-forest based algorithm. The documents all reference RFECS as the method developed to integrate histone modification profiles for identifying enhancers. The key points are that it's a Random Forest algorithm, uses chromatin states, and was applied to different cell types. I need to make sure the answer is concise and includes the citation. The document IDs are all from 23526891, with chunk IDs ranging from 0 to 3. The main citation would be [23526891:23526891_2], but also others mention it. However, the answer should reference the primary source. The confidence level is high because the evidence directly states that RFECS exists and is based on random forest. So base_confidence should be 1.0. </think> { \"answer\": \"Yes, RFECS (Random Forest based Enhancer identification from Chromatin States", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if there's an algorithm for enhancer identification from chromatin state. Looking at the evidence provided, there's a mention of RFECS, which is a random-forest based algorithm. First, I need to check the evidence chunks. The first chunk [23526891:23526891_2] directly mentions RFECS as a random-forest algorithm for enhancer identification from chromatin state. The other chunks elaborate on this, explaining that it uses histone modification profiles and was applied to different cell types. So the answer should point to RFECS as the algorithm. The confidence here is pretty high because the evidence clearly states that RFECS was developed for this purpose. The base_confidence can be 1.0 since the information is directly stated in the provided documents. </think> { \"answer\": \"Yes, RFECS (Random Forest based Enhancer identification from Chromatin States) is a random-forest based algorithm for enhancer identification from chromatin state [23526891:2352", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this query. The user is asking if there's an algorithm for enhancer identification from chromatin state. Looking at the evidence provided, there's a mention of RFECS, which is a random-forest based algorithm. The documents all point to RFECS being developed to integrate histone modification profiles for identifying enhancers. First, I need to confirm that RFECS is indeed an algorithm. The citations clearly state that RFECS is a Random-Forest based algorithm. So the answer should include that. The key points are the name of the algorithm, the method (Random Forest), and its purpose (enhancer identification from chromatin states). The confidence level: Since all three documents mention RFECS and its use in enhancer identification, the model is pretty confident. The confidence score should be high, maybe 0.95 or so. But I need to check if there's any conflicting info. No, all sources agree. So base_confidence is 1.0? Wait, but sometimes even if multiple sources agree, maybe there's some uncertainty. However, in this case, the evidence is consistent. So setting", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["22328731", "23526891"], "ideal_answer": "yes Yes. RFECS is a random-forest based algorithm for enhancer identification from chromatin state. It integrates histone modification profiles for the identification of enhancers, and can be used to identify enhancers in a number of cell-types. RFECS not only leads to more accurate and precise prediction of enhancers than previous methods, but also helps identify the most informative and robust set of three chromatin marks for enhancer prediction."}
{"question_id": "532498959b2d7acc7e000017", "question": "Which enzyme is targeted by the drug Imetelstat?", "retrieved_chunks": [{"doc_id": "26332545", "chunk_id": "26332545_1", "score": 7.462790012359619, "text": "Imetelstat is a 13-mer lipid-conjugated oligonucleotide that targets the RNA template of human telomerase reverse transcriptase.METHODS: We sought to obtain preliminary information on the therapeutic activity and safety of imetelstat in patients with high-risk or intermediate-2-risk myelofibrosis."}, {"doc_id": "23545855", "chunk_id": "23545855_2", "score": 6.191839218139648, "text": "This enzyme is expressed in approximately 90% of human tumors, but not in the majority of normal somatic cells. imetelstat sodium (GRN163L), is a 13-mer oligonucleotide N3'→P5' thio-phosphoramidate lipid conjugate, which represents the latest generation of telomerase inhibitors targeting the template region of the human functional telomerase RNA (hTR) subunit."}, {"doc_id": "22906540", "chunk_id": "22906540_4", "score": 4.5024590492248535, "text": "We sought to evaluate the potential of the thio-phosphoramidate oligonucleotide inhibitor of telomerase, imetelstat, as a drug candidate for treatment of esophageal cancer. Our results showed that imetelstat inhibited telomerase activity in a dose-dependent manner in esophageal cancer cells"}], "context": "[26332545:26332545_1] Imetelstat is a 13-mer lipid-conjugated oligonucleotide that targets the RNA template of human telomerase reverse transcriptase.METHODS: We sought to obtain preliminary information on the therapeutic activity and safety of imetelstat in patients with high-risk or intermediate-2-risk myelofibrosis.\n[23545855:23545855_2] This enzyme is expressed in approximately 90% of human tumors, but not in the majority of normal somatic cells. imetelstat sodium (GRN163L), is a 13-mer oligonucleotide N3'→P5' thio-phosphoramidate lipid conjugate, which represents the latest generation of telomerase inhibitors targeting the template region of the human functional telomerase RNA (hTR) subunit.\n[22906540:22906540_4] We sought to evaluate the potential of the thio-phosphoramidate oligonucleotide inhibitor of telomerase, imetelstat, as a drug candidate for treatment of esophageal cancer. Our results showed that imetelstat inhibited telomerase activity in a dose-dependent manner in esophageal cancer cells", "answer": "<think> Okay, let's tackle this question. The user is asking which enzyme Imetelstat targets. I need to look through the provided evidence to find the answer. First, looking at the first document: it says Imetelstat targets the RNA template of human telomerase reverse transcriptase. That seems like a direct answer. But wait, the second document mentions that the enzyme is expressed in 90% of tumors but not in normal cells. It also states that imetelstat is a telomerase inhibitor targeting the template region of hTR. The third document confirms that imetelstat inhibits telomerase activity in cancer cells. So putting this together, the enzyme in question is telomerase. But wait, telomerase is an enzyme, right? The human telomerase reverse transcriptase is the enzyme component of telomerase. The RNA component is the hTR. So the drug targets the telomerase enzyme, specifically its RNA template. However, the answer needs to be concise. The first document explicitly states that Imetelstat targets the RNA template of human telomerase reverse transcriptase. Therefore, the correct answer is", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which enzyme Imetelstat targets. I need to look through the provided evidence to find the answer. First, looking at the first document: it says Imetelstat targets the RNA template of human telomerase reverse transcriptase. That seems like a direct answer. But wait, the second document mentions that the enzyme is expressed in 90% of tumors but not in normal cells. It also states that imetelstat is a telomerase inhibitor targeting the template region of hTR. The third document confirms that imetelstat inhibits telomerase activity in cancer cells. So putting this together, the enzyme in question is telomerase. But wait, telomerase is an enzyme, right? The human telomerase reverse transcriptase is the enzyme component of telomerase. The RNA component is the hTR. So the drug targets the telomerase enzyme, specifically its RNA template. However, the answer needs to be concise. The first document explicitly states that Imetelstat targets the RNA template of human telomerase reverse transcriptase. Therefore, the correct answer is", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which enzyme Imetelstat targets. I need to look at the evidence provided. First, evidence document 26332545:26332545_1 says that Imetelstat targets the RNA template of human telomerase reverse transcriptase. So that's a direct mention of the enzyme being telomerase reverse transcriptase. But wait, the term \"telomerase reverse transcriptase\" refers to the protein component of telomerase, right? The enzyme here is telomerase, which has two components: the protein and the RNA. However, the question is about the enzyme targeted by the drug. Looking at another document, 23545855:23545855_2 mentions that Imetelstat targets the template region of the human functional telomerase RNA (hTR) subunit. So here, it's talking about the RNA component. But the enzyme is telomerase, which uses this RNA as a template. But wait, the question is about the enzyme. Telom", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to figure out which enzyme Imetelstat targets based on the provided evidence. Let's look at the evidence documents. The first document [26332545:26332545_1] says that Imetelstat targets the RNA template of human telomerase reverse transcriptase. So that's a direct mention of the enzyme being telomerase, specifically the reverse transcriptase part. But wait, telomerase is an enzyme, right? Or is it the RNA component? The second document [23545855:2354585-than] mentions that the enzyme is expressed in 90% of tumors but not in normal cells. It also states that Imetelstat is a telomerase inhibitor targeting the template region of the hTR subunit. The hTR is the RNA component of telomerase. So maybe the enzyme here is telomerase, but the drug targets the RNA part of it. The third document [22906540:22906540_4] talks about imet", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["19908230", "20048334", "20072842", "20232321", "20824134", "21062983", "21208905", "21332640", "21549308", "21845093", "22382179", "22870217", "22906540", "23272238", "23326372", "23386830", "23467584", "23516479", "23521791", "23545855", "23558965", "23727752", "24327604"], "ideal_answer": "Imetelstat sodium (GRN163L), is a 13-mer oligonucleotide N3'→P5' thio-phosphoramidate lipid conjugate, which represents the latest generation of telomerase inhibitors targeting the template region of the human functional telomerase RNA subunit. In preclinical trials, this compound has been found to inhibit telomerase activity in multiple cancer cell lines, as well as in vivo xenograft mouse models."}
{"question_id": "56c1f005ef6e39474100003a", "question": "Which interleukins are inhibited by Dupilumab?", "retrieved_chunks": [{"doc_id": "26836729", "chunk_id": "26836729_1", "score": 8.000005722045898, "text": "OBJECTIVE: To assess inhibition of interleukins 4 and 13 with dupilumab in patients with chronic sinusitis and nasal polyposis."}, {"doc_id": "25006719", "chunk_id": "25006719_1", "score": 7.312871932983398, "text": "BACKGROUND: Dupilumab, a fully human monoclonal antibody that blocks interleukin-4 and interleukin-13, has shown efficacy in patients with asthma and elevated eosinophil levels. The blockade by dupilumab of these key drivers of type 2 helper T-cell (Th2)-mediated inflammation could help in the treatment of related diseases, including atopic dermatitis."}, {"doc_id": "26454361", "chunk_id": "26454361_0", "score": 6.365976333618164, "text": "Data from early-stage studies suggested that interleukin (IL)-4 and IL-13 are requisite drivers of atopic dermatitis, evidenced by marked improvement after treatment with dupilumab, a fully-human monoclonal antibody that blocks both pathways."}], "context": "[26836729:26836729_1] OBJECTIVE: To assess inhibition of interleukins 4 and 13 with dupilumab in patients with chronic sinusitis and nasal polyposis.\n[25006719:25006719_1] BACKGROUND: Dupilumab, a fully human monoclonal antibody that blocks interleukin-4 and interleukin-13, has shown efficacy in patients with asthma and elevated eosinophil levels. The blockade by dupilumab of these key drivers of type 2 helper T-cell (Th2)-mediated inflammation could help in the treatment of related diseases, including atopic dermatitis.\n[26454361:26454361_0] Data from early-stage studies suggested that interleukin (IL)-4 and IL-13 are requisite drivers of atopic dermatitis, evidenced by marked improvement after treatment with dupilumab, a fully-human monoclonal antibody that blocks both pathways.", "answer": "<think> Okay, so the user is asking which interleukins are inhibited by Dupilumab. Let me look through the evidence provided. First, there's a document [25006719:25006719_1] that says Dupilumab blocks IL-4 and IL-13. It mentions that it's a monoclonal antibody targeting these two interleukins, which are part of the Th2-mediated inflammation. Another document [26454361:26454361_0] also talks about Dupilumab blocking both IL-4 and IL-: Wait, the third evidence [26836729:26836729_1] specifically mentions inhibition of IL-4 and IL-13 in chronic sinusitis patients. So all three documents point to IL-4 and IL-13 being inhibited by Dupilumab. The answer should list those two interleukins. The confidence is high since multiple sources confirm this. I'll make sure the JSON has the answer with citations and a confidence score", "citations": [{"doc_id": "25006719", "chunk_id": "25006719_1"}, {"doc_id": "26454361", "chunk_id": "26454361_0"}, {"doc_id": "26836729", "chunk_id": "26836729_1"}], "candidates": [{"answer": "<think> Okay, so the user is asking which interleukins are inhibited by Dupilumab. Let me look through the evidence provided. First, there's a document [25006719:25006719_1] that says Dupilumab blocks IL-4 and IL-13. It mentions that it's a monoclonal antibody targeting these two interleukins, which are part of the Th2-mediated inflammation. Another document [26454361:26454361_0] also talks about Dupilumab blocking both IL-4 and IL-: Wait, the third evidence [26836729:26836729_1] specifically mentions inhibition of IL-4 and IL-13 in chronic sinusitis patients. So all three documents point to IL-4 and IL-13 being inhibited by Dupilumab. The answer should list those two interleukins. The confidence is high since multiple sources confirm this. I'll make sure the JSON has the answer with citations and a confidence score", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which interleukins are inhibited by Dupilumab. Looking at the evidence provided, there are three references. First, the document 26836729:26836729_1 mentions that dupilumab inhibits IL-4 and IL-13 in patients with chronic sinusitis and nasal polyposis. That's a direct statement. Then, 25006719:25006719_1 says Dupilumab blocks IL-4 and IL-13, explaining its efficacy in asthma and other Th2-mediated diseases. This reinforces the same answer. The third document, 26454361:26454361_0, also states that dupilumab blocks both IL-4 and IL-: So all three sources consistently point to IL-4 and IL-13 being inhibited. The confidence here is high because multiple studies are cited. I should present the answer with those interleukins and a confidence level around 1.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which interleukins are inhibited by Dupilumab. Looking at the evidence provided, there are three documents. First, document 26836729:26836729_1 mentions that dupilumab inhibits IL-4 and IL-13 in patients with chronic sinusitis and nasal polyposis. That's a direct statement. Then, document 25006719:25006719_1 states that Dupilumab blocks IL-4 and IL-13, explaining its efficacy in asthma and other Th2-mediated conditions. This reinforces the same answer. The third document, 26454361:26454361_0, also mentions that dupilumab blocks both IL-4 and IL-13, leading to improvement in atopic dermatitis. All three sources consistently point to IL-4 and IL-13 being the interleukins inhibited by Dupilumab. The confidence here is high because all evidence", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["23688323", "24275927", "25006719", "25214796", "25482871", "25584909", "25645542"], "ideal_answer": "Dupilumab, a fully human monoclonal antibody that blocks interleukin-4 and interleukin-13, has shown efficacy in patients with asthma and elevated eosinophil levels."}
{"question_id": "513ce3c8bee46bd34c000008", "question": "Which human genes are more commonly related to craniosynostosis?", "retrieved_chunks": [{"doc_id": "19530187", "chunk_id": "19530187_1", "score": 6.263801097869873, "text": "craniosynostosis genes (FGFR2, FGFR3)"}, {"doc_id": "12407713", "chunk_id": "12407713_0", "score": 6.244341850280762, "text": "Mutations in five genes (FGFR1-, -2, -3, TWIST, and MSX2) causing craniosynostosis as the main clinical feature were described."}, {"doc_id": "15880747", "chunk_id": "15880747_0", "score": 5.983407020568848, "text": "loinsufficiency of the human TWIST1 gene, which causes the craniosynostosis disorder Saethre-Chotzen syndrome (SCS), is related to failure to repress transcription of CDKN1A (which encodes p21/WAF1/CIP1), promoting osteoblast differentiation. We have e"}], "context": "[19530187:19530187_1] craniosynostosis genes (FGFR2, FGFR3)\n[12407713:12407713_0] Mutations in five genes (FGFR1-, -2, -3, TWIST, and MSX2) causing craniosynostosis as the main clinical feature were described.\n[15880747:15880747_0] loinsufficiency of the human TWIST1 gene, which causes the craniosynostosis disorder Saethre-Chotzen syndrome (SCS), is related to failure to repress transcription of CDKN1A (which encodes p21/WAF1/CIP1), promoting osteoblast differentiation. We have e", "answer": "<think> Okay, let's tackle this question. The user wants to know which human genes are more commonly related to craniosynostosis. The evidence provided has three chunks. First chunk: [19530187:19530187_1] mentions FGFR2 and FGFR3. That's two genes. Second chunk: [12407713:12407713_0] lists FGFR1, FGFR2, FGFR3, TWIST, and MSX2. So that's five genes. Third chunk: [15880747:15880747_0] talks about TWIST1. Wait, TWIST1 is mentioned here, but the second chunk mentions TWIST. Are they the same? Maybe a typo or different gene. But TWIST1 is a variant of TWIST, so maybe that's another one. So combining all the evidence, the main genes are FGFR1, FGFR2, FGFR3, TWIST, MSX2, and TWIST1. However, the", "citations": [{"doc_id": "19530187", "chunk_id": "19530187_1"}, {"doc_id": "12407713", "chunk_id": "12407713_0"}, {"doc_id": "15880747", "chunk_id": "15880747_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user wants to know which human genes are more commonly related to craniosynostosis. The evidence provided has three chunks. First chunk: [19530187:19530187_1] mentions FGFR2 and FGFR3. That's two genes. Second chunk: [12407713:12407713_0] lists FGFR1, FGFR2, FGFR3, TWIST, and MSX2. So that's five genes. Third chunk: [15880747:15880747_0] talks about TWIST1. Wait, TWIST1 is mentioned here, but the second chunk mentions TWIST. Are they the same? Maybe a typo or different gene. But TWIST1 is a variant of TWIST, so maybe that's another one. So combining all the evidence, the main genes are FGFR1, FGFR2, FGFR3, TWIST, MSX2, and TWIST1. However, the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user wants to know which human genes are more commonly related to craniosynostosis. The evidence provided has three chunks. First chunk: [19530187:19530187_1] mentions FGFR2 and FGFR3. So those are two genes listed here. Second chunk: [12407713:12407713_0] lists five genes: FGFR1, FGFR2, FGFR3, TWIST, and MSX2. So that's more genes, including the ones from the first chunk plus others. Third chunk: [15880747:15880747_0] talks about TWIST1 gene related to Saethre-Chotzen syndrome (SCS), which is a type of craniosynostosis. So TWIST1 is another gene here. Now, the answer needs to be concise with citations. The question asks for genes more commonly related. From the evidence, FGFR2, FGFR3 are mentioned in", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user wants to know which human genes are more commonly related to craniosynostosis. The evidence provided has three references. First, I need to look at each of the证据 points. The first one mentions FGFR2 and FGFR3. The second says mutations in FGFR1, FGFR2, FGFR3, TWIST, and MSX2. The third talks about TWIST1 gene related to Saethre-Chotzen syndrome, which is a type of craniosynostosis. So the main genes here are FGFRs (FGFR1, 2, 3) and TWIST1, MSX2, TWIST. Wait, the third evidence mentions TWIST1, but the second one includes TWIST. Need to check if they're the same. TWIST1 is a gene, and TWIST might be a different gene or a variant. But in the context of craniosynostosis, TWIST1 is known for Saethre-Chotzen syndrome. So maybe TWIST here refers to TWIST1. The answer should list the genes from the evidence.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["10914960", "10951518", "11197897", "11341328", "11428324", "11484208", "11746040", "11820058", "12407713", "14672347", "15964893", "16258006", "17042739", "17955513", "18000908", "19530187", "20643727", "8106171", "9042914", "9600744", "9917362", "9934984"], "ideal_answer": "The genes that are most commonly linked to craniosynostoses are the members of the Fibroblast Growth Factor Receptor family FGFR3 and to a lesser extent FGFR1 and FGFR2. Some variants of the disease have been associated with the triplication of the MSX2 gene and mutations in NELL-1. NELL-1 is being regulated bu RUNX2, which has also been associated to cases of craniosynostosis. Other genes reported to have a role in the development of the disease are RECQL4, TWIST, SOX6 and GNAS."}
{"question_id": "553f78c7ab98a37113000008", "question": "Are transcribed ultraconserved regions involved in cancer?", "retrieved_chunks": [{"doc_id": "21298224", "chunk_id": "21298224_1", "score": 9.260063171386719, "text": "The transcribed-ultraconserved regions: a novel class of long noncoding RNAs involved in cancer susceptibility."}, {"doc_id": "18323801", "chunk_id": "18323801_1", "score": 9.163840293884277, "text": "Moreover, the recent demonstration that other ncRNAs, the ultraconserved genes (UCGs) or transcribed ultraconserved regions (T-UCRs), are involved in human cancerogenesis, suggests that the wider family of ncRNAs (including both miRNAs and UCGs) could contribute to the development of the malignant phenotype."}, {"doc_id": "18323801", "chunk_id": "18323801_0", "score": 9.045459747314453, "text": "Moreover, the recent demonstration that other ncRNAs, the ultraconserved genes (UCGs) or transcribed ultraconserved regions (T-UCRs), are involved in human cancerogenesis, suggests that the wider family of ncRNAs (including both miRNAs and UCGs) could contribute to the development of the malignant phenotype"}], "context": "[21298224:21298224_1] The transcribed-ultraconserved regions: a novel class of long noncoding RNAs involved in cancer susceptibility.\n[18323801:18323801_1] Moreover, the recent demonstration that other ncRNAs, the ultraconserved genes (UCGs) or transcribed ultraconserved regions (T-UCRs), are involved in human cancerogenesis, suggests that the wider family of ncRNAs (including both miRNAs and UCGs) could contribute to the development of the malignant phenotype.\n[18323801:18323801_0] Moreover, the recent demonstration that other ncRNAs, the ultraconserved genes (UCGs) or transcribed ultraconserved regions (T-UCRs), are involved in human cancerogenesis, suggests that the wider family of ncRNAs (including both miRNAs and UCGs) could contribute to the development of the malignant phenotype", "answer": "<think> Okay, let's tackle this question. The user is asking if transcribed ultraconserved regions (T-UCRs) are involved in cancer. I need to look at the provided evidence to find answers. Looking at the evidence, there are three documents. The first one, 21298224:21298224_1, mentions that T-UCRs are a novel class of long noncoding RNAs involved in cancer susceptibility. That's a direct statement linking T-UCRs to cancer. The second document, 18323801:18323801_1, says that UCGs or T-UCRs are involved in human cancerogenesis. The same is stated again in 18323801:18323801_0. So multiple sources point to their involvement in cancer development. I need to make sure the answer is concise and includes citations. The answer should mention that T-UCRs are involved in cancer, citing the relevant documents. The confidence level is high because multiple sources support this. So base", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if transcribed ultraconserved regions (T-UCRs) are involved in cancer. I need to look at the provided evidence to find answers. Looking at the evidence, there are three documents. The first one, 21298224:21298224_1, mentions that T-UCRs are a novel class of long noncoding RNAs involved in cancer susceptibility. That's a direct statement linking T-UCRs to cancer. The second document, 18323801:18323801_1, says that UCGs or T-UCRs are involved in human cancerogenesis. The same is stated again in 18323801:18323801_0. So multiple sources point to their involvement in cancer development. I need to make sure the answer is concise and includes citations. The answer should mention that T-UCRs are involved in cancer, citing the relevant documents. The confidence level is high because multiple sources support this. So base", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this query. The user is asking if transcribed ultraconserved regions (T-UCRs) are involved in cancer. The evidence provided has three documents. First, I need to check each document for relevant information. Document 21298224:21298224_1 mentions that T-UCRs are a novel class of long noncoding RNAs involved in cancer susceptibility. That's a direct answer. Then, documents 18323801:18323801_1 and 18323801:18323801_0 both state that T-UCRs are involved in human cancerogenesis. The key term here is \"involved in human cancerogenesis,\" which directly addresses the question. So, there's clear evidence from two different sources supporting the involvement of T-UCRs in cancer. The confidence level should be high since multiple studies point to this. However, I need to make sure that the answer is concise and properly cites the documents. The answer should include the specific document IDs and", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. The question is whether transcribed ultraconserved regions are involved in cancer. Let me look at the evidence provided. The first document, 21298224:21298224_1, has a title that says \"The transcribed-ultraconserved regions: a novel class of long noncoding RNAs involved in cancer susceptibility.\" That seems directly relevant. The title mentions they are involved in cancer susceptibility, so that's a strong point. Then there's document 18323801:18323801_1 and 18323801:18323801_0. Both mention that ultraconserved genes (UCGs) or transcribed ultraconserved regions (T-UCRs) are involved in human cancerogenesis. The term \"cancerogenesis\" refers to the development of cancer, so this supports the idea that T-UCRs are involved in cancer. The user wants a concise answer with citations in [doc_id:chunk_id] format", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["18323801", "20383195", "20802525", "21298224", "22328099", "22617881", "24037088", "24247010"], "ideal_answer": "Yes, it appears that there is widespread T-UCR (Transcribed - UltraConserved Region) involvement in diverse cellular processes that are deregulated in the process of tumourigenesis. Transcribed ultraconserved regions (T-UCRs) are a subset of 481 sequences longer than 200 bp, which are absolutely conserved between orthologous regions of human, rat and mouse genomes, and are actively transcribed. It has recently been proven in cancer systems that differentially expressed T-UCRs could alter the functional characteristics of malignant cells."}
{"question_id": "56d06e043975bb303a000011", "question": "In which breast cancer patients can palbociclib be used?", "retrieved_chunks": [{"doc_id": "25524798", "chunk_id": "25524798_0", "score": 6.14046573638916, "text": "We aimed to assess the safety and efficacy of palbociclib in combination with letrozole as first-line treatment of patients with advanced, oestrogen receptor-positive, HER2-negative breast cancer."}, {"doc_id": "26236140", "chunk_id": "26236140_0", "score": 4.330217361450195, "text": "Women with hormone receptor-positive, human epidermal growth factor receptor 2- negative breast cancer-the most common subtype-have new options as palbociclib and similar drugs debut."}, {"doc_id": "26642065", "chunk_id": "26642065_0", "score": 4.2563557624816895, "text": "SUMMARY: Palbociclib, abemaciclib and ribociclib have demonstrated very promising clinical activity in breast cancer, liposarcoma, mantel cell lymphoma and melanoma. Moreover, CDK4/6 inhibitors have shown promising preclinical activity in glioblastoma, renal and ovarian cancer models that may provide directions for their future clinical development."}], "context": "[25524798:25524798_0] We aimed to assess the safety and efficacy of palbociclib in combination with letrozole as first-line treatment of patients with advanced, oestrogen receptor-positive, HER2-negative breast cancer.\n[26236140:26236140_0] Women with hormone receptor-positive, human epidermal growth factor receptor 2- negative breast cancer-the most common subtype-have new options as palbociclib and similar drugs debut.\n[26642065:26642065_0] SUMMARY: Palbociclib, abemaciclib and ribociclib have demonstrated very promising clinical activity in breast cancer, liposarcoma, mantel cell lymphoma and melanoma. Moreover, CDK4/6 inhibitors have shown promising preclinical activity in glioblastoma, renal and ovarian cancer models that may provide directions for their future clinical development.", "answer": "<think> Okay, I need to figure out the answer to the question about which breast cancer patients can use palbociclib based on the given evidence. Let me look at the evidence provided. The first document says that palbociclib is used in combination with letrozole as first-line treatment for advanced, estrogen receptor-positive, HER2-negative breast cancer. So that's a specific group: advanced, ER+HER2-. The second document mentions women with hormone receptor-positive, HER2-negative breast cancer, which is the most common subtype. They have new options with palbociclib. So this seems to align with the first point, reinforcing that it's for HR+/HER2- breast cancer. The third document talks about CDK4/6 inhibitors like palbociclib being active in various cancers, but the question is specifically about breast cancer patients. However, this document doesn't specify the patient criteria, so maybe it's not directly relevant here. So putting it together, the answer should be that palbociclib is used in patients with advanced, hormone receptor-positive, HER2-negative breast cancer. The citations would be from the first", "citations": [], "candidates": [{"answer": "<think> Okay, I need to figure out the answer to the question about which breast cancer patients can use palbociclib based on the given evidence. Let me look at the evidence provided. The first document says that palbociclib is used in combination with letrozole as first-line treatment for advanced, estrogen receptor-positive, HER2-negative breast cancer. So that's a specific group: advanced, ER+HER2-. The second document mentions women with hormone receptor-positive, HER2-negative breast cancer, which is the most common subtype. They have new options with palbociclib. So this seems to align with the first point, reinforcing that it's for HR+/HER2- breast cancer. The third document talks about CDK4/6 inhibitors like palbociclib being active in various cancers, but the question is specifically about breast cancer patients. However, this document doesn't specify the patient criteria, so maybe it's not directly relevant here. So putting it together, the answer should be that palbociclib is used in patients with advanced, hormone receptor-positive, HER2-negative breast cancer. The citations would be from the first", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question about when palbociclib can be used in breast cancer patients. The user wants a concise answer with citations and a confidence score. First, I need to look at the evidence provided. There are three chunks here. Let me parse each one. The first chunk (25524798:25524798_0) says palbociclib is used in combination with letrozole as first-line treatment for advanced, estrogen receptor-positive, HER2-negative breast cancer. That's a specific indication. The second chunk (26236140:2623614ity_0) mentions hormone receptor-positive, HER2-negative breast cancer as the most common subtype, and palbociclib is an option here. So this supports the first chunk's information. The third chunk (26642065:26642065_0) talks about CDK4/6 inhibitors like palbociclib being active in various cancers, but it's more general and mentions other cancers too. However, the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question about when palbociclib can be used in breast cancer patients. The user wants a concise answer with citations and a confidence score. First, I need to look at the evidence provided. There are three chunks here. Let me parse each one. The first chunk (25524798:25524798_0) says palbociclib is used in combination with letrozole as first-line treatment for advanced, estrogen receptor-positive, HER2-negative breast cancer. That's specific. So that's a direct mention of the patient population. The second chunk (26236140:2623614ity_0) mentions women with hormone receptor-positive, HER2-negative breast cancer as the most common subtype, and palbociclib is an option here. This seems to align with the first chunk's description. The third chunk (26642065:26642065_0) talks about CDK4/6 inhibitors, including palbociclib, in various cancers, but", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["25524798", "25792301", "26236140"], "ideal_answer": "Palbociclib is useful for women with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer."}
{"question_id": "56d8b27651531f7e33000003", "question": "Do patients with Pendred syndrome present congenital deafness?", "retrieved_chunks": [{"doc_id": "8979104", "chunk_id": "8979104_0", "score": 8.861767768859863, "text": "Pendred&apos;s syndrome is manifested by congenital sensorineural deafness in association with familial goiter due to defective organic binding of iodine in the thyroid gland. The majority of patients with Pendred&apos;s syndrome are euthyroid. We report on an unusual case of a patient with Pendred&apos;s syndrome presenting with amenorrhea and late-onset hypothyroidism."}, {"doc_id": "1810081", "chunk_id": "1810081_0", "score": 8.521949768066406, "text": "The occurrence of congenital deafness, mutism and goitre unassociated with cretinism or mental retardation in euthyroid patients is known as Pendred&apos;s Syndrome. It has been estimated that 4-10 % of children with congenital deafness suffer from this condition."}, {"doc_id": "8630498", "chunk_id": "8630498_0", "score": 8.521946907043457, "text": "The cause of the congenital deafness in Pendred syndrome is obscure, although a Mondini type malformation of the cochlea exists in some patients."}], "context": "[8979104:8979104_0] Pendred&apos;s syndrome is manifested by congenital sensorineural deafness in association with familial goiter due to defective organic binding of iodine in the thyroid gland. The majority of patients with Pendred&apos;s syndrome are euthyroid. We report on an unusual case of a patient with Pendred&apos;s syndrome presenting with amenorrhea and late-onset hypothyroidism.\n[1810081:1810081_0] The occurrence of congenital deafness, mutism and goitre unassociated with cretinism or mental retardation in euthyroid patients is known as Pendred&apos;s Syndrome. It has been estimated that 4-10 % of children with congenital deafness suffer from this condition.\n[8630498:8630498_0] The cause of the congenital deafness in Pendred syndrome is obscure, although a Mondini type malformation of the cochlea exists in some patients.", "answer": "<think> Okay, I need to generate a JSON answer based on the evidence provided. The question is whether patients with Pendred syndrome present congenital deafness. Let me look at the evidence. First, document 8979104 says that Pendred's syndrome is manifested by congenital sensorineural deafness associated with familial goiter due to defective iodine binding in the thyroid. Also mentions most patients are euthyroid. So that's a direct statement about congenital deafness. Document 1810081 states that congenital deafness, mutism, and goitre without cretinism or mental retardation in euthyroid patients is Pendred's syndrome. It also says 4-10% of children with congenital deafness have this condition. So again, confirms the presence of congenital deafness. Document 8630498 mentions that the cause of congenital deafness in Pendred syndrome is obscure, but some patients have Mondini cochlear malformation. This supports that deafness is a feature, even though the cause isn't clear. So all three documents indicate that congenital deafness is", "citations": [], "candidates": [{"answer": "<think> Okay, I need to generate a JSON answer based on the evidence provided. The question is whether patients with Pendred syndrome present congenital deafness. Let me look at the evidence. First, document 8979104 says that Pendred's syndrome is manifested by congenital sensorineural deafness associated with familial goiter due to defective iodine binding in the thyroid. Also mentions most patients are euthyroid. So that's a direct statement about congenital deafness. Document 1810081 states that congenital deafness, mutism, and goitre without cretinism or mental retardation in euthyroid patients is Pendred's syndrome. It also says 4-10% of children with congenital deafness have this condition. So again, confirms the presence of congenital deafness. Document 8630498 mentions that the cause of congenital deafness in Pendred syndrome is obscure, but some patients have Mondini cochlear malformation. This supports that deafness is a feature, even though the cause isn't clear. So all three documents indicate that congenital deafness is", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to answer whether patients with Pendred syndrome present congenital deafness based on the given evidence. Let me look at the evidence provided. First document: It says Pendred's syndrome is manifested by congenital sensorineural deafness associated with familial goiter due to defective iodine binding in the thyroid. Most patients are euthyroid. So this directly states that congenital deafness is present. Second document: Mentions congenital deafness, mutism, and goitre in euthyroid patients, which is Pendred's syndrome. Also says 4-10% of children with congenital deafness have this condition. This reinforces the presence of deafness. Third document: Talks about the cause being obscure but mentions a Mondini malformation in some patients. While it doesn't directly state deafness, the other documents clearly mention it. However, since the question is about presenting congenital deafness, the first two documents are more relevant. So all three documents support that Pendred syndrome includes congenital deafness. The first document explicitly states it, and the second confirms it. The third might be a bit less direct but doesn't contradict", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to generate a JSON answer based on the evidence provided. Let's start by understanding the question: Do patients with Pendred syndrome present congenital deafness? Looking at the evidence: First document (8979104) says that Pendred's syndrome is manifested by congenital sensorineural deafness associated with familial goiter due to defective iodine binding in the thyroid. It also mentions that most patients are euthyroid, but there's a case with amenorrhea and late-onset hypothyroidism. Second document (1810081) states that Pendred's syndrome involves congenital deafness, mutism, and goitre without cretinism or mental retardation in euthyroid patients. It also mentions 4-10% of children with congenital deafness have this condition. Third document (8630498) says the cause of congenital deafness in Pendred syndrome is obscure, but some have Mondini cochlear malformations. So all three documents mention congenital deafness as a feature of Pendred syndrome. The first two explicitly state that congenital deaf", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["10037079", "10443670", "10502702", "10602116", "10700480", "11375792", "11716048", "14727345", "15320950", "16482981", "16924389", "17299139", "1810081", "18250610", "19318451", "21274344", "21551164", "21704276", "22109890", "22717225", "23459462", "8476169", "8630498", "8706311", "8979104", "9070918", "9398842", "9585042", "9920104"], "ideal_answer": "Congenital deafness is one of the characteristics of Pendred syndrome patients."}
{"question_id": "571e1e11bb137a4b0c000004", "question": "List side effects of SGLT2 inhibitors?", "retrieved_chunks": [{"doc_id": "37482684", "chunk_id": "37482684_0", "score": 7.503031253814697, "text": "SGLT2 inhibitors inhibit the reabsorption of sodium and glucose in the proximal tubule of the kidney and then recovers tubuloglomerular feedback, whereby SGLT2 inhibitors reduce glomerular hyperfiltration. This simple demonstration of their beneficial effects has perplexed experts in seeking more plausible and as yet undisclosed explanations for the whole effects of SGLT2 inhibitors, including metabolism reprogramming and the modulation of hypoxia, inflammation, and oxidative stress."}, {"doc_id": "35999803", "chunk_id": "35999803_0", "score": 7.159795761108398, "text": "Large clinical trials now provide strong evidence that SGLT2 inhibitors decrease the risk of cardiovascular death, heart failure, progressive kidney dysfunction, myocardial infarction, stroke and gout."}, {"doc_id": "33336169", "chunk_id": "33336169_2", "score": 6.874668121337891, "text": "Sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) are a new type of drug for the treatment of diabetes, and they have been proven to have a good hypoglycemic effect. Several lines of clinical evidence have shown that SGLT2 inhibitors can significantly reduce the risks of atherosclerosis, hospitalization for heart failure, cardiovascular death, and all-cause mortality and delay the progression of chronic kidney disease. Because of the protective effects of SGLT2 inhibitors on the heart and kidney, they are being studied for the treatment of heart failure and chronic kidney disease in patients without diabetes."}], "context": "[37482684:37482684_0] SGLT2 inhibitors inhibit the reabsorption of sodium and glucose in the proximal tubule of the kidney and then recovers tubuloglomerular feedback, whereby SGLT2 inhibitors reduce glomerular hyperfiltration. This simple demonstration of their beneficial effects has perplexed experts in seeking more plausible and as yet undisclosed explanations for the whole effects of SGLT2 inhibitors, including metabolism reprogramming and the modulation of hypoxia, inflammation, and oxidative stress.\n[35999803:35999803_0] Large clinical trials now provide strong evidence that SGLT2 inhibitors decrease the risk of cardiovascular death, heart failure, progressive kidney dysfunction, myocardial infarction, stroke and gout.\n[33336169:33336169_2] Sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) are a new type of drug for the treatment of diabetes, and they have been proven to have a good hypoglycemic effect. Several lines of clinical evidence have shown that SGLT2 inhibitors can significantly reduce the risks of atherosclerosis, hospitalization for heart failure, cardiovascular death, and all-cause mortality and delay the progression of chronic kidney disease. Because of the protective effects of SGLT2 inhibitors on the heart and kidney, they are being studied for the treatment of heart failure and chronic kidney disease in patients without diabetes.", "answer": "<think> Okay, let's tackle this question. The user is asking for the side effects of SGLT2 inhibitors. I need to look through the provided evidence to find any mentions of side effects. Looking at the first document, 37482684:37482684_0, it talks about the mechanism of action and some beneficial effects, but not side effects. The second document, 35999803:35999803_0, mentions that SGLT2 inhibitors decrease risks of cardiovascular events, heart failure, kidney dysfunction, etc. But that's more about benefits, not side effects. The third document, 33336169:33336169_2, again discusses the beneficial effects like reducing atherosclerosis, hospitalization for heart failure, cardiovascular death, and delaying kidney disease. Hmm, none of these documents mention any side effects. They all focus on the positive outcomes. The user might be expecting some common side effects like urinary tract infections or hypoglycemia, but according to the given evidence,", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking for the side effects of SGLT2 inhibitors. I need to look through the provided evidence to find any mentions of side effects. Looking at the first document, 37482684:37482684_0, it talks about the mechanism of action and some beneficial effects, but not side effects. The second document, 35999803:35999803_0, mentions that SGLT2 inhibitors decrease risks of cardiovascular events, heart failure, kidney dysfunction, etc. But that's more about benefits, not side effects. The third document, 33336169:33336169_2, again discusses the beneficial effects like reducing atherosclerosis, hospitalization for heart failure, cardiovascular death, and delaying kidney disease. Hmm, none of these documents mention any side effects. They all focus on the positive outcomes. The user might be expecting some common side effects like urinary tract infections or hypoglycemia, but according to the given evidence,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.95, "sup_label": "No", "sup_prob": 1.0, "use_score": 1, "use_prob": 0.8, "notes": "Evidence provides benefits of SGLT2 inhibitors, not side effects. Answer lacks relevant information."}, "score": 0.5}, {"answer": "<think> Okay, I need to generate a candidate biomedical answer about the side effects of SGLT2 inhibitors based on the provided evidence. Let me start by carefully reading through the evidence given. First, looking at the three documents provided. The first one (37482684:37482684_0) talks about how SGLT2 inhibitors work by inhibiting sodium and glucose reabsorption in the kidney's proximal tubule, which leads to tubuloglomerular feedback and reduces glomerular hyperfiltration. However, it mentions that this mechanism has perplexed experts, leading them to seek more explanations like metabolism reprogramming, hypoxia, inflammation, and oxidative stress. Wait, but this seems more about the mechanisms and possible underlying effects rather than side effects. The document doesn't explicitly list side effects. The second document (35999803:35999803_0) discusses clinical trials showing that SGLT2 inhibitors decrease cardiovascular death, heart failure, kidney dysfunction, myocardial infarction, stroke, and gout. These are all positive outcomes,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to generate a JSON answer about the side effects of SGLT2 inhibitors based on the provided evidence. Let me look at the evidence again. The first document (37482684) talks about how SGLT2 inhibitors work by inhibiting sodium and glucose reabsorption in the kidney, which leads to tubuloglomerular feedback and reduces glomerular hyperfiltration. It mentions that this mechanism has perplexed experts, but it's more about the mechanism than side effects. The second document (35999803) states that SGLT2 inhibitors decrease the risk of cardiovascular death, heart failure, progressive kidney dysfunction, myocardial infarction, stroke, and gout. Wait, these are benefits, not side effects. But the question is about side effects. So maybe this document isn't directly relevant. The third document (33336169) mentions that SGLT2 inhibitors have a good hypoglycemic effect and reduce risks of atherosclerosis, heart failure hospitalization, cardiovascular death, all-cause mortality, and delay chronic kidney disease progression.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["22977310", "23042029", "23807940", "24341330", "24400675", "24455799", "24631482", "24825435", "25488697", "25962253"], "ideal_answer": "SGLT2 inhibitors can be associated with urogenital infections related to the enhanced glycosuria, and low blood pressure."}
{"question_id": "552fa32fbc4f83e828000001", "question": "Is CD56 useful in Ewing sarcoma prognosis?", "retrieved_chunks": [{"doc_id": "21467162", "chunk_id": "21467162_4", "score": 8.278963088989258, "text": "Excellent prognosis in a subset of patients with Ewing sarcoma identified at diagnosis by CD56 using flow cytometry."}, {"doc_id": "21467162", "chunk_id": "21467162_3", "score": 8.064037322998047, "text": "Excellent prognosis in a subset of patients with Ewing sarcoma identified at diagnosis by CD56 using flow cytometry"}, {"doc_id": "22498946", "chunk_id": "22498946_0", "score": 4.642483234405518, "text": "Three years after diagnosis the patient presented with severe respiratory difficulty and following resection, the final pathology revealed multiple tumors with foci of high grade sarcoma compatible with primitive neuroectodermal tumor/extraskeletal Ewing sarcoma based on morphology and immunohistochemistry (CD99, CD56)."}], "context": "[21467162:21467162_4] Excellent prognosis in a subset of patients with Ewing sarcoma identified at diagnosis by CD56 using flow cytometry.\n[21467162:21467162_3] Excellent prognosis in a subset of patients with Ewing sarcoma identified at diagnosis by CD56 using flow cytometry\n[22498946:22498946_0] Three years after diagnosis the patient presented with severe respiratory difficulty and following resection, the final pathology revealed multiple tumors with foci of high grade sarcoma compatible with primitive neuroectodermal tumor/extraskeletal Ewing sarcoma based on morphology and immunohistochemistry (CD99, CD56).", "answer": "<think> Okay, let's tackle this question. The user is asking if CD56 is useful in the prognosis of Ewing sarcoma. I need to look at the provided evidence to find answers. First, looking at the evidence documents. The first two entries, 21467162:21467162_4 and 21467162:21467162_3, both mention that a subset of Ewing sarcoma patients have an excellent prognosis identified by CD56 using flow cytometry at diagnosis. So that's a direct statement linking CD56 to a good prognosis. The third document, 22498946:22498946_0, talks about a patient with severe respiratory issues three years post-diagnosis. The pathology showed multiple tumors with high-grade sarcoma, which is primitive neuroectodermal tumor or extraskeletal Ewing sarcoma. They mention immunohistochemistry markers CD99 and CD56. But this seems more about the diagnosis rather than prognosis. It doesn't directly state that CD56", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if CD56 is useful in the prognosis of Ewing sarcoma. I need to look at the provided evidence to find answers. First, looking at the evidence documents. The first two entries, 21467162:21467162_4 and 21467162:21467162_3, both mention that a subset of Ewing sarcoma patients have an excellent prognosis identified by CD56 using flow cytometry at diagnosis. So that's a direct statement linking CD56 to a good prognosis. The third document, 22498946:22498946_0, talks about a patient with severe respiratory issues three years post-diagnosis. The pathology showed multiple tumors with high-grade sarcoma, which is primitive neuroectodermal tumor or extraskeletal Ewing sarcoma. They mention immunohistochemistry markers CD99 and CD56. But this seems more about the diagnosis rather than prognosis. It doesn't directly state that CD56", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if CD56 is useful in the prognosis of Ewing sarcoma. I need to look at the provided evidence to find answers. Looking at the evidence, there are three entries. The first two (21467162:21467162_4 and 21467162:21467162_3) both mention that a subset of Ewing sarcoma patients have an excellent prognosis identified by CD56 using flow cytometry at diagnosis. So that's a direct statement linking CD56 to prognosis. The third entry (22498946:22498946_0) talks about a patient with multiple tumors, including primitive neuroectodermal tumor/extraskeletal Ewing sarcoma, and mentions immunohistochemistry markers like CD99 and CD56. But this seems more about diagnosis rather than prognosis. The key here is that the first two pieces of evidence directly state that CD56 is used to identify a subset with excellent prognosis. The third", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if CD56 is useful in the prognosis of Ewing sarcoma. I need to look at the provided evidence to find answers. First, looking at the evidence documents. The first two entries, 21467162:21467162_4 and 21467162:21467162_3, both mention that a subset of Ewing sarcoma patients have an excellent prognosis identified by CD56 using flow cytometry at diagnosis. So that's a direct statement about CD56 being a prognostic marker. The third entry, 22498946:22498946_0, talks about a patient with severe respiratory issues three years after diagnosis. The pathology showed multiple tumors with high-grade sarcoma, and they mention CD99 and CD56 in immunohistochemistry. However, this seems more like a case report of a patient who had Ewing sarcoma, but the focus here is on the presence of CD56 in the tumor", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["21467162", "22498946", "9692823"], "ideal_answer": "Excellent prognosis in a subset of patients with Ewing sarcoma identified at diagnosis by CD56 using flow cytometryIn patients with localized nonpelvic disease, those expressing low/negative CD56 had 100% PFS versus 40% in the high expressing group (P = 0.02) CD56 expression could be used to reveal Ewing sarcoma patients with excellent prognosis or patients predisposed to relapse, thus improving treatment stratification and implementation of personalized therapy."}
{"question_id": "5509f433c2af5d5b70000008", "question": "What is the method FASP used for?", "retrieved_chunks": [{"doc_id": "23603217", "chunk_id": "23603217_0", "score": 7.183816432952881, "text": "filter assisted sample preparation (FASP) method"}, {"doc_id": "24022122", "chunk_id": "24022122_0", "score": 5.113892078399658, "text": "In the second step the isolated cells are lysed and processed using 'filter aided sample preparation' (FASP) technique."}, {"doc_id": "22324799", "chunk_id": "22324799_0", "score": 5.07862663269043, "text": "Filter Aided Sample Preparation (FASP), a type of proteomic reactor, in which samples dissolved in sodium dodecyl sulfate (SDS) are digested in an ultrafiltration unit."}], "context": "[23603217:23603217_0] filter assisted sample preparation (FASP) method\n[24022122:24022122_0] In the second step the isolated cells are lysed and processed using 'filter aided sample preparation' (FASP) technique.\n[22324799:22324799_0] Filter Aided Sample Preparation (FASP), a type of proteomic reactor, in which samples dissolved in sodium dodecyl sulfate (SDS) are digested in an ultrafiltration unit.", "answer": "<think> Okay, so the user is asking about the method FASP and what it's used for. Let me look at the evidence provided. First, the evidence has three chunks. The first one says \"filter assisted sample preparation (FASP) method\" which seems like a direct definition. The second chunk mentions that isolated cells are lysed and processed using FASP technique. The third chunk describes FASP as a proteomic reactor where samples are digested in an ultrafiltration unit. So, putting this together, FASP is a method used in proteomics. The key points here are that it's used for sample preparation, particularly in processing cells by lysing them and digesting in an ultrafiltration unit. The term \"proteomic reactor\" from the third chunk suggests it's related to protein analysis. The answer needs to be concise with citations. The first chunk directly mentions FASP as a method, so that's a good starting point. The second and third chunks support the use in cell processing and proteomics. The confidence level: Since all three sources agree on FASP being a sample preparation technique, especially in the context of proteomics, I can", "citations": [], "candidates": [{"answer": "<think> Okay, so the user is asking about the method FASP and what it's used for. Let me look at the evidence provided. First, the evidence has three chunks. The first one says \"filter assisted sample preparation (FASP) method\" which seems like a direct definition. The second chunk mentions that isolated cells are lysed and processed using FASP technique. The third chunk describes FASP as a proteomic reactor where samples are digested in an ultrafiltration unit. So, putting this together, FASP is a method used in proteomics. The key points here are that it's used for sample preparation, particularly in processing cells by lysing them and digesting in an ultrafiltration unit. The term \"proteomic reactor\" from the third chunk suggests it's related to protein analysis. The answer needs to be concise with citations. The first chunk directly mentions FASP as a method, so that's a good starting point. The second and third chunks support the use in cell processing and proteomics. The confidence level: Since all three sources agree on FASP being a sample preparation technique, especially in the context of proteomics, I can", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking what the FASP method is used for. The evidence provided has three chunks. First, chunk [23603217:23603217_0] says FASP is a filter assisted sample preparation method. That's a direct definition. Then, chunk [24022122:24022122_0] mentions that isolated cells are lysed and processed using FASP technique in the second step. So it's part of a process involving cell lysis. The third chunk [22324799:22324799_0] describes FASP as a proteomic reactor where samples in SDS are digested in an ultrafiltration unit. Putting this together, FASP is used for sample preparation, specifically in proteomics. It involves lysing cells and processing them, possibly in a proteomic context. The key points are filter-assisted, sample preparation, and proteomic reactors with SDS digestion. The confidence here is high because multiple chunks mention similar aspects. I should cite", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking what the FASP method is used for. The evidence provided has three documents. First, I need to look at each document to extract relevant information. Document [23603217:23603217_0] says \"filter assisted sample preparation (FASP) method\". That's a direct mention of FASP being a method. But it's pretty vague. Then, [24022122:24022122_0] mentions that isolated cells are lysed and processed using the FASP technique in the second step. So this is about cell lysis and processing. The third document, [22324799:22324799_0], describes FASP as a proteomic reactor where samples dissolved in SDS are digested in an ultrafiltration unit. This seems to be more specific, talking about proteomics and digestion. Putting this together, FASP is used in sample preparation, particularly in proteomics. The key points are lysis of cells,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["22092713", "22324799", "22949036", "23126408", "23214492", "23436586", "23603217", "23784971", "24022122", "24051509", "24288579", "24289162", "24309553"], "ideal_answer": "Filter Aided Sample Preparation (FASP), a type of proteomic reactor, in which samples dissolved in sodium dodecyl sulfate (SDS) are digested in an ultrafiltration unit."}
{"question_id": "553fa2201d53b76422000005", "question": "What is the role of extracellular signal-related kinases 1 and 2 (ERK1/2) proteins in craniosynostosis?", "retrieved_chunks": [{"doc_id": "23987506", "chunk_id": "23987506_0", "score": 5.583812236785889, "text": "Here, we show that two scaffold proteins, caveolin-1 and IQGAP1, are required for phosphorylation of the actin associated pool of extracellular signal regulated kinase 1 and 2 (ERK1/2) in response to protein kinase C activation."}, {"doc_id": "24265417", "chunk_id": "24265417_0", "score": 2.600245952606201, "text": "We specifically identified that the Spa homology domain (aa 250-420) of GIT1 is required for GIT1-cortactin complex localization to the leading edge. The mechanisms involved extracellular signal-regulated kinases 1 and 2-mediated Cortactin-S405 phosphorylation and activation of Rac1/Cdc42."}, {"doc_id": "33989615", "chunk_id": "33989615_0", "score": 1.4627001285552979, "text": "Type 1 salt-inducible kinases (SIK1) has been shown to act as a mediator during the cellular adaptation to variations in intracellular sodium in a variety of cell types. Type 2 SIK (SIK2) modulates various biological functions and acts as a signal transmitter in various pathways."}], "context": "[23987506:23987506_0] Here, we show that two scaffold proteins, caveolin-1 and IQGAP1, are required for phosphorylation of the actin associated pool of extracellular signal regulated kinase 1 and 2 (ERK1/2) in response to protein kinase C activation.\n[24265417:24265417_0] We specifically identified that the Spa homology domain (aa 250-420) of GIT1 is required for GIT1-cortactin complex localization to the leading edge. The mechanisms involved extracellular signal-regulated kinases 1 and 2-mediated Cortactin-S405 phosphorylation and activation of Rac1/Cdc42.\n[33989615:33989615_0] Type 1 salt-inducible kinases (SIK1) has been shown to act as a mediator during the cellular adaptation to variations in intracellular sodium in a variety of cell types. Type 2 SIK (SIK2) modulates various biological functions and acts as a signal transmitter in various pathways.", "answer": "<think> Okay, let's tackle this question about ERK1/2's role in craniosynostosis. First, I need to recall what ERK1/2 are. They're part of the MAPK signaling pathway, involved in cell growth, differentiation, and other processes. Now, craniosynostosis is a condition where bones in the skull fuse too early, affecting brain development. Looking at the evidence provided, the first document says that caveolin-1 and IQGAP1 are needed for phosphorylation of ERK1/2 in response to PKC activation. Phosphorylation is key for signaling, so this suggests ERK1/2 are involved in cellular responses triggered by PKC. The second document mentions ERK1/2 mediating Cortactin-S405 phosphorylation and Rac1/Cdc42 activation, which are involved in cell motility and cytoskeleton rearrangement. These processes are crucial for bone remodeling. If ERK1/2 are active in these pathways, they might influence the processes that lead to craniosynostosis. The third document talks about SIK1 and SIK2, but those", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question about ERK1/2's role in craniosynostosis. First, I need to recall what ERK1/2 are. They're part of the MAPK signaling pathway, involved in cell growth, differentiation, and other processes. Now, craniosynostosis is a condition where bones in the skull fuse too early, affecting brain development. Looking at the evidence provided, the first document says that caveolin-1 and IQGAP1 are needed for phosphorylation of ERK1/2 in response to PKC activation. Phosphorylation is key for signaling, so this suggests ERK1/2 are involved in cellular responses triggered by PKC. The second document mentions ERK1/2 mediating Cortactin-S405 phosphorylation and Rac1/Cdc42 activation, which are involved in cell motility and cytoskeleton rearrangement. These processes are crucial for bone remodeling. If ERK1/2 are active in these pathways, they might influence the processes that lead to craniosynostosis. The third document talks about SIK1 and SIK2, but those", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question about ERK1/2's role in craniosynostosis. First, I need to recall what craniosynostosis is. It's a condition where one or more of the bones in an infant's skull fuse too soon, leading to abnormal head shape and potential brain development issues. The question is about the role of ERK1/2 proteins in this condition. Looking at the evidence provided, there are three references. Let me go through each one to see if they mention ERK1/2 in the context of craniosynostosis. The first reference (23987506) talks about caveolin-1 and IQGAP1 being involved in phosphorylating ERK1/2 in response to PKC activation. But there's no mention of craniosynostosis here. It seems more related to cell signaling pathways involving actin and protein kinase C. The second reference (24265417) discusses GIT1, cortactin, Rac1/Cdc42, and ERK1/2-mediated phosphorylation of Cortactin-S405", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question about ERK1/2's role in craniosynostosis. First, I need to recall what ERK1/2 are. They're part of the MAPK signaling pathway, involved in cell proliferation, differentiation, and survival. Now, the user is asking specifically about their role in craniosynostosis, which is a condition where bones in the skull fuse too early. Looking at the evidence provided, there are three references. The first one mentions caveolin-1 and IQGAP1 scaffolds being needed for phosphorylation of ERK1/2 in response to PKC activation. The second reference talks about GIT1's Spa homology domain interacting with cortactin, involving ERK1/2-mediated phosphorylation of Cortactin-S405 and activation of Rac1/Cdc42. The third is about SIK1 and SIK2, which are different from ERK1/2, so maybe not directly relevant here. So the question is about ERK1/2's role in craniosynostosis. The evidence points to ERK1/2 being involved in phosphorylation", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["23354439"], "ideal_answer": "Reduced dosage of ERF, which encodes an inhibitory ETS transcription factor directly bound by ERK1/2 causes complex craniosynostosis (premature fusion of the cranial sutures) in humans and mice. Features of this newly recognized clinical disorder include multiple-suture synostosis, craniofacial dysmorphism, Chiari malformation and language delay."}
{"question_id": "52fa73c62059c6d71c000058", "question": "Are there any urine biomarkers for chronic kidney disease?", "retrieved_chunks": [{"doc_id": "20425065", "chunk_id": "20425065_0", "score": 7.5342206954956055, "text": "Identification of urine biomarkers has proven to be beneficial in recent years because of ease of handling, stability, and the ability to standardize the various markers to creatinine or other peptides generally already present in the urine. Recent markers such as neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and podocin have garnered a lot of attention. The emergence of these and other biomarkers is largely because of the evolution of novel genomic and proteomic applications in investigations of acute kidney injury and chronic kidney disease."}, {"doc_id": "23952327", "chunk_id": "23952327_0", "score": 7.334392547607422, "text": "Renal biomarkers, especially those present in urine, may be useful for the study of both acute and chronic nephropathies."}, {"doc_id": "21538916", "chunk_id": "21538916_0", "score": 4.137395858764648, "text": "Kidney and urine proteomic biomarkers are considered as promising diagnostic tools to predict CKD progression early in diabetic nephropathy, facilitating timely and selective intervention that may reduce the related health-care expenditures."}], "context": "[20425065:20425065_0] Identification of urine biomarkers has proven to be beneficial in recent years because of ease of handling, stability, and the ability to standardize the various markers to creatinine or other peptides generally already present in the urine. Recent markers such as neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and podocin have garnered a lot of attention. The emergence of these and other biomarkers is largely because of the evolution of novel genomic and proteomic applications in investigations of acute kidney injury and chronic kidney disease.\n[23952327:23952327_0] Renal biomarkers, especially those present in urine, may be useful for the study of both acute and chronic nephropathies.\n[21538916:21538916_0] Kidney and urine proteomic biomarkers are considered as promising diagnostic tools to predict CKD progression early in diabetic nephropathy, facilitating timely and selective intervention that may reduce the related health-care expenditures.", "answer": "<think> Okay, I need to generate a JSON answer based on the evidence provided. The question is about whether there are urine biomarkers for chronic kidney disease. First, looking at the evidence: The first document (20425065) mentions several urine biomarkers like NGAL, KIM-1, and podocin. It also talks about their benefits for CKD. The second document (23952327) says renal biomarkers in urine are useful for both acute and chronic nephropathies. The third (21538916) discusses proteomic biomarkers in urine being promising for predicting CKD progression in diabetic nephropathy. So the answer should confirm that there are urine biomarkers for CKD, citing these sources. The confidence is high because all three documents support this. I need to make sure the answer is concise and includes the correct citations. Also, the base_confidence should be a float between 0 and 1. Since all evidence points to the existence of such biomarkers, I'll set it to 1.0. </think> { \"answer\": \"Yes, urine", "citations": [], "candidates": [{"answer": "<think> Okay, I need to generate a JSON answer based on the evidence provided. The question is about whether there are urine biomarkers for chronic kidney disease. First, looking at the evidence: The first document (20425065) mentions several urine biomarkers like NGAL, KIM-1, and podocin. It also talks about their benefits for CKD. The second document (23952327) says renal biomarkers in urine are useful for both acute and chronic nephropathies. The third (21538916) discusses proteomic biomarkers in urine being promising for predicting CKD progression in diabetic nephropathy. So the answer should confirm that there are urine biomarkers for CKD, citing these sources. The confidence is high because all three documents support this. I need to make sure the answer is concise and includes the correct citations. Also, the base_confidence should be a float between 0 and 1. Since all evidence points to the existence of such biomarkers, I'll set it to 1.0. </think> { \"answer\": \"Yes, urine", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if there are any urine biomarkers for chronic kidney disease. I need to look at the provided evidence to find answers. First, looking at the first evidence snippet (20425065:20425065_0), it mentions several urine biomarkers like NGAL, KIM-1, and podocin. These are specifically noted in the context of chronic kidney disease. That's a direct hit. The second snippet (23952327:23952327_0) talks about renal biomarkers in urine being useful for both acute and chronic nephropathies, which includes CKD. The third snippet (21538916:21538916_0) discusses kidney and urine proteomic biomarkers as promising tools for predicting CKD progression, especially in diabetic nephropathy. So combining these, the answer should include the specific biomarkers mentioned in the first evidence. The confidence level would be high because multiple sources directly mention urine biomarkers for CKD. I need", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if there are any urine biomarkers for chronic kidney disease. I need to look at the provided evidence to find answers. First, looking at the first evidence document [20425065:20425065_0], it mentions several urine biomarkers like NGAL, KIM-1, and podocin. These are specifically noted for chronic kidney disease. That's a direct answer. The confidence here is pretty high because it's explicitly stating these markers are used for CKD. The second document [23952327:23952327_0] talks about renal biomarkers in urine being useful for both acute and chronic nephropathies. While it's general, it supports the idea that urine biomarkers exist for chronic kidney disease. But it's more of a broad statement, so maybe slightly less confidence than the first document. The third document [21538916:21538916_0] mentions kidney and urine proteomic biomarkers as promising tools for predicting", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["20425065", "21151537", "21286212", "21538916", "21816077", "22189039", "22914685", "23061738", "23339563", "23344473", "23617441", "23758910", "24065527", "24133923", "24152229", "24205707", "24224012", "24281781", "24308223", "24315007"], "ideal_answer": "Chronic kidney disease (CKD), is a progressive loss in renal function over a period of months or years. The symptoms of worsening kidney function are non-specific, and might include feeling generally unwell and experiencing a reduced appetite. Often, chronic kidney disease is diagnosed as a result of screening of people known to be at risk of kidney problems, such as those with high blood pressure or diabetes and those with a blood relative with chronic kidney disease. Chronic kidney disease may also be identified when it leads to one of its recognized complications, such as cardiovascular disease, anemia or pericarditis. It is differentiated from acute kidney disease in that the reduction in kidney function must be present for over 3 months. Yes, there is a number of urine biomarkers used for early detection of chronic kidney disease."}
{"question_id": "533f9df0c45e133714000016", "question": "What is being measured with an accelerometer in back pain patients", "retrieved_chunks": [{"doc_id": "19945334", "chunk_id": "19945334_0", "score": 6.112344264984131, "text": "physical activity (PA) in individuals with chronic low back pain (CLBP). Thirty-eight participants with non-specific CLBP (29=distressed; 9=non-distressed) were recruited. PA levels were measured using an accelerometer (activPAL activity monitor) over a one week period. The following parameters of physical activity were recorded: time upright (standing or walking), time standing, time walking, and step count."}, {"doc_id": "16437292", "chunk_id": "16437292_0", "score": 3.7190608978271484, "text": "nighttime activity data from 18 patients diagnosed with chronic back pain. The patients were followed for 6 days and 5 nights. Pain levels were collected every 90 min between 0800 hours and 2,200 hours using a computerized electronic diary. Activity levels were collected using a wrist accelerometer (Actiwatch AW-64). The Actiwatch sampled activity counts every 1 min. Patients were asked to wear the Actiwatch on their non-dominant arm."}, {"doc_id": "20921030", "chunk_id": "20921030_0", "score": 3.1743996143341064, "text": "objective activity data to determine whether patients with chronic lower back pain report their activity levels as accurately as controls do. DESIGN: A cross-sectional study was performed in patients and controls. SETTING: The study was carried out in the daily environment of the subjects. SUBJECTS: Thirty-two chronic lower back pain patients with symptoms more than three months and 20 healthy controls from the Netherlands, aged 18-65 years. MAIN MEASURES: A tri-axial accelerometer was worn for five weekdays"}], "context": "[19945334:19945334_0] physical activity (PA) in individuals with chronic low back pain (CLBP). Thirty-eight participants with non-specific CLBP (29=distressed; 9=non-distressed) were recruited. PA levels were measured using an accelerometer (activPAL activity monitor) over a one week period. The following parameters of physical activity were recorded: time upright (standing or walking), time standing, time walking, and step count.\n[16437292:16437292_0] nighttime activity data from 18 patients diagnosed with chronic back pain. The patients were followed for 6 days and 5 nights. Pain levels were collected every 90 min between 0800 hours and 2,200 hours using a computerized electronic diary. Activity levels were collected using a wrist accelerometer (Actiwatch AW-64). The Actiwatch sampled activity counts every 1 min. Patients were asked to wear the Actiwatch on their non-dominant arm.\n[20921030:20921030_0] objective activity data to determine whether patients with chronic lower back pain report their activity levels as accurately as controls do. DESIGN: A cross-sectional study was performed in patients and controls. SETTING: The study was carried out in the daily environment of the subjects. SUBJECTS: Thirty-two chronic lower back pain patients with symptoms more than three months and 20 healthy controls from the Netherlands, aged 18-65 years. MAIN MEASURES: A tri-axial accelerometer was worn for five weekdays", "answer": "<think> Okay, let's tackle this question. The user is asking what an accelerometer measures in back pain patients. I need to look at the evidence provided. First, document 19945334:19945334_0 mentions that PA levels were measured using an accelerometer (activPAL) over a week. They recorded parameters like time upright, standing, walking, and step count. So, this indicates that accelerometers measure physical activity parameters such as time spent in different activities and step counts. Then document 16437292:16437292_0 talks about nighttime activity data using a wrist accelerometer (Actiwatch). It samples activity counts every minute. So here, the accelerometer is tracking activity levels, possibly including movement intensity or frequency. Document 20921030:2092103ity_0 mentions a tri-axial accelerometer worn for five weekdays to collect objective activity data. The main measures include activity levels, which likely involve movement patterns and possibly other metrics. Putting this together, accelerometers in these studies measure physical activity parameters such as", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking what an accelerometer measures in back pain patients. I need to look at the evidence provided. First, document 19945334:19945334_0 mentions that PA levels were measured using an accelerometer (activPAL) over a week. They recorded parameters like time upright, standing, walking, and step count. So, this indicates that accelerometers measure physical activity parameters such as time spent in different activities and step counts. Then document 16437292:16437292_0 talks about nighttime activity data using a wrist accelerometer (Actiwatch). It samples activity counts every minute. So here, the accelerometer is tracking activity levels, possibly including movement intensity or frequency. Document 20921030:2092103ity_0 mentions a tri-axial accelerometer worn for five weekdays to collect objective activity data. The main measures include activity levels, which likely involve movement patterns and possibly other metrics. Putting this together, accelerometers in these studies measure physical activity parameters such as", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user wants to know what an accelerometer measures in back pain patients. Looking at the evidence provided, there are three documents. First document [19945334:19945334_0] mentions that PA levels were measured using an activPAL activity monitor over a week. They recorded time upright, standing, walking, and step count. So that's physical activity parameters. Second document [16437292:16437292_0] uses a wrist accelerometer (Actiwatch) to collect activity levels. It samples every minute, so it's about movement counts over time. Third document [20921030:20921030_0] talks about a tri-axial accelerometer worn for five weekdays. The main measures include objective activity data, which likely refers to movement and physical activity levels. So the common theme is that accelerometers measure physical activity parameters like time spent standing, walking, step count, and movement counts. The answer should be concise, citing the relevant documents. The confidence level", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking what an accelerometer measures in back pain patients. I need to look at the evidence provided and find the relevant information. First, looking at the first piece of evidence: it mentions that an accelerometer (activPAL) measured physical activity parameters like time upright, standing, walking, and step count. So that's one aspect—physical activity metrics. The second evidence talks about a wrist accelerometer (Actiwatch) collecting nighttime activity data. It samples activity counts every minute. So this is about activity levels, possibly including movement during the day and night. Third evidence mentions a tri-axial accelerometer worn for five weekdays to collect objective activity data. The main measures here are likely the same as the first one: time spent in different activities, steps, etc. Also, it's comparing patients' reports with controls, so the accelerometer is measuring actual physical activity rather than self-reported data. Putting this together, accelerometers in these studies measure various aspects of physical activity. The answer should mention parameters like time upright, standing, walking, step cou", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["11387574", "15271728", "16426878", "16437292", "18752975", "19402888", "19895697", "19945334", "19945891", "20457489", "20921030", "21195646", "21872993", "23560880", "23865908"], "ideal_answer": "Accelerometer assessment measuring overall physical activity (PAL), constant strain postures (CSP), standing time (ST) and lying time (LT)... The following parameters of physical activity were recorded: time upright (standing or walking), time standing, time walking, and step count."}
{"question_id": "56a3a386496b62f23f000007", "question": "List the releases of JASPAR database", "retrieved_chunks": [{"doc_id": "31701148", "chunk_id": "31701148_0", "score": 6.770306587219238, "text": "JASPAR (http://jaspar.genereg.net) is an open-access database of curated, non-redundant transcription factor (TF)-binding profiles stored as position frequency matrices (PFMs) for TFs across multiple species in six taxonomic groups. In this 8th release of JASPAR, the CORE collection has been expanded with 245 new PFMs (169 for vertebrates, 42 for plants, 17 for nematodes, 10 for insects, and 7 for fungi), and 156 PFMs were updated (125 for vertebrates, 28 for plants and 3 for insects). These new profiles represent an 18% expansion compared to the previous release. JASPAR 2020 comes with a novel collection of unvalidated TF-binding profiles for which our curators did not find orthogonal supporting evidence in the literature. This collection has a dedicated web form to engage the community in the curation of unvalidated TF-binding profiles. Moreover, we created a Q&A forum to ease the communication between the user community and JASPAR curators. Finally, we updated the genomic tracks, inference tool, and TF-binding profile similarity clusters. All the data is available through the JASPAR website, its associated RESTful API, and through the JASPAR2020 R/Bioconductor package."}, {"doc_id": "34850907", "chunk_id": "34850907_1", "score": 6.43587589263916, "text": "JASPAR 2022: the 9th release of the open-access database of transcription factor binding profiles."}, {"doc_id": "37962376", "chunk_id": "37962376_0", "score": 6.349301338195801, "text": "JASPAR (https://jaspar.elixir.no/) is a widely-used open-access database presenting manually curated high-quality and non-redundant DNA-binding profiles for transcription factors (TFs) across taxa. In this 10th release and 20th-anniversary update, the CORE collection has expanded with 329 new profiles. We updated three existing profiles and provided orthogonal support for 72 profiles from the previous release's UNVALIDATED collection. Altogether, the JASPAR 2024 update provides a 20% increase in CORE profiles from the previous release."}], "context": "[31701148:31701148_0] JASPAR (http://jaspar.genereg.net) is an open-access database of curated, non-redundant transcription factor (TF)-binding profiles stored as position frequency matrices (PFMs) for TFs across multiple species in six taxonomic groups. In this 8th release of JASPAR, the CORE collection has been expanded with 245 new PFMs (169 for vertebrates, 42 for plants, 17 for nematodes, 10 for insects, and 7 for fungi), and 156 PFMs were updated (125 for vertebrates, 28 for plants and 3 for insects). These new profiles represent an 18% expansion compared to the previous release. JASPAR 2020 comes with a novel collection of unvalidated TF-binding profiles for which our curators did not find orthogonal supporting evidence in the literature. This collection has a dedicated web form to engage the community in the curation of unvalidated TF-binding profiles. Moreover, we created a Q&A forum to ease the communication between the user community and JASPAR curators. Finally, we updated the genomic tracks, inference tool, and TF-binding profile similarity clusters. All the data is available through the JASPAR website, its associated RESTful API, and through the JASPAR2020 R/Bioconductor package.\n[34850907:34850907_1] JASPAR 2022: the 9th release of the open-access database of transcription factor binding profiles.\n[37962376:37962376_0] JASPAR (https://jaspar.elixir.no/) is a widely-used open-access database presenting manually curated high-quality and non-redundant DNA-binding profiles for transcription factors (TFs) across taxa. In this 10th release and 20th-anniversary update, the CORE collection has expanded with 329 new profiles. We updated three existing profiles and provided orthogonal support for 72 profiles from the previous release's UNVALIDATED collection. Altogether, the JASPAR 2024 update provides a 20% increase in CORE profiles from the previous release.", "answer": "<think> Okay, let me try to figure this out. The user is asking for the releases of the JASPAR database. I need to look at the evidence provided to find the versions mentioned. Looking at the first evidence snippet, it mentions the 8th release of JASPAR, which is called JASPAR 2020. Then there's another snippet that says JASPAR 2022 is the 9th release. The third snippet talks about the 10th release and a 20th-anniversary update, which would be JASPAR 2024. So the releases listed are 8th (2020), 9th (2022), and 10th (2024). The answer should list these with their respective years. I need to make sure the citations are correct. The first one is [31701148:31701148_0] for the 8th release, [34850907:34850907_1] for the 9", "citations": [{"doc_id": "31701148", "chunk_id": "31701148_0"}, {"doc_id": "34850907", "chunk_id": "34850907_1"}], "candidates": [{"answer": "<think> Okay, let me try to figure this out. The user is asking for the releases of the JASPAR database. I need to look at the evidence provided to find the versions mentioned. Looking at the first evidence snippet, it mentions the 8th release of JASPAR, which is called JASPAR 2020. Then there's another snippet that says JASPAR 2022 is the 9th release. The third snippet talks about the 10th release and a 20th-anniversary update, which would be JASPAR 2024. So the releases listed are 8th (2020), 9th (2022), and 10th (2024). The answer should list these with their respective years. I need to make sure the citations are correct. The first one is [31701148:31701148_0] for the 8th release, [34850907:34850907_1] for the 9", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this query. The user is asking for the releases of the JASPAR database. Looking at the evidence provided, there are three documents mentioned. First, document [31701148:31701148_0] talks about the 8th release, JASPAR 2020. Then, [34850907:34850907_1] mentions the 9th release, JASPAR . Finally, [37962376:37962376_0] refers to the 10th release, JASPAR 2024. Wait, but the user wants a list of releases. The answer should include all the versions mentioned in the evidence. Let me check again. The first one is 8th release (2020), then 9th (2022), and 10th (2024). So the answer should list these three releases with their respective details. However, the user's question says \"re", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to generate a JSON answer based on the evidence provided. The user is asking for the releases of the JASPAR database. First, looking at the evidence: - The first document mentions the 8th release (JASPAR 2020) with details about new PFMs and updates. - The second document states the 9th release (JASPAR .2022). - The third document talks about the 10th release (JASPAR 2024), which is also the 20th anniversary update. So, the releases listed are 8th (2020), 9th (2022), and 10th (2024). The answer should list these. I need to make sure each entry has the correct citation. The base confidence is high because the information is directly from the evidence provided. But wait, the third document says \"10th release and 20th-anniversary update,\" so that's JASPAR 2024. So the releases are 8th (2020), 9th", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["14681366", "16381983", "18006571", "19906716", "24194598"], "ideal_answer": "JASPAR, JASPAR CORE, JASPAR FAM, JASPAR phyloFACTS, JASPAR 2008 update, JASPAR 2010, JASPAR 2014."}
{"question_id": "56c1f038ef6e394741000051", "question": "List symptoms of the IFAP syndrome.", "retrieved_chunks": [{"doc_id": "10694306", "chunk_id": "10694306_0", "score": 7.237981796264648, "text": "Atrichia, ichthyosis, follicular hyperkeratosis, chronic candidiasis, keratitis, seizures, mental retardation and inguinal hernia: a severe manifestation of IFAP syndrome?"}, {"doc_id": "25685152", "chunk_id": "25685152_0", "score": 6.121890068054199, "text": "The IFAP syndrome is a rare X-linked genetic disorder characterized by the triad of follicular ichthyosis, atrichia, and photophobia."}, {"doc_id": "10326971", "chunk_id": "10326971_0", "score": 5.426234245300293, "text": "Ichthyosis follicularis, atrichia, and photophobia (IFAP) are typical features of a rare neuroichthyosis termed IFAP syndrome."}], "context": "[10694306:10694306_0] Atrichia, ichthyosis, follicular hyperkeratosis, chronic candidiasis, keratitis, seizures, mental retardation and inguinal hernia: a severe manifestation of IFAP syndrome?\n[25685152:25685152_0] The IFAP syndrome is a rare X-linked genetic disorder characterized by the triad of follicular ichthyosis, atrichia, and photophobia.\n[10326971:10326971_0] Ichthyosis follicularis, atrichia, and photophobia (IFAP) are typical features of a rare neuroichthyosis termed IFAP syndrome.", "answer": "<think> Okay, the user is asking for symptoms of IFAP syndrome. Let me look at the evidence provided. First document: 10694306 mentions Atrichia, ichthyosis, follicular hyperkeratosis, chronic candidiasis, keratitis, seizures, mental retardation, and inguinal hernia. That's a list of several symptoms. Second document: 25685152 says the triad is follicular ichthyosis, atrichia, and photophobia. So those three are key features. Third document: 10326971 repeats the triad plus mentions ichthyosis follicularis, atrichia, and photophobia. So that's the same as the second one. The question is to list symptoms, so I need to combine these. The first document has more symptoms but maybe some are not part of the standard triad. However, the user might want a comprehensive list. But the answer should be concise with citations. Looking at the documents, the main points are the triad (ichthyosis, atrichia, photophobia)", "citations": [], "candidates": [{"answer": "<think> Okay, the user is asking for symptoms of IFAP syndrome. Let me look at the evidence provided. First document: 10694306 mentions Atrichia, ichthyosis, follicular hyperkeratosis, chronic candidiasis, keratitis, seizures, mental retardation, and inguinal hernia. That's a list of several symptoms. Second document: 25685152 says the triad is follicular ichthyosis, atrichia, and photophobia. So those three are key features. Third document: 10326971 repeats the triad plus mentions ichthyosis follicularis, atrichia, and photophobia. So that's the same as the second one. The question is to list symptoms, so I need to combine these. The first document has more symptoms but maybe some are not part of the standard triad. However, the user might want a comprehensive list. But the answer should be concise with citations. Looking at the documents, the main points are the triad (ichthyosis, atrichia, photophobia)", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. The question is asking for symptoms of IFAP syndrome. Let me look at the evidence provided. First document: 10694306 mentions Atrichia, ichthyosis, follicular hyperkeratosis, chronic candidiasis, keratitis, seizures, mental retardation, and inguinal hernia. That's a list of symptoms. Second document: 25685152 states the triad is follicular ichthyosis, atrichia, and photophobia. So those are three main features. Third document: 10326971 repeats the triad of ichthyosis follicularis, atrichia, and photophobia. So combining these, the primary symptoms are the triad mentioned in documents 2 and 3. But the first document adds more symptoms like chronic candidiasis, keratitis, seizures, mental retardation, inguinal hernia. However, the question says \"list symptoms,\" so maybe I should include both the triad and the additional ones from the first document", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. The question is asking for symptoms of IFAP syndrome. Let me look at the evidence provided. First document: 10694306:10694306_0 mentions Atrichia, ichthyosis, follicular hyperkeratosis, chronic candidiasis, keratitis, seizures, mental retardation, and inguinal hernia. That's a list of symptoms. Second document: 25685152:25685152_0 states the triad is follicular ichthyosis, atrichia, and photophobia. So those are three key symptoms. Third document: 10326971:10326977_0 repeats the triad of ichthyosis follicularis, atrichia, and photophobia. So same as the second one. The user wants a concise answer with citations. The answer should list the symptoms. The first document has more symptoms, but the other two mention the triad. The main symptoms", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["10326971", "10398262", "10694306", "12004300", "1456297", "14708109", "15370546", "16268889", "1915513", "19689518", "21315478", "21886760", "24090718", "24313295", "25685152"], "ideal_answer": "The IFAP syndrome is a rare X-linked genetic disorder characterized by the triad of follicular ichthyosis, atrichia, and photophobia."}
{"question_id": "531a34d5b166e2b806000036", "question": "Which gene is required for the efficient function of clopidogrel?", "retrieved_chunks": [{"doc_id": "22088980", "chunk_id": "22088980_0", "score": 3.451876640319824, "text": "Variants in the CYP2C19 gene influence the pharmacologic and clinical response to the standard 75-mg daily maintenance dose of the antiplatelet drug clopidogrel. OBJECTIVE: To test whether higher doses (up to 300 mg daily) improve the response to clopidogrel in the setting of loss-of-function CYP2C19 genotypes."}, {"doc_id": "22154242", "chunk_id": "22154242_0", "score": 2.7283222675323486, "text": "The antiplatelet effect of clopidogrel has been linked to cytochrome P450 2C19 (CYP2C19) carrier status. The presence of loss of function and gain of function variants were found to have a gene-dose effect on clopidogrel metabolism. However, genotyping is only one aspect of predicting response to clopidogrel and several platelet function tests are available to measure platelet response."}, {"doc_id": "15933261", "chunk_id": "15933261_1", "score": 2.6336846351623535, "text": "ssociation of a functional polymorphism in the clopidogrel target receptor gene, P2Y12"}], "context": "[22088980:22088980_0] Variants in the CYP2C19 gene influence the pharmacologic and clinical response to the standard 75-mg daily maintenance dose of the antiplatelet drug clopidogrel. OBJECTIVE: To test whether higher doses (up to 300 mg daily) improve the response to clopidogrel in the setting of loss-of-function CYP2C19 genotypes.\n[22154242:22154242_0] The antiplatelet effect of clopidogrel has been linked to cytochrome P450 2C19 (CYP2C19) carrier status. The presence of loss of function and gain of function variants were found to have a gene-dose effect on clopidogrel metabolism. However, genotyping is only one aspect of predicting response to clopidogrel and several platelet function tests are available to measure platelet response.\n[15933261:15933261_1] ssociation of a functional polymorphism in the clopidogrel target receptor gene, P2Y12", "answer": "<think> Okay, let's tackle this question. The user is asking which gene is required for the efficient function of clopidogrel. The evidence provided has three documents. First, looking at document [22088980:22088980_0], it mentions that variants in the CYP2C19 gene influence the pharmacologic and clinical response to clopidogrel. That seems directly relevant because CYP2C19 is involved in metabolizing drugs, so if there's a variant here, it would affect how well clopidogrel works. The study also talks about higher doses improving response in cases of loss-of-function CYP2C19 genotypes. So this document definitely points to CYP2C19 as the gene in question. Next, document [22154242:22154242_0] reinforces that the antiplatelet effect of clopidogrel is linked to CYP2C19 carrier status. It also mentions gene-dose effects on metabolism, which again supports CYP2C19 being crucial here. The mention", "citations": [{"doc_id": "22088980", "chunk_id": "22088980_0"}, {"doc_id": "22154242", "chunk_id": "22154242_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which gene is required for the efficient function of clopidogrel. The evidence provided has three documents. First, looking at document [22088980:22088980_0], it mentions that variants in the CYP2C19 gene influence the pharmacologic and clinical response to clopidogrel. That seems directly relevant because CYP2C19 is involved in metabolizing drugs, so if there's a variant here, it would affect how well clopidogrel works. The study also talks about higher doses improving response in cases of loss-of-function CYP2C19 genotypes. So this document definitely points to CYP2C19 as the gene in question. Next, document [22154242:22154242_0] reinforces that the antiplatelet effect of clopidogrel is linked to CYP2C19 carrier status. It also mentions gene-dose effects on metabolism, which again supports CYP2C19 being crucial here. The mention", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which gene is required for the efficient function of clopidogrel. The evidence provided has three documents. First, looking at document [22088980:22088980_0], it mentions that variants in the CYP2C19 gene influence the pharmacologic and clinical response to clopidogrel. That suggests CYP2C19 is involved in how clopidogrel works. The objective of the study is about higher doses improving response in cases of loss-of-function CYP2C19 genotypes, so this seems directly relevant. Next, document [22154242:22154242_0] also talks about the antiplatelet effect being linked to CYP2C19 carrier status. It mentions that loss and gain of function variants affect metabolism, which again points to CYP2C19 being crucial for clopidogrel's efficiency. The third document [15933261:15933265_1] refers to", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which gene is required for the efficient function of clopidogrel. The evidence provided has three documents. First, looking at document [22088980:22088980_0], it mentions that variants in the CYP2C19 gene influence the pharmacologic and clinical response to clopidogrel. That seems directly relevant because CYP2C19 is involved in metabolizing clopidogrel, so if there's a variant here, it would affect how well the drug works. The objective of the study is about higher doses improving response in cases of loss-of-function CYP2C19 genotypes, which suggests that CYP2C19 is crucial for the drug's effectiveness. Document [22154242:22154242_0] also talks about the antiplatelet effect being linked to CYP2C19 carrier status. It mentions that loss of function and gain of function variants affect clopidogrel metabolism, reinforcing that CYP2C19 is key here", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["15933261", "19463375", "20826260", "21099121", "21806387", "23150151", "23506580"], "ideal_answer": "The prodrug clopidogrel requires activation by cytochrome P-450 (CYP) enzymes for its antiplatelet effect. Variability in clopidogrel response might be influenced by polymorphisms in genes coding for drug metabolism enzymes (cytochrome P450 CYP2C19), transport proteins (P-glycoprotein) and/or target proteins for the drug (adenosine diphosphate-receptor P2Y12). The CYP2C19 loss-of-function alleles had a gene dose effect on the pharmacodynamics and composite ischemic events of clopidogrel in our study population. Neither the ABCB1 nor the PON1 genotype significantly influenced the antiplatelet effect and clinical outcomes of clopidogrel in these patients"}
{"question_id": "56c1f029ef6e39474100004a", "question": "Is valproic acid effective for glioblastoma treatment?", "retrieved_chunks": [{"doc_id": "23523186", "chunk_id": "23523186_3", "score": 9.02035903930664, "text": "Valproic acid use during radiation therapy for glioblastoma associated with improved survival."}, {"doc_id": "23523186", "chunk_id": "23523186_2", "score": 8.75424575805664, "text": "Valproic acid use during radiation therapy for glioblastoma associated with improved survival"}, {"doc_id": "24328881", "chunk_id": "24328881_1", "score": 8.459839820861816, "text": "Several retrospective studies in seizure patients with glioblastoma treated with chemotherapy have provided evidence for a moderately improved survival with the use of valproic acid, possibly due to inhibition of histone deacetylase."}], "context": "[23523186:23523186_3] Valproic acid use during radiation therapy for glioblastoma associated with improved survival.\n[23523186:23523186_2] Valproic acid use during radiation therapy for glioblastoma associated with improved survival\n[24328881:24328881_1] Several retrospective studies in seizure patients with glioblastoma treated with chemotherapy have provided evidence for a moderately improved survival with the use of valproic acid, possibly due to inhibition of histone deacetylase.", "answer": "<think> Okay, let's tackle this question. The user is asking if valproic acid is effective for glioblastoma treatment. The evidence given has three chunks. First, I need to check each chunk. The first two chunks (23523186:23523186_3 and 23523186:23523186_2) both say that using valproic acid during radiation therapy for glioblastoma is associated with improved survival. The third chunk (24328881:24328881_1) mentions retrospective studies in seizure patients with glioblastoma treated with chemotherapy showing moderately improved survival with valproic acid, possibly due to HDAC inhibition. So, the answer needs to combine these points. The key here is that valproic acid is linked to better outcomes in both radiation therapy and chemotherapy settings. However, the third chunk specifies that this is in patients with seizures, which might be a subset of the overall patient population. But since the question is about glioblastoma treatment in general, the", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if valproic acid is effective for glioblastoma treatment. The evidence given has three chunks. First, I need to check each chunk. The first two chunks (23523186:23523186_3 and 23523186:23523186_2) both say that using valproic acid during radiation therapy for glioblastoma is associated with improved survival. The third chunk (24328881:24328881_1) mentions retrospective studies in seizure patients with glioblastoma treated with chemotherapy showing moderately improved survival with valproic acid, possibly due to HDAC inhibition. So, the answer needs to combine these points. The key here is that valproic acid is linked to better outcomes in both radiation therapy and chemotherapy settings. However, the third chunk specifies that this is in patients with seizures, which might be a subset of the overall patient population. But since the question is about glioblastoma treatment in general, the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if valproic acid is effective for glioblastoma treatment. The evidence given has three chunks. First, I need to check each chunk. The first two chunks are the same: they mention that using valproic acid during radiation therapy for glioblastoma is associated with improved survival. The third chunk talks about retrospective studies in seizure patients with glioblastoma treated with chemotherapy showing moderately improved survival with valproic acid, possibly due to HDAC inhibition. So, the answer needs to combine these points. Valproic acid seems effective in two contexts: during radiation therapy and in chemotherapy settings. The confidence level should be moderate because the evidence is from studies, but maybe not all are prospective. The base_confidence would be around 0.7 since there's some evidence but it's retrospective studies. I need to make sure the answer is concise and cites the relevant chunks. The answer should mention both contexts (radiation and chemotherapy) and the possible mechanism. Then the confidence is a float between 0 and 1. Let me check the JSON structure again. The keys are 'answer' and", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if valproic acid is effective for glioblastoma treatment. The evidence given has three chunks. First, I need to check each chunk. The first two chunks (23523186:23523186_3 and 23523186:23523186_2) both mention that using valproic acid during radiation therapy for glioblastoma is associated with improved survival. The third chunk (24328881:24328881_1) talks about retrospective studies in seizure patients with glioblastoma treated with chemotherapy showing moderately improved survival with valproic acid, possibly due to HDAC inhibition. So, the answer needs to be concise and cite the relevant documents. The first two chunks are duplicates, so maybe they're the same study. The third chunk is another study, but it's about chemotherapy rather than radiation. The question is about treatment effectiveness. Both studies suggest improved survival, but one is during radiation and the other during chemo. However", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["21880994", "23523186", "23680820", "24874578", "24899645", "25066904", "26194676"], "ideal_answer": "Yes, valproic acid prolong survival of glioblastoma patients. Valproic acid is an antiepileptic agent with histone deacetylase inhibitor activity shown to sensitize glioblastoma cells to radiation in preclinical models."}
{"question_id": "56cdf40d5795f9a73e00003d", "question": "Which transcription factor is considered as a master regulator of lysosomal genes?", "retrieved_chunks": [{"doc_id": "25060788", "chunk_id": "25060788_0", "score": 9.593612670898438, "text": "Transcription factor EB (TFEB) is the only known transcription factor that is a master regulator of lysosomal biogenesis although its role in macrophages has not been studied."}, {"doc_id": "22343943", "chunk_id": "22343943_1", "score": 9.345966339111328, "text": "Here, we show that the Transcription Factor EB (TFEB), a master regulator of lysosomal biogenesis, colocalizes with master growth regulator mTOR complex 1 (mTORC1) on the lysosomal membrane."}, {"doc_id": "23604321", "chunk_id": "23604321_1", "score": 9.21290397644043, "text": "the transcription factor EB (TFEB), a master regulator of lysosomal biogenesis and autophagy, is induced by starvation through an autoregulatory feedback loop and exerts a global transcriptional control on lipid catabolism"}], "context": "[25060788:25060788_0] Transcription factor EB (TFEB) is the only known transcription factor that is a master regulator of lysosomal biogenesis although its role in macrophages has not been studied.\n[22343943:22343943_1] Here, we show that the Transcription Factor EB (TFEB), a master regulator of lysosomal biogenesis, colocalizes with master growth regulator mTOR complex 1 (mTORC1) on the lysosomal membrane.\n[23604321:23604321_1] the transcription factor EB (TFEB), a master regulator of lysosomal biogenesis and autophagy, is induced by starvation through an autoregulatory feedback loop and exerts a global transcriptional control on lipid catabolism", "answer": "<think> Okay, let's tackle this question. The user is asking which transcription factor is considered a master regulator of lysosomal genes. The evidence provided has three chunks. First chunk (25060788) says TFEB is the only known transcription factor that's a master regulator of lysosomal biogenesis, though its role in macrophages isn't studied. Second chunk (22343943) mentions TFEB again as a master regulator of lysosomal biogenesis and colocalizes with mTORC1 on lysosomal membranes. Third chunk (23604321) states that TFEB is a master regulator of lysosomal biogenesis and autophagy, induced by starvation and controlling lipid catabolism. All three chunks consistently refer to TFEB as the master regulator. The first one explicitly says \"only known\" which strengthens the answer. The other two support this by mentioning its role in biogenesis and interactions. The question is about lysosomal genes, and the evidence uses \"lysosomal biogenesis,\" which is closely related. So the answer should be TFEB with citations from all three documents. Confidence is high", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which transcription factor is considered a master regulator of lysosomal genes. The evidence provided has three chunks. First chunk (25060788) says TFEB is the only known transcription factor that's a master regulator of lysosomal biogenesis, though its role in macrophages isn't studied. Second chunk (22343943) mentions TFEB again as a master regulator of lysosomal biogenesis and colocalizes with mTORC1 on lysosomal membranes. Third chunk (23604321) states that TFEB is a master regulator of lysosomal biogenesis and autophagy, induced by starvation and controlling lipid catabolism. All three chunks consistently refer to TFEB as the master regulator. The first one explicitly says \"only known\" which strengthens the answer. The other two support this by mentioning its role in biogenesis and interactions. The question is about lysosomal genes, and the evidence uses \"lysosomal biogenesis,\" which is closely related. So the answer should be TFEB with citations from all three documents. Confidence is high", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which transcription factor is considered a master regulator of lysosomal genes. The evidence provided has three chunks. First, I need to look at each chunk to see what they say. The first chunk mentions TFEB as the only known transcription factor that's a master regulator of lysosomal biogenesis, even though its role in macrophages isn't studied. The second chunk repeats that TFEB is a master regulator of lysosomal biogenesis and colocalizes with mTORC1. The third chunk also states that TFEB is a master regulator of lysosomal biogenesis and autophagy, and it's induced by starvation. So all three chunks point to TFEB being the master regulator. The question is about lysosomal genes, and the evidence uses \"lysosomal biogenesis,\" which is related. The answer should be TFEB. The citations are from different documents, but all support TFEB. The confidence can be high since all three sources agree. I need to make sure the answer is concise with the correct citation. The base_confidence should be 1.0 since all evidence points to TFEB without conflicting information", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which transcription factor is considered a master regulator of lysosomal genes. The evidence provided has three chunks. First, I need to look at each chunk to find the answer. The first chunk says TFEB is the only known transcription factor that's a master regulator of lysosomal biogenesis. The second chunk mentions TFEB again as a master regulator of lysosomal biogenesis and colocalizes with mTORC1. The third chunk also refers to TFEB as a master regulator of lysosomal biogenesis and autophagy. All three chunks consistently point to TFEB as the answer. The question is about lysosomal genes, and the evidence uses \"lysosomal biogenesis,\" which is related. The confidence here is high because all three sources agree. So the answer should be TFEB with citations from all three documents. The base confidence can be 1.0 since there's consensus across the evidence. </think> { \"answer\": \"Transcription factor EB (TFEB) [25060788:25060788_0, 223439", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["21617040", "21752829", "21804531", "22343943", "23393155", "23401004", "23457305", "23524842", "23604321", "23609508", "23830905", "25060788", "25315655", "25605940", "25750174"], "ideal_answer": "Transcription factor EB (TFEB) is a master regulator of lysosomal biogenesis and autophagy, driving lysosome adaptation to environmental cues, such as starvation, and therefore targeting of TFEB may provide a novel therapeutic strategy for modulating lysosomal function in human disease."}
{"question_id": "571529efcb4ef8864c000001", "question": "Which antibiotics target peptidoglycan biosynthesis?", "retrieved_chunks": [{"doc_id": "9210483", "chunk_id": "9210483_3", "score": 8.609790802001953, "text": "The lantibiotic mersacidin inhibits peptidoglycan biosynthesis at the level of transglycosylation."}, {"doc_id": "7590155", "chunk_id": "7590155_0", "score": 8.544648170471191, "text": "Bacitracin and other antibiotics that inhibit late stages in peptidoglycan biosynthesis induce vancomycin resistance in a high-level, inducibly vancomycin-resistant strain of Enterococcus faecium."}, {"doc_id": "21867549", "chunk_id": "21867549_1", "score": 8.408501625061035, "text": "Antibiotics which inhibit bacterial peptidoglycan biosynthesis are the most widely used in current clinical practice."}], "context": "[9210483:9210483_3] The lantibiotic mersacidin inhibits peptidoglycan biosynthesis at the level of transglycosylation.\n[7590155:7590155_0] Bacitracin and other antibiotics that inhibit late stages in peptidoglycan biosynthesis induce vancomycin resistance in a high-level, inducibly vancomycin-resistant strain of Enterococcus faecium.\n[21867549:21867549_1] Antibiotics which inhibit bacterial peptidoglycan biosynthesis are the most widely used in current clinical practice.", "answer": "<think> Okay, so the user is asking which antibiotics target peptidoglycan biosynthesis. Let me look at the evidence provided. First, the evidence has three chunks. The first one mentions mersacidin, a lantibiotic that inhibits peptidoglycan biosynthesis at the transglycosylation level. The second chunk talks about bacitracin and other antibiotics that inhibit late stages in peptidoglycan biosynthesis, leading to vancomycin resistance. The third chunk states that antibiotics inhibiting peptidoglycan biosynthesis are the most widely used clinically. The question is about which antibiotics target this process. From the evidence, mersacidin is mentioned as a specific example. Then bacitracin is another one. Also, the third chunk mentions \"antibiotics which inhibit bacterial peptidoglycan biosynthesis\" in general, but the answer needs to be specific. So, the answer should include mersacidin and bacitracin. The first chunk cites [9210483:9210483_3], the second [759", "citations": [{"doc_id": "9210483", "chunk_id": "9210483_3"}], "candidates": [{"answer": "<think> Okay, so the user is asking which antibiotics target peptidoglycan biosynthesis. Let me look at the evidence provided. First, the evidence has three chunks. The first one mentions mersacidin, a lantibiotic that inhibits peptidoglycan biosynthesis at the transglycosylation level. The second chunk talks about bacitracin and other antibiotics that inhibit late stages in peptidoglycan biosynthesis, leading to vancomycin resistance. The third chunk states that antibiotics inhibiting peptidoglycan biosynthesis are the most widely used clinically. The question is about which antibiotics target this process. From the evidence, mersacidin is mentioned as a specific example. Then bacitracin is another one. Also, the third chunk mentions \"antibiotics which inhibit bacterial peptidoglycan biosynthesis\" in general, but the answer needs to be specific. So, the answer should include mersacidin and bacitracin. The first chunk cites [9210483:9210483_3], the second [759", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which antibiotics target peptidoglycan biosynthesis. I need to look at the evidence provided. First, the evidence has three chunks. Let me go through each one. The first chunk [9210483:9210483_3] mentions mersacidin, a lantibiotic that inhibits peptidoglycan biosynthesis at transglycosylation. So mersacidin is an example here. But the question is about which antibiotics, so maybe this is one of them. The second chunk [7590155:7590155_0] talks about bacitracin and other antibiotics that inhibit late stages in peptidoglycan biosynthesis. It also mentions vancomycin resistance, but the key point here is that bacitracin is an antibiotic targeting this process. The third chunk [21867549:21867549_1] states that antibiotics inhibiting peptidoglycan biosynthesis are widely used.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which antibiotics target peptidoglycan biosynthesis. The evidence provided has three chunks. First, chunk 9210483:9210483_3 mentions mersacidin, a lantibiotic that inhibits peptidoglycan biosynthesis at the transglycosylation level. That's a direct example of an antibiotic targeting this process. Next, chunk 7590155:7590155_0 talks about bacitracin and others that inhibit late stages in peptidoglycan biosynthesis, leading to vancomycin resistance. So bacitracin is another example here. The third chunk, 21867549:21867549_1, states that antibiotics inhibiting peptidoglycan biosynthesis are the most widely used clinically. While this supports the idea that such antibiotics are common, it doesn't name specific ones. So the answer needs to list the antibiotics mentioned in the evidence. Mersacidin and bac", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["10801476", "11751110", "12197711", "12440876", "16832063", "18558445", "20515462", "21091161", "21867549", "22280885", "22815801", "2334153", "25224006", "7590155", "7793878", "8891144", "9210483"], "ideal_answer": "Under some conditions, both ramoplanin and vancomycin probes produce helicoid staining patterns along the cylindrical walls of B. subtilis cells. This work has implications for the design of ramoplanin derivatives and may influence how other proposed substrate binding antibiotics are studied. This was confirmed by in vitro studies involving a wall-membrane particulate fraction from Gaffkya homari in which peptidoglycan synthesis from UDP-MurNAc-tetrapeptide was inhibited by ramoplanin but not by vancomycin. New results support a two-state model for septal and peripheral PG synthesis at mid-cell, involvement of essential cell division proteins in PG remodeling, and mid-cell localization of proteins that organize PG biosynthesis and that form the protein translocation apparatus. Antibiotics which inhibit bacterial peptidoglycan biosynthesis are the most widely used in current clinical practice. Cells treated with ampicillin, D-cycloserine, or fosfomycin had only one chloroplast after cell division, suggesting that the cells divided without chloroplast division. The antibiotics bacitracin and vancomycin showed no obvious effect. Colchicine inhibits Closterium cell elongation after division. Surprisingly, also cinnamycin of Streptomyces cinnamoneus cinnamoneus), previously known to bind specifically to phosphatidylethanolamin of biological membranes, provoked strong cell wall biosynthetic stress. Other substances include fluorescent derivatives of two PG-binding antibiotics, vancomycin and ramoplanin. The muraymycins constitute a new antibiotic family whose core structure contains a glycosylated uronic acid derivative joined by an aminopropane group to a hexahydro-2-imino-4-pyrimidylglycyl residue (epicapreomycidine) containing dipeptide that is further extended by a urea-valine moiety. The muraymycins inhibited peptidoglycan biosynthesis. Ramoplanin is a cyclicdepsipeptide antibiotic that inhibits peptidoglycan biosynthesis. The lantibiotic mersacidin inhibits peptidoglycan biosynthesis at the level of transglycosylation. Ramoplanin, a new lipoglycopeptide antibiotic, inhibits cell wall peptidoglycan biosynthesis in gram-positive bacteria."}
{"question_id": "52b2ec744003448f55000001", "question": "Can Levoxyl (levothyroxine sodium) cause insomnia?", "retrieved_chunks": [{"doc_id": "19701833", "chunk_id": "19701833_0", "score": 0.06616200506687164, "text": "METHODS: Seventy-one patients diagnosed with primary hypothyroidism were randomly allocated into two study groups: the first group received usual dose of levothyroxine and the second group received combination of levothyroxine and liothyronine for at least 4 months. The main outcomes were psychosocial problems (Goldberg's General Health Questionnaire, GHQ-28), bodyweight, heart rate, blood pressure, and serum lipid levels. RESULTS: In both groups serum thyroid-stimulating hormone levels remained unchanged compared with baseline. Psychosocial scores, body weight, heart rate, blood pressure, and lipid profile in the two groups remained constant. The only exception was a small but significant reduction in anxiety/insomnia in combined treatment group as compared with monotherapy."}, {"doc_id": "16449486", "chunk_id": "16449486_0", "score": -1.9887151718139648, "text": "Adverse experiences included nausea, dizziness, and insomnia."}, {"doc_id": "36473030", "chunk_id": "36473030_0", "score": -2.662900686264038, "text": "Daridorexant is a novel dual orexin receptor antagonist used in treating insomnia disorder."}], "context": "[19701833:19701833_0] METHODS: Seventy-one patients diagnosed with primary hypothyroidism were randomly allocated into two study groups: the first group received usual dose of levothyroxine and the second group received combination of levothyroxine and liothyronine for at least 4 months. The main outcomes were psychosocial problems (Goldberg's General Health Questionnaire, GHQ-28), bodyweight, heart rate, blood pressure, and serum lipid levels. RESULTS: In both groups serum thyroid-stimulating hormone levels remained unchanged compared with baseline. Psychosocial scores, body weight, heart rate, blood pressure, and lipid profile in the two groups remained constant. The only exception was a small but significant reduction in anxiety/insomnia in combined treatment group as compared with monotherapy.\n[16449486:16449486_0] Adverse experiences included nausea, dizziness, and insomnia.\n[36473030:36473030_0] Daridorexant is a novel dual orexin receptor antagonist used in treating insomnia disorder.", "answer": "<think> Okay, let's tackle this question. The user wants to know if Levoxyl (levothyroxine sodium) can cause insomnia. The evidence provided has three documents. First, looking at document 19701833: It mentions a study with two groups taking levothyroxine either alone or combined with liothyronine. The results say that psychosocial scores, including anxiety and insomnia, were mostly unchanged. However, there was a small significant reduction in anxiety/insomnia in the combined treatment group compared to monotherapy. Wait, so the study found that combining levothyroxine with another hormone led to less insomnia. But the question is about levothyroxine alone causing insomnia. Hmm. The study didn't report insomnia as an issue in either group, but there was a reduction in anxiety/insomnia in the combined group. That's a bit confusing. Maybe the combined treatment had a better effect, but does that mean levothyroxine alone can cause it? Not sure yet. Next, document 16449486: It lists adverse experiences as nausea, dizziness,", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user wants to know if Levoxyl (levothyroxine sodium) can cause insomnia. The evidence provided has three documents. First, looking at document 19701833: It mentions a study with two groups taking levothyroxine either alone or combined with liothyronine. The results say that psychosocial scores, including anxiety and insomnia, were mostly unchanged. However, there was a small significant reduction in anxiety/insomnia in the combined treatment group compared to monotherapy. Wait, so the study found that combining levothyroxine with another hormone led to less insomnia. But the question is about levothyroxine alone causing insomnia. Hmm. The study didn't report insomnia as an issue in either group, but there was a reduction in anxiety/insomnia in the combined group. That's a bit confusing. Maybe the combined treatment had a better effect, but does that mean levothyroxine alone can cause it? Not sure yet. Next, document 16449486: It lists adverse experiences as nausea, dizziness,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, the user is asking if Levoxyl (levothyroxine sodium) can cause insomnia. Let me look at the evidence provided. First, there's the study from 19701833. It mentions that in two groups, one receiving levothyroxine alone and the other with a combination of levothyroxine and liothyronine, there were no significant changes in most outcomes. However, the combined treatment group had a small but significant reduction in anxiety/insomnia compared to monotherapy. Wait, that's interesting. So the study found that combining levothyroxine with another hormone led to less insomnia. But does that mean levothyroxine alone can cause insomnia? Maybe not directly. The study didn't report insomnia as an issue in either group, but the combined group had reduced anxiety/insomnia. Hmm. Then there's another source, 16449486, which lists adverse experiences including insomnia. But that's a general list of adverse effects. However, the study might have been about a different drug or a broader context. Wait, the first study was about", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user wants to know if Levoxyl (levothyroxine sodium) can cause insomnia. The evidence provided has three documents. First, looking at document [19701833:19701833_0], it mentions a study with 71 patients with hypothyroidism. They were divided into two groups: one got levothyroxine alone, the other got levothyroxine plus liothyronine. The results said that psychosocial scores, including anxiety and insomnia, remained constant. However, there was a small significant reduction in anxiety/insomnia in the combined treatment group compared to monotherapy. Wait, so the study found that in the group taking both medications, there was less anxiety and insomnia. But the question is about levothyroxine alone causing insomnia. The study says that in both groups, psychosocial scores were constant. So maybe the combination didn't cause more issues, but the monotherapy group might have had some? Or maybe the combined treatment reduced symptoms. Hmm. Then there's [16449", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["19701833"], "ideal_answer": "Levoxyl monotherapy is associated with increased insomnia compared to a combination of levothyroxine and liothyronine."}
{"question_id": "530e42e65937551c09000007", "question": "Is fatigue prevalent in patients receiving treatment for glioblastoma?", "retrieved_chunks": [{"doc_id": "21514945", "chunk_id": "21514945_1", "score": 6.969281196594238, "text": "This study demonstrated a progressive increase in physical fatigue in patients with glioblastoma relapse treated with irinotecan-bevacizumab."}, {"doc_id": "26902850", "chunk_id": "26902850_2", "score": 5.355546951293945, "text": "CONCLUSIONS: While treatment was well-tolerated, an 8-week course of armodafinil did not improve fatigue or QOL in glioma patients undergoing RT in this pilot study."}, {"doc_id": "26902850", "chunk_id": "26902850_5", "score": 5.135473728179932, "text": "While treatment was well-tolerated, an 8-week course of armodafinil did not improve fatigue or QOL in glioma patients undergoing RT in this pilot study."}], "context": "[21514945:21514945_1] This study demonstrated a progressive increase in physical fatigue in patients with glioblastoma relapse treated with irinotecan-bevacizumab.\n[26902850:26902850_2] CONCLUSIONS: While treatment was well-tolerated, an 8-week course of armodafinil did not improve fatigue or QOL in glioma patients undergoing RT in this pilot study.\n[26902850:26902850_5] While treatment was well-tolerated, an 8-week course of armodafinil did not improve fatigue or QOL in glioma patients undergoing RT in this pilot study.", "answer": "<think> Okay, let's tackle this question. The user is asking if fatigue is prevalent in patients treated for glioblastoma. The evidence given has three chunks. First, chunk 21514945_1 says that a study found a progressive increase in physical fatigue in patients with glioblastoma relapse treated with irinotecan-bevacizumab. That directly supports the idea that fatigue is present and increasing, so that's a strong point. Then there are two chunks from 26902850:21514945_5 and 26902850_5 (though they seem to be duplicates). Both mention that armodafinil didn't improve fatigue or QOL in glioma patients undergoing RT. However, this study's conclusion is about the lack of improvement, not the prevalence. So these chunks indicate that fatigue exists but treatment didn't help, which might imply that fatigue is a common issue. So combining these, the first chunk directly states increased fatigue, and the other two suggest that even with treatment, fatigue isn't improved, implying it's prevalent.", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if fatigue is prevalent in patients treated for glioblastoma. The evidence given has three chunks. First, chunk 21514945_1 says that a study found a progressive increase in physical fatigue in patients with glioblastoma relapse treated with irinotecan-bevacizumab. That directly supports the idea that fatigue is present and increasing, so that's a strong point. Then there are two chunks from 26902850:21514945_5 and 26902850_5 (though they seem to be duplicates). Both mention that armodafinil didn't improve fatigue or QOL in glioma patients undergoing RT. However, this study's conclusion is about the lack of improvement, not the prevalence. So these chunks indicate that fatigue exists but treatment didn't help, which might imply that fatigue is a common issue. So combining these, the first chunk directly states increased fatigue, and the other two suggest that even with treatment, fatigue isn't improved, implying it's prevalent.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, the user is asking if fatigue is common in patients treated for glioblastoma. Let me look at the evidence provided. First, there's a study (21514945:21514945_1) that shows a progressive increase in physical fatigue in patients with glioblastoma relapse treated with irinotecan-bevacizumab. That suggests fatigue is indeed prevalent here. Then there are two entries from 26902850:26902850_2 and 5, both stating that armodafinil didn't improve fatigue or QOL in glioma patients undergoing RT. While this study didn't find improvement, it still indicates that fatigue exists because they were trying to address it. So combining these, the first study directly mentions an increase in fatigue, and the second study implies that fatigue is present enough to be a focus of treatment. The confidence here would be high since there's direct evidence from a study showing increased fatigue. However, the second study's conclusion about no improvement might suggest that fatigue is a persistent issue, but it", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if fatigue is prevalent in patients treated for glioblastoma. I need to look at the evidence provided. First, there's the study with ID 21514945:21514945_1. It says that physical fatigue increases progressively in patients with glioblastoma relapse treated with irinotecan-bevacizumab. That suggests fatigue is a common issue here. Then there's the two entries from 26902850:26902850_2 and 26902850:26902850_5. Both mention that armodafinil didn't improve fatigue or QOL in glioma patients undergoing RT. But wait, this is a pilot study, so maybe the sample size was small. However, the fact that they couldn't improve fatigue might indicate that fatigue is present and not easily addressed by treatment. So combining these points: one study shows increasing fatigue with a specific treatment, another shows that even with a different treatment (armod", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["14649883", "18477765", "18581057", "18758912", "18990027", "19593660", "19904263", "20200024", "20308655", "20510539", "20665891", "20729242", "21514945", "2168357", "21986722", "22079725", "22090453", "22832897", "23086432", "23184145", "23419575", "23422478", "23642624", "3008359"], "ideal_answer": "Yes, fatigue is a common complication of glioblastoma patients receiving chemotherapy or radiotherapy."}
{"question_id": "53358cd2d6d3ac6a3400004e", "question": "List two common features of Tay syndrome.", "retrieved_chunks": [{"doc_id": "18376101", "chunk_id": "18376101_0", "score": 7.093444347381592, "text": "Tay syndrome or IBIDS is a rare autosomal recessive genetic disorder characterized by congenital ichthyosis and abnormal brittle hair (trichothiodystrophy). Other features include photosensitivity, abnormal nails and multiple developmental defects affecting organs mainly derived from neuroectoderm."}, {"doc_id": "10797890", "chunk_id": "10797890_0", "score": 3.905810832977295, "text": "Tay-syndrome is a rare monogen-inherited ektodermal dysplastic syndrome with ichtyosis, fragility of the hair and physical and mental retardation. The congenital ichtyosis is ubiquitous. Only the skin on the flexion side of the extremity joints are not involved (orthocerathosis combined with paraceratotic strings)."}, {"doc_id": "9050052", "chunk_id": "9050052_1", "score": 3.506389856338501, "text": "We present a case of Tay syndrome in which a cranial MRI revealed an almost total lack of myelin within the cerebral hemispheres and a patchy hypomyelination of the cerebellum. In accordance, a strongly prolonged visual evoked response pointed to a dysfunction of the white matter in Tay syndrome."}], "context": "[18376101:18376101_0] Tay syndrome or IBIDS is a rare autosomal recessive genetic disorder characterized by congenital ichthyosis and abnormal brittle hair (trichothiodystrophy). Other features include photosensitivity, abnormal nails and multiple developmental defects affecting organs mainly derived from neuroectoderm.\n[10797890:10797890_0] Tay-syndrome is a rare monogen-inherited ektodermal dysplastic syndrome with ichtyosis, fragility of the hair and physical and mental retardation. The congenital ichtyosis is ubiquitous. Only the skin on the flexion side of the extremity joints are not involved (orthocerathosis combined with paraceratotic strings).\n[9050052:9050052_1] We present a case of Tay syndrome in which a cranial MRI revealed an almost total lack of myelin within the cerebral hemispheres and a patchy hypomyelination of the cerebellum. In accordance, a strongly prolonged visual evoked response pointed to a dysfunction of the white matter in Tay syndrome.", "answer": "<think> Okay, let's tackle this query. The user is asking for two common features of Tay syndrome based on the provided evidence. First, I need to go through each document and extract the relevant information. Looking at the first document: It mentions congenital ichthyosis and abnormal brittle hair (trichothiodystrophy) as key features. Also, photosensitivity, nail abnormalities, and developmental defects in neuroectoderm-derived organs are noted. So that's a few points here. The second document talks about ichtyosis, hair fragility, physical and mental retardation. It also specifies that the congenital ichthyosis is widespread except for the skin on the flexion side of joints. So ichthyosis and hair issues again, plus developmental problems. The third document discusses MRI findings of lack of myelin in cerebral hemispheres and hypomyelination in cerebellum, along with visual evoked response indicating white matter dysfunction. That's more about neurological aspects. Now, the question is to list two common features. The most recurring ones across all documents are congenital ichthyosis (or ichtyosis) and abnormal brittle hair (trich", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this query. The user is asking for two common features of Tay syndrome based on the provided evidence. First, I need to go through each document and extract the relevant information. Looking at the first document: It mentions congenital ichthyosis and abnormal brittle hair (trichothiodystrophy) as key features. Also, photosensitivity, nail abnormalities, and developmental defects in neuroectoderm-derived organs are noted. So that's a few points here. The second document talks about ichtyosis, hair fragility, physical and mental retardation. It also specifies that the congenital ichthyosis is widespread except for the skin on the flexion side of joints. So ichthyosis and hair issues again, plus developmental problems. The third document discusses MRI findings of lack of myelin in cerebral hemispheres and hypomyelination in cerebellum, along with visual evoked response indicating white matter dysfunction. That's more about neurological aspects. Now, the question is to list two common features. The most recurring ones across all documents are congenital ichthyosis (or ichtyosis) and abnormal brittle hair (trich", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user wants two common features of Tay syndrome based on the provided evidence. First, I need to look through the evidence documents. Let me check each one. Document 18376101: It mentions congenital ichthyosis and abnormal brittle hair (trichothiodystrophy) as key features. Also, photosensitivity, nail abnormalities, and developmental defects in neuroectoderm-derived organs. So that's a couple of points here. Document 10797890: Talks about ichtyosis, hair fragility, physical and mental retardation. It also notes that the congenital ichthyosis is widespread except for the skin on flexion sides of joints. So ichthyosis and hair issues are again mentioned here, plus intellectual disability. Document 9050052: This one mentions myelination issues in the brain, like hypomyelination in cerebellum and prolonged visual evoked responses indicating white matter dysfunction. But this seems more specific to the nervous system, maybe not as common as the others. The question asks for two common features. The", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to generate a JSON answer based on the evidence provided for the question about two common features of Tay syndrome. Let me start by reading through the evidence carefully. First, looking at the first document: It mentions congenital ichthyosis and abnormal brittle hair (trichothiodystrophy) as key features. Also, photosensitivity, abnormal nails, and developmental defects in neuroectoderm-derived organs are noted. So ichthyosis and brittle hair are two points here. The second document talks about ichtyosis, fragility of the hair, physical and mental retardation. It also specifies that congenital ichtyosis is widespread except for the skin on the flexion side of joints. So again, ichtyosis and hair fragility are common. The third document discusses myelination issues in the brain and visual evoked response problems, but those seem more specific to the nervous system rather than general features. The question asks for two common features. From the first two documents, ichthyosis (congenital ichtyosis) and brittle hair (trichothiodystrophy or hair fragility) are mentioned in both.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["10797890", "17504703", "18376101", "20687499", "2087835", "6538137", "9050052"], "ideal_answer": "Tay syndrome is a rare autosomal recessive genetic disorder characterized by congenital ichthyosis and trichothiodystrophy (abnormal brittle hair). Other less common features of this syndrome are photosensitivity, low birth weight, short stature, mental retardation, delayed neuromuscular development and other CNS anomalies, dysplasia of nails, hypoplasia of subcutaneous fatty tissue, prematurely aged facial appearance, hypogonadism, cataracts, osteosclerosis, dysphonia, and increased susceptibility to infections."}
{"question_id": "52b2d405f828ad283c000009", "question": "Which cell types are known to be driving Rheumatoid Arthritis?", "retrieved_chunks": [{"doc_id": "16567358", "chunk_id": "16567358_2", "score": 5.197886943817139, "text": "These rheumatoid arthritis synovial fibroblasts (RASFs) constitute a quite unique cell type that distinguishes RA from other inflammatory conditions of the joints"}, {"doc_id": "22586171", "chunk_id": "22586171_0", "score": 4.091127395629883, "text": "Mesenchymal stem cells are conditionally therapeutic in preclinical models of rheumatoid arthritis."}, {"doc_id": "19863844", "chunk_id": "19863844_0", "score": 2.269672393798828, "text": "MSC interaction with B cells provides stimuli for B-cell survival and therefore may contribute to the pathogenesis of rheumatoid arthritis"}], "context": "[16567358:16567358_2] These rheumatoid arthritis synovial fibroblasts (RASFs) constitute a quite unique cell type that distinguishes RA from other inflammatory conditions of the joints\n[22586171:22586171_0] Mesenchymal stem cells are conditionally therapeutic in preclinical models of rheumatoid arthritis.\n[19863844:19863844_0] MSC interaction with B cells provides stimuli for B-cell survival and therefore may contribute to the pathogenesis of rheumatoid arthritis", "answer": "<think> Okay, let's tackle this question. The user is asking which cell types are known to be driving Rheumatoid Arthritis (RA). The evidence provided has three chunks. First chunk [16567358:16567358_2] mentions rheumatoid arthritis synovial fibroblasts (RASFs) as a unique cell type distinguishing RA from other joint inflammatory conditions. That seems directly relevant. So RASFs are definitely a key player here. Second chunk [22586171:22586171_0] talks about mesenchymal stem cells (MSCs) being conditionally therapeutic in preclinical RA models. Wait, the question is about cell types driving RA, not therapies. But MSCs are mentioned here. However, the chunk says they're \"conditionally therapeutic,\" which might imply they have a role, but maybe it's more about their potential as therapy rather than their pathogenic role. But the third chunk [19863844:19863845_0] states that MSC interaction with B", "citations": [{"doc_id": "16567358", "chunk_id": "16567358_2"}, {"doc_id": "22586171", "chunk_id": "22586171_0"}, {"doc_id": "19863844", "chunk_id": "19863845_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which cell types are known to be driving Rheumatoid Arthritis (RA). The evidence provided has three chunks. First chunk [16567358:16567358_2] mentions rheumatoid arthritis synovial fibroblasts (RASFs) as a unique cell type distinguishing RA from other joint inflammatory conditions. That seems directly relevant. So RASFs are definitely a key player here. Second chunk [22586171:22586171_0] talks about mesenchymal stem cells (MSCs) being conditionally therapeutic in preclinical RA models. Wait, the question is about cell types driving RA, not therapies. But MSCs are mentioned here. However, the chunk says they're \"conditionally therapeutic,\" which might imply they have a role, but maybe it's more about their potential as therapy rather than their pathogenic role. But the third chunk [19863844:19863845_0] states that MSC interaction with B", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which cell types are known to drive Rheumatoid Arthritis (RA). The evidence provided has three chunks. First, chunk 16567358:2 mentions rheumatoid arthritis synovial fibroblasts (RASFs) as a unique cell type distinguishing RA from other joint inflammation. That's a direct mention of RASFs being involved. Then chunk 22586171:0 talks about mesenchymal stem cells (MSCs) being conditionally therapeutic in preclinical RA models. So MSCs are mentioned here, but the context is their potential therapeutic role, not necessarily their pathogenic role. However, the question is about cell types driving the disease, so maybe MSCs are involved in the pathology. Chunk 19863844:0 says MSC interaction with B cells contributes to RA pathogenesis. So MSCs interact with B cells, which might be part of the disease mechanism. But the main cell types here are RASFs and MSCs, as per the evidence. Wait, the question is about cell types", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which cell types are known to drive Rheumatoid Arthritis (RA). The evidence provided has three chunks. First, chunk 16567358:2 mentions rheumatoid arthritis synovial fibroblasts (RASFs) as a unique cell type distinguishing RA from other joint inflammations. That's a direct mention of RASFs being involved. Then, chunk 22586171:0 talks about mesenchymal stem cells (MSCs) being conditionally therapeutic in preclinical RA models. So MSCs are mentioned here, but the context is their therapeutic potential, not necessarily their role in driving the disease. However, the next chunk, 19863844:0, says that MSC interaction with B cells contributes to RA pathogenesis. So MSCs are linked to B cells in causing RA. So the answer should include RASFs and MSCs. But wait, the second chunk is about MSCs being therapeutic, but the third chunk connects them to B cells in pathogenesis. The first chunk clearly states R", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["12060849", "15641091", "15692990", "16567358", "17875202", "18613841", "19863844", "20519953", "21160042", "23036591", "24276088"], "ideal_answer": "Macrophages, T cells and their respective cytokines play a pivotal role in RA. Rheumatoid arthritis synovial fibroblasts (RASFs) constitute a quite unique cell type that distinguishes RA from other inflammatory conditions of the joints. Activated synovial fibroblasts (SFs) have the ability to invade joint cartilage, actively contributing to joint destruction in RA."}
{"question_id": "550324d7e9bde6963400002f", "question": "What is the association between personality trait of neuroticism and risk for Alzheimer's disease?", "retrieved_chunks": [{"doc_id": "23040035", "chunk_id": "23040035_1", "score": 6.989013195037842, "text": "Neuroticism (r = 0.26), low agreeableness (r = -0.34), and some facets were also significantly associated with advanced stages of neurofibrillary tangles, but the associations between personality traits and risk of clinical dementia were mostly unchanged by controlling for the extent of neurofibrillary tangles and A� neuritic plaques."}, {"doc_id": "23040035", "chunk_id": "23040035_0", "score": 4.656019687652588, "text": "Individuals with higher baseline scores on vulnerability to stress, anxiety, and depression (neuroticism: odds ratio, 2.0; 95% confidence interval, 1.2-3.5), or lower scores on order and competence (conscientiousness: odds ratio, 0.4; 95% confidence interval, 0.2-0.9) were less likely to remain asymptomatic in the presence of AD neuropathology. Neuroticism (r = 0.26), low agreeableness (r = -0.34), and some facets were also significantly associated with advanced stages of neurofibrillary tangles, but the associations between personality traits and risk of clinical dementia were mostly unchanged by controlling for the extent of neurofibrillary tangles and Aβ neuritic plaques."}, {"doc_id": "10718200", "chunk_id": "10718200_1", "score": 3.856438398361206, "text": "Multiple studies of individuals with Alzheimer disease have substantiated significant levels of informant-rated change in several domains and facets of the Neuroticism-Extraversion-Openness Personality Inventory, including increases in Neuroticism and decreases in Extraversion and Conscientiousness relative to premorbid personality traits."}], "context": "[23040035:23040035_1] Neuroticism (r = 0.26), low agreeableness (r = -0.34), and some facets were also significantly associated with advanced stages of neurofibrillary tangles, but the associations between personality traits and risk of clinical dementia were mostly unchanged by controlling for the extent of neurofibrillary tangles and A� neuritic plaques.\n[23040035:23040035_0] Individuals with higher baseline scores on vulnerability to stress, anxiety, and depression (neuroticism: odds ratio, 2.0; 95% confidence interval, 1.2-3.5), or lower scores on order and competence (conscientiousness: odds ratio, 0.4; 95% confidence interval, 0.2-0.9) were less likely to remain asymptomatic in the presence of AD neuropathology. Neuroticism (r = 0.26), low agreeableness (r = -0.34), and some facets were also significantly associated with advanced stages of neurofibrillary tangles, but the associations between personality traits and risk of clinical dementia were mostly unchanged by controlling for the extent of neurofibrillary tangles and Aβ neuritic plaques.\n[10718200:10718200_1] Multiple studies of individuals with Alzheimer disease have substantiated significant levels of informant-rated change in several domains and facets of the Neuroticism-Extraversion-Openness Personality Inventory, including increases in Neuroticism and decreases in Extraversion and Conscientiousness relative to premorbid personality traits.", "answer": "<think> Okay, let's tackle this question. The user is asking about the association between neuroticism and Alzheimer's disease risk. First, I need to look at the evidence provided. There are three documents here. Let me check each one. Document 23040035: The first chunk says that neuroticism has a correlation of 0.26 with advanced stages of neurofibrillary tangles. But when controlling for those factors and Aβ plaques, the associations with clinical dementia risk didn't change much. The second chunk in the same document mentions that higher neuroticism scores (odds ratio 2.0) are linked to a higher risk of clinical dementia, while lower conscientiousness is associated with lower risk. Also, neuroticism's correlation with tangles remains significant even after adjusting for other factors. Document 10718200: It talks about studies showing increases in Neuroticism and decreases in Extraversion and Conscientiousness in individuals with Alzheimer's compared to their premorbid traits. This suggests that neuroticism might be a trait that's associated with the disease progression, but", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking about the association between neuroticism and Alzheimer's disease risk. First, I need to look at the evidence provided. There are three documents here. Let me check each one. Document 23040035: The first chunk says that neuroticism has a correlation of 0.26 with advanced stages of neurofibrillary tangles. But when controlling for those factors and Aβ plaques, the associations with clinical dementia risk didn't change much. The second chunk in the same document mentions that higher neuroticism scores (odds ratio 2.0) are linked to a higher risk of clinical dementia, while lower conscientiousness is associated with lower risk. Also, neuroticism's correlation with tangles remains significant even after adjusting for other factors. Document 10718200: It talks about studies showing increases in Neuroticism and decreases in Extraversion and Conscientiousness in individuals with Alzheimer's compared to their premorbid traits. This suggests that neuroticism might be a trait that's associated with the disease progression, but", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the association between neuroticism and Alzheimer's disease risk. First, I need to look at the evidence provided. There are three documents here. Let me check each one. Document 23040035: The first chunk says that neuroticism (r = 0.26) is associated with advanced stages of neurofibrillary tangles. But when controlling for those factors, the association with clinical dementia risk didn't change much. The second chunk in the same document mentions that higher neuroticism scores (odds ratio 2.0) are linked to a higher risk of clinical dementia, even after adjusting for neuropathology. So this seems like a direct link. Document 10718200: This talks about changes in personality traits in people with Alzheimer's, showing increases in neuroticism and decreases in other traits. But this is about changes in patients, not necessarily the risk factor. It might indicate that as the disease progresses, neuroticism increases, but it's not clear if that's a cause or effect. So the key points", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to generate a JSON answer based on the evidence provided. The question is about the association between neuroticism and Alzheimer's disease risk. First, looking at the evidence documents. Document 23040035 has two chunks. Chunk 1 mentions that neuroticism (r = 0.26) is associated with advanced stages of neurofibrillary tangles. But when controlling for those factors and Aβ plaques, the association with clinical dementia risk remains mostly unchanged. Chunk 0 says higher neuroticism scores are linked to higher odds of dementia (OR 2.0, 95% CI 1.2-3.5). Also, lower conscientiousness is associated with lower likelihood of remaining asymptomatic with AD neuropathology. Another document, 10718200, says that in Alzheimer's patients, there's an increase in neuroticism compared to premorbid traits. But this is about individuals already diagnosed, so maybe it's a longitudinal study showing progression. So the key points are: higher neuroticism is associated with increased risk of dementia (OR 2", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["10679843", "10718200", "12767492", "15358438", "16252381", "16314587", "16974109", "17244848", "18079420", "18590355", "18694539", "19153372", "20438208", "20973606", "21427641", "21835104", "21905097", "22040898", "23040035", "23079898", "23567438", "23706517", "25274849", "7493597", "9924832"], "ideal_answer": "High neuroticism is associated with increased risk to develop Alzheimer's disease. Greater neuroticism is also associated more advanced Alzheimer's disease neuropathology and younger age of dementia onset. Neuroticism's association with late-life dementia mainly reflects vulnerability to stress and anxiety. Neuroticism moderates the relationship between APOE-4 genotype and cognitive outcomes in elderly. Neuroticism also predicts Mild Cognitive Impairment, Aging-Associated Cognitive Decline and cognitive decline among elderly. Alzheimer's disease patients have greater neuroticism relative to controls."}
{"question_id": "52f125332059c6d71c000007", "question": "What is the mode of action of everolimus?", "retrieved_chunks": [{"doc_id": "16625599", "chunk_id": "16625599_0", "score": 4.762641906738281, "text": "Target of rapamycin inhibitors (TOR-I) (sirolimus, everolimus) are immunosuppressive agents with a novel mode of action"}, {"doc_id": "21279702", "chunk_id": "21279702_0", "score": 4.04683780670166, "text": "Although the mTOR inhibitor everolimus is effective for the treatment of patients who have failed TKI therapy, it is important to consider all available treatment options before switching therapy mode of action."}, {"doc_id": "22136276", "chunk_id": "22136276_1", "score": 1.8632574081420898, "text": "Everolimus is an orally administered inhibitor of the mammalian target of rapamycin (mTOR). Everolimus (starting dosage 3.0 mg/m(2)) was associated with a significant reduction in the volume of the largest subependymal giant cell astrocytoma (SEGA) in 28 patients aged ≥3 years with tuberous sclerosis complex (TSC) in a phase II trial (C2485)."}], "context": "[16625599:16625599_0] Target of rapamycin inhibitors (TOR-I) (sirolimus, everolimus) are immunosuppressive agents with a novel mode of action\n[21279702:21279702_0] Although the mTOR inhibitor everolimus is effective for the treatment of patients who have failed TKI therapy, it is important to consider all available treatment options before switching therapy mode of action.\n[22136276:22136276_1] Everolimus is an orally administered inhibitor of the mammalian target of rapamycin (mTOR). Everolimus (starting dosage 3.0 mg/m(2)) was associated with a significant reduction in the volume of the largest subependymal giant cell astrocytoma (SEGA) in 28 patients aged ≥3 years with tuberous sclerosis complex (TSC) in a phase II trial (C2485).", "answer": "<think> Okay, let's tackle this question about the mode of action of everolimus. The user wants a biomedical answer from the provided evidence, in strict JSON format. First, I need to look at the evidence given. There are three chunks here. Let me go through each one. The first chunk [16625599:16625599_0] says that everolimus is a TOR-I (Target of Rapamycin inhibitor) and has a novel mode of action as an immunosuppressive agent. That's a good starting point. The second chunk [21279702:21279702_0] mentions it's an mTOR inhibitor but doesn't specify the exact mechanism. The third chunk [22136276:22136276_1] states that everolimus inhibits mTOR and gives a specific example of its use in TSC patients. So, combining these, the main point is that everolimus inhibits mTOR. The first chunk mentions TOR-I, which is the same as mTOR", "citations": [{"doc_id": "16625599", "chunk_id": "16625599_0"}, {"doc_id": "21279702", "chunk_id": "21279702_0"}, {"doc_id": "22136276", "chunk_id": "22136276_1"}], "candidates": [{"answer": "<think> Okay, let's tackle this question about the mode of action of everolimus. The user wants a biomedical answer from the provided evidence, in strict JSON format. First, I need to look at the evidence given. There are three chunks here. Let me go through each one. The first chunk [16625599:16625599_0] says that everolimus is a TOR-I (Target of Rapamycin inhibitor) and has a novel mode of action as an immunosuppressive agent. That's a good starting point. The second chunk [21279702:21279702_0] mentions it's an mTOR inhibitor but doesn't specify the exact mechanism. The third chunk [22136276:22136276_1] states that everolimus inhibits mTOR and gives a specific example of its use in TSC patients. So, combining these, the main point is that everolimus inhibits mTOR. The first chunk mentions TOR-I, which is the same as mTOR", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to figure out the mode of action of everolimus based on the provided evidence. Let me look at the evidence again. The first document says that everolimus is a TOR-I, which inhibits the target of rapamycin, and it's an immunosuppressive agent with a novel mode of action. The second mention talks about it being an mTOR inhibitor effective for treating patients who haven't responded to TKI therapy. The third document states that everolimus is an orally administered inhibitor of the mammalian target of rapamycin (mTOR). So, putting this together, the key point is that everolimus inhibits mTOR. The first and third documents both mention mTOR inhibition. The second document refers to it as an mTOR inhibitor as well, even though it's talking about its effectiveness in a specific treatment scenario. The answer should be concise, citing the relevant documents. The base confidence is high because multiple sources point to mTOR inhibition. The confidence level would be 0.95 or so since all three documents support this, but there's no conflicting information. I need to make sure the citation is", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to figure out the mode of action of everolimus based on the provided evidence. Let me look at the evidence again. The first document says that everolimus is a TOR-I (Target of Rapamycin inhibitors) and that it's an immunosuppressive agent with a novel mode of action. So that's a key point. The second document mentions that everolimus is an mTOR inhibitor, which is part of the TOR pathway. The third document also states that everolimus inhibits the mammalian target of rapamycin (mTOR) and talks about its use in a trial for SEGA in TSC patients. Putting this together, the mode of action is that everolimus inhibits mTOR. The first document refers to it as a TOR-I, which is the same as an mTOR inhibitor. The third document explicitly says it's an inhibitor of mTOR. So the answer should be that everolimus inhibits the mTOR pathway. Now, checking the citations. The first document [16625599:16625599_0] mentions TOR-I and", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["16625599", "16699448", "17890266", "18025810", "19299048", "19620795", "20384580", "21279702", "22139982", "24183081"], "ideal_answer": "Everolimus is a drug that binds to mTORC1 and inhibits activation of the mTOR signalling pathway. It is used in targeted cancer therapy protocols or after transplantation for maintenance immunosuppression, against allograft rejection."}
{"question_id": "5158a5b8d24251bc05000097", "question": "Have Quantitative Trait Loci affecting splicing (splicing QTLs) been linked to disease?", "retrieved_chunks": [{"doc_id": "24586654", "chunk_id": "24586654_0", "score": 3.467390537261963, "text": "Quantitative trait locus (QTL) analysis identified seven genomic loci influencing fibrosis phenotypes (pQTLs) with genome-wide significance on chromosomes 4, 5, 7, 12, and 17."}, {"doc_id": "18464913", "chunk_id": "18464913_1", "score": 2.7305212020874023, "text": "The identification of protein quantitative trait loci (pQTLs) may be a powerful complementary method of improving our understanding of disease pathways."}, {"doc_id": "25480033", "chunk_id": "25480033_0", "score": -0.12967151403427124, "text": "By studying the genetic variation affecting gene expression levels (cis expression quantitative trait loci [cis-eQTLs]) and protein levels (cis protein QTLs [cis-pQTLs]), we determined that young, primate-specific genes are enriched in cis-eQTLs and cis-pQTLs."}], "context": "[24586654:24586654_0] Quantitative trait locus (QTL) analysis identified seven genomic loci influencing fibrosis phenotypes (pQTLs) with genome-wide significance on chromosomes 4, 5, 7, 12, and 17.\n[18464913:18464913_1] The identification of protein quantitative trait loci (pQTLs) may be a powerful complementary method of improving our understanding of disease pathways.\n[25480033:25480033_0] By studying the genetic variation affecting gene expression levels (cis expression quantitative trait loci [cis-eQTLs]) and protein levels (cis protein QTLs [cis-pQTLs]), we determined that young, primate-specific genes are enriched in cis-eQTLs and cis-pQTLs.", "answer": "<think> Okay, let's tackle this question. The user is asking if Quantitative Trait Loci affecting splicing (splicing QTLs) have been linked to disease. The evidence provided includes three references. First, I need to check each piece of evidence. The first reference talks about pQTLs (protein QTLs) related to fibrosis phenotypes. But the question is about splicing QTLs, not protein levels or fibrosis specifically. So maybe this isn't directly relevant. The second reference mentions pQTLs as a method to understand disease pathways. While it's about pQTLs, the question is about splicing QTLs. Splicing QTLs are different because they affect alternative splicing, which is a separate aspect of gene regulation. So this might not directly answer the question either. The third reference discusses cis-eQTLs and cis-pQTLs related to gene expression and protein levels in young primate-specific genes. Again, this is about expression and protein levels, not splicing. Wait, none of the evidence explicitly mentions splicing QTLs. The term \"splicing QTLs\" isn", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if Quantitative Trait Loci affecting splicing (splicing QTLs) have been linked to disease. The evidence provided includes three references. First, I need to check each piece of evidence. The first reference talks about pQTLs (protein QTLs) related to fibrosis phenotypes. But the question is about splicing QTLs, not protein levels or fibrosis specifically. So maybe this isn't directly relevant. The second reference mentions pQTLs as a method to understand disease pathways. While it's about pQTLs, the question is about splicing QTLs. Splicing QTLs are different because they affect alternative splicing, which is a separate aspect of gene regulation. So this might not directly answer the question either. The third reference discusses cis-eQTLs and cis-pQTLs related to gene expression and protein levels in young primate-specific genes. Again, this is about expression and protein levels, not splicing. Wait, none of the evidence explicitly mentions splicing QTLs. The term \"splicing QTLs\" isn", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if Quantitative Trait Loci affecting splicing (splicing QTLs) have been linked to disease. The evidence provided includes three references. First, I need to check each reference for any mention of splicing QTLs or their link to disease. Looking at the first evidence: [24586654:24586654_0] talks about QTLs influencing fibrosis phenotypes on specific chromosomes. But it's about fibrosis, not splicing. Also, it mentions pQTLs (protein QTLs), but not splicing specifically. Second evidence: [18464913:18464913_1] discusses pQTLs as a method to understand disease pathways. It's general and doesn't mention splicing. Third evidence: [25480033:25480033_0] talks about cis-eQTLs and cis-pQTLs related to gene expression and protein levels in young primate-specific genes. Again,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if Quantitative Trait Loci affecting splicing (splicing QTLs) have been linked to disease. The evidence provided includes three different studies. First, I need to check each of the evidence points. The first one mentions pQTLs related to fibrosis phenotypes, but it's about fibrosis, not splicing. The second study talks about pQTLs as a method to understand disease pathways, which is relevant but doesn't specifically mention splicing. The third study discusses cis-eQTLs and cis-pQTLs related to gene expression and protein levels, but again, not splicing. Wait, the question is about splicing QTLs. None of the evidence directly mentions splicing. The closest is the second study mentioning pQTLs in general, which are protein quantitative trait loci. However, splicing QTLs are a specific type of QTL that affects alternative splicing. Since the provided evidence doesn't mention splicing, I can't directly link any of the studies to splicing QTLs and disease. The answer needs to be concise with citations", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["20707912", "20856809", "21846806", "22784570"], "ideal_answer": "Yes, mutations in the DNA that affect the splicing pattern of genes have been linked in transcriptome population studies to a number of diseases."}
{"question_id": "553653a5bc4f83e828000007", "question": "Which technique is used for detection of EWS/FLI1 fusion transcripts?", "retrieved_chunks": [{"doc_id": "16157025", "chunk_id": "16157025_0", "score": 8.568425178527832, "text": "Molecular detection of EWS-Fli1 fusion transcripts in formalin-fixed paraffin-embedded material by nested RT-PCR is feasible and is useful for the diagnosis and differential diagnosis of ES/pPNETs."}, {"doc_id": "15565546", "chunk_id": "15565546_0", "score": 7.7695841789245605, "text": "Using our different sets of exon specific primer pairs, it was possible to detect 4 different breakpoints of ews/fli1 fusion transcripts and the ews/erg fusion by RT-PCR in RNA isolates from formalin-fixed, paraffin-embedded Ewing's tumor tissue."}, {"doc_id": "15363317", "chunk_id": "15363317_0", "score": 7.717473983764648, "text": "[Detection of EWS-FLI1 fusion transcript in Ewing's sarcoma/peripheral primitive neuroectodermal tumors by one-step RT-PCR using paraffin-embedded tissues]."}], "context": "[16157025:16157025_0] Molecular detection of EWS-Fli1 fusion transcripts in formalin-fixed paraffin-embedded material by nested RT-PCR is feasible and is useful for the diagnosis and differential diagnosis of ES/pPNETs.\n[15565546:15565546_0] Using our different sets of exon specific primer pairs, it was possible to detect 4 different breakpoints of ews/fli1 fusion transcripts and the ews/erg fusion by RT-PCR in RNA isolates from formalin-fixed, paraffin-embedded Ewing's tumor tissue.\n[15363317:15363317_0] [Detection of EWS-FLI1 fusion transcript in Ewing's sarcoma/peripheral primitive neuroectodermal tumors by one-step RT-PCR using paraffin-embedded tissues].", "answer": "<think> Okay, let's tackle this question. The user is asking which technique is used for detecting EWS/FLI1 fusion transcripts. The evidence provided has three documents. First, I need to look at each document to see what technique they mention. Document 16157025: It mentions nested RT-PCR for detecting EWS-Fli1 fusion transcripts in paraffin-embedded tissues. That's a technique called nested RT-PCR. Document 15565546: This talks about using exon-specific primer pairs to detect 4 breakpoints and the EWS/ERG fusion with RT-PCR. So here, RT-PCR is mentioned, but they used specific primers. However, the question is about EWS/FLI1 specifically. Document 15363317: This one says one-step RT-PCR using paraffin-embedded tissues. So that's another method, one-step RT-PCR. Now, the answer needs to be concise with citations. The question is about EWS/FLI1, so I should focus on which technique is used. Looking", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which technique is used for detecting EWS/FLI1 fusion transcripts. The evidence provided has three documents. First, I need to look at each document to see what technique they mention. Document 16157025: It mentions nested RT-PCR for detecting EWS-Fli1 fusion transcripts in paraffin-embedded tissues. That's a technique called nested RT-PCR. Document 15565546: This talks about using exon-specific primer pairs to detect 4 breakpoints and the EWS/ERG fusion with RT-PCR. So here, RT-PCR is mentioned, but they used specific primers. However, the question is about EWS/FLI1 specifically. Document 15363317: This one says one-step RT-PCR using paraffin-embedded tissues. So that's another method, one-step RT-PCR. Now, the answer needs to be concise with citations. The question is about EWS/FLI1, so I should focus on which technique is used. Looking", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let me tackle this question. The user is asking which technique is used for detecting EWS/FLI1 fusion transcripts. The evidence provided has three documents. First, I need to look at each document to see what techniques they mention. Document 16157025:16157025_0 talks about nested RT-PCR for detecting EWS-Fli1 in formalin-fixed paraffin-embedded (FFPE) material. That's a technique mentioned here. Then document 15565546:15565546_0 mentions using different exon-specific primer pairs to detect 4 breakpoints of EWS/FLI1 and EWS/ERG fusion transcripts via RT-PCR in RNA from FFPE tissue. So RT-PCR is the technique here, but they used specific primers. Document 15363317:15363317_0 refers to one-step RT-PCR using paraffin-embedded tissues for detecting EWS-FLI1 fusion transcripts. One-step RT-PCR is another method mentioned here", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which technique is used for detecting EWS/FLI1 fusion transcripts. The evidence provided has three documents. First, I need to look at each document to see what technique they mention. Document 16157025: It says molecular detection using nested RT-PCR in formalin-fixed paraffin-embedded material. That's a specific method. Document 15565546 mentions using different exon-specific primer pairs with RT-PCR to detect the fusion transcripts. So that's also RT-PCR, but maybe with specific primers. Document 15363317 talks about one-step RT-PCR using paraffin-embedded tissues. So all three documents mention RT-PCR variants: nested RT-PCR, RT-PCR with specific primers, and one-step RT-PCR. The question is asking for the technique used. The answer needs to be concise and cite the documents. The key here is that all the evidence points to RT-PCR as the technique, but with variations. However, the most direct mention is in", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["10379685", "15363317", "15565546", "16157025", "17154184", "20231617", "23475435", "24293381", "9135495", "9552022"], "ideal_answer": "Molecular detection of EWS-FLI1 chimeric transcripts in Ewing family tumors is carried out by reverse transcription-polymerase chain reaction (RT-PCR)."}
{"question_id": "5344310baeec6fbd0700000c", "question": "Does the CTCF protein co-localize with cohesin?", "retrieved_chunks": [{"doc_id": "22952237", "chunk_id": "22952237_0", "score": 8.85129451751709, "text": "Recent genome-wide studies mapping the binding sites of CTCF and its interacting partner, cohesin, using chromatin immunoprecipitation coupled with deep sequencing (ChIP-seq) revealded that CTCF globally co-localizes with cohesin"}, {"doc_id": "28368372", "chunk_id": "28368372_2", "score": 7.01765251159668, "text": "Using an in vivo biotinylation tagging approach in mice, we show that the nucleotide excision repair (NER) structure-specific endonuclease ERCC1-XPF complex interacts with the insulator binding protein CTCF, the cohesin subunits SMC1A and SMC3 and with MBD2; the factors co-localize with ATRX at the promoters and control regions (ICRs) of imprinted genes during postnatal hepatic development. Loss of Ercc1 or exposure to MMC triggers the localization of CTCF to heterochromatin, the dissociation of the CTCF-cohesin complex and ATRX from promoters and ICRs, altered histone marks and the aberrant developmental expression of imprinted genes without altering DNA methylation. We propose that ERCC1-XPF cooperates with CTCF and cohesin to facilitate the developmental silencing of imprinted genes and that persistent DNA damage triggers chromatin changes that affect gene expression programs associated with NER disorders."}, {"doc_id": "21550623", "chunk_id": "21550623_0", "score": 6.858308792114258, "text": "CTCF colocalizes with cohesin but not RNA Polymerase II."}], "context": "[22952237:22952237_0] Recent genome-wide studies mapping the binding sites of CTCF and its interacting partner, cohesin, using chromatin immunoprecipitation coupled with deep sequencing (ChIP-seq) revealded that CTCF globally co-localizes with cohesin\n[28368372:28368372_2] Using an in vivo biotinylation tagging approach in mice, we show that the nucleotide excision repair (NER) structure-specific endonuclease ERCC1-XPF complex interacts with the insulator binding protein CTCF, the cohesin subunits SMC1A and SMC3 and with MBD2; the factors co-localize with ATRX at the promoters and control regions (ICRs) of imprinted genes during postnatal hepatic development. Loss of Ercc1 or exposure to MMC triggers the localization of CTCF to heterochromatin, the dissociation of the CTCF-cohesin complex and ATRX from promoters and ICRs, altered histone marks and the aberrant developmental expression of imprinted genes without altering DNA methylation. We propose that ERCC1-XPF cooperates with CTCF and cohesin to facilitate the developmental silencing of imprinted genes and that persistent DNA damage triggers chromatin changes that affect gene expression programs associated with NER disorders.\n[21550623:21550623_0] CTCF colocalizes with cohesin but not RNA Polymerase II.", "answer": "<think> Okay, let's tackle this question. The user is asking if the CTCF protein co-localizes with cohesin. I need to look at the evidence provided and see which sources support that. First, looking at the first evidence chunk: [22952237:22952237_0] says that genome-wide studies using ChIP-seq showed CTCF globally co-localizes with cohesin. That's a direct statement. The confidence here is pretty high because it's a study using a method (ChIP-seq) that's commonly used for such purposes. Then there's [21550623:21550623_0], which states that CTCF colocalizes with cohesin but not RNA Polymerase II. This is another direct confirmation, so that adds more support. However, the third chunk [28368372:28368372_2] talks about interactions with other proteins like ERCC1-XPF and ATRX, but it also mentions that CTCF's localization", "citations": [{"doc_id": "22952237", "chunk_id": "22952237_0"}, {"doc_id": "21550623", "chunk_id": "21550623_0"}, {"doc_id": "28368372", "chunk_id": "28368372_2"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if the CTCF protein co-localizes with cohesin. I need to look at the evidence provided and see which sources support that. First, looking at the first evidence chunk: [22952237:22952237_0] says that genome-wide studies using ChIP-seq showed CTCF globally co-localizes with cohesin. That's a direct statement. The confidence here is pretty high because it's a study using a method (ChIP-seq) that's commonly used for such purposes. Then there's [21550623:21550623_0], which states that CTCF colocalizes with cohesin but not RNA Polymerase II. This is another direct confirmation, so that adds more support. However, the third chunk [28368372:28368372_2] talks about interactions with other proteins like ERCC1-XPF and ATRX, but it also mentions that CTCF's localization", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if the CTCF protein co-localizes with cohesin. I need to look at the provided evidence to find the answer. First, looking at the evidence documents. The first one, 22952237:22952237_0, says that genome-wide studies using ChIP-seq showed CTCF globally co-localizes with cohesin. That's a direct statement. Then there's another document, 21550623:21550623_0, which also states that CTCF colocalizes with cohesin but not RNA Polymerase II. So both of these documents support the answer \"yes\". The third document, 28368372:28368372_2, talks about interactions between ERCC1-XPF and CTCF, cohesin subunits, and others, but it mentions that CTCF's localization to heterochromatin and dissociation of the complex occur under certain conditions. However, this", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if the CTCF protein co-localizes with cohesin. I need to look at the provided evidence to find the answer. First, looking at the evidence documents. The first one, 22952237:22952237_0, says that genome-wide studies using ChIP-seq showed CTCF globally co-localizes with cohesin. That's a direct statement. Then there's another document, 21550623:21550623_0, which also states that CTCF colocalizes with cohesin but not RNA Polymerase II. So two sources here confirm the co-localization. The third document, 28368372:28368372_2, talks about interactions between ERCC1-XPF and CTCF, cohesin subunits, and others, but it mentions that CTCF's localization to heterochromatin might happen under certain conditions. However, the main point here is that in normal", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["18550811", "18623068", "19109133", "19158269", "19308701", "19369356", "20133600", "20219941", "21106760", "21444719", "21606361", "21628529", "21876668", "21880767", "21948239", "21970734", "22440186", "22550178", "22780989", "22952237", "23010778", "23204437", "23295672", "23498937", "23804403", "23945083", "24257606", "24321385"], "ideal_answer": "Recent genome-wide studies mapping the binding sites of CTCF and its interacting partner, cohesin, using chromatin immunoprecipitation coupled with deep sequencing (ChIP-seq) revealded that CTCF globally co-localizes with cohesin. Recent genome-wide studies mapping the binding sites of CTCF and its interacting partner, cohesin, using chromatin immunoprecipitation coupled with deep sequencing (ChIP-seq) revealded that CTCF globally co-localizes with cohesin"}
{"question_id": "56c868a95795f9a73e000017", "question": "What is the application of the Bimolecular Fluorescence Complementation (BiFC) assay in Drosophila embryos?", "retrieved_chunks": [{"doc_id": "25151172", "chunk_id": "25151172_0", "score": 8.351340293884277, "text": "Bimolecular fluorescence complementation (BiFC) is a powerful method for studying protein-protein interactions in different cell types and organisms. This method was recently developed in the fruit fly Drosophila melanogaster, allowing analyzing protein interaction properties in a physiologically relevant developing context. Here we present a detailed protocol for performing BiFC with the Venus fluorescent protein in live Drosophila embryos, taking the Hox-PBC partnership as an illustrative test case. This protocol applies to any transcription factor and split fluorescent protein in general."}, {"doc_id": "21276241", "chunk_id": "21276241_3", "score": 8.002887725830078, "text": "The bimolecular fluorescence complementation (BiFC) technology offers this possibility as it enables the direct visualization of protein interactions in living cells. However, its potential has rarely been applied in embryos of animal model organisms and was only performed under transient protein expression levels."}, {"doc_id": "19771334", "chunk_id": "19771334_0", "score": 7.822848320007324, "text": "The bimolecular fluorescence complementation (BiFC) assay provides an approach for the visualization of protein interactions and modifications in living cells."}], "context": "[25151172:25151172_0] Bimolecular fluorescence complementation (BiFC) is a powerful method for studying protein-protein interactions in different cell types and organisms. This method was recently developed in the fruit fly Drosophila melanogaster, allowing analyzing protein interaction properties in a physiologically relevant developing context. Here we present a detailed protocol for performing BiFC with the Venus fluorescent protein in live Drosophila embryos, taking the Hox-PBC partnership as an illustrative test case. This protocol applies to any transcription factor and split fluorescent protein in general.\n[21276241:21276241_3] The bimolecular fluorescence complementation (BiFC) technology offers this possibility as it enables the direct visualization of protein interactions in living cells. However, its potential has rarely been applied in embryos of animal model organisms and was only performed under transient protein expression levels.\n[19771334:19771334_0] The bimolecular fluorescence complementation (BiFC) assay provides an approach for the visualization of protein interactions and modifications in living cells.", "answer": "<think> Okay, let's tackle this question. The user is asking about the application of the Bimolecular Fluorescence Complementation (BiFC) assay in Drosophila embryos. First, I need to look at the evidence provided. There are three documents here. Let me go through each one. The first document [25151172:25151172_0] says that BiFC was developed in Drosophila melanogaster to analyze protein interactions in a physiologically relevant context. It mentions using Venus fluorescent protein in live embryos with Hox-PBC as an example. So this suggests that the application is studying protein-protein interactions in developing embryos. The second document [21276241:21276241_3] states that BiFC allows visualization of protein interactions in living cells but notes that its use in animal embryos is rare and usually under transient expression. So this indicates that while it's possible, it's not commonly applied in embryos. The third document [19771334:19771334_0", "citations": [{"doc_id": "25151172", "chunk_id": "25151172_0"}, {"doc_id": "21276241", "chunk_id": "21276241_3"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking about the application of the Bimolecular Fluorescence Complementation (BiFC) assay in Drosophila embryos. First, I need to look at the evidence provided. There are three documents here. Let me go through each one. The first document [25151172:25151172_0] says that BiFC was developed in Drosophila melanogaster to analyze protein interactions in a physiologically relevant context. It mentions using Venus fluorescent protein in live embryos with Hox-PBC as an example. So this suggests that the application is studying protein-protein interactions in developing embryos. The second document [21276241:21276241_3] states that BiFC allows visualization of protein interactions in living cells but notes that its use in animal embryos is rare and usually under transient expression. So this indicates that while it's possible, it's not commonly applied in embryos. The third document [19771334:19771334_0", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the application of the Bimolecular Fluorescence Complementation (BiFC) assay in Drosophila embryos. First, I need to look at the evidence provided. There are three documents here. Let me go through each one. The first document [25151172:25151172_0] says that BiFC was developed in Drosophila melanogaster to analyze protein interactions in a physiologically relevant context. It mentions using Venus fluorescent protein in live embryos with Hox-PBC as an example. So this is about applying BiFC in embryos to study interactions. The second document [21276241:21276241_3] states that BiFC allows visualization of protein interactions in living cells but notes it's rarely applied in animal embryos and was done under transient expression. So this suggests that while there's potential, it's not commonly used in embryos. The third document [19771334:19771334_0] mentions Bi", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to generate a candidate biomedical answer based on the provided evidence. Let me start by understanding the question: What is the application of the Bimolecular Fluorescence Complementation (BiFC) assay in Drosophila embryos? First, I'll look at the evidence given. There are three documents mentioned. Let me go through each one to find relevant information. The first document [25151172:25151172_0] says that BiFC is used to study protein-protein interactions in different cell types and organisms, specifically mentioning Drosophila melanogaster. It talks about analyzing interaction properties in a physiologically relevant developing context, using Hox-PBC as an example. The protocol applies to any transcription factor and split fluorescent protein. The second document [21276241:21276241_3] mentions that BiFC allows direct visualization of protein interactions in living cells but notes that its application in animal embryos is rare and usually under transient expression. Third document [19771334:197713", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["16454041", "17406412", "17534848", "18155474", "18573091", "19771334", "21091444", "21276241", "23317900", "25151172"], "ideal_answer": "Bimolecular fluorescence complementation (BiFC) is a powerful method for studying protein-protein interactions in different cell types and organisms. This method was recently developed in the fruit fly Drosophila melanogaster, allowing analyzing protein interaction properties in a physiologically relevant developing context."}
{"question_id": "54dcb29dc0bb8dce23000004", "question": "Which pathological condition of the heart is known as hypertrophic cardiomyopathy (HCM)?", "retrieved_chunks": [{"doc_id": "21507890", "chunk_id": "21507890_0", "score": 8.439990043640137, "text": "Hypertrophic cardiomyopathy (HCM) is a clinically heterogeneous autosomal dominant heart disease characterised by left ventricular hypertrophy in the absence of another cardiac or systemic disease that is capable of producing significant wall thickening."}, {"doc_id": "23782526", "chunk_id": "23782526_0", "score": 7.941522598266602, "text": "Hypertrophic cardiomyopathy (HCM) is a clinically heterogeneous genetic heart disease characterized by left ventricular hypertrophy in the absence of another disease that could explain the wall thickening."}, {"doc_id": "22665960", "chunk_id": "22665960_0", "score": 7.792171955108643, "text": "Hypertrophic cardiomyopathy (HCM) is an autosomal dominant inherited genetic disease characterized by compensatory pathological left ventricle (LV) hypertrophy due to sarcomere dysfunction."}], "context": "[21507890:21507890_0] Hypertrophic cardiomyopathy (HCM) is a clinically heterogeneous autosomal dominant heart disease characterised by left ventricular hypertrophy in the absence of another cardiac or systemic disease that is capable of producing significant wall thickening.\n[23782526:23782526_0] Hypertrophic cardiomyopathy (HCM) is a clinically heterogeneous genetic heart disease characterized by left ventricular hypertrophy in the absence of another disease that could explain the wall thickening.\n[22665960:22665960_0] Hypertrophic cardiomyopathy (HCM) is an autosomal dominant inherited genetic disease characterized by compensatory pathological left ventricle (LV) hypertrophy due to sarcomere dysfunction.", "answer": "<think> Okay, so the user is asking which pathological condition of the heart is known as hypertrophic cardiomyopathy (HCM). Let me look at the evidence provided. The first document says HCM is a clinically heterogeneous autosomal dominant heart disease with left ventricular hypertrophy and no other disease causing the thickening. The second one mentions it's a genetic heart disease with the same symptoms. The third one adds that it's an inherited condition due to sarcomere dysfunction. All three sources define HCM as a condition characterized by left ventricular hypertrophy without another cause. The key here is that HCM is already the name of the condition, so the answer should be that HCM itself is the pathological condition. The citations are all from different documents but they all confirm the definition. The confidence can be high since all three sources agree. So the answer is Hypertrophic cardiomyopathy (HCM) is the condition, and the confidence is 1.0 as all evidence points to that. </think> { \"answer\": \"Hypertrophic cardiomyopathy (HCM) is a pathological condition characterized by left ventricular hypertrophy in the absence of other", "citations": [], "candidates": [{"answer": "<think> Okay, so the user is asking which pathological condition of the heart is known as hypertrophic cardiomyopathy (HCM). Let me look at the evidence provided. The first document says HCM is a clinically heterogeneous autosomal dominant heart disease with left ventricular hypertrophy and no other disease causing the thickening. The second one mentions it's a genetic heart disease with the same symptoms. The third one adds that it's an inherited condition due to sarcomere dysfunction. All three sources define HCM as a condition characterized by left ventricular hypertrophy without another cause. The key here is that HCM is already the name of the condition, so the answer should be that HCM itself is the pathological condition. The citations are all from different documents but they all confirm the definition. The confidence can be high since all three sources agree. So the answer is Hypertrophic cardiomyopathy (HCM) is the condition, and the confidence is 1.0 as all evidence points to that. </think> { \"answer\": \"Hypertrophic cardiomyopathy (HCM) is a pathological condition characterized by left ventricular hypertrophy in the absence of other", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's see. The user is asking which pathological condition of the heart is known as hypertrophic cardiomyopathy (HCM). The evidence provided has three chunks. First, I need to check each chunk to find the answer. The question is about defining HCM. The first chunk says it's a clinically heterogeneous autosomal dominant heart disease with left ventricular hypertrophy and no other disease causing thickening. The second chunk is similar but mentions genetic. The third one says it's an autosomal dominant inherited genetic disease with compensatory LV hypertrophy due to sarcomere dysfunction. So, all three chunks define HCM as a condition with left ventricular hypertrophy, but they add different details like autosomal dominant, genetic, and sarcomere dysfunction. The answer needs to be concise and cite the documents. Since all three are talking about HCM, I need to pick one. Maybe the first chunk is the main one. But wait, the third chunk mentions sarcomere dysfunction, which is a key pathophysiological feature. However, the question is about the pathological condition, so maybe the answer is just that it's a disease characterized by left ventricular", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which pathological condition of the heart is known as hypertrophic cardiomyopathy (HCM). The evidence provided has three documents. First, I need to understand what each document says. All three mention HCM as a genetic or inherited disease with left ventricular hypertrophy. Document 21507890:21507890_0 states it's an autosomal dominant heart disease with left ventricular hypertrophy without another disease causing the thickening. Document 23782526:23782526_0 also mentions genetic HCM with similar characteristics. Document 22665960:22665960_0 says it's an autosomal dominant inherited genetic disease with compensatory LV hypertrophy due to sarcomere dysfunction. So, all three sources agree that HCM is a genetic condition characterized by left ventricular hypertrophy without other diseases causing it. The key here is that the answer should be the name of the condition, which is already given as hypertrophic cardiomyopathy (H", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["21507890", "22665960", "23782526", "25044876", "25081404", "25191275", "25209314", "25228955", "25309450", "25328416"], "ideal_answer": "Hypertrophic cardiomyopathy (HCM) has been recently recognized as the most common inherited cardiovascular disorder, affecting 1 in 500 adults worldwide. HCM is characterized by myocyte hypertrophy resulting in thickening of the ventricular wall, myocyte disarray, interstitial and/or replacement fibrosis, decreased ventricular cavity volume and diastolic dysfunction. HCM is also the most common cause of sudden death in the young particularly among athletes. A large proportion of patients diagnosed with HCM have mutations in sarcomeric proteins. HCM is the most prevalent genetic disorder affecting the heart and is typically inherited in an autosomal dominant pattern. Adults with cardiomyopathy suffer SCD or adverse events such as stroke and heart failure from HCM."}
{"question_id": "516e5f41298dcd4e5100007f", "question": "What is the genetic basis of Rubinstein-Taybi syndrome?", "retrieved_chunks": [{"doc_id": "15706485", "chunk_id": "15706485_1", "score": 5.573284149169922, "text": "Genetic heterogeneity in Rubinstein-Taybi syndrome: mutations in both the CBP and EP300 genes cause disease"}, {"doc_id": "16359492", "chunk_id": "16359492_1", "score": 5.386285305023193, "text": "Mutations in the CREBBP (CREB-binding protein gene) cause Rubinstein-Taybi syndrome (RSTS)."}, {"doc_id": "20689175", "chunk_id": "20689175_1", "score": 4.817389965057373, "text": "Rubinstein-Taybi syndrome (RSTS), a developmental disorder comprising abnormalities that include mental retardation, an unusual facial appearance, broad thumbs and big toes is frequently associated with molecular lesions in the CREB-binding protein gene, CREBBP"}], "context": "[15706485:15706485_1] Genetic heterogeneity in Rubinstein-Taybi syndrome: mutations in both the CBP and EP300 genes cause disease\n[16359492:16359492_1] Mutations in the CREBBP (CREB-binding protein gene) cause Rubinstein-Taybi syndrome (RSTS).\n[20689175:20689175_1] Rubinstein-Taybi syndrome (RSTS), a developmental disorder comprising abnormalities that include mental retardation, an unusual facial appearance, broad thumbs and big toes is frequently associated with molecular lesions in the CREB-binding protein gene, CREBBP", "answer": "<think> Okay, I need to generate a JSON answer about the genetic basis of Rubinstein-Taybi syndrome based on the provided evidence. Let me look at the evidence first. The user provided three references. The first one says that there's genetic heterogeneity, with mutations in both CBP and EP300 genes causing the disease. The second mentions CREBBP gene mutations cause RSTS. The third also points to CREB-binding protein gene (CREBBP) lesions being associated with RSTS. So, the answer should mention the genes involved. From the evidence, CREBBP is mentioned in two sources, and CBP (which is the same as CREBBP?) and EP300 are mentioned in the first source. Wait, CBP and EP300 are different genes. The first reference says mutations in both CBP and EP300 cause the disease. But the other references talk about CREBBP. Wait, maybe CBP is the same as CREBBP? Because CREBBP is the gene that codes for CREB-binding protein, which is also known as CBP. So, the first reference says mutations in both CBP", "citations": [], "candidates": [{"answer": "<think> Okay, I need to generate a JSON answer about the genetic basis of Rubinstein-Taybi syndrome based on the provided evidence. Let me look at the evidence first. The user provided three references. The first one says that there's genetic heterogeneity, with mutations in both CBP and EP300 genes causing the disease. The second mentions CREBBP gene mutations cause RSTS. The third also points to CREB-binding protein gene (CREBBP) lesions being associated with RSTS. So, the answer should mention the genes involved. From the evidence, CREBBP is mentioned in two sources, and CBP (which is the same as CREBBP?) and EP300 are mentioned in the first source. Wait, CBP and EP300 are different genes. The first reference says mutations in both CBP and EP300 cause the disease. But the other references talk about CREBBP. Wait, maybe CBP is the same as CREBBP? Because CREBBP is the gene that codes for CREB-binding protein, which is also known as CBP. So, the first reference says mutations in both CBP", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question about the genetic basis of Rubinstein-Taybi syndrome. The user provided three evidence snippets, so I need to parse those carefully. First, looking at the evidence: 15706485:15706485_1 mentions that there's genetic heterogeneity, with mutations in both CBP and EP300 genes causing the disease. So that's two genes here. 16359492:16359492_1 states that CREBBP gene mutations cause RSTS. Wait, CREBBP is the same as CBP, right? Because CREB-binding protein is the protein product of the CREBBP gene. So this is referring to the same gene mentioned in the first snippet. Then 20689175:20689175_1 says that molecular lesions in the CREB-binding protein gene (CREBBP) are associated with RSTS. Again, reinforcing that CREBBP is involved. So putting this together, the main genes involved are CREBBP (CBP) and EP", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the genetic basis of Rubinstein-Taybi syndrome. I need to look at the provided evidence to find the answer. First, looking at the evidence documents. Document [15706485:15706485_1] says that there's genetic heterogeneity, with mutations in both CBP and EP300 genes causing the disease. So that's two genes mentioned here. Then document [16359492:16359492_1] specifically mentions CREBBP (CREB-binding protein gene) mutations causing RSTS. That's one gene. Document [20689175:20689175_1] also talks about molecular lesions in the CREB-binding protein gene, CREBBP, which is the same as the second document. So that reinforces that CREBBP is involved. Wait, but the first document mentions both CBP and EP300. But the other two mention CREBBP. I need to check if CBP", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["14974086", "15706485", "16359492", "18773673", "20684013", "20689175", "22269667", "22303793", "22991675", "23432975", "7630403"], "ideal_answer": "Rubinstein-Taybi syndrome (RTS) is a rare autosomal dominant disorder (prevalence 1:125,000) characterised by broad thumbs and halluces, facial dysmorphism, psychomotor development delay, skeletal defects, abnormalities in the posterior fossa and short stature. The known genetic causes are a microdeletion at 16p13.3 or mutations or deletions of the cAMP-response element binding protein-BP (CREBBP) (50-60% of the cases) and of the homologous gene E1A-binding protein (EP300) at 22q13 (5%). Direct sequencing of CREBBP performed in 13 RSTS patients identified the three zinc fingers (CH1, CH2, CH3) and HAT domain as mutational hotspots. Thus about 55% of patients have cytogenetic or molecular abnormalities in the Crebbp or E1A binding protein p300 (Ep300) gene, leaving the diagnosis in 45% of patients to rest on clinical features only."}
{"question_id": "511a51331159fa8212000009", "question": "What is the function of the viral KP4 protein?", "retrieved_chunks": [{"doc_id": "21116630", "chunk_id": "21116630_0", "score": 6.323906898498535, "text": "Killer protein 4 (KP4) is a well studied viral toxin secreted by the maize smut fungus Ustilago maydis that kills sensitive Ustilago strains as well as inhibits Fusarium and plant root growth by inhibiting calcium uptake."}, {"doc_id": "17522822", "chunk_id": "17522822_0", "score": 5.440125942230225, "text": "The viral gene for the killer protein 4 (KP4) has been explored for its antifungal effect"}, {"doc_id": "11901234", "chunk_id": "11901234_0", "score": 3.2708823680877686, "text": "KP4 is a virally encoded fungal toxin secreted by the P4 killer strain of Ustilago maydis."}], "context": "[21116630:21116630_0] Killer protein 4 (KP4) is a well studied viral toxin secreted by the maize smut fungus Ustilago maydis that kills sensitive Ustilago strains as well as inhibits Fusarium and plant root growth by inhibiting calcium uptake.\n[17522822:17522822_0] The viral gene for the killer protein 4 (KP4) has been explored for its antifungal effect\n[11901234:11901234_0] KP4 is a virally encoded fungal toxin secreted by the P4 killer strain of Ustilago maydis.", "answer": "<think> Okay, let's tackle this question. The user wants to know the function of the viral KP4 protein, and they provided three evidence snippets. First, I need to look at each piece of evidence. The first one says that KP4 is a viral toxin secreted by the maize smut fungus Ustilago maydis. It kills sensitive strains and inhibits growth of Fusarium and plants by blocking calcium uptake. That seems like a direct function: inhibiting calcium uptake, which affects other organisms. The second evidence mentions the viral gene for KP4 has been explored for antifungal effects. So that's another point about its function being antifungal. But wait, the first snippet already says it kills Ustilago strains and inhibits Fusarium, so maybe that's part of the antifungal effect. Third evidence states that KP4 is a virally encoded toxin by the P4 killer strain of Ustilago maydis. This confirms it's a viral protein but doesn't specify the function beyond what's in the first snippet. So combining these, the main function is that KP4 inhibits calcium uptake, which helps the virus kill other strains", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user wants to know the function of the viral KP4 protein, and they provided three evidence snippets. First, I need to look at each piece of evidence. The first one says that KP4 is a viral toxin secreted by the maize smut fungus Ustilago maydis. It kills sensitive strains and inhibits growth of Fusarium and plants by blocking calcium uptake. That seems like a direct function: inhibiting calcium uptake, which affects other organisms. The second evidence mentions the viral gene for KP4 has been explored for antifungal effects. So that's another point about its function being antifungal. But wait, the first snippet already says it kills Ustilago strains and inhibits Fusarium, so maybe that's part of the antifungal effect. Third evidence states that KP4 is a virally encoded toxin by the P4 killer strain of Ustilago maydis. This confirms it's a viral protein but doesn't specify the function beyond what's in the first snippet. So combining these, the main function is that KP4 inhibits calcium uptake, which helps the virus kill other strains", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user wants to know the function of the viral KP4 protein. Looking at the evidence provided, there are three documents. First, document [21116630:21116630_0] says that KP4 is a viral toxin secreted by the maize smut fungus Ustilago maydis. It kills sensitive strains of Ustilago and inhibits Fusarium and plant root growth by blocking calcium uptake. That seems like a direct function. Then, document [17522822:17522822_0] mentions the viral gene for KP4 has been explored for antifungal effects. So that's another point about its function. The third document [11901234:11901234_0] confirms that KP4 is a virally encoded toxin from the P4 killer strain of Ustilago maydis, which aligns with the first document. So combining these, the main functions are killing other Ustilago strains, inhibiting Fusarium and plant", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user wants to know the function of the viral KP4 protein, and they've provided three evidence snippets. First, I need to look at each piece of evidence. The first one says that KP4 is a viral toxin secreted by the maize smut fungus Ustilago maydis. It kills sensitive strains of Ustilago and inhibits Fusarium and plant root growth by blocking calcium uptake. That seems like a direct function: killing other fungal strains and inhibiting growth by affecting calcium. The second evidence mentions that the viral gene for KP4 has been explored for its antifungal effect. So, this supports the idea that it's antifungal, which aligns with the first point about killing Ustilago strains. The third snippet states that KP4 is a virally encoded toxin secreted by the P4 killer strain of Ustilago maydis. This confirms that it's a viral protein from this specific fungus. Now, combining these, the main function seems to be that KP4 is a toxin that kills other fungal strains and inhibits plant growth by interfering with calcium uptake. The antif", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["10748529", "11532143", "11901234", "17522822", "17849147", "21116630", "21303448", "7582897", "7966296", "8145639", "8616260", "8809749"], "ideal_answer": "The virally encoded fungal toxin KP4 specifically blocks L-type voltage-gated calcium channels."}
{"question_id": "56ed27012ac5ed145900000b", "question": "What is the function of the AIRE gene at the embryonic stage?", "retrieved_chunks": [{"doc_id": "22540148", "chunk_id": "22540148_4", "score": 6.223471641540527, "text": "The recent discovery of Aire expression in stem cells and early embryonic cells and its function in the self-renewal of embryonic stem (ES) cells highlight the importance of Aire in these cells. In this study, we present evidence that Aire promotes the expression of the pluripotent factor Lin28 and the self-renewal of ES cells."}, {"doc_id": "20226168", "chunk_id": "20226168_2", "score": 6.099332332611084, "text": "Aire regulates the expression of differentiation-associated genes and self-renewal of embryonic stem cells."}, {"doc_id": "20226168", "chunk_id": "20226168_1", "score": 5.756678104400635, "text": "Aire regulates the expression of differentiation-associated genes and self-renewal of embryonic stem cells"}], "context": "[22540148:22540148_4] The recent discovery of Aire expression in stem cells and early embryonic cells and its function in the self-renewal of embryonic stem (ES) cells highlight the importance of Aire in these cells. In this study, we present evidence that Aire promotes the expression of the pluripotent factor Lin28 and the self-renewal of ES cells.\n[20226168:20226168_2] Aire regulates the expression of differentiation-associated genes and self-renewal of embryonic stem cells.\n[20226168:20226168_1] Aire regulates the expression of differentiation-associated genes and self-renewal of embryonic stem cells", "answer": "<think> Okay, let's tackle this question. The user is asking about the function of the AIRE gene at the embryonic stage. I need to look at the provided evidence to find relevant information. First, looking at the evidence documents. Document 22540148 mentions that Aire is expressed in stem cells and early embryonic cells, and it promotes the expression of Lin28, a pluripotent factor, which helps in the self-renewal of ES cells. So that's a key point about self-renewal. Then there's document 20226168, which is cited twice. Both mention that Aire regulates differentiation-associated genes and self-renewal of embryonic stem cells. So the main functions here are regulating gene expression related to differentiation and maintaining self-renewal in ES cells. The question specifically asks about the embryonic stage. The answer should tie into how AIRE contributes to the self-renewal of embryonic stem cells, which is crucial for early development. Also, the mention of Lin28 in the first document supports that AIRE helps maintain pluripotency and self-renew", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking about the function of the AIRE gene at the embryonic stage. I need to look at the provided evidence to find relevant information. First, looking at the evidence documents. Document 22540148 mentions that Aire is expressed in stem cells and early embryonic cells, and it promotes the expression of Lin28, a pluripotent factor, which helps in the self-renewal of ES cells. So that's a key point about self-renewal. Then there's document 20226168, which is cited twice. Both mention that Aire regulates differentiation-associated genes and self-renewal of embryonic stem cells. So the main functions here are regulating gene expression related to differentiation and maintaining self-renewal in ES cells. The question specifically asks about the embryonic stage. The answer should tie into how AIRE contributes to the self-renewal of embryonic stem cells, which is crucial for early development. Also, the mention of Lin28 in the first document supports that AIRE helps maintain pluripotency and self-renew", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the function of the AIRE gene at the embryonic stage. I need to look at the provided evidence to form an answer. First, I'll check each piece of evidence. The first one (22540148:22540148_4) mentions that Aire is expressed in stem cells and early embryonic cells, and it promotes the expression of Lin28, a pluripotent factor, which aids in the self-renewal of ES cells. That's relevant because self-renewal is crucial for embryonic development. The second and third pieces (20226168:20226168_2 and qualities) both state that Aire regulates differentiation-associated genes and self-renewal of embryonic stem cells. So, combining these, the key points are that AIRE is involved in regulating genes related to differentiation and maintaining the self-renewal of ES cells during embryonic development. I need to make sure the answer is concise and cites the correct documents. The answer should mention both aspects:", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the function of the AIRE gene at the embryonic stage. I need to look at the provided evidence to form an answer. First, I'll check each evidence snippet. The first one (22540148:22540148_4) mentions that Aire is expressed in stem cells and early embryonic cells, and it promotes the expression of Lin28, a pluripotent factor, which helps in the self-renewal of ES cells. So that's about self-renewal and pluripotency. The second and third evidence (20226168:20226168_2 and 1) both state that Aire regulates differentiation-associated genes and self-renewal of embryonic stem cells. So there's a mention of both regulation of differentiation genes and self-renewal. The question is specifically about the embryonic stage. The first evidence talks about early embryonic cells, so that's relevant. The other two are about embryonic stem cells, which are part of the embryonic", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["19008896", "19302042", "20226168", "21952165", "22540148"], "ideal_answer": "Aire regulates the expression of differentiation-associated genes and self-renewal of embryonic stem cells. Aire and Deaf1 help regulate the ectopic expression of diverse tissue-specific antigens to establish self-immune tolerance. Knockdown of Aire in mouse ESCs resulted in significantly decreased clone-forming efficiency as well as attenuated cell cycle, suggesting Aire plays a role in ESC self-renewal. Aire promotes the expression of the pluripotent factor Lin28 and the self-renewal of ES cells. Autoimmune regulator (Aire) is one of the most well-characterized molecules in autoimmunity, but its function outside the immune system is largely unknown. The recent discovery of Aire expression in stem cells and early embryonic cells and its function in the self-renewal of embryonic stem (ES) cells highlight the importance of Aire in these cells. The recent discovery of Aire expression in stem cells and early embryonic cells and its function in the self-renewal of embryonic stem (ES) cells highlight the importance of Aire in these cells. The correlation between Aire and Lin28 expression in germ cells and early embryos indicated an in vivo function for Aire in toti- and pluripotent stem cells. Moreover, it presents the first evidence that microRNAs contribute to the regulatory function of Aire and highlights a novel function of Aire in stem cell biology and reproduction. Monitoring Aire expression in MSCs may thus be a critical parameter for clinical use."}
{"question_id": "533c388dc45e133714000008", "question": "What is the principle of the PAR-CLIP methodology?", "retrieved_chunks": [{"doc_id": "22844102", "chunk_id": "22844102_0", "score": 4.5211286544799805, "text": "Photo-Activatable Ribonucleoside-enhanced CrossLinking and ImmunoPrecipitation (PAR-CLIP) method was recently developed for global identification of RNAs interacting with proteins."}, {"doc_id": "22152485", "chunk_id": "22152485_0", "score": 4.404881000518799, "text": "A recent method, PAR-CLIP, uses photoreactive nucleosides to crosslink RBPs to target RNAs in cells prior to immunoprecipitation."}, {"doc_id": "21572407", "chunk_id": "21572407_0", "score": 3.6989479064941406, "text": "We developed a method for CLIP data analysis, and applied it to compare CLIP with photoactivatable ribonucleoside-enhanced CLIP (PAR-CLIP) and to uncover how differences in cross-linking and ribonuclease digestion affect the identified sites."}], "context": "[22844102:22844102_0] Photo-Activatable Ribonucleoside-enhanced CrossLinking and ImmunoPrecipitation (PAR-CLIP) method was recently developed for global identification of RNAs interacting with proteins.\n[22152485:22152485_0] A recent method, PAR-CLIP, uses photoreactive nucleosides to crosslink RBPs to target RNAs in cells prior to immunoprecipitation.\n[21572407:21572407_0] We developed a method for CLIP data analysis, and applied it to compare CLIP with photoactivatable ribonucleoside-enhanced CLIP (PAR-CLIP) and to uncover how differences in cross-linking and ribonuclease digestion affect the identified sites.", "answer": "<think> Okay, I need to figure out the principle of the PAR-CLIP methodology based on the given evidence. Let me look at the evidence provided. The first document says that PAR-CLIP uses photoreactive nucleosides to crosslink RBPs to target RNAs in cells before immunoprecipitation. The second one mentions that it's a method for global identification of RNAs interacting with proteins. The third talks about analyzing CLIP data and comparing it with PAR-CLIP, highlighting cross-linking and ribonuclease digestion effects. So the key points here are photoreactive nucleosides, crosslinking of RBPs to RNAs, and immunoprecipitation. The principle would involve using these nucleosides to link proteins to RNA, then isolating those complexes. The answer should mention photoreactive nucleosides, crosslinking, and immunoprecipitation. I need to check the citations. The first evidence is from 22844102:22844102_0, which mentions the method's purpose. The second is 2215248", "citations": [], "candidates": [{"answer": "<think> Okay, I need to figure out the principle of the PAR-CLIP methodology based on the given evidence. Let me look at the evidence provided. The first document says that PAR-CLIP uses photoreactive nucleosides to crosslink RBPs to target RNAs in cells before immunoprecipitation. The second one mentions that it's a method for global identification of RNAs interacting with proteins. The third talks about analyzing CLIP data and comparing it with PAR-CLIP, highlighting cross-linking and ribonuclease digestion effects. So the key points here are photoreactive nucleosides, crosslinking of RBPs to RNAs, and immunoprecipitation. The principle would involve using these nucleosides to link proteins to RNA, then isolating those complexes. The answer should mention photoreactive nucleosides, crosslinking, and immunoprecipitation. I need to check the citations. The first evidence is from 22844102:22844102_0, which mentions the method's purpose. The second is 2215248", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question about the PAR-CLIP methodology. The user wants the principle explained based on the provided evidence. First, I need to look at the evidence snippets. The first one says PAR-CLIP uses photoreactive nucleosides to crosslink RBPs to target RNAs before immunoprecipitation. The second mentions photoactivatable ribonucleosides for crosslinking RBPs to RNAs. The third talks about analyzing CLIP data and comparing with PAR-CLIP, noting differences in cross-linking and digestion. So the key points are photoreactive nucleosides, crosslinking of RBPs to RNAs, and immunoprecipitation. The principle is that PAR-CLIP uses these nucleosides to link proteins to RNA, then isolates them via immunoprecipitation. I need to make sure the answer is concise and cites the correct documents. The first evidence snippet [22844102:22844102_0] mentions the method's purpose, while [22152485:22152", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question about the PAR-CLIP methodology. The user wants the principle explained with citations and a confidence score. First, I need to look at the evidence provided. There are three documents mentioned. Let me read through them. The first document says PAR-CLIP uses photoreactive nucleosides to crosslink RBPs to target RNAs before immunoprecipitation. The second one mentions the same thing: photoreactive nucleosides for crosslinking RBPs to RNAs prior to immunoprecipitation. The third talks about analyzing CLIP data and comparing with PAR-CLIP, but it's more about analysis than the principle. So the key points are photoreactive nucleosides, crosslinking of RBPs to RNAs, and immunoprecipitation. The answer should combine these elements. The citations would be from the first two documents since they directly explain the method. The third document is about application but not the principle. Now, the answer needs to be concise. So something like: PAR-CLIP uses photoreactive nucleosides to crosslink RNA-binding proteins (RBPs) to", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["20371350", "20644507", "21559008", "21572407", "21816340", "21851591", "22152485", "22213601", "22844102", "22885304", "22926237", "23368412", "23706177", "24297251"], "ideal_answer": "In particular, PAR-CLIP utilizes a photoactivatable nucleoside for more efficient crosslinking. A recent method, PAR-CLIP, uses photoreactive nucleosides to crosslink RBPs to target RNAs in cells prior to immunoprecipitation. One characteristic feature of cDNA libraries prepared by PAR-CliP is that the precise position of crosslinking can be identified by mutations residing in the sequenced cDNA. A powerful cell-based crosslinking approach to determine at high resolution and transcriptome-wide the binding sites of cellular RBPs and miRNPs was termed PAR-CliP (Photoactivatable-Ribonucleoside-Enhanced Crosslinking and Immunoprecipitation). PAR-CLIP shows high efficiency of RNA co-immunoprecipitation, but it also lead to T to C conversion in miRNA-RNA-protein crosslinking regions. It relies on the intracellular incorporation of photoactivatable ribonucleoside analogs into nascent transcripts, and yields characteristic sequence changes upon crosslinking that facilitate the separation of signal from noise. AR-CliP--a method to identify transcriptome-wide the binding sites of RNA binding proteinsOne characteristic feature of cDNA libraries prepared by PAR-CliP is that the precise position of crosslinking can be identified by mutations residing in the sequenced cDNA. In particular, PAR-CLIP utilizes a photoactivatable nucleoside for more efficient crosslinking. A recent method, PAR-CLIP, uses photoreactive nucleosides to crosslink RBPs to target RNAs in cells prior to immunoprecipitation. In particular, PAR-CLIP utilizes a photoactivatable nucleoside for more efficient crosslinking. A recent method, PAR-CLIP, uses photoreactive nucleosides to crosslink RBPs to target RNAs in cells prior to immunoprecipitation. One characteristic feature of cDNA libraries prepared by PAR-CliP is that the precise position of crosslinking can be identified by mutations residing in the sequenced cDNA. Photo-Activatable Ribonucleoside-enhanced CrossLinking and ImmunoPrecipitation (PAR-CLIP) method was recently developed for global identification of RNAs interacting with proteins. PAR-CLIP shows high efficiency of RNA co-immunoprecipitation, but it also lead to T to C conversion in miRNA-RNA-protein crosslinking regions"}
{"question_id": "518cb4b5310faafe08000006", "question": "Which drugs are utilized to treat amiodarone-induced thyroitoxicosis?", "retrieved_chunks": [{"doc_id": "7946779", "chunk_id": "7946779_1", "score": 7.66983699798584, "text": "Two patients with amiodarone-induced thyrotoxicosis were treated successfully with potassium perchlorate and carbimazole while treatment with amiodarone was continued."}, {"doc_id": "16544025", "chunk_id": "16544025_1", "score": 7.4176177978515625, "text": "the addition of lithium carbonate to the two other drugs resulted in a successful and safety therapy in controlling amiodarone-induced thyrotoxicosis."}, {"doc_id": "9217642", "chunk_id": "9217642_0", "score": 6.463123321533203, "text": "lithium is a useful and safe medication for treatment of iodine-induced thyrotoxicosis caused by amiodarone."}], "context": "[7946779:7946779_1] Two patients with amiodarone-induced thyrotoxicosis were treated successfully with potassium perchlorate and carbimazole while treatment with amiodarone was continued.\n[16544025:16544025_1] the addition of lithium carbonate to the two other drugs resulted in a successful and safety therapy in controlling amiodarone-induced thyrotoxicosis.\n[9217642:9217642_0] lithium is a useful and safe medication for treatment of iodine-induced thyrotoxicosis caused by amiodarone.", "answer": "<think> Okay, let's tackle this question. The user wants to know which drugs are used to treat amiodarone-induced thyrotoxicosis, based on the provided evidence. First, I need to look at the evidence snippets. The first one mentions potassium perchlorate and carbimazole were used successfully along with continuing amiodarone treatment. The second snippet says adding lithium carbonate to two other drugs was successful and safe. The third states that lithium is useful and safe for iodine-induced thyrotoxicosis from amiodarone. So, the drugs mentioned are potassium perchlorate, carbimazole, and lithium carbonate. Wait, but the third evidence mentions lithium, which is the same as lithium carbonate? Or is there a difference? The third snippet says \"lithium is a useful... medication,\" so maybe it's referring to lithium itself, not carbonate. But the second snippet specifies lithium carbonate. Hmm, need to check if they are the same. Lithium carbonate is a form of lithium, so perhaps in the context of the evidence, both are considered. However, the third snippet says \"lithium\" as the medication, which might", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user wants to know which drugs are used to treat amiodarone-induced thyrotoxicosis, based on the provided evidence. First, I need to look at the evidence snippets. The first one mentions potassium perchlorate and carbimazole were used successfully along with continuing amiodarone treatment. The second snippet says adding lithium carbonate to two other drugs was successful and safe. The third states that lithium is useful and safe for iodine-induced thyrotoxicosis from amiodarone. So, the drugs mentioned are potassium perchlorate, carbimazole, and lithium carbonate. Wait, but the third evidence mentions lithium, which is the same as lithium carbonate? Or is there a difference? The third snippet says \"lithium is a useful... medication,\" so maybe it's referring to lithium itself, not carbonate. But the second snippet specifies lithium carbonate. Hmm, need to check if they are the same. Lithium carbonate is a form of lithium, so perhaps in the context of the evidence, both are considered. However, the third snippet says \"lithium\" as the medication, which might", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which drugs are used to treat amiodarone-induced thyrotoxicosis. The evidence provided has three chunks. First chunk: Potassium perchlorate and carbimazole were used successfully in two patients while continuing amiodarone. So those two drugs are mentioned here. Second chunk: Adding lithium carbonate to the two other drugs resulted in successful and safe therapy. Wait, the \"two other drugs\" would be potassium perchlorate and carbimazole from the first chunk? Or maybe the previous ones? But the first chunk mentions two drugs, so maybe the second chunk is adding lithium carbonate to those two? But the wording says \"the addition of lithium carbonate to the two other drugs\", which might mean that in addition to the two drugs, lithium is added. So that would make three drugs: potassium perchlorate, carbimazole, and lithium carbonate. Third chunk: Lithium is useful and safe for iodine-induced thyrotoxicosis caused by amiodarone. This seems to support the second chunk's mention of lithium carbonate. So combining these, the answer should include potassium perch", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user wants to know which drugs are used to treat amiodarone-induced thyrotoxicosis, based on the provided evidence. First, I need to look at the evidence given. There are three references here. Let me break them down one by one. The first piece of evidence (7946779:7946779_1) says that two patients were treated successfully with potassium perchlorate and carbimazole while continuing amiodarone therapy. So that's two drugs: potassium perchlorate and carbimazole. The second reference (16544025:16544021) mentions adding lithium carbonate to the two other drugs, resulting in successful and safe therapy. Wait, the \"two other drugs\" would be the ones from the first evidence, right? So that would mean lithium carbonate is added to potassium perchlorate and carbimazole. But the way it's phrased, maybe the two other drugs are separate from the initial ones? Or does it mean that in addition to those two, lithium is added?", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["11901034", "12727944", "16544025", "16910349", "19675515", "21135419", "2781955", "7946779", "9217642"], "ideal_answer": "Amiodarone-induced thyrotoxicosis treatment includes anti-thyroid drugs and steroid therapy Radio Iodine Treatment (RIT) may be a safe and useful method of AIT therapy in patients with low RAIU, in whom other treatment methods are contraindicated. Lithium is a useful and safe medication for treatment of iodine-induced thyrotoxicosis caused by amiodarone. Thyrodectomy may be necessary in presence of unresponsiveness to standard medical treatments"}
{"question_id": "56c3323a50c68dd416000009", "question": "How is spastic diplegia diagnosed?", "retrieved_chunks": [{"doc_id": "23085499", "chunk_id": "23085499_2", "score": 4.601202964782715, "text": "Hereditary spastic paraplegia (HSP) and spastic diplegia (SD) patients share a strong clinical resemblance. Thus, HSP patients are frequently misdiagnosed with a mild form of SD. Clinical gait analysis (CGA) has been highlighted as a possible tool to support the differential diagnosis of HSP and SD"}, {"doc_id": "24182356", "chunk_id": "24182356_0", "score": 3.9041900634765625, "text": "The aim of this study was to explore the physical status and gait patterns of children with spastic diplegia secondary to human immunodeficiency virus encephalopathy (HIVE). A cross-sectional study was conducted on children diagnosed with HIVE and spastic diplegia."}, {"doc_id": "1743414", "chunk_id": "1743414_0", "score": 3.2611911296844482, "text": "Hip flexion combined with knee extension (leg elevation) and isolated knee movements were not seen in diplegic infants, but were seen in all control preterm infants with a good prognosis, after five and six months corrected age, respectively. The absence of these movements is a useful diagnostic item for spastic diplegia."}], "context": "[23085499:23085499_2] Hereditary spastic paraplegia (HSP) and spastic diplegia (SD) patients share a strong clinical resemblance. Thus, HSP patients are frequently misdiagnosed with a mild form of SD. Clinical gait analysis (CGA) has been highlighted as a possible tool to support the differential diagnosis of HSP and SD\n[24182356:24182356_0] The aim of this study was to explore the physical status and gait patterns of children with spastic diplegia secondary to human immunodeficiency virus encephalopathy (HIVE). A cross-sectional study was conducted on children diagnosed with HIVE and spastic diplegia.\n[1743414:1743414_0] Hip flexion combined with knee extension (leg elevation) and isolated knee movements were not seen in diplegic infants, but were seen in all control preterm infants with a good prognosis, after five and six months corrected age, respectively. The absence of these movements is a useful diagnostic item for spastic diplegia.", "answer": "<think> Okay, let's tackle this question about diagnosing spastic diplegia. The user wants a concise answer with citations and a confidence level. First, I need to look at the evidence provided. There are three documents here. Let me go through each one. The first document says that HSP and SD patients look similar, so CGA is used to differentiate them. That's about using clinical gait analysis. The second document talks about a study on children with HIVE and spastic diplegia, but it doesn't mention diagnosis methods directly. The third document mentions that in diplegic infants, certain movements like hip flexion with knee extension aren't present, which is a useful diagnostic sign. So the answer should probably include the gait analysis from the first doc and the absence of specific movements from the third. But wait, the question is about diagnosis. The third document says that the absence of those movements is a useful diagnostic item. That's a direct point. The first document mentions CGA as a tool for differential diagnosis between HSP and SD. So maybe combining both points. But the answer needs to be concise. Let me check if there are other", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question about diagnosing spastic diplegia. The user wants a concise answer with citations and a confidence level. First, I need to look at the evidence provided. There are three documents here. Let me go through each one. The first document says that HSP and SD patients look similar, so CGA is used to differentiate them. That's about using clinical gait analysis. The second document talks about a study on children with HIVE and spastic diplegia, but it doesn't mention diagnosis methods directly. The third document mentions that in diplegic infants, certain movements like hip flexion with knee extension aren't present, which is a useful diagnostic sign. So the answer should probably include the gait analysis from the first doc and the absence of specific movements from the third. But wait, the question is about diagnosis. The third document says that the absence of those movements is a useful diagnostic item. That's a direct point. The first document mentions CGA as a tool for differential diagnosis between HSP and SD. So maybe combining both points. But the answer needs to be concise. Let me check if there are other", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. Let me start by understanding the question: How is spastic diplegia diagnosed? Looking at the evidence provided, there are three chunks. The first one mentions that Hereditary Spastic Paraplegia (HSP) and Spastic Diplegia (SD) are often misdiagnosed, and Clinical Gait Analysis (CGA) can help differentiate them. The second chunk talks about a study on children with HIVE and spastic diplegia, but it's more about their physical status and gait patterns rather than diagnosis. The third chunk says that the absence of certain movements (hip flexion with knee extension and isolated knee movements) in diplegic infants is a useful diagnostic item. So, the answer should focus on the diagnostic indicators mentioned. The third chunk directly states that the absence of those specific movements is a useful diagnostic feature. The first chunk mentions CGA as a tool for differential diagnosis. However, the question is about how spastic diplegia is diagnosed, not just differentiating it from HSP. The third chunk's information seems more direct. The answer", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question about how spastic diplegia is diagnosed. The user wants a concise answer with citations and a confidence score. First, I need to look at the evidence provided. There are three documents here. Let me go through each one. The first document says that HSP and SD patients look similar, so CGA (clinical gait analysis) is a tool to differentiate them. That's relevant because it mentions using gait analysis as part of diagnosis. The second document talks about a study on children with HIVE and spastic diplegia. It mentions a cross-sectional study on their physical status and gait patterns. So, this suggests that assessing gait patterns is part of the diagnostic process. The third document states that in diplegic infants, certain movements like hip flexion with knee extension and isolated knee movements are absent. The presence of these movements in control preterm infants is a useful diagnostic item for spastic diplegia. So, this points to specific motor tests as diagnostic criteria. Putting this together, the diagnosis involves clinical gait analysis and observing specific motor patterns. The third document gives a concrete test (absence of", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["10427678", "12549749", "15157997", "16344032", "1743414", "17509240", "17826455", "20829081", "21310339", "23085499", "23121133", "24182356", "24239880", "24409030", "24901761", "25276040", "25700542", "2600179", "2816867", "7270517"], "ideal_answer": "Diagnosis of spastic diplegia is mainly carried out with through clinical gait analysis (CGA), with variations such as 1-minute walk, LSU, and 10-meter walk tests, or Gross Motor Function Measure-88 (GMFM-88). Other methods used for evaluation of patients include brain magnetic resonance imaging (MRI) and motor function, presence of epileptic episodes, and IQ or developmental quotient. Clinical gait analysis (CGA) has been highlighted as a possible tool to support the differential diagnosis of Hereditary Spastic Paraplegia (HSP) and Spastic Diplegia (SD). Argininaimia should be considered more frequently in the differential diagnosis of a patient with slowly progressive neurologic manifestations, especially progressive spastic diplegia. Gait Analysis (GA) complements traditional clinical evaluations, making it possible to distinguish, clearly, between motor ability in HSP and in SD patients; the duration of the knee hyperextension during midstance was found to discriminate between the two gait patterns."}
{"question_id": "52f223e02059c6d71c00000e", "question": "Which is the genetic defect causing Neurofibromatosis type 1?", "retrieved_chunks": [{"doc_id": "16835897", "chunk_id": "16835897_2", "score": 8.793728828430176, "text": "Neurofibromatosis type 1 (NF1), characterized by skin neurofibromas and an excess of café-au-lait spots, is due to mutations in the neurofibromin (NF1) gene. Identifying the genetic defect in individuals with the disease represents a significant challenge because the gene is extremely large with a high incidence of sporadic mutations across the entire gene ranging from single nucleotide substitutes to large deletions."}, {"doc_id": "19117870", "chunk_id": "19117870_2", "score": 7.752963542938232, "text": "Neurofibromatosis type 1 (NF1) is an autosomal dominant condition with a worldwide incidence of approximately 1 per 2500 to 3000 individuals. Caused by a germ-line-inactivating mutation in the NF1 gene on chromosome 17, the disease is associated with increased morbidity and mortality. In the past several years, significant progress has been made in standardizing management of the major clinical features of neurofibromatosis type 1."}, {"doc_id": "17573495", "chunk_id": "17573495_0", "score": 6.448944568634033, "text": "Neurofibromatosis type 1 (NF1) is a common disorder of dysregulated tissue growth secondary to mutations in the tumor suppressor gene NF1"}], "context": "[16835897:16835897_2] Neurofibromatosis type 1 (NF1), characterized by skin neurofibromas and an excess of café-au-lait spots, is due to mutations in the neurofibromin (NF1) gene. Identifying the genetic defect in individuals with the disease represents a significant challenge because the gene is extremely large with a high incidence of sporadic mutations across the entire gene ranging from single nucleotide substitutes to large deletions.\n[19117870:19117870_2] Neurofibromatosis type 1 (NF1) is an autosomal dominant condition with a worldwide incidence of approximately 1 per 2500 to 3000 individuals. Caused by a germ-line-inactivating mutation in the NF1 gene on chromosome 17, the disease is associated with increased morbidity and mortality. In the past several years, significant progress has been made in standardizing management of the major clinical features of neurofibromatosis type 1.\n[17573495:17573495_0] Neurofibromatosis type 1 (NF1) is a common disorder of dysregulated tissue growth secondary to mutations in the tumor suppressor gene NF1", "answer": "<think> Okay, let's tackle this question. The user is asking about the genetic defect causing Neurofibromatosis type 1. I need to look at the provided evidence to find the correct answer. First, I'll go through each of the evidence chunks. The first chunk [16835897:16835897_2] says that NF1 is due to mutations in the neurofibromin (NF1) gene. That seems directly relevant. It also mentions the gene is large with various types of mutations, but the key point here is the NF1 gene. The second chunk [19117870:19117870_2] states that NF1 is caused by a germ-line-inactivating mutation in the NF1 gene on chromosome 17. This reinforces the same answer but adds info about the chromosome location, which might be extra but not needed for the answer. The third chunk [17573495:17573495_0] mentions mutations in the tumor suppressor gene NF1. Again, pointing", "citations": [{"doc_id": "16835897", "chunk_id": "16835897_2"}, {"doc_id": "19117870", "chunk_id": "19117870_2"}, {"doc_id": "17573495", "chunk_id": "17573495_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking about the genetic defect causing Neurofibromatosis type 1. I need to look at the provided evidence to find the correct answer. First, I'll go through each of the evidence chunks. The first chunk [16835897:16835897_2] says that NF1 is due to mutations in the neurofibromin (NF1) gene. That seems directly relevant. It also mentions the gene is large with various types of mutations, but the key point here is the NF1 gene. The second chunk [19117870:19117870_2] states that NF1 is caused by a germ-line-inactivating mutation in the NF1 gene on chromosome 17. This reinforces the same answer but adds info about the chromosome location, which might be extra but not needed for the answer. The third chunk [17573495:17573495_0] mentions mutations in the tumor suppressor gene NF1. Again, pointing", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the genetic defect causing Neurofibromatosis type 1. I need to look at the provided evidence to find the correct answer. First, I'll go through each of the evidence chunks. The first chunk [16835897:16835897_2] says that NF1 is due to mutations in the neurofibromin (NF1) gene. It also mentions the gene is large with various types of mutations. That seems relevant. The second chunk [19117870:19117870_2] states that NF1 is caused by a germ-line-inactivating mutation in the NF1 gene on chromosome 17. This also points to the NF1 gene as the cause. The third chunk [17573495:17573495_0] mentions mutations in the tumor suppressor gene NF1. All three chunks consistently point to the NF1 gene. So, the answer should be that the genetic defect is a mutation in", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to figure out the answer to the question about the genetic defect causing Neurofibromatosis type 1. Let me look at the evidence provided. The first piece of evidence says that NF1 is due to mutations in the neurofibromin (NF1) gene. The second one mentions a germ-line-inactivating mutation in the NF1 gene on chromosome 17. The third one states that it's caused by mutations in the tumor suppressor gene NF1. All three sources point to the NF1 gene as the cause. The question is asking for the genetic defect, so the answer should be that it's a mutation in the NF1 gene. The citations are from different chunks but all refer to the same gene. The confidence level should be high since all three sources agree. I'll check if there's any conflicting info, but none here. So the answer is mutations in the NF1 gene, and the confidence can be 1.0 as it's consistently mentioned across the evidence. </think> { \"answer\": \"Mutations in the NF1 gene [16835897:1683", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["14722917", "16323217", "16835897", "2129297", "21567923"], "ideal_answer": "Neurofibromatosis type 1 (NF1) is due to all types of mutations in the neurofibromin (NF1) gene."}
{"question_id": "5343caffaeec6fbd07000002", "question": "Which is the human selenoprotein that contains several Se-Cys residues?", "retrieved_chunks": [{"doc_id": "15777501", "chunk_id": "15777501_0", "score": 5.630316734313965, "text": "Human selenoprotein P (HSelP) is unique protein that contains 10 selenocysteines encoded by 10 inframe UGA"}, {"doc_id": "20417644", "chunk_id": "20417644_0", "score": 4.525123596191406, "text": "selenoprotein P and several other selenoproteins are known to contain multiple selenocysteines"}, {"doc_id": "10692426", "chunk_id": "10692426_0", "score": 3.756789207458496, "text": "Selenoprotein P is unique in that its mRNA encodes 10-12 selenocysteine residues"}], "context": "[15777501:15777501_0] Human selenoprotein P (HSelP) is unique protein that contains 10 selenocysteines encoded by 10 inframe UGA\n[20417644:20417644_0] selenoprotein P and several other selenoproteins are known to contain multiple selenocysteines\n[10692426:10692426_0] Selenoprotein P is unique in that its mRNA encodes 10-12 selenocysteine residues", "answer": "<think> Okay, let's tackle this question. The user is asking which human selenoprotein contains several Se-Cys residues. The evidence provided has three references. First, I need to understand what a selenoprotein is. Selenoproteins are proteins that contain selenium in the form of selenocysteine (Sec), which is a rare amino acid. The question specifically mentions \"Se-Cys\" residues, which I think refers to selenocysteines. Looking at the evidence: 1. Reference 15777501: It says Human selenoprotein P (HSelP) has 10 selenocysteines encoded by 10 in-frame UGA codons. So this directly mentions HSelP with multiple Se-Cys. 2. Reference 20417644: States that selenoprotein P and others have multiple selenocysteines. This supports the idea that HSelP is one such protein, but it's more general. 3. Reference 10692426: Mentions Selenoprotein P has", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which human selenoprotein contains several Se-Cys residues. The evidence provided has three references. First, I need to understand what a selenoprotein is. Selenoproteins are proteins that contain selenium in the form of selenocysteine (Sec), which is a rare amino acid. The question specifically mentions \"Se-Cys\" residues, which I think refers to selenocysteines. Looking at the evidence: 1. Reference 15777501: It says Human selenoprotein P (HSelP) has 10 selenocysteines encoded by 10 in-frame UGA codons. So this directly mentions HSelP with multiple Se-Cys. 2. Reference 20417644: States that selenoprotein P and others have multiple selenocysteines. This supports the idea that HSelP is one such protein, but it's more general. 3. Reference 10692426: Mentions Selenoprotein P has", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which human selenoprotein contains several Se-Cys residues. The evidence provided has three references. First, I need to understand what a selenoprotein is. Selenoproteins are proteins that contain selenium in the form of selenocysteine (Sec), which is encoded by the UGA codon. The question specifies \"several Se-Cys residues,\" so we're looking for a protein with multiple selenocysteines. Looking at the evidence: 1. Reference 15777501: It mentions human selenoprotein P (HSelP) has 10 selenocysteines encoded by 10 in-frame UGA. This directly points to HSelP as a candidate with multiple Se-Cys. 2. Reference 20417644: States that selenoprotein P and others have multiple selenocysteines. This supports the idea that HSelP is one such protein, but it's more general. 3. Reference 10692426: Says", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which human selenoprotein contains several Se-Cys residues. The evidence provided has three documents. First, I need to understand what a selenoprotein is. Selenoproteins are proteins that contain selenium in the form of selenocysteine (Sec), which is encoded by the UGA codon. The question is about a specific human selenoprotein with multiple Se-Cys residues. Looking at the evidence: Document 15777501: It mentions Human selenoprotein P (HSelP) has 10 selenocysteines encoded by 10 inframe UGA. So this directly points to HSelP having multiple Se-Cys. Document 20417644: States that selenoprotein P and others have multiple selenocysteines. This supports the idea that HSelP is one such protein, but it's more specific than the first document. Document 10692426: Says Selenoprotein P has 10-12 s", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["10692426", "11122377", "15104205", "15777501", "17000762", "19345254", "20417644", "7637580", "9288402"], "ideal_answer": "Selenoprotein P, that contains 10 selenocysteines."}
{"question_id": "56a39d60496b62f23f000006", "question": "Which package is available for analysing genomic interactions in R/Bioconductor?", "retrieved_chunks": [{"doc_id": "23671339", "chunk_id": "23671339_2", "score": 7.724725723266602, "text": "r3Cseq: an R/Bioconductor package for the discovery of long-range genomic interactions from chromosome conformation capture and next-generation sequencing data."}, {"doc_id": "23671339", "chunk_id": "23671339_1", "score": 7.5556960105896, "text": "r3Cseq: an R/Bioconductor package for the discovery of long-range genomic interactions from chromosome conformation capture and next-generation sequencing data"}, {"doc_id": "26424858", "chunk_id": "26424858_5", "score": 6.306248664855957, "text": "regioneR: an R/Bioconductor package for the association analysis of genomic regions based on permutation tests"}], "context": "[23671339:23671339_2] r3Cseq: an R/Bioconductor package for the discovery of long-range genomic interactions from chromosome conformation capture and next-generation sequencing data.\n[23671339:23671339_1] r3Cseq: an R/Bioconductor package for the discovery of long-range genomic interactions from chromosome conformation capture and next-generation sequencing data\n[26424858:26424858_5] regioneR: an R/Bioconductor package for the association analysis of genomic regions based on permutation tests", "answer": "r3Cseq [23671339:23671339_2]", "citations": [{"doc_id": "23671339", "chunk_id": "23671339_2"}], "candidates": [{"answer": "r3Cseq [23671339:23671339_2]", "base_prob": 1.0, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 1.0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which package is available for analysing genomic interactions in R/Bioconductor. The evidence provided has three entries. First, I need to look at each piece of evidence. The first two entries both mention \"r3Cseq\" as an R/Bioconductor package for discovering long-range genomic interactions from chromosome conformation capture and next-gen sequencing data. The third entry talks about \"regioneR\" for association analysis of genomic regions using permutation tests. The question specifically asks about analysing genomic interactions, which aligns with the description of r3Cseq. The other package, regioneR, is mentioned in the context of association analysis, not directly about interactions. So, the correct answer should be r3Cseq. I need to check if there are any confidence levels. The evidence entries don't have confidence scores, but the user wants a base_confidence between 0 and 1. Since both mentions of r3Cseq are identical and relevant, I can set the confidence high, maybe 0.95. The other package isn't related to interactions, so it's not the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which package is available for analysing genomic interactions in R/Bioconductor. The evidence provided has three entries. First, I need to look at each piece of evidence. The first two entries both mention \"r3Cseq\" as an R/Bioconductor package for discovering long-range genomic interactions from chromosome conformation capture and next-gen sequencing data. The third entry talks about \"regioneR\" for association analysis of genomic regions using permutation tests. The question is specifically about analysing genomic interactions, which aligns with the description of r3Cseq. The other package, regioneR, is mentioned in the context of association analysis, not directly interacting with genomic interactions. So, the correct answer should be r3Cseq. Now, checking the confidence. Since two out of three entries mention r3Cseq, and the third is a different package, the base confidence would be high. The model can be confident because there's clear evidence supporting r3Cseq. However, since there's another package mentioned, but it's not relevant to the question, the confidence should still be high but", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 1.0, "gold_docs": ["23671339"], "ideal_answer": "r3Cseq is an R/Bioconductor package designed to perform 3C-seq data analysis in a number of different experimental designs. The package reads a common aligned read input format, provides data normalization, allows the visualization of candidate interaction regions and detects statistically significant chromatin interactions, thus greatly facilitating hypothesis generation and the interpretation of experimental results."}
{"question_id": "5150b807d24251bc05000072", "question": "How many clinical trials for off-label drugs in neonates are cited in the literature.", "retrieved_chunks": [{"doc_id": "20821198", "chunk_id": "20821198_0", "score": 5.636474609375, "text": "Of the 17 Paediatric Investigation Plans submitted, 14 have resulted in an EMA Decision, 3 were withdrawn by the applicants, 8 were granted a full waiver from development, and 1 resulted in a negative opinion. Decisions as issued included 15 clinical trials, with at least 1,282 children to be recruited into studies across five different products. Neonates were included in four of the products. CONCLUSIONS: The small number of submissions indicates a lack of new drugs being developed for the management of pain. Ethical concerns that too many vulnerable children will be recruited into clinical trials must be balanced against limiting the number of off-label prescribing and obtaining age-appropriate information on paediatric use."}, {"doc_id": "23093633", "chunk_id": "23093633_1", "score": -0.7523602247238159, "text": "Treatment of PE typically involves pharmacotherapy, particularly when lifelong. Although there are numerous reports on the off-label use of selective serotonin reuptake inhibitors (SSRIs) and other compounds, only 2 treatments have been evaluated in randomized controlled phase 3 clinical trials: PSD502 and dapoxetine (SSRI)"}, {"doc_id": "23700188", "chunk_id": "23700188_0", "score": -3.842088222503662, "text": "<AbstractText Label=\"CONCLUSIONS\" NlmCategory=\"CONCLUSIONS\">In our study, off-label rituximab was mainly used for the treatment of hematological, kidney, and systemic connective tissue disorders, and the response among our patient cohort was variable depending on the specific disease."}], "context": "[20821198:20821198_0] Of the 17 Paediatric Investigation Plans submitted, 14 have resulted in an EMA Decision, 3 were withdrawn by the applicants, 8 were granted a full waiver from development, and 1 resulted in a negative opinion. Decisions as issued included 15 clinical trials, with at least 1,282 children to be recruited into studies across five different products. Neonates were included in four of the products. CONCLUSIONS: The small number of submissions indicates a lack of new drugs being developed for the management of pain. Ethical concerns that too many vulnerable children will be recruited into clinical trials must be balanced against limiting the number of off-label prescribing and obtaining age-appropriate information on paediatric use.\n[23093633:23093633_1] Treatment of PE typically involves pharmacotherapy, particularly when lifelong. Although there are numerous reports on the off-label use of selective serotonin reuptake inhibitors (SSRIs) and other compounds, only 2 treatments have been evaluated in randomized controlled phase 3 clinical trials: PSD502 and dapoxetine (SSRI)\n[23700188:23700188_0] <AbstractText Label=\"CONCLUSIONS\" NlmCategory=\"CONCLUSIONS\">In our study, off-label rituximab was mainly used for the treatment of hematological, kidney, and systemic connective tissue disorders, and the response among our patient cohort was variable depending on the specific disease.", "answer": "<think> Okay, let's tackle this question. The user is asking how many clinical trials for off-label drugs in neonates are cited in the literature, based on the provided evidence. First, I need to look through the evidence documents to find any mentions of clinical trials involving neonates and off-label drugs. Let's check each document one by one. The first document (20821198:20821198_0) talks about Paediatric Investigation Plans and mentions that 15 clinical trials were included in the decisions. It also states that neonates were included in four of the products. However, this doesn't specify how many of those trials were for off-label drugs. The conclusion mentions a lack of new drugs for pain management, but it's not clear if the trials mentioned are off-label. The mention of \"off-label prescribing\" is there, but the exact number of trials for neonates isn't given directly. The second document (23093633:23093633_1) discusses off-label use of SSRIs and other compounds but only mentions two phase 3 trials", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking how many clinical trials for off-label drugs in neonates are cited in the literature, based on the provided evidence. First, I need to look through the evidence documents to find any mentions of clinical trials involving neonates and off-label drugs. Let's check each document one by one. The first document (20821198:20821198_0) talks about Paediatric Investigation Plans and mentions that 15 clinical trials were included in the decisions. It also states that neonates were included in four of the products. However, this doesn't specify how many of those trials were for off-label drugs. The conclusion mentions a lack of new drugs for pain management, but it's not clear if the trials mentioned are off-label. The mention of \"off-label prescribing\" is there, but the exact number of trials for neonates isn't given directly. The second document (23093633:23093633_1) discusses off-label use of SSRIs and other compounds but only mentions two phase 3 trials", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking how many clinical trials for off-label drugs in neonates are cited in the literature based on the provided evidence. First, I need to look through each of the evidence documents to find any mentions of clinical trials involving neonates and off-label drugs. Looking at the first document (20821198:20821198_0), it talks about 15 clinical trials as part of the EMA decisions. It also mentions that neonates were included in four of the products. However, the document doesn't specify how many of those trials were for off-label drugs. The conclusion part says there's a lack of new drugs for pain management, but that's more about the number of submissions rather than specific trials. The second document (23093633:23093633_1) discusses off-label use of SSRIs and other compounds but mentions only two treatments evaluated in phase 3 trials: PSD502 and dapoxetine. However, this doesn't mention neonates specifically. The third document (237", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to figure out how many clinical trials for off-label drugs in neonates are cited in the literature based on the given evidence. Let's look at each of the three documents provided. First, document 20821198:20821198_0 mentions that there are 15 clinical trials as part of the EMA decisions. It also states that neonates were included in four of the products. However, this doesn't explicitly say how many of those trials are off-label. The conclusion talks about a lack of new drugs for pain management and ethical concerns, but I don't see a direct count of off-label trials specifically for neonates here. Next, document 23093633:23093633_1 discusses off-label use of SSRIs and other compounds but only mentions two phase 3 trials (PSD502 and dapoxetine). However, this is about PE treatment and doesn't specifically mention neonates. So maybe not directly relevant to the question. Then there's document 23700188:2370", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["20821198"], "ideal_answer": "There are no reports on clinical trials of off-label drugs in neonates. An analysis of Pediatric Investigation Plans submitted between 2007 and 2010 shows that neonates were included in the study of 4 products, but it is unknown if the trial drugs are off-label and if the trials are being conducted at all."}
{"question_id": "56c81fd15795f9a73e00000c", "question": "Are stress granules involved in the pathogenesis of Amyotrophic Lateral Sclerosis?", "retrieved_chunks": [{"doc_id": "24090136", "chunk_id": "24090136_2", "score": 8.315494537353516, "text": "Amyotrophic lateral sclerosis (ALS)-linked fused in sarcoma/translocated in liposarcoma (FUS/TLS or FUS) is concentrated within cytoplasmic stress granules under conditions of induced stress. Since only the mutants, but not the endogenous wild-type FUS, are associated with stress granules under most of the stress conditions reported to date, the relationship between FUS and stress granules represents a mutant-specific phenotype and thus may be of significance in mutant-induced pathogenesis."}, {"doc_id": "20699327", "chunk_id": "20699327_2", "score": 6.118817329406738, "text": "Mutant FUS proteins that cause amyotrophic lateral sclerosis incorporate into stress granules."}, {"doc_id": "20699327", "chunk_id": "20699327_1", "score": 5.525748252868652, "text": "Mutant FUS proteins that cause amyotrophic lateral sclerosis incorporate into stress granules"}], "context": "[24090136:24090136_2] Amyotrophic lateral sclerosis (ALS)-linked fused in sarcoma/translocated in liposarcoma (FUS/TLS or FUS) is concentrated within cytoplasmic stress granules under conditions of induced stress. Since only the mutants, but not the endogenous wild-type FUS, are associated with stress granules under most of the stress conditions reported to date, the relationship between FUS and stress granules represents a mutant-specific phenotype and thus may be of significance in mutant-induced pathogenesis.\n[20699327:20699327_2] Mutant FUS proteins that cause amyotrophic lateral sclerosis incorporate into stress granules.\n[20699327:20699327_1] Mutant FUS proteins that cause amyotrophic lateral sclerosis incorporate into stress granules", "answer": "<think> Okay, let's tackle this question. The user is asking if stress granules are involved in the pathogenesis of ALS. The evidence provided has three chunks. First, I need to understand what each chunk says. The first one (24090136:24090136_2) mentions that ALS-linked FUS/TLS is concentrated in stress granules under stress conditions. It also notes that only mutant FUS, not the wild-type, is associated with these granules under most stress conditions. So this suggests a link between mutant FUS and stress granules, which might be relevant to pathogenesis. The second chunk (20699327:20699327_2) states that mutant FUS proteins causing ALS incorporate into stress granules. Similarly, the third chunk is the same as the second one, so it's a duplicate. So the key points are that mutant FUS proteins are involved in forming stress granules, and since these mutants are linked to ALS, there's a connection between stress granules and the pathogenesis of ALS. However, the evidence specifically", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if stress granules are involved in the pathogenesis of ALS. The evidence provided has three chunks. First, I need to understand what each chunk says. The first one (24090136:24090136_2) mentions that ALS-linked FUS/TLS is concentrated in stress granules under stress conditions. It also notes that only mutant FUS, not the wild-type, is associated with these granules under most stress conditions. So this suggests a link between mutant FUS and stress granules, which might be relevant to pathogenesis. The second chunk (20699327:20699327_2) states that mutant FUS proteins causing ALS incorporate into stress granules. Similarly, the third chunk is the same as the second one, so it's a duplicate. So the key points are that mutant FUS proteins are involved in forming stress granules, and since these mutants are linked to ALS, there's a connection between stress granules and the pathogenesis of ALS. However, the evidence specifically", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if stress granules are involved in the pathogenesis of ALS. The evidence provided has three chunks. First, I need to understand what each chunk says. The first one (24090136:24090136_2) mentions that ALS-linked FUS/TLS is concentrated in stress granules under stress conditions. It also states that only mutant FUS, not the wild-type, associates with stress granules under most stress conditions. So this suggests a link between mutant FUS and stress granules, which might be relevant to pathogenesis. The second chunk (20699327:20699327_2) says that mutant FUS proteins causing ALS incorporate into stress granules. Similarly, the third chunk is the same as the second one, so it's redundant. So the key points are that mutant FUS proteins are involved in forming stress granules, and since these mutants are associated with ALS, there's a connection. The question is whether stress granules themselves are part of the pathogenesis. The evidence", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if stress granules are involved in the pathogenesis of ALS. The evidence provided has three chunks. First, chunk 24090136_2 mentions that ALS-linked FUS/TLS is concentrated in stress granules under stress conditions. It also says that only mutant FUS, not wild-type, associates with stress granules under most stress conditions. So this suggests a link between mutant FUS and stress granules, which might be relevant to pathogenesis. Then chunk 20699327_2 and 1 both state that mutant FUS proteins causing ALS incorporate into stress granules. These are two separate mentions of the same point, reinforcing that the mutant FUS is involved in forming stress granules. So putting this together, the evidence shows that mutant FUS, which is associated with ALS, does form stress granules. The connection here is that the presence of these mutant proteins in stress granules could contribute to the disease process. However, the base confidence would depend on how directly the evidence links stress granules to pathogenesis. Since the chunks mention that the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["19765185", "20606625", "20674093", "20699327", "21173160", "22405725", "23152885", "23257289", "23474818", "23629963", "24013423", "24090136", "24297750", "24312274", "24336168", "24920614", "25216585", "25429138", "25888396", "26557057"], "ideal_answer": "Stress granules are cytoplasmic inclusions that repress translation of a subset of RNAs in times of cellular stress, and several proteins implicated in neurodegeneration (i.e. Ataxin-2 and SMN) interact with stress granules. Mutant FUS proteins that cause amyotrophic lateral sclerosis incorporate into stress granules. ALS-linked mutations in profilin 1 alter stress granule dynamics, providing further evidence for the potential role of stress granules in ALS pathogenesis. ALS mutations in FUS NLS can impair FUS nuclear localization, induce cytoplasmic inclusions and stress granules, and potentially perturb RNA metabolism. Yes, stress granules (SGs) have been linked to several pathologies including inflammatory diseases, cancer, viral infection, and neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD)."}
{"question_id": "52f5083d2059c6d71c00001e", "question": "Does TGF-beta play a role in cardiac regeneration after myocardial infarction?", "retrieved_chunks": [{"doc_id": "15883211", "chunk_id": "15883211_0", "score": 8.152061462402344, "text": "TGF-beta conducted the myogenic differentiation of CD117+ stem cells by upregulating GATA-4 and NKx-2.5 expression. Therefore, the intramyocardial implantation of TGF-beta-preprogrammed CD117+ cells effectively assisted the myocardial regeneration and induced therapeutic angiogenesis, contributing to functional cardiac regeneration."}, {"doc_id": "18620057", "chunk_id": "18620057_0", "score": 6.200766563415527, "text": "Transforming growth factor (TGF)-beta plays a crucial role in cardiac repair by suppressing inflammation while promoting myofibroblast phenotypic modulation and extracellular matrix deposition."}, {"doc_id": "22146760", "chunk_id": "22146760_1", "score": 5.676668643951416, "text": "To investigate whether transmyocardial drilling revascularization combined with heparinized basic fibroblast growth factor (bFGF)-incorporating degradable stent implantation (TMDRSI) can promote myocardial regeneration after acute myocardial infarction"}], "context": "[15883211:15883211_0] TGF-beta conducted the myogenic differentiation of CD117+ stem cells by upregulating GATA-4 and NKx-2.5 expression. Therefore, the intramyocardial implantation of TGF-beta-preprogrammed CD117+ cells effectively assisted the myocardial regeneration and induced therapeutic angiogenesis, contributing to functional cardiac regeneration.\n[18620057:18620057_0] Transforming growth factor (TGF)-beta plays a crucial role in cardiac repair by suppressing inflammation while promoting myofibroblast phenotypic modulation and extracellular matrix deposition.\n[22146760:22146760_1] To investigate whether transmyocardial drilling revascularization combined with heparinized basic fibroblast growth factor (bFGF)-incorporating degradable stent implantation (TMDRSI) can promote myocardial regeneration after acute myocardial infarction", "answer": "<think> Okay, let's tackle this question. The user is asking if TGF-beta plays a role in cardiac regeneration after a myocardial infarction. I need to look at the evidence provided and see which parts support that. First, evidence document [15883211:15883211_0] says that TGF-beta helps myogenic differentiation of CD117+ stem cells by upregulating GATA-4 and NKx-2.5. This leads to myocardial regeneration and therapeutic angiogenesis. So that's a direct link between TGF-beta and cardiac regeneration. Then there's [18620057:18620057_0], which mentions TGF-beta's role in suppressing inflammation and promoting myofibroblast phenotypic modulation and ECM deposition. These processes are part of the repair process, so that also supports a role in cardiac regeneration. The third evidence [22146760:22146760_1] is about a study on TMDRSI with bFGF, but it doesn", "citations": [{"doc_id": "15883211", "chunk_id": "15883211_0"}, {"doc_id": "18620057", "chunk_id": "18620057_0"}, {"doc_id": "22146760", "chunk_id": "22146760_1"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if TGF-beta plays a role in cardiac regeneration after a myocardial infarction. I need to look at the evidence provided and see which parts support that. First, evidence document [15883211:15883211_0] says that TGF-beta helps myogenic differentiation of CD117+ stem cells by upregulating GATA-4 and NKx-2.5. This leads to myocardial regeneration and therapeutic angiogenesis. So that's a direct link between TGF-beta and cardiac regeneration. Then there's [18620057:18620057_0], which mentions TGF-beta's role in suppressing inflammation and promoting myofibroblast phenotypic modulation and ECM deposition. These processes are part of the repair process, so that also supports a role in cardiac regeneration. The third evidence [22146760:22146760_1] is about a study on TMDRSI with bFGF, but it doesn", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if TGF-beta plays a role in cardiac regeneration after a myocardial infarction. I need to look at the evidence provided. First, evidence document [15883211:15883211_0] says that TGF-beta helps myogenic differentiation of CD117+ stem cells by upregulating GATA-4 and NKx-2.5. This leads to myocardial regeneration and therapeutic angiogenesis. So that's a direct mention of TGF-beta's role in cardiac regeneration. Then, document [18620057:18620057_0] states that TGF-beta is crucial in cardiac repair by suppressing inflammation, promoting myofibroblast phenotypic modulation, and extracellular matrix deposition. These processes are part of the healing and regeneration process, so this also supports the role of TGF-beta. The third document [22146760:22146760_1] is about a study on TMDRSI combining bFG", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if TGF-beta plays a role in cardiac regeneration after a myocardial infarction. I need to look at the evidence provided. First, looking at the evidence documents. Document 15883211:15883211_0 mentions that TGF-beta helps in myogenic differentiation of CD117+ stem cells by upregulating GATA-4 and NKx-2.5. This leads to myocardial regeneration and therapeutic angiogenesis. So that's a direct link between TGF-beta and cardiac regeneration. Then document 18620057:18620057_0 states that TGF-beta is crucial in cardiac repair by suppressing inflammation, promoting myofibroblast phenotypic modulation, and extracellular matrix deposition. These processes are part of the healing and structural recovery after heart damage, which would contribute to regeneration. The third document, 22146760:22146760_1, talks about a study on TMDRSI combining drilling and", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["10198196", "12374778", "15883211", "16842199", "17322368", "18985280", "19966054", "22513374", "23293297"], "ideal_answer": "TGFβ signaling orchestrates the beneficial interplay between scar-based repair and cardiomyocyte-based regeneration to achieve complete heart regeneration."}
{"question_id": "56cf413f3975bb303a000009", "question": "Is there a genetic component for happiness?", "retrieved_chunks": [{"doc_id": "22885141", "chunk_id": "22885141_0", "score": 3.399440288543701, "text": "Although twin studies estimate that genetic factors account for 35-50% of the variance in human happiness, knowledge of specific genes is limited."}, {"doc_id": "26060713", "chunk_id": "26060713_0", "score": 3.2153449058532715, "text": "inally, a systematic review performed based on existing information. Results of studies on genetic factors indicated an average effectiveness of genetic about 35 -50 percent on happiness."}, {"doc_id": "20440640", "chunk_id": "20440640_0", "score": 2.9747071266174316, "text": "Biometric studies have shown that happiness is strongly affected by genes."}], "context": "[22885141:22885141_0] Although twin studies estimate that genetic factors account for 35-50% of the variance in human happiness, knowledge of specific genes is limited.\n[26060713:26060713_0] inally, a systematic review performed based on existing information. Results of studies on genetic factors indicated an average effectiveness of genetic about 35 -50 percent on happiness.\n[20440640:20440640_0] Biometric studies have shown that happiness is strongly affected by genes.", "answer": "<think> Okay, the user is asking if there's a genetic component to happiness. Let me look at the evidence provided. First, there's the twin studies mentioned in [22885141:22885141_0], which say that genetic factors account for 35-50% of variance in happiness. That's a direct statement about genetics. Then [26060713:26060713_0] repeats the same figure, 35-50%, from a systematic review. And [20440640:20440640_0] mentions biometric studies showing genes strongly affect happiness. So all three sources point to a genetic component, with the percentages varying slightly but generally around 35-50%. The confidence here is pretty high because multiple studies are cited. The model's base confidence should be high, maybe 0.95, since there's consensus across different types of studies (twin, systematic review, biometric). I need to make sure the answer is concise and cites the", "citations": [{"doc_id": "22885141", "chunk_id": "22885141_0"}, {"doc_id": "26060713", "chunk_id": "26060713_0"}, {"doc_id": "20440640", "chunk_id": "20440640_0"}], "candidates": [{"answer": "<think> Okay, the user is asking if there's a genetic component to happiness. Let me look at the evidence provided. First, there's the twin studies mentioned in [22885141:22885141_0], which say that genetic factors account for 35-50% of variance in happiness. That's a direct statement about genetics. Then [26060713:26060713_0] repeats the same figure, 35-50%, from a systematic review. And [20440640:20440640_0] mentions biometric studies showing genes strongly affect happiness. So all three sources point to a genetic component, with the percentages varying slightly but generally around 35-50%. The confidence here is pretty high because multiple studies are cited. The model's base confidence should be high, maybe 0.95, since there's consensus across different types of studies (twin, systematic review, biometric). I need to make sure the answer is concise and cites the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, the user is asking if there's a genetic component to happiness. Let me look at the evidence provided. First, there are three documents mentioned. The first one says twin studies estimate genetic factors account for 35-50% of variance in happiness, but specific genes are limited. The second document repeats a systematic review finding an average effectiveness of genetic factors at 35-50%. The third mentions biometric studies showing genes strongly affect happiness. So all three sources agree that genetics play a significant role, with the percentage ranging between 35-50%. However, the first and second documents note that specific genes aren't well understood yet. The answer needs to be concise and include citations. The answer should state that there is a genetic component, citing the twin studies and systematic review. The confidence level should be high since multiple sources support this. But I need to check if any of the evidence contradicts. No, all three back the genetic influence. So base_confidence can be 0.95 or so. Wait, but the first document mentions \"knowledge of specific genes is limited,\" so maybe the confidence isn't 10", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, the user is asking if there's a genetic component to happiness. Let me look at the evidence provided. First, the evidence has three chunks. The first one says twin studies estimate genetic factors account for 35-50% of variance in happiness, but specific genes are limited. The second chunk repeats that genetic factors have an average effectiveness of 35-50% on happiness. The third mentions biometric studies showing happiness is strongly affected by genes. So all three sources point to a genetic component, with the percentage ranging between 35-50%. The confidence here is pretty high since multiple studies are cited. However, the first chunk notes that specific genes aren't well understood, but that doesn't negate the presence of a genetic component. The answer should mention the range and cite the relevant chunks. The base confidence can be set to 0.95 because the evidence consistently supports the genetic link, even if specifics are limited. </think> { \"answer\": \"Yes, twin studies and biometric research indicate a genetic component for happiness, with genetic factors accounting for 35-50% of variance in human happiness [2", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["19569406", "19728071", "20397744", "20440640", "20981772", "22885141", "23769682", "24690898", "26060713"], "ideal_answer": "Results of studies on genetic factors indicated an average effectiveness of genetic about 35 -50 percent on happiness. The MAOA gene predicts happiness in women. The heritability of happiness was estimated at 22% for males and 41% in females."}
{"question_id": "56c1d857ef6e394741000033", "question": "What enzyme is inhibied by Opicapone?", "retrieved_chunks": [{"doc_id": "24925090", "chunk_id": "24925090_2", "score": 2.872832775115967, "text": "Opicapone is a novel third generation catechol-O-methyltransferase (COMT) inhibitor."}, {"doc_id": "23248072", "chunk_id": "23248072_1", "score": 2.8310461044311523, "text": "Opicapone is a novel catechol-O-methyltransferase (COMT) inhibitor."}, {"doc_id": "24925090", "chunk_id": "24925090_0", "score": 2.387336492538452, "text": "BACKGROUND AND OBJECTIVES: Opicapone is a novel third generation catechol-O-methyltransferase (COMT) inhibitor. The purpose of this study was to compare the levodopa pharmacokinetic profile throughout a day driven by the COMT inhibition either following repeated doses of opicapone or concomitant administration with entacapone."}], "context": "[24925090:24925090_2] Opicapone is a novel third generation catechol-O-methyltransferase (COMT) inhibitor.\n[23248072:23248072_1] Opicapone is a novel catechol-O-methyltransferase (COMT) inhibitor.\n[24925090:24925090_0] BACKGROUND AND OBJECTIVES: Opicapone is a novel third generation catechol-O-methyltransferase (COMT) inhibitor. The purpose of this study was to compare the levodopa pharmacokinetic profile throughout a day driven by the COMT inhibition either following repeated doses of opicapone or concomitant administration with entacapone.", "answer": "<think> Okay, let's tackle this question. The user is asking which enzyme is inhibited by Opicapone. The evidence provided has three entries. First, looking at the evidence documents. The first one, 24925090:24925090_2, says Opicapone is a novel third-generation COMT inhibitor. The second document, 23248072:23248072_1, also states it's a novel COMT inhibitor. The third document, 24925090:24925090_0, mentions the same thing about COMT inhibition. So all three sources consistently point to COMT as the enzyme inhibited by Opicapone. The answer should be COMT. The citations are from documents 24925090 and 23248072. The confidence is high since all three pieces of evidence agree. So base_confidence would be 1.0. </think> { \"answer\": \"Opicapone inhibits catechol-O-methyltransfer", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which enzyme is inhibited by Opicapone. The evidence provided has three entries. First, looking at the evidence documents. The first one, 24925090:24925090_2, says Opicapone is a novel third-generation COMT inhibitor. The second document, 23248072:23248072_1, also states it's a novel COMT inhibitor. The third document, 24925090:24925090_0, mentions the same thing about COMT inhibition. So all three sources consistently point to COMT as the enzyme inhibited by Opicapone. The answer should be COMT. The citations are from documents 24925090 and 23248072. The confidence is high since all three pieces of evidence agree. So base_confidence would be 1.0. </think> { \"answer\": \"Opicapone inhibits catechol-O-methyltransfer", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which enzyme is inhibited by Opicapone. Looking at the evidence provided, there are three references. First, the evidence mentions that Opicapone is a novel third-generation catechol-O-methyltransferase (COMT) inhibitor. Then another reference states it's a novel COMT inhibitor. The third one is a background section that again refers to COMT inhibition. All three documents point to COMT as the enzyme being inhibited. I need to make sure there's no conflicting information here. All the chunks from the evidence consistently mention COMT. The answer should be straightforward. The confidence level is high since all sources agree. So the answer is COMT, and the confidence can be set to 1.0 because the evidence is unanimous. </think> { \"answer\": \"Opicapone inhibits catechol-O-methyltransferase (COMT) [24925090:24925090_2][23248072:23248072_1][2492509", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which enzyme is inhibited by Opicapone. Looking at the evidence provided, there are three references. First, the documents mention that Opicapone is a novel third-generation catechol-O-methyltransferase (COMT) inhibitor. The first two entries [24925090:24925090_2] and [23248072:23248072_1] both state that Opicapone is a COMT inhibitor. The third entry [24925090:24925090_0] also mentions the same thing, talking about comparing levodopa pharmacokinetics with COMT inhibition from opicapone. So all three sources consistently point to COMT as the enzyme inhibited by Opicapone. The answer should be COMT. Now, for the confidence, since all three documents agree, the confidence is high. The model can be confident here because there's no conflicting information. So base_confidence would be 1.0. </think> {", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["23248072", "23336248", "24148813", "24271646", "24925090"], "ideal_answer": "Opicapone is a novel catechol-O-methyltransferase (COMT) inhibitor to be used as adjunctive therapy in levodopa-treated patients with Parkinson's disease"}
{"question_id": "5140569623fec90375000003", "question": "What kind of affinity purification would you use in order to isolate soluble lysosomal proteins?", "retrieved_chunks": [{"doc_id": "18370023", "chunk_id": "18370023_0", "score": 6.215539455413818, "text": "This chapter describes the process of production, purification, separation, and mass spectrometry identification of soluble lysosomal proteins. The rationale for purification of these proteins resides in their characteristic sugar, the mannose-6-phosphate (M6P), which allows an easy purification by affinity chromatography on immobilized M6P receptor (MPR"}, {"doc_id": "15789345", "chunk_id": "15789345_0", "score": 5.750038146972656, "text": "Proteins containing mannose 6-phosphate (Man6-P), a carbohydrate modification used for targeting resident soluble lysosomal proteins to the lysosome, were affinity-purified using immobilized Man6-P receptor."}, {"doc_id": "11079561", "chunk_id": "11079561_0", "score": 4.473684787750244, "text": "Since lysosomal soluble proteins are characterized by the presence of mannose-6-phosphate, they were purified on an affinity support bearing mannose-6-phosphate receptor"}], "context": "[18370023:18370023_0] This chapter describes the process of production, purification, separation, and mass spectrometry identification of soluble lysosomal proteins. The rationale for purification of these proteins resides in their characteristic sugar, the mannose-6-phosphate (M6P), which allows an easy purification by affinity chromatography on immobilized M6P receptor (MPR\n[15789345:15789345_0] Proteins containing mannose 6-phosphate (Man6-P), a carbohydrate modification used for targeting resident soluble lysosomal proteins to the lysosome, were affinity-purified using immobilized Man6-P receptor.\n[11079561:11079561_0] Since lysosomal soluble proteins are characterized by the presence of mannose-6-phosphate, they were purified on an affinity support bearing mannose-6-phosphate receptor", "answer": "<think> Okay, let's tackle this question. The user is asking about the type of affinity purification used to isolate soluble lysosomal proteins. Looking at the evidence provided, all three sources mention mannose-6-phosphate (M6P) and the Man6-P receptor. First, I need to recall what affinity chromatography involves. It's a technique where a molecule is used to bind specifically to the target protein, allowing for its isolation. The key here is the M6P tag on lysosomal proteins. The first evidence mentions immobilized M6P receptor (MPR). The second and third references talk about using the Man6-P receptor. Wait, are MPR and Man6-P receptor the same thing? Probably yes, since they're both related to mannose-6-phosphate. So the answer should be affinity chromatography using immobilized M6P receptor or Man6-P receptor. I need to check if all sources agree. All three mention using the M6P or Man6-P receptor for purification. The answer should cite the relevant documents. The confidence level is high since all three pieces of evidence point to the same method. So base_confidence would", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking about the type of affinity purification used to isolate soluble lysosomal proteins. Looking at the evidence provided, all three sources mention mannose-6-phosphate (M6P) and the Man6-P receptor. First, I need to recall what affinity chromatography involves. It's a technique where a molecule is used to bind specifically to the target protein, allowing for its isolation. The key here is the M6P tag on lysosomal proteins. The first evidence mentions immobilized M6P receptor (MPR). The second and third references talk about using the Man6-P receptor. Wait, are MPR and Man6-P receptor the same thing? Probably yes, since they're both related to mannose-6-phosphate. So the answer should be affinity chromatography using immobilized M6P receptor or Man6-P receptor. I need to check if all sources agree. All three mention using the M6P or Man6-P receptor for purification. The answer should cite the relevant documents. The confidence level is high since all three pieces of evidence point to the same method. So base_confidence would", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the type of affinity purification used to isolate soluble lysosomal proteins. Looking at the evidence provided, there are three documents mentioned. First, document 18370023:18370023_0 talks about mannose-6-phosphate (M6P) being a characteristic sugar for these proteins and that affinity chromatography on immobilized M6P receptor is used. Then, document 15789345:15789345_0 mentions Man6-P receptor for affinity purification. The third document, 11079561:11079561_0, also refers to mannose-6-phosphate receptor. So all three sources point to using affinity chromatography with immobilized M6P or Man6-P receptors. The key here is the mannose-6-phosphate (M6P) tag, which is specific to lysosomal proteins. The answer should mention that the method uses an affinity support with the M6P receptor. The confidence is high since all", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the type of affinity purification used to isolate soluble lysosomal proteins. Looking at the evidence provided, all three sources mention mannose-6-phosphate (M6P) and the Man6-P receptor. First, I need to recall what affinity chromatography involves. It's a technique where a protein is purified by binding to a specific ligand attached to a matrix. The key here is the M6P on lysosomal proteins. The first evidence mentions immobilized M6P receptor (MPR). The second and third references talk about using the Man6-P receptor. Wait, are MPR and Man6-P receptor the same thing? I think they are related. The M6P receptor is a protein that binds to M6P, which is found on lysosomal proteins. So, affinity purification would involve using a column with this receptor to capture the proteins. So the answer should be affinity chromatography using immobilized Man6-P receptor. The confidence is high because all three sources point to this method. The citations are from different chunks but all support the same approach. I need to make sure the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["11079561", "15789345", "16145712", "16399764", "16709564", "17258946", "18370023", "18507433", "18977398", "19383612", "22158965"], "ideal_answer": "The rationale for purification of the soluble lysosomal proteins resides in their characteristic sugar, the mannose-6-phosphate (M6P), which allows an easy purification by affinity chromatography on immobilized M6P receptors."}
{"question_id": "552faa43bc4f83e828000004", "question": "Which are the genes thought to be regulated by EWS/FLI?", "retrieved_chunks": [{"doc_id": "17114343", "chunk_id": "17114343_1", "score": 7.314212799072266, "text": "The gene that was most reproducibly up-regulated by EWS/FLI was NR0B1."}, {"doc_id": "17114343", "chunk_id": "17114343_0", "score": 7.126935958862305, "text": "The gene that was most reproducibly up-regulated by EWS/FLI was NR0B1"}, {"doc_id": "18927503", "chunk_id": "18927503_0", "score": 6.539081573486328, "text": "We recently showed that EWS/FLI interacts with GGAA-microsatellites to regulate some of its target genes, including NR0B1, an EWS/FLI-regulated gene that is required for the oncogenic phenotype of Ewings sarcoma."}], "context": "[17114343:17114343_1] The gene that was most reproducibly up-regulated by EWS/FLI was NR0B1.\n[17114343:17114343_0] The gene that was most reproducibly up-regulated by EWS/FLI was NR0B1\n[18927503:18927503_0] We recently showed that EWS/FLI interacts with GGAA-microsatellites to regulate some of its target genes, including NR0B1, an EWS/FLI-regulated gene that is required for the oncogenic phenotype of Ewings sarcoma.", "answer": "<think> Okay, let's tackle this question. The user wants to know which genes are thought to be regulated by EWS/FLI, based on the provided evidence. First, I'll look at the evidence given. There are three documents here. The first two (17114343:17114343_0 and 17114343:17114343_1) both mention that NR0B1 is the gene most reproducibly up-regulated by EWS/FLI. The third document (18927503:18927506_0) states that EWS/FLI interacts with GGAA microsatellites to regulate some target genes, including NR0B1, which is required for the oncogenic phenotype of Ewing's sarcoma. So, NR0B1 is mentioned multiple times as a gene regulated by EWS/FLI. The third document adds that NR0B1 is part of the target genes regulated by EWS/FLI. The other documents confirm its up-regulation.", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user wants to know which genes are thought to be regulated by EWS/FLI, based on the provided evidence. First, I'll look at the evidence given. There are three documents here. The first two (17114343:17114343_0 and 17114343:17114343_1) both mention that NR0B1 is the gene most reproducibly up-regulated by EWS/FLI. The third document (18927503:18927506_0) states that EWS/FLI interacts with GGAA microsatellites to regulate some target genes, including NR0B1, which is required for the oncogenic phenotype of Ewing's sarcoma. So, NR0B1 is mentioned multiple times as a gene regulated by EWS/FLI. The third document adds that NR0B1 is part of the target genes regulated by EWS/FLI. The other documents confirm its up-regulation.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user wants to know which genes are thought to be regulated by EWS/FLI, based on the provided evidence. Looking at the evidence, there are three references. The first two (17114343:17114343_0 and 17114343:17114343_1) both mention that NR0B1 is the gene most reproducibly up-regulated by EWS/FLI. The third reference (18927503:18927503_0) says that EWS/FLI interacts with GGAA microsatellites to regulate some target genes, including NR0B1, which is required for the oncogenic phenotype of Ewing's sarcoma. So, NR0B1 is mentioned in all three sources. The first two directly state it's the most up-regulated gene, and the third confirms it as a regulated gene. The other genes mentioned are not specific, so the answer should focus on NR0B1. The confidence level", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which genes are thought to be regulated by EWS/FLI. The evidence provided has three chunks. First, I need to look at each chunk. The first two chunks from 17114343 both mention that NR0B1 is the most reproducibly up-regulated gene by EWS/FLI. The third chunk from 18927503 says that EWS/FLI interacts with GGAA microsatellites to regulate some target genes, including NR0B1, which is an EWS/FLI-regulated gene required for the oncogenic phenotype. So, NR0B1 is mentioned in multiple sources. The first two chunks directly state it's the most up-regulated, and the third chunk adds that it's part of the regulated genes. The answer should be NR0B1, citing all three sources. But wait, the third chunk is a bit different. It says EWS/FLI regulates some target genes, including NR0B1. So NR0B1 is indeed regulated by EWS/FLI. The", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["15492248", "16697960", "17114343", "18927503", "19718047", "19920188", "23527175"], "ideal_answer": "The EWS/FLI translocation product is the causative oncogene in Ewing sarcoma and acts as an aberrant transcription factor. EWS/FLI dysregulates gene expression during tumorigenesis by abnormally activating or repressing genes. The expression levels of a significant number of genes are affected in Ewing sarcoma, some of which are known to be directly or indirectly regulated by EWS/FLI. Such genes are BCL11B, NRoB1, GSTM4, NKX2.2 and p53."}
{"question_id": "52fe58f82059c6d71c00007a", "question": "Do archaeal genomes contain one or multiple origins of replication?", "retrieved_chunks": [{"doc_id": "15337158", "chunk_id": "15337158_0", "score": 8.68394660949707, "text": "Until recently, the only archaeon for which a bona fide origin of replication was reported was Pyrococcus abyssi, where a single origin was identified. Although several in silico analyses have suggested that some archaeal species might contain more than one origin, this has only been demonstrated recently."}, {"doc_id": "24822028", "chunk_id": "24822028_1", "score": 7.2660698890686035, "text": "In bacteria and eukaryotes, replication initiates from single and multiple origins, respectively, while archaea can adopt either of the two modes."}, {"doc_id": "22978470", "chunk_id": "22978470_1", "score": 7.046987533569336, "text": "While multiple replication origins have been observed in archaea, considerably less is known about their evolutionary processes."}], "context": "[15337158:15337158_0] Until recently, the only archaeon for which a bona fide origin of replication was reported was Pyrococcus abyssi, where a single origin was identified. Although several in silico analyses have suggested that some archaeal species might contain more than one origin, this has only been demonstrated recently.\n[24822028:24822028_1] In bacteria and eukaryotes, replication initiates from single and multiple origins, respectively, while archaea can adopt either of the two modes.\n[22978470:22978470_1] While multiple replication origins have been observed in archaea, considerably less is known about their evolutionary processes.", "answer": "<think> Okay, let's tackle this question. The user wants to know if archaeal genomes have one or multiple origins of replication. The evidence provided has three references. First, reference 15337158:15337158_0 mentions that Pyrococcus abyssi had a single origin, but some in silico analyses suggested others might have multiple, though this hasn't been demonstrated yet. Then, reference 24822028:24822028_1 states that archaea can use either single or multiple origins. The third reference, 22978470:22978470_1, says multiple origins have been observed in archaea but less is known about their evolution. So, the answer needs to be concise. The key points are that some archaea have one, others may have multiple, but it's not fully established. The confidence should reflect that there's some evidence for both possibilities, but the recent studies show that multiple origins are possible. However, the first reference says only Pyrococcus had a single origin, but others", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user wants to know if archaeal genomes have one or multiple origins of replication. The evidence provided has three references. First, reference 15337158:15337158_0 mentions that Pyrococcus abyssi had a single origin, but some in silico analyses suggested others might have multiple, though this hasn't been demonstrated yet. Then, reference 24822028:24822028_1 states that archaea can use either single or multiple origins. The third reference, 22978470:22978470_1, says multiple origins have been observed in archaea but less is known about their evolution. So, the answer needs to be concise. The key points are that some archaea have one, others may have multiple, but it's not fully established. The confidence should reflect that there's some evidence for both possibilities, but the recent studies show that multiple origins are possible. However, the first reference says only Pyrococcus had a single origin, but others", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking whether archaeal genomes have one or multiple origins of replication. The evidence provided has three documents. First, document 15337158:15337158_0 mentions that Pyrococcus abyssi, an archaeon, had a single origin identified. However, some in silico analyses suggested other species might have multiple origins, but this hasn't been demonstrated yet. So this document seems to indicate that while there's one known case of a single origin, others might have multiple, but it's not confirmed. Then, document 24822028:24822028_1 states that archaea can adopt either single or multiple origins, similar to bacteria and eukaryotes. This suggests that archaeal genomes can have either one or multiple origins, depending on the species. The third document, 22978470:22978470_1, mentions that multiple origins are observed in archaea but less is known about their evolutionary processes. This supports the idea that some archae", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking whether archaeal genomes have one or multiple origins of replication. The evidence provided has three documents. First, document 15337158:15337158_0 mentions that Pyrococcus abyssi, an archaeon, had a single origin identified. However, some in silico analyses suggested other species might have multiple origins, but this hasn't been demonstrated yet. So this seems to indicate that while some archaea may have multiple, it's not confirmed yet. Then document 24822028:24822028_1 states that archaea can adopt either single or multiple origins, similar to bacteria and eukaryotes. This suggests that it's possible for archaea to have either, but not certain. The third document, 22978470:22978470_1, says that multiple origins are observed in archaea, but less is known about their evolutionary processes. So this supports the idea that some have multiple, but there's limited knowledge. Putting it", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["11521661", "11967086", "12237132", "12646230", "14526006", "15197606", "15337158", "15876567", "16249118", "16321966", "16980466", "17350933", "17392430", "17511521", "17956224", "18922777", "20667100", "20850498", "20978102", "21364800", "21784908", "22812406", "22942672", "22978470", "23375370", "24185008", "2541880"], "ideal_answer": "Some archaea replicate from single origins but most archaea and all eukaryotes replicate using multiple origins. Multiple functional sites of origin of replication may exist in the genomes of most archaea. This has only been demonstrated recently. Two studies have shown that multiple origins of replication function in two archaeal species."}
{"question_id": "533c3af6c45e13371400000d", "question": "Which pathological conditions are caused by mutations in the CYLD gene?", "retrieved_chunks": [{"doc_id": "20838385", "chunk_id": "20838385_0", "score": 5.68389368057251, "text": "In contrast with previous studies showing the development of benign tumors by mutations in the CYLD gene, here we provide evidence that the occurrence of mutations in the CYLD gene in tumorigenic epidermal cells (carrying previous mutations) increases the aggressiveness of carcinomas, mainly through enhancement of the expression of angiogenic factors, having therefore a key role in epidermal cancer malignancy"}, {"doc_id": "17851586", "chunk_id": "17851586_1", "score": 5.580933094024658, "text": "rooke-Spiegler syndrome, familial cylindromatosis, and familial trichoepithelioma are autosomal-dominant genetic predispositions for benign tumors of skin appendages caused by mutations in the CYLD gene localized on chromosome 16q12-q13"}, {"doc_id": "19076795", "chunk_id": "19076795_0", "score": 4.799892902374268, "text": "Mutations in the CYLD gene, which is also the gene responsible for familial cylindromatosis, have been reported recently"}], "context": "[20838385:20838385_0] In contrast with previous studies showing the development of benign tumors by mutations in the CYLD gene, here we provide evidence that the occurrence of mutations in the CYLD gene in tumorigenic epidermal cells (carrying previous mutations) increases the aggressiveness of carcinomas, mainly through enhancement of the expression of angiogenic factors, having therefore a key role in epidermal cancer malignancy\n[17851586:17851586_1] rooke-Spiegler syndrome, familial cylindromatosis, and familial trichoepithelioma are autosomal-dominant genetic predispositions for benign tumors of skin appendages caused by mutations in the CYLD gene localized on chromosome 16q12-q13\n[19076795:19076795_0] Mutations in the CYLD gene, which is also the gene responsible for familial cylindromatosis, have been reported recently", "answer": "<think> Okay, let's tackle this question. The user is asking which pathological conditions are caused by mutations in the CYLD gene. I need to look at the evidence provided to find the answer. First, looking at the evidence: The first document (20838385) talks about CYLD gene mutations leading to more aggressive carcinomas through angiogenic factors. But it mentions \"tumorigenic epidermal cells\" and \"carcinomas,\" which seems like a malignant condition. However, the initial studies mentioned were about benign tumors, but this evidence suggests a different outcome. The second document (17851586) explicitly states that rooke-Spiegler syndrome, familial cylindromatosis, and familial trichoepithelioma are autosomal-dominant conditions caused by CYLD gene mutations. These are all related to benign skin tumors. The third document (19076795) reiterates that CYLD mutations are responsible for familial cylindromatosis, which matches the second document. So, the answer should include the conditions mentioned in the second and third documents: rooke-S", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which pathological conditions are caused by mutations in the CYLD gene. I need to look at the evidence provided to find the answer. First, looking at the evidence: The first document (20838385) talks about CYLD gene mutations leading to more aggressive carcinomas through angiogenic factors. But it mentions \"tumorigenic epidermal cells\" and \"carcinomas,\" which seems like a malignant condition. However, the initial studies mentioned were about benign tumors, but this evidence suggests a different outcome. The second document (17851586) explicitly states that rooke-Spiegler syndrome, familial cylindromatosis, and familial trichoepithelioma are autosomal-dominant conditions caused by CYLD gene mutations. These are all related to benign skin tumors. The third document (19076795) reiterates that CYLD mutations are responsible for familial cylindromatosis, which matches the second document. So, the answer should include the conditions mentioned in the second and third documents: rooke-S", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user wants to know which pathological conditions are caused by mutations in the CYLD gene. Looking at the evidence provided, there are three references. First, reference 20838385 talks about CYLD mutations leading to benign tumors but also mentions increased aggressiveness of carcinomas through angiogenic factors. So that's a possible condition, maybe some type of skin cancer? Then, reference 17851586 mentions rook-Spiegler syndrome, familial cylindromatosis, and familial trichoepithelioma as autosomal-dominant conditions caused by CYLD mutations. These are all related to benign skin tumors. The third reference, 19076795, just states that CYLD mutations are responsible for familial cylindromatosis, which is mentioned in the second reference. So that's a repeat of the same condition. Putting this together, the main conditions are the ones listed in the second reference: rook-Spiegler syndrome, familial cylindromatosis, and familial trichoepithelioma. The first reference mentions", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to figure out which pathological conditions are caused by mutations in the CYLD gene based on the provided evidence. Let me start by looking at each of the three evidence snippets. The first one mentions that mutations in CYLD lead to benign tumors, but there's a contrast with previous studies. It also says that these mutations increase the aggressiveness of carcinomas through angiogenic factors. So this suggests that CYLD mutations are involved in both benign and more aggressive cancers. The second snippet talks about three conditions: rooke-Spiegler syndrome, familial cylindromatosis, and familial trichoepithelioma. All of these are autosomal dominant and cause benign skin tumors due to CYLD gene mutations on chromosome 16q12-q13. So those three are definitely related. The third snippet just states that CYLD mutations are responsible for familial cylindromatosis, which is mentioned again in the second snippet. So that's a repeat of the same condition. Putting this together, the main conditions from the evidence are the three listed in the second snippet: rooke-Spiegler syndrome, familial cylindromatosis,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["12190880", "15024746", "15541090", "16922728", "17083363", "17851586", "18806492", "19076795", "19668078", "19730223", "19911186", "19917957", "20132422", "20151946", "20607853", "20838385", "20972631", "21345146", "21389835", "21552290", "21577203", "21598248", "22077640", "23404581", "23426135", "23641715", "23694822"], "ideal_answer": "Since loss of CYLD expression can be observed in different types of human cancer, it is now well established that CYLD acts as a tumor suppressor gene. Pathogenic mutations in CYLD can be identified in patients affected with Brooke-Spiegler syndrome, (Familial) Cylindromatosis or multiple familial trichoepithelioma. CYLD expression has also been reported to be dramatically downregulated in basal cell carcinoma (BCC), the most common cancer in humans."}
{"question_id": "56c5fd325795f9a73e000005", "question": "Which is the genetic basis of Spinal Muscular Atrophy (SMA)?", "retrieved_chunks": [{"doc_id": "17076267", "chunk_id": "17076267_0", "score": 10.008273124694824, "text": "The molecular genetic basis of spinal muscular atrophy (SMA), an autosomal recessive neuromuscular disorder, is the loss of function of the survival motor neuron gene (SMN1)"}, {"doc_id": "30368521", "chunk_id": "30368521_0", "score": 8.076568603515625, "text": "Spinal Muscular Atrophy (SMA) is caused by genetic mutations in the SMN1 gene, resulting in drastically reduced levels of Survival of Motor Neuron (SMN) protein."}, {"doc_id": "29799103", "chunk_id": "29799103_0", "score": 7.4662556648254395, "text": "Spinal muscular atrophy (SMA) is an autosomal recessive genetic disorder caused by survival motor neuron (SMN) protein deficiency leading the loss of motor neurons in the anterior horns of the spinal cord and brainstem."}], "context": "[17076267:17076267_0] The molecular genetic basis of spinal muscular atrophy (SMA), an autosomal recessive neuromuscular disorder, is the loss of function of the survival motor neuron gene (SMN1)\n[30368521:30368521_0] Spinal Muscular Atrophy (SMA) is caused by genetic mutations in the SMN1 gene, resulting in drastically reduced levels of Survival of Motor Neuron (SMN) protein.\n[29799103:29799103_0] Spinal muscular atrophy (SMA) is an autosomal recessive genetic disorder caused by survival motor neuron (SMN) protein deficiency leading the loss of motor neurons in the anterior horns of the spinal cord and brainstem.", "answer": "<think> Okay, so the user is asking about the genetic basis of Spinal Muscular Atrophy (SMA). Let me look at the evidence provided. First, I see three references. The first one says the molecular genetic basis is the loss of function of the SMN1 gene. The second mentions mutations in SMN1 leading to reduced SMN protein. The third talks about SMN protein deficiency causing the disorder. All three sources point to SMN1 as the gene involved. The first two specifically mention mutations in SMN1, and the third refers to SMN protein deficiency, which is related to the SMN1 gene. The key here is that all the evidence consistently identifies SMN1 as the genetic cause. The answer needs to be concise with citations. So I should mention SMN1 and cite the relevant chunks. The confidence level is high since all three sources agree. Let me check if there's any conflicting info, but no, they all align. So the answer is SMN1 gene mutations, citing the first two chunks. Base confidence would be 1.0 since it's consistent across all evidence. </think> { \"answer\":", "citations": [], "candidates": [{"answer": "<think> Okay, so the user is asking about the genetic basis of Spinal Muscular Atrophy (SMA). Let me look at the evidence provided. First, I see three references. The first one says the molecular genetic basis is the loss of function of the SMN1 gene. The second mentions mutations in SMN1 leading to reduced SMN protein. The third talks about SMN protein deficiency causing the disorder. All three sources point to SMN1 as the gene involved. The first two specifically mention mutations in SMN1, and the third refers to SMN protein deficiency, which is related to the SMN1 gene. The key here is that all the evidence consistently identifies SMN1 as the genetic cause. The answer needs to be concise with citations. So I should mention SMN1 and cite the relevant chunks. The confidence level is high since all three sources agree. Let me check if there's any conflicting info, but no, they all align. So the answer is SMN1 gene mutations, citing the first two chunks. Base confidence would be 1.0 since it's consistent across all evidence. </think> { \"answer\":", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking for the genetic basis of Spinal Muscular Atrophy (SMA). I need to look at the provided evidence to find the answer. Looking at the first piece of evidence: it mentions that SMA is caused by the loss of function of the SMN1 gene. The second one says mutations in SMN1 lead to reduced SMN protein. The third one also points to SMN protein deficiency due to the SMN1 gene. All three sources consistently mention SMN1 as the gene involved. The answer should be that the genetic basis is the SMN1 gene. The citations are from different chunks but all point to SMN1. The confidence level should be high since all three sources agree. So, I'll set the answer to \"the survival motor neuron gene (SMN1)\" with citations from all three documents. Base confidence can be 1.0 since there's consensus across all evidence. </think> { \"answer\": \"the survival motor neuron gene (SMN1) [17076267:17076267_0,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question about the genetic basis of Spinal Muscular Atrophy (SMA). The user wants a concise answer with citations and a confidence score. First, I need to look at the evidence provided. There are three references here. All of them mention the SMN1 gene as being involved in SMA. The first one says the molecular basis is the loss of function of the SMN1 gene. The second reference also points out mutations in SMN1 leading to reduced SMN protein. The third mentions SMN protein deficiency causing the disorder. So, the common thread here is that SMA is caused by issues with the SMN1 gene. All three sources agree on this. The answer should state that the genetic basis is the SMN1 gene. Now, I need to cite the documents. The first and second references both mention SMN1, but the third one also refers to the same gene. However, the third one uses \"survival motor neuron (SMN) protein\" but the gene is still SMN1. So, the citations can be from any of them. Let's check the chunk IDs. The first document is", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["10339583", "11442327", "12115944", "12220455", "17076267", "19062530", "19646678", "20225030", "22323744", "22628388", "9073029", "9731538"], "ideal_answer": "The molecular genetic basis of spinal muscular atrophy (SMA), an autosomal recessive neuromuscular disorder, is the loss of function of the survival motor neuron gene (SMN1). Mutations of the SMN1 gene are responsible for SMA. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. A critical question is why only the homozygous loss of SMN1, and not SMN2, results in spinal muscular atrophy (SMA). H4F5 is also highly deleted in type I SMA chromosomes, and thus is a candidate phenotypic modifier for SMA. The molecular genetic basis of spinal muscular atrophy (SMA), an autosomal recessive neuromuscular disorder, is the loss of function of the survival motor neuron gene (SMN1)."}
{"question_id": "571f3b320fd6f91b68000007", "question": "Which are the common symptoms of Cushing's syndrome?", "retrieved_chunks": [{"doc_id": "24062268", "chunk_id": "24062268_0", "score": 8.759344100952148, "text": "Cushing syndrome is the constellation of signs and symptoms caused by protracted exposure to glucocorticoids. The most common cause of Cushing syndrome in children and adolescents is exogenous administration of glucocorticoids. Presenting features commonly include weight gain, growth retardation, hirsutism, obesity, striae, acne and hypertension"}, {"doc_id": "28413388", "chunk_id": "28413388_0", "score": 6.186100006103516, "text": "Cushing's syndrome is a rare endocrine disorder that comprises a large group of signs and symptoms resulting from chronic exposure to excess corticosteroids. Most cases of Cushing's syndrome are due to increased adrenocorticotropic hormone production from a pituitary adenoma, which is referred to as Cushing's disease"}, {"doc_id": "17322955", "chunk_id": "17322955_0", "score": 4.435247898101807, "text": "This is a rare syndrome and its main endocrine manifestation, primary pigmented nodular adrenal disease (PPNAD), is an uncommon cause of adrenocorticotropic hormone-independent Cushing's syndrome.We report the case of a 20-year-old patient with a history of weight gain, hirsutism, acne, secondary amenorrhea and facial lentiginosis."}], "context": "[24062268:24062268_0] Cushing syndrome is the constellation of signs and symptoms caused by protracted exposure to glucocorticoids. The most common cause of Cushing syndrome in children and adolescents is exogenous administration of glucocorticoids. Presenting features commonly include weight gain, growth retardation, hirsutism, obesity, striae, acne and hypertension\n[28413388:28413388_0] Cushing's syndrome is a rare endocrine disorder that comprises a large group of signs and symptoms resulting from chronic exposure to excess corticosteroids. Most cases of Cushing's syndrome are due to increased adrenocorticotropic hormone production from a pituitary adenoma, which is referred to as Cushing's disease\n[17322955:17322955_0] This is a rare syndrome and its main endocrine manifestation, primary pigmented nodular adrenal disease (PPNAD), is an uncommon cause of adrenocorticotropic hormone-independent Cushing's syndrome.We report the case of a 20-year-old patient with a history of weight gain, hirsutism, acne, secondary amenorrhea and facial lentiginosis.", "answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. The question is about common symptoms of Cushing's syndrome. First, I'll look at the evidence provided. The first document mentions weight gain, growth retardation, hirsutism, obesity, striae, acne, and hypertension as presenting features. The second document talks about a rare disorder with signs from chronic corticosteroid exposure but doesn't list specific symptoms. The third document mentions weight gain, hirsutism, acne, secondary amenorrhea, and facial lentiginosis. So the common symptoms across these sources are weight gain, hirsutism, obesity, acne, striae, hypertension, and maybe secondary amenorrhea. However, the third document's symptoms might be more specific to certain types of Cushing's syndrome. The first document is more general. The answer should be concise, so I'll list the most common ones mentioned in multiple sources. The base confidence would be high since these are repeated across different chunks. Let me check each chunk again to make sure. Yes, weight gain, hirsutism, acne, obesity, striae,", "citations": [], "candidates": [{"answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. The question is about common symptoms of Cushing's syndrome. First, I'll look at the evidence provided. The first document mentions weight gain, growth retardation, hirsutism, obesity, striae, acne, and hypertension as presenting features. The second document talks about a rare disorder with signs from chronic corticosteroid exposure but doesn't list specific symptoms. The third document mentions weight gain, hirsutism, acne, secondary amenorrhea, and facial lentiginosis. So the common symptoms across these sources are weight gain, hirsutism, obesity, acne, striae, hypertension, and maybe secondary amenorrhea. However, the third document's symptoms might be more specific to certain types of Cushing's syndrome. The first document is more general. The answer should be concise, so I'll list the most common ones mentioned in multiple sources. The base confidence would be high since these are repeated across different chunks. Let me check each chunk again to make sure. Yes, weight gain, hirsutism, acne, obesity, striae,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. The question is about common symptoms of Cushing's syndrome. First, I'll look at the evidence provided. The first document mentions weight gain, growth retardation, hirsutism, obesity, striae, acne, and hypertension as presenting features. The second document talks about a rare disorder with excess corticosteroids and mentions that most cases are due to pituitary adenoma. The third document lists weight gain, hirsutism, acne, secondary amenorrhea, and facial lentiginosis as symptoms. I need to combine these symptoms into a concise answer. The common ones across the documents are weight gain, hirsutism, obesity, acne, striae, hypertension, and maybe growth retardation. Also, secondary amenorrhea and facial lentiginosis are mentioned in one of the sources. But since the question asks for common symptoms, I should focus on the most frequently listed ones. The answer should include citations. The first document has multiple symptoms, so I'll cite that. The third document adds some more, but maybe they're less common. However,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking for common symptoms of Cushing's syndrome, and I need to generate a biomedical answer based on the provided evidence. First, I'll look through the evidence documents. The first one mentions weight gain, growth retardation, hirsutism, obesity, striae, acne, and hypertension as presenting features. The second document talks about a rare disorder caused by excess corticosteroids, but it doesn't list specific symptoms. The third document mentions weight gain, hirsutism, acne, secondary amenorrhea, and facial lentiginosis. So the common symptoms from the first and third documents are weight gain, hirsutism, acne, obesity, striae, hypertension, and maybe secondary amenorrhea. Growth retardation is mentioned in the first document but might be more specific to children. The second document doesn't list symptoms, so I should focus on the first and third. I need to compile these into a concise answer with citations. The answer should include the most common ones. Let me check if all these are present in the evidence. Yes, weight gain, hirsutism", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["17322955", "24062268"], "ideal_answer": "Cushing syndrome is the constellation of signs and symptoms caused by protracted exposure to glucocorticoids. Presenting features commonly include weight gain, growth retardation, hirsutism, obesity, striae, acne and hypertension."}
{"question_id": "5319ac99b166e2b806000034", "question": "Which is the third subunit of the TSC1-TSC2 complex upstream of mTORC1?", "retrieved_chunks": [{"doc_id": "22795129", "chunk_id": "22795129_0", "score": 6.695413589477539, "text": "Here, we identify and biochemically characterize TBC1D7 as a stably associated and ubiquitous third core subunit of the TSC1-TSC2 complex. We demonstrate that the TSC1-TSC2-TBC1D7 (TSC-TBC) complex is the functional complex that senses specific cellular growth conditions and possesses Rheb-GAP activity."}, {"doc_id": "32854217", "chunk_id": "32854217_0", "score": 4.389609336853027, "text": "The mammalian target of rapamycin (mTOR) is an evolutionary conserved Ser/Thr protein kinase that senses multiple upstream stimuli to control cell growth, metabolism, and autophagy. mTOR is the catalytic subunit of mTOR complex 1 (mTORC1). A significant amount of research has uncovered the signaling pathways regulated by mTORC1, and the involvement of these signaling cascades in human diseases like cancer, diabetes, and ageing. Here, we review advances in mTORC1 regulation by upstream stimuli."}, {"doc_id": "19245654", "chunk_id": "19245654_0", "score": 3.7657012939453125, "text": "AMPK directly phosphorylates at least two proteins to induce rapid suppression of mTORC1 activity, the TSC2 tumour suppressor and the critical mTORC1 binding subunit raptor."}], "context": "[22795129:22795129_0] Here, we identify and biochemically characterize TBC1D7 as a stably associated and ubiquitous third core subunit of the TSC1-TSC2 complex. We demonstrate that the TSC1-TSC2-TBC1D7 (TSC-TBC) complex is the functional complex that senses specific cellular growth conditions and possesses Rheb-GAP activity.\n[32854217:32854217_0] The mammalian target of rapamycin (mTOR) is an evolutionary conserved Ser/Thr protein kinase that senses multiple upstream stimuli to control cell growth, metabolism, and autophagy. mTOR is the catalytic subunit of mTOR complex 1 (mTORC1). A significant amount of research has uncovered the signaling pathways regulated by mTORC1, and the involvement of these signaling cascades in human diseases like cancer, diabetes, and ageing. Here, we review advances in mTORC1 regulation by upstream stimuli.\n[19245654:19245654_0] AMPK directly phosphorylates at least two proteins to induce rapid suppression of mTORC1 activity, the TSC2 tumour suppressor and the critical mTORC1 binding subunit raptor.", "answer": "<think> Okay, let's tackle this question. The user is asking for the third subunit of the TSC1-TSC2 complex that's upstream of mTORC1. First, I need to look at the evidence provided. The first document (22795129) mentions TBC1D7 as the third core subunit of the TSC1-TSC2 complex. It specifically states that the TSC1-TSC2-TBC1D7 complex is the functional one and has Rheb-GAP activity. That seems directly relevant. The other documents talk about mTORC1 and its regulation, but they don't mention the third subunit of the TSC complex. The second document (32854217) discusses mTORC1's role but not the subunits of TSC. The third document (19245654) mentions AMPK affecting TSC2 and raptor, but again, not the third subunit. So the answer should be TBC1D7 based on the first evidence. The confidence is high because the document explicitly states it's the third subunit", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking for the third subunit of the TSC1-TSC2 complex that's upstream of mTORC1. First, I need to look at the evidence provided. The first document (22795129) mentions TBC1D7 as the third core subunit of the TSC1-TSC2 complex. It specifically states that the TSC1-TSC2-TBC1D7 complex is the functional one and has Rheb-GAP activity. That seems directly relevant. The other documents talk about mTORC1 and its regulation, but they don't mention the third subunit of the TSC complex. The second document (32854217) discusses mTORC1's role but not the subunits of TSC. The third document (19245654) mentions AMPK affecting TSC2 and raptor, but again, not the third subunit. So the answer should be TBC1D7 based on the first evidence. The confidence is high because the document explicitly states it's the third subunit", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking for the third subunit of the TSC1-TSC2 complex that's upstream of mTORC1. First, I need to look at the evidence provided. The first document (22795129) mentions that TBC1D7 is the third core subunit of the TSC1-TSC2 complex. It also states that the TSC1-TSC2-TBC1D7 complex is the functional one that senses cellular growth conditions and has Rheb-GAP activity. That seems directly relevant. The other documents talk about mTORC1 and its regulation, but they don't mention the third subunit of the TSC complex. The second document (32854217) discusses mTOR as the catalytic subunit of mTORC1, but not the TSC complex. The third document (19245654) mentions AMPK affecting TSC2 and raptor, but again, not the third subunit. So the key evidence is from the first document, which clearly states TBC1D7 as", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking for the third subunit of the TSC1-TSC2 complex that's upstream of mTORC1. First, I need to look at the evidence provided. The first document (22795129) mentions that TBC1D7 is the third core subunit of the TSC1-TSC2 complex. It specifically states that the TSC1-TSC2-TBC1D7 complex is the functional one that senses cellular growth conditions and has Rheb-GAP activity. That seems directly relevant. The other documents talk about mTORC1 and its regulation, but they don't mention the third subunit of the TSC complex. The second document (32854217) discusses mTOR as the catalytic subunit of mTORC1, but not the TSC complex. The third document (19245654) talks about AMPK affecting TSC2 and raptor, but again, not the third subunit. So the answer should be TBC1D7 based on the first evidence. The confidence", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["22795129"], "ideal_answer": "TBC1D7 was identified as a stably associated and ubiquitous third core subunit of the TSC1-TSC2 complex. It was demonstrated that TSC1-TSC2-TBC1D7 (TSC-TBC) is the functional complex that senses specific cellular growth conditions and possesses Rheb-GAP activity to negatively regulate mTORC1 activity. In agreement with this, TBC1D7 knockdown was shown to result in increased mTORC1 signaling, delayed induction of autophagy, and enhanced cell growth under poor growth conditions."}
{"question_id": "54f89e1a06d9727f76000001", "question": "Which kinase is inhibited by the small molecule KN-93?", "retrieved_chunks": [{"doc_id": "7690557", "chunk_id": "7690557_0", "score": 6.929267406463623, "text": "A novel Ca2+/calmodulin-dependent protein kinase II (CaM Kinase II) inhibitor, KN-93 potently inhibits gastric acid secretion from parietal cells."}, {"doc_id": "10712242", "chunk_id": "10712242_1", "score": 6.916120529174805, "text": "CaM kinase II activation was inhibited by KN-93 pretreatment (IC(50) approximately 1 microM)."}, {"doc_id": "10712242", "chunk_id": "10712242_0", "score": 6.8043975830078125, "text": "CaM kinase II activation was inhibited by KN-93 pretreatment (IC(50) approximately 1 microM)"}], "context": "[7690557:7690557_0] A novel Ca2+/calmodulin-dependent protein kinase II (CaM Kinase II) inhibitor, KN-93 potently inhibits gastric acid secretion from parietal cells.\n[10712242:10712242_1] CaM kinase II activation was inhibited by KN-93 pretreatment (IC(50) approximately 1 microM).\n[10712242:10712242_0] CaM kinase II activation was inhibited by KN-93 pretreatment (IC(50) approximately 1 microM)", "answer": "<think> Okay, let's tackle this question. The user is asking which kinase is inhibited by the small molecule KN-93. The evidence provided has three chunks. First, looking at chunk [7690557:7690557_0], it mentions that KN-93 is a inhibitor of Ca2+/calmodulin-dependent protein kinase II (CaM Kinase II). That seems directly relevant. Then, chunks [10712242:10712242_0] and [10712242:10712242_1] both state that KN-93 inhibits CaM kinase II activation with an IC50 of about 1 microM. So, all three pieces of evidence point to CaM Kinase II being the target. The answer should be CaM Kinase II, and the citations would be from the first chunk and the two others. But since the user wants a concise answer with citations, I can list the main one. The confidence is high because multiple sources confirm this. So base_confidence would", "citations": [{"doc_id": "7690557", "chunk_id": "7690557_0"}, {"doc_id": "10712242", "chunk_id": "10712242_0"}, {"doc_id": "10712242", "chunk_id": "10712242_1"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which kinase is inhibited by the small molecule KN-93. The evidence provided has three chunks. First, looking at chunk [7690557:7690557_0], it mentions that KN-93 is a inhibitor of Ca2+/calmodulin-dependent protein kinase II (CaM Kinase II). That seems directly relevant. Then, chunks [10712242:10712242_0] and [10712242:10712242_1] both state that KN-93 inhibits CaM kinase II activation with an IC50 of about 1 microM. So, all three pieces of evidence point to CaM Kinase II being the target. The answer should be CaM Kinase II, and the citations would be from the first chunk and the two others. But since the user wants a concise answer with citations, I can list the main one. The confidence is high because multiple sources confirm this. So base_confidence would", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which kinase is inhibited by the small molecule KN-93. The evidence provided has three entries. First, looking at the evidence documents. The first one, [7690557:7690557_0], mentions that KN-93 is a inhibitor of Ca2+/calmodulin-dependent protein kinase II (CaM Kinase II). That seems directly relevant. The other two documents, [10712242:10712242_1] and [10712242:10712242_0], both state that CaM kinase II activation was inhibited by KN-93 pretreatment with an IC50 of about 1 microM. So, the key point here is that all three pieces of evidence point to CaM Kinase II being the target of KN-93. The first document explicitly states that KN-93 is a inhibitor of CaM Kinase II. The other two support this by showing inhibition of its activation. I need", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which kinase is inhibited by the small molecule KN-93. The evidence provided has three entries. First, looking at the evidence documents. The first one [7690557:7690557_0] mentions that KN-93 is a inhibitor of Ca2+/calmodulin-dependent protein kinase II, also known as CaM Kinase II. That's a direct statement linking KN-93 to CaM Kinase II. The other two documents [10712242:10712242_1] and [10712242:10712242_0] both talk about CaM kinase II activation being inhibited by KN-93 pretreatment with an IC50 of around 1 microM. These are supporting pieces of evidence that reinforce the first statement. So, all three sources point to CaM Kinase II as the target. The answer should be straightforward. The confidence level is high because multiple documents cite the same kinase. I need to", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["10712242", "11164895", "11248432", "11827960", "14749212", "15175389", "15569687", "1662507", "16896952", "17457979", "21187407", "22290426", "7690557", "8939965", "9596994", "9864285"], "ideal_answer": "The calcium/calmodulin-dependent protein kinase-II (CaMK-II) is inhibited by the small molecule KN-93. KN-93 is a membrane-permeant calcium/calmodulin- dependent kinase II (CaMK-II)-selective inhibitor"}
{"question_id": "5357bd56f1005d6b58000009", "question": "What is the effect of Chk2 splice variants on wild-type Chk2 kinase activity?", "retrieved_chunks": [{"doc_id": "20080130", "chunk_id": "20080130_1", "score": 9.371012687683105, "text": "Chk2 splice variants express a dominant-negative effect on the wild-type Chk2 kinase activity."}, {"doc_id": "20080130", "chunk_id": "20080130_0", "score": 9.245957374572754, "text": "Chk2 splice variants express a dominant-negative effect on the wild-type Chk2 kinase activity"}, {"doc_id": "20080130", "chunk_id": "20080130_2", "score": 6.583565711975098, "text": "Here we evaluated the function of four Chk2 splice proteins for which mRNA splice variants were identified in human breast carcinomas. These splice variants were stably expressed as nuclear proteins. Two splice forms (Chk2Delta4 and Chk2del(2-3)) expressed kinase activity while variants Chk2Delta11 and Chk2isoI were essentially kinase inactive. Independent of intrinsic kinase activity, each splice variant impaired wild-type Chk2 activity through heterodimerization."}], "context": "[20080130:20080130_1] Chk2 splice variants express a dominant-negative effect on the wild-type Chk2 kinase activity.\n[20080130:20080130_0] Chk2 splice variants express a dominant-negative effect on the wild-type Chk2 kinase activity\n[20080130:20080130_2] Here we evaluated the function of four Chk2 splice proteins for which mRNA splice variants were identified in human breast carcinomas. These splice variants were stably expressed as nuclear proteins. Two splice forms (Chk2Delta4 and Chk2del(2-3)) expressed kinase activity while variants Chk2Delta11 and Chk2isoI were essentially kinase inactive. Independent of intrinsic kinase activity, each splice variant impaired wild-type Chk2 activity through heterodimerization.", "answer": "<think> Okay, let's tackle this question. The user is asking about the effect of Chk2 splice variants on wild-type Chk2 kinase activity. The evidence provided has three chunks. First, I need to parse each chunk. The first two chunks are duplicates, both stating that Chk2 splice variants have a dominant-negative effect. The third chunk adds more details: four splice variants were evaluated, two had kinase activity (Chk2Delta4 and Chk2del(2-3)), while the others were inactive. However, all variants impaired wild-type Chk2 through heterodimerization, regardless of their intrinsic activity. So the answer should mention that the splice variants have a dominant-negative effect, as per the first two chunks. The third chunk supports this by explaining that even though some have kinase activity, they still impair the wild-type activity via heterodimerization. The confidence here is high because multiple sources confirm the dominant-negative effect. The citation would be from the first chunk, but since there are duplicates, maybe use one of them. The base_confidence should be 1.0 since all evidence points to the same conclusion. </think> { \"", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking about the effect of Chk2 splice variants on wild-type Chk2 kinase activity. The evidence provided has three chunks. First, I need to parse each chunk. The first two chunks are duplicates, both stating that Chk2 splice variants have a dominant-negative effect. The third chunk adds more details: four splice variants were evaluated, two had kinase activity (Chk2Delta4 and Chk2del(2-3)), while the others were inactive. However, all variants impaired wild-type Chk2 through heterodimerization, regardless of their intrinsic activity. So the answer should mention that the splice variants have a dominant-negative effect, as per the first two chunks. The third chunk supports this by explaining that even though some have kinase activity, they still impair the wild-type activity via heterodimerization. The confidence here is high because multiple sources confirm the dominant-negative effect. The citation would be from the first chunk, but since there are duplicates, maybe use one of them. The base_confidence should be 1.0 since all evidence points to the same conclusion. </think> { \"", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the effect of Chk2 splice variants on wild-type Chk2 kinase activity. I need to look at the provided evidence to form an answer. First, looking at the evidence documents. Document 20080130_1 and actually, wait, there are three entries here, but two of them are duplicates. The first two entries both say that Chk2 splice variants have a dominant-negative effect on wild-type activity. Then document 20080130_2 provides more details: it mentions four splice variants, some have kinase activity while others don't. Specifically, Chk2Delta4 and Chk2del(2-3) have kinase activity, but the others (Chk2Delta11 and Chk2isoI) are inactive. However, all of them impair wild-type Chk2 activity through heterodimerization, regardless of their intrinsic activity. So the answer needs to combine these points. The dominant-negative effect is mentioned in the first two documents, and the third document adds that even though some variants have kinase activity, they", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the effect of Chk2 splice variants on wild-type Chk2 kinase activity. The evidence provided has three chunks. First, I need to parse each chunk. The first two chunks are duplicates, both stating that Chk2 splice variants have a dominant-negative effect. The third chunk adds more detail: four splice variants were evaluated, two (Chk2Delta4 and Chk2del(2-3)) have kinase activity, but others are inactive. Also, all variants impair wild-type Chk2 through heterodimerization, regardless of their intrinsic activity. So the answer needs to combine these points. The dominant-negative effect is mentioned in chunks 1 and 2. Chunk 3 explains that even though some variants have kinase activity, they still impair the wild-type. So the main point is that the splice variants inhibit the wild-type Chk2 activity, possibly through heterodimerization. I need to make sure the answer is concise and cites the relevant chunks. The confidence should be high since multiple sources confirm the dominant-negative effect. However, chunk 3 adds more specifics, so maybe the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["20080130"], "ideal_answer": "Chk2 splice variants have been demonstrated to exert a dominant-negative effect on wild-type Chk2 kinase activity."}
{"question_id": "54d65b6b3706e8952800000c", "question": "List genes that have been found mutated in CMT1A (Charcot-Marie-Tooth disease type 1 A).", "retrieved_chunks": [{"doc_id": "8128981", "chunk_id": "8128981_0", "score": 6.516853332519531, "text": "Charcot-Marie-Tooth disease type 1A (CMT1A) is the most common form, exhibiting autosomal dominant inheritance and linkage to chromosome 17p11.2p12."}, {"doc_id": "12872253", "chunk_id": "12872253_1", "score": 6.464328289031982, "text": "In a previous study, we have shown that N-myc downstream-regulated gene 1 (NDRG1), classified in databases as a tumor suppressor and heavy metal-response protein, is mutated in hereditary motor and sensory neuropathy Lom (HMSNL), a severe autosomal recessive form of Charcot-Marie-Tooth (CMT) disease."}, {"doc_id": "8655146", "chunk_id": "8655146_0", "score": 6.375247001647949, "text": "Autosomal dominant Charcot-Marie-Tooth type-1A neuropathy (CMT1A) is a demyelinating peripheral nerve disorder that is commonly associated with a submicroscopic tandem DNA duplication of a 1.5-Mb region of 17p11.2p12 that contains the peripheral myelin gene PMP22."}], "context": "[8128981:8128981_0] Charcot-Marie-Tooth disease type 1A (CMT1A) is the most common form, exhibiting autosomal dominant inheritance and linkage to chromosome 17p11.2p12.\n[12872253:12872253_1] In a previous study, we have shown that N-myc downstream-regulated gene 1 (NDRG1), classified in databases as a tumor suppressor and heavy metal-response protein, is mutated in hereditary motor and sensory neuropathy Lom (HMSNL), a severe autosomal recessive form of Charcot-Marie-Tooth (CMT) disease.\n[8655146:8655146_0] Autosomal dominant Charcot-Marie-Tooth type-1A neuropathy (CMT1A) is a demyelinating peripheral nerve disorder that is commonly associated with a submicroscopic tandem DNA duplication of a 1.5-Mb region of 17p11.2p12 that contains the peripheral myelin gene PMP22.", "answer": "<think> Okay, let's tackle this query. The user wants a list of genes mutated in CMT1A, and they provided some evidence. First, looking at the evidence. The first snippet mentions CMT1A is linked to chromosome 17p11.2p12. The third snippet says that CMT1A is associated with a duplication of a region containing the PMP22 gene. So PMP22 is definitely a gene involved here. The second snippet talks about NDRG1 being mutated in HMSNL, which is a different type (autosomal recessive) of CMT. But the question is specifically about CMT1A, which is dominant. So NDRG1 might not be relevant here. However, I need to check if the evidence explicitly states that NDRG1 is mutated in CMT1A or another type. The evidence says it's linked to HMSNL, a severe form of CMT, but not necessarily CMT1A. So maybe that's a different mutation. So the answer should focus on PMP22 as the gene associated with CMT1A. The other gene mentioned is", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this query. The user wants a list of genes mutated in CMT1A, and they provided some evidence. First, looking at the evidence. The first snippet mentions CMT1A is linked to chromosome 17p11.2p12. The third snippet says that CMT1A is associated with a duplication of a region containing the PMP22 gene. So PMP22 is definitely a gene involved here. The second snippet talks about NDRG1 being mutated in HMSNL, which is a different type (autosomal recessive) of CMT. But the question is specifically about CMT1A, which is dominant. So NDRG1 might not be relevant here. However, I need to check if the evidence explicitly states that NDRG1 is mutated in CMT1A or another type. The evidence says it's linked to HMSNL, a severe form of CMT, but not necessarily CMT1A. So maybe that's a different mutation. So the answer should focus on PMP22 as the gene associated with CMT1A. The other gene mentioned is", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user wants a list of genes mutated in CMT1A, and they provided some evidence. First, I need to look at the evidence given. The first document says CMT1A is linked to chromosome 17p11.2p12. The third document mentions PMP22 as being duplicated in CMT1A. So PMP22 is definitely a gene involved here. The second document talks about NDRG1 being mutated in HMSNL, which is a different type of CMT (autosomal recessive). But the question is specifically about CMT1A, which is autosomal dominant. Since HMSNL is a different form, NDRG1 might not be relevant here. However, I should check if there's any mention of NDRG1 in CMT1A. The evidence says it's mutated in HMSNL, but the question is about CMT1A. So maybe that's a red herring. So the only gene directly mentioned in the evidence for CMT1A is PMP22. The other document refers to a duplication of the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this query. The user is asking for genes mutated in CMT1A. Looking at the evidence provided, there are three chunks. First chunk [8128981:8128981_0] mentions that CMT1A is linked to chromosome 17p11.2p12, but it doesn't specify a gene. The second chunk [12872253:12872253_1] talks about NDRG1 being mutated in HMSNL, which is a different type of CMT (autosomal recessive), not CMT1A. The third chunk [8655146:8655146_0] states that CMT1A is associated with a duplication of the 1.5-Mb region containing PMP22. So, from the evidence, PMP22 is mentioned as a gene in the context of CMT1A. The other references don't mention genes directly related to CMT1A mutations. NDRG1 is for a different type", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["24819634", "25150498", "25385046", "25400662", "25429913", "25430934", "25500726", "25519680", "25522693"], "ideal_answer": "PMP22 is the common gene found mutated through a duplication in CMT1A. Other genes are MPZ and SH3TC2"}
{"question_id": "517a8c918ed59a060a000043", "question": "Which viruses are best known to cause myocarditis?", "retrieved_chunks": [{"doc_id": "32720461", "chunk_id": "32720461_2", "score": 9.665445327758789, "text": "other viruses such as Parvovirus B19 and human herpesvirus-6 are increasingly reported as causes of myocarditis in the United States, with the most recent example being the severe acute respiratory syndrome coronavirus 2, causing the Coronavirus Disease-19."}, {"doc_id": "3889351", "chunk_id": "3889351_0", "score": 8.944942474365234, "text": "Coxsackie B viruses (types 1 to 5) are the most frequent reported cause of acute viral myocarditis."}, {"doc_id": "8682098", "chunk_id": "8682098_0", "score": 8.620274543762207, "text": "Overall, the enteroviruses, and particularly the Coxsackie-B viruses, predominate among viruses as the cause of myocarditis. As new molecular biological techniques have become available, the cytomegaloviruses (CMV) seem to have emerged as a more common cause of myocarditis than was previously recognized. Among the bacterial myocarditides, diphtheric myocarditis has become a serious threat in Russia and adjacent states during the 1990s. Among newly identified bacteria, Borrelia burgdorferi infection is accompanied by cardiac involvement in 1-8% of cases, where myocarditis with conduction disturbances is the most prominent feature. Chlamydia pneumoniae may be associated with myocarditis and sudden unexpected death."}], "context": "[32720461:32720461_2] other viruses such as Parvovirus B19 and human herpesvirus-6 are increasingly reported as causes of myocarditis in the United States, with the most recent example being the severe acute respiratory syndrome coronavirus 2, causing the Coronavirus Disease-19.\n[3889351:3889351_0] Coxsackie B viruses (types 1 to 5) are the most frequent reported cause of acute viral myocarditis.\n[8682098:8682098_0] Overall, the enteroviruses, and particularly the Coxsackie-B viruses, predominate among viruses as the cause of myocarditis. As new molecular biological techniques have become available, the cytomegaloviruses (CMV) seem to have emerged as a more common cause of myocarditis than was previously recognized. Among the bacterial myocarditides, diphtheric myocarditis has become a serious threat in Russia and adjacent states during the 1990s. Among newly identified bacteria, Borrelia burgdorferi infection is accompanied by cardiac involvement in 1-8% of cases, where myocarditis with conduction disturbances is the most prominent feature. Chlamydia pneumoniae may be associated with myocarditis and sudden unexpected death.", "answer": "<think> Okay, let's see. The user is asking which viruses are best known to cause myocarditis. I need to look at the evidence provided. First, there's a mention of Coxsackie B viruses (types 1 to 5) being the most frequent reported cause of acute viral myocarditis in [3889351:3889351_0]. Then another part says that enteroviruses, especially Coxsackie-B, predominate in causing myocarditis [8682098:8682098_0]. Also, there's a note about CMV emerging as a more common cause with new techniques [8682098:8682098_0]. Additionally, Parvovirus B19 and herpesvirus-6 are mentioned as increasingly reported in the US [32720461:32720461_2], and even SARS-CoV-2 is noted as a recent example. So, the main answer should focus on Coxsackie B viruses as the most", "citations": [{"doc_id": "3889351", "chunk_id": "3889351_0"}, {"doc_id": "8682098", "chunk_id": "8682098_0"}, {"doc_id": "8682098", "chunk_id": "8682098_0"}, {"doc_id": "32720461", "chunk_id": "32720461_2"}], "candidates": [{"answer": "<think> Okay, let's see. The user is asking which viruses are best known to cause myocarditis. I need to look at the evidence provided. First, there's a mention of Coxsackie B viruses (types 1 to 5) being the most frequent reported cause of acute viral myocarditis in [3889351:3889351_0]. Then another part says that enteroviruses, especially Coxsackie-B, predominate in causing myocarditis [8682098:8682098_0]. Also, there's a note about CMV emerging as a more common cause with new techniques [8682098:8682098_0]. Additionally, Parvovirus B19 and herpesvirus-6 are mentioned as increasingly reported in the US [32720461:32720461_2], and even SARS-CoV-2 is noted as a recent example. So, the main answer should focus on Coxsackie B viruses as the most", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user wants to know which viruses are best known to cause myocarditis, based on the provided evidence. First, I need to look through the evidence given. The first piece mentions Parvovirus B19, HHV-6, and SARS-CoV-2 as increasingly reported causes. The second one says Coxsackie B viruses (types 1-5) are the most frequent. The third mentions enteroviruses, especially Coxsackie-B, as predominant. Also, CMV is noted as emerging as a more common cause. So the main points here are Coxsackie B viruses and enteroviruses, with CMV being a newer concern. But the question asks for the best-known viruses. The second evidence explicitly states that Coxsackie B is the most frequent reported cause, and the third says enteroviruses, particularly Coxsackie-B, predominate. So Coxsackie B is a key answer here. The first evidence also mentions other viruses, but the question is about the best-known, so the answer should focus on the ones that are", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user wants to know which viruses are best known to cause myocarditis. Looking at the evidence provided, there are a few references here. First, document [3889351:3889351_0] mentions Coxsackie B viruses (types 1 to 5) as the most frequent reported cause of acute viral myocarditis. That's a strong point. Then, [8682098:8682098_0] also states that enteroviruses, particularly Coxsackie-B, are predominant in causing myocarditis. Additionally, it mentions CMV emerging as a more common cause with new techniques. However, the question is about viruses best known, so maybe Coxsackie B is the primary one here. Another mention in [32720461:32720461_2] talks about Parvovirus B19 and HSV-6, but also notes that SARS-CoV-2 is a recent example. However, the main point from the other documents seems to", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["14993139", "18039618", "18277927", "2641165", "3889351", "8199011"], "ideal_answer": "The most frequent viruses causing myocarditis are Enterovirus, Adenovirus and Coxsackie B viruses."}
{"question_id": "571f2b5bbb137a4b0c000010", "question": "Which genes have been associated with Cerebral Cavernous Malformation?", "retrieved_chunks": [{"doc_id": "25451273", "chunk_id": "25451273_1", "score": 9.703950881958008, "text": "The three cerebral cavernous malformations (CCMs) genes namely CCM1/KRIT1, CCM2/MGC4607 and CCM3/PDCD10 have been identified for which mutations cause cerebral cavernous malformations"}, {"doc_id": "12172908", "chunk_id": "12172908_0", "score": 9.533917427062988, "text": "Mutation and expression analysis of the KRIT1 gene associated with cerebral cavernous malformations (CCM1)."}, {"doc_id": "14697511", "chunk_id": "14697511_1", "score": 9.104315757751465, "text": "At least 45% of families affected with cerebral cavernous malformations harbour a mutation in Krev interaction trapped-1 (Krit1) gene (cerebral cavernous malformation gene-1, CCM1)."}], "context": "[25451273:25451273_1] The three cerebral cavernous malformations (CCMs) genes namely CCM1/KRIT1, CCM2/MGC4607 and CCM3/PDCD10 have been identified for which mutations cause cerebral cavernous malformations\n[12172908:12172908_0] Mutation and expression analysis of the KRIT1 gene associated with cerebral cavernous malformations (CCM1).\n[14697511:14697511_1] At least 45% of families affected with cerebral cavernous malformations harbour a mutation in Krev interaction trapped-1 (Krit1) gene (cerebral cavernous malformation gene-1, CCM1).", "answer": "<think> Okay, the user is asking which genes are associated with Cerebral Cavernous Malformation (CCM). Let me look at the evidence provided. First, the first document says that the three CCM genes are CCM1/KRIT1, CCM2/MGC4607, and CCM3/PDCD10. That's a direct statement. The second document mentions KRIT1 gene related to CCM1, and the third one talks about Krit1 gene mutations in 45% of families. So the answer should list all three genes mentioned in the first source. The confidence here is high because the first document explicitly states them. The other documents support the KRIT1/CCM1 part but don't add the other two genes. So the main answer comes from the first evidence. I need to make sure the answer includes all three genes with their alternative names. The confidence should be 1.0 since the first source is clear and specific. </think> { \"answer\": \"The genes associated with cerebral cavernous malformation (CCM) are CCM1/KRIT1, CCM2", "citations": [], "candidates": [{"answer": "<think> Okay, the user is asking which genes are associated with Cerebral Cavernous Malformation (CCM). Let me look at the evidence provided. First, the first document says that the three CCM genes are CCM1/KRIT1, CCM2/MGC4607, and CCM3/PDCD10. That's a direct statement. The second document mentions KRIT1 gene related to CCM1, and the third one talks about Krit1 gene mutations in 45% of families. So the answer should list all three genes mentioned in the first source. The confidence here is high because the first document explicitly states them. The other documents support the KRIT1/CCM1 part but don't add the other two genes. So the main answer comes from the first evidence. I need to make sure the answer includes all three genes with their alternative names. The confidence should be 1.0 since the first source is clear and specific. </think> { \"answer\": \"The genes associated with cerebral cavernous malformation (CCM) are CCM1/KRIT1, CCM2", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which genes are associated with cerebral cavernous malformations (CCMs). I need to look at the provided evidence to find the answer. First, looking at the first evidence snippet: it mentions three genes—CCM1/KRIT1, CCM2/MGC4607, and CCM3/PDCD10. That's a direct list of genes linked to CCMs. The second snippet talks about the KRIT1 gene (also known as CCM1) and its mutations. The third one confirms that at least 45% of families have mutations in the Krit1 gene, which is CCM1 again. So combining these, the main genes are CCM1, CCM2, and CCM3. The first evidence snippet clearly lists all three, so that's a solid source. The other snippets support the role of KRIT1 (CCM1) but don't add new genes. The answer should include all three genes mentioned in the first reference. The confidence can be high since the first source is explicit and the others back up the individual genes", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which genes are associated with Cerebral Cavernous Malformation (CCM). I need to look at the evidence provided. First, the first piece of evidence mentions three genes: CCM1/KRIT1, CCM2/MGC4607, and CCM3/PDCD10. That's a direct statement from a source, so that's a strong point. The second evidence talks about KRIT1 gene related to CCM1, which is part of the first list. The third evidence reinforces that Krit1 (CCM1) mutations are present in 45% of families. So the answer should include all three genes mentioned in the first source. The confidence here is high because multiple sources back up the three genes. The base_confidence can be 0.95 since there's clear evidence supporting all three. I need to make sure the answer is concise and cites the correct document chunks. </think> { \"answer\": \"The genes associated with Cerebral Cavernous Malformation (CCM) are CCM1/KRIT1", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["11310633", "12140362", "12172908", "12877753", "14697511", "15543491", "16100539", "16465592", "20592472", "24251678", "24287896", "24466005", "24481819", "24990152", "25086949", "25122144", "25451273", "26246098"], "ideal_answer": "Loss-of-function mutations in genes encoding CCM1 (also known as KRIT1), CCM2 (also known as OSM and malcavernin) or CCM3 (also known as PDCD10) cause cerebral cavernous malformations (CCMs)."}
{"question_id": "52fb4b462059c6d71c00005f", "question": "Is DITPA a thyroid hormone analog utilized in experimental and clinical studies", "retrieved_chunks": [{"doc_id": "19903697", "chunk_id": "19903697_0", "score": 4.402287006378174, "text": "Diiodothyropropionic acid (DITPA) and GC-1, a noniodinated thyroid hormone analog,"}, {"doc_id": "16384862", "chunk_id": "16384862_0", "score": 4.2870774269104, "text": ",5-diiodothyropropionic acid (DITPA), a thyroid hormone analog"}, {"doc_id": "15454853", "chunk_id": "15454853_0", "score": 4.100543022155762, "text": "The thyroid analog DITPA enhances endothelial nitric oxide and beta-adrenergic-mediated vasorelaxation by increasing nitric oxide in the vasculature."}], "context": "[19903697:19903697_0] Diiodothyropropionic acid (DITPA) and GC-1, a noniodinated thyroid hormone analog,\n[16384862:16384862_0] ,5-diiodothyropropionic acid (DITPA), a thyroid hormone analog\n[15454853:15454853_0] The thyroid analog DITPA enhances endothelial nitric oxide and beta-adrenergic-mediated vasorelaxation by increasing nitric oxide in the vasculature.", "answer": "<think> Okay, let's tackle this question. The user is asking if DITPA is a thyroid hormone analog used in experimental and clinical studies. The evidence provided has three chunks. First, I need to check each chunk for information about DITPA. The first chunk mentions DITPA as a thyroid hormone analog. The second chunk also refers to DITPA as a thyroid hormone analog. The third chunk states that DITPA is a thyroid analog and talks about its effects on nitric oxide and vasorelaxation. So, all three chunks confirm that DITPA is a thyroid hormone analog. Now, the question is whether it's used in experimental and clinical studies. The third chunk mentions enhancing endothelial nitric oxide and beta-adrenergic-mediated vasorelaxation, which sounds like experimental research. However, the evidence doesn't explicitly mention clinical studies. The answer needs to be concise with citations. The first two chunks are from different sources, so I should cite both. The third chunk supports the mechanism of action. But since the question is about usage in studies, maybe the third chunk's mention of enhancing vasorelaxation is part", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if DITPA is a thyroid hormone analog used in experimental and clinical studies. The evidence provided has three chunks. First, I need to check each chunk for information about DITPA. The first chunk mentions DITPA as a thyroid hormone analog. The second chunk also refers to DITPA as a thyroid hormone analog. The third chunk states that DITPA is a thyroid analog and talks about its effects on nitric oxide and vasorelaxation. So, all three chunks confirm that DITPA is a thyroid hormone analog. Now, the question is whether it's used in experimental and clinical studies. The third chunk mentions enhancing endothelial nitric oxide and beta-adrenergic-mediated vasorelaxation, which sounds like experimental research. However, the evidence doesn't explicitly mention clinical studies. The answer needs to be concise with citations. The first two chunks are from different sources, so I should cite both. The third chunk supports the mechanism of action. But since the question is about usage in studies, maybe the third chunk's mention of enhancing vasorelaxation is part", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if DITPA is a thyroid hormone analog used in experimental and clinical studies. The evidence provided has three chunks. First, I need to check each chunk for information about DITPA. The first chunk mentions DITPA and GC-1 as a noniodinated thyroid hormone analog. That's a direct statement that DITPA is a thyroid hormone analog. The second chunk refers to DITPA as a thyroid hormone analog again. The third chunk says DITPA is a thyroid analog that enhances endothelial nitric oxide and beta-adrenergic-mediated vasorelaxation. So all three chunks confirm that DITPA is a thyroid hormone analog. Now, the question also asks about its use in experimental and clinical studies. The third chunk talks about enhancing nitric oxide and vasorelaxation, which sounds like an experimental study. But does it mention clinical studies? The evidence doesn't have any mention of clinical trials. However, the first two chunks are from different sources (19903697 and 16384862) which might be research", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if DITPA is a thyroid hormone analog used in experimental and clinical studies. The evidence provided has three chunks. First, I need to check each chunk for information about DITPA. The first chunk says DITPA is a thyroid hormone analog. The second chunk also mentions DITPA as a thyroid hormone analog. The third chunk refers to DITPA as a thyroid analog and explains its effects on nitric oxide and vasorelaxation. So, all three chunks confirm that DITPA is a thyroid hormone analog. Now, the question is about its use in experimental and clinical studies. The third chunk talks about enhancing endothelial nitric oxide and beta-adrenergic-mediated vasorelaxation, which suggests it's been studied experimentally. However, the evidence doesn't explicitly mention clinical studies. But since the question says \"experimental and clinical,\" maybe the answer can include that it's used in experimental studies, and there's no mention of clinical studies in the evidence. Wait, the user's question is whether DITPA is utilized in both. The evidence only mentions experimental studies (", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["10329215", "10474790", "10710355", "10749704", "11040100", "12145478", "12165118", "12414442", "1403782", "15072976", "15148346", "15454853", "15572044", "16384862", "16616210", "17612639", "17710084", "18030062", "18353884", "18954857", "19286941", "19506112", "19903697", "20080837", "20192904", "21131480", "21215270", "21658725", "22993035", "7828308", "8353891", "8936682", "9069582", "9618233"], "ideal_answer": "There is very large body of evidence that DITPA is a true thyroid hormone analog, largely utilized in experimental and clinical studies."}
{"question_id": "56c1d848ef6e39474100002f", "question": "What is Tarlov Cyst?", "retrieved_chunks": [{"doc_id": "23400656", "chunk_id": "23400656_0", "score": 10.25108528137207, "text": "Tarlov cyst syndrome is a rare, often asymptomatic disorder, characterised by isolated or multiple nerve-root cysts, usually occurring in the sacral spine, near the dorsal root ganglion, between the perineurium and endoneurium."}, {"doc_id": "21139800", "chunk_id": "21139800_0", "score": 9.790163040161133, "text": "Tarlov cysts (sacral perineural cysts) are nerve root cysts found most commonly in the sacral roots,"}, {"doc_id": "19110185", "chunk_id": "19110185_0", "score": 9.135313034057617, "text": "Tarlov cysts are sacral perineural cysts. This case report describes the clinical course after biopsy of a very large Tarlov cyst via laparoscopy, which was thought preoperatively to be an adnexal mass."}], "context": "[23400656:23400656_0] Tarlov cyst syndrome is a rare, often asymptomatic disorder, characterised by isolated or multiple nerve-root cysts, usually occurring in the sacral spine, near the dorsal root ganglion, between the perineurium and endoneurium.\n[21139800:21139800_0] Tarlov cysts (sacral perineural cysts) are nerve root cysts found most commonly in the sacral roots,\n[19110185:19110185_0] Tarlov cysts are sacral perineural cysts. This case report describes the clinical course after biopsy of a very large Tarlov cyst via laparoscopy, which was thought preoperatively to be an adnexal mass.", "answer": "<think> Okay, so I need to generate a biomedical answer about Tarlov Cyst based on the given evidence. Let me start by reading through the evidence provided. First, the user has three chunks of information from different documents. The first one says that Tarlov cyst syndrome is a rare, often asymptomatic disorder with nerve-root cysts in the sacral spine near the dorsal root ganglion. The second mentions that Tarlov cysts are sacral perineural cysts commonly found in the sacral roots. The third chunk states that Tarlov cysts are sacral perineural cysts and describes a case where a large one was biopsied via laparoscopy. The question is asking for what Tarlov Cyst is. So I need to combine these pieces of information into a concise answer. Let me check the key points: they are nerve root cysts, located in the sacral spine, near the dorsal root ganglion, and are considered sacral perineural cysts. Also, they're often asymptomatic and can be found in the sacral roots. I need to make sure the answer is accurate and includes citations from the evidence. The answer", "citations": [], "candidates": [{"answer": "<think> Okay, so I need to generate a biomedical answer about Tarlov Cyst based on the given evidence. Let me start by reading through the evidence provided. First, the user has three chunks of information from different documents. The first one says that Tarlov cyst syndrome is a rare, often asymptomatic disorder with nerve-root cysts in the sacral spine near the dorsal root ganglion. The second mentions that Tarlov cysts are sacral perineural cysts commonly found in the sacral roots. The third chunk states that Tarlov cysts are sacral perineural cysts and describes a case where a large one was biopsied via laparoscopy. The question is asking for what Tarlov Cyst is. So I need to combine these pieces of information into a concise answer. Let me check the key points: they are nerve root cysts, located in the sacral spine, near the dorsal root ganglion, and are considered sacral perineural cysts. Also, they're often asymptomatic and can be found in the sacral roots. I need to make sure the answer is accurate and includes citations from the evidence. The answer", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question about Tarlov Cysts. The user wants a concise answer with citations and a confidence score. First, I need to understand what Tarlov Cyst is based on the evidence provided. Looking at the evidence snippets: - The first document says Tarlov cyst syndrome is a rare, asymptomatic disorder with nerve-root cysts in the sacral spine near the dorsal root ganglion. - The second mentions Tarlov cysts are sacral perineural cysts commonly found in the sacral roots. - The third confirms they're sacral perineural cysts and talks about a case where a large one was biopsied via laparoscopy. So, combining these, the answer should define Tarlov Cysts as nerve root cysts located in the sacral region, specifically around the dorsal root ganglion. The key points are that they're rare, usually asymptomatic, and found in the sacral spine. Also, the third document adds that they can be large and sometimes mistaken for other masses like adnexal masses. Now, I need to cite the relevant documents. The first and second documents both mention the location and nature", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to generate a biomedical answer about Tarlov Cyst based on the provided evidence. Let me start by understanding what the user is asking. The question is \"What is Tarlov Cyst?\" and there are three evidence snippets provided. First, I'll look at each of the evidence points. The first snippet [23400656:23400656_0] says that Tarlov cyst syndrome is a rare, often asymptomatic disorder with nerve-root cysts in the sacral spine near the dorsal root ganglion. The second one [21139800:21139800_0] states that Tarlov cysts are sacral perineural cysts commonly found in the sacral roots. The third [19110185:19110185_0] confirms that Tarlov cysts are sacral perineural cysts and mentions a case report about a biopsy via laparoscopy. So, putting this together, Tarlov cysts are a type of nerve root cyst located in the sacral", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["10758434", "11453427", "19110185", "19569467", "20102100", "20712856", "21139800", "21830055", "23400656", "25191117", "25216402"], "ideal_answer": "Tarlov or perineural cysts are nerve root cysts found most commonly at the sacral spine level arising between covering layers of the perineurium and the endoneurium near the dorsal root ganglion and are usually asymptomatic."}
{"question_id": "571e275dbb137a4b0c000005", "question": "What are 'vildagliptin', 'sitagliptin', 'saxagliptin', 'alogliptin', 'linagliptin', and 'dutogliptin'?", "retrieved_chunks": [{"doc_id": "22215383", "chunk_id": "22215383_2", "score": 7.2689433097839355, "text": "the words \"sitagliptin,\" \"vildagliptin,\" \"saxagliptin,\" \"alogliptin,\" \"linagliptin,\" and/or \"dutogliptin.\" Completed but unpublished trials were identified through a search of the ClinicalTrials.gov website,"}, {"doc_id": "22106978", "chunk_id": "22106978_0", "score": 6.798078536987305, "text": "An extensive Medline and Embase search for 'vildagliptin', 'sitagliptin', 'saxagliptin', 'alogliptin', 'linagliptin', and 'dutogliptin' was performed, collecting all randomized clinical trials on humans up to March 1, 2011."}, {"doc_id": "24793580", "chunk_id": "24793580_1", "score": 6.570303916931152, "text": "An extensive Medline, Embase, and Cochrane Database search for \"vildagliptin\", \"sitagliptin\", \"saxagliptin\", \"alogliptin\", \"linagliptin\", and \"dutogliptin\" was performed, collecting all randomized clinical trials on humans up to October 1st, 2013."}], "context": "[22215383:22215383_2] the words \"sitagliptin,\" \"vildagliptin,\" \"saxagliptin,\" \"alogliptin,\" \"linagliptin,\" and/or \"dutogliptin.\" Completed but unpublished trials were identified through a search of the ClinicalTrials.gov website,\n[22106978:22106978_0] An extensive Medline and Embase search for 'vildagliptin', 'sitagliptin', 'saxagliptin', 'alogliptin', 'linagliptin', and 'dutogliptin' was performed, collecting all randomized clinical trials on humans up to March 1, 2011.\n[24793580:24793580_1] An extensive Medline, Embase, and Cochrane Database search for \"vildagliptin\", \"sitagliptin\", \"saxagliptin\", \"alogliptin\", \"linagliptin\", and \"dutogliptin\" was performed, collecting all randomized clinical trials on humans up to October 1st, 2013.", "answer": "<think> Okay, the user is asking about these six drugs: vildagliptin, sitagliptin, saxagliptin, alogliptin, linagliptin, and dutogliptin. They want a concise answer with citations and a confidence score. First, I need to check the evidence provided. All three documents mention searches for these drugs. The first one talks about trials from ClinicalTrials.gov, the second and third ones are Medline/Embase searches up to different dates. The key point is that these drugs are being studied in clinical trials. The answer should state that they are drugs under investigation, citing the sources. The confidence is high because multiple sources mention extensive searches for them. But I need to make sure not to overstate. Since all three documents confirm their presence in trials, the base confidence can be 0.95. I should structure the answer to list the drugs and note that they are being studied in clinical trials, with citations from the evidence. The user probably wants to know what these drugs are, so mentioning they're part of a class (DPP-4 inhibitors) might help, but", "citations": [], "candidates": [{"answer": "<think> Okay, the user is asking about these six drugs: vildagliptin, sitagliptin, saxagliptin, alogliptin, linagliptin, and dutogliptin. They want a concise answer with citations and a confidence score. First, I need to check the evidence provided. All three documents mention searches for these drugs. The first one talks about trials from ClinicalTrials.gov, the second and third ones are Medline/Embase searches up to different dates. The key point is that these drugs are being studied in clinical trials. The answer should state that they are drugs under investigation, citing the sources. The confidence is high because multiple sources mention extensive searches for them. But I need to make sure not to overstate. Since all three documents confirm their presence in trials, the base confidence can be 0.95. I should structure the answer to list the drugs and note that they are being studied in clinical trials, with citations from the evidence. The user probably wants to know what these drugs are, so mentioning they're part of a class (DPP-4 inhibitors) might help, but", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, the user is asking about these six drugs: vildagliptin, sitagliptin, saxagliptin, alogliptin, linagliptin, and dutogliptin. They want a concise answer with citations and a confidence score. First, I need to check the evidence provided. All three documents mention searches for these drugs. The first document mentions that trials were identified through ClinicalTrials.gov. The second and third documents talk about Medline, Embase, Cochrane Database searches up to different dates (March 2011 and October 2013). The answer should state that these are DPP-4 inhibitors, which are used for type 2 diabetes. The citations would be from the three evidence sources. But wait, the user wants one candidate answer. So I need to pick the most relevant ones. The first document mentions the trials, but the others talk about searches. However, all three documents confirm that these drugs were part of studies. The answer should mention that they are DPP-4 inhibitors used for type 2 diabetes, and cite the evidence. Since the user wants", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, the user is asking about these six drugs: vildagliptin, sitagliptin, saxagliptin, alogliptin, linagliptin, and dutogliptin. They want a concise answer with citations and a confidence score. First, I need to check the evidence provided. All three documents mention searches for these drugs. The first document says they are words found in trials from ClinicalTrials.gov. The second and third documents talk about Medline, Embase, Cochrane Database searches up to different dates, collecting randomized clinical trials on humans. So the answer should state that these are DPP-4 inhibitors, used for type 2 diabetes, based on the evidence. Each of the three documents supports that they were searched in various databases for clinical trials. The confidence is high because multiple sources mention them as drugs studied in trials. But I need to check if any of the documents actually define them. Wait, the first document mentions the words \"sitagliptin,\" etc., but doesn't explain their class. However, the other documents talk about searching for them in clinical trials. Since the user's question is", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["17100408", "18223196", "19791828", "20690781", "21320267", "21431099", "21500969", "21913883", "22106978", "22162539", "22215383", "22429011", "22686547", "23136353", "23140189", "23501107", "23743694", "23803146", "23837679", "24186878", "24320733", "24567800", "24793219", "24793580", "24996141", "25687897", "25860270"], "ideal_answer": "\"Sitagliptin,\" \"vildagliptin,\" \"saxagliptin,\" \"alogliptin,\" \"linagliptin,\" and \"dutogliptin\" are dipeptidyl peptidase-4 (DPP-4) inhibitors."}
{"question_id": "51739df58ed59a060a00001c", "question": "Which is the most important prognosis sub-classification in Chronic Lymphocytic Leukemia?", "retrieved_chunks": [{"doc_id": "22560084", "chunk_id": "22560084_0", "score": 5.855644226074219, "text": "One of the most reliable prognostic markers in chronic lymphocytic leukemia (CLL) is the mutational status of immunoglobulin heavy variable (IGHV) genes, which defines 2 subsets, mutated CLL (M-CLL) and unmutated CLL (U-CLL), with different clinical courses."}, {"doc_id": "22150006", "chunk_id": "22150006_0", "score": -0.7385619878768921, "text": "Nine genes that are mutated at significant frequencies were identified, including four with established roles in chronic lymphocytic leukemia (TP53 in 15% of patients, ATM in 9%, MYD88 in 10%, and NOTCH1 in 4%) and five with unestablished roles (SF3B1, ZMYM3, MAPK1, FBXW7, and DDX3X). SF3B1, which functions at the catalytic core of the spliceosome, was the second most frequently mutated gene (with mutations occurring in 15% of patients)."}, {"doc_id": "22362000", "chunk_id": "22362000_0", "score": -0.8143677115440369, "text": "In chronic lymphocytic leukemia (CLL), Syk becomes activated by external signals from the tissue microenvironment, and was targeted in a first clinical trial with R788 (fostamatinib), a relatively nonspecific Syk inhibitor."}], "context": "[22560084:22560084_0] One of the most reliable prognostic markers in chronic lymphocytic leukemia (CLL) is the mutational status of immunoglobulin heavy variable (IGHV) genes, which defines 2 subsets, mutated CLL (M-CLL) and unmutated CLL (U-CLL), with different clinical courses.\n[22150006:22150006_0] Nine genes that are mutated at significant frequencies were identified, including four with established roles in chronic lymphocytic leukemia (TP53 in 15% of patients, ATM in 9%, MYD88 in 10%, and NOTCH1 in 4%) and five with unestablished roles (SF3B1, ZMYM3, MAPK1, FBXW7, and DDX3X). SF3B1, which functions at the catalytic core of the spliceosome, was the second most frequently mutated gene (with mutations occurring in 15% of patients).\n[22362000:22362000_0] In chronic lymphocytic leukemia (CLL), Syk becomes activated by external signals from the tissue microenvironment, and was targeted in a first clinical trial with R788 (fostamatinib), a relatively nonspecific Syk inhibitor.", "answer": "<think> Okay, so the user is asking about the most important prognosis sub-classification in Chronic Lymphocytic Leukemia (CLL). Let me look at the evidence provided. The first document says that the mutational status of IGHV genes is a key prognostic marker, dividing CLL into mutated (M-CLL) and unmutated (U-CLL) subsets with different clinical courses. That seems directly relevant. The second document talks about several mutated genes, including TP53, ATM, MYD88, NOTCH1, etc., but it mentions that IGHV mutations are the main one. The third document discusses Syk activation and a trial with R788, which doesn't seem related to prognosis sub-classification. So the answer should be about IGHV mutational status. The confidence is high because the first evidence explicitly states that IGHV status is the most reliable prognostic marker. The other genes mentioned are part of mutations but not the primary classification. Therefore, the answer should cite the first document and have a base confidence of 1.0. </think> { \"answer\": \"The mut", "citations": [], "candidates": [{"answer": "<think> Okay, so the user is asking about the most important prognosis sub-classification in Chronic Lymphocytic Leukemia (CLL). Let me look at the evidence provided. The first document says that the mutational status of IGHV genes is a key prognostic marker, dividing CLL into mutated (M-CLL) and unmutated (U-CLL) subsets with different clinical courses. That seems directly relevant. The second document talks about several mutated genes, including TP53, ATM, MYD88, NOTCH1, etc., but it mentions that IGHV mutations are the main one. The third document discusses Syk activation and a trial with R788, which doesn't seem related to prognosis sub-classification. So the answer should be about IGHV mutational status. The confidence is high because the first evidence explicitly states that IGHV status is the most reliable prognostic marker. The other genes mentioned are part of mutations but not the primary classification. Therefore, the answer should cite the first document and have a base confidence of 1.0. </think> { \"answer\": \"The mut", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which is the most important prognosis sub-classification in Chronic Lymphocytic Leukemia (CLL). The evidence provided has three chunks. First chunk (22560084:22560084_0) says that the mutational status of IGHV genes defines two subsets: mutated CLL (M-CLL) and unmutated CLL (U-CLL), with different clinical courses. This seems directly relevant because it mentions prognosis sub-classifications based on IGHV mutation status. Second chunk (22150006:22150006_0) talks about several mutated genes, including TP53, ATM, MYD88, NOTCH1, etc. It mentions that SF3B1 is the second most frequently mutated gene. However, this chunk focuses more on specific genetic mutations rather than a sub-classification for prognosis. The question is about the most important sub-classification, so maybe IGHV mutation status is more directly related. Third chunk (22362000", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which is the most important prognosis sub-classification in Chronic Lymphocytic Leukemia (CLL). The evidence provided has three documents. First, looking at document [22560084:22560084_0], it mentions that the mutational status of IGHV genes is a reliable prognostic marker, dividing CLL into mutated (M-CLL) and unmutated (U-CLL) subsets with different clinical courses. That seems directly relevant to prognosis sub-classifications. The second document [22150006:22150006_0] talks about specific genes like TP53, ATM, MYD88, NOTCH1, etc., and their mutations. It mentions that SF3B1 is the second most frequently mutated gene. However, this document focuses on the frequency of mutations rather than prognosis. The first document specifically links IGHV mutation status to different clinical courses, which directly relates to prognosis. The third document [22362000:2", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["16014569", "16083281", "16825496", "17786276", "19127482", "19500131", "20090781", "20353875", "22560084", "23468975"], "ideal_answer": "The mutational status of the immunoglobulin heavy variable (IGHV) genes, defines two subsets: mutated and unmutated CLL. Unmutated CLL patients show a shorter progression-free and overall survival than mutated CLL patients."}
{"question_id": "5168023b298dcd4e51000061", "question": "Is MammaPrint cleared by the United States Food and Drug Administration?", "retrieved_chunks": [{"doc_id": "19546609", "chunk_id": "19546609_0", "score": 8.190268516540527, "text": "The MammaPrint assay has the advantages of a 510(k) clearance by the US Food and Drug Administration, a larger gene number which may enhance further utility, and the potentially wider patient eligibility including lymph node-positive, ER-negative,"}, {"doc_id": "19879448", "chunk_id": "19879448_0", "score": 5.072415828704834, "text": "on MammaPrint, the first and only assay for breast cancer management that has been cleared by the FDA."}, {"doc_id": "21479927", "chunk_id": "21479927_4", "score": 3.8779995441436768, "text": "n FDA-cleared 70-gene signature of MammaPrint panel"}], "context": "[19546609:19546609_0] The MammaPrint assay has the advantages of a 510(k) clearance by the US Food and Drug Administration, a larger gene number which may enhance further utility, and the potentially wider patient eligibility including lymph node-positive, ER-negative,\n[19879448:19879448_0] on MammaPrint, the first and only assay for breast cancer management that has been cleared by the FDA.\n[21479927:21479927_4] n FDA-cleared 70-gene signature of MammaPrint panel", "answer": "<think> Okay, I need to answer whether MammaPrint is cleared by the US Food and Drug Administration based on the given evidence. Let me look at the evidence provided. First, document [19546609:19546609_0] mentions that the MammaPrint assay has a 510(k) clearance by the FDA. A 510(k) is a premarket approval process for medical devices in the US, so that's a clear indication of FDA clearance. Then, document [19879448:19879448_0] states that MammaPrint is the first and only assay for breast cancer management cleared by the FDA. This directly answers the question with a definitive yes. The third document [21479927:21479927_4] refers to an FDA-cleared 70-gene signature of the MammaPrint panel. This also supports the idea that MammaPrint is cleared by the FDA. All three documents consistently state that MammaPrint has been cleared by the FDA.", "citations": [{"doc_id": "19546609", "chunk_id": "19546609_0"}, {"doc_id": "19879448", "chunk_id": "19879448_0"}, {"doc_id": "21479927", "chunk_id": "21479927_4"}], "candidates": [{"answer": "<think> Okay, I need to answer whether MammaPrint is cleared by the US Food and Drug Administration based on the given evidence. Let me look at the evidence provided. First, document [19546609:19546609_0] mentions that the MammaPrint assay has a 510(k) clearance by the FDA. A 510(k) is a premarket approval process for medical devices in the US, so that's a clear indication of FDA clearance. Then, document [19879448:19879448_0] states that MammaPrint is the first and only assay for breast cancer management cleared by the FDA. This directly answers the question with a definitive yes. The third document [21479927:21479927_4] refers to an FDA-cleared 70-gene signature of the MammaPrint panel. This also supports the idea that MammaPrint is cleared by the FDA. All three documents consistently state that MammaPrint has been cleared by the FDA.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if MammaPrint is cleared by the US Food and Drug Administration. I need to check the evidence provided. Looking at the evidence, there are three documents. The first one mentions that the MammaPrint assay has a 510(k) clearance by the FDA. The second document states that MammaPrint is the first and only assay for breast cancer management cleared by the FDA. The third document refers to it as an FDA-cleared 70-gene signature. All three sources consistently mention FDA clearance. The first document specifically talks about 510(k) clearance, which is a premarket approval process for medical devices in the US. The second confirms it's cleared by the FDA. The third reiterates that it's FDA-cleared. I need to make sure there's no conflicting information. All three chunks support the idea that MammaPrint is FDA-cleared. The answer should be concise, citing the relevant documents. The confidence level should be high since all sources agree. So, the answer would state that MammaPrint is cleared by the FDA, citing the second document as", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if MammaPrint is cleared by the US Food and Drug Administration. I need to check the provided evidence to find the answer. Looking at the evidence, there are three documents. The first one mentions that MammaPrint has 510(k) clearance by the FDA. The second document states that MammaPrint is the first and only assay cleared by the FDA. The third document refers to it as an FDA-cleared 70-gene signature. All three sources consistently indicate that MammaPrint has received FDA clearance. The 510(k) clearance is a specific type of approval for medical devices, which aligns with what's mentioned. The second document explicitly says \"cleared by the FDA,\" and the third confirms it as an FDA-cleared panel. So the answer should be yes, based on these citations. The confidence level is high since all three pieces of evidence support this. I'll structure the JSON accordingly with the relevant document IDs and chunk IDs. </think> { \"answer\": \"Yes, MammaPrint is cleared by the United States Food and Drug Administration [1", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["18786252", "19506735", "21479927"], "ideal_answer": "Yes. MammaPrint is cleared by the FDA for breast cancer recurrence."}
{"question_id": "530f7cdde3eabad021000001", "question": "Is amantadine effective for treatment of disorders conciousness?", "retrieved_chunks": [{"doc_id": "22375973", "chunk_id": "22375973_1", "score": 3.846940755844116, "text": "Amantadine hydrochloride is one of the most commonly prescribed medications for patients with prolonged disorders of consciousness after traumatic brain injury. Preliminary studies have suggested that amantadine may promote functional recovery."}, {"doc_id": "22375973", "chunk_id": "22375973_0", "score": 3.717376947402954, "text": "Amantadine accelerated the pace of functional recovery during active treatment in patients with post-traumatic disorders of consciousness."}, {"doc_id": "27642581", "chunk_id": "27642581_0", "score": 2.484919309616089, "text": "Amantadine is an N-methyl-D-aspartic acid or N-methyl-D-aspartate (NMDA) receptor antagonist that can be effective against postoperative pain."}], "context": "[22375973:22375973_1] Amantadine hydrochloride is one of the most commonly prescribed medications for patients with prolonged disorders of consciousness after traumatic brain injury. Preliminary studies have suggested that amantadine may promote functional recovery.\n[22375973:22375973_0] Amantadine accelerated the pace of functional recovery during active treatment in patients with post-traumatic disorders of consciousness.\n[27642581:27642581_0] Amantadine is an N-methyl-D-aspartic acid or N-methyl-D-aspartate (NMDA) receptor antagonist that can be effective against postoperative pain.", "answer": "<think> Okay, let's tackle this question. The user is asking if amantadine is effective for treating disorders of consciousness. The evidence provided has three chunks. First, chunk 22375973_1 says amantadine is commonly prescribed for prolonged disorders of consciousness after traumatic brain injury and that preliminary studies suggest it promotes functional recovery. That's a direct mention of effectiveness. Chunk 22375973_0 adds that amantadine accelerated functional recovery in post-traumatic disorders of consciousness during active treatment. So two chunks from the same document support the efficacy. Chunk 27642581_0 mentions amantadine as an NMDA receptor antagonist effective against postoperative pain. But the question is about disorders of consciousness, not postoperative pain. That seems unrelated. So maybe that chunk isn't relevant here. So the answer should focus on the first two chunks. The model's confidence would be high because two separate studies support the effectiveness. However, the third chunk might lower it slightly if there's any doubt, but since it's about a different condition, probably not. So base_conf", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if amantadine is effective for treating disorders of consciousness. The evidence provided has three chunks. First, chunk 22375973_1 says amantadine is commonly prescribed for prolonged disorders of consciousness after traumatic brain injury and that preliminary studies suggest it promotes functional recovery. That's a direct mention of effectiveness. Chunk 22375973_0 adds that amantadine accelerated functional recovery in post-traumatic disorders of consciousness during active treatment. So two chunks from the same document support the efficacy. Chunk 27642581_0 mentions amantadine as an NMDA receptor antagonist effective against postoperative pain. But the question is about disorders of consciousness, not postoperative pain. That seems unrelated. So maybe that chunk isn't relevant here. So the answer should focus on the first two chunks. The model's confidence would be high because two separate studies support the effectiveness. However, the third chunk might lower it slightly if there's any doubt, but since it's about a different condition, probably not. So base_conf", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if amantadine is effective for treating disorders of consciousness. The evidence provided has three chunks. First, chunk 22375973_1 says amantadine is commonly prescribed for prolonged disorders of consciousness after traumatic brain injury and that preliminary studies suggest it may promote functional recovery. That's a direct mention of its use in this context. Chunk 22375973_0 adds that amantadine accelerated functional recovery in patients with post-traumatic disorders of consciousness during active treatment. This supports the effectiveness. Chunk 27642581_0 mentions amantadine as an NMDA receptor antagonist effective against postoperative pain. However, the question is about disorders of consciousness, not postoperative pain. So this chunk might be relevant but not directly addressing the disorder itself. But wait, maybe the user is considering if it's used for other conditions? But the question specifically asks about disorders of consciousness. So the answer should focus on chunks 22375973_1 and 0. The third chunk is about", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to answer whether amantadine is effective for treating disorders of consciousness based on the given evidence. Let's look at the evidence provided. First, there are three chunks. The first one says that amantadine is commonly prescribed for prolonged disorders of consciousness after traumatic brain injury and that preliminary studies suggest it may promote functional recovery. The second chunk mentions that amantadine accelerated functional recovery during active treatment in post-traumatic disorders of consciousness. The third chunk talks about amantadine being an NMDA receptor antagonist effective against postoperative pain, but that's a different condition. So the question is about disorders of consciousness. The first two chunks directly mention this. The third chunk is about postoperative pain, which isn't relevant here. The answer should focus on the first two documents. The answer needs to be concise with citations. The base confidence is a float between 0 and 1. Since two out of three evidence points support effectiveness for disorders of consciousness, but one is unrelated, the confidence should be high. Maybe 0.95? But wait, the third chunk is about p", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["15759228", "15825541", "18540467", "19404190", "19894299", "20129511", "20460949", "20658796", "22375973", "24025054", "24025056", "24025057"], "ideal_answer": "Amantadine, a dopaminergic agent, has been shown to be effective for induction of recovery from disorders of consciousness. Amantadine is a commonly prescribed medication for patients with prolonged disorders of consciousness after traumatic brain injury. Amantadine accelerates the pace of functional recovery during active treatment in patients with post-traumatic disorders of consciousness. Higher dosing of amantadine may be considered in the setting of brain injury."}
{"question_id": "56e857ae42442bac75000004", "question": "What is needed for MMP proteins to be functional?", "retrieved_chunks": [{"doc_id": "26013370", "chunk_id": "26013370_0", "score": -0.9851698875427246, "text": "matrix metalloproteinase (MMP)-9"}, {"doc_id": "26087627", "chunk_id": "26087627_0", "score": -2.5397515296936035, "text": "matrix metalloproteinase-3 (MMP-3) gene"}, {"doc_id": "26613891", "chunk_id": "26613891_0", "score": -2.581878662109375, "text": "Kupffer cells (KCs) are the main source of MMP."}], "context": "[26013370:26013370_0] matrix metalloproteinase (MMP)-9\n[26087627:26087627_0] matrix metalloproteinase-3 (MMP-3) gene\n[26613891:26613891_0] Kupffer cells (KCs) are the main source of MMP.", "answer": "<think> Okay, let's tackle this question. The user is asking what is needed for MMP proteins to be functional. The evidence provided includes three different documents. First, I need to understand what each document says. The first one is about MMP-9, the second about MMP-3 gene, and the third talks about Kupffer cells being the main source of MMP. Wait, the question is about what's needed for MMPs to be functional. So I need to look for information on the factors that enable MMP proteins to function. The third document mentions Kupffer cells as the main source, but that's more about where they are produced, not necessarily the requirements for functionality. The second document refers to the MMP-3 gene. Maybe that's related to the genetic aspect? But the question is about what's needed for them to be functional, which could include factors like proper processing, cleavage, or activation. Looking back, the first document mentions matrix metalloproteinase (MMP)-9. Maybe it discusses the structure or the conditions required for MMPs to function. However, without more details, I need to infer based on general knowledge. Typically,", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking what is needed for MMP proteins to be functional. The evidence provided includes three different documents. First, I need to understand what each document says. The first one is about MMP-9, the second about MMP-3 gene, and the third talks about Kupffer cells being the main source of MMP. Wait, the question is about what's needed for MMPs to be functional. So I need to look for information on the factors that enable MMP proteins to function. The third document mentions Kupffer cells as the main source, but that's more about where they are produced, not necessarily the requirements for functionality. The second document refers to the MMP-3 gene. Maybe that's related to the genetic aspect? But the question is about what's needed for them to be functional, which could include factors like proper processing, cleavage, or activation. Looking back, the first document mentions matrix metalloproteinase (MMP)-9. Maybe it discusses the structure or the conditions required for MMPs to function. However, without more details, I need to infer based on general knowledge. Typically,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking what's needed for MMP proteins to be functional. The evidence provided includes three documents. First, I need to understand what each document says. The first one is about MMP-9, but the snippet doesn't have specific details. The second is about the MMP-3 gene, which might relate to the structure or regulation of MMPs. The third mentions Kupffer cells as the main source of MMP, which suggests that the presence of these cells is important for MMP activity. Wait, the question is about what's needed for MMPs to be functional. So I need to find information on the requirements for their function. The MMP-3 gene might be part of the genetic requirement, like having the gene itself. But Kupffer cells being the main source implies that their presence or activity is necessary. However, the question is about what's needed for the proteins to function, not just where they're produced. Looking at the evidence again, maybe the MMP-3 gene is relevant because genes are required for protein synthesis. So if the gene is present, the protein can be made. But the answer needs to be", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking what's needed for MMP proteins to be functional. The evidence given includes three documents. First, I need to look at each document's content. The first one mentions MMP-9, but the chunk doesn't have specific info on functionality. The second document talks about the MMP-3 gene, which suggests that the gene itself is necessary for producing the protein. The third document states that Kupffer cells are the main source of MMP, so maybe their presence or activity is required. But wait, the question is about what's needed for MMP proteins to be functional. So, factors like the gene (MMP-3) being expressed, proper processing, and possibly the cellular environment (like Kupffer cells). However, the third document only says they are the main source, not necessarily that they're required for function. The second document directly mentions the gene, so that's a key point. The answer should be concise. The MMP-3 gene is needed for production. But the question is about general MMP proteins. However, the evidence given doesn't mention other factors like zinc ions or specific substrates. The", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["22257051", "23001203", "24570026", "25360794", "26013370", "26087627", "26150355"], "ideal_answer": "Extracellular matrix metalloproteinases (MMPs) are a family of zinc-dependent neutral endopeptidases."}
{"question_id": "5509c52f1180f13250000004", "question": "What is hyperosmia", "retrieved_chunks": [{"doc_id": "21250223", "chunk_id": "21250223_0", "score": 7.778868675231934, "text": "Hyperosmia is increased olfactory acuity"}, {"doc_id": "24302690", "chunk_id": "24302690_0", "score": 3.917745351791382, "text": "Hyperosmia is suspected in pregnancy; however, no empirical study using validated measures of olfactory function has clearly confirmed the anecdotal reports of this phenomenon."}, {"doc_id": "23520356", "chunk_id": "23520356_0", "score": 3.3061461448669434, "text": "subjective hyperosmia is associated with primarily negative odor-related experiences."}], "context": "[21250223:21250223_0] Hyperosmia is increased olfactory acuity\n[24302690:24302690_0] Hyperosmia is suspected in pregnancy; however, no empirical study using validated measures of olfactory function has clearly confirmed the anecdotal reports of this phenomenon.\n[23520356:23520356_0] subjective hyperosmia is associated with primarily negative odor-related experiences.", "answer": "<think> Okay, I need to generate a JSON answer for the question \"What is hyperosmia?\" based on the provided evidence. Let me start by understanding what hyperosmia is. Looking at the evidence, the first document says hyperosmia is increased olfactory acuity. That's a direct definition. The second mention talks about it being suspected in pregnancy but no studies have confirmed it. The third one mentions subjective hyperosmia being linked to negative odor experiences. The user wants a concise answer with citations in the format [doc_id:chunk_id]. The answer should be based on the evidence provided. The first chunk from 21250223:21250223_0 gives a clear definition. The other chunks provide additional context but maybe not as directly relevant to the main definition. So the answer should be \"Hyperosmia is increased olfactory acuity [21250223:21250223_0]\". Then, the base confidence. Since the first source directly defines it, that's the most reliable. The other sources are more about associations or studies, but", "citations": [{"doc_id": "21250223", "chunk_id": "21250223_0"}], "candidates": [{"answer": "<think> Okay, I need to generate a JSON answer for the question \"What is hyperosmia?\" based on the provided evidence. Let me start by understanding what hyperosmia is. Looking at the evidence, the first document says hyperosmia is increased olfactory acuity. That's a direct definition. The second mention talks about it being suspected in pregnancy but no studies have confirmed it. The third one mentions subjective hyperosmia being linked to negative odor experiences. The user wants a concise answer with citations in the format [doc_id:chunk_id]. The answer should be based on the evidence provided. The first chunk from 21250223:21250223_0 gives a clear definition. The other chunks provide additional context but maybe not as directly relevant to the main definition. So the answer should be \"Hyperosmia is increased olfactory acuity [21250223:21250223_0]\". Then, the base confidence. Since the first source directly defines it, that's the most reliable. The other sources are more about associations or studies, but", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this query. The user is asking for a biomedical answer about hyperosmia, and they want it in strict JSON format with an answer and base_confidence. First, I need to understand what hyperosmia is. From the evidence provided, the first document says it's increased olfactory acuity. That's a direct definition. The other documents mention associations with pregnancy and negative odor experiences, but those are more about related factors rather than the definition itself. The answer should be concise and cite the relevant document. The first evidence [21250223:21250223_0] clearly defines hyperosmia. So the answer would be \"Hyperosmia is increased olfactory acuity [21250223:21250223_0]\". Now, the base_confidence. The first source is a direct definition, so that's high confidence. The other sources are about associations, which might not be as certain. But since the question is about the definition, the first one is the most relevant. I should set the confidence to 1.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this query. The user is asking for a biomedical answer about hyperosmia, and they want it in strict JSON format with an answer and base confidence. First, I need to understand what hyperosmia is. From the evidence provided, the first document says hyperosmia is increased olfactory acuity. That's a direct definition. The other documents mention associations with pregnancy and negative odor experiences, but those are more about related conditions or studies. The user wants a concise answer with citations. So the main point is that hyperosmia is increased olfactory acuity, as per the first source. The confidence here is high because that's a direct definition. The other points are additional info but not the primary definition. I should make sure to cite the correct chunk ID. The base confidence should be 1.0 since the definition is clearly stated in the evidence. No conflicting information here. Just need to present the answer accurately. </think> { \"answer\": \"Hyperosmia is increased olfactory acuity [21250223:21250223_0]\", \"base_confidence", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["21250223", "23520356", "24302690"], "ideal_answer": "Hyperosmia is increased olfactory acuity increased olfactory acuity"}
{"question_id": "535d2cf09a4572de6f000004", "question": "What is the number of long non coding RNAs in the human genome", "retrieved_chunks": [{"doc_id": "23369519", "chunk_id": "23369519_0", "score": 8.83507251739502, "text": "BACKGROUND: Over 10,000 long intergenic non-coding RNAs (lincRNAs) have been identified in the human genome."}, {"doc_id": "17270048", "chunk_id": "17270048_0", "score": 4.220420837402344, "text": "Our genome-wide screens in two mammalian species reveal no more than three abundant large non-coding polyadenylated RNAs in the nucleus; the canonical large noncoding RNA XIST and NEAT1 and NEAT2"}, {"doc_id": "26207516", "chunk_id": "26207516_0", "score": 4.079282760620117, "text": "Protein-coding genes account for only 2% of the human genome, whereas the vast majority of transcripts are noncoding RNAs including long noncoding RNAs. LncRNAs are involved in the regulation of a diverse array of biological processes, including cancer progression"}], "context": "[23369519:23369519_0] BACKGROUND: Over 10,000 long intergenic non-coding RNAs (lincRNAs) have been identified in the human genome.\n[17270048:17270048_0] Our genome-wide screens in two mammalian species reveal no more than three abundant large non-coding polyadenylated RNAs in the nucleus; the canonical large noncoding RNA XIST and NEAT1 and NEAT2\n[26207516:26207516_0] Protein-coding genes account for only 2% of the human genome, whereas the vast majority of transcripts are noncoding RNAs including long noncoding RNAs. LncRNAs are involved in the regulation of a diverse array of biological processes, including cancer progression", "answer": "<think> Okay, let's tackle this question. The user is asking for the number of long non-coding RNAs (lncRNAs) in the human genome. First, I need to look at the evidence provided. The first piece of evidence says that over 10,000 lincRNAs have been identified. The term \"lincRNAs\" here is likely referring to long intergenic non-coding RNAs, which are a type of lncRNA. So that's a direct mention of a number, 10,000 or more. The second evidence talks about three abundant large non-coding polyadenylated RNAs, but those are specific examples (XIST, NEAT1, NEAT2) and not the total count. The third evidence mentions that protein-coding genes make up 2% of the genome, but it doesn't give a number for lncRNAs. So the main citation here is the first one: [23369519:23369519_0] which states over 10,000. The answer should be that", "citations": [{"doc_id": "23369519", "chunk_id": "23369519_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking for the number of long non-coding RNAs (lncRNAs) in the human genome. First, I need to look at the evidence provided. The first piece of evidence says that over 10,000 lincRNAs have been identified. The term \"lincRNAs\" here is likely referring to long intergenic non-coding RNAs, which are a type of lncRNA. So that's a direct mention of a number, 10,000 or more. The second evidence talks about three abundant large non-coding polyadenylated RNAs, but those are specific examples (XIST, NEAT1, NEAT2) and not the total count. The third evidence mentions that protein-coding genes make up 2% of the genome, but it doesn't give a number for lncRNAs. So the main citation here is the first one: [23369519:23369519_0] which states over 10,000. The answer should be that", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking for the number of long non-coding RNAs (lncRNAs) in the human genome. Looking at the evidence provided, the first document [23369519:23369519_0] mentions that over 10,000 lincRNAs have been identified. The term \"lincRNAs\" here likely refers to long intergenic non-coding RNAs, which are a subset of lncRNAs. However, the question is about the total number of lncRNAs, not just lincRNAs. The other documents don't provide specific numbers. The second one talks about three abundant large non-coding polyadenylated RNAs, but that's a small number and likely not the total count. The third document states that protein-coding genes make up 2% of the genome, with most transcripts being noncoding, including lncRNAs, but no specific number is given. So the only concrete number comes from the first evidence. However, I need to check if \"lincRNAs\"", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking for the number of long non-coding RNAs (lncRNAs) in the human genome. Looking at the evidence provided, there's a mention from document [23369519:23369519_0] that says over 10,000 lincRNAs have been identified. But wait, the question specifies \"long non-coding RNAs\" in general, not just lincRNAs. The other documents don't mention a specific number. One document talks about three abundant large non-coding polyadenylated RNAs, but that's a different category. The answer should be based on the evidence given. Since the only concrete number is 10,000+ lincRNAs, even though the question is about lncRNAs in general, maybe that's the best available data. However, I need to check if lincRNAs are a subset of lncRNAs. If so, then the number might be higher. But the evidence doesn't say that. The answer should refer to the provided", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["23126680", "23369519", "23846593"], "ideal_answer": "Different estimates put currently the number of human long non coding RNAs between 10,000 and 20,000"}
{"question_id": "55475dc2f35db75526000001", "question": "Which is the most known bacterium responsible for botulism (sausage-poisoning)?", "retrieved_chunks": [{"doc_id": "21130733", "chunk_id": "21130733_0", "score": 5.988029479980469, "text": "The botulinum neurotoxins (BoNTs) produced by different strains of the bacterium Clostridium botulinum are responsible for the disease botulism and include a group of immunologically distinct serotypes (A, B, E, and F) that are considered to be the most lethal natural proteins known for humans."}, {"doc_id": "23025151", "chunk_id": "23025151_0", "score": 5.031538009643555, "text": "Botulism is caused by botulinum neurotoxin produced by the bacterium Clostridium botulinum."}, {"doc_id": "24253240", "chunk_id": "24253240_0", "score": 4.231901168823242, "text": "Botulism is a serious foodborne neuroparalytic disease, caused by botulinum neurotoxin (BoNT), produced by the anaerobic bacterium Clostridium botulinum."}], "context": "[21130733:21130733_0] The botulinum neurotoxins (BoNTs) produced by different strains of the bacterium Clostridium botulinum are responsible for the disease botulism and include a group of immunologically distinct serotypes (A, B, E, and F) that are considered to be the most lethal natural proteins known for humans.\n[23025151:23025151_0] Botulism is caused by botulinum neurotoxin produced by the bacterium Clostridium botulinum.\n[24253240:24253240_0] Botulism is a serious foodborne neuroparalytic disease, caused by botulinum neurotoxin (BoNT), produced by the anaerobic bacterium Clostridium botulinum.", "answer": "Clostridium botulinum [21130733:21130733_0]", "citations": [{"doc_id": "21130733", "chunk_id": "21130733_0"}], "candidates": [{"answer": "Clostridium botulinum [21130733:21130733_0]", "base_prob": 1.0, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 1.0}, {"answer": "<think> Okay, let's tackle this question. The user is asking which is the most known bacterium responsible for botulism, also called sausage-poisoning. I need to look at the evidence provided. First, I check the evidence documents. The first one says that Clostridium botulinum produces BoNTs which cause botulism, and mentions serotypes A, B, E, F. The second document states that botulism is caused by botulinum neurotoxin from C. botulinum. The third one confirms this again, mentioning it's produced by the anaerobic bacterium C. botulinum. So all three sources point to Clostridium botulinum as the causative agent. The question is about the \"most known\" bacterium, which likely refers to the most well-known or commonly recognized one. Since all evidence consistently names C. botulinum, that's the answer. The confidence is high because all three documents agree. I should cite the first document since it provides more details about the serotypes, but any of them would be correct. Let me check the citation format again. The answer should include", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which is the most known bacterium responsible for botulism, also called sausage-poisoning. I need to look at the provided evidence to find the answer. Looking at the evidence, there are three documents. The first one says that Clostridium botulinum produces BoNTs which cause botulism, and mentions serotypes A, B, E, F. The second document states that botulism is caused by the neurotoxin from C. botulinum. The third one confirms that it's caused by BoNT from C. botulinum. All three sources consistently point to Clostridium botulinum as the bacterium responsible. The question is about the \"most known\" bacterium, so the answer should be C. botulinum. The citations are all from different chunks but all refer to the same bacterium. The confidence level should be high since all evidence supports this. I'll set base_confidence to 1.0 as there's no conflicting information. </think> { \"answer\": \"Clostridium botulinum [211", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 1.0, "gold_docs": ["11153358", "15027048", "15839401", "16080379", "17458494", "18388640", "19573697", "20569065", "20961439", "21130733", "21171846", "21747146", "21975066", "23025151", "23239346", "23421373", "23523511", "23971804", "23971806", "23971808", "24206405", "24246230", "24252222", "24252701", "24253240", "24961027", "24997242"], "ideal_answer": "Botulism is a severe neuroparalytic disease caused by botulinum neurotoxin (BoNT), and affects humans, all warm-blooded animals, birds, and some fishes. Botulinum toxin is produced under anaerobic conditions by the bacterium Clostridium botulinum, which is the most known etiological agent of the disease, and some other clostridia, and is one of the most dangerous toxin in the world."}
{"question_id": "56c073fcef6e394741000020", "question": "What is the association of spermidine with α-synuclein neurotoxicity?", "retrieved_chunks": [{"doc_id": "25483063", "chunk_id": "25483063_3", "score": 5.142975807189941, "text": "Spermidine protects against α-synuclein neurotoxicity."}, {"doc_id": "25483063", "chunk_id": "25483063_2", "score": 4.860856533050537, "text": "Spermidine protects against α-synuclein neurotoxicity"}, {"doc_id": "22662273", "chunk_id": "22662273_0", "score": 4.129438877105713, "text": "Together with the fact that spermidine facilitates late stages of α-Syn aggregation, our data demonstrate that spermidine promotes the very early stages of protein aggregation including α-Syn misfolding and dimerization. This finding suggests that increased levels of spermidine and potentially other polyamines can initiate the disease-related process of α-Syn."}], "context": "[25483063:25483063_3] Spermidine protects against α-synuclein neurotoxicity.\n[25483063:25483063_2] Spermidine protects against α-synuclein neurotoxicity\n[22662273:22662273_0] Together with the fact that spermidine facilitates late stages of α-Syn aggregation, our data demonstrate that spermidine promotes the very early stages of protein aggregation including α-Syn misfolding and dimerization. This finding suggests that increased levels of spermidine and potentially other polyamines can initiate the disease-related process of α-Syn.", "answer": "<think> Okay, let's tackle this question. The user is asking about the association between spermidine and α-synuclein neurotoxicity. I need to look at the provided evidence to form an answer. Looking at the evidence, there are three entries. The first two [25483063:25483063_3] and [25483063:25483063_2] both state that spermidine protects against α-synuclein neurotoxicity. That's a direct statement. The third entry [22662273:22662273_0] says that spermidine facilitates late stages of α-Syn aggregation but also promotes early stages like misfolding and dimerization. It suggests that higher spermidine levels might initiate the disease process. Wait, so there's a contradiction here? The first two pieces of evidence say protection, while the third says it promotes aggregation. But the third one mentions that spermidine facilitates late stages but also early stages. However, the conclusion is that", "citations": [{"doc_id": "25483063", "chunk_id": "25483063_3"}, {"doc_id": "25483063", "chunk_id": "25483063_2"}, {"doc_id": "22662273", "chunk_id": "22662273_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking about the association between spermidine and α-synuclein neurotoxicity. I need to look at the provided evidence to form an answer. Looking at the evidence, there are three entries. The first two [25483063:25483063_3] and [25483063:25483063_2] both state that spermidine protects against α-synuclein neurotoxicity. That's a direct statement. The third entry [22662273:22662273_0] says that spermidine facilitates late stages of α-Syn aggregation but also promotes early stages like misfolding and dimerization. It suggests that higher spermidine levels might initiate the disease process. Wait, so there's a contradiction here? The first two pieces of evidence say protection, while the third says it promotes aggregation. But the third one mentions that spermidine facilitates late stages but also early stages. However, the conclusion is that", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the association between spermidine and α-synuclein neurotoxicity. The evidence provided has three chunks. First, I need to understand what each chunk says. The first two chunks (25483063:25483063_3 and 25483063:25483063_2) both state that spermidine protects against α-synuclein neurotoxicity. That's pretty straightforward. The third chunk (22662273:22662273_0) mentions that spermidine facilitates late stages of α-Syn aggregation but also promotes early stages like misfolding and dimerization. It suggests that higher spermidine levels might initiate the disease process. Now, the question is about the association. The answer needs to be concise with citations. The first two chunks directly state protection, while the third chunk adds more complexity by showing both promotion of aggregation and protection. However, the user's question is about the association, so I", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the association between spermidine and α-synuclein neurotoxicity. Looking at the evidence provided, there are three entries. The first two mention that spermidine protects against α-synuclein neurotoxicity. The third one says that spermidine facilitates late stages of α-Syn aggregation but also promotes early stages like misfolding and dimerization. This suggests that while spermidine might have a protective effect, it's also involved in the aggregation process. Wait, there's a contradiction here. The first two pieces of evidence say protection, but the third says it promotes aggregation. But the third one is from a different study? Or maybe the same study? Let me check the doc IDs. The first two are 25483063:25483063_2 and _3, so they're from the same document. Then the third is from 22662273:22662273_0. So maybe there's a study that says spermidine protects, but", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["22662273", "25483063"], "ideal_answer": "Spermidine protects against α-synuclein neurotoxicity. In the fruit fly, simple feeding with spermidine inhibited loss of climbing activity and early organismal death upon heterologous expression of human α-synuclein, which is thought to be the principal toxic trigger of Parkinson's Disease (PD). In this line, administration of spermidine rescued α-synuclein-induced loss of dopaminergic neurons, a hallmark of PD, in nematodes. Alleviation of PD-related neurodegeneration by spermidine was accompanied by induction of autophagy, suggesting that this cytoprotective process may be responsible for the beneficial effects of spermidine administration."}
{"question_id": "550320cbe9bde6963400002d", "question": "List symptoms of 4H leukodystrophy.", "retrieved_chunks": [{"doc_id": "22451160", "chunk_id": "22451160_0", "score": 6.0272369384765625, "text": "OBJECTIVE: To report a novel clinical and genetic presentation of a patient with 4H syndrome, which is a recently described leukodystrophy syndrome characterized by ataxia, hypomyelination, hypodontia, and hypogonadotropic hypogonadism."}, {"doc_id": "23307887", "chunk_id": "23307887_1", "score": 5.465768814086914, "text": "4H syndrome is a rare and distinct leukodystrophy characterized by hypomyelination, hypogonadotropic hypogonadism, and hypodontia."}, {"doc_id": "23307887", "chunk_id": "23307887_0", "score": 5.309710502624512, "text": "4H syndrome is a rare and distinct leukodystrophy characterized by hypomyelination, hypogonadotropic hypogonadism, and hypodontia"}], "context": "[22451160:22451160_0] OBJECTIVE: To report a novel clinical and genetic presentation of a patient with 4H syndrome, which is a recently described leukodystrophy syndrome characterized by ataxia, hypomyelination, hypodontia, and hypogonadotropic hypogonadism.\n[23307887:23307887_1] 4H syndrome is a rare and distinct leukodystrophy characterized by hypomyelination, hypogonadotropic hypogonadism, and hypodontia.\n[23307887:23307887_0] 4H syndrome is a rare and distinct leukodystrophy characterized by hypomyelination, hypogonadotropic hypogonadism, and hypodontia", "answer": "<think> Okay, let's tackle this query. The user wants a JSON answer with the symptoms of 4H leukodystrophy. First, I need to look at the evidence provided. Looking at the evidence documents, there are three entries. The first one (22451160) mentions ataxia, hypomyelination, hypodontia, and hypogonadotropic hypogonadism. The other two (23307887) both state hypomyelination, hypogonadotropic hypogonadism, and hypodontia. So, the key symptoms here are hypomyelination, hypodontia, and hypogonadotropic hypogonadism. The first document also includes ataxia. But wait, the other documents don't mention ataxia. However, the user is asking for a list of symptoms, so maybe ataxia is part of it. But I need to check if all sources agree. Since two of the three documents include hypomyelination, hypodontia, and hypogonadotropic hypogonadism, those are definitely", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this query. The user wants a JSON answer with the symptoms of 4H leukodystrophy. First, I need to look at the evidence provided. Looking at the evidence documents, there are three entries. The first one (22451160) mentions ataxia, hypomyelination, hypodontia, and hypogonadotropic hypogonadism. The other two (23307887) both state hypomyelination, hypogonadotropic hypogonadism, and hypodontia. So, the key symptoms here are hypomyelination, hypodontia, and hypogonadotropic hypogonadism. The first document also includes ataxia. But wait, the other documents don't mention ataxia. However, the user is asking for a list of symptoms, so maybe ataxia is part of it. But I need to check if all sources agree. Since two of the three documents include hypomyelination, hypodontia, and hypogonadotropic hypogonadism, those are definitely", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this query. The user is asking for the symptoms of 4H leukodystrophy. First, I need to look at the provided evidence. Looking at the evidence documents, there are three entries. The first one (22451160) mentions a patient with 4H syndrome having ataxia, hypomyelination, hypodontia, and hypogonadotropic hypogonadism. The other two documents (23307887) both state that 4H syndrome is characterized by hypomyelination, hypogonadotropic hypogonadism, and hypodontia. So the main symptoms listed across the evidence are hypomyelination, hypodontia, and hypogonadotropic hypogonadism. The first document also mentions ataxia. However, the other two documents don't include ataxia. But since the user is asking for a list of symptoms, I should include all mentioned symptoms, even if one source adds an extra one. But wait, the question says \"list symptoms,\" so maybe the answer should be comprehensive based", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this query. The user wants a JSON answer with the symptoms of 4H leukodystrophy. First, I need to look at the evidence provided. Looking at the evidence, there are three documents. The first one mentions ataxia, hypomyelination, hypodontia, and hypogonadotropic hypogonadism. The other two documents from 23307887 mention hypomyelination, hypogonadotropic hypogonadism, and hypodontia. So the main symptoms listed are hypomyelination, hypodontia, and hypogonadotropic hypogonadism. The first document also includes ataxia. But I need to check if all these are consistently mentioned across the evidence. The second and third documents don't mention ataxia, so maybe that's a variation. However, the user asked for symptoms, so I should include all mentioned ones but note if there's inconsistency. Wait, the first document says \"4H syndrome is a recently described leukodystrophy syndrome characterized by ataxia, hypomyelination, hypodont", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["18671210", "21855841", "22451160", "22855961", "23242285", "23307887", "24190003", "25339210"], "ideal_answer": "Hypomyelination, hypodontia, and hypogonadotropic hypogonadism are major symptoms of 4H leukodystrophy."}
{"question_id": "53312464d6d3ac6a3400003a", "question": "What is the extracellular core \"matrisome\"?", "retrieved_chunks": [{"doc_id": "21937732", "chunk_id": "21937732_0", "score": 6.092093467712402, "text": "Completion of genome sequences for many organisms allows a reasonably complete definition of the complement of extracellular matrix (ECM) proteins. In mammals this \"core matrisome\" comprises ∼300 proteins."}, {"doc_id": "23539364", "chunk_id": "23539364_0", "score": 3.829200029373169, "text": "Over 300 ECM molecules have been defined as comprising the \"core matrisome\" in mammals through the analysis of whole genome sequences."}, {"doc_id": "22159717", "chunk_id": "22159717_0", "score": 1.637834906578064, "text": "we have developed a bioinformatic approach to predict the in silico \"matrisome\" defined as the ensemble of ECM proteins and associated factors."}], "context": "[21937732:21937732_0] Completion of genome sequences for many organisms allows a reasonably complete definition of the complement of extracellular matrix (ECM) proteins. In mammals this \"core matrisome\" comprises ∼300 proteins.\n[23539364:23539364_0] Over 300 ECM molecules have been defined as comprising the \"core matrisome\" in mammals through the analysis of whole genome sequences.\n[22159717:22159717_0] we have developed a bioinformatic approach to predict the in silico \"matrisome\" defined as the ensemble of ECM proteins and associated factors.", "answer": "<think> Okay, let's tackle this question about the extracellular core \"matrisome.\" The user wants a concise answer with citations and a confidence score. First, I need to understand what the matrisome is. From the evidence provided, there are three references. The first two mention that the core matrisome in mammals comprises around 300 proteins, as defined by genome sequences. The third reference talks about a bioinformatic approach to predict the matrisome, which includes ECM proteins and associated factors. The question is asking for the definition of the extracellular core \"matrisome.\" So the answer should state that it's the set of ECM proteins, specifically around 300 in mammals, as per the genome sequences. The citations would be from the first two documents since they directly mention the number and the definition. The third document supports the concept but doesn't specify the number, so maybe it's a supporting citation but not necessary for the answer. Confidence: The first two sources are very direct. They both state that the core matrisome is about 300 proteins. The third is more about the method to predict it, so less", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question about the extracellular core \"matrisome.\" The user wants a concise answer with citations and a confidence score. First, I need to understand what the matrisome is. From the evidence provided, there are three references. The first two mention that the core matrisome in mammals comprises around 300 proteins, as defined by genome sequences. The third reference talks about a bioinformatic approach to predict the matrisome, which includes ECM proteins and associated factors. The question is asking for the definition of the extracellular core \"matrisome.\" So the answer should state that it's the set of ECM proteins, specifically around 300 in mammals, as per the genome sequences. The citations would be from the first two documents since they directly mention the number and the definition. The third document supports the concept but doesn't specify the number, so maybe it's a supporting citation but not necessary for the answer. Confidence: The first two sources are very direct. They both state that the core matrisome is about 300 proteins. The third is more about the method to predict it, so less", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to generate a candidate biomedical answer about the extracellular core \"matrisome\" based on the provided evidence. Let me start by understanding what the question is asking. The user wants to know what the matrisome is, specifically the extracellular core part. Looking at the evidence, there are three references. The first one says that genome sequences allow a complete definition of ECM proteins, and in mammals, the \"core matrisome\" comprises about 300 proteins. The second reference confirms this, stating over 300 ECM molecules make up the core matrisome in mammals through whole genome analysis. The third mentions a bioinformatic approach to predict the matrisome, which includes ECM proteins and associated factors. So the answer should define the matrisome as the set of ECM proteins, specifically around 300 in mammals. I need to combine these points. The citations are from different documents, but they all agree on the number being around 300. The first two references both mention 300, so maybe I can use one of them. Let me check the chunk IDs. The first document's chunk is", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question about the extracellular core \"matrisome.\" The user wants a concise answer with citations and a confidence score. First, I need to recall what the matrisome is. From the evidence provided, there are three documents. The first two mention that the core matrisome in mammals comprises around 300 proteins. The third one talks about predicting the matrisome using bioinformatics, but that's more about the method than the definition. The answer should state that the matrisome is the set of ECM proteins, specifically around 300 in mammals. The citations would be from documents 21937732 and 23539364, both of which mention the 300-protein count. The third document doesn't directly define it but supports the concept. Confidence is high because two sources independently state the same number, 300. So base_confidence should be 1.0. Need to make sure the answer is concise and correctly cites the chunks. </think> { \"answer\": \"The extracellular core 'matrisome' refers to", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["21937732", "22159717", "23539364"], "ideal_answer": "The \"matrisome\" is defined as the ensemble of extracellular matrix proteins (ECM) proteins and associated factors. The core matrisome have been defined in mammals through the analysis of whole genome sequences and comprises of ~ 300 proteins."}
{"question_id": "56f3f6b12ac5ed145900001a", "question": "Is GAGA associated with nucleosome-free regions (NFR)?", "retrieved_chunks": [{"doc_id": "7737124", "chunk_id": "7737124_0", "score": 4.937474250793457, "text": "The interactions of GAGA factor and heat shock factor with their binding sites in chromatin occurred in two modes. Their interaction with binding sites in the nucleosome-free regions did not require ATP. In the presence of ATP both factors interacted also with nucleosomal binding sites, causing nucleosome rearrangements and a refinement of nucleosome positions"}, {"doc_id": "11158316", "chunk_id": "11158316_0", "score": 4.5600175857543945, "text": "The HS3 sequence contains consensus binding sites for the GAGA factor, a protein implicated in the formation of nucleosome-free regions of chromatin, and Pleiohomeotic (Pho), a Polycomb group protein that is related to the mammalian transcription factor YY1."}, {"doc_id": "15579691", "chunk_id": "15579691_0", "score": 4.08709716796875, "text": "One of the three nuclease hypersensitive sites in the Fab-7 boundary, HS1, contains multiple consensus-binding sequences for the GAGA factor, a protein known to be involved in the formation and/or maintenance of nucleosome-free regions of chromatin."}], "context": "[7737124:7737124_0] The interactions of GAGA factor and heat shock factor with their binding sites in chromatin occurred in two modes. Their interaction with binding sites in the nucleosome-free regions did not require ATP. In the presence of ATP both factors interacted also with nucleosomal binding sites, causing nucleosome rearrangements and a refinement of nucleosome positions\n[11158316:11158316_0] The HS3 sequence contains consensus binding sites for the GAGA factor, a protein implicated in the formation of nucleosome-free regions of chromatin, and Pleiohomeotic (Pho), a Polycomb group protein that is related to the mammalian transcription factor YY1.\n[15579691:15579691_0] One of the three nuclease hypersensitive sites in the Fab-7 boundary, HS1, contains multiple consensus-binding sequences for the GAGA factor, a protein known to be involved in the formation and/or maintenance of nucleosome-free regions of chromatin.", "answer": "<think> Okay, I need to determine if GAGA is associated with nucleosome-free regions (NFR) based on the provided evidence. Let me look at each of the three documents. First, document 7737124:7737124_0 mentions that the GAGA factor interacts with binding sites in nucleosome-free regions without ATP. It also says that in the presence of ATP, these factors can interact with nucleosomal sites, causing rearrangements. So this suggests that GAGA is involved with NFRs because it binds there. Then document 11158316:11158316_0 states that the HS3 sequence has binding sites for GAGA, which is implicated in forming NFRs. This directly links GAGA to NFRs. The third document, 15579691:15579691_0, talks about HS1 containing multiple consensus-binding sequences for GAGA, which is known for formation and maintenance of NFRs. So again, this supports the association. All three pieces", "citations": [], "candidates": [{"answer": "<think> Okay, I need to determine if GAGA is associated with nucleosome-free regions (NFR) based on the provided evidence. Let me look at each of the three documents. First, document 7737124:7737124_0 mentions that the GAGA factor interacts with binding sites in nucleosome-free regions without ATP. It also says that in the presence of ATP, these factors can interact with nucleosomal sites, causing rearrangements. So this suggests that GAGA is involved with NFRs because it binds there. Then document 11158316:11158316_0 states that the HS3 sequence has binding sites for GAGA, which is implicated in forming NFRs. This directly links GAGA to NFRs. The third document, 15579691:15579691_0, talks about HS1 containing multiple consensus-binding sequences for GAGA, which is known for formation and maintenance of NFRs. So again, this supports the association. All three pieces", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to answer whether GAGA is associated with nucleosome-free regions (NFR) based on the given evidence. Let me look at the evidence provided. First, document 7737124 mentions that the GAGA factor interacts with binding sites in nucleosome-free regions without ATP. Also, in the presence of ATP, it can interact with nucleosomal sites, causing rearrangements. So this suggests GAGA is involved with NFRs. Then, document 11158316 states that the HS3 sequence has a consensus binding site for GAGA, which is implicated in forming NFRs. That directly links GAGA to NFRs. Document 15579691 talks about HS1 containing multiple GAGA-binding sites, which are involved in formation/maintenance of NFRs. So again, this supports the association. All three documents mention GAGA's role in NFRs. The first one shows interaction in NFRs without ATP, others link binding sites to NFR formation. Therefore, the answer should be yes, with high confidence. The", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if GAGA is associated with nucleosome-free regions (NFR). I need to look at the evidence provided. First, evidence from [11158316:11158316_0] mentions that the HS3 sequence has a binding site for the GAGA factor, which is implicated in forming NFR. That's a direct link. Then, [15579691:15579691_0] talks about HS1 containing multiple consensus-binding sites for GAGA, and it's known for involvement in formation/maintenance of NFR. So two sources here connect GAGA to NFR. Another evidence point is [7737124:7737124_0], which says that GAGA interacts with binding sites in NFR without ATP, and with nucleosomal sites requiring ATP. But this doesn't directly state that GAGA is associated with NFR, more about how it interacts. However, the other two pieces of evidence are more direct. So", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["11158316", "15579691", "7737124", "8474442"], "ideal_answer": "The GAGA factor is a protein known to be involved in the formation and/or maintenance of nucleosome-free regions of chromatin. The interactions of GAGA factor and heat shock factor with their binding sites in chromatin occurred in two modes. Their interaction with binding sites in the nucleosome-free regions did not require ATP. In the presence of ATP both factors interacted also with nucleosomal binding sites, causing nucleosome rearrangements and a refinement of nucleosome positions. While chromatin remodeling upon transcription factor interaction has previously been interpreted to involve nucleosome disruption, the data suggest energy-dependent nucleosome sliding as main principle of chromatin reorganization. The HS3 sequence contains consensus binding sites for the GAGA factor, a protein implicated in the formation of nucleosome-free regions of chromatin, and Pleiohomeotic (Pho), a Polycomb group protein that is related to the mammalian transcription factor YY1. To study the contribution of transcription factors to the establishment of this specific chromatin configuration we assembled nucleosomes on the hsp26 promoter using a cell-free reconstitution system derived from fly embryos. This (CT)n element appears to contribute to formation of the wild-type chromatin structure of hsp26, an organized nucleosome array that leaves the HSEs in nucleosome-free, DNase I-hypersensitive (DH) sites (Q. Lu, L.L. Wallrath, B.D. Allan, R.L. Glaser, J.T. Lis, and S.C.R. Elgin, J. Mol. Biol. Both DH sites were readily reconstituted from extract components. One of the three nuclease hypersensitive sites in the Fab-7 boundary, HS1, contains multiple consensus-binding sequences for the GAGA factor, a protein known to be involved in the formation and/or maintenance of nucleosome-free regions of chromatin."}
{"question_id": "511a4d391159fa8212000003", "question": "Which are the plant DNA (cytosine-5) methyltransferase families?", "retrieved_chunks": [{"doc_id": "18640997", "chunk_id": "18640997_0", "score": 6.045825004577637, "text": "To explore possible relationships between DNA methylation level and accumulation of DNA-(cytosine-5) methyltransferase (DNMT) transcripts, the full-length coding sequences corresponding to three different DNMT families in oil palm, namely the MET, CMT, and DRM classes, have been isolated and characterized."}, {"doc_id": "9680985", "chunk_id": "9680985_0", "score": 5.337103843688965, "text": "In the present study, the isolation and characterization of two distinct cDNAs that code for carrot DNA (cytosine-5)-methyltransferase (DNA-METase) are reported."}, {"doc_id": "15289832", "chunk_id": "15289832_0", "score": 5.209707260131836, "text": "DNA (cytosine-5-)-methyltransferase 1 (DNMT1) plays an important role in the maintenance of DNA methylation patterns via complicated networks including signaling pathways and transcriptional factors, relating to cell differentiation or carcinogenesis."}], "context": "[18640997:18640997_0] To explore possible relationships between DNA methylation level and accumulation of DNA-(cytosine-5) methyltransferase (DNMT) transcripts, the full-length coding sequences corresponding to three different DNMT families in oil palm, namely the MET, CMT, and DRM classes, have been isolated and characterized.\n[9680985:9680985_0] In the present study, the isolation and characterization of two distinct cDNAs that code for carrot DNA (cytosine-5)-methyltransferase (DNA-METase) are reported.\n[15289832:15289832_0] DNA (cytosine-5-)-methyltransferase 1 (DNMT1) plays an important role in the maintenance of DNA methylation patterns via complicated networks including signaling pathways and transcriptional factors, relating to cell differentiation or carcinogenesis.", "answer": "<think> Okay, let's tackle this question. The user is asking about the plant DNA (cytosine-5) methyltransferase families. Looking at the evidence provided, I need to extract the relevant information. First, evidence [18640997:18640997_0] mentions three different DNMT families in oil palm: MET, CMT, and DRM. That seems directly relevant. The other documents talk about DNA-METase in carrots and DNMT1's role, but they don't specify family names. So the answer should list the three families mentioned in the first evidence. The confidence here is high because it's a direct statement from a study on oil palm. However, I need to check if there are other families mentioned elsewhere. The other documents don't provide additional families, so the answer is based solely on that evidence. I should make sure the answer is concise and cites the correct document. The base confidence would be 1.0 since the information is explicitly stated in the evidence. </think> { \"answer\": \"The plant DNA (cytosine-5) methyltransferase families", "citations": [{"doc_id": "18640997", "chunk_id": "18640997_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking about the plant DNA (cytosine-5) methyltransferase families. Looking at the evidence provided, I need to extract the relevant information. First, evidence [18640997:18640997_0] mentions three different DNMT families in oil palm: MET, CMT, and DRM. That seems directly relevant. The other documents talk about DNA-METase in carrots and DNMT1's role, but they don't specify family names. So the answer should list the three families mentioned in the first evidence. The confidence here is high because it's a direct statement from a study on oil palm. However, I need to check if there are other families mentioned elsewhere. The other documents don't provide additional families, so the answer is based solely on that evidence. I should make sure the answer is concise and cites the correct document. The base confidence would be 1.0 since the information is explicitly stated in the evidence. </think> { \"answer\": \"The plant DNA (cytosine-5) methyltransferase families", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the plant DNA (cytosine-5) methyltransferase families. I need to look at the evidence provided to find the answer. Looking at the first piece of evidence: [18640997:18640997_0] mentions three different DNMT families in oil palm: MET, CMT, and DRM classes. That's a direct mention of families. The second evidence [9680985:9680985_0] talks about two distinct cDNAs for carrot DNA-METase, but it's specifying the MET class again. The third evidence [15289832:15289832_0] mentions DNMT1, which is part of the MET family, I think. So the answer should include the three families from the first study: MET, CMT, DRM. The carrot study supports that MET is one of them. DNMT1 is part of the MET family. So the main answer is MET, CMT, and DRM.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, so the user is asking about the plant DNA (cytosine-5) methyltransferase families. Let me look at the evidence provided. First, the evidence from 18640997:18640997_0 mentions three different DNMT families in oil palm: MET, CMT, and DRM. That seems directly relevant. The other two references talk about DNA-METase in carrots and DNMT1's role, but they don't specify families. The question is about plant families, so the first source is the key here. The answer should list the three families mentioned: MET, CMT, and DRM. The confidence is high because it's a direct statement from the evidence. The other sources don't mention different families, so they aren't needed here. I need to make sure the answer is concise and cites the correct document chunk. </think> { \"answer\": \"The plant DNA (cytosine-5) methyltransferase families include MET, CMT, and DRM classes, as identified in oil palm [18640997:18640", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["10781108", "10845458", "11353082", "17689048", "18640997", "19132393", "20331964", "21060858", "21542302", "8152926", "8389441", "9680985"], "ideal_answer": "The plant DNA (cytosine-5)methyltransferases are classified into the families: MET, CMT, and the de novo DRM."}
{"question_id": "52fe52702059c6d71c000078", "question": "Where is the histone variant CENPA preferentially localized?", "retrieved_chunks": [{"doc_id": "16248679", "chunk_id": "16248679_0", "score": 2.5027849674224854, "text": "Variant histone H2A.Z is globally localized to the promoters of inactive yeast genes and regulates nucleosome positioning."}, {"doc_id": "22693454", "chunk_id": "22693454_1", "score": 2.5000107288360596, "text": "In budding yeast, as well as in other eukaryotes, the Cse4 histone variant (known in vertebrates as CENP-A) is believed to substitute for histone H3 at the centromeric nucleosome"}, {"doc_id": "22516971", "chunk_id": "22516971_5", "score": 1.742027759552002, "text": "The Mis18 complex has been identified as a critical factor for the centromeric localization of a histone H3 variant, centromeric protein A (CENP-A), which is responsible for the specification of centromere identity in the chromosome."}], "context": "[16248679:16248679_0] Variant histone H2A.Z is globally localized to the promoters of inactive yeast genes and regulates nucleosome positioning.\n[22693454:22693454_1] In budding yeast, as well as in other eukaryotes, the Cse4 histone variant (known in vertebrates as CENP-A) is believed to substitute for histone H3 at the centromeric nucleosome\n[22516971:22516971_5] The Mis18 complex has been identified as a critical factor for the centromeric localization of a histone H3 variant, centromeric protein A (CENP-A), which is responsible for the specification of centromere identity in the chromosome.", "answer": "<think> Okay, let's tackle this question. The user is asking where the histone variant CENPA is preferentially localized. The evidence provided has three references. First, I need to understand what each reference says. The first one talks about H2A.Z in yeast genes promoters. The second mentions Cse4, which is CENP-A in vertebrates, substituting for H3 at centromeric nucleosomes. The third refers to the Mis18 complex helping localize CENP-A to centromeres. So, the question is about CENPA (CENP-A). From the second evidence, it says that Cse4 (which is CENP-A in vertebrates) substitutes for H3 at centromeric nucleosomes. The third evidence says that the Mis18 complex is critical for the centromeric localization of CENP-A. So, putting this together, CENPA is localized at centromeres. The answer should be that CENPA is preferentially localized at centromeres. The citations would be from the second and third references. But the user wants one candidate answer with citations. Let me check if", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking where the histone variant CENPA is preferentially localized. The evidence provided has three references. First, I need to understand what each reference says. The first one talks about H2A.Z in yeast genes promoters. The second mentions Cse4, which is CENP-A in vertebrates, substituting for H3 at centromeric nucleosomes. The third refers to the Mis18 complex helping localize CENP-A to centromeres. So, the question is about CENPA (CENP-A). From the second evidence, it says that Cse4 (which is CENP-A in vertebrates) substitutes for H3 at centromeric nucleosomes. The third evidence says that the Mis18 complex is critical for the centromeric localization of CENP-A. So, putting this together, CENPA is localized at centromeres. The answer should be that CENPA is preferentially localized at centromeres. The citations would be from the second and third references. But the user wants one candidate answer with citations. Let me check if", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking where the histone variant CENPA is preferentially localized. The evidence provided has three references. First, looking at the evidence: Reference [22693454:22693454_1] says that Cse4 (which is known as CENP-A in vertebrates) substitutes for histone H3 at the centromeric nucleosome in budding yeast and other eukaryotes. So this suggests that CENPA (Cse4) is localized at centromeres. Another reference [22516971:22516971_5] mentions the Mis18 complex being involved in the centromeric localization of CENP-A. This reinforces the idea that CENPA is located at centromeres. The first reference talks about H2A.Z in yeast promoters, but that's a different variant (H2A.Z) and different location (promoters of inactive genes). So that's not relevant here. So the answer should be centromeres. The confidence is high because two", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking where the histone variant CENPA is preferentially localized. The evidence provided has three chunks. First, chunk 16248679 talks about H2A.Z being localized to promoters of inactive yeast genes. But the question is about CENPA, which is mentioned in chunk 22693454. That chunk says Cse4 (CENP-A in vertebrates) substitutes for H3 at centromeric nucleosomes. So that suggests centromeres. Another chunk, 22516971, mentions the Mis18 complex being involved in centromeric localization of CENP-A. So combining these two, it seems that CENPA (Cse4) is localized at centromeres. The answer should be centromeres, citing the relevant chunks. The confidence is high because two chunks directly mention centromere localization. So base_confidence would be 0.95 or so. </think> { \"answer\": \"CENPA (Cse4 histone variant) is preferentially localized at cent", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["10655499", "12011073", "12217960", "12906131", "12953060", "16314512", "18314594", "18411404", "19778997", "20119530", "20940262", "21508988", "21888900", "23439889", "23562479", "24213134", "9465302", "9605877"], "ideal_answer": "Centromere protein A (Cenpa for mouse, CENP-A for other species) is an essential histone H3-like protein that localizes to the centromeric region of eukaryotic chromosomes, where it replaces conventional histone H3 and together with centromere-specific-DNA-binding factors directs the assembly of active kinetochores. THe histone variant CENPA is preferentially located at Centromeric chromatin"}
{"question_id": "517137c18ed59a060a000001", "question": "In which proteins is the chromodomain present?", "retrieved_chunks": [{"doc_id": "18450745", "chunk_id": "18450745_0", "score": 8.233509063720703, "text": "In vertebrates, HP1-like chromodomains are also present in the chromodomain Y chromosome (CDY) family of proteins adjacent to a putative catalytic motif. The human genome encodes three CDY family proteins, CDY, CDYL, and CDYL2."}, {"doc_id": "11956312", "chunk_id": "11956312_0", "score": 8.006998062133789, "text": "The chromodomain (CD) is a highly conserved motif present in a variety of animal and plant proteins, and its probable role is to assemble a variety of macromolecular complexes in chromatin."}, {"doc_id": "20493168", "chunk_id": "20493168_1", "score": 7.554388999938965, "text": "The chromatin organizer modifier domain (chromodomain) is present in proteins that contribute to chromatin organization and mediates their binding to methylated histone H3."}], "context": "[18450745:18450745_0] In vertebrates, HP1-like chromodomains are also present in the chromodomain Y chromosome (CDY) family of proteins adjacent to a putative catalytic motif. The human genome encodes three CDY family proteins, CDY, CDYL, and CDYL2.\n[11956312:11956312_0] The chromodomain (CD) is a highly conserved motif present in a variety of animal and plant proteins, and its probable role is to assemble a variety of macromolecular complexes in chromatin.\n[20493168:20493168_1] The chromatin organizer modifier domain (chromodomain) is present in proteins that contribute to chromatin organization and mediates their binding to methylated histone H3.", "answer": "<think> Okay, let's tackle this question. The user is asking which proteins contain the chromodomain. The evidence provided has three documents. First, looking at document [18450745:18450745_0], it mentions HP1-like chromodomains in the CDY family proteins: CDY, CDYL, and CDYL2. That's a direct answer. Then document [11956312:11956312_0] states that the chromodomain is present in various proteins, but it's more general. It doesn't name specific proteins, so maybe not as helpful here. Document [20493168:20493168_1] talks about the chromodomain being in proteins that contribute to chromatin organization and bind to methylated H3. Again, it's general. So the main specific answer comes from the first document. The CDY family proteins are mentioned. But wait, the question is about proteins with the chromodomain. The first evidence says \"HP1-like chromodomains", "citations": [{"doc_id": "18450745", "chunk_id": "18450745_0"}, {"doc_id": "11956312", "chunk_id": "11956312_0"}, {"doc_id": "20493168", "chunk_id": "20493168_1"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which proteins contain the chromodomain. The evidence provided has three documents. First, looking at document [18450745:18450745_0], it mentions HP1-like chromodomains in the CDY family proteins: CDY, CDYL, and CDYL2. That's a direct answer. Then document [11956312:11956312_0] states that the chromodomain is present in various proteins, but it's more general. It doesn't name specific proteins, so maybe not as helpful here. Document [20493168:20493168_1] talks about the chromodomain being in proteins that contribute to chromatin organization and bind to methylated H3. Again, it's general. So the main specific answer comes from the first document. The CDY family proteins are mentioned. But wait, the question is about proteins with the chromodomain. The first evidence says \"HP1-like chromodomains", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which proteins contain the chromodomain. The evidence provided has three documents. First, looking at document [18450745:18450745_0], it mentions HP1-like chromodomains in the CDY family proteins: CDY, CDYL, and CDYL2. That's a direct answer. Then, document [11956312:11956312_0] says the chromodomain is present in various proteins, but it's more general. It doesn't name specific proteins, so maybe not as helpful for a precise answer. Document [20493168:20493168_1] talks about the chromodomain being in proteins that contribute to chromatin organization and bind to methylated H3. Again, general, but maybe supports the CDY family mention from the first document. So the main evidence pointing to specific proteins is the first document. The answer should list those three CDY proteins with their citations. The confidence would be high", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which proteins contain the chromodomain. The evidence provided has three documents. First, looking at document [18450745:18450745_0], it mentions HP1-like chromodomains in the CDY family proteins: CDY, CDYL, and CDYL2. That's a direct answer. Then, document [11956312:11956312_0] states that the chromodomain is present in various proteins, but it's more general. It doesn't name specific proteins, so maybe not as useful for a precise answer. Document [20493168:20493168_1] talks about the chromodomain being in proteins that contribute to chromatin organization and bind to methylated H3. Again, general, but maybe supports the idea that CDY family proteins are examples. So the most specific answer comes from the first document. The CDY family proteins are explicitly mentioned. The other documents don't list specific names,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["10199952", "10908644", "11500496", "11859155", "11956312", "12137948", "12186646", "12397079", "12819141", "15304225", "15457214", "16095617", "16157682", "16183644", "16339723", "16407326", "16412250", "16537902", "16613610", "16738128", "16949368", "17101786", "17224041", "17253929", "17428788", "17542647", "17603073", "18369641", "18450745", "18725928", "18846226", "19029895", "19142019", "19205716", "19279158", "19399177", "19798443", "19808672", "19897549", "19956676", "20308527", "20389031", "20493168", "20568999", "20657587", "20860631", "20950435", "21047797", "21060834", "21094707", "21146514", "21158681", "21177652", "21195088", "21211724", "21224386", "21245376", "21278251", "21358630", "21369828", "21419134", "21447119", "21448134", "21505064", "21596839", "21623345", "21636313", "21646535", "21659642", "21669865", "21720545", "21726377", "21730028", "21799255", "21830056", "21836164", "21860208", "21875659", "21901784", "21953552", "21972924", "21979373", "22009739", "22022377", "22033296", "22033927", "22039057", "22052799", "22073269", "22081013", "22081016", "22083954", "22083958", "22086334", "22145013", "22172672", "22179824", "22186629", "22193973", "22203189", "22212480", "22216243", "22219182", "22223433", "22231402", "22235338", "22242120", "22302795", "22325148", "22412383", "22419124", "22427862", "22462537", "22491446", "22514736", "22528993", "22551706", "22569126", "22569290", "22607268", "22646239", "22683269", "22691070", "22705977", "22715096", "22727667", "22728643", "22768949", "22815475", "22834704", "22855185", "22892537", "22897906", "23020525", "23022495", "23071088", "23071455", "23071553", "23142031", "23202694", "23239876", "23271156", "23282990", "23285124", "23285239", "23314848", "23318260", "23319608", "23320494", "23388053", "23403278", "23417793", "23448600", "23471993", "7720711", "8460153", "8663349"], "ideal_answer": "The chromodomain (chromatin organizer modifier domain) is a highly conserved motif, 40-50 amino acids in length, present in a wide range of animal and plant proteins involved in chromatin organization. Chromodomain-containing proteins can be classified into boader families based, particularly, on the presence of other types of domains. Chromodomain is present in: the heterochromatin proteins HP1 alpha and HP1 beta, chromointgrases (e.g. Tf1 integrase) the chromodomain helicase DNA-binding proteins (CHD) and CHD 1-like (CHD1L), CReMM (chromatin-related mesenchymal modulator), dna methyltransferase 3 (cmt3), the chromointegrase of the LTR-retrotransposons, the Polycomb group (PcG) proteins, the mouse Polycomb homologs (Cbx2, Cbx4, Cbx6, Cbx7, Cbx8), the chromodomain Y chromosome (CDY) family of proteins and the CDY-like protein (CDYL), the histone acetyltransferases TgMYST-A and –B, MRG-1 and -15 (MORF4-Related Gene on chromosome 15), ADP/ATP translocase 1, MPP8, MSL3, NlMof, Chp1, Chriz, dMi-2, Corto, cpSRP43, KISMET, PICKLE (PKL), ScoHET1 and ScoHET2."}
{"question_id": "56b3efc38525abca1e000006", "question": "What is Genomicus?", "retrieved_chunks": [{"doc_id": "23193262", "chunk_id": "23193262_0", "score": 10.184164047241211, "text": "Genomicus (http://www.dyogen.ens.fr/genomicus/) is a database and an online tool that allows easy comparative genomic visualization in &gt;150 eukaryote genomes."}, {"doc_id": "23193262", "chunk_id": "23193262_1", "score": 10.181413650512695, "text": "Genomicus (http://www.dyogen.ens.fr/genomicus/) is a database and an online tool that allows easy comparative genomic visualization in >150 eukaryote genomes."}, {"doc_id": "23193262", "chunk_id": "23193262_2", "score": 10.120392799377441, "text": "Genomicus (http://www.dyogen.ens.fr/genomicus/) is a database and an online tool that allows easy comparative genomic visualization in>150 eukaryote genomes"}], "context": "[23193262:23193262_0] Genomicus (http://www.dyogen.ens.fr/genomicus/) is a database and an online tool that allows easy comparative genomic visualization in &gt;150 eukaryote genomes.\n[23193262:23193262_1] Genomicus (http://www.dyogen.ens.fr/genomicus/) is a database and an online tool that allows easy comparative genomic visualization in >150 eukaryote genomes.\n[23193262:23193262_2] Genomicus (http://www.dyogen.ens.fr/genomicus/) is a database and an online tool that allows easy comparative genomic visualization in>150 eukaryote genomes", "answer": "<think> Okay, so the user is asking what Genomicus is. Let me look at the evidence provided. There are three chunks here, all from the same document ID. Each chunk says that Genomicus is a database and online tool for comparative genomic visualization in over 150 eukaryote genomes. First, I need to make sure that all the chunks are consistent. They all state the same thing, so there's no conflicting information. The answer should be concise, so I'll combine the key points: it's a database and online tool, used for comparative genomics, and it covers more than 150 eukaryote genomes. I need to cite the source. Since all chunks are from the same document ID, I can use that. The user wants the citation in the format [doc_id:chunk_id]. But since all chunks are the same, maybe pick one of them. However, the problem is that each chunk has a different chunk_id but same doc_id. But the answer should include one citation. Wait, the example shows that in the evidence, there are three entries with the same doc_id but different chunk_ids. So", "citations": [], "candidates": [{"answer": "<think> Okay, so the user is asking what Genomicus is. Let me look at the evidence provided. There are three chunks here, all from the same document ID. Each chunk says that Genomicus is a database and online tool for comparative genomic visualization in over 150 eukaryote genomes. First, I need to make sure that all the chunks are consistent. They all state the same thing, so there's no conflicting information. The answer should be concise, so I'll combine the key points: it's a database and online tool, used for comparative genomics, and it covers more than 150 eukaryote genomes. I need to cite the source. Since all chunks are from the same document ID, I can use that. The user wants the citation in the format [doc_id:chunk_id]. But since all chunks are the same, maybe pick one of them. However, the problem is that each chunk has a different chunk_id but same doc_id. But the answer should include one citation. Wait, the example shows that in the evidence, there are three entries with the same doc_id but different chunk_ids. So", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to generate a JSON answer for the question \"What is Genomicus?\" based on the provided evidence. Let me look at the evidence first. The evidence has three entries, all with the same doc_id and chunk_id. They all say that Genomicus is a database and online tool for comparative genomic visualization in over 150 eukaryote genomes. The URLs are the same in each case. So the answer should be concise, mentioning that it's a database and tool for comparative genomics in >150 eukaryotes. The citations are all from the same document, so I can reference that. The base confidence is a float between 0 and 1. Since all three chunks are identical, the model is confident. Maybe 0.95 or 1.0? But maybe 1.0 since all evidence points to the same answer. Wait, but sometimes duplicates might be redundant. However, in this case, they're all exact copies. So the confidence should be high. Let me set it to 1.0. Now structure the JSON with answer and base_confidence. The answer should", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to generate a candidate biomedical answer for the question \"What is Genomicus?\" using the provided evidence. Let me start by looking at the evidence given. The user provided three chunks, all from the same document ID [23193262] with different chunk IDs. Each of them says that Genomicus is a database and online tool for comparative genomic visualization in over 150 eukaryote genomes. The URLs are the same in each case, so that's consistent. The answer should be concise and include citations in the format [doc_id:chunk_id]. Since all three chunks are duplicates, I can pick one of them. Let's choose the first one, [23193262:23193262_0], as the citation. Now, the answer part needs to be a brief statement defining Genomicus. The key points are that it's a database, an online tool, and allows comparative genomic visualization in more than 150 eukaryote genomes. I should make sure to mention all these elements. For the base_confidence, since all", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["20185404", "23193262", "25378326"], "ideal_answer": "Genomicus had been developed as a database and a browser to study gene synteny in modern and ancestral genomes. It allows easy comparative genomic visualization in >150 eukaryote genomes and in four different phyla (Vertebrate, Fungi, Metazoan and Plants). It provides a way to explore spatial information related to gene organization within and between genomes and temporal relationships related to gene and genome evolution. For the specific vertebrate phylum, it also provides access to ancestral gene order reconstructions and conserved non-coding elements information. The graphical modules of Genomicus show how it is capable of revealing differential gene loss and gain, segmental or genome duplications and facilitate the study of the evolution of a locus through homology relationships. The Genomicus server provides access to ancestral gene orders, as well as computationally predicted regulatory interactions, thanks to the representation of conserved non-coding elements with their putative gene targets."}
{"question_id": "5509df4ac2af5d5b70000003", "question": "Is amiodarone a class I anti-arrhythmic drug?", "retrieved_chunks": [{"doc_id": "20041841", "chunk_id": "20041841_0", "score": 10.485806465148926, "text": "Although amiodarone is considered a class III anti-arrhythmic agent, it also has class I, II, IV actions, making it a unique and effective anti-arrhythmic agent"}, {"doc_id": "11825323", "chunk_id": "11825323_1", "score": 10.47260856628418, "text": "Amiodarone has been used as an anti-arrhythmic drug since the 1970s and has an established role in the treatment of ventricular tachyarrhythmias. Although considered to be a class III anti-arrhythmic, amiodarone also has class I, II and IV actions, which gives it a unique pharmacological and anti-arrhythmic profile."}, {"doc_id": "11825323", "chunk_id": "11825323_0", "score": 10.18978500366211, "text": "Although considered to be a class III anti-arrhythmic, amiodarone also has class I, II and IV actions, which gives it a unique pharmacological and anti-arrhythmic profile"}], "context": "[20041841:20041841_0] Although amiodarone is considered a class III anti-arrhythmic agent, it also has class I, II, IV actions, making it a unique and effective anti-arrhythmic agent\n[11825323:11825323_1] Amiodarone has been used as an anti-arrhythmic drug since the 1970s and has an established role in the treatment of ventricular tachyarrhythmias. Although considered to be a class III anti-arrhythmic, amiodarone also has class I, II and IV actions, which gives it a unique pharmacological and anti-arrhythmic profile.\n[11825323:11825323_0] Although considered to be a class III anti-arrhythmic, amiodarone also has class I, II and IV actions, which gives it a unique pharmacological and anti-arrhythmic profile", "answer": "<think> Okay, let's tackle this question. The user is asking if amiodarone is a class I anti-arrhythmic drug. The evidence provided mentions that amiodarone is considered a class III agent but also has actions in classes I, II, and IV. First, I need to recall the classification of anti-arrhythmic drugs. Class I agents are further divided into subclasses Ia and Ib, which block sodium channels. Class III agents prolong the action potential duration, like amiodarone. However, the evidence states that amiodarone has class I, II, IV actions. So even though it's primarily class III, it does have class I properties. The answer should be concise, citing the relevant documents. The confidence level is based on the evidence provided. Since the documents clearly state that amiodarone has class I actions, the base confidence should be high, maybe 0.95. But wait, the question is whether it's a class I drug. However, the primary classification is III, but the answer needs to reflect that it also has class I actions. So the correct answer is yes, but with the caveat", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if amiodarone is a class I anti-arrhythmic drug. The evidence provided mentions that amiodarone is considered a class III agent but also has actions in classes I, II, and IV. First, I need to recall the classification of anti-arrhythmic drugs. Class I agents are further divided into subclasses Ia and Ib, which block sodium channels. Class III agents prolong the action potential duration, like amiodarone. However, the evidence states that amiodarone has class I, II, IV actions. So even though it's primarily class III, it does have class I properties. The answer should be concise, citing the relevant documents. The confidence level is based on the evidence provided. Since the documents clearly state that amiodarone has class I actions, the base confidence should be high, maybe 0.95. But wait, the question is whether it's a class I drug. However, the primary classification is III, but the answer needs to reflect that it also has class I actions. So the correct answer is yes, but with the caveat", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if amiodarone is a class I anti-arrhythmic drug. The evidence provided mentions that amiodarone is considered a class III agent but also has actions in classes I, II, and IV. First, I need to recall the classification of anti-arrhythmic drugs. Class I agents are further divided into subclasses Ia and Ib, which block sodium channels. Class III agents prolong the action potential duration, like amiodarone. However, the evidence states that amiodarone has class I, II, IV actions. So, even though it's primarily class III, it does have class I properties. The answer should be concise, citing the relevant documents. The confidence level is important here. Since the evidence clearly states that amiodarone has class I actions, but the main classification is III, the answer should reflect that it's not solely class I but also has those actions. However, the question is whether it's a class I drug. The answer would be yes, because it does have class I actions, even though it's mainly class III. But I need to", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, the user is asking if amiodarone is a class I anti-arrhythmic drug. Let me look at the evidence provided. The first document says that amiodarone is considered a class III agent but also has class I, II, IV actions. The second and third documents mention similar things, stating it's mainly class III but also has other classes. So, even though it's primarily class III, it does have class I properties. The answer needs to be concise with citations. The key point is that while it's mainly class III, it does have class I actions. So the answer should mention that it's considered class III but also has class I effects. The confidence level should be high because multiple sources agree on this. Let me check the document IDs and chunk IDs again to make sure the citations are correct. The first document is 20041841:20041841_0, and others reference 11825323. So I'll include those. The base confidence can be 0.95 since the evidence consistently states this. </think> {", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["11825323", "12491809", "15989900", "17352036", "20041841", "21626366", "21728182"], "ideal_answer": "Although considered to be a class III anti-arrhythmic, amiodarone also has class I, II and IV actions, which gives it a unique pharmacological and anti-arrhythmic profile Amiodarone has been used as an anti-arrhythmic drug since the 1970s and has an established role in the treatment of ventricular tachyarrhythmias. Although considered to be a class III anti-arrhythmic, amiodarone also has class I, II and IV actions, which gives it a unique pharmacological and anti-arrhythmic profile. Common class I agents are excluded due to the inherent abnormal cardiac structure and function in the setting of cardiogenic shock. Class III drug options include dofetilide and amiodarone. Amiodarone has been used as an anti-arrhythmic drug since the 1970s and has an established role in the treatment of ventricular tachyarrhythmias. Although considered to be a class III anti-arrhythmic, amiodarone also has class I, II and IV actions, which gives it a unique pharmacological and anti-arrhythmic profile. No. Common class I agents are excluded due to the inherent abnormal cardiac structure and function in the setting of cardiogenic shock. Although considered to be a class III anti-arrhythmic, amiodarone also has class I, II and IV actions, which gives it a unique pharmacological and anti-arrhythmic profile. Amiodarone, an iodinated benzofuran derivative, introduced in 1960 s as an anti-anginal agent, emerged as a potent anti-arrhythmic agent by 1970 s and is currently one of the most commonly prescribed drugs in US for ventricular and atrial arrhythmias. Although amiodarone is considered a class III anti-arrhythmic agent, it also has class I, II, IV actions, making it a unique and effective anti-arrhythmic agent."}
{"question_id": "5339ecf4d6d3ac6a3400005f", "question": "Which is the prognostic meaning of delayed enhancement documented in patients hypertrophic cardiomyopathy?", "retrieved_chunks": [{"doc_id": "17885521", "chunk_id": "17885521_1", "score": 4.007968425750732, "text": "Patterns of delayed enhancement are different in dilated cardiomyopathy and ischemic cardiomyopathy, reflecting the presence of scarring or various degrees of fibrosis in left ventricular myocardium. The presence of subendocardial or transmural delayed enhancement at contrast-enhanced cardiovascular magnetic resonance allowed distinction between dilated cardiomyopathy and ischemic cardiomyopathy with high sensitivity (88%) and specificity (100%)."}, {"doc_id": "17885521", "chunk_id": "17885521_0", "score": 3.9407756328582764, "text": "In the dilated cardiomyopathy group, only seven (29%) patients showed delayed enhancement and its pattern was characterized by mid-wall, patchy or diffuse location."}, {"doc_id": "19317068", "chunk_id": "19317068_0", "score": 3.1009156703948975, "text": "one case was dilated cardiomyopathy, in which the delayed enhancement was diffuse small midwall spots"}], "context": "[17885521:17885521_1] Patterns of delayed enhancement are different in dilated cardiomyopathy and ischemic cardiomyopathy, reflecting the presence of scarring or various degrees of fibrosis in left ventricular myocardium. The presence of subendocardial or transmural delayed enhancement at contrast-enhanced cardiovascular magnetic resonance allowed distinction between dilated cardiomyopathy and ischemic cardiomyopathy with high sensitivity (88%) and specificity (100%).\n[17885521:17885521_0] In the dilated cardiomyopathy group, only seven (29%) patients showed delayed enhancement and its pattern was characterized by mid-wall, patchy or diffuse location.\n[19317068:19317068_0] one case was dilated cardiomyopathy, in which the delayed enhancement was diffuse small midwall spots", "answer": "<think> Okay, let's tackle this question. The user is asking about the prognostic meaning of delayed enhancement in patients with hypertrophic cardiomyopathy. Wait, but the evidence provided talks about dilated and ischemic cardiomyopathies. Hmm, maybe there's a mix-up here. Hypertrophic cardiomyopathy (HCM) is different from dilated cardiomyopathy (DCM). The evidence mentions delayed enhancement in DCM and ischemic cardiomyopathy, but not HCM. Looking at the evidence: [17885521:17885521_0] says that in DCM, 29% had delayed enhancement with mid-wall, patchy, or diffuse locations. [19317068:19317068_0] mentions one case of DCM with diffuse small midwall spots. But the question is about HCM. Since the evidence doesn't mention HCM, maybe the answer can't be derived from the given data. However, perhaps the user made a mistake in the question, and they meant DCM instead of HCM. Alternatively,", "citations": [{"doc_id": "17885521", "chunk_id": "17885521_0"}, {"doc_id": "19317068", "chunk_id": "19317068_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking about the prognostic meaning of delayed enhancement in patients with hypertrophic cardiomyopathy. Wait, but the evidence provided talks about dilated and ischemic cardiomyopathies. Hmm, maybe there's a mix-up here. Hypertrophic cardiomyopathy (HCM) is different from dilated cardiomyopathy (DCM). The evidence mentions delayed enhancement in DCM and ischemic cardiomyopathy, but not HCM. Looking at the evidence: [17885521:17885521_0] says that in DCM, 29% had delayed enhancement with mid-wall, patchy, or diffuse locations. [19317068:19317068_0] mentions one case of DCM with diffuse small midwall spots. But the question is about HCM. Since the evidence doesn't mention HCM, maybe the answer can't be derived from the given data. However, perhaps the user made a mistake in the question, and they meant DCM instead of HCM. Alternatively,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the prognostic meaning of delayed enhancement in patients with hypertrophic cardiomyopathy. Wait, but the evidence provided talks about dilated and ischemic cardiomyopathy. Hmm, maybe there's a confusion between types of cardiomyopathy here. First, I need to recall what delayed enhancement means in cardiac imaging. It refers to areas where contrast remains in the myocardium after injection, indicating fibrosis or scarring. The question is about hypertrophic cardiomyopathy (HCM), but the evidence given is about dilated and ischemic cardiomyopathies. That's a problem because the answer needs to be based on the provided evidence. Looking at the evidence: - Document 17885521 mentions that delayed enhancement helps distinguish between dilated and ischemic cardiomyopathy. In dilated, only 29% had delayed enhancement with mid-wall, patchy, or diffuse patterns. One case (document 19317068) had diffuse small midwall spots in dilated cardiomyopathy. But the question is about HCM. However, the evidence", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the prognostic meaning of delayed enhancement in patients with hypertrophic cardiomyopathy. Wait, but the evidence provided talks about dilated and ischemic cardiomyopathies. Hmm, maybe there's a mix-up here. Hypertrophic cardiomyopathy (HCM) is different from dilated cardiomyopathy (DCM). The evidence mentions delayed enhancement in DCM and ischemic cardiomyopathy, but not HCM. Looking at the evidence, the first document says that delayed enhancement helps distinguish between DCM and ischemic cardiomyopathy. The second part states that in DCM, 29% had delayed enhancement with specific patterns. The third snippet mentions a case of DCM with diffuse small midwall spots. But the question is about HCM. Wait, maybe there's a confusion between terms. Hypertrophic cardiomyopathy is a different condition. The evidence doesn't mention HCM at all. So, perhaps the user made an error in the question, but I need to stick to the given evidence. Since the evidence only discusses DCM and ischemic cardiomyopathy, maybe", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["12224720", "15861263", "18204915", "18208827", "18562248", "19474054", "19477402", "19740409", "19784900", "19808288", "20079992", "20102955", "20339815", "20667520", "20688032", "21234292", "21498307", "22128204", "22135401", "22348519", "22498326", "22687593", "22935464", "23376948"], "ideal_answer": "Delayed enhancement by CMR has prognostic value in predicting adverse cardiovascular events among HCM patients, and is associated with cardiovascular mortality, heart failure death, and all-cause mortality in HCM."}
{"question_id": "56ae35bc0a360a5e45000007", "question": "What is the COUGER tool?", "retrieved_chunks": [{"doc_id": "24861628", "chunk_id": "24861628_6", "score": 6.761025428771973, "text": "Here, we present an interactive web implementation of COUGER, a classification-based framework for identifying protein co-factors that might provide specificity to paralogous TFs. COUGER takes as input two sets of genomic regions bound by paralogous TFs, and it identifies a small set of putative co-factors that best distinguish the two sets of sequences. To achieve this task, COUGER uses a classification approach, with features that reflect the DNA-binding specificities of the putative co-factors. The identified co-factors are presented in a user-friendly output page, together with information that allows the user to understand and to explore the contributions of individual co-factor features. COUGER can be run as a stand-alone tool or through a web interface: http://couger.oit.duke.edu."}, {"doc_id": "24861628", "chunk_id": "24861628_5", "score": 6.428504943847656, "text": "Here, we present an interactive web implementation of COUGER, a classification-based framework for identifying protein co-factors that might provide specificity to paralogous TFs. COUGER takes as input two sets of genomic regions bound by paralogous TFs, and it identifies a small set of putative co-factors that best distinguish the two sets of sequences."}, {"doc_id": "24861628", "chunk_id": "24861628_2", "score": 6.034642219543457, "text": "COUGER takes as input two sets of genomic regions bound by paralogous TFs, and it identifies a small set of putative co-factors that best distinguish the two sets of sequences. To achieve this task, COUGER uses a classification approach, with features that reflect the DNA-binding specificities of the putative co-factors."}], "context": "[24861628:24861628_6] Here, we present an interactive web implementation of COUGER, a classification-based framework for identifying protein co-factors that might provide specificity to paralogous TFs. COUGER takes as input two sets of genomic regions bound by paralogous TFs, and it identifies a small set of putative co-factors that best distinguish the two sets of sequences. To achieve this task, COUGER uses a classification approach, with features that reflect the DNA-binding specificities of the putative co-factors. The identified co-factors are presented in a user-friendly output page, together with information that allows the user to understand and to explore the contributions of individual co-factor features. COUGER can be run as a stand-alone tool or through a web interface: http://couger.oit.duke.edu.\n[24861628:24861628_5] Here, we present an interactive web implementation of COUGER, a classification-based framework for identifying protein co-factors that might provide specificity to paralogous TFs. COUGER takes as input two sets of genomic regions bound by paralogous TFs, and it identifies a small set of putative co-factors that best distinguish the two sets of sequences.\n[24861628:24861628_2] COUGER takes as input two sets of genomic regions bound by paralogous TFs, and it identifies a small set of putative co-factors that best distinguish the two sets of sequences. To achieve this task, COUGER uses a classification approach, with features that reflect the DNA-binding specificities of the putative co-factors.", "answer": "<think> Okay, I need to generate a JSON answer about what the COUGER tool is, based on the provided evidence. Let me start by reading through the evidence carefully. The user provided three chunks from the same document (all with doc_id 24861628). The first chunk mentions that COUGER is an interactive web implementation of a classification-based framework for identifying protein co-factors that provide specificity to paralogous TFs. It takes two sets of genomic regions bound by paralogous TFs and identifies co-factors that distinguish these sequences. It uses a classification approach with features reflecting DNA-binding specificities. The tool can be run as standalone or via a web interface. The second chunk is similar, just shorter. The third chunk repeats the input and output parts again. So the key points are: COUGER is a framework for identifying co-factors, it takes two sets of genomic regions, uses classification with DNA-binding features, and has a web interface. I need to make sure the answer is concise and includes citations. The answer should mention that COUGER is a classification-based framework for identifying protein co-factors (from chunk", "citations": [], "candidates": [{"answer": "<think> Okay, I need to generate a JSON answer about what the COUGER tool is, based on the provided evidence. Let me start by reading through the evidence carefully. The user provided three chunks from the same document (all with doc_id 24861628). The first chunk mentions that COUGER is an interactive web implementation of a classification-based framework for identifying protein co-factors that provide specificity to paralogous TFs. It takes two sets of genomic regions bound by paralogous TFs and identifies co-factors that distinguish these sequences. It uses a classification approach with features reflecting DNA-binding specificities. The tool can be run as standalone or via a web interface. The second chunk is similar, just shorter. The third chunk repeats the input and output parts again. So the key points are: COUGER is a framework for identifying co-factors, it takes two sets of genomic regions, uses classification with DNA-binding features, and has a web interface. I need to make sure the answer is concise and includes citations. The answer should mention that COUGER is a classification-based framework for identifying protein co-factors (from chunk", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this query. The user is asking what the COUGER tool is. I need to generate a concise answer based on the provided evidence. First, I'll look through the evidence snippets. There are three chunks here, all from the same document ID. The first chunk mentions that COUGER is a classification-based framework for identifying protein co-factors that provide specificity to paralogous TFs. It takes two sets of genomic regions bound by paralogous TFs and identifies co-factors that distinguish them. It also says it uses a classification approach with features reflecting DNA-binding specificities and can be run as a standalone tool or via a web interface. The second chunk is similar, repeating the main points. The third chunk again states that COUGER takes two sets of genomic regions and identifies co-factors to distinguish sequences. The key elements here are: classification-based framework, identifying co-factors, input of two genomic region sets, using DNA-binding features, and web implementation. I need to combine these into a concise answer. The answer should include the main function of COUGER, its purpose, and maybe the method it uses. Also,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to generate a JSON answer about what the COUGER tool is, based on the provided evidence. Let me start by reading through the evidence carefully. The user provided three chunks from the same document (24861628). All of them mention COUGER as a classification-based framework for identifying protein co-factors that help specify paralogous TFs. The key points are: it's a web tool, takes two sets of genomic regions bound by paralogous TFs, identifies co-factors that distinguish these sequences, uses a classification approach with DNA-binding features, and has a user-friendly output. The answer should be concise, so I need to combine these elements without going into too much detail. The citations should include the document ID and chunk IDs. Since all chunks are from the same doc_id, but different chunks, I should list them all. However, the question is about what COUGER is, so the main points are its purpose, input, method, and output. The base confidence is a float between 0 and 1. The evidence seems consistent across the three chunks, so I can be confident. Maybe", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["24861628"], "ideal_answer": "COUGER takes as input two sets of genomic regions bound by paralogous TFs, and it identifies a small set of putative co-factors that best distinguish the two sets of sequences. COUGER is a classification-based framework for identifying protein co-factors that might provide specificity to paralogous TFs. It takes as input two sets of genomic regions bound by paralogous TFs, and it identifies a small set of putative co-factors that best distinguish the two sets of sequences. To achieve this task, COUGER uses a classification approach, with features that reflect the DNA-binding specificities of the putative co-factors. The identified co-factors are presented in a user-friendly output page, together with information that allows the user to understand and to explore the contributions of individual co-factor features."}
{"question_id": "532083389b2d7acc7e000003", "question": "Are there drugs for Tick-borne Encephalitis?", "retrieved_chunks": [{"doc_id": "23017222", "chunk_id": "23017222_0", "score": 4.434618949890137, "text": "POWV) is a rare tick-borne agent of encephalitis in North America. Historically, confirmed cases occurred mainly in the northeastern United State"}, {"doc_id": "37517630", "chunk_id": "37517630_0", "score": 3.1705055236816406, "text": "Several arboviral vaccines have been licensed for many years and can be used to prevent infection in travelers, namely Japanese encephalitis, yellow fever, and tick-borne encephalitis vaccines. Recommendations on use of these vaccines in pregnancy vary. Other arboviral vaccines have been licensed but are not indicated for use in pregnant travelers (e.g., dengue vaccines) or are in development (e.g., chikungunya, Zika vaccines)."}, {"doc_id": "18471057", "chunk_id": "18471057_0", "score": 2.8067634105682373, "text": "Tick-borne encephalitis virus (TBEV) and Louping ill virus (LIV) are viruses in the Mammalian tick-borne virus group/genus Flavivirus, causing central nervous system disease."}], "context": "[23017222:23017222_0] POWV) is a rare tick-borne agent of encephalitis in North America. Historically, confirmed cases occurred mainly in the northeastern United State\n[37517630:37517630_0] Several arboviral vaccines have been licensed for many years and can be used to prevent infection in travelers, namely Japanese encephalitis, yellow fever, and tick-borne encephalitis vaccines. Recommendations on use of these vaccines in pregnancy vary. Other arboviral vaccines have been licensed but are not indicated for use in pregnant travelers (e.g., dengue vaccines) or are in development (e.g., chikungunya, Zika vaccines).\n[18471057:18471057_0] Tick-borne encephalitis virus (TBEV) and Louping ill virus (LIV) are viruses in the Mammalian tick-borne virus group/genus Flavivirus, causing central nervous system disease.", "answer": "<think> Okay, let's tackle this question. The user is asking if there are drugs for Tick-borne Encephalitis. I need to look at the provided evidence to find answers. First, looking at the evidence documents. The first one mentions POWV as a rare tick-borne agent causing encephalitis in North America. But it doesn't talk about drugs. The second document says several arboviral vaccines are licensed, including tick-borne encephalitis vaccines. Wait, vaccines are different from drugs, but maybe there's confusion here. The third document talks about TBEV and LIV being flaviviruses causing CNS disease. Still no mention of drugs. Wait, the question is about drugs, not vaccines. But the second evidence says that tick-borne encephalitis vaccines are available. However, vaccines are preventive, not treatments. So maybe there's a misunderstanding in the user's question. But according to the evidence, there's no information on drugs (medications) for treating TBE. The answer should be based on the given evidence. So, the answer would be that there are vaccines, but the question is about drugs", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if there are drugs for Tick-borne Encephalitis. I need to look at the provided evidence to find answers. First, looking at the evidence documents. The first one mentions POWV as a rare tick-borne agent causing encephalitis in North America. But it doesn't talk about drugs. The second document says several arboviral vaccines are licensed, including tick-borne encephalitis vaccines. Wait, vaccines are different from drugs, but maybe there's confusion here. The third document talks about TBEV and LIV being flaviviruses causing CNS disease. Still no mention of drugs. Wait, the question is about drugs, not vaccines. But the second evidence says that tick-borne encephalitis vaccines are available. However, vaccines are preventive, not treatments. So maybe there's a misunderstanding in the user's question. But according to the evidence, there's no information on drugs (medications) for treating TBE. The answer should be based on the given evidence. So, the answer would be that there are vaccines, but the question is about drugs", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, so the user is asking if there are drugs for Tick-borne Encephalitis. Let me look at the evidence provided. First, the evidence mentions that there are vaccines for tick-borne encephalitis. The second document says several arboviral vaccines have been licensed, including tick-borne encephalitis vaccines. So vaccines exist, but the question is about drugs. Wait, vaccines and drugs are different. Vaccines prevent infection, while drugs would be treatments for those already infected. But maybe the user is using \"drugs\" to mean vaccines? Or perhaps there's a treatment available. Let me check the other documents. The first document talks about confirmed cases in the US, but doesn't mention treatment. The third document mentions TBEV and LIV as viruses causing CNS disease, but no specific drugs. So based on the evidence, there are vaccines, but not drugs. However, sometimes vaccines are considered part of drug therapy. But strictly speaking, the answer should differentiate between vaccines and drugs. The user's question is about drugs, so maybe the answer is that there are no specific drugs, but vaccines are available. However,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if there are drugs for Tick-borne Encephalitis. I need to look at the evidence provided to find out. First, looking at the evidence snippets. The first one mentions POWV as a rare tick-borne agent causing encephalitis in North America. But it doesn't talk about drugs. The second snippet says several arboviral vaccines are licensed, including tick-borne encephalitis vaccines. So that's about vaccines, not drugs. The third snippet talks about TBEV and LIV being flaviviruses causing CNS disease, but again, no mention of drugs. Wait, the question is about drugs, not vaccines. The evidence mentions vaccines, like Japanese encephalitis, yellow fever, and tick-borne encephalitis vaccines. But vaccines are preventive, not treatments. So maybe there's a confusion here between vaccines and drugs. However, the user specifically asked for drugs. But in the evidence, there's no mention of antiviral drugs or medications used to treat TBE. The second document says vaccines are available, but that's prevention. So", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["20656033", "22535622", "22727684", "22730949", "22984545", "23096037", "23259984", "23377671", "23452322", "23638205", "23697658", "23784447", "23919605", "24001228", "24035586", "24076358", "24096319", "24159517", "24225644", "24256889"], "ideal_answer": "No drug therapy available today"}
{"question_id": "571e3d42bb137a4b0c000007", "question": "Is SLC22A3 expressed in the brain?", "retrieved_chunks": [{"doc_id": "19280114", "chunk_id": "19280114_2", "score": 8.831168174743652, "text": "Slc22a3) encodes an isoform of the organic cation transporters and is expressed widely across the whole brain."}, {"doc_id": "19280114", "chunk_id": "19280114_4", "score": 7.8712968826293945, "text": "The organic cation transporter 3 (OCT3; synonymous: extraneuronal monoamine transporter, EMT, Slc22a3) encodes an isoform of the organic cation transporters and is expressed widely across the whole brain."}, {"doc_id": "19280114", "chunk_id": "19280114_3", "score": 7.553462982177734, "text": "The organic cation transporter 3 (OCT3; synonymous: extraneuronal monoamine transporter, EMT, Slc22a3) encodes an isoform of the organic cation transporters and is expressed widely across the whole brain"}], "context": "[19280114:19280114_2] Slc22a3) encodes an isoform of the organic cation transporters and is expressed widely across the whole brain.\n[19280114:19280114_4] The organic cation transporter 3 (OCT3; synonymous: extraneuronal monoamine transporter, EMT, Slc22a3) encodes an isoform of the organic cation transporters and is expressed widely across the whole brain.\n[19280114:19280114_3] The organic cation transporter 3 (OCT3; synonymous: extraneuronal monoamine transporter, EMT, Slc22a3) encodes an isoform of the organic cation transporters and is expressed widely across the whole brain", "answer": "<think> Okay, let's tackle this question. The user wants to know if SLC22A3 is expressed in the brain. The evidence provided has three chunks, all from the same document ID. Let me check each of them. Looking at chunk 19280114_2: It says Slc22a3 encodes an isoform of organic cation transporters and is expressed widely across the whole brain. So that's a direct statement. Then chunks 19280114_4 and 19280114_3 both mention OCT3, which is synonymous with Slc22a3, and again state it's expressed widely in the whole brain. All three pieces of evidence point to the same conclusion. The term \"whole brain\" clearly indicates expression in the brain. There's no conflicting information here. The model can confidently say yes based on these references. The confidence level should be high, maybe 0.95 since all three chunks support it. Need to make sure the answer is concise and includes the citations. Let me structure the JSON accordingly. </think> {", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user wants to know if SLC22A3 is expressed in the brain. The evidence provided has three chunks, all from the same document ID. Let me check each of them. Looking at chunk 19280114_2: It says Slc22a3 encodes an isoform of organic cation transporters and is expressed widely across the whole brain. So that's a direct statement. Then chunks 19280114_4 and 19280114_3 both mention OCT3, which is synonymous with Slc22a3, and again state it's expressed widely in the whole brain. All three pieces of evidence point to the same conclusion. The term \"whole brain\" clearly indicates expression in the brain. There's no conflicting information here. The model can confidently say yes based on these references. The confidence level should be high, maybe 0.95 since all three chunks support it. Need to make sure the answer is concise and includes the citations. Let me structure the JSON accordingly. </think> {", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if SLC22A3 is expressed in the brain. The evidence provided has three chunks, all from the same document ID. Let me check each of them. Looking at chunk 19280114_2: It says Slc22a3 encodes an isoform of organic cation transporters and is expressed widely across the whole brain. So that's a direct answer. Then chunk 19280114_4 mentions OCT3, which is synonymous with EMT and Slc22a3, and again states it's expressed widely in the whole brain. The third chunk is the same as the second one. All three chunks confirm that SLC22A3 (also known as OCT3) is expressed throughout the brain. The key here is that \"whole brain\" directly answers the question. The confidence should be high since all three sources agree. The model can be confident because there's no conflicting information. So the answer is yes, and the confidence is 1.0. </think> { \"answer\": \"Yes,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if SLC22A3 is expressed in the brain. The evidence provided has three chunks, all from the same document ID. Let me check each of them. First chunk: It says Slc22a3 encodes an isoform of organic cation transporters and is expressed widely across the whole brain. So that's a direct statement. Second chunk: Talks about OCT3, which is synonymous with EMT and Slc22a3. It again states it's expressed widely in the whole brain. Third chunk is the same as the second one. So all three chunks confirm that SLC22A3 (OCT3) is expressed throughout the brain. The answer should be yes, based on these citations. The confidence is high since all three sources agree. I need to make sure the answer is concise and includes the correct citation. The base confidence can be 1.0 since all evidence points to the same conclusion. </think> { \"answer\": \"Yes, SLC22A3 is expressed in the brain. [19280114", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["15028779", "18513366", "19033200", "19280114", "19702534", "20402963", "21352605"], "ideal_answer": "Yes, SLC22A3 (organic cation transporter (OCT3)) is widely expressed in various organs in humans, and involved in the disposition of many exogenous and endogenous compounds. Several lines of evidence have suggested that OCT3 expressed in the brain plays an important role in the regulation of neurotransmission."}
{"question_id": "53386282d6d3ac6a3400005a", "question": "Has the protein TIEG1 been associated with apoptosis?", "retrieved_chunks": [{"doc_id": "17308981", "chunk_id": "17308981_0", "score": 7.436781883239746, "text": "In human and murine tissues it has been shown that TIEG1 and TIEG2 induce apoptosis and inhibit cell growth"}, {"doc_id": "12065093", "chunk_id": "12065093_0", "score": 6.3900299072265625, "text": "TIEG1 (TGF-beta inducible early gene) is a recently characterized transcription factor regulated by TGF-beta that induces apoptosis when overexpressed in pancreatic adenocarcinoma cell lines"}, {"doc_id": "14743447", "chunk_id": "14743447_0", "score": 6.38329553604126, "text": "overexpression of TIEG1 in OLI-neu cells induced apoptosis"}], "context": "[17308981:17308981_0] In human and murine tissues it has been shown that TIEG1 and TIEG2 induce apoptosis and inhibit cell growth\n[12065093:12065093_0] TIEG1 (TGF-beta inducible early gene) is a recently characterized transcription factor regulated by TGF-beta that induces apoptosis when overexpressed in pancreatic adenocarcinoma cell lines\n[14743447:14743447_0] overexpression of TIEG1 in OLI-neu cells induced apoptosis", "answer": "<think> Okay, let's tackle this question. The user is asking if the protein TIEG1 has been associated with apoptosis. I need to look at the provided evidence to find answers. First, looking at the evidence documents: Document 17308981: It says that both TIEG1 and TIEG2 induce apoptosis and inhibit cell growth in human and murine tissues. That's a direct mention of apoptosis linked to TIEG1. Document 12065093: This one states that TIEG1 is a transcription factor regulated by TGF-beta and induces apoptosis when overexpressed in pancreatic adenocarcinoma cell lines. Again, clear evidence of TIEG1 causing apoptosis. Document 14743447: Overexpression of TIEG1 in OLI-neu cells induced apoptosis. Another direct statement linking TIEG1 to apoptosis. All three sources mention that TIEG1 is associated with inducing apoptosis. The confidence here is high because multiple independent studies (different documents) all point to the same conclusion. The model can be confident about this answer. So the", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if the protein TIEG1 has been associated with apoptosis. I need to look at the provided evidence to find answers. First, looking at the evidence documents: Document 17308981: It says that both TIEG1 and TIEG2 induce apoptosis and inhibit cell growth in human and murine tissues. That's a direct mention of apoptosis linked to TIEG1. Document 12065093: This one states that TIEG1 is a transcription factor regulated by TGF-beta and induces apoptosis when overexpressed in pancreatic adenocarcinoma cell lines. Again, clear evidence of TIEG1 causing apoptosis. Document 14743447: Overexpression of TIEG1 in OLI-neu cells induced apoptosis. Another direct statement linking TIEG1 to apoptosis. All three sources mention that TIEG1 is associated with inducing apoptosis. The confidence here is high because multiple independent studies (different documents) all point to the same conclusion. The model can be confident about this answer. So the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if the protein TIEG1 has been associated with apoptosis. I need to check the provided evidence to find answers. Looking at the first piece of evidence: [17308981:17308981_0] says that both TIEG1 and TIEG2 induce apoptosis and inhibit cell growth in human and murine tissues. That's a direct statement linking TIEG1 to apoptosis. The second evidence: [12065093:12065093_0] mentions that TIEG1 is a transcription factor regulated by TGF-beta and induces apoptosis when overexpressed in pancreatic adenocarcinoma cell lines. Again, this supports the association. Third evidence: [14743447:14743447_0] states that overexpression of TIEG1 in OLI-neu cells induced apoptosis. This is another confirmation. All three sources clearly state that TIEG1 is involved in inducing apoptosis. The confidence level should be high since", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if the protein TIEG1 has been associated with apoptosis. I need to look at the provided evidence to find answers. First, looking at the evidence documents: Document 17308981: It says that both TIEG1 and TIEG2 induce apoptosis and inhibit cell growth in human and murine tissues. That's a direct mention of TIEG1 causing apoptosis. Document 12065093: This mentions TIEG1 as a transcription factor regulated by TGF-beta. It specifically states that when overexpressed in pancreatic adenocarcinoma cell lines, it induces apoptosis. So overexpression leads to apoptosis here. Document 14743447: Overexpression of TIEG1 in OLI-neu cells induced apoptosis. Another instance where overexpression causes apoptosis. So all three documents link TIEG1 to inducing apoptosis, either through overexpression or in certain cell lines. The answer should be yes, and the confidence is high since multiple sources support this. The base_confidence would be 1.0", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["10471833", "10573529", "12065093", "12771931", "12788480", "14743447", "17308981", "17659279", "17729309", "17951258", "18798273", "18930345", "20201061", "20691807", "20945337", "21423731", "21524276", "22025675", "22349513", "22563190", "23244828", "23815903"], "ideal_answer": "Yes, TIEG1 (also known as KLF10) seems to play a role in regulating apoptosis."}
{"question_id": "5717d64f29809bbe7a000001", "question": "Which is the cellular localization of the protein Opa1?", "retrieved_chunks": [{"doc_id": "12504110", "chunk_id": "12504110_5", "score": 5.455992698669434, "text": "we identified two isoforms of OPA1 proteins in HeLa cells and examined their submitochondrial localization and complex formations."}, {"doc_id": "12504110", "chunk_id": "12504110_4", "score": 5.361574172973633, "text": "Here, we identified two isoforms of OPA1 proteins in HeLa cells and examined their submitochondrial localization and complex formations."}, {"doc_id": "12504110", "chunk_id": "12504110_3", "score": 5.138701438903809, "text": "Here, we identified two isoforms of OPA1 proteins in HeLa cells and examined their submitochondrial localization and complex formations"}], "context": "[12504110:12504110_5] we identified two isoforms of OPA1 proteins in HeLa cells and examined their submitochondrial localization and complex formations.\n[12504110:12504110_4] Here, we identified two isoforms of OPA1 proteins in HeLa cells and examined their submitochondrial localization and complex formations.\n[12504110:12504110_3] Here, we identified two isoforms of OPA1 proteins in HeLa cells and examined their submitochondrial localization and complex formations", "answer": "<think> Okay, let's tackle this question. The user is asking about the cellular localization of the protein Opa1. The evidence provided has three entries, all from the same source, 12504110, but different chunk IDs. All of them mention identifying two isoforms of OPA1 in HeLa cells and examining their submitochondrial localization and complex formations. First, I need to parse what \"submitochondrial localization\" means. The term \"submitochondrial\" suggests that the protein is localized within the mitochondria. But wait, maybe it's a typo or a specific term? Let me think. \"Submitochondrial\" might refer to locations within the mitochondria, like the inner membrane or matrix. However, Opa1 is known to be a mitochondrial protein involved in outer membrane formation. But the evidence here says \"submitochondrial,\" which could be a mistake. Alternatively, maybe it's referring to subcellular localization relative to the mitochondria. Looking at the chunks, they all mention examining submitochondrial localization. The key point here is that the study looked at the localization of OPA1 isoforms within the mitochondria.", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking about the cellular localization of the protein Opa1. The evidence provided has three entries, all from the same source, 12504110, but different chunk IDs. All of them mention identifying two isoforms of OPA1 in HeLa cells and examining their submitochondrial localization and complex formations. First, I need to parse what \"submitochondrial localization\" means. The term \"submitochondrial\" suggests that the protein is localized within the mitochondria. But wait, maybe it's a typo or a specific term? Let me think. \"Submitochondrial\" might refer to locations within the mitochondria, like the inner membrane or matrix. However, Opa1 is known to be a mitochondrial protein involved in outer membrane formation. But the evidence here says \"submitochondrial,\" which could be a mistake. Alternatively, maybe it's referring to subcellular localization relative to the mitochondria. Looking at the chunks, they all mention examining submitochondrial localization. The key point here is that the study looked at the localization of OPA1 isoforms within the mitochondria.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the cellular localization of the protein Opa1. The evidence provided are three chunks from a study involving HeLa cells. First, I need to parse the evidence. All three chunks mention that two isoforms of OPA1 were identified in HeLa cells and that their submitochondrial localization and complex formations were examined. The key term here is \"submitochondrial localization,\" which suggests that the protein is located within the mitochondria. Wait, but what does \"submitochondrial\" mean exactly? It refers to structures inside the mitochondria, like the inner membrane or matrix. However, Opa1 is a mitochondrial protein involved in maintaining the inner membrane structure. The study looked at their localization, so the answer should be that Opa1 is localized to the mitochondria, specifically the inner membrane. But the evidence doesn't specify the exact subcompartment. However, given that Opa1 is known to be part of the mitochondrial outer membrane, but wait, no—Opa1 is actually a component of the outer mitochondrial membrane, involved in fusion and shaping. Wait, maybe I should check my", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the cellular localization of the protein Opa1. The evidence provided consists of three chunks from a source with ID 12504110. All three chunks mention identifying two isoforms of OPA1 in HeLa cells and examining their submitochondrial localization and complex formations. First, I need to parse what \"submitochondrial localization\" means. The term \"submitochondrial\" suggests that the protein is localized within the mitochondria. The word \"submitochondrial\" is a bit tricky. Let me break it down: \"sub-\" meaning under or inside, and \"mitochondrial\" related to mitochondria. So, submitochondrial would mean inside the mitochondria, not outside. Therefore, the localization is within the mitochondria. The chunks don't specify further details like matrix, inner membrane, or outer membrane, but they do mention that the study looked at submitochondrial localization. Since all three evidence points are from the same source and they all refer to submitting mitochondrial localization, it's safe to conclude that Opa1 is localized within the mitochondria. The answer should be", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["11017079", "11847212", "12123827", "12504110", "14970223", "16413305", "16737747", "17545159", "17709430", "18074630", "18281461", "19168126", "20045077", "20079867", "20652258", "20678484", "21397211", "21459773", "21980395", "21983901", "22406748", "22579715", "23663851", "23906536", "24282027", "24632637", "24633199", "25112877", "25298396", "25579226", "25582749", "25744979", "25847151"], "ideal_answer": "The Opa1 protein localizes to the mitochondria. Opa1 is found normally in the mitochondrial intermembrane space."}
{"question_id": "531d7430267d7dd053000008", "question": "Which are the drugs utilized for the burning mouth syndrome?", "retrieved_chunks": [{"doc_id": "20415926", "chunk_id": "20415926_0", "score": 1.8541138172149658, "text": "Burning mouth syndrome (BMS) is characterized by burning pain in the tongue or other oral mucous membrane often associated with symptoms such as subjective dryness of the mouth, paraesthesia and altered taste for which no medical or dental cause can be found."}, {"doc_id": "18625105", "chunk_id": "18625105_0", "score": 1.8320467472076416, "text": "Burning mouth syndrome (BMS) is a chronic disease characterized by burning of the oral mucosa associated with a sensation of dry mouth and/or taste alterations."}, {"doc_id": "15773524", "chunk_id": "15773524_1", "score": 1.6587865352630615, "text": "Burning mouth syndrome (BMS) is a predominantly oral condition characterized by the occurrence of a chronic burning that commonly involves the anterior tongue, painful sensation, dryness and taste alterations."}], "context": "[20415926:20415926_0] Burning mouth syndrome (BMS) is characterized by burning pain in the tongue or other oral mucous membrane often associated with symptoms such as subjective dryness of the mouth, paraesthesia and altered taste for which no medical or dental cause can be found.\n[18625105:18625105_0] Burning mouth syndrome (BMS) is a chronic disease characterized by burning of the oral mucosa associated with a sensation of dry mouth and/or taste alterations.\n[15773524:15773524_1] Burning mouth syndrome (BMS) is a predominantly oral condition characterized by the occurrence of a chronic burning that commonly involves the anterior tongue, painful sensation, dryness and taste alterations.", "answer": "<think> Okay, I need to figure out which drugs are used for burning mouth syndrome based on the provided evidence. Let me look at the evidence again. The first document says BMS is characterized by burning pain with symptoms like dry mouth, paraesthesia, and altered taste, but there's no mention of specific drugs. The second document also describes BMS similarly without mentioning treatment. The third document does the same, focusing on symptoms but not treatments. Wait, none of the evidence actually lists any drugs used for BMS. They all describe the symptoms and characteristics of the condition. Since the question is about drugs utilized, but the evidence doesn't provide any information on medications, I can't find a citation here. The user might have expected some answer, but according to the given documents, there's no mention of drugs. So the answer would be that there's no information in the provided evidence about drugs used for BMS. Therefore, the answer should indicate that, with a confidence level. Since the evidence doesn't include any drug names, the base_confidence would be low, maybe 0.0 because the documents don't mention any treatments. </think> { \"answer\":", "citations": [], "candidates": [{"answer": "<think> Okay, I need to figure out which drugs are used for burning mouth syndrome based on the provided evidence. Let me look at the evidence again. The first document says BMS is characterized by burning pain with symptoms like dry mouth, paraesthesia, and altered taste, but there's no mention of specific drugs. The second document also describes BMS similarly without mentioning treatment. The third document does the same, focusing on symptoms but not treatments. Wait, none of the evidence actually lists any drugs used for BMS. They all describe the symptoms and characteristics of the condition. Since the question is about drugs utilized, but the evidence doesn't provide any information on medications, I can't find a citation here. The user might have expected some answer, but according to the given documents, there's no mention of drugs. So the answer would be that there's no information in the provided evidence about drugs used for BMS. Therefore, the answer should indicate that, with a confidence level. Since the evidence doesn't include any drug names, the base_confidence would be low, maybe 0.0 because the documents don't mention any treatments. </think> { \"answer\":", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user wants to know which drugs are used for burning mouth syndrome. Looking at the evidence provided, all three documents describe BMS symptoms but don't mention any specific medications. The first two documents talk about symptoms like burning pain, dryness, and taste changes. The third one adds that it's a chronic condition with burning, painful sensation, dryness, and taste alterations. None of them list drugs or treatments. So, the answer should be that there's no information in the evidence about drugs used for BMS. The confidence is low because the evidence doesn't address treatment options. I need to make sure the JSON structure is correct with the answer and base_confidence. Since the documents only discuss symptoms and not medications, the answer is based on the absence of information. </think> { \"answer\": \"The provided evidence does not mention any specific drugs used for burning mouth syndrome (BMS). The documents describe BMS as a condition characterized by burning pain, dryness, and taste alterations but do not list pharmacological treatments [20415926:20415926_0,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking about drugs used for burning mouth syndrome. First, I need to look through the provided evidence to see if any medications are mentioned. Looking at the three documents: The first one mentions symptoms like burning pain, dryness, paraesthesia, and altered taste, but doesn't list any drugs. The second document also describes the symptoms but again, no medications. The third document does the same—describes the condition's features but doesn't mention any treatments or drugs. Since none of the evidence provided actually lists any drugs used for BMS, I can't find a direct answer here. The user might be expecting common treatments, like antifungal meds if there's a fungal cause, or something else, but according to the given evidence, there's no information on pharmacological treatments. So, the answer should state that there's no information in the provided documents about drugs used for BMS. The confidence would be low because the evidence doesn't mention any medications. I need to make sure the JSON is strict and only includes the answer and base_confidence as specified. </think> { \"answer\": \"", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["10425973", "10431669", "10625850", "11441716", "11485137", "11838624", "11871678", "12110042", "12536654", "14650993", "14704612", "14765022", "1508523", "15195716", "15210564", "16637799", "16903201", "17287703", "17541900", "17559486", "1776404", "17849966", "18343329", "18548844", "18558051", "18588600", "18625105", "18976257", "1923398", "19450321", "19658340", "19689438", "19837207", "20415927", "20597947", "20690412", "20969436", "2098940", "21223496", "21528119", "21743413", "21743415", "22040716", "22044166", "22092585", "22260804", "22344742", "22612823", "22669143", "22750263", "22819057", "22957483", "23201368", "23229252", "23429751", "23772971", "24164777", "24558551", "2726203", "2811814", "7629360", "8323246", "8543701", "8725589", "9830647", "9844361"], "ideal_answer": "Dopaminergic drugs should be given in patients with BMS. Catuama reduces the symptoms of BMS and may be a novel therapeutic strategy for the treatment of this disease. Capsaicin, alpha-lipoic acid (ALA), and clonazepam were those that showed more reduction in symptoms of BMS. Treatment with placebos produced a response that was 72% as large as the response to active drugs"}
{"question_id": "55031650e9bde69634000026", "question": "Is PTEN involved in follicular thyroid carcinoma?", "retrieved_chunks": [{"doc_id": "12203792", "chunk_id": "12203792_1", "score": 9.70567512512207, "text": "The transcriptional silencing of PTEN was significantly associated with the anaplastic subtype, suggesting that PTEN is involved in the carcinogenesis of highly malignant or late-stage thyroid cancers, whereas this particular mechanism appears to be of minor importance in differentiated follicular thyroid tumors."}, {"doc_id": "12203792", "chunk_id": "12203792_0", "score": 9.505852699279785, "text": "The transcriptional silencing of PTEN was significantly associated with the anaplastic subtype, suggesting that PTEN is involved in the carcinogenesis of highly malignant or late-stage thyroid cancers, whereas this particular mechanism appears to be of minor importance in differentiated follicular thyroid tumors"}, {"doc_id": "21417916", "chunk_id": "21417916_1", "score": 7.3812456130981445, "text": "Two of the 259 patients (0.8%), with both follicular thyroid carcinoma and macrocephaly, were found to carry a germline mutation in the PTEN gene. The PTEN mutation frequency in unselected cases of follicular thyroid carcinoma was 4.8%"}], "context": "[12203792:12203792_1] The transcriptional silencing of PTEN was significantly associated with the anaplastic subtype, suggesting that PTEN is involved in the carcinogenesis of highly malignant or late-stage thyroid cancers, whereas this particular mechanism appears to be of minor importance in differentiated follicular thyroid tumors.\n[12203792:12203792_0] The transcriptional silencing of PTEN was significantly associated with the anaplastic subtype, suggesting that PTEN is involved in the carcinogenesis of highly malignant or late-stage thyroid cancers, whereas this particular mechanism appears to be of minor importance in differentiated follicular thyroid tumors\n[21417916:21417916_1] Two of the 259 patients (0.8%), with both follicular thyroid carcinoma and macrocephaly, were found to carry a germline mutation in the PTEN gene. The PTEN mutation frequency in unselected cases of follicular thyroid carcinoma was 4.8%", "answer": "<think> Okay, let's tackle this question. The user is asking if PTEN is involved in follicular thyroid carcinoma. I need to look at the evidence provided. First, evidence document [12203792:12203792_1] and [12203792:12203792_0] both mention that PTEN silencing is linked to the anaplastic subtype of thyroid cancers, which are more aggressive. However, it says this mechanism is of minor importance in differentiated follicular thyroid tumors. So, PTEN's role here seems limited to more malignant types, not the follicular ones. Then there's document [21417916:21417916_1], which states that 0.8% of patients with follicular thyroid carcinoma had a PTEN mutation, and the overall frequency was 4.8%. Wait, but 4.8% seems higher than 0.8%, maybe that's a typo? Or perhaps the 0.8% is among those with macrocephaly? Either way,", "citations": [{"doc_id": "12203792", "chunk_id": "12203792_1"}, {"doc_id": "12203792", "chunk_id": "12203792_0"}, {"doc_id": "21417916", "chunk_id": "21417916_1"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if PTEN is involved in follicular thyroid carcinoma. I need to look at the evidence provided. First, evidence document [12203792:12203792_1] and [12203792:12203792_0] both mention that PTEN silencing is linked to the anaplastic subtype of thyroid cancers, which are more aggressive. However, it says this mechanism is of minor importance in differentiated follicular thyroid tumors. So, PTEN's role here seems limited to more malignant types, not the follicular ones. Then there's document [21417916:21417916_1], which states that 0.8% of patients with follicular thyroid carcinoma had a PTEN mutation, and the overall frequency was 4.8%. Wait, but 4.8% seems higher than 0.8%, maybe that's a typo? Or perhaps the 0.8% is among those with macrocephaly? Either way,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if PTEN is involved in follicular thyroid carcinoma. I need to look at the evidence provided. First, evidence document [12203792:12203792_1] and [12203792:12203792_0] both mention that PTEN silencing is linked to anaplastic thyroid cancers, which are more aggressive. However, it says this mechanism is of minor importance in differentiated follicular thyroid tumors. So, PTEN's role here seems limited to more malignant subtypes, not the follicular ones. Then there's document [21417916:21417916_1], which states that 0.8% of patients with follicular thyroid carcinoma had a PTEN germline mutation, and 4.8% in unselected cases. Wait, that seems contradictory. If 4.8% have mutations, isn't that significant? But the first documents say it's minor. Maybe there's a difference between germline mutations", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if PTEN is involved in follicular thyroid carcinoma. I need to look at the evidence provided. First, evidence document [12203792:12203792_1] says that PTEN silencing is linked to anaplastic subtype, which is a more aggressive form. It mentions that this mechanism is of minor importance in differentiated follicular thyroid tumors. So, the answer here is that PTEN isn't heavily involved in follicular thyroid carcinoma, but maybe in other subtypes. Then there's another entry [12203792:12203792_0], which is a duplicate of the first one. It reinforces the same point about PTEN being minor in follicular tumors. The third evidence [21417916:21417916_1] talks about a study where 0.8% of patients with follicular thyroid carcinoma had a PTEN mutation, and 4.8% in unselected cases. Wait, that seems contradictory. If 4", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["11297621", "12203792", "16487009", "18055323", "21417916", "9790504", "9832031"], "ideal_answer": "The PTEN mutation frequency in unselected cases of follicular thyroid carcinoma was 4.8%."}
{"question_id": "56c8f4615795f9a73e00001a", "question": "Which genome browser database for DNA shape annotations is available?", "retrieved_chunks": [{"doc_id": "25326329", "chunk_id": "25326329_4", "score": 9.115104675292969, "text": "GBshape: a genome browser database for DNA shape annotations."}, {"doc_id": "25326329", "chunk_id": "25326329_3", "score": 8.954812049865723, "text": "GBshape: a genome browser database for DNA shape annotations"}, {"doc_id": "25326329", "chunk_id": "25326329_6", "score": 8.713098526000977, "text": "Our Genome Browser for DNA shape annotations (GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape/) provides minor groove width, propeller twist, roll, helix twist and hydroxyl radical cleavage predictions for the entire genomes of 94 organisms. Additional genomes can easily be added using the GBshape framework."}], "context": "[25326329:25326329_4] GBshape: a genome browser database for DNA shape annotations.\n[25326329:25326329_3] GBshape: a genome browser database for DNA shape annotations\n[25326329:25326329_6] Our Genome Browser for DNA shape annotations (GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape/) provides minor groove width, propeller twist, roll, helix twist and hydroxyl radical cleavage predictions for the entire genomes of 94 organisms. Additional genomes can easily be added using the GBshape framework.", "answer": "<think> Okay, let's tackle this question. The user is asking which genome browser database for DNA shape annotations is available. The evidence provided has three chunks from the same document, all mentioning \"GBshape.\" First, I need to check if all the evidence points to the same answer. The first two chunks directly state that GBshape is a genome browser database for DNA shape annotations. The third chunk adds more details about its functionality and availability. The answer should be concise, citing the document. Since all relevant information is in the same document, I can use the doc_id:25326329 and any of the chunk IDs. However, the user wants the answer to include citations with [doc_id:chunk_id]. The first chunk is 25326329_4, but the third one (25326329_6) has more details. But since the question is about which database exists, the main citation would be from the first occurrence. However, maybe using the third chunk's info is better because it mentions availability. Wait, the question is just asking for the name of the database, so the answer", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which genome browser database for DNA shape annotations is available. The evidence provided has three chunks from the same document, all mentioning \"GBshape.\" First, I need to check if all the evidence points to the same answer. The first two chunks directly state that GBshape is a genome browser database for DNA shape annotations. The third chunk adds more details about its functionality and availability. The answer should be concise, citing the document. Since all relevant information is in the same document, I can use the doc_id:25326329 and any of the chunk IDs. However, the user wants the answer to include citations with [doc_id:chunk_id]. The first chunk is 25326329_4, but the third one (25326329_6) has more details. But since the question is about which database exists, the main citation would be from the first occurrence. However, maybe using the third chunk's info is better because it mentions availability. Wait, the question is just asking for the name of the database, so the answer", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this query. The user is asking which genome browser database for DNA shape annotations is available. The evidence provided has three chunks from the same document, all mentioning \"GBshape\". First, I need to check if all the evidence points to the same answer. The first two chunks directly state that GBshape is a genome browser database for DNA shape annotations. The third chunk adds more details about its features and availability. The answer should be concise, so I'll mention GBshape and cite the relevant documents. Since all three chunks support the same answer, the confidence level should be high. The base_confidence can be 1.0 because the evidence clearly states that GBshape is the database in question. I need to make sure the JSON structure is correct with the keys \"answer\" and \"base_confidence\". The answer should include the citation in the format [doc_id:chunk_id]. Since all chunks are from the same document, I can use one of them, maybe the first one. So the answer would be \"GBshape: a genome browser database for DNA shape annotations [25326329:2532", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which genome browser database for DNA shape annotations is available. The evidence provided has three chunks from the same document, all mentioning \"GBshape\". First, I need to check if all the evidence points to the same answer. The first two chunks directly state that GBshape is a genome browser database for DNA shape annotations. The third chunk adds more details about its features and availability. The answer should be concise and include citations. Since all three chunks are from the same document (25326329), I can use one of the chunk IDs. Maybe the first one, 25326329_4, as it's the first mention. For confidence, the model is pretty sure because all evidence points to GBshape. The third chunk even mentions it's freely available, which confirms its existence. So the base_confidence should be high, like 0.95. I need to make sure the JSON structure is correct with the keys \"answer\" and \"base_confidence\". No other keys are needed. Let me put that together. </think> { \"answer", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["25326329"], "ideal_answer": "The Genome Browser for DNA shape annotations (GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape/) provides minor groove width, propeller twist, roll, helix twist and hydroxyl radical cleavage predictions for the entire genomes of 94 organisms. Additional genomes can easily be added using the GBshape framework. GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at nucleotide resolution."}
{"question_id": "54fc97b86ad7dcbc12000002", "question": "What is known about clinical efficacy of ceftriaxone for treatment of amyotrophic lateral sclerosis?", "retrieved_chunks": [{"doc_id": "19008722", "chunk_id": "19008722_0", "score": 6.620931148529053, "text": "OBJECTIVE: Ceftriaxone has been reported to reduce neuronal damage in amyotrophic lateral sclerosis and in an in-vitro model of neuronal ischaemia through increased expression and activity of the glutamate transporter, GLT1."}, {"doc_id": "22680643", "chunk_id": "22680643_0", "score": 6.612826347351074, "text": "Importantly, ceftriaxone is currently in clinical trials for the treatment of amyotrophic lateral sclerosis."}, {"doc_id": "24771634", "chunk_id": "24771634_0", "score": 6.298827171325684, "text": "The cephalosporin antibiotic ceftriaxone was evaluated as a potential therapeutic agent for the treatment of amyotrophic lateral sclerosis (ALS)."}], "context": "[19008722:19008722_0] OBJECTIVE: Ceftriaxone has been reported to reduce neuronal damage in amyotrophic lateral sclerosis and in an in-vitro model of neuronal ischaemia through increased expression and activity of the glutamate transporter, GLT1.\n[22680643:22680643_0] Importantly, ceftriaxone is currently in clinical trials for the treatment of amyotrophic lateral sclerosis.\n[24771634:24771634_0] The cephalosporin antibiotic ceftriaxone was evaluated as a potential therapeutic agent for the treatment of amyotrophic lateral sclerosis (ALS).", "answer": "<think> Okay, let's tackle this query. The user is asking about the clinical efficacy of ceftriaxone for treating ALS. First, I need to look at the provided evidence. The first document says that ceftriaxone reduces neuronal damage in ALS and an in-vitro model of neuronal ischemia by increasing GLT1 expression and activity. That's a study showing mechanism of action, but it's in vitro. The second document mentions that ceftriaxone is in clinical trials for ALS. The third document states that it was evaluated as a potential therapeutic agent for ALS. So, the answer needs to combine these points. The first evidence talks about reduced neuronal damage in animal models and in-vitro studies. The second says it's in clinical trials, which suggests some ongoing research but not yet proven efficacy. The third confirms that it's been evaluated, possibly in human trials. The user wants a concise answer with citations. The answer should mention the in vitro findings and the fact that it's in clinical trials. But since the question is about clinical efficacy, the trials part is important. However, the evidence doesn't say if the trials", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this query. The user is asking about the clinical efficacy of ceftriaxone for treating ALS. First, I need to look at the provided evidence. The first document says that ceftriaxone reduces neuronal damage in ALS and an in-vitro model of neuronal ischemia by increasing GLT1 expression and activity. That's a study showing mechanism of action, but it's in vitro. The second document mentions that ceftriaxone is in clinical trials for ALS. The third document states that it was evaluated as a potential therapeutic agent for ALS. So, the answer needs to combine these points. The first evidence talks about reduced neuronal damage in animal models and in-vitro studies. The second says it's in clinical trials, which suggests some ongoing research but not yet proven efficacy. The third confirms that it's been evaluated, possibly in human trials. The user wants a concise answer with citations. The answer should mention the in vitro findings and the fact that it's in clinical trials. But since the question is about clinical efficacy, the trials part is important. However, the evidence doesn't say if the trials", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this query. The user is asking about the clinical efficacy of ceftriaxone for treating ALS. I need to look at the provided evidence to form an answer. First, evidence document 19008722:19008722_0 mentions that ceftriaxone reduces neuronal damage in ALS and an in-vitro model of neuronal ischaemia by increasing GLT1 expression and activity. That's a study showing a mechanism of action, but it's in vitro. So maybe not clinical yet. Then document 22680643:22680643_0 states that ceftriaxone is currently in clinical trials for ALS. So there's ongoing research, but no conclusive results yet. Document 24771634:24771634_0 says it was evaluated as a potential therapeutic agent. That suggests some investigation has been done, but again, not sure about the outcomes. So combining these, the answer should mention that there's evidence from in vitro studies and ongoing clinical", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this query. The user is asking about the clinical efficacy of ceftriaxone for treating ALS. I need to look at the provided evidence to form an answer. First, evidence document 19008722 mentions that ceftriaxone reduces neuronal damage in ALS and an in-vitro model of neuronal ischaemia by increasing GLT1 expression and activity. That's a study showing a mechanism of action, but it's in vitro. Then, document 22680643 says ceftriaxone is in clinical trials for ALS. So there's ongoing research. Document 24771634 states that ceftriaxone was evaluated as a potential therapeutic agent for ALS. So the answer should mention both the in vitro findings and the fact that it's in clinical trials. But the question is about clinical efficacy. The in vitro results are promising but not yet proven in humans. The clinical trials part indicates that there's ongoing investigation, but no conclusive results yet. Therefore, the answer should state that while there's evidence of potential effectiveness in", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["15635412", "15907788", "16723044", "16832072", "17212618", "18326497", "19008722", "19694903", "19697382", "20638444", "21970974", "22680643", "23613806", "24771634", "25297012", "8161465"], "ideal_answer": "There have been a few case reports to suggest that ceftriaxone can be effective for treatment of amyotrophic lateral sclerosis. However, other case reports did not report clinical benefit of ceftriaxone therapy for ALS. Ceftriaxone has been reported to reduce neuronal damage in amyotrophic lateral sclerosis a through increased expression and activity of the glutamate transporter, GLT1. Clinical trials investigating potential clinical benefits of ceftriaxone in ALS are ongoing."}
{"question_id": "56ccae765795f9a73e000035", "question": "What is the relationship between TailorX and Oncotype?", "retrieved_chunks": [{"doc_id": "23411384", "chunk_id": "23411384_3", "score": 4.149637222290039, "text": "The TAILORx trial uses the Oncotype DX recurrence score to assign estrogen receptor-positive (ER+), node-negative patients to chemotherapy plus hormonal therapy versus hormonal therapy alone."}, {"doc_id": "23643806", "chunk_id": "23643806_0", "score": 3.821352958679199, "text": "Each patient is stratified into a risk category based on a recurrence score (RS) and the TAILORx trial is determining the benefit of chemotherapy for patients with mid-range RSs. We tested if Oncotype DX and TAILORx risk categories could be predicted by standard pathological features and protein markers corresponding to 10 genes in the assay (ER, PR, Ki67, HER2, BCL2, CD68, Aurora A kinase, survivin, cyclin B1 and BAG1) on 52 patients who enrolled on TAILORx."}, {"doc_id": "23411384", "chunk_id": "23411384_2", "score": 3.7790775299072266, "text": "The TAILORx trial uses the Oncotype DX recurrence score to assign estrogen receptor-positive (ER+), node-negative patients to chemotherapy plus hormonal therapy versus hormonal therapy alone"}], "context": "[23411384:23411384_3] The TAILORx trial uses the Oncotype DX recurrence score to assign estrogen receptor-positive (ER+), node-negative patients to chemotherapy plus hormonal therapy versus hormonal therapy alone.\n[23643806:23643806_0] Each patient is stratified into a risk category based on a recurrence score (RS) and the TAILORx trial is determining the benefit of chemotherapy for patients with mid-range RSs. We tested if Oncotype DX and TAILORx risk categories could be predicted by standard pathological features and protein markers corresponding to 10 genes in the assay (ER, PR, Ki67, HER2, BCL2, CD68, Aurora A kinase, survivin, cyclin B1 and BAG1) on 52 patients who enrolled on TAILORx.\n[23411384:23411384_2] The TAILORx trial uses the Oncotype DX recurrence score to assign estrogen receptor-positive (ER+), node-negative patients to chemotherapy plus hormonal therapy versus hormonal therapy alone", "answer": "<think> Okay, let's tackle this question. The user is asking about the relationship between TailorX and Oncotype. From the evidence provided, there are a few documents mentioning both. First, document [23411384:23411384_3] says that the TAILORx trial uses the Oncotype DX recurrence score to assign patients to different treatment groups. So that's a direct link. Then, another document [23411384:23411384_2] repeats the same point, confirming that Oncotype DX is used in TAILORx. The third document [23643806:23643807_0] talks about how TAILORx determines the benefit of chemotherapy based on the recurrence score, which comes from Oncotype DX. It also mentions that they tested if Oncotype DX and TAILORx risk categories could be predicted by other markers. So putting this together, the answer should state that TAILORx uses the Oncotype DX recurrence score to stratify patients into risk categories for", "citations": [{"doc_id": "23411384", "chunk_id": "23411384_3"}, {"doc_id": "23411384", "chunk_id": "23411384_2"}, {"doc_id": "23643806", "chunk_id": "23643807_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking about the relationship between TailorX and Oncotype. From the evidence provided, there are a few documents mentioning both. First, document [23411384:23411384_3] says that the TAILORx trial uses the Oncotype DX recurrence score to assign patients to different treatment groups. So that's a direct link. Then, another document [23411384:23411384_2] repeats the same point, confirming that Oncotype DX is used in TAILORx. The third document [23643806:23643807_0] talks about how TAILORx determines the benefit of chemotherapy based on the recurrence score, which comes from Oncotype DX. It also mentions that they tested if Oncotype DX and TAILORx risk categories could be predicted by other markers. So putting this together, the answer should state that TAILORx uses the Oncotype DX recurrence score to stratify patients into risk categories for", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's see. The user is asking about the relationship between TailorX and Oncotype. I need to look at the evidence provided. First, the evidence has three chunks. The first one says that the TAILORx trial uses the Oncotype DX recurrence score to assign patients to different treatment groups. So there's a direct link here. The second chunk mentions that the TAILORx trial is determining the benefit of chemotherapy based on the recurrence score, which is from Oncotype DX. Also, they tested if Oncotype DX and TAILORx risk categories could be predicted by some markers. The third chunk repeats the first point, confirming that Oncotype DX is used in TAILORx. So putting this together, the answer should state that TailorX uses Oncotype DX's recurrence score to determine chemotherapy eligibility. The confidence is high because multiple chunks mention this. The citations are from doc_id 23411384, chunk 3 and 2. Wait, but in the evidence, the first and third chunks are the same. So maybe cite both? But the user wants a concise answer with citations. Let me check", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the relationship between TailorX and Oncotype. From the evidence provided, there are a few documents mentioning both. First, document [23411384:23411384_3] says that the TAILORx trial uses the Oncotype DX recurrence score to assign patients to different treatment groups. So that's a direct link. Then, another document [23411384:23411384_2] repeats the same point, confirming that Oncotype DX is used in TAILORx. The third document [23643806:2364380เหลือ_0] talks about how TAILORx determines chemotherapy benefit based on recurrence score and mentions Oncotype DX and TAILORx risk categories being predicted by certain markers. So it's connecting the two, showing that Oncotype DX is part of the trial's methodology. Putting this together, the answer should state that TAILORx uses Oncotype DX recurrence scores to stratify patients, determining chemotherapy", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["18922117", "20665886", "23411384", "23643806", "25240289"], "ideal_answer": "The TAILORx trial uses the Oncotype DX recurrence score to assign estrogen receptor-positive (ER+), node-negative patients to chemotherapy plus hormonal therapy versus hormonal therapy alone."}
{"question_id": "51598b08d24251bc0500009f", "question": "Does strenuous physical activity affect thyroid hormone metabolism?", "retrieved_chunks": [{"doc_id": "16175495", "chunk_id": "16175495_0", "score": 8.087591171264648, "text": "There are controversial results concerning thyroid hormone metabolism during strenuous exercise in adult athletes and only scant data concerning the impact of strenuous exercise on thyroid hormone metabolism in children and adolescents."}, {"doc_id": "7198038", "chunk_id": "7198038_0", "score": 4.207489490509033, "text": "brief strenuous swimming or moderate bicycle exercise had minor or no effect on thyroid hormone concentrations when consideration was given to the attendant hemoconcentration."}, {"doc_id": "2807143", "chunk_id": "2807143_0", "score": 2.991506814956665, "text": "Reductions in plasma T4, T3 and T3/T4 ratio are probably due to inhibition of T4 secretion and 5'-monodeiodination with possible conversion of T4 to reverse T3 (rT3). These processes may represent a mechanism for regulation of thyroid hormone metabolism during strenuous and extended flight."}], "context": "[16175495:16175495_0] There are controversial results concerning thyroid hormone metabolism during strenuous exercise in adult athletes and only scant data concerning the impact of strenuous exercise on thyroid hormone metabolism in children and adolescents.\n[7198038:7198038_0] brief strenuous swimming or moderate bicycle exercise had minor or no effect on thyroid hormone concentrations when consideration was given to the attendant hemoconcentration.\n[2807143:2807143_0] Reductions in plasma T4, T3 and T3/T4 ratio are probably due to inhibition of T4 secretion and 5'-monodeiodination with possible conversion of T4 to reverse T3 (rT3). These processes may represent a mechanism for regulation of thyroid hormone metabolism during strenuous and extended flight.", "answer": "<think> Okay, let's tackle this question. The user is asking if strenuous physical activity affects thyroid hormone metabolism. I need to look at the provided evidence to form an answer. First, evidence document [16175495:16175495_0] says there are controversial results in adults and little data in children and adolescents. So, it's not clear-cut. Then, [7198038:7198038_0] mentions that brief strenuous swimming or moderate cycling had minor or no effect on thyroid hormones when considering hemoconcentration. That suggests maybe no significant effect in some cases. But [2807143:2807143_0] talks about reductions in T4, T3, and T3/T4 ratio during strenuous exercise, possibly due to inhibited secretion and deiodination. So there's a contradiction here. Some studies show no effect, others show reduction. The answer needs to be concise with citations. The base confidence should reflect the conflicting evidence. Since there are both positive and negative findings, maybe the confidence", "citations": [{"doc_id": "16175495", "chunk_id": "16175495_0"}, {"doc_id": "7198038", "chunk_id": "7198038_0"}, {"doc_id": "2807143", "chunk_id": "2807143_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if strenuous physical activity affects thyroid hormone metabolism. I need to look at the provided evidence to form an answer. First, evidence document [16175495:16175495_0] says there are controversial results in adults and little data in children and adolescents. So, it's not clear-cut. Then, [7198038:7198038_0] mentions that brief strenuous swimming or moderate cycling had minor or no effect on thyroid hormones when considering hemoconcentration. That suggests maybe no significant effect in some cases. But [2807143:2807143_0] talks about reductions in T4, T3, and T3/T4 ratio during strenuous exercise, possibly due to inhibited secretion and deiodination. So there's a contradiction here. Some studies show no effect, others show reduction. The answer needs to be concise with citations. The base confidence should reflect the conflicting evidence. Since there are both positive and negative findings, maybe the confidence", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if strenuous physical activity affects thyroid hormone metabolism. I need to look at the provided evidence to form an answer. First, evidence document [16175495:16175495_0] says there are controversial results in adults and little data in children and adolescents. That suggests that the effect might not be consistent or well-studied. But then, document [7198038:7198038_0] mentions that brief strenuous swimming or moderate cycling had minor or no effect on thyroid hormones when considering hemoconcentration. So there's some evidence of minimal impact. Then, document [2807143:2807143_0] talks about reductions in T4, T3, and the ratio during strenuous activity, possibly due to inhibited secretion and deiodination. This suggests that there is an effect, but it's a bit conflicting with the previous point. The mention of reverse T3 might indicate some change. So putting this together: There's some evidence showing minor", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to generate a biomedical answer based on the provided evidence. The question is whether strenuous physical activity affects thyroid hormone metabolism. Looking at the evidence: First piece [16175495:16175495_0] says there are controversial results in adults and limited data in children and adolescents. So this suggests that the effect isn't clear, especially in different age groups. Then [7198038:7198038_0] mentions that brief strenuous swimming or moderate cycling had minor or no effect on thyroid hormone concentrations, considering hemoconcentration. This indicates that in some cases, there's no significant impact. The third evidence [2807143:2807143_0] talks about reductions in T4, T3, and T3/T4 ratio during strenuous activity, possibly due to inhibited secretion and deiodination, leading to possible conversion to reverse T3. This suggests that there is an effect, but it's more pronounced in certain conditions. So combining these points: some studies show no significant effect, others", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["14637241", "16175495", "18057380", "2807143", "3101339", "596247", "7198038", "8325717", "8743723"], "ideal_answer": "YES"}
{"question_id": "56f112932ac5ed145900000d", "question": "Which is the main function of \"RNA sponges\"?", "retrieved_chunks": [{"doc_id": "28018143", "chunk_id": "28018143_1", "score": 6.0878448486328125, "text": "Several circRNAs have been shown to function as microRNA \"sponges\" to counteract microRNA mediated repression of mRNA."}, {"doc_id": "29387208", "chunk_id": "29387208_1", "score": 4.849767684936523, "text": "Presently, certain circRNAs have been reported to function as microRNA sponges and RNA-binding protein sponges to regulate downstream gene transcription, which suggests a potential for circRNAs in cancer diagnosis, prognosis and clinical therapy."}, {"doc_id": "23446346", "chunk_id": "23446346_4", "score": 4.345890045166016, "text": "Natural RNA circles function as efficient microRNA sponges"}], "context": "[28018143:28018143_1] Several circRNAs have been shown to function as microRNA \"sponges\" to counteract microRNA mediated repression of mRNA.\n[29387208:29387208_1] Presently, certain circRNAs have been reported to function as microRNA sponges and RNA-binding protein sponges to regulate downstream gene transcription, which suggests a potential for circRNAs in cancer diagnosis, prognosis and clinical therapy.\n[23446346:23446346_4] Natural RNA circles function as efficient microRNA sponges", "answer": "<think> Okay, the user is asking about the main function of \"RNA sponges.\" Let me look at the evidence provided. First, the evidence mentions that circRNAs function as microRNA sponges. The first document says they counteract microRNA-mediated repression of mRNA. The second one adds that they also act as RNA-binding protein sponges, regulating gene transcription, which might be relevant to cancer. The third document states that natural RNA circles are efficient microRNA sponges. So the main function seems to be acting as microRNA sponges. The answer should be concise and cite the documents. The confidence is high because multiple sources mention this. I need to pick the most direct citation. Document 28018143:28018143_1 is the first one, but document 23446346:23446346_4 also mentions microRNA sponges. However, the question is about RNA sponges in general, not just circRNAs. Wait, the term \"RNA sponges\" might refer to circRNAs as per the", "citations": [], "candidates": [{"answer": "<think> Okay, the user is asking about the main function of \"RNA sponges.\" Let me look at the evidence provided. First, the evidence mentions that circRNAs function as microRNA sponges. The first document says they counteract microRNA-mediated repression of mRNA. The second one adds that they also act as RNA-binding protein sponges, regulating gene transcription, which might be relevant to cancer. The third document states that natural RNA circles are efficient microRNA sponges. So the main function seems to be acting as microRNA sponges. The answer should be concise and cite the documents. The confidence is high because multiple sources mention this. I need to pick the most direct citation. Document 28018143:28018143_1 is the first one, but document 23446346:23446346_4 also mentions microRNA sponges. However, the question is about RNA sponges in general, not just circRNAs. Wait, the term \"RNA sponges\" might refer to circRNAs as per the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to generate a candidate biomedical answer about the main function of \"RNA sponges\" based on the provided evidence. Let me start by understanding what the user is asking. The question is about the main function of RNA sponges. The evidence given comes from three different studies. Each of them mentions that circRNAs act as microRNA sponges. The first study says they counteract microRNA mediated repression of mRNA. The second one adds that they also act as RNA-binding protein sponges, regulating gene transcription and possibly having roles in cancer. The third study states that natural RNA circles are efficient microRNA sponges. So the main function seems to be acting as microRNA sponges. But I need to check if there's a more specific answer. The term \"RNA sponges\" is used in the question, but the evidence specifically mentions circRNAs functioning as microRNA sponges. However, the user's question is about RNA sponges in general, not just circRNAs. Wait, but the evidence provided only talks about circRNAs being sponges. So maybe the answer should be that RNA s", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to generate a candidate biomedical answer about the main function of \"RNA sponges\" based on the provided evidence. Let me start by understanding the question and the given evidence. The user is asking for the main function of RNA sponges. The evidence comes from three different studies. Let me look at each one: First, [28018143:28018143_1] says that several circRNAs function as microRNA \"sponges\" to counteract microRNA-mediated repression of mRNA. So here, the main point is that they sponge microRNAs to prevent them from repressing mRNA. Second, [29387208:29387208_1] mentions that circRNAs act as both microRNA sponges and RNA-binding protein sponges, regulating gene transcription. This suggests a broader role in regulating downstream gene expression, possibly through multiple mechanisms. Third, [23446346:23446346_4] states that natural RNA circles (which I think are circRN", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["23446346", "23615404", "25404635", "25483404", "25580223", "25630703", "25957803", "26052092"], "ideal_answer": "Natural RNA circles function as efficient microRNA sponges. Recently, miRNA activity has been shown to be affected by the presence of miRNA sponge transcripts, the so-called competing endogenous RNA in humans and target mimicry in plants. Recently, miRNA activity has been shown to be affected by the presence of miRNA sponge transcripts, the so-called competing endogenous RNA in humans and target mimicry in plants. Natural RNA sponges sequestering cellular noncoding RNA molecules have been found in diverse organisms. In this issue, Lalaouna et al. (2015) report another type of RNA sponge, showing that stable intermediates of bacterial tRNA processing control endogenous small RNAs. Furthermore, survival analysis suggests that high OCT4-pg4 level is significantly correlated with poor prognosis of HCC patients."}
{"question_id": "56cf50253975bb303a00000b", "question": "Is the gene MAOA epigenetically modified by methylation?", "retrieved_chunks": [{"doc_id": "20421737", "chunk_id": "20421737_0", "score": 6.18554162979126, "text": "Given that DNA methylation is linked to the regulation of gene expression, we hypothesized that epigenetic mechanisms factor into the MAOA expression"}, {"doc_id": "22948232", "chunk_id": "22948232_0", "score": 4.726548194885254, "text": "Evidence that the methylation state of the monoamine oxidase A (MAOA) gene predicts brain activity of MAO A enzyme in healthy men."}, {"doc_id": "18454435", "chunk_id": "18454435_0", "score": 4.475069999694824, "text": "In recent years, the role of epigenetic phenomenon, such as methylation, in mediating vulnerability to behavioral illness has become increasingly appreciated. One prominent locus at which epigenetic phenomena are thought to be in play is the monoamine oxidase A (MAOA) locus."}], "context": "[20421737:20421737_0] Given that DNA methylation is linked to the regulation of gene expression, we hypothesized that epigenetic mechanisms factor into the MAOA expression\n[22948232:22948232_0] Evidence that the methylation state of the monoamine oxidase A (MAOA) gene predicts brain activity of MAO A enzyme in healthy men.\n[18454435:18454435_0] In recent years, the role of epigenetic phenomenon, such as methylation, in mediating vulnerability to behavioral illness has become increasingly appreciated. One prominent locus at which epigenetic phenomena are thought to be in play is the monoamine oxidase A (MAOA) locus.", "answer": "<think> Okay, let's tackle this question. The user is asking if the gene MAOA is epigenetically modified by methylation. I need to look at the provided evidence to form an answer. First, I'll check each of the three evidence points. The first evidence (20421737) mentions that DNA methylation is linked to regulating gene expression and that epigenetic mechanisms, including methylation, factor into MAOA expression. This directly supports the idea that methylation affects MAOA. The second evidence (22948232) states that the methylation state of the MAOA gene predicts brain activity of the MAO A enzyme in men. This shows a correlation between methylation and MAOA function, which is relevant. The third evidence (18454435) talks about epigenetic phenomena like methylation being involved in the MAOA locus, linking methylation to the gene's regulation. All three pieces of evidence point to methylation being an epigenetic modification affecting MAOA. The answer should be a concise statement citing these sources. The confidence level is high since all three references support the", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if the gene MAOA is epigenetically modified by methylation. I need to look at the provided evidence to form an answer. First, I'll check each of the three evidence points. The first evidence (20421737) mentions that DNA methylation is linked to regulating gene expression and that epigenetic mechanisms, including methylation, factor into MAOA expression. This directly supports the idea that methylation affects MAOA. The second evidence (22948232) states that the methylation state of the MAOA gene predicts brain activity of the MAO A enzyme in men. This shows a correlation between methylation and MAOA function, which is relevant. The third evidence (18454435) talks about epigenetic phenomena like methylation being involved in the MAOA locus, linking methylation to the gene's regulation. All three pieces of evidence point to methylation being an epigenetic modification affecting MAOA. The answer should be a concise statement citing these sources. The confidence level is high since all three references support the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if the gene MAOA is epigenetically modified by methylation. The evidence provided has three chunks. First chunk: DNA methylation is linked to regulating gene expression, and they hypothesized that epigenetic mechanisms, including methylation, affect MAOA expression. So this suggests that methylation does play a role in MAOA regulation. Second chunk: Methylation state of the MAOA gene predicts brain activity of the MAO A enzyme in healthy men. This directly links methylation to MAOA's function, implying an epigenetic modification. Third chunk: Epigenetic phenomena like methylation are involved in mediating vulnerability to behavioral illness, with a specific mention of the MAOA locus. This reinforces that methylation is indeed related to MAOA. So all three pieces of evidence point towards methylation affecting MAOA. The answer should state that yes, MAOA is epigenetically modified by methylation, citing the relevant documents. The confidence would be high since all three sources support this. </think> { \"answer\": \"Yes, the gene MAOA is epigenetically modified by methylation [2", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if the gene MAOA is epigenetically modified by methylation. I need to look at the evidence provided to form a concise answer with citations and a confidence level. First, looking at the evidence: The first document [20421737:20421737_0] says that DNA methylation is linked to gene expression regulation and mentions that epigenetic mechanisms factor into MAOA expression. That suggests that methylation does play a role in MAOA. The second document [22948232:22948232_0] states that the methylation state of the MAOA gene predicts brain activity of the MAO A enzyme. This directly links methylation to MAOA's activity, supporting the idea that it's epigenetically modified. The third document [18454435:18454435_0] talks about epigenetic phenomena like methylation being involved in vulnerability to behavioral illness, specifically mentioning the MAOA locus. This reinforces that methylation is relevant here", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["16893905", "18454435", "19777560", "20421737", "20505345", "22139575", "22198720", "22436428", "22906985", "22948232", "23116433"], "ideal_answer": "In recent years, the role of epigenetic phenomenon, such as methylation, in mediating vulnerability to behavioral illness has become increasingly appreciated. One prominent locus at which epigenetic phenomena are thought to be in play is the monoamine oxidase A (MAOA) locus. We conclude that methylation of MAOA may play a significant role in common psychiatric illness and that further examination of epigenetic processes at this locus is in order."}
{"question_id": "5523f1a62c8b63434a000002", "question": "Which mutations of phopspholamban have been found in patients with cardiomyopathy?", "retrieved_chunks": [{"doc_id": "22820313", "chunk_id": "22820313_2", "score": 7.793552398681641, "text": "Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy."}, {"doc_id": "12705874", "chunk_id": "12705874_0", "score": 7.6367998123168945, "text": "Using neonatal rat cardiomyocytes, the mutation, -77A-->G, increased the phospholamban promoter activity. No nucleotide change in the phospholamban coding region was found in 99 patients with cardiomyopathy. We suspect that the mutation plays an important role in the development of hypertrophic cardiomyopathy."}, {"doc_id": "22155237", "chunk_id": "22155237_1", "score": 7.241402626037598, "text": "Phospholamban (PLN) is a key regulator of SR and cardiac function, and PLN mutations in humans have been associated with dilated cardiomyopathy (DCM). We previously reported the deletion of the highly conserved amino acid residue arginine 14 (nucleic acids 39, 40 and 41) in DCM patients."}], "context": "[22820313:22820313_2] Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy.\n[12705874:12705874_0] Using neonatal rat cardiomyocytes, the mutation, -77A-->G, increased the phospholamban promoter activity. No nucleotide change in the phospholamban coding region was found in 99 patients with cardiomyopathy. We suspect that the mutation plays an important role in the development of hypertrophic cardiomyopathy.\n[22155237:22155237_1] Phospholamban (PLN) is a key regulator of SR and cardiac function, and PLN mutations in humans have been associated with dilated cardiomyopathy (DCM). We previously reported the deletion of the highly conserved amino acid residue arginine 14 (nucleic acids 39, 40 and 41) in DCM patients.", "answer": "<think> Okay, let's tackle this question. The user is asking which mutations of phospholamban have been found in patients with cardiomyopathy. I need to look at the provided evidence to find the relevant information. First, looking at the evidence documents: The first one, [22820313:22820313_2], mentions a Phospholamban R14del mutation in patients with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy. That's a specific mutation, R14del, which is a deletion of the 14th residue. So that's one mutation. The second document, [12705874:12705874_0], talks about a -77A-->G mutation in the promoter region. However, it states that there were no nucleotide changes in the coding region of phospholamban in 99 patients. So this mutation is in the promoter, not the coding region. The study suggests it might be involved in hypertrophic cardiomyopathy, but since the coding region didn't have", "citations": [{"doc_id": "22820313", "chunk_id": "22820313_2"}, {"doc_id": "12705874", "chunk_id": "12705874_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which mutations of phospholamban have been found in patients with cardiomyopathy. I need to look at the provided evidence to find the relevant information. First, looking at the evidence documents: The first one, [22820313:22820313_2], mentions a Phospholamban R14del mutation in patients with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy. That's a specific mutation, R14del, which is a deletion of the 14th residue. So that's one mutation. The second document, [12705874:12705874_0], talks about a -77A-->G mutation in the promoter region. However, it states that there were no nucleotide changes in the coding region of phospholamban in 99 patients. So this mutation is in the promoter, not the coding region. The study suggests it might be involved in hypertrophic cardiomyopathy, but since the coding region didn't have", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which mutations of phospholamban have been found in patients with cardiomyopathy. I need to look at the evidence provided to find the relevant mutations. First, looking at the evidence documents: Document [22820313:22820313_2] mentions a Phospholamban R14del mutation associated with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy. That's one mutation. Then, document [22155237:22155237_1] talks about a deletion of arginine 14 (R14del) in DCM patients. So that's the same mutation as mentioned in the first document. The third document [12705874:12705874_0] discusses a -77A-->G mutation in the promoter region, but it says no coding region changes were found in 99 patients. So this might be a regulatory mutation rather than a coding region mutation. The question specifically", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which mutations of phospholamban have been found in patients with cardiomyopathy. The evidence provided has three references. First, I need to look at each document to find the relevant mutations mentioned. Looking at the first reference [22820313:22820313_2], it mentions a Phospholamban R14del mutation associated with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy. That's one mutation. The second reference [12705874:12705874_0] talks about a -77A-->G mutation in the promoter region, but it says there's no nucleotide change in the coding region in 99 patients. So this might be a regulatory mutation rather than a coding region mutation. However, the question is about mutations of phospholamban, which could include promoter regions. But the answer needs to be concise and cite the documents. The user might be looking for coding mutations, but I should check if the promoter is considered part", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["12610310", "12639993", "16432188", "16829191", "17010801", "21282613", "21332051", "22137083", "22155237", "22707725", "22820313", "23568436", "23871674"], "ideal_answer": "PLN mutation R14del [or c.40_42delAGA(p.Arg14del)] was identified in 12 (12 %) ARVC patients and in 39 (15 %) DCM patients. Another PLN mutation is a T116G point mutation, substituting a termination codon for Leu-39 (L39stop), and it was identified in two families with hereditary heart failure. Hereditary mutants of phospholamban, such as Arg(9) to Cys, Arg(9) to Leu, Arg(9) to His, cause lethal, hereditary dilated cardiomyopathy.in specific, two patients presented a G-T missense mutation at the G26 nucleotide, which encodes an Arg-Leu substitution at codon 9 (R9L).One patient presented a G-A missense mutation at the same nucleotide, which encodes an Arg-His substitution at codon 9 (R9H). A missense mutation in PLN cytoplasmic domain (R9C) triggers dilated cardiomyopathy in humans, leading to premature death."}
{"question_id": "52df8ce798d023950500000d", "question": "Which are the supplemental antioxidant in athletes?", "retrieved_chunks": [{"doc_id": "19838998", "chunk_id": "19838998_0", "score": 6.129538059234619, "text": "Supplementation with antioxidant vitamin E to athletes at 267 mg (400 IUs) or greater has been reported to reduce levels of LP associated with exercise."}, {"doc_id": "21400082", "chunk_id": "21400082_0", "score": 4.592637062072754, "text": "The two strains, L. rhamnosus IMC 501(®) and L. paracasei IMC 502(®), exert strong antioxidant activity. Athletes and all those exposed to oxidative stress may benefit from the ability of these probiotics to increase antioxidant levels and neutralize the effects of reactive oxygen species."}, {"doc_id": "24323888", "chunk_id": "24323888_0", "score": 1.3399267196655273, "text": "Although these supplementations are increasingly used by master athletes, very few data are available on their effects on oxidative stress, muscle recovery, and physical performance. The potential benefits of supplement use in athletes are thus questionable. Some studies indicate no benefits, while others highlight potential negative side effects of vitamin supplementation."}], "context": "[19838998:19838998_0] Supplementation with antioxidant vitamin E to athletes at 267 mg (400 IUs) or greater has been reported to reduce levels of LP associated with exercise.\n[21400082:21400082_0] The two strains, L. rhamnosus IMC 501(®) and L. paracasei IMC 502(®), exert strong antioxidant activity. Athletes and all those exposed to oxidative stress may benefit from the ability of these probiotics to increase antioxidant levels and neutralize the effects of reactive oxygen species.\n[24323888:24323888_0] Although these supplementations are increasingly used by master athletes, very few data are available on their effects on oxidative stress, muscle recovery, and physical performance. The potential benefits of supplement use in athletes are thus questionable. Some studies indicate no benefits, while others highlight potential negative side effects of vitamin supplementation.", "answer": "<think> Okay, let's tackle this question. The user is asking about supplemental antioxidants in athletes. I need to look at the provided evidence to find which specific supplements are mentioned. First document: It talks about vitamin E supplementation at 267 mg or more reducing LP levels related to exercise. So vitamin E is one. Second document mentions two probiotic strains, L. rhamnosus and L. paracasei, which have strong antioxidant activity. These are probiotics, so they're another type of supplement. Third document is a bit vague, saying that while supplements are used by master athletes, there's limited data on their effects. It also mentions some studies show no benefits or negative side effects. But it doesn't name specific antioxidants here. So the answer should include both vitamin E and the probiotics mentioned. The confidence level: the first document is pretty direct, the second one is about probiotics. The third one is more about the lack of data, so maybe lower confidence there. But since the question is about which are the supplements, the two mentioned in docs 1 and 2 are the ones. So answer should be vitamin E and those prob", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking about supplemental antioxidants in athletes. I need to look at the provided evidence to find which specific supplements are mentioned. First document: It talks about vitamin E supplementation at 267 mg or more reducing LP levels related to exercise. So vitamin E is one. Second document mentions two probiotic strains, L. rhamnosus and L. paracasei, which have strong antioxidant activity. These are probiotics, so they're another type of supplement. Third document is a bit vague, saying that while supplements are used by master athletes, there's limited data on their effects. It also mentions some studies show no benefits or negative side effects. But it doesn't name specific antioxidants here. So the answer should include both vitamin E and the probiotics mentioned. The confidence level: the first document is pretty direct, the second one is about probiotics. The third one is more about the lack of data, so maybe lower confidence there. But since the question is about which are the supplements, the two mentioned in docs 1 and 2 are the ones. So answer should be vitamin E and those prob", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking about supplemental antioxidants for athletes. I need to look at the provided evidence to find which specific supplements are mentioned. First, evidence [19838998:19838998_0] talks about vitamin E supplementation at 267 mg or more reducing LP levels in athletes. So vitamin E is one candidate. Then, [21400082:21400082_0] mentions two probiotic strains, L. rhamnosus and L. paracasei, which have strong antioxidant activity. These are probiotics, so they're a different type of supplement. The text says athletes might benefit from them because they can increase antioxidant levels and neutralize reactive oxygen species. The third evidence [24323888:24323888_0] is more about the potential benefits being questionable, but it doesn't name specific supplements. It mentions vitamin supplementation in general, but the other two docs do specify. So the answer should include both vitamin E and the probiotics", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, the user is asking about supplemental antioxidants for athletes. Let me look at the evidence provided. First, evidence 19838998 mentions vitamin E supplementation at 267 mg or higher reducing LP levels associated with exercise. So vitamin E is mentioned here as a supplement. Then, evidence 21400082 talks about probiotics like L. rhamnosus and L. paracasei having strong antioxidant activity. These are probiotics, which might be considered supplements. The third evidence, 24323888, is more cautious, saying that while some supplements are used, the data on their effects is limited and benefits are questionable. The question is about \"supplemental antioxidants,\" so both vitamin E and the probiotics mentioned in 21400082 could be answers. But I need to check if they are classified as antioxidants. Vitamin E is a well-known antioxidant, so that's clear. The probiotics in 21400082 exert antioxidant activity, so they might be considered as supplements that act as antioxidants. However, the answer should", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["16575496", "18562771", "19089749", "19597720", "19838998", "20308973", "21116022", "21400082", "21813916", "21830999", "21990004", "22080314", "22212240", "22828460", "23349254", "23436649", "23600891", "23717765", "23717772", "23800565", "23980734", "24323888"], "ideal_answer": "There are several antioxidant supplements belonging to different families, i.e. Vitamins, Polyphenols, alpha-lipoic acid, ubiquinones, n-3- polyunsaturated acids (PUFAs), minerals and others. Nonetheless the widespread use of these supplements, it is still debated their true usefulness, and it is not unanimously advised their use in athletes."}
{"question_id": "5713c4a11174fb1755000013", "question": "Is glycyl-tRNA synthetase gene involved in the development of Charcot-Marie-Tooth disease?", "retrieved_chunks": [{"doc_id": "25420567", "chunk_id": "25420567_1", "score": 7.194414138793945, "text": "A novel mutation in glycyl-tRNA synthetase caused Charcot-Marie-Tooth disease type 2D with facial and respiratory muscle involvement."}, {"doc_id": "22144914", "chunk_id": "22144914_2", "score": 6.991029262542725, "text": "Charcot-Marie-Tooth disease type 2D (CMT2D) is a dominantly inherited peripheral neuropathy caused by missense mutations in the glycyl-tRNA synthetase gene (GARS). In addition to GARS, mutations in three other tRNA synthetase genes cause similar neuropathies, although the underlying mechanisms are not fully understood."}, {"doc_id": "25420567", "chunk_id": "25420567_0", "score": 6.908804416656494, "text": "A novel mutation in glycyl-tRNA synthetase caused Charcot-Marie-Tooth disease type 2D with facial and respiratory muscle involvement"}], "context": "[25420567:25420567_1] A novel mutation in glycyl-tRNA synthetase caused Charcot-Marie-Tooth disease type 2D with facial and respiratory muscle involvement.\n[22144914:22144914_2] Charcot-Marie-Tooth disease type 2D (CMT2D) is a dominantly inherited peripheral neuropathy caused by missense mutations in the glycyl-tRNA synthetase gene (GARS). In addition to GARS, mutations in three other tRNA synthetase genes cause similar neuropathies, although the underlying mechanisms are not fully understood.\n[25420567:25420567_0] A novel mutation in glycyl-tRNA synthetase caused Charcot-Marie-Tooth disease type 2D with facial and respiratory muscle involvement", "answer": "<think> Okay, let's tackle this question. The user is asking if the glycyl-tRNA synthetase gene is involved in Charcot-Marie-Tooth disease (CMT). I need to check the provided evidence. Looking at the evidence, there are two entries from 25420567 and one from 22144914. The first one mentions a novel mutation in glycyl-tRNA synthetase causing CMT2D. The second entry says that CMT2D is dominantly inherited and caused by missense mutations in the GARS gene. Another entry repeats the same point about the mutation leading to CMT2D. So, the answer should be yes, the gene is involved. The citations are from 22144914_2 and 25420567_1 (and others). The confidence is high because multiple sources confirm this link. I'll structure the JSON with the answer and base confidence. </think> { \"answer\": \"Yes, the glycyl-tRNA synthetase gene (GARS) is involved in Charcot-Marie-Tooth", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if the glycyl-tRNA synthetase gene is involved in Charcot-Marie-Tooth disease (CMT). I need to check the provided evidence. Looking at the evidence, there are two entries from 25420567 and one from 22144914. The first one mentions a novel mutation in glycyl-tRNA synthetase causing CMT2D. The second entry says that CMT2D is dominantly inherited and caused by missense mutations in the GARS gene. Another entry repeats the same point about the mutation leading to CMT2D. So, the answer should be yes, the gene is involved. The citations are from 22144914_2 and 25420567_1 (and others). The confidence is high because multiple sources confirm this link. I'll structure the JSON with the answer and base confidence. </think> { \"answer\": \"Yes, the glycyl-tRNA synthetase gene (GARS) is involved in Charcot-Marie-Tooth", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if the glycyl-tRNA synthetase gene is involved in Charcot-Marie-Tooth (CMT) disease. Looking at the evidence provided, there are two documents that mention this. First, document 25420567 has two chunks. Both chunks mention a mutation in the glycyl-tRNA synthetase gene causing CMT2D. The second document, 22144914, specifically states that CMT2D is dominantly inherited and caused by missense mutations in the GARS gene. It also notes that other tRNA synthetase genes can cause similar neuropathies, but mechanisms aren't fully understood. So, the answer should confirm that the glycyl-tRNA synthetase gene (GARS) is indeed involved in CMT2D. The citations from both documents support this. The confidence level is high because two separate sources back this claim. I need to make sure the answer is concise and includes the correct document chunks. Also, the base_confidence should be a float, probably 0.95 or higher since there", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if the glycyl-tRNA synthetase gene is involved in Charcot-Marie-Tooth (CMT) disease. Looking at the evidence provided, there are two documents that mention this. First, document 25420567 has two chunks. Both chunks mention a mutation in glycyl-tRNA synthetase causing CMT2D. The second document, 22144914, specifically states that CMT2D is dominantly inherited and caused by missense mutations in the GARS gene. It also notes that other tRNA synthetase genes can cause similar neuropathies, but mechanisms aren't fully understood. So, the answer should confirm that the gene is involved. The confidence level is high because two separate sources directly link the mutation to CMT2D. The base confidence would be 1.0 since the evidence clearly supports this. The answer needs to cite the relevant documents. The first chunk from 25420567 and the second document 22144914_2 are key here. I", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["12690580", "16982418", "17035524", "17545306", "19470612", "22144914", "23279345", "23990368", "24368416", "24669931", "24898252", "25168514", "25420567"], "ideal_answer": "Dominant mutations in GARS, encoding the essential enzyme glycyl-tRNA synthetase (GlyRS), result in a form of Charcot-Marie-Tooth disease, type 2D (CMT2D), predominantly characterized by lower motor nerve degeneration. Charcot-Marie-Tooth disease type 2D (CMT2D) is an autosomal-dominant axonal peripheral neuropathy characterized by impaired motor and sensory function in the distal extremities. Mutations in the glycyl-tRNA synthetase (GARS) gene cause CMT2D"}
{"question_id": "5311cdcce3eabad021000007", "question": "Is there any software for automated analysis of FISH images?", "retrieved_chunks": [{"doc_id": "21310746", "chunk_id": "21310746_0", "score": 7.469486713409424, "text": "Fluorescence in situ hybridization (FISH) is used to study the organization and the positioning of specific DNA sequences within the cell nucleus. Analyzing the data from FISH images is a tedious process that invokes an element of subjectivity. Automated FISH image analysis offers savings in time as well as gaining the benefit of objective data analysis. While several FISH image analysis software tools have been developed, they often use a threshold-based segmentation algorithm for nucleus segmentation. As fluorescence signal intensities can vary significantly from experiment to experiment, from cell to cell, and within a cell, threshold-based segmentation is inflexible and often insufficient for automatic image analysis, leading to additional manual segmentation and potential subjective bias. To overcome these problems, we developed a graphical software tool called FISH Finder to automatically analyze FISH images that vary significantly. By posing the nucleus segmentation as a classification problem, compound Bayesian classifier is employed so that contextual information is utilized, resulting in reliable classification and boundary extraction. This makes it possible to analyze FISH images efficiently and objectively without adjustment of input parameters. Additionally, FISH Finder was designed to analyze the distances between differentially stained FISH probes."}, {"doc_id": "22935778", "chunk_id": "22935778_1", "score": 3.9800524711608887, "text": "hybridization (FISH) tests provide promising molecular imaging biomarkers to more accurately and reliably detect and diagnose cancers and genetic disorders. Since current manual FISH signal analysis is low-efficient and inconsistent, which limits its clinical utility, developing automated FISH image scanning systems and computer-aided detection (CAD) schemes has been attracting research interests. To acquire high-resolution FISH images in a multi-spectral scanning mode, a huge amount of image data with the stack of the multiple three-dimensional (3-D) image slices is generated from a single specimen. Automated preprocessing these scanned images to eliminate the non-useful and redundant data is important to make the automated FISH tests acceptable in clinical applications. In this study, a dual-detector fluorescence image scanning system was applied to scan four specimen slides with FISH-probed chromosome X. A CAD scheme was developed to detect analyzable interphase cells and map the multiple imaging slices recorded FISH-probed signals into the 2-D projection images. CAD scheme was then applied to each projection image to detect analyzable interphase cells using an adaptive multiple-threshold algorithm, identify FISH-probed signals using a top-hat transform, and compute the ratios between the normal and abnormal cells. To assess CAD performance, the FISH-probed signals were also independently visually detected by an observer. The Kappa coefficients for agreement between CAD and observer ranged from 0.69 to 1.0 in detecting/counting FISH signal spots in four testing samples."}, {"doc_id": "22935778", "chunk_id": "22935778_0", "score": 3.720496654510498, "text": "he study demonstrated the feasibility of automated FISH signal analysis that applying a CAD scheme to the automated generated 2-D projection images."}], "context": "[21310746:21310746_0] Fluorescence in situ hybridization (FISH) is used to study the organization and the positioning of specific DNA sequences within the cell nucleus. Analyzing the data from FISH images is a tedious process that invokes an element of subjectivity. Automated FISH image analysis offers savings in time as well as gaining the benefit of objective data analysis. While several FISH image analysis software tools have been developed, they often use a threshold-based segmentation algorithm for nucleus segmentation. As fluorescence signal intensities can vary significantly from experiment to experiment, from cell to cell, and within a cell, threshold-based segmentation is inflexible and often insufficient for automatic image analysis, leading to additional manual segmentation and potential subjective bias. To overcome these problems, we developed a graphical software tool called FISH Finder to automatically analyze FISH images that vary significantly. By posing the nucleus segmentation as a classification problem, compound Bayesian classifier is employed so that contextual information is utilized, resulting in reliable classification and boundary extraction. This makes it possible to analyze FISH images efficiently and objectively without adjustment of input parameters. Additionally, FISH Finder was designed to analyze the distances between differentially stained FISH probes.\n[22935778:22935778_1] hybridization (FISH) tests provide promising molecular imaging biomarkers to more accurately and reliably detect and diagnose cancers and genetic disorders. Since current manual FISH signal analysis is low-efficient and inconsistent, which limits its clinical utility, developing automated FISH image scanning systems and computer-aided detection (CAD) schemes has been attracting research interests. To acquire high-resolution FISH images in a multi-spectral scanning mode, a huge amount of image data with the stack of the multiple three-dimensional (3-D) image slices is generated from a single specimen. Automated preprocessing these scanned images to eliminate the non-useful and redundant data is important to make the automated FISH tests acceptable in clinical applications. In this study, a dual-detector fluorescence image scanning system was applied to scan four specimen slides with FISH-probed chromosome X. A CAD scheme was developed to detect analyzable interphase cells and map the multiple imaging slices recorded FISH-probed signals into the 2-D projection images. CAD scheme was then applied to each projection image to detect analyzable interphase cells using an adaptive multiple-threshold algorithm, identify FISH-probed signals using a top-hat transform, and compute the ratios between the normal and abnormal cells. To assess CAD performance, the FISH-probed signals were also independently visually detected by an observer. The Kappa coefficients for agreement between CAD and observer ranged from 0.69 to 1.0 in detecting/counting FISH signal spots in four testing samples.\n[22935778:22935778_0] he study demonstrated the feasibility of automated FISH signal analysis that applying a CAD scheme to the automated generated 2-D projection images.", "answer": "<think> Okay, let's tackle this question. The user is asking if there's any software for automated analysis of FISH images. I need to look through the provided evidence to find mentions of such software. Looking at the first document (21310746:21310746_0), it talks about a tool called FISH Finder. That seems like a direct answer. The description says it's a graphical software tool developed to automatically analyze FISH images, using a compound Bayesian classifier. So that's one example. The second document (22935778:22935778_1) mentions automated FISH image scanning systems and computer-aided detection (CAD) schemes. While it doesn't name specific software, it does talk about a CAD scheme developed in the study. However, since the question is about existing software, maybe this is more of a research effort rather than an established tool. But the third part of that document (22935778:22935778_0) says the study demonstrated the feasibility of automated FISH signal", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if there's any software for automated analysis of FISH images. I need to look through the provided evidence to find mentions of such software. Looking at the first document (21310746:21310746_0), it talks about a tool called FISH Finder. That seems like a direct answer. The description says it's a graphical software tool developed to automatically analyze FISH images, using a compound Bayesian classifier. So that's one example. The second document (22935778:22935778_1) mentions automated FISH image scanning systems and computer-aided detection (CAD) schemes. While it doesn't name specific software, it does talk about a CAD scheme developed in the study. However, since the question is about existing software, maybe this is more of a research effort rather than an established tool. But the third part of that document (22935778:22935778_0) says the study demonstrated the feasibility of automated FISH signal", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to generate a JSON answer based on the provided evidence. The question is whether there's any software for automated analysis of FISH images. Looking at the evidence, the first document mentions \"FISH Finder\" as a graphical software tool developed to automatically analyze FISH images. It uses a compound Bayesian classifier for nucleus segmentation, which is different from threshold-based methods. That's a clear example of software. The second document talks about developing automated FISH image scanning systems and CAD schemes. While it doesn't name specific software, it mentions a dual-detector system and a CAD scheme. However, the first document specifically names FISH Finder, so that's a direct answer. The third document also refers to the feasibility of automated analysis using CAD schemes but again doesn't name software. So the main citation here is the first one about FISH Finder. I need to make sure the answer is concise and includes the citation. The base confidence should be high since the first document explicitly mentions the software. The confidence level would be 1.0 because the evidence directly states that FISH Finder exists as such a tool. </thi", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if there's any software for automated analysis of FISH images. I need to look through the provided evidence to find mentions of specific software. Looking at the first document (21310746:21310746_0), it talks about a tool called FISH Finder. That's a direct mention of software. The description says it's developed to automatically analyze FISH images, using a compound Bayesian classifier for nucleus segmentation. So that's one example. The second document (22935778:22935778_1) mentions automated FISH image scanning systems and computer-aided detection (CAD) schemes. While it doesn't name a specific software, it describes a CAD scheme developed in the study. However, the answer needs to be concise with citations. Since the first document explicitly names FISH Finder, that's the primary evidence. The third document (22935778:22935778_0) again refers to automated FISH signal analysis using a CAD scheme,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["11818019", "15351517", "15887538", "16749443", "17674627", "17889539", "20639591", "20966547", "21310746", "21656271", "22163442", "22665392", "22935778", "23903043", "24240725"], "ideal_answer": "FISH is a popular molecular cytogenetic method. The output of a single FISH analysis is a set of several tens or hundreds microscopic images — a single evaluated sample is of roughly 20mm diameter. The goal of an automated evaluation is to replace the subjective evaluation of images by the laboratory technician to achieve higher uniformity of results. Following explanation of the principle of the method and the typical contents of images, the processing flow of image segmentation is outlined and the results are presented on several example images. Based on results there are software for automated analysis of FISH images."}
{"question_id": "51659356298dcd4e5100005a", "question": "How do histone methyltransferases cause histone modification?", "retrieved_chunks": [{"doc_id": "32762486", "chunk_id": "32762486_0", "score": 7.150076866149902, "text": "Histone methylation modification affects chromatin through the addition of methyl groups to lysine or arginine residues of histones H3 and H4 by means of histone methyl transferases or histone demethylases."}, {"doc_id": "22483804", "chunk_id": "22483804_0", "score": 6.639518737792969, "text": "Histone methyltransferases catalyze site-specific deposition of methyl groups, enabling recruitment of transcriptional regulators. In mammals, trimethylation of lysine 4 in histone H3, a modification localized at the transcription start sites of active genes, is catalyzed by six enzymes (SET1a and SET1b, MLL1-MLL4) whose specific functions are largely unknown."}, {"doc_id": "17517655", "chunk_id": "17517655_0", "score": 6.20196533203125, "text": "histone modification is catalyzed by protein lysine methyltransferases (PKMTs). PKMTs contain a conserved SET domain"}], "context": "[32762486:32762486_0] Histone methylation modification affects chromatin through the addition of methyl groups to lysine or arginine residues of histones H3 and H4 by means of histone methyl transferases or histone demethylases.\n[22483804:22483804_0] Histone methyltransferases catalyze site-specific deposition of methyl groups, enabling recruitment of transcriptional regulators. In mammals, trimethylation of lysine 4 in histone H3, a modification localized at the transcription start sites of active genes, is catalyzed by six enzymes (SET1a and SET1b, MLL1-MLL4) whose specific functions are largely unknown.\n[17517655:17517655_0] histone modification is catalyzed by protein lysine methyltransferases (PKMTs). PKMTs contain a conserved SET domain", "answer": "<think> Okay, I need to generate a biomedical answer about how histone methyltransferases cause histone modification. Let me look at the evidence provided. First, the user provided three documents. Let me parse each one. Document 32762486: It says that histone methylation involves adding methyl groups to lysine or arginine residues of H3 and H4 by histone methyltransferases or demethylases. So this explains the mechanism, mentioning the addition of methyl groups by these enzymes. Document 22483804: Talks about methyltransferases catalyzing site-specific deposition of methyl groups, allowing recruitment of transcriptional regulators. It also gives an example of trimethylation of K4 in H3 by specific enzymes like SET1a, SET1b, MLL1-MLL4. This shows the role in gene regulation. Document 17517655: States that histone modification is catalyzed by PKMTs, which have a conserved SET domain. This connects the enzyme (PKMTs) to the mechanism involving the SET domain. Now, the answer needs to", "citations": [], "candidates": [{"answer": "<think> Okay, I need to generate a biomedical answer about how histone methyltransferases cause histone modification. Let me look at the evidence provided. First, the user provided three documents. Let me parse each one. Document 32762486: It says that histone methylation involves adding methyl groups to lysine or arginine residues of H3 and H4 by histone methyltransferases or demethylases. So this explains the mechanism, mentioning the addition of methyl groups by these enzymes. Document 22483804: Talks about methyltransferases catalyzing site-specific deposition of methyl groups, allowing recruitment of transcriptional regulators. It also gives an example of trimethylation of K4 in H3 by specific enzymes like SET1a, SET1b, MLL1-MLL4. This shows the role in gene regulation. Document 17517655: States that histone modification is catalyzed by PKMTs, which have a conserved SET domain. This connects the enzyme (PKMTs) to the mechanism involving the SET domain. Now, the answer needs to", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user wants to know how histone methyltransferases cause histone modification. The evidence provided has three chunks. First, chunk 32762486 says that histone methylation involves adding methyl groups to lysine or arginine residues of H3 and H4 by histone methyl transferases or demethylases. So that's a direct statement about the mechanism. Chunk 22483804 explains that these enzymes catalyze site-specific deposition of methyl groups, allowing recruitment of transcriptional regulators. It also mentions specific examples like trimethylation of K4 in H3 by certain enzymes. This shows the functional role of these enzymes in modifying histones and their impact on gene expression. Chunk 17517655 states that histone modification is done by PKMTs, which have a conserved SET domain. The SET domain is important for the enzymatic activity here. Putting this together, the answer should mention that histone methyltransferases add methyl groups to specific residues (like K4 in H3) via their SET domains, leading to chromatin changes and", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, the user is asking how histone methyltransferases cause histone modification. Let me look at the evidence provided. First, the evidence from 32762486 says that histone methylation involves adding methyl groups to lysine or arginine residues of H3 and H4 by histone methyl transferases or demethylases. So that's a direct statement about the mechanism. Then, 22483804 explains that these enzymes catalyze site-specific deposition of methyl groups, allowing transcriptional regulators to recruit. It mentions specific examples like trimethylation of K4 in H3 by certain enzymes. This shows the process of adding methyl groups and its functional role. The third evidence, 17517655, states that histone modification is done by PKMTs containing a conserved SET domain. The SET domain is a key structural feature in these enzymes, so that's important for the mechanism. Putting this together, the answer should mention that histone methyltransferases add methyl groups to specific residues (like K4 in H3) via their SET domains, which then allows transcriptional regulators", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["11316813", "11850410", "12154089", "12893173", "14690609", "15775980", "16409643", "16581777", "17468742", "17548343", "17584191", "17846168", "18058811", "18231586", "18498648", "18846226", "19571682", "20026581", "20305384", "22357272", "22393255", "22476432", "22483804", "23150054", "23195220"], "ideal_answer": "Histone methyltransferases (HMTs) are responsible for the site-specific addition of covalent modifications on the histone tails, which serve as markers for the recruitment of chromatin organization complexes. There are two major types of HMTs: histone-lysine N-Methyltransferases and histone-arginine N-methyltransferases. The former methylate specific lysine (K) residues such as 4, 9, 27, 36, and 79 on histone H3 and residue 20 on histone H4. The latter methylate arginine (R) residues such as 2, 8, 17, and 26 on histone H3 and residue 3 on histone H4. Depending on what residue is modified and the degree of methylation (mono-, di- and tri-methylation), lysine methylation of histones is linked to either transcriptionally active or silent chromatin."}
{"question_id": "54ede5df94afd61504000007", "question": "Is there an increased risk for cancer in Dyskeratosis Congenita?", "retrieved_chunks": [{"doc_id": "23619122", "chunk_id": "23619122_1", "score": 9.735652923583984, "text": "Patients with dyskeratosis congenita (DC) have an increased risk of cancer, but also exhibit heightened radiation sensitivity."}, {"doc_id": "23619122", "chunk_id": "23619122_0", "score": 9.648103713989258, "text": "Patients with dyskeratosis congenita (DC) have an increased risk of cancer, but also exhibit heightened radiation sensitivity"}, {"doc_id": "22932338", "chunk_id": "22932338_2", "score": 8.47535514831543, "text": "Dyskeratosis congenita is a rare condition; however, it is vital to recognise the increased risk of upper aerodigestive tract cancers in these patients."}], "context": "[23619122:23619122_1] Patients with dyskeratosis congenita (DC) have an increased risk of cancer, but also exhibit heightened radiation sensitivity.\n[23619122:23619122_0] Patients with dyskeratosis congenita (DC) have an increased risk of cancer, but also exhibit heightened radiation sensitivity\n[22932338:22932338_2] Dyskeratosis congenita is a rare condition; however, it is vital to recognise the increased risk of upper aerodigestive tract cancers in these patients.", "answer": "<think> Okay, I need to generate a JSON answer based on the evidence provided. The question is whether there's an increased cancer risk in Dyskeratosis Congenita. Looking at the evidence, there are three chunks. The first two chunks (23619122:23619122_1 and 0) both state that patients with DC have an increased risk of cancer and heightened radiation sensitivity. The third chunk (22932338:22932338_2) mentions that DC is rare but important to recognize the increased risk of upper aerodigestive tract cancers. So, the answer should confirm the increased cancer risk. The citations are from documents 23619122 and 22932338. The base confidence is high because multiple sources mention the increased risk. I'll combine the chunks into a concise answer, citing the relevant documents. The confidence level should be 1.0 since all evidence points to the same conclusion. </think> { \"answer\": \"Yes, patients with Dyskeratosis Congenita (DC", "citations": [], "candidates": [{"answer": "<think> Okay, I need to generate a JSON answer based on the evidence provided. The question is whether there's an increased cancer risk in Dyskeratosis Congenita. Looking at the evidence, there are three chunks. The first two chunks (23619122:23619122_1 and 0) both state that patients with DC have an increased risk of cancer and heightened radiation sensitivity. The third chunk (22932338:22932338_2) mentions that DC is rare but important to recognize the increased risk of upper aerodigestive tract cancers. So, the answer should confirm the increased cancer risk. The citations are from documents 23619122 and 22932338. The base confidence is high because multiple sources mention the increased risk. I'll combine the chunks into a concise answer, citing the relevant documents. The confidence level should be 1.0 since all evidence points to the same conclusion. </think> { \"answer\": \"Yes, patients with Dyskeratosis Congenita (DC", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. The question is whether there's an increased cancer risk in Dyskeratosis Congenita. Let me look at the evidence provided. The first two entries from 23619122 both state that patients with DC have an increased risk of cancer and are radiation sensitive. The third entry from 22932338 mentions that DC is rare but important to recognize the increased risk of upper aerodigestive tract cancers. So, all three pieces of evidence point to an increased cancer risk. The answer should be concise, citing the relevant documents. The base confidence is high since multiple sources agree. I should pick the most relevant citations. Maybe use 23619122_0 and 22932338_2. The confidence level would be 1.0 because all evidence supports the claim without contradiction. </think> { \"answer\": \"Yes, patients with dyskeratosis congenita (DC) have an increased risk of cancer, as noted in [23619122:2", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user wants to know if there's an increased cancer risk in Dyskeratosis Congenita. The evidence provided has three chunks. First, I need to check each chunk for relevant information. The first two chunks (23619122_1 and 23619122_0) both state that patients with DC have an increased risk of cancer. They also mention heightened radiation sensitivity, but the question is about cancer risk, so that's extra info. The third chunk (22932338_2) emphasizes that DC is rare but important to recognize the increased risk of upper aerodigestive tract cancers. So all three pieces of evidence support the idea that there's an increased cancer risk. The answer should be concise, citing the relevant chunks. The confidence level should be high since multiple sources agree. I need to make sure the answer includes the correct document IDs and chunk IDs. Let me structure the JSON accordingly. </think> { \"answer\": \"Yes, patients with dyskeratosis congenita (DC) have an increased risk of cancer, as", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["17825470", "18054794", "18938267", "19327580", "19558498", "20301779", "20507306", "20925138", "22058220", "22362038", "22932338", "23352883", "23541441", "23619122", "24034063"], "ideal_answer": "People with DC are at increased risk for progressive bone marrow failure (BMF), myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML), solid tumors (usually squamous cell carcinoma of the head/neck or anogenital cancer), and pulmonary fibrosis Yes. Clinical progression of the disease can lead to aplastic anemia (86% of all patients) and to pulmonary or hepatic complications. These patients also have an increased risk of cancer. Adverse events include severe bone marrow failure (BMF), myelodysplastic syndrome (MDS), acute myeloid leukaemia (AML), and solid tumours (ST) People with Dyskeratosis Congenita are at increased risk for progressive bone marrow failure (BMF), myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML), solid tumors (usually squamous cell carcinoma of the head/neck or anogenital cancer), and pulmonary fibrosis."}
{"question_id": "54f4703764850a5854000008", "question": "Does MicroRNA-21 (miR-21) contribute to cardiovascular disease?", "retrieved_chunks": [{"doc_id": "20560046", "chunk_id": "20560046_2", "score": 9.697111129760742, "text": "MicroRNA-21 (miR-21) is a highly expressed microRNA (miRNA) in cardiovascular system. Recent studies have revealed that its expression is deregulated in heart and vasculature under cardiovascular disease conditions such as proliferative vascular disease, cardiac hypertrophy and heart failure, and ischemic heart disease. miR-21 is found to play important roles in vascular smooth muscle cell proliferation and apoptosis, cardiac cell growth and death, and cardiac fibroblast functions. Accordingly, miR-21 is proven to be involved in the pathogenesis of the above-mentioned cardiovascular diseases as demonstrated by both loss-of-function and gain-of-function approaches."}, {"doc_id": "21712654", "chunk_id": "21712654_1", "score": 8.08331298828125, "text": "The small regulatory RNA microRNA-21 (miR-21) plays a crucial role in a plethora of biological functions and diseases including development, cancer, cardiovascular diseases and inflammation."}, {"doc_id": "19043405", "chunk_id": "19043405_2", "score": 8.05282211303711, "text": "Our results validate miR-21 as a disease target in heart failure and establish the therapeutic efficacy of microRNA therapeutic intervention in a cardiovascular disease setting."}], "context": "[20560046:20560046_2] MicroRNA-21 (miR-21) is a highly expressed microRNA (miRNA) in cardiovascular system. Recent studies have revealed that its expression is deregulated in heart and vasculature under cardiovascular disease conditions such as proliferative vascular disease, cardiac hypertrophy and heart failure, and ischemic heart disease. miR-21 is found to play important roles in vascular smooth muscle cell proliferation and apoptosis, cardiac cell growth and death, and cardiac fibroblast functions. Accordingly, miR-21 is proven to be involved in the pathogenesis of the above-mentioned cardiovascular diseases as demonstrated by both loss-of-function and gain-of-function approaches.\n[21712654:21712654_1] The small regulatory RNA microRNA-21 (miR-21) plays a crucial role in a plethora of biological functions and diseases including development, cancer, cardiovascular diseases and inflammation.\n[19043405:19043405_2] Our results validate miR-21 as a disease target in heart failure and establish the therapeutic efficacy of microRNA therapeutic intervention in a cardiovascular disease setting.", "answer": "<think> Okay, let's tackle this question. The user wants to know if MicroRNA-21 (miR-21) contributes to cardiovascular disease. The evidence provided has three documents. First, looking at document 20560046:20560046_2. It says miR-21 is highly expressed in the cardiovascular system and its expression is deregulated in various cardiovascular diseases like heart failure, hypertension, and ischemic heart disease. It also mentions that miR-21 plays roles in vascular smooth muscle cell proliferation, cardiac cell growth and death, and fibroblast functions. The document states that miR-21 is involved in the pathogenesis of these diseases through loss-of-function and gain-of-function studies. That's pretty strong evidence. Next, document 21712654:21712654_1 mentions that miR-21 is involved in cardiovascular diseases along with other diseases like cancer and inflammation. This supports the idea that it contributes to cardiovascular disease. Document 19043405:1904340", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user wants to know if MicroRNA-21 (miR-21) contributes to cardiovascular disease. The evidence provided has three documents. First, looking at document 20560046:20560046_2. It says miR-21 is highly expressed in the cardiovascular system and its expression is deregulated in various cardiovascular diseases like heart failure, hypertension, and ischemic heart disease. It also mentions that miR-21 plays roles in vascular smooth muscle cell proliferation, cardiac cell growth and death, and fibroblast functions. The document states that miR-21 is involved in the pathogenesis of these diseases through loss-of-function and gain-of-function studies. That's pretty strong evidence. Next, document 21712654:21712654_1 mentions that miR-21 is involved in cardiovascular diseases along with other diseases like cancer and inflammation. This supports the idea that it contributes to cardiovascular disease. Document 19043405:1904340", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if MicroRNA-21 (miR-21) contributes to cardiovascular disease. I need to look at the evidence provided. First, the first document says that miR-21 is highly expressed in the cardiovascular system and its expression is deregulated in various cardiovascular diseases like heart failure, cardiac hypertrophy, and ischemic heart disease. It also mentions that miR-21 plays roles in vascular smooth muscle cell proliferation, apoptosis, cardiac cell growth and death, and fibroblast functions. The study uses both loss-of-function and gain-of-function approaches to show its involvement in pathogenesis. The second document states that miR-21 is involved in cardiovascular diseases along with other conditions like cancer and inflammation. That's a direct mention of contributing to cardiovascular disease. The third document talks about miR-21 being a target in heart failure and validates therapeutic intervention in cardiovascular disease settings. This supports the idea that it's related to the disease. So, all three documents point to miR-21's role in cardiovascular diseases. The answer should be yes, with citations from all three sour", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if MicroRNA-21 (miR-21) contributes to cardiovascular disease. I need to look at the provided evidence to form a concise answer with citations and a confidence level. First, I'll check each document. Document 20560046: This one says miR-21 is highly expressed in the cardiovascular system and its expression is deregulated in various cardiovascular diseases like heart failure, cardiac hypertrophy, etc. It also mentions roles in vascular smooth muscle cell proliferation, apoptosis, cardiac cell growth/death, and fibroblast functions. They even mention that loss-of-function and gain-of-function studies show it's involved in the pathogenesis of these diseases. That seems pretty strong evidence. Document 21712654: This states that miR-21 is involved in cardiovascular diseases along with other conditions like cancer and inflammation. So this supports the idea that it contributes to cardiovascular disease. Document 19043405: This talks about miR-21 being a target in heart failure and therapeutic efficacy in cardiovascular disease.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["19043405", "19336275", "19706597", "20015039", "20219857", "20560046", "20649511", "20959496", "20980922", "21464712", "21712654", "22038740", "22859901", "22882958", "22960625", "23691029"], "ideal_answer": "MicroRNA-21 (miR-21) is a highly expressed microRNA (miRNA) in cardiovascular system. Recent studies have revealed that its expression is deregulated in heart and vasculature under cardiovascular disease conditions such as proliferative vascular disease, cardiac hypertrophy and heart failure, and ischemic heart disease. miR-21 is found to play important roles in vascular smooth muscle cell proliferation and apoptosis, cardiac cell growth and death, and cardiac fibroblast functions. Accordingly, miR-21 is proven to be involved in the pathogenesis of the above-mentioned cardiovascular diseases as demonstrated by both loss-of-function and gain-of-function approaches"}
{"question_id": "552421082c8b63434a000005", "question": "What is the enzymatic activity of the breast cancer associated gene BRCA1?", "retrieved_chunks": [{"doc_id": "16479151", "chunk_id": "16479151_0", "score": 6.5967020988464355, "text": "Discovering the precise function of the breast and ovarian specific tumor suppressor, BRCA1, has proven to be quite complicated. It has been determined that BRCA1, together with BARD1, comprise an E3 ubiquitin ligase. Since it is now known that BRCA1 is an enzyme, the challenge for BRCA1 research is to learn how this enzymatic activity functions in normal breast and ovarian cells in order to suppress cancerous transformation."}, {"doc_id": "20681793", "chunk_id": "20681793_0", "score": 6.250486373901367, "text": "E3-ubiquitin ligase activity is the only known enzymatic activity of BRCA1, which is mediated by the N-terminal RING finger domain."}, {"doc_id": "24278741", "chunk_id": "24278741_0", "score": 6.209160804748535, "text": "BRCA1 nuclear transport and ubiquitin E3 ligase enzymatic activity are tightly regulated by the BRCA1 dimeric binding partner BARD1 and further modulated by cancer mutations and diverse signaling pathways."}], "context": "[16479151:16479151_0] Discovering the precise function of the breast and ovarian specific tumor suppressor, BRCA1, has proven to be quite complicated. It has been determined that BRCA1, together with BARD1, comprise an E3 ubiquitin ligase. Since it is now known that BRCA1 is an enzyme, the challenge for BRCA1 research is to learn how this enzymatic activity functions in normal breast and ovarian cells in order to suppress cancerous transformation.\n[20681793:20681793_0] E3-ubiquitin ligase activity is the only known enzymatic activity of BRCA1, which is mediated by the N-terminal RING finger domain.\n[24278741:24278741_0] BRCA1 nuclear transport and ubiquitin E3 ligase enzymatic activity are tightly regulated by the BRCA1 dimeric binding partner BARD1 and further modulated by cancer mutations and diverse signaling pathways.", "answer": "<think> Okay, let's tackle this question. The user is asking about the enzymatic activity of the BRCA1 gene, which is associated with breast cancer. First, I need to look at the provided evidence. There are three documents here. Let me go through each one. Document 16479151: It mentions that BRCA1, along with BARD1, forms an E3 ubiquitin ligase. Also, it states that BRCA1 is an enzyme, but the exact function is still being studied. This suggests that E3 ubiquitin ligase activity is part of its enzymatic role. Document 20681793: This one specifically says that the only known enzymatic activity of BRCA1 is E3-ubiquitin ligase, mediated by the N-terminal RING finger domain. That's a direct statement about the enzymatic activity. Document 24278741: It talks about how BRCA1's nuclear transport and ubiquitin E3 ligase activity are regulated by BARD1 and other factors. This reinforces that the E3 ligase activity is indeed the enzymatic", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking about the enzymatic activity of the BRCA1 gene, which is associated with breast cancer. First, I need to look at the provided evidence. There are three documents here. Let me go through each one. Document 16479151: It mentions that BRCA1, along with BARD1, forms an E3 ubiquitin ligase. Also, it states that BRCA1 is an enzyme, but the exact function is still being studied. This suggests that E3 ubiquitin ligase activity is part of its enzymatic role. Document 20681793: This one specifically says that the only known enzymatic activity of BRCA1 is E3-ubiquitin ligase, mediated by the N-terminal RING finger domain. That's a direct statement about the enzymatic activity. Document 24278741: It talks about how BRCA1's nuclear transport and ubiquitin E3 ligase activity are regulated by BARD1 and other factors. This reinforces that the E3 ligase activity is indeed the enzymatic", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to generate a JSON answer based on the provided evidence. The question is about the enzymatic activity of BRCA1. Let me look at the evidence again. First, document 16479151 says that BRCA1 is part of an E3 ubiquitin ligase with BARD1. Then, document 20681793 specifically mentions that the only known enzymatic activity of BRCA1 is E3-ubiquitin ligase activity mediated by the N-terminal RING finger domain. The third document talks about regulation by BARD1 and mutations but doesn't specify the enzymatic activity. So the main point here is that the enzymatic activity is E3 ubiquitin ligase. The confidence should be high because two documents directly state this. The first one mentions it as a complex, but the second confirms it's the only known activity. So I can combine those references. The answer should include the key points and cite the relevant chunks. </think> { \"answer\": \"BRCA1 exhibits E3-ubiquitin ligase enzymatic activity, mediated by its N-terminal RING finger", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. The question is about the enzymatic activity of BRCA1. Looking at the evidence, the first document says that BRCA1 is an enzyme and part of an E3 ubiquitin ligase with BARD1. The second document specifically mentions that the only known enzymatic activity of BRCA1 is E3-ubiquitin ligase activity mediated by the N-terminal RING finger domain. The third document reinforces this by talking about BRCA1's ubiquitin E3 ligase activity being regulated by BARD1 and other factors. So the main point here is that the enzymatic activity of BRCA1 is as an E3 ubiquitin ligase, specifically using the RING finger domain. The confidence should be high because two documents directly state this. The answer needs to be concise with citations. The base confidence can be 0.95 since it's supported by multiple sources. </think> { \"answer\": \"BRCA1 exhibits E3-ubiquitin ligase activity, mediated by its N-terminal RING finger domain [20681793:", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["15254397", "16479151", "16710298", "17420471", "19088202", "20681793", "22034435", "24278741"], "ideal_answer": "E3-ubiquitin ligase activity is the only known enzymatic activity of BRCA1, which is mediated by the N-terminal RING finger domain.BRCA1 nuclear transport and ubiquitin E3 ligase enzymatic activity are tightly regulated by the BRCA1 dimeric binding partner BARD1 and further modulated by cancer mutations and diverse signaling pathways. Discovering the precise function of the breast and ovarian specific tumor suppressor, BRCA1, has proven to be quite complicated. The protein encoded by BRCA1 interacts in vivo with the related BARD1 protein to form a heterodimeric complex that acts as a ubiquitin E3 ligase. E3-ubiquitin ligase activity is the only known enzymatic activity of BRCA1, which is mediated by the N-terminal RING finger domain."}
{"question_id": "5505b9ff8e1671127b000001", "question": "List markers for autophagy.", "retrieved_chunks": [{"doc_id": "23117929", "chunk_id": "23117929_0", "score": 7.200627326965332, "text": "autophagy marker LC3"}, {"doc_id": "22807527", "chunk_id": "22807527_0", "score": 7.200627326965332, "text": "autophagy marker LC3"}, {"doc_id": "23608825", "chunk_id": "23608825_0", "score": 7.187827110290527, "text": "the autophagy marker LC3,"}], "context": "[23117929:23117929_0] autophagy marker LC3\n[22807527:22807527_0] autophagy marker LC3\n[23608825:23608825_0] the autophagy marker LC3,", "answer": "<think> Okay, let's see. The user is asking for markers of autophagy. The evidence provided mentions LC3 multiple times as an autophagy marker. I need to generate a concise answer with citations and a confidence level. First, check the evidence. There are three entries all pointing to LC3 being a marker. So the answer should list LC3 as the main marker. The citations are from different documents but all refer to LC3. The confidence should be high since it's mentioned multiple times. Maybe 0.95 or so. Need to make sure the JSON is strict with the keys answer and base_confidence. Also, ensure that the answer is concise and correctly formatted with the citation format. Let me put that together. </think> { \"answer\": \"LC3 is a key autophagy marker [23117929:23117929_0], [22807527:22807527_0], [23608825:23608825_0].\", \"base_confidence\":", "citations": [{"doc_id": "23117929", "chunk_id": "23117929_0"}, {"doc_id": "22807527", "chunk_id": "22807527_0"}, {"doc_id": "23608825", "chunk_id": "23608825_0"}], "candidates": [{"answer": "<think> Okay, let's see. The user is asking for markers of autophagy. The evidence provided mentions LC3 multiple times as an autophagy marker. I need to generate a concise answer with citations and a confidence level. First, check the evidence. There are three entries all pointing to LC3 being a marker. So the answer should list LC3 as the main marker. The citations are from different documents but all refer to LC3. The confidence should be high since it's mentioned multiple times. Maybe 0.95 or so. Need to make sure the JSON is strict with the keys answer and base_confidence. Also, ensure that the answer is concise and correctly formatted with the citation format. Let me put that together. </think> { \"answer\": \"LC3 is a key autophagy marker [23117929:23117929_0], [22807527:22807527_0], [23608825:23608825_0].\", \"base_confidence\":", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this query. The user is asking for markers of autophagy. From the evidence provided, there are three entries mentioning LC3 as an autophagy marker. Each of these references points to LC3 being a marker. The first two entries are from the same document ID but different chunk IDs, which might be duplicates or different sections of the same source. The third entry is a different document ID but still refers to LC3. I need to make sure that LC3 is indeed the correct answer here. Autophagy markers include various proteins and processes, but the evidence specifically highlights LC3. The confidence level should be high since all the evidence points to LC3. However, I should check if there's any conflicting information, but in this case, all sources agree. So the answer should be LC3 with citations from the provided documents. The base confidence can be set to 1.0 since the evidence is consistent. </think> { \"answer\": \"LC3 is a key autophagy marker [23117929:23117929_0, 228075", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, so the user is asking for markers of autophagy. Let me look at the evidence provided. The evidence has three entries, all mentioning LC3 as an autophagy marker. The first two are from different study IDs but both cite LC3. The third one also mentions LC3 again. I need to make sure that LC3 is indeed a valid marker for autophagy. From what I remember, LC3 is a well-known marker used in the detection of autophagosomes. It's involved in the formation of the autophagosomal membrane. So, it's a standard marker in autophagy research. The user wants a concise answer with citations. The evidence has three entries, but they all point to LC3. So the answer should list LC3 as the marker, citing all the relevant documents. However, since the user said \"one candidate,\" maybe I can pick one of them. But the instructions say to use the evidence provided. Wait, the answer should be concise. The answer is just \"LC3\" with citations. The base confidence is 1.0 because all the evidence points to LC3 being a marker.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["22652752", "22807527", "23117929", "23182945", "23193914", "23437259", "23598404", "23608825", "23626658", "23727153", "23737395", "23822101", "23940944", "24126619", "24141623", "24231340", "24255881", "24291536"], "ideal_answer": "Expression of LC3-II and BECN1 as well as SQSTM1 are used as markers of autophagy activity."}
{"question_id": "56b29bf545561f0573000003", "question": "Are there any statistical methods for normalizing and identifying differential regions in histone modification ChIP-seq data?", "retrieved_chunks": [{"doc_id": "22870189", "chunk_id": "22870189_0", "score": 9.591415405273438, "text": "ChIPnorm: a statistical method for normalizing and identifying differential regions in histone modification ChIP-seq libraries."}, {"doc_id": "22870189", "chunk_id": "22870189_2", "score": 9.457307815551758, "text": "In this paper we propose a two-stage statistical method, called ChIPnorm, to normalize ChIP-seq data, and to find differential regions in the genome, given two libraries of histone modifications of different cell types. We show that the ChIPnorm method removes most of the noise and bias in the data and outperforms other normalization methods."}, {"doc_id": "22870189", "chunk_id": "22870189_1", "score": 9.222414016723633, "text": "In this paper we propose a two-stage statistical method, called ChIPnorm, to normalize ChIP-seq data, and to find differential regions in the genome, given two libraries of histone modifications of different cell types."}], "context": "[22870189:22870189_0] ChIPnorm: a statistical method for normalizing and identifying differential regions in histone modification ChIP-seq libraries.\n[22870189:22870189_2] In this paper we propose a two-stage statistical method, called ChIPnorm, to normalize ChIP-seq data, and to find differential regions in the genome, given two libraries of histone modifications of different cell types. We show that the ChIPnorm method removes most of the noise and bias in the data and outperforms other normalization methods.\n[22870189:22870189_1] In this paper we propose a two-stage statistical method, called ChIPnorm, to normalize ChIP-seq data, and to find differential regions in the genome, given two libraries of histone modifications of different cell types.", "answer": "<think> Okay, let's tackle this question. The user is asking if there are statistical methods for normalizing and identifying differential regions in histone modification ChIP-seq data. Looking at the evidence provided, there's a mention of \"ChIPnorm\" in several chunks. The first chunk directly states that ChIPnorm is a statistical method for normalization and identifying differential regions. The second and third chunks elaborate on it, explaining it's a two-stage method proposed in the paper. They also mention that it outperforms other methods and removes noise and bias. So, the answer should point to ChIPnorm as the method. The citation is from document 22870189, and the specific chunks are 0, 1, and 2. But since the answer needs to be concise with citations, I can reference the first chunk as the primary source. The confidence level should be high because the evidence clearly states that ChIPnorm is the method in question. The base_confidence would be 1.0 since the evidence directly answers the question without ambiguity. </think> { \"answer\": \"Yes, ChIPnorm is a statistical method for normal", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if there are statistical methods for normalizing and identifying differential regions in histone modification ChIP-seq data. Looking at the evidence provided, there's a mention of \"ChIPnorm\" in several chunks. The first chunk directly states that ChIPnorm is a statistical method for normalization and identifying differential regions. The second and third chunks elaborate on it, explaining it's a two-stage method proposed in the paper. They also mention that it outperforms other methods and removes noise and bias. So, the answer should point to ChIPnorm as the method. The citation is from document 22870189, and the specific chunks are 0, 1, and 2. But since the answer needs to be concise with citations, I can reference the first chunk as the primary source. The confidence level should be high because the evidence clearly states that ChIPnorm is the method in question. The base_confidence would be 1.0 since the evidence directly answers the question without ambiguity. </think> { \"answer\": \"Yes, ChIPnorm is a statistical method for normal", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, so the user is asking if there are any statistical methods for normalizing and identifying differential regions in histone modification ChIP-seq data. Let me look at the evidence provided. The evidence has three chunks from the same document, which is about the ChIPnorm method. The first chunk directly mentions that ChIPnorm is a statistical method for normalization and identifying differential regions. The second and third chunks elaborate on the two-stage approach proposed in the paper. They mention that it's used for different cell types and that it outperforms other methods. The answer needs to be concise, citing the document with chunk IDs. The base confidence should be a float between 0 and 1. Since all the evidence points to ChIPnorm being the method, I can confidently say that yes, there is such a method. The confidence would be high, maybe 0.95 or so, because the paper clearly states this. The citation should be [22870189:22870189_0] as that's where it's first mentioned. Wait, but the user wants the answer to include the citations in", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this query. The user is asking if there are statistical methods for normalizing and identifying differential regions in histone modification ChIP-seq data. First, I need to look at the provided evidence. There's one document with three chunks. Let me read through them. Chunk 22870189_0 says that ChIPnorm is a statistical method for normalization and finding differential regions in histone modification ChIP-seq libraries. That directly answers the question. Chunk 22870189_2 explains that ChIPnorm is a two-stage method proposed to normalize data and find differential regions between two cell types. It also mentions that it outperforms other methods, which adds confidence. Chunk 22870189_1 is similar to chunk 22870189_2, reiterating the proposal of ChIPnorm for normalization and differential region identification. So, all three chunks point to ChIPnorm being the method. The answer should mention ChIPnorm with citations from the document. The confidence can be high since the evidence clearly states this. The", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["22870189"], "ideal_answer": "Yes. ChIPnorm is a two-stage statistical method to normalize ChIP-seq data, and to find differential regions in the genome, given two libraries of histone modifications of different cell types."}
{"question_id": "52ef7170c8da898910000012", "question": "Is CD84 genetically associated with arthritis?", "retrieved_chunks": [{"doc_id": "23555300", "chunk_id": "23555300_0", "score": 2.0527539253234863, "text": "Our study demonstrates that an allele associated with response to etanercept therapy is also associated with CD84 gene expression, and further that CD84 expression correlates with disease activity"}, {"doc_id": "17341507", "chunk_id": "17341507_0", "score": 1.170168161392212, "text": "Anti-citrullinated peptide antibodies (ACPA) and the C1858T missense single-nucleotide polymorphism (SNP) in the PTPN22 gene are both associated with the development of rheumatoid arthritis (RA)"}, {"doc_id": "17666451", "chunk_id": "17666451_1", "score": 0.36346912384033203, "text": "HLA-DRB1 shared epitope (HLA-SE), PTPN22 and CTLA4 alleles are associated with cyclic citrullinated peptide (CCP) and rheumatoid arthritis (RA)"}], "context": "[23555300:23555300_0] Our study demonstrates that an allele associated with response to etanercept therapy is also associated with CD84 gene expression, and further that CD84 expression correlates with disease activity\n[17341507:17341507_0] Anti-citrullinated peptide antibodies (ACPA) and the C1858T missense single-nucleotide polymorphism (SNP) in the PTPN22 gene are both associated with the development of rheumatoid arthritis (RA)\n[17666451:17666451_1] HLA-DRB1 shared epitope (HLA-SE), PTPN22 and CTLA4 alleles are associated with cyclic citrullinated peptide (CCP) and rheumatoid arthritis (RA)", "answer": "<think> Okay, let's tackle this question. The user is asking if CD84 is genetically associated with arthritis. I need to look at the evidence provided. First, check the evidence documents. The first one [23555300:23555300_0] mentions that an allele linked to response to etanercept therapy is associated with CD84 gene expression and correlates with disease activity. So this suggests a connection between CD84 and arthritis, maybe rheumatoid arthritis since it's about disease activity. The second evidence [17341507:17341507_0] talks about ACPA and a SNP in PTPN22 related to RA. But that's about PTPN22, not CD84. The third one [17666451:17666452_1] mentions HLA-DRB1, PTPN22, and CTLA4 associated with CCP and RA. Again, PTPN22 and CTLA4, not CD84. So the", "citations": [{"doc_id": "23555300", "chunk_id": "23555300_0"}, {"doc_id": "17341507", "chunk_id": "17341507_0"}, {"doc_id": "17666451", "chunk_id": "17666452_1"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if CD84 is genetically associated with arthritis. I need to look at the evidence provided. First, check the evidence documents. The first one [23555300:23555300_0] mentions that an allele linked to response to etanercept therapy is associated with CD84 gene expression and correlates with disease activity. So this suggests a connection between CD84 and arthritis, maybe rheumatoid arthritis since it's about disease activity. The second evidence [17341507:17341507_0] talks about ACPA and a SNP in PTPN22 related to RA. But that's about PTPN22, not CD84. The third one [17666451:17666452_1] mentions HLA-DRB1, PTPN22, and CTLA4 associated with CCP and RA. Again, PTPN22 and CTLA4, not CD84. So the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if CD84 is genetically associated with arthritis. I need to look at the provided evidence to find any mentions of CD84 and arthritis. Looking at the first evidence snippet: [23555300:23555300_0] says that an allele linked to response to etanercept therapy is associated with CD84 gene expression, and that CD84 expression correlates with disease activity. So this suggests a connection between CD84 and disease activity, which could be related to arthritis. But the study here mentions etanercept therapy, which is used for rheumatoid arthritis, so maybe there's an association here. The second snippet [17341507:17341507_0] talks about ACPA and a SNP in PTPN22 gene being associated with RA. But that's about PTPN22, not CD84. The third snippet [17666451:1766645than_1] mentions HLA-", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, the user is asking if CD84 is genetically associated with arthritis. Let me look at the evidence provided. First, the first evidence snippet says that an allele linked to response to etanercept therapy is associated with CD84 gene expression and correlates with disease activity. So that suggests a connection between CD84 and arthritis, maybe rheumatoid arthritis since it's about disease activity. The second snippet mentions ACPA and a SNP in PTPN22 related to RA. The third one talks about HLA-DRB1, PTPN22, and CTLA4 being associated with CCP and RA. But the question is specifically about CD84. So the first evidence directly connects CD84 gene expression to disease activity, which is part of arthritis. However, the other snippets don't mention CD84. The answer should be based on the evidence given. The confidence here would be moderate because only one source directly mentions CD84, but it's in the context of disease activity. But since the question is about genetic association, and the first snippet talks about an allele associated with CD84, that's a direct", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["21094032", "21255096", "23555300"], "ideal_answer": "Three members of this gene family, Ly108, Ly9, and CD84, exhibit polymorphisms that strongly influence susceptibility to systemic autoimmunity, notably in mice, but also in some human populations. Our study demonstrates that an allele associated with response to etanercept therapy is also associated with CD84 gene expression, and further that CD84 expression correlates with Rheumatoid Arthritis disease activity."}
{"question_id": "5719f5b27de986d80d00000c", "question": "What is the function of Neu5Gc (N-Glycolylneuraminic acid)?", "retrieved_chunks": [{"doc_id": "23520510", "chunk_id": "23520510_1", "score": 7.762966156005859, "text": "N-glycolylneuraminic acid (Neu5Gc) is an immunogenic sugar of dietary origin that metabolically incorporates into diverse native glycoconjugates in humans."}, {"doc_id": "25003133", "chunk_id": "25003133_1", "score": 7.173343658447266, "text": "N-Glycolylneuraminic acid (Neu5Gc) is a sialic acid synthesized by animals, but not by humans or birds. However, it can be incorporated in human cells and can trigger immune response."}, {"doc_id": "25517696", "chunk_id": "25517696_0", "score": 7.135473728179932, "text": "Mammals express the sialic acids N-acetylneuraminic acid (Neu5Ac) and N-glycolylneuraminic acid (Neu5Gc) on cell surfaces, where they act as receptors for pathogens, including influenza A virus (IAV). Neu5Gc is synthesized from Neu5Ac by the enzyme cytidine monophosphate-N-acetylneuraminic acid hydroxylase (CMAH)."}], "context": "[23520510:23520510_1] N-glycolylneuraminic acid (Neu5Gc) is an immunogenic sugar of dietary origin that metabolically incorporates into diverse native glycoconjugates in humans.\n[25003133:25003133_1] N-Glycolylneuraminic acid (Neu5Gc) is a sialic acid synthesized by animals, but not by humans or birds. However, it can be incorporated in human cells and can trigger immune response.\n[25517696:25517696_0] Mammals express the sialic acids N-acetylneuraminic acid (Neu5Ac) and N-glycolylneuraminic acid (Neu5Gc) on cell surfaces, where they act as receptors for pathogens, including influenza A virus (IAV). Neu5Gc is synthesized from Neu5Ac by the enzyme cytidine monophosphate-N-acetylneuraminic acid hydroxylase (CMAH).", "answer": "<think> Okay, I need to generate a biomedical answer about the function of Neu5Gc based on the provided evidence. Let me start by reading through the evidence carefully. First, the user provided three documents. Document 23520510:23520510_1 says that Neu5Gc is an immunogenic sugar from dietary origin and incorporates into human glycoconjugates. Then document 25003133:25003133_1 mentions that Neu5Gc is a sialic acid synthesized by animals but not humans or birds, yet it can be incorporated into human cells and trigger immune responses. The third document, 25517696:25517696_0, states that mammals have both Neu5Ac and Neu5Gc on cell surfaces as pathogen receptors, including IAV. Neu5Gc is made from Neu5Ac via the CMAH enzyme. So, putting this together, the function of Neu5Gc seems to be related to its role as a receptor for pathogens like influenza,", "citations": [], "candidates": [{"answer": "<think> Okay, I need to generate a biomedical answer about the function of Neu5Gc based on the provided evidence. Let me start by reading through the evidence carefully. First, the user provided three documents. Document 23520510:23520510_1 says that Neu5Gc is an immunogenic sugar from dietary origin and incorporates into human glycoconjugates. Then document 25003133:25003133_1 mentions that Neu5Gc is a sialic acid synthesized by animals but not humans or birds, yet it can be incorporated into human cells and trigger immune responses. The third document, 25517696:25517696_0, states that mammals have both Neu5Ac and Neu5Gc on cell surfaces as pathogen receptors, including IAV. Neu5Gc is made from Neu5Ac via the CMAH enzyme. So, putting this together, the function of Neu5Gc seems to be related to its role as a receptor for pathogens like influenza,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question about Neu5Gc. The user wants to know its function based on the provided evidence. First, I need to look at the evidence given. There are three chunks here. Let me go through each one. The first chunk says Neu5Gc is an immunogenic sugar from dietary origin that incorporates into human glycoconjugates. So that's about it being immunogenic and part of human cells. The second chunk mentions that Neu5Gc is a sialic acid synthesized by animals but not humans or birds. However, it can be incorporated into human cells and trigger immune responses. So this adds that it's a sialic acid and that it can cause immune reactions. Third chunk states that mammals have both Neu5Ac and Neu5Gc on cell surfaces as pathogen receptors, including IAV. Also, Neu5Gc is made from Neu5Ac via the CMAH enzyme. So this links it to being a receptor for pathogens like flu virus. Now, the question is about the function of Neu5Gc. The main points from the evidence are: 1. It's a sialic", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question about Neu5Gc. The user wants a concise answer with citations and a confidence score. First, I need to look at the evidence provided. There are three chunks here. Let me read through them carefully. Chunk 23520510_1 says Neu5Gc is an immunogenic sugar from dietary origin that incorporates into human glycoconjugates. So that's one point: it's immunogenic and dietary, but how does that tie into function? Chunk 25003133_1 mentions that Neu5Gc is a sialic acid synthesized by animals but not humans or birds. However, it can be incorporated in human cells and trigger immune responses. So here, the function might be related to triggering immune responses. Chunk 25517696_0 states that mammals have both Neu5Ac and Neu5Gc on cell surfaces as pathogen receptors, including IAV. Neu5Gc is made from Neu5Ac via CMAH. So here, the function is acting as a receptor for pathogens like influenza. Putting this together:", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["11786991", "18669916", "23520510", "23945141", "25003133", "25124893"], "ideal_answer": "N-glycolylneuraminic acid (Neu5Gc) is an immunogenic sugar of dietary origin that metabolically incorporates into diverse native glycoconjugates in humans. Humans lack a functional cytidine monophosphate-N-acetylneuraminic acid hydroxylase (CMAH) protein and cannot synthesize the sugar Neu5Gc, an innate mammalian signal of self. N-Glycolylneuraminic acid (Neu5Gc) can be incorporated in human cells and can trigger immune response, a response that is diverse and polyclonal. As dietary Neu5Gc is primarily found in red meat and milk products, it is suggested that this ongoing antigen-antibody reaction may generate chronic inflammation, possibly contributing to the high frequency of diet-related carcinomas and other diseases in humans."}
{"question_id": "532f08b8d6d3ac6a34000029", "question": "Are there any specific antidotes for rivaroxaban?", "retrieved_chunks": [{"doc_id": "23866358", "chunk_id": "23866358_0", "score": 9.071479797363281, "text": "In early 2013 there is no antidote for dabigatran, rivaroxaban or apixaban, nor any specific treatment with proven efficacy for severe bleeding linked to these drugs."}, {"doc_id": "24103671", "chunk_id": "24103671_0", "score": 7.834539413452148, "text": "Novel oral anticoagulants (NOACs)--apixaban, dabigatran, and rivaroxaban--have a significantly smaller risk of intracerebral hemorrhage (ICH). However, two facts make this situation complicated: First, the risk of hematoma expansion is unknown for NOACs. Second, there is no specific antidote for neither of the NOACs."}, {"doc_id": "19351313", "chunk_id": "19351313_0", "score": 7.154416561126709, "text": "Rivaroxaban, which inhibits activated factor X (Xa), is currently in clinical trials and is the most advanced factor Xa inhibitor. The drug offers once-daily oral dosing, with no need for injections, dose titration, or frequent blood tests to monitor the international normalised ratio. It has a rapid onset of action and, although there is no specific antidote, it has a short plasma elimination half-life (about 5-9 hours)."}], "context": "[23866358:23866358_0] In early 2013 there is no antidote for dabigatran, rivaroxaban or apixaban, nor any specific treatment with proven efficacy for severe bleeding linked to these drugs.\n[24103671:24103671_0] Novel oral anticoagulants (NOACs)--apixaban, dabigatran, and rivaroxaban--have a significantly smaller risk of intracerebral hemorrhage (ICH). However, two facts make this situation complicated: First, the risk of hematoma expansion is unknown for NOACs. Second, there is no specific antidote for neither of the NOACs.\n[19351313:19351313_0] Rivaroxaban, which inhibits activated factor X (Xa), is currently in clinical trials and is the most advanced factor Xa inhibitor. The drug offers once-daily oral dosing, with no need for injections, dose titration, or frequent blood tests to monitor the international normalised ratio. It has a rapid onset of action and, although there is no specific antidote, it has a short plasma elimination half-life (about 5-9 hours).", "answer": "<think> Okay, let's tackle this question. The user is asking if there are any specific antidotes for rivaroxaban. I need to look at the provided evidence to find the answer. First, I'll check each of the three documents. Document 23866358: It says in early 2013 there was no antidote for rivaroxaban. That's a direct statement. But the date is 2013, so maybe things have changed since then? However, the other documents might have more recent info. Document 24103671: This mentions that there's no specific antidote for NOACs, including rivaroxaban. It also states that the risk of hematoma expansion is unknown. So this document confirms no specific antidote exists. Document 19351313: This says there's no specific antidote for rivaroxaban, but it's in clinical trials. The half-life is short, which might affect how it's handled if someone overdoses, but that's not an antidote. So this also supports the idea that there's", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if there are any specific antidotes for rivaroxaban. I need to look at the provided evidence to find the answer. First, I'll check each of the three documents. Document 23866358: It says in early 2013 there was no antidote for rivaroxaban. That's a direct statement. But the date is 2013, so maybe things have changed since then? However, the other documents might have more recent info. Document 24103671: This mentions that there's no specific antidote for NOACs, including rivaroxaban. It also states that the risk of hematoma expansion is unknown. So this document confirms no specific antidote exists. Document 19351313: This says there's no specific antidote for rivaroxaban, but it's in clinical trials. The half-life is short, which might affect how it's handled if someone overdoses, but that's not an antidote. So this also supports the idea that there's", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if there are any specific antidotes for rivaroxaban. I need to look at the provided evidence to find the answer. First, I'll check each of the evidence documents. The first document [23866358:23866358_0] says there's no antidote for rivaroxaban as of early 2013. The second document [24103671:24103671_0] also states there's no specific antidote for NOACs, including rivaroxaban. The third document [19351313:19351313_0] mentions that there's no specific antidote for rivaroxaban, but it's in clinical trials. All three sources consistently say there's no specific antidote. The confidence here is high because multiple documents confirm this. The model's confidence should be 1.0 since all evidence points to the same conclusion. The answer should be concise, citing the relevant documents. </think>", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if there are any specific antidotes for rivaroxaban. I need to look at the provided evidence to find the answer. First, I'll check each of the evidence chunks. The first chunk [23866358:23866358_0] says that in early 2013, there was no antidote for dabigatran, rivaroxaban, or apixaban. So that's a direct statement about rivaroxaban. The second chunk [24103671:24103671_0] also mentions that there's no specific antidote for neither of the NOACs, which includes rivaroxaban. This reinforces the first point. The third chunk [19351313:19351313_0] states that there's no specific antidote for rivaroxaban, even though it's in clinical trials. So all three sources agree that there's no specific antidote. Now, I need to make sure", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["12871541", "19351313", "20858186", "22177763", "22308807", "22353706", "23117666", "23312927", "23460104", "23628464", "23634925", "23657589", "23790307", "23810130", "23821689", "23866358", "23953907", "24103671", "24170233"], "ideal_answer": "Currently, there is no specific antidote for rivaroxaban"}
{"question_id": "5710a592cf1c32585100002a", "question": "Which metabolite activates AtxA?", "retrieved_chunks": [{"doc_id": "8577251", "chunk_id": "8577251_2", "score": 3.6464056968688965, "text": "The atxA gene product activates transcription of the anthrax toxin genes and is essential for virulence."}, {"doc_id": "21911592", "chunk_id": "21911592_0", "score": 3.059494733810425, "text": "The B. anthracis pleiotropic regulator CodY activates toxin gene expression by post-translationally regulating the accumulation of the global regulator AtxA."}, {"doc_id": "9199422", "chunk_id": "9199422_3", "score": 3.0112147331237793, "text": "Regulation of anthrax toxin activator gene (atxA) expression in Bacillus anthracis: temperature, not CO2/bicarbonate, affects AtxA synthesis."}], "context": "[8577251:8577251_2] The atxA gene product activates transcription of the anthrax toxin genes and is essential for virulence.\n[21911592:21911592_0] The B. anthracis pleiotropic regulator CodY activates toxin gene expression by post-translationally regulating the accumulation of the global regulator AtxA.\n[9199422:9199422_3] Regulation of anthrax toxin activator gene (atxA) expression in Bacillus anthracis: temperature, not CO2/bicarbonate, affects AtxA synthesis.", "answer": "<think> Okay, let's tackle this question. The user is asking which metabolite activates AtxA. The evidence provided has three chunks. First, chunk 8577251_2 says that the atxA gene product activates transcription of the anthrax toxin genes and is essential for virulence. But this talks about the gene product itself, not a metabolite. So maybe not directly relevant. Next, chunk 21911592_0 mentions CodY activating toxin gene expression by post-translationally regulating AtxA. Here, CodY is a regulator, but the question is about a metabolite. So CodY might be a protein, not a metabolite. But wait, maybe metabolites are small molecules. So this chunk might not be the answer either. Then there's chunk 9199422_3 which states that temperature, not CO2/bicarbonate, affects AtxA synthesis. This suggests that environmental factors like temperature influence AtxA production. However, the question is about a metabolite. The mention of temperature is an environmental condition, not a specific metabolite. Wait, maybe I'm missing something.", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which metabolite activates AtxA. The evidence provided has three chunks. First, chunk 8577251_2 says that the atxA gene product activates transcription of the anthrax toxin genes and is essential for virulence. But this talks about the gene product itself, not a metabolite. So maybe not directly relevant. Next, chunk 21911592_0 mentions CodY activating toxin gene expression by post-translationally regulating AtxA. Here, CodY is a regulator, but the question is about a metabolite. So CodY might be a protein, not a metabolite. But wait, maybe metabolites are small molecules. So this chunk might not be the answer either. Then there's chunk 9199422_3 which states that temperature, not CO2/bicarbonate, affects AtxA synthesis. This suggests that environmental factors like temperature influence AtxA production. However, the question is about a metabolite. The mention of temperature is an environmental condition, not a specific metabolite. Wait, maybe I'm missing something.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, the user is asking which metabolite activates AtxA. Let me look at the evidence provided. First, evidence [8577251:8577251_2] says that the atxA gene product activates transcription of the anthrax toxin genes and is essential for virulence. But this talks about the gene product itself, not a metabolite. So maybe not directly relevant. Next, [21911592:21911592_0] mentions that CodY activates toxin gene expression by regulating AtxA accumulation. Here, CodY is a regulator, but it's post-translationally regulating AtxA. However, this doesn't specify a metabolite. It might be a regulatory protein rather than a metabolite. Then there's [9199422:9199422_3], which states that temperature, not CO2/bicarbonate, affects AtxA synthesis. This suggests environmental factors like temperature influence AtxA expression, but again, not a specific metabolite. Wait, the question is about a metabolite. The evidence provided doesn't", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which metabolite activates AtxA. The evidence provided has three references. First, I need to look at each of the evidence points. The first one says that the atxA gene product activates the anthrax toxin genes and is essential for virulence. But this talks about the gene product itself, not a metabolite. So maybe not directly relevant. The second reference mentions CodY activating toxin gene expression by regulating AtxA accumulation. Here, CodY is a regulator, but it's post-translationally regulating AtxA. However, the question is about a metabolite, so maybe CodY isn't the metabolite but a regulator. But I need to check if there's a metabolite mentioned here. The third evidence says that temperature, not CO2/bicarbonate, affects AtxA synthesis. This suggests that environmental factors like temperature influence AtxA production, but it doesn't mention a specific metabolite. Wait, the question is about a metabolite that activates AtxA. The second reference talks about CodY regulating AtxA accumulation. But CodY is a regulator, not a metabolite. Maybe there", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["15149039", "17302798", "21923765", "24661624", "8577251", "9106214", "9199422", "9234759"], "ideal_answer": "Upon infection of a mammalian host, Bacillus anthracis responds to host cues, and particularly to elevated temperature (37°C) and bicarbonate/CO2 concentrations, with increased expression of virulence factors that include the anthrax toxins and extracellular capsular layer. Cultures grown with elevated CO(2) /bicarbonate exhibited increased AtxA dimer/monomer ratios and increased AtxA activity, relative to cultures grown without added CO(2) /bicarbonate, suggesting that this host-associated signal enhances AtxA function by shifting the dimer/monomer equilibrium towards the dimeric state. CO2-enhanced toxin gene transcription is not observed in atx4-null mutants. Overall data indicate a clear association of atxA with CO2-enhanced gene expression in B. anthracis and provide evidence that atxA regulates genes other than the structural genes for the anthrax toxin proteins. Comparison of the resulting protein patterns indicated that synthesis of non-toxin proteins is influenced by growth in elevated CO2 and the toxin gene regulator, atxA. The Bacillus anthracis toxin genes, cya, lef, and pag, can be viewed as a regulon, in which transcription of all three genes is activated in trans by the same regulatory gene, atxA, in response to the same signal, CO2. However, the steady-state level of atxA mRNA in cells grown in elevated CO2/bicarbonate at 37 degrees C is five- to sixfold higher than that observed in cells grown in the same conditions at 28 degrees C. A corresponding difference in AtxA protein was also seen at the different growth temperatures. All mutants multimerized, but one mutation, C402S, prevented cross-linking."}
{"question_id": "57169662cb4ef8864c000008", "question": "What is the function of 6SRNA in bacteria?", "retrieved_chunks": [{"doc_id": "23667906", "chunk_id": "23667906_1", "score": -0.18775302171707153, "text": "The release reaction depends on a characteristic property of 6S RNAs, namely to act as template for the de novo synthesis of small RNAs, termed pRNAs.Here, we used limited hydrolysis with structure-specific RNases and in-line probing of isolated 6S RNA and 6SRNA ∼ pRNA complexes to investigate the molecular details leading to the release reaction."}, {"doc_id": "23667906", "chunk_id": "23667906_0", "score": -0.4380175769329071, "text": "The release reaction depends on a characteristic property of 6S RNAs, namely to act as template for the de novo synthesis of small RNAs, termed pRNAs.Here, we used limited hydrolysis with structure-specific RNases and in-line probing of isolated 6S RNA and 6SRNA ∼ pRNA complexes to investigate the molecular details leading to the release reaction"}, {"doc_id": "21463569", "chunk_id": "21463569_0", "score": -4.963072776794434, "text": "ittle is known about the structure and function of most nucleoid-associated proteins (NAPs) in bacteria"}], "context": "[23667906:23667906_1] The release reaction depends on a characteristic property of 6S RNAs, namely to act as template for the de novo synthesis of small RNAs, termed pRNAs.Here, we used limited hydrolysis with structure-specific RNases and in-line probing of isolated 6S RNA and 6SRNA ∼ pRNA complexes to investigate the molecular details leading to the release reaction.\n[23667906:23667906_0] The release reaction depends on a characteristic property of 6S RNAs, namely to act as template for the de novo synthesis of small RNAs, termed pRNAs.Here, we used limited hydrolysis with structure-specific RNases and in-line probing of isolated 6S RNA and 6SRNA ∼ pRNA complexes to investigate the molecular details leading to the release reaction\n[21463569:21463569_0] ittle is known about the structure and function of most nucleoid-associated proteins (NAPs) in bacteria", "answer": "<think> Okay, let's tackle this question. The user is asking about the function of 6SRNA in bacteria. Looking at the evidence provided, there are a couple of documents mentioned. First, document [23667906:23667906_1] and [23667906:23667906_0] both mention that the release reaction depends on 6S RNAs acting as a template for de novo synthesis of small RNAs called pRNAs. Wait, but the question is about 6SRNA, not 6S RNA. Hmm, maybe there's a typo or confusion between 6S RNA and 6SRNA? Or perhaps they are referring to the same thing. The first two documents seem to be duplicates, talking about the same thing. The third document [21463569:21463569_0] says that little is known about NAPs in bacteria, but that's not directly related to 6SRNA. So the main evidence here is from the first two documents.", "citations": [{"doc_id": "23667906", "chunk_id": "23667906_1"}, {"doc_id": "23667906", "chunk_id": "23667906_0"}, {"doc_id": "21463569", "chunk_id": "21463569_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking about the function of 6SRNA in bacteria. Looking at the evidence provided, there are a couple of documents mentioned. First, document [23667906:23667906_1] and [23667906:23667906_0] both mention that the release reaction depends on 6S RNAs acting as a template for de novo synthesis of small RNAs called pRNAs. Wait, but the question is about 6SRNA, not 6S RNA. Hmm, maybe there's a typo or confusion between 6S RNA and 6SRNA? Or perhaps they are referring to the same thing. The first two documents seem to be duplicates, talking about the same thing. The third document [21463569:21463569_0] says that little is known about NAPs in bacteria, but that's not directly related to 6SRNA. So the main evidence here is from the first two documents.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, so the user is asking about the function of 6SRNA in bacteria. Let me look at the evidence provided. The first two documents (23667906:23667906_1 and 23667906:23667906_0) both mention that the release reaction depends on a characteristic property of 6S RNAs, which is acting as a template for de novo synthesis of small RNAs called pRNAs. The third document (21463569:21463569_0) talks about little being known about NAPs, but that's not directly related to 6SRNA. So the key point here is that 6S RNA functions as a template for making pRNAs. The documents refer to \"6S RNAs\" and \"6SRNA ∼ pRNA complexes,\" which suggests that 6SRNA is involved in the synthesis of pRNAs. The term \"de novo synthesis\" means it's creating new RNA from scratch, so the function is templating the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to figure out the function of 6SRNA in bacteria based on the provided evidence. Let me look at the evidence again. The first two documents (23667906:23667906_1 and 23667906:23667906_0) both mention that the release reaction depends on a characteristic property of 6S RNAs, which is acting as a template for de novo synthesis of small RNAs called pRNAs. The third document (21463569:21463569_0) talks about little being known about NAPs, but that's not directly related to 6SRNA. So the key point here is that 6S RNAs are involved in synthesizing pRNAs. The term \"6SRNA\" might be a variant or a specific type of 6S RNA. The answer should state that 6SRNA functions as a template for the de novo synthesis of small RNAs (pRNAs), leading to the release reaction. The confidence is", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["15262935", "17332013", "22214309", "23667906", "2579060", "58611"], "ideal_answer": "6S RNA, first described as a ncRNA in E. coli, mimics an open promoter structure, which has a large bulge with two hairpin/stalk structures that regulate transcription through interactions with RNA polymerase. Escherichia coli 6S RNA represents a non-coding RNA (ncRNA), which, based on the conserved secondary structure and previous functional studies, had been suggested to interfere with transcription. The carboxy terminus containing the Arg-Gly-Gly (RGG) repeat domains in these proteins are necessary for cis-repression of transcription activation and HAT activity by the N-terminal glutamine-rich domain. Escherichia coli 6S RNA represents a non-coding RNA (ncRNA), which, based on the conserved secondary structure and previous functional studies, had been suggested to interfere with transcription. 6S RNA-deficient cells are at a disadvantage for survival in stationary phase, a time when 6S RNA regulates transcription. 6S RNA regulation of both sigma(70) and sigma(S) activities contributes to increased cell persistence during nutrient deprivation. 6S RNA acts as a template for the transcription of defined RNA molecules in the absence of DNA. 6S RNA, first described as a ncRNA in E. coli, mimics an open promoter structure, which has a large bulge with two hairpin/stalk structures that regulate transcription through interactions with RNA polymerase. 6S RNA function enhances long-term cell survival."}
{"question_id": "54d77f0e3706e8952800001b", "question": "Is cytisine superior to nicotine replacement therapy for smoking cessation?", "retrieved_chunks": [{"doc_id": "25517706", "chunk_id": "25517706_0", "score": 9.402652740478516, "text": "CONCLUSIONS: When combined with brief behavioral support, cytisine was found to be superior to nicotine-replacement therapy in helping smokers quit smoking, but it was associated with a higher frequency of self-reported adverse events."}, {"doc_id": "25517706", "chunk_id": "25517706_1", "score": 8.057287216186523, "text": "The effectiveness of cytisine for continuous abstinence was superior to that of nicotine-replacement therapy at 1 week, 2 months, and 6 months. In a prespecified subgroup analysis of the primary outcome, cytisine was superior to nicotine-replacement therapy among women and noninferior among men."}, {"doc_id": "17698433", "chunk_id": "17698433_1", "score": 1.96224045753479, "text": "Our results showed that auricular acupuncture did not have a better efficacy in smoking cessation compared to sham acupuncture. Combined acupuncture with behavior counseling or with nicotine replacement therapy should be used in further smoking cessation trials to enhance the success rate of smoking cessation."}], "context": "[25517706:25517706_0] CONCLUSIONS: When combined with brief behavioral support, cytisine was found to be superior to nicotine-replacement therapy in helping smokers quit smoking, but it was associated with a higher frequency of self-reported adverse events.\n[25517706:25517706_1] The effectiveness of cytisine for continuous abstinence was superior to that of nicotine-replacement therapy at 1 week, 2 months, and 6 months. In a prespecified subgroup analysis of the primary outcome, cytisine was superior to nicotine-replacement therapy among women and noninferior among men.\n[17698433:17698433_1] Our results showed that auricular acupuncture did not have a better efficacy in smoking cessation compared to sham acupuncture. Combined acupuncture with behavior counseling or with nicotine replacement therapy should be used in further smoking cessation trials to enhance the success rate of smoking cessation.", "answer": "<think> Okay, let's tackle this question. The user is asking if cytisine is superior to nicotine replacement therapy (NRT) for smoking cessation. I need to look at the evidence provided. First, the first evidence chunk says that when combined with brief behavioral support, cytisine was found to be superior to NRT in helping smokers quit. Also, it mentions a higher frequency of adverse events. The second chunk adds that cytisine's effectiveness was superior at 1 week, 2 months, and 6 months. There's also a subgroup analysis showing it's better for women and non-inferior for men. The third chunk talks about auricular acupuncture not being better than sham acupuncture, but that's about a different treatment, so maybe not relevant here. So the answer should focus on the studies comparing cytisine and NRT. The key points are that cytisine is superior in some outcomes, especially with behavioral support. The confidence level would be high because there are multiple studies supporting this. But I need to check if there's any conflicting info. The third chunk doesn't mention cytisine, so it's not a factor here. Therefore,", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if cytisine is superior to nicotine replacement therapy (NRT) for smoking cessation. I need to look at the evidence provided. First, the first evidence chunk says that when combined with brief behavioral support, cytisine was found to be superior to NRT in helping smokers quit. Also, it mentions a higher frequency of adverse events. The second chunk adds that cytisine's effectiveness was superior at 1 week, 2 months, and 6 months. There's also a subgroup analysis showing it's better for women and non-inferior for men. The third chunk talks about auricular acupuncture not being better than sham acupuncture, but that's about a different treatment, so maybe not relevant here. So the answer should focus on the studies comparing cytisine and NRT. The key points are that cytisine is superior in some outcomes, especially with behavioral support. The confidence level would be high because there are multiple studies supporting this. But I need to check if there's any conflicting info. The third chunk doesn't mention cytisine, so it's not a factor here. Therefore,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. The question is whether cytisine is superior to nicotine replacement therapy (NRT) for smoking cessation. Looking at the evidence, the first document [25517706:25517706_0] says that when combined with brief behavioral support, cytisine was found to be superior to NRT. It also mentions higher adverse events. Then, [25517706:25517706_1] states that cytisine's effectiveness was superior at 1 week, 2 months, and 6 months. Subgroup analysis showed it's better for women and noninferior for men. The third document [17698433:17698433_1] talks about auricular acupuncture not being better than sham, but that's about a different treatment, so maybe not relevant here. So the answer should be that cytisine is superior to NRT, citing the first two documents. The confidence level would be high because there are multiple points supporting", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if cytisine is superior to nicotine replacement therapy (NRT) for smoking cessation. I need to look at the provided evidence to form an answer. First, check the evidence documents. The first document [25517706:25517706_0] says that when combined with brief behavioral support, cytisine was superior to NRT in helping smokers quit. But it had more self-reported adverse events. Then, the same document [25517706:25517706_1] mentions that cytisine's effectiveness was superior at 1 week, 2 months, and 6 months. Also, in a subgroup analysis, it was better for women and noninferior for men. The second document [17698433:17698433_1] talks about auricular acupuncture not being better than sham acupuncture, but suggests combining acupuncture with behavior counseling or NRT could enhance success rates. However, this doesn't directly compare cytisine to N", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["17130378", "17220536", "17253581", "17825502", "18076335", "18646137", "20040957", "21154363", "21328282", "21385905", "22104038", "22513936", "23404838", "23728690", "23834141", "23978314", "24574554", "24831822", "25517706"], "ideal_answer": "Yes, one clinical trial that directly compared smoking cessation rates with cytisine versus nicotine replacement therapy reported that cytisine was superior to nicotine-replacement therapy in helping smokers quit smoking, but it was associated with a higher frequency of self-reported adverse events."}
{"question_id": "532366f09b2d7acc7e000015", "question": "Which amino acid residue appears mutated in most of the cases reported with cadasil syndrome?", "retrieved_chunks": [{"doc_id": "23587639", "chunk_id": "23587639_0", "score": 4.318347930908203, "text": "CADASIL is caused mostly by missense mutations in the NOTCH3 gene, invariably involving a cysteine residue."}, {"doc_id": "15304596", "chunk_id": "15304596_0", "score": 3.377903461456299, "text": "The authors report a family with CADASIL carrying a deletion in the Notch3 gene that did not involve a cysteine residue"}, {"doc_id": "21616505", "chunk_id": "21616505_0", "score": 3.2787647247314453, "text": "Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an inherited cerebrovascular disease due to mutations involving loss or gain of a cysteine residue in the NOTCH3 gene. A cluster of mutations around exons 3 and 4 was originally reported"}], "context": "[23587639:23587639_0] CADASIL is caused mostly by missense mutations in the NOTCH3 gene, invariably involving a cysteine residue.\n[15304596:15304596_0] The authors report a family with CADASIL carrying a deletion in the Notch3 gene that did not involve a cysteine residue\n[21616505:21616505_0] Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an inherited cerebrovascular disease due to mutations involving loss or gain of a cysteine residue in the NOTCH3 gene. A cluster of mutations around exons 3 and 4 was originally reported", "answer": "<think> Okay, let's tackle this question about CADASIL syndrome. The user is asking which amino acid residue is most commonly mutated. The evidence given has three documents. First, document [23587639:23587639_0] states that CADASIL is mostly caused by missense mutations in NOTCH3, involving a cysteine residue. That seems direct. Then there's another document [15304596:15304596_0] mentioning a family with a deletion not involving cysteine. But that's an exception, right? The third document [21616505:21616505_0] confirms that mutations involve loss or gain of cysteine in NOTCH3. So the main point is that cysteine is involved. However, the second document says there's a case without cysteine. But the question says \"most cases\", so even though there's an exception, the majority still involve cysteine. The answer should be cysteine, citing the first and third documents.", "citations": [{"doc_id": "23587639", "chunk_id": "23587639_0"}, {"doc_id": "15304596", "chunk_id": "15304596_0"}, {"doc_id": "21616505", "chunk_id": "21616505_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question about CADASIL syndrome. The user is asking which amino acid residue is most commonly mutated. The evidence given has three documents. First, document [23587639:23587639_0] states that CADASIL is mostly caused by missense mutations in NOTCH3, involving a cysteine residue. That seems direct. Then there's another document [15304596:15304596_0] mentioning a family with a deletion not involving cysteine. But that's an exception, right? The third document [21616505:21616505_0] confirms that mutations involve loss or gain of cysteine in NOTCH3. So the main point is that cysteine is involved. However, the second document says there's a case without cysteine. But the question says \"most cases\", so even though there's an exception, the majority still involve cysteine. The answer should be cysteine, citing the first and third documents.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question about CADASIL syndrome. The user is asking which amino acid residue is most commonly mutated. First, I'll look at the evidence provided. The first document says that CADASIL is mostly caused by missense mutations in the NOTCH3 gene, specifically involving a cysteine residue. That's a strong hint that cysteine is the answer. But wait, there's a second document that mentions a family with CADASIL having a deletion in Notch3 that didn't involve cysteine. However, the question says \"most of the cases,\" so even though one case doesn't involve cysteine, the majority do. The third document also mentions loss or gain of a cysteine residue in NOTCH3, reinforcing that cysteine is the key here. So even though there's an exception, the answer should still be cysteine because it's mentioned in the majority of the evidence. The confidence would be high, maybe 0.95, since the majority of sources point to cysteine, and only one case is an exception. </think> { \"answer\": \"Cyste", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question about CADASIL and the amino acid residue involved. The user is asking which amino acid is most commonly mutated in CADASIL. First, I need to look at the evidence provided. The first document says that CADASIL is mostly caused by missense mutations in NOTCH3, involving a cysteine residue. The second document mentions a family with a deletion not involving cysteine, but that's an exception. The third document states that mutations involve loss or gain of cysteine in NOTCH3. So the majority of cases (as per the first and third documents) involve cysteine. The second document is an exception, but it's a single case. Since the question asks for \"most of the cases,\" the answer should be cysteine. The confidence would be high, maybe 0.95, because the majority of evidence points to cysteine, with one exception that's not the norm. </think> { \"answer\": \"Cysteine [23587639:23587639_0]\", \"base_confidence\":", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["11706120", "15304596", "16717210", "17726918", "18313300", "18710532", "19006080", "19043263", "20224942", "21038489", "21616505", "21772710", "22082899", "22367627", "22623959", "23587639", "23597439", "23799017", "24086431"], "ideal_answer": "CADASIL is caused mostly by missense mutations in the NOTCH3 gene, invariably involving a cysteine residue."}
{"question_id": "57090784cf1c325851000011", "question": "Which syndromes are associated with mutations in the EZH2 gene?", "retrieved_chunks": [{"doc_id": "22190405", "chunk_id": "22190405_1", "score": 7.855245590209961, "text": "The EZH2 mutation spectrum in Weaver syndrome shows considerable overlap with the inactivating somatic EZH2 mutations recently reported in myeloid malignancies"}, {"doc_id": "22177091", "chunk_id": "22177091_0", "score": 7.683099269866943, "text": "Mutations in EZH2 cause Weaver syndrome"}, {"doc_id": "22177091", "chunk_id": "22177091_1", "score": 7.58050537109375, "text": "These data show that mutations in EZH2 cause Weaver syndrome"}], "context": "[22190405:22190405_1] The EZH2 mutation spectrum in Weaver syndrome shows considerable overlap with the inactivating somatic EZH2 mutations recently reported in myeloid malignancies\n[22177091:22177091_0] Mutations in EZH2 cause Weaver syndrome\n[22177091:22177091_1] These data show that mutations in EZH2 cause Weaver syndrome", "answer": "<think> Okay, let's tackle this question. The user is asking which syndromes are associated with mutations in the EZH2 gene. The evidence provided has three entries. First, I need to look at each of the evidence chunks. The first one mentions that EZH2 mutations in Weaver syndrome overlap with somatic mutations in myeloid malignancies. The second and third entries both state that mutations in EZH2 cause Weaver syndrome. So, the main point here is that Weaver syndrome is linked to EZH2 mutations. The other mention of myeloid malignancies might be a related condition but the question specifically asks for syndromes, which are typically genetic disorders. Myeloid malignancies are cancers, not syndromes. Therefore, the primary answer should be Weaver syndrome. The confidence level: All three pieces of evidence point to Weaver syndrome. The first one mentions overlap but the others directly state that EZH2 mutations cause Weaver syndrome. So the base confidence should be high, maybe 0.95 or so. But since there's a mention of another condition, but it's not a syndrome, I should focus on Weaver syndrome. So the", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which syndromes are associated with mutations in the EZH2 gene. The evidence provided has three entries. First, I need to look at each of the evidence chunks. The first one mentions that EZH2 mutations in Weaver syndrome overlap with somatic mutations in myeloid malignancies. The second and third entries both state that mutations in EZH2 cause Weaver syndrome. So, the main point here is that Weaver syndrome is linked to EZH2 mutations. The other mention of myeloid malignancies might be a related condition but the question specifically asks for syndromes, which are typically genetic disorders. Myeloid malignancies are cancers, not syndromes. Therefore, the primary answer should be Weaver syndrome. The confidence level: All three pieces of evidence point to Weaver syndrome. The first one mentions overlap but the others directly state that EZH2 mutations cause Weaver syndrome. So the base confidence should be high, maybe 0.95 or so. But since there's a mention of another condition, but it's not a syndrome, I should focus on Weaver syndrome. So the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which syndromes are associated with mutations in the EZH2 gene. The evidence provided has three entries. First, I need to parse each piece of evidence. The first one says that EZH2 mutations in Weaver syndrome overlap with inactivating somatic mutations in myeloid malignancies. The second and third entries both state that mutations in EZH2 cause Weaver syndrome. So the main point here is that Weaver syndrome is linked to EZH2 mutations. The other mention of myeloid malignancies might be a related condition, but the question specifically asks for syndromes. Myeloid malignancies are cancers, not syndromes. So the primary answer should be Weaver syndrome. I need to check if there's any other syndrome mentioned. The evidence doesn't list any others. The first document mentions overlap with myeloid mutations, but that's a different category. Therefore, the only syndrome associated here is Weaver syndrome. The confidence level: all three pieces of evidence point to Weaver syndrome. The first one talks about overlap, but the other two directly state that EZH2 mutations cause", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which syndromes are associated with mutations in the EZH2 gene. The evidence provided has three entries. First, I need to look at each of the evidence chunks. The first one mentions that EZH2 mutations in Weaver syndrome overlap with somatic mutations in myeloid malignancies. The second and third chunks both state that mutations in EZH2 cause Weaver syndrome. So, the main point here is that Weaver syndrome is linked to EZH2 mutations. The other mention of myeloid malignancies might be a related condition, but the question specifically asks for syndromes, which are generally genetic disorders, not cancers. However, sometimes cancer types can be considered as syndromes in a broader sense, but I'm not sure. The evidence doesn't explicitly call myeloid malignancies a syndrome, so maybe it's safer to stick with Weaver syndrome. The answer should be concise, citing the relevant documents. The base confidence is high because multiple sources point to Weaver syndrome. The first document mentions overlap, but the second and third clearly state that mutations cause Weaver syndrome. So the main answer is", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["10780782", "21856302", "22177091", "22190405", "22475286", "23099237", "23592277", "24214728", "24218139", "24507812", "24760151", "24852293", "24953053", "25177364"], "ideal_answer": "EZH2 mutations that cause Weaver syndrome are primarily missense variants and the rare truncating mutations reported to date are in the last exon, suggesting that simple haploinsufficiency is unlikely to be generating the overgrowth phenotype although the exact mechanism has not yet been determined. Recent studies have shown that EZH2 mutations are often associated with RUNX1 mutations in MDS patients, although its pathological function remains to be addressed. These data show that mutations in EZH2 cause Weaver syndrome. The EZH2 gene is a homolog of the Drosophila Polycomb group (PcG) gene enhancer of zest, a crucial regulator of homeotic gene expression. Loss-of-function mutations of EZH2, a catalytic component of polycomb repressive complex 2 (PRC2), are observed in ~\\n10% of patients with myelodysplastic syndrome (MDS), but are rare in acute myeloid leukaemia (AML). Constitutional NSD1 and EZH2 mutations cause Sotos and Weaver syndromes respectively, overgrowth syndromes with considerable phenotypic overlap. Mutations at tyrosine 641 (Y641F, Y641N, Y641S and Y641H) in the SET domain of EZH2 have been identified in patients with certain subtypes of non-Hodgkin lymphoma (NHL). The EZH2 gene is involved in the pathogenesis of 7q35-q36 aberrations in myeloid leukaemia."}
{"question_id": "55414a763f2354b713000003", "question": "Which databases exist for experimentally determined topologies of α-helical transmembrane proteins ?", "retrieved_chunks": [{"doc_id": "20601677", "chunk_id": "20601677_1", "score": 8.483235359191895, "text": "ExTopoDB is a publicly accessible database of experimentally derived topological models of transmembrane proteins. It contains information collected from studies in the literature that report the use of biochemical methods for the determination of the topology of α-helical transmembrane proteins. Transmembrane protein topology is highly important in order to understand their function and ExTopoDB provides an up to date, complete and comprehensive dataset of experimentally determined topologies of α-helical transmembrane proteins. Topological information is combined with transmembrane topology prediction resulting in more reliable topological models. AVAILABILITY: http://bioinformatics.biol.uoa.gr/ExTopoDB"}, {"doc_id": "12520035", "chunk_id": "12520035_2", "score": 7.597048282623291, "text": "TMPDB is a database of experimentally-characterized transmembrane (TM) topologies. TMPDB release 6.2 contains a total of 302 TM protein sequences, in which 276 are alpha-helical sequences, 17 beta-stranded, and 9 alpha-helical sequences with short pore-forming helices buried in the membrane. The TM topologies in TMPDB were determined experimentally by means of X-ray crystallography, NMR, gene fusion technique, substituted cysteine accessibility method, N-linked glycosylation experiment and other biochemical methods. TMPDB would be useful as a test and/or training dataset in improving the proposed TM topology prediction methods or developing novel methods with higher performance, and as a guide for both the bioinformaticians and biologists to better understand TM proteins. TMPDB and its subsets are freely available at the following web site: http://bioinfo.si.hirosaki-u.ac.jp/~TMPDB/"}, {"doc_id": "20601677", "chunk_id": "20601677_5", "score": 6.574993133544922, "text": "Transmembrane protein topology is highly important in order to understand their function and ExTopoDB provides an up to date, complete and comprehensive dataset of experimentally determined topologies of α-helical transmembrane proteins."}], "context": "[20601677:20601677_1] ExTopoDB is a publicly accessible database of experimentally derived topological models of transmembrane proteins. It contains information collected from studies in the literature that report the use of biochemical methods for the determination of the topology of α-helical transmembrane proteins. Transmembrane protein topology is highly important in order to understand their function and ExTopoDB provides an up to date, complete and comprehensive dataset of experimentally determined topologies of α-helical transmembrane proteins. Topological information is combined with transmembrane topology prediction resulting in more reliable topological models. AVAILABILITY: http://bioinformatics.biol.uoa.gr/ExTopoDB\n[12520035:12520035_2] TMPDB is a database of experimentally-characterized transmembrane (TM) topologies. TMPDB release 6.2 contains a total of 302 TM protein sequences, in which 276 are alpha-helical sequences, 17 beta-stranded, and 9 alpha-helical sequences with short pore-forming helices buried in the membrane. The TM topologies in TMPDB were determined experimentally by means of X-ray crystallography, NMR, gene fusion technique, substituted cysteine accessibility method, N-linked glycosylation experiment and other biochemical methods. TMPDB would be useful as a test and/or training dataset in improving the proposed TM topology prediction methods or developing novel methods with higher performance, and as a guide for both the bioinformaticians and biologists to better understand TM proteins. TMPDB and its subsets are freely available at the following web site: http://bioinfo.si.hirosaki-u.ac.jp/~TMPDB/\n[20601677:20601677_5] Transmembrane protein topology is highly important in order to understand their function and ExTopoDB provides an up to date, complete and comprehensive dataset of experimentally determined topologies of α-helical transmembrane proteins.", "answer": "<think> Okay, the user is asking about databases for experimentally determined topologies of alpha-helical transmembrane proteins. Let me check the evidence provided. First, there's ExTopoDB mentioned in two chunks. The first chunk says it's a database with experimentally derived topological models, specifically for alpha-helical transmembrane proteins. It also mentions that it combines experimental data with predictions. The third chunk repeats this info, reinforcing that ExTopoDB is relevant. Then there's TMPDB in the second chunk. It states that TMPDB includes 276 alpha-helical sequences and uses various experimental methods like X-ray crystallography and NMR. So TMPDB also fits the criteria. The question is which databases exist, so both ExTopoDB and TMPDB are valid answers. The user wants a concise answer with citations. I need to list both databases with their respective chunk IDs. For confidence, since both databases are explicitly mentioned in the evidence, the model can be confident. But I should check if there's any conflicting info. No, both are separate databases. So base_confidence would be 1.0.", "citations": [], "candidates": [{"answer": "<think> Okay, the user is asking about databases for experimentally determined topologies of alpha-helical transmembrane proteins. Let me check the evidence provided. First, there's ExTopoDB mentioned in two chunks. The first chunk says it's a database with experimentally derived topological models, specifically for alpha-helical transmembrane proteins. It also mentions that it combines experimental data with predictions. The third chunk repeats this info, reinforcing that ExTopoDB is relevant. Then there's TMPDB in the second chunk. It states that TMPDB includes 276 alpha-helical sequences and uses various experimental methods like X-ray crystallography and NMR. So TMPDB also fits the criteria. The question is which databases exist, so both ExTopoDB and TMPDB are valid answers. The user wants a concise answer with citations. I need to list both databases with their respective chunk IDs. For confidence, since both databases are explicitly mentioned in the evidence, the model can be confident. But I should check if there's any conflicting info. No, both are separate databases. So base_confidence would be 1.0.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking about databases for experimentally determined topologies of alpha-helical transmembrane proteins. Looking at the evidence provided, there are two main databases mentioned: ExTopoDB and TMPDB. First, I need to check each document to see what they say. Document [20601677:20601677_1] talks about ExTopoDB being a database of experimentally derived topological models for transmembrane proteins, specifically mentioning alpha-helical ones. It also states that it's publicly accessible and provides up-to-date data. Then, document [12520035:12520035_2] describes TMPDB as containing 302 TM sequences, with 276 being alpha-helical. It mentions various experimental methods used to determine the topologies. The third document is a repeat of the first, reinforcing that ExTopoDB focuses on alpha-helical proteins. So both databases are relevant, but the question specifies alpha-helical. Both ExTopoDB and TMP", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, the user is asking about databases for experimentally determined topologies of alpha-helical transmembrane proteins. Let me check the evidence provided. Looking at the first document, it mentions ExTopoDB, which is described as a database with experimentally derived topological models of transmembrane proteins. It specifically focuses on alpha-helical ones and provides information from biochemical methods. The citation is [20601677:20601677_1]. That's a good candidate. The second document talks about TMPDB, which includes 302 TM sequences, with 276 being alpha-helical. It states that the topologies were determined experimentally using various methods like X-ray crystallography and NMR. The citation is [12520035:12520035_2]. So TMPDB is another valid answer. The third document repeats information from the first about ExTopoDB, so it's not a new source but reinforces the first point. Now, the user wants one candidate answer. The question is which databases exist.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["12520035", "20601677"], "ideal_answer": "ExTopoDB and TMPDB."}
{"question_id": "55000cc4e9bde69634000004", "question": "Which disease is characterized by congenital absence of intrinsic ganglion cells of the gastrointestinal tract?", "retrieved_chunks": [{"doc_id": "8894691", "chunk_id": "8894691_1", "score": 9.31020736694336, "text": "Hirschsprung disease (HSCR) is a congenital disorder associated with the absence of intrinsic ganglion cells in the distal gastrointestinal tract."}, {"doc_id": "8894691", "chunk_id": "8894691_0", "score": 9.197052001953125, "text": "Hirschsprung disease (HSCR) is a congenital disorder associated with the absence of intrinsic ganglion cells in the distal gastrointestinal tract"}, {"doc_id": "8896569", "chunk_id": "8896569_0", "score": 9.06171989440918, "text": "Hirschsprung disease (HSCR, aganglionic megacolon) is a common congenital malformation leading to bowel obstruction, with an incidence of 1/5,000 live births. It is characterized by the absence of intrinsic ganglion cells in the myenteric and submucosal plexuses along variable lengths of the gastrointestinal tract."}], "context": "[8894691:8894691_1] Hirschsprung disease (HSCR) is a congenital disorder associated with the absence of intrinsic ganglion cells in the distal gastrointestinal tract.\n[8894691:8894691_0] Hirschsprung disease (HSCR) is a congenital disorder associated with the absence of intrinsic ganglion cells in the distal gastrointestinal tract\n[8896569:8896569_0] Hirschsprung disease (HSCR, aganglionic megacolon) is a common congenital malformation leading to bowel obstruction, with an incidence of 1/5,000 live births. It is characterized by the absence of intrinsic ganglion cells in the myenteric and submucosal plexuses along variable lengths of the gastrointestinal tract.", "answer": "<think> Okay, let's tackle this question. The user is asking which disease is characterized by congenital absence of intrinsic ganglion cells in the gastrointestinal tract. The evidence provided has three chunks, all pointing to Hirschsprung disease (HSCR). First, I need to make sure that all the evidence supports the same answer. Looking at the evidence: - The first two chunks (8894691:8894691_1 and 0) both state that HSCR is associated with the absence of intrinsic ganglion cells in the distal gastrointestinal tract. - The third chunk (8896569:8896569_0) adds more details, mentioning that HSCR is a common congenital malformation leading to bowel obstruction and that it's characterized by the absence of these cells in the myenteric and submucosal plexuses along variable lengths of the tract. All three pieces of evidence consistently mention Hirschsprung disease as the condition with the absence of ganglion cells. There's no conflicting information here. The answer should be Hirschsprung disease, and the citations", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which disease is characterized by congenital absence of intrinsic ganglion cells in the gastrointestinal tract. The evidence provided has three chunks, all pointing to Hirschsprung disease (HSCR). First, I need to make sure that all the evidence supports the same answer. Looking at the evidence: - The first two chunks (8894691:8894691_1 and 0) both state that HSCR is associated with the absence of intrinsic ganglion cells in the distal gastrointestinal tract. - The third chunk (8896569:8896569_0) adds more details, mentioning that HSCR is a common congenital malformation leading to bowel obstruction and that it's characterized by the absence of these cells in the myenteric and submucosal plexuses along variable lengths of the tract. All three pieces of evidence consistently mention Hirschsprung disease as the condition with the absence of ganglion cells. There's no conflicting information here. The answer should be Hirschsprung disease, and the citations", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which disease is characterized by congenital absence of intrinsic ganglion cells in the gastrointestinal tract. The evidence provided has three chunks, all pointing to Hirschsprung disease (HSCR). First, I need to make sure that all the evidence supports the same answer. Looking at the evidence: - The first two chunks (8894691:8894691_1 and 0) both state that HSCR is associated with the absence of intrinsic ganglion cells in the distal gastrointestinal tract. - The third chunk (8896569:8896569_0) expands on this, mentioning that HSCR is a common congenital malformation leading to bowel obstruction and characterized by the absence of these cells in the myenteric and submucosal plexuses along variable lengths of the gastrointestinal tract. All three pieces of evidence consistently identify Hirschsprung disease as the condition in question. There's no conflicting information here. The key terms are \"congenital absence of intrinsic ganglion cells\" and \"gastrointestinal", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which disease is characterized by congenital absence of intrinsic ganglion cells in the gastrointestinal tract. Looking at the evidence provided, there are three entries. All of them mention Hirschsprung disease (HSCR) and its association with the absence of these cells. The first two entries from 8894691 both state that HSCR is a congenital disorder with absent ganglion cells in the distal GI tract. The third entry from 8896569 expands on this, mentioning that HSCR is a common malformation leading to bowel obstruction and that it's characterized by the absence of intrinsic ganglion cells in the myenteric and submucosal plexuses along variable lengths of the GI tract. So all the evidence points to Hirschsprung disease as the answer. The confidence here is pretty high because all three sources are consistent. The model can be confident in this answer. The citations are from the same document, but since they're all supporting the same conclusion, it's safe to use one of them. Let me check if there's any conflicting information, but", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["10980580", "16080919", "16618617", "20860806", "21656899", "22131258", "22184102", "22974608", "23043324", "23272425", "23836442", "8401580", "8894691", "8896569", "9556633"], "ideal_answer": "Hirschsprung disease (HSCR, aganglionic megacolon) is a common congenital malformation leading to bowel obstruction, with an incidence of 1/5,000 live births. It is characterized by the absence of intrinsic ganglion cells in the myenteric and submucosal plexuses along variable lengths of the gastrointestinal tract. The medical condition characterized by the congenital absence of intrinsic ganglion cells in the myenteric and submucosal plexuses along variable lengths of the gastrointestinal tract is called aganlionic megacolon or Hirschsprung disease. Hirschsprung disease (HSCR) is a congenital disorder associated with the absence of intrinsic ganglion cells in the distal gastrointestinal tract.This severe congenital condition is caused by the absence of colonic neural ganglia and thus lack of intrinsic innervation of the colon due in turn to improper colonization of the developing intestines by ENS progenitor cells. Hirschsprungs disease (HSCR), also known as aganglionic megacolon, derives from a congenital malformation of the enteric nervous system (ENS). This severe congenital condition is caused by the absence of colonic neural ganglia and thus lack of intrinsic innervation of the colon due in turn to improper colonization of the developing intestines by ENS progenitor cells."}
{"question_id": "54ede28094afd61504000003", "question": "What is the disease in which patients are sensitive to DNA crosslinking agents, presenting with a high frequency of chromosomal aberrations?", "retrieved_chunks": [{"doc_id": "20132664", "chunk_id": "20132664_0", "score": 6.169626712799072, "text": "FA patients exhibit spontaneous chromosome breakage and FA cells are sensitive to DNA interstrand crosslink agents and expresses high frequency of chromosome breakage"}, {"doc_id": "8876687", "chunk_id": "8876687_1", "score": 5.680403709411621, "text": "Fanconi anemia (FA) is characterized at the cellular level by a high frequency of spontaneous chromosomal aberrations; crosslinking agents cause an abnormal increase in the frequency of chromosomal damage, and semiconservative DNA synthesis is severely inhibited."}, {"doc_id": "7116934", "chunk_id": "7116934_1", "score": 5.602928161621094, "text": "An elevated frequency of chromosome aberrations, which is further exaggerated by exposure of cells to DNA crosslinking agents, is a general feature of Fanconi's anemia."}], "context": "[20132664:20132664_0] FA patients exhibit spontaneous chromosome breakage and FA cells are sensitive to DNA interstrand crosslink agents and expresses high frequency of chromosome breakage\n[8876687:8876687_1] Fanconi anemia (FA) is characterized at the cellular level by a high frequency of spontaneous chromosomal aberrations; crosslinking agents cause an abnormal increase in the frequency of chromosomal damage, and semiconservative DNA synthesis is severely inhibited.\n[7116934:7116934_1] An elevated frequency of chromosome aberrations, which is further exaggerated by exposure of cells to DNA crosslinking agents, is a general feature of Fanconi's anemia.", "answer": "<think> Okay, let's tackle this question. The user is asking for a biomedical answer about a disease where patients are sensitive to DNA crosslinking agents and have high chromosomal aberrations. The evidence provided mentions Fanconi anemia (FA) multiple times. First, I need to check each piece of evidence. The first document says FA patients have spontaneous chromosome breakage and are sensitive to DNA interstrand crosslink agents. The second one states that FA is characterized by high frequency of spontaneous chromosomal aberrations and that crosslinking agents increase chromosomal damage. The third mentions that FA has an elevated frequency of chromosome aberrations, which is worse with crosslinking agents. All three sources point to Fanconi anemia as the disease in question. The answer should be concise, citing the documents. The confidence level is high because all three pieces of evidence consistently support FA. So the answer is Fanconi anemia, and the confidence is 1.0. </think> { \"answer\": \"Fanconi anemia (FA) [8876687:8876687_1][7116934:71", "citations": [{"doc_id": "8876687", "chunk_id": "8876687_1"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking for a biomedical answer about a disease where patients are sensitive to DNA crosslinking agents and have high chromosomal aberrations. The evidence provided mentions Fanconi anemia (FA) multiple times. First, I need to check each piece of evidence. The first document says FA patients have spontaneous chromosome breakage and are sensitive to DNA interstrand crosslink agents. The second one states that FA is characterized by high frequency of spontaneous chromosomal aberrations and that crosslinking agents increase chromosomal damage. The third mentions that FA has an elevated frequency of chromosome aberrations, which is worse with crosslinking agents. All three sources point to Fanconi anemia as the disease in question. The answer should be concise, citing the documents. The confidence level is high because all three pieces of evidence consistently support FA. So the answer is Fanconi anemia, and the confidence is 1.0. </think> { \"answer\": \"Fanconi anemia (FA) [8876687:8876687_1][7116934:71", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking about a disease where patients are sensitive to DNA crosslinking agents and have a high frequency of chromosomal aberrations. The evidence provided mentions Fanconi anemia (FA) multiple times. First, I need to check each piece of evidence. The first document says FA patients have spontaneous chromosome breakage and are sensitive to DNA interstrand crosslink agents. The second one states that FA is characterized by high frequency of spontaneous chromosomal aberrations and that crosslinking agents increase chromosomal damage. The third document also mentions elevated chromosome aberrations exacerbated by DNA crosslinking agents, linking it to Fanconi's anemia. All three sources point to Fanconi anemia as the disease in question. The answer should be concise, citing the documents. The confidence level is high since all three pieces of evidence consistently support FA. So the answer is Fanconi anemia, with citations from the three documents. The base_confidence should be 1.0 because the evidence is consistent across multiple sources. </think> { \"answer\": \"Fanconi anemia (FA) [20132664:", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking for a biomedical answer about a disease where patients are sensitive to DNA crosslinking agents and have high chromosomal aberrations. The evidence provided mentions FA (Fanconi anemia) multiple times. First, I need to check each of the evidence chunks. The first one says FA patients have spontaneous chromosome breakage and are sensitive to DNA interstrand crosslink agents. The second chunk from 8876687:8876687_1 states that FA is characterized by high frequency of chromosomal aberrations and that crosslinking agents increase damage. The third chunk from 7116934:7116934_1 mentions that chromosome aberrations are elevated and exacerbated by DNA crosslinking agents, which is a feature of Fanconi's anemia. All three pieces of evidence point to Fanconi anemia as the answer. The key terms here are \"DNA crosslinking agents\" and \"chromosomal aberrations.\" The confidence level should be high since all three sources consistently mention FA. I need to make sure the answer is concise and includes", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["16115458", "20132664", "21568838", "7011307", "7116934", "8058745", "8876687"], "ideal_answer": "Fanconi anemia (FA) is an autosomal disorder that causes genome instability and manifests by defects in DNA repair, hypersensitivity to DNA crosslinking agents, and a high degree of chromosomal aberrations. Fanconi anemia (FA) is an autosomal disorder that causes genome instability. FA patients suffer developmental abnormalities, early-onset bone marrow failure, and a predisposition to cancer. The disease is manifested by defects in DNA repair, hypersensitivity to DNA crosslinking agents, and a high degree of chromosomal aberrations. Fanconi anemia (FA) is an autosomal disorder that causes genome instability. FA patients suffer developmental abnormalities, early-onset bone marrow failure, and a predisposition to cancer. The disease is manifested by defects in DNA repair, hypersensitivity to DNA crosslinking agents, and a high degree of chromosomal aberrations."}
{"question_id": "56ecfd572ac5ed1459000002", "question": "How is oprozomib administered?", "retrieved_chunks": [{"doc_id": "24712303", "chunk_id": "24712303_1", "score": 4.230853080749512, "text": "Further, new orally administered second-generation PI oprozomib is being investigated."}, {"doc_id": "24712303", "chunk_id": "24712303_0", "score": 3.957716226577759, "text": "Further, new orally administered second-generation PI oprozomib is being investigated"}, {"doc_id": "24712303", "chunk_id": "24712303_2", "score": 3.9564599990844727, "text": "new orally administered second-generation PI oprozomib is being investigated."}], "context": "[24712303:24712303_1] Further, new orally administered second-generation PI oprozomib is being investigated.\n[24712303:24712303_0] Further, new orally administered second-generation PI oprozomib is being investigated\n[24712303:24712303_2] new orally administered second-generation PI oprozomib is being investigated.", "answer": "<think> Okay, let's tackle this question. The user is asking how oprozomib is administered. The evidence provided has three chunks, all pointing to the fact that it's orally administered. First, I need to check each chunk for relevant information. All three chunks mention \"orally administered,\" so that's consistent. The answer should be concise, stating that it's taken orally. The citations are from the same document, so I'll use the first chunk's ID and the first chunk's identifier. Now, confidence level. Since all evidence points to oral administration and there's no conflicting information, the model can be confident. The confidence should be high, maybe 0.95. Let me make sure there's no other possible way it's administered. The evidence doesn't mention any other routes like injection or IV, so oral is the only one. So the answer is straightforward: oprozomib is administered orally, citing the first chunk. Confidence is 0.95. </think> { \"answer\": \"Oprozomib is administered orally [24712303:2471230", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking how oprozomib is administered. The evidence provided has three chunks, all pointing to the fact that it's orally administered. First, I need to check each chunk for relevant information. All three chunks mention \"orally administered,\" so that's consistent. The answer should be concise, stating that it's taken orally. The citations are from the same document, so I'll use the first chunk's ID and the first chunk's identifier. Now, confidence level. Since all evidence points to oral administration and there's no conflicting information, the model can be confident. The confidence should be high, maybe 0.95. Let me make sure there's no other possible way it's administered. The evidence doesn't mention any other routes like injection or IV, so oral is the only one. So the answer is straightforward: oprozomib is administered orally, citing the first chunk. Confidence is 0.95. </think> { \"answer\": \"Oprozomib is administered orally [24712303:2471230", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user wants to know how oprozomib is administered. Looking at the evidence provided, there are three chunks from the same document ID. All of them mention that oprozomib is \"orally administered.\" The key point here is the word \"orally,\" which directly answers the method of administration. First, I need to make sure that all the evidence supports the oral route. Each chunk repeats the same information, so there's consistency. The confidence level should be high since all sources agree. The model's base_confidence would likely be 1.0 here because the evidence is unanimous and straightforward. I should structure the answer to include the citation as specified. The answer should be concise, so just stating \"orally administered\" with the document ID and chunk ID. The base confidence is 1.0 since there's no conflicting information. Let me double-check if there's any other possible way it's administered, but the evidence doesn't mention anything else. So the answer is correct. </think> { \"answer\": \"Oprozomib is orally administered [247123", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking how oprozomib is administered. The evidence provided has three chunks, all pointing to the fact that it's orally administered. First, I need to check each chunk for relevant information. All three chunks mention \"orally administered,\" so that's consistent. The key point here is the route of administration. The answer should state that oprozomib is taken orally. Now, the citations are all from the same document, 24712303, but different chunk IDs. The first chunk is 24712303_1, then 24712303_0, and 会被引用的应该是哪个呢？不过问题中的证据部分有三个，但每个都指向相同的文档。可能需要选择其中一个作为引用，比如第一个或者第三个。不过用户给的例子中，可能每个chunk都是同一内容的不同实例，所以可能只需要引用一个。 然后确定base_confidence。因为所有证据都一致，模型应该很确定，所以置信度应该是1.0。但需要确认是否有其他因素，比如是否", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["22763387", "22929803", "24103732", "24239172", "24471924", "24712303", "24915039"], "ideal_answer": "Oprozomib is administered orally."}
{"question_id": "54f57892d0d681a040000009", "question": "What is a Caveolae?", "retrieved_chunks": [{"doc_id": "24308657", "chunk_id": "24308657_0", "score": 9.42665958404541, "text": "Caveolae are flask-shaped plasma membrane invaginations formed by constitutive caveolin proteins and regulatory cavin proteins."}, {"doc_id": "24023653", "chunk_id": "24023653_0", "score": 8.941503524780273, "text": "Caveolae are cholesterol-rich microdomains that form mechanically deformable invaginations of the sarcolemma."}, {"doc_id": "23787000", "chunk_id": "23787000_0", "score": 8.930827140808105, "text": "Caveolae are membrane microdomains where important signalling pathways are assembled and molecular effects transduced."}], "context": "[24308657:24308657_0] Caveolae are flask-shaped plasma membrane invaginations formed by constitutive caveolin proteins and regulatory cavin proteins.\n[24023653:24023653_0] Caveolae are cholesterol-rich microdomains that form mechanically deformable invaginations of the sarcolemma.\n[23787000:23787000_0] Caveolae are membrane microdomains where important signalling pathways are assembled and molecular effects transduced.", "answer": "<think> Okay, I need to generate a biomedical answer about Caveolae based on the provided evidence. Let me start by reading through the question and the evidence carefully. The user is asking for a concise answer explaining what Caveolae are, with citations from the given documents. The answer should be in JSON format with two keys: \"answer\" and \"base_confidence\". The answer needs to include citations in the format [doc_id:chunk_id], and the confidence level should be a float between 0 and 1. Looking at the evidence: 1. Document 24308657 mentions that Caveolae are flask-shaped invaginations formed by caveolin and cavin proteins. 2. Document 24023653 states they're cholesterol-rich, mechanically deformable invaginations of the sarcolemma. 3. Document 23787000 says they're membrane microdomains where signaling pathways are assembled. I need to combine these points into a single answer. The answer should be concise but include key aspects: structure (flask-shaped, invaginations), composition (caveolin, cavin proteins,", "citations": [], "candidates": [{"answer": "<think> Okay, I need to generate a biomedical answer about Caveolae based on the provided evidence. Let me start by reading through the question and the evidence carefully. The user is asking for a concise answer explaining what Caveolae are, with citations from the given documents. The answer should be in JSON format with two keys: \"answer\" and \"base_confidence\". The answer needs to include citations in the format [doc_id:chunk_id], and the confidence level should be a float between 0 and 1. Looking at the evidence: 1. Document 24308657 mentions that Caveolae are flask-shaped invaginations formed by caveolin and cavin proteins. 2. Document 24023653 states they're cholesterol-rich, mechanically deformable invaginations of the sarcolemma. 3. Document 23787000 says they're membrane microdomains where signaling pathways are assembled. I need to combine these points into a single answer. The answer should be concise but include key aspects: structure (flask-shaped, invaginations), composition (caveolin, cavin proteins,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to generate a biomedical answer about Caveolae based on the provided evidence. Let me start by understanding what the question is asking. The user wants a concise answer that includes citations from the given documents and a confidence score. First, I'll look at the evidence provided. There are three chunks from different document IDs. Each chunk gives a slightly different perspective on Caveolae. The first mentions they are flask-shaped invaginations formed by caveolin and cavin proteins. The second says they're cholesterol-rich microdomains that are mechanically deformable parts of the sarcolemma. The third talks about them being sites for signaling pathways. I need to combine these into a single answer. The answer should be concise, so I'll have to merge the key points. The main features from the evidence are: flask-shaped invaginations, formed by caveolin and cavin proteins, cholesterol-rich, mechanically deformable, part of the sarcolemma, and involved in signaling. But since the user wants a strict JSON with answer and base_confidence, I need to pick the most accurate and comprehensive information. The first chunk is from 2430865", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question about Caveolae. The user wants a concise answer with citations and a confidence score. First, I need to look at the evidence provided. There are three documents here. Let me read each one carefully. The first document says caveolae are flask-shaped invaginations formed by constitutive caveolin and regulatory cavin proteins. The second mentions they're cholesterol-rich microdomains that form mechanically deformable invaginations of the sarcolemma. The third states they're membrane microdomains where signaling pathways are assembled and molecular effects transduced. So, the answer needs to combine these points. The key elements are their shape (flask-shaped), composition (caveolin and cavin proteins, cholesterol-rich), function (signaling pathways), and structure (invaginations of the sarcolemma). I should pick the most accurate and comprehensive information. The first document gives a definition, the second adds about cholesterol and mechanical properties, and the third talks about their functional role. Combining these into a single answer would be best. But I need to cite one source. However, the user said \"citations [doc_id:chunk_id", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["23340574", "23521716", "23593340", "23610576", "23727353", "23787000", "23899671", "24013596", "24013648", "24023653", "24308657", "7407830"], "ideal_answer": "Caveolae, plasma membrane invaginations of 60-80nm in diameter, are a subset of lipid rafts enriched in cholesterol and sphingolipids."}
{"question_id": "56ebfa13107309bc2f000004", "question": "Which are the roles of chromatin compartments in the eukaryotic nucleus?", "retrieved_chunks": [{"doc_id": "9291094", "chunk_id": "9291094_0", "score": 5.984580993652344, "text": "Chromatin domains and nuclear compartments: establishing sites of gene expression in eukaryotic nuclei."}, {"doc_id": "21444719", "chunk_id": "21444719_3", "score": 4.725714683532715, "text": "ecent studies have shown that the protein CTCF, which plays an important role in insulation and in large-scale organization of chromatin within the eukaryotic nucleus, depends for both activities on recruitment of the cohesin complex"}, {"doc_id": "15868422", "chunk_id": "15868422_0", "score": 4.665445327758789, "text": "DNA in eukaryotes is packed into chromatin. The basic component of chromatin is the nucleosome consisting of DNA wrapped around a histone octamer. Inside the cell nucleus, chromatin is folded into higher-order structures through various mechanisms, including repositioning of nucleosomes along the DNA, packing of nucleosomes into more condensed 3-dimensional configurations, looping of chromatin fibres, and tethering of chromosomal regions to nuclear structures."}], "context": "[9291094:9291094_0] Chromatin domains and nuclear compartments: establishing sites of gene expression in eukaryotic nuclei.\n[21444719:21444719_3] ecent studies have shown that the protein CTCF, which plays an important role in insulation and in large-scale organization of chromatin within the eukaryotic nucleus, depends for both activities on recruitment of the cohesin complex\n[15868422:15868422_0] DNA in eukaryotes is packed into chromatin. The basic component of chromatin is the nucleosome consisting of DNA wrapped around a histone octamer. Inside the cell nucleus, chromatin is folded into higher-order structures through various mechanisms, including repositioning of nucleosomes along the DNA, packing of nucleosomes into more condensed 3-dimensional configurations, looping of chromatin fibres, and tethering of chromosomal regions to nuclear structures.", "answer": "<think> Okay, let's tackle this question about the roles of chromatin compartments in the eukaryotic nucleus. The user provided some evidence from three different documents. First, I need to understand what chromatin compartments are. From the evidence, document [15868422:15868422_0] mentions that DNA is packed into chromatin, which forms higher-order structures through mechanisms like nucleosome repositioning, packing into 3D configurations, looping, and tethering to nuclear structures. That sounds like it's talking about the structural organization of chromatin, which might relate to compartments. Then, document [9291094:9291094_0] is titled \"Chromatin domains and nuclear compartments: establishing sites of gene expression.\" The title itself suggests that chromatin compartments are involved in defining where genes are expressed. So maybe the roles include organizing gene expression sites. Document [21444719:21444719_3] talks about CTCF protein and cohesin complex. It says CTCF is important for", "citations": [{"doc_id": "15868422", "chunk_id": "15868422_0"}, {"doc_id": "9291094", "chunk_id": "9291094_0"}, {"doc_id": "21444719", "chunk_id": "21444719_3"}], "candidates": [{"answer": "<think> Okay, let's tackle this question about the roles of chromatin compartments in the eukaryotic nucleus. The user provided some evidence from three different documents. First, I need to understand what chromatin compartments are. From the evidence, document [15868422:15868422_0] mentions that DNA is packed into chromatin, which forms higher-order structures through mechanisms like nucleosome repositioning, packing into 3D configurations, looping, and tethering to nuclear structures. That sounds like it's talking about the structural organization of chromatin, which might relate to compartments. Then, document [9291094:9291094_0] is titled \"Chromatin domains and nuclear compartments: establishing sites of gene expression.\" The title itself suggests that chromatin compartments are involved in defining where genes are expressed. So maybe the roles include organizing gene expression sites. Document [21444719:21444719_3] talks about CTCF protein and cohesin complex. It says CTCF is important for", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to generate a biomedical answer about the roles of chromatin compartments in the eukaryotic nucleus based on the provided evidence. Let me start by understanding what the question is asking. The user wants to know the roles of chromatin compartments, so I should look through the evidence to find relevant information. Looking at the first evidence snippet: \"Chromatin domains and nuclear compartments: establishing sites of gene expression in eukaryotic nuclei.\" This seems directly related. The term \"chromatin domains\" might be part of what's referred to as chromatin compartments. The mention of \"sites of gene expression\" suggests that one role is in regulating gene expression by organizing regions of the nucleus where genes are active. The second snippet talks about CTCF and cohesin complex. It says that CTCF is involved in insulation and large-scale organization of chromatin. Insulation here might relate to creating boundaries between different regions, which would be part of compartmentalization. The cohesin complex's role in these activities implies that chromatin compartments help in structural organization and maybe in maintaining the three-dimensional struc", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to generate a candidate biomedical answer about the roles of chromatin compartments in the eukaryotic nucleus based on the provided evidence. Let me start by understanding what the question is asking. The user wants to know the roles of chromatin compartments, so I should look through the evidence to find relevant information. Looking at the first evidence document [9291094:9291094_0], it mentions \"Chromatin domains and nuclear compartments: establishing sites of gene expression in eukaryotic nuclei.\" That seems directly related. The title suggests that chromatin compartments help in determining where genes are expressed. So maybe one role is organizing gene expression sites. The second document [21444719:21444719_3] talks about CTCF and cohesin complex. It says CTCF is involved in insulation and large-scale chromatin organization. Insulation might relate to keeping certain regions separate, which could be part of compartmentalization. Also, the cohesin complex's role here might be part of how chromatin is structured into compartments. The third", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["11186332", "11909528", "15140983", "15791412", "18434402", "18974210", "21637796", "22198682", "24002784", "25409831", "9291094", "9587055", "9636146"], "ideal_answer": "The complexity in composition and function of the eukaryotic nucleus is achieved through its organization in specialized nuclear compartments. Chromosome conformation capture approaches have shown that interphase chromatin is partitioned into spatially segregated Mb-sized compartments and sub-Mb-sized topological domains. This compartmentalization is thought to facilitate the matching of genes and regulatory elements. Cohesin-based chromatin interactions enable regulated gene expression within preexisting architectural compartments. Therefore, concentrating proteins needed to perform different steps of RNA synthesis within specialized nuclear compartments is important in orchestrating events required for efficient gene expression."}
{"question_id": "56c0708eef6e39474100001f", "question": "Is the abnormal dosage of ultraconserved elements disfavored in cancer cells?", "retrieved_chunks": [{"doc_id": "25340765", "chunk_id": "25340765_0", "score": 9.857267379760742, "text": "Abnormal dosage of ultraconserved elements is highly disfavored in healthy cells but not cancer cells."}, {"doc_id": "25340765", "chunk_id": "25340765_5", "score": 0.8188755512237549, "text": "Ultraconserved elements (UCEs) are strongly depleted from segmental duplications and copy number variations (CNVs) in the human genome, suggesting that deletion or duplication of a UCE can be deleterious to the mammalian cell."}, {"doc_id": "25340765", "chunk_id": "25340765_4", "score": 0.37329816818237305, "text": "Ultraconserved elements (UCEs) are strongly depleted from segmental duplications and copy number variations (CNVs) in the human genome, suggesting that deletion or duplication of a UCE can be deleterious to the mammalian cell"}], "context": "[25340765:25340765_0] Abnormal dosage of ultraconserved elements is highly disfavored in healthy cells but not cancer cells.\n[25340765:25340765_5] Ultraconserved elements (UCEs) are strongly depleted from segmental duplications and copy number variations (CNVs) in the human genome, suggesting that deletion or duplication of a UCE can be deleterious to the mammalian cell.\n[25340765:25340765_4] Ultraconserved elements (UCEs) are strongly depleted from segmental duplications and copy number variations (CNVs) in the human genome, suggesting that deletion or duplication of a UCE can be deleterious to the mammalian cell", "answer": "<think> Okay, let's tackle this question. The user is asking if abnormal dosage of ultraconserved elements (UCEs) is disfavored in cancer cells. The evidence provided has three chunks. First, I need to parse each chunk. The first one says that abnormal dosage of UCEs is highly disfavored in healthy cells but not in cancer cells. That directly answers the question. The second and third chunks both mention that UCEs are depleted from CNVs and segmental duplications, implying that altering their dosage is harmful. But wait, the question is about cancer cells specifically. The first chunk explicitly states that in cancer cells, abnormal dosage isn't disfavored. The other chunks talk about general deleterious effects, but the question is about cancer. So the answer should focus on the first chunk. The confidence here is high because the first chunk directly addresses the scenario in cancer cells. The other chunks support why UCEs are important but don't directly address cancer. So the answer should cite the first chunk and have a base confidence of 1.0 since the evidence directly states that abnormal dosage isn't disfavored in cancer cells. </think>", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if abnormal dosage of ultraconserved elements (UCEs) is disfavored in cancer cells. The evidence provided has three chunks. First, I need to parse each chunk. The first one says that abnormal dosage of UCEs is highly disfavored in healthy cells but not in cancer cells. That directly answers the question. The second and third chunks both mention that UCEs are depleted from CNVs and segmental duplications, implying that altering their dosage is harmful. But wait, the question is about cancer cells specifically. The first chunk explicitly states that in cancer cells, abnormal dosage isn't disfavored. The other chunks talk about general deleterious effects, but the question is about cancer. So the answer should focus on the first chunk. The confidence here is high because the first chunk directly addresses the scenario in cancer cells. The other chunks support why UCEs are important but don't directly address cancer. So the answer should cite the first chunk and have a base confidence of 1.0 since the evidence directly states that abnormal dosage isn't disfavored in cancer cells. </think>", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if abnormal dosage of ultraconserved elements is disfavored in cancer cells. First, I need to look at the evidence provided. There are three chunks from the same document (25340765). The first chunk says that abnormal dosage of UCEs is highly disfavored in healthy cells but not in cancer cells. That directly answers the question. So the answer would be based on this chunk. The second and third chunks mention that UCEs are depleted from CNVs and segmental duplications, implying that deleting or duplicating a UCE is harmful. But these chunks talk about healthy cells, not cancer cells. However, they do suggest that such variations are deleterious. But the first chunk specifically states that in cancer cells, it's not disfavored. So the main evidence here is the first chunk. The answer should be derived from that. The confidence would be high because the first chunk directly addresses the question. The other chunks support the idea that UCEs are important, but they don't mention cancer cells. So the base confidence is 1.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if abnormal dosage of ultraconserved elements (UCEs) is disfavored in cancer cells. The evidence provided has three chunks. First, I need to parse each chunk. The first one says that abnormal dosage of UCEs is highly disfavored in healthy cells but not in cancer cells. That directly answers the question. The other two chunks mention that UCEs are depleted from CNVs and that deletions or duplications can be deleterious, which suggests that having abnormal doses might be bad for normal cells, but not necessarily in cancer. So the key point is the first chunk explicitly states that in cancer cells, it's not disfavored. The other chunks support that in healthy cells, UCEs are important and their duplication is harmful. Therefore, the answer should reference the first chunk. The confidence would be high because the first chunk directly addresses the question. The other evidence supports the idea that UCEs are important in normal cells but not in cancer, so the answer is based on the first chunk's information. </think> { \"answer\": \"Yes, abnormal dosage of ultra", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["25340765"], "ideal_answer": "No. Abnormal dosage of ultraconserved elements is highly disfavored in healthy cells but not cancer cells."}
{"question_id": "515ac533d24251bc050000a9", "question": "Does thyroid hormone regulate calcium transient in the myocardium?", "retrieved_chunks": [{"doc_id": "2428004", "chunk_id": "2428004_0", "score": 2.460783004760742, "text": "hese results indicate that the thyroid state influences the time course of the calcium transient and are consistent with the abbreviation in the duration of contraction that is observed in the hyperthyroid state."}, {"doc_id": "9875761", "chunk_id": "9875761_0", "score": 1.618147850036621, "text": "In normal porcine myocardium T3 had no effect on the extent of isometric force generation but accelerated the time course of force development (p < 0.05) and increased the calcium transient (p < 0.001). After induction of myocardial depression by epinephrine exposure T3 accelerated the intracellular calcium transients and reduced diastolic calcium"}, {"doc_id": "20730619", "chunk_id": "20730619_1", "score": 0.5367825627326965, "text": "It has been previously shown that regulators of physiological growth such as thyroid hormone (TH) can favorably remodel the post ischaemic myocardium."}], "context": "[2428004:2428004_0] hese results indicate that the thyroid state influences the time course of the calcium transient and are consistent with the abbreviation in the duration of contraction that is observed in the hyperthyroid state.\n[9875761:9875761_0] In normal porcine myocardium T3 had no effect on the extent of isometric force generation but accelerated the time course of force development (p < 0.05) and increased the calcium transient (p < 0.001). After induction of myocardial depression by epinephrine exposure T3 accelerated the intracellular calcium transients and reduced diastolic calcium\n[20730619:20730619_1] It has been previously shown that regulators of physiological growth such as thyroid hormone (TH) can favorably remodel the post ischaemic myocardium.", "answer": "<think> Okay, let's tackle this question. The user is asking if thyroid hormone regulates calcium transients in the myocardium. I need to look at the evidence provided to find answers. First, looking at the evidence: The first document (2428004:2428004_0) says that thyroid state affects the time course of calcium transient and is consistent with the duration of contraction in hyperthyroid states. That suggests a connection between thyroid function and calcium transients. The second document (9875761:9875761_0) mentions that T3 (thyroid hormone) accelerates the time course of force development and increases the calcium transient in normal porcine myocardium. Also, after epinephrine-induced depression, T3 speeds up calcium transients. This directly links thyroid hormone to changes in calcium transients. The third document (20730619:20730619_1) talks about thyroid hormone remodeling post-ischaemic myocardium, but it's more general and doesn't specifically mention calcium transients. So maybe not", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if thyroid hormone regulates calcium transients in the myocardium. I need to look at the evidence provided to find answers. First, looking at the evidence: The first document (2428004:2428004_0) says that thyroid state affects the time course of calcium transient and is consistent with the duration of contraction in hyperthyroid states. That suggests a connection between thyroid function and calcium transients. The second document (9875761:9875761_0) mentions that T3 (thyroid hormone) accelerates the time course of force development and increases the calcium transient in normal porcine myocardium. Also, after epinephrine-induced depression, T3 speeds up calcium transients. This directly links thyroid hormone to changes in calcium transients. The third document (20730619:20730619_1) talks about thyroid hormone remodeling post-ischaemic myocardium, but it's more general and doesn't specifically mention calcium transients. So maybe not", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user wants to know if thyroid hormone regulates calcium transients in the myocardium. I need to look at the provided evidence and see which parts support that. First, looking at evidence [9875761:9875761_0], it says that T3 (thyroid hormone) accelerates the time course of force development and increases the calcium transient in normal porcine myocardium. There's a p-value mentioned, which suggests statistical significance. So this directly indicates that thyroid hormone does affect calcium transients. Another piece is [2428004:2428004_0], which mentions that thyroid state influences the time course of the calcium transient, consistent with the duration of contraction in hyperthyroid states. This also supports the idea that thyroid hormones regulate calcium transients. The third evidence [20730619:20730619_1] talks about thyroid hormone remodeling post-ischaemic myocardium, but it's more about growth regulation rather than directly addressing calcium transients. So maybe less direct.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if thyroid hormone regulates calcium transients in the myocardium. I need to look at the provided evidence to find answers. First, evidence from [9875761:9875761_0] says that T3 (a form of thyroid hormone) accelerates the time course of force development and increases the calcium transient in normal porcine myocardium. There's a p-value mentioned, which suggests statistical significance. So this directly supports the idea that thyroid hormone affects calcium transients. Another piece is [2428004:2428004_0], which mentions that thyroid state influences the calcium transient's time course, aligning with the duration of contraction in hyperthyroid states. This also points to a regulatory role. The third evidence [20730619:20730619_1] talks about thyroid hormone remodeling post-ischaemic myocardium, but it's more about growth regulation rather than directly addressing calcium transients. So maybe less relevant here. So the main points are from the", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["19298522", "2428004", "9773867", "9875761"], "ideal_answer": "YES"}
{"question_id": "533c2230c45e133714000002", "question": "What are the biological roles proposed for proteins containing the SPRY domain?", "retrieved_chunks": [{"doc_id": "23139046", "chunk_id": "23139046_0", "score": 5.252073764801025, "text": "SPRY domain is a protein interaction module found in 77 murine and ~100 human proteins, and is implicated in important biological pathways, including those that regulate innate and adaptive immunity"}, {"doc_id": "23139046", "chunk_id": "23139046_1", "score": 2.7821950912475586, "text": "function of the SPRY/B30.2 domain proteins involved in innate immunity"}, {"doc_id": "12479811", "chunk_id": "12479811_1", "score": 0.8123128414154053, "text": "SPRY-domain and SOCS-box containing protein, GUSTAVUS."}], "context": "[23139046:23139046_0] SPRY domain is a protein interaction module found in 77 murine and ~100 human proteins, and is implicated in important biological pathways, including those that regulate innate and adaptive immunity\n[23139046:23139046_1] function of the SPRY/B30.2 domain proteins involved in innate immunity\n[12479811:12479811_1] SPRY-domain and SOCS-box containing protein, GUSTAVUS.", "answer": "<think> Okay, let's tackle this question. The user is asking about the biological roles of proteins with the SPRY domain. I need to look at the provided evidence to form an answer. First, looking at the evidence: The first document (23139046:23139046_0) says that the SPRY domain is involved in regulating innate and adaptive immunity. That's a key point. The second chunk (23139046:23139046_1) specifically mentions the SPRY/B30.2 domain proteins being involved in innate immunity. The third document (12479811:12479811_1) talks about a protein with both SPRY and SOCS-box domains, but it's not clear if that's a role or just an example. So the main roles seem to be in immune pathways. The first two documents both point to innate and adaptive immunity. The third one might be a supporting example but doesn't add new information about the roles. I should combine the information from the first two chunks", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking about the biological roles of proteins with the SPRY domain. I need to look at the provided evidence to form an answer. First, looking at the evidence: The first document (23139046:23139046_0) says that the SPRY domain is involved in regulating innate and adaptive immunity. That's a key point. The second chunk (23139046:23139046_1) specifically mentions the SPRY/B30.2 domain proteins being involved in innate immunity. The third document (12479811:12479811_1) talks about a protein with both SPRY and SOCS-box domains, but it's not clear if that's a role or just an example. So the main roles seem to be in immune pathways. The first two documents both point to innate and adaptive immunity. The third one might be a supporting example but doesn't add new information about the roles. I should combine the information from the first two chunks", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to generate a biomedical answer about the biological roles of proteins with the SPRY domain. Let me start by looking at the evidence provided. The first piece of evidence says that the SPRY domain is involved in regulating innate and adaptive immunity. The second mentions that SPRY/B30.2 domain proteins are specifically involved in innate immunity. The third one talks about a protein called GUSTAVUS, which contains both SPRY and SOCS-box domains. So, putting this together, the main roles seem to be in immune pathways. The first two references directly mention innate and adaptive immunity. The third might be an example of a specific protein, but the key point is the role in immunity. I should make sure to cite the relevant documents. The answer needs to be concise, so I'll combine the mentions of innate and adaptive immunity, citing the first two sources. The confidence level should be high since multiple sources support this. Let me check if there's any conflicting information, but all evidence points to immune-related functions. So the answer is that SPRY domain proteins are involved in regulating innate and adaptive immunity, with citations from 23139", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the biological roles of proteins with the SPRY domain. I need to look at the provided evidence to form an answer. First, evidence [23139046:23139046_0] says that SPRY domain is in proteins involved in innate and adaptive immunity. Then [23139046:23139046_1] specifically mentions the function related to innate immunity. The third piece, [12479811:12479812_1], talks about SPRY-domain and SOCS-box containing protein GUSTAVUS. But I'm not sure if that's a specific role or just an example. So the main points are innate and adaptive immunity. The answer should combine these. Also, the confidence level: since two sources mention immunity, and one gives an example, maybe the confidence is high. Let me check the chunks again. The first two chunks directly talk about roles in immunity pathways. The third might be a specific example but not a general role. So", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["12479811", "15689398", "15857996", "16226405", "16313355", "16648259", "17431422", "19184407", "21035437", "22337885", "22872646", "23091002", "23139046", "23775985", "23886867"], "ideal_answer": "defence against retroviral infection innate and adaptative immunity vesicular trafficking neural differentiation embryonic development"}
{"question_id": "511979b04eab811676000003", "question": "How could we infer functional associations from gene fusion events?", "retrieved_chunks": [{"doc_id": "12519996", "chunk_id": "12519996_1", "score": 6.628170967102051, "text": "Functional links between proteins can often be inferred from genomic associations between the genes that encode them: groups of genes that are required for the same function tend to show similar species coverage, are often located in close proximity on the genome (in prokaryotes), and tend to be involved in gene-fusion events. The database STRING is a precomputed global resource for the exploration and analysis of these associations."}, {"doc_id": "12519996", "chunk_id": "12519996_0", "score": 6.149778842926025, "text": "Functional links between proteins can often be inferred from genomic associations between the genes that encode them: groups of genes that are required for the same function tend to show similar species coverage, are often located in close proximity on the genome (in prokaryotes), and tend to be involved in gene-fusion events."}, {"doc_id": "18546511", "chunk_id": "18546511_0", "score": 5.7166643142700195, "text": "The detection of gene fusion events across genomes can be used for the prediction of functional associations of proteins, including physical interactions or complex formation."}], "context": "[12519996:12519996_1] Functional links between proteins can often be inferred from genomic associations between the genes that encode them: groups of genes that are required for the same function tend to show similar species coverage, are often located in close proximity on the genome (in prokaryotes), and tend to be involved in gene-fusion events. The database STRING is a precomputed global resource for the exploration and analysis of these associations.\n[12519996:12519996_0] Functional links between proteins can often be inferred from genomic associations between the genes that encode them: groups of genes that are required for the same function tend to show similar species coverage, are often located in close proximity on the genome (in prokaryotes), and tend to be involved in gene-fusion events.\n[18546511:18546511_0] The detection of gene fusion events across genomes can be used for the prediction of functional associations of proteins, including physical interactions or complex formation.", "answer": "<think> Okay, I need to generate a candidate biomedical answer based on the given evidence. Let me start by understanding the question: How could we infer functional associations from gene fusion events? Looking at the evidence provided, there are three documents. The first two (12519996) mention that functional links can be inferred from genomic associations, including gene fusion events. They talk about genes required for the same function showing similar species coverage, proximity in the genome, and involvement in gene-fusion events. The third document (18546511) states that detecting gene fusion events across genomes can predict protein functional associations, like physical interactions or complex formation. So, the answer should tie together the idea that gene fusions are a method to infer functional links. The confidence level needs to be set based on how strongly the evidence supports this. Since two of the three documents directly mention using gene fusions for predicting functional associations, and the third reinforces that, I think the confidence is pretty high. Maybe around 0.95? Now, structuring the answer: It should be concise, citing the relevant documents. The ans", "citations": [], "candidates": [{"answer": "<think> Okay, I need to generate a candidate biomedical answer based on the given evidence. Let me start by understanding the question: How could we infer functional associations from gene fusion events? Looking at the evidence provided, there are three documents. The first two (12519996) mention that functional links can be inferred from genomic associations, including gene fusion events. They talk about genes required for the same function showing similar species coverage, proximity in the genome, and involvement in gene-fusion events. The third document (18546511) states that detecting gene fusion events across genomes can predict protein functional associations, like physical interactions or complex formation. So, the answer should tie together the idea that gene fusions are a method to infer functional links. The confidence level needs to be set based on how strongly the evidence supports this. Since two of the three documents directly mention using gene fusions for predicting functional associations, and the third reinforces that, I think the confidence is pretty high. Maybe around 0.95? Now, structuring the answer: It should be concise, citing the relevant documents. The ans", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to generate a candidate biomedical answer based on the provided evidence. Let me start by understanding the question: How could we infer functional associations from gene fusion events? Looking at the evidence, there are three documents. The first two (12519996) mention that functional links can be inferred from genomic associations, including gene-fusion events. They also talk about similar species coverage, proximity in the genome, and gene-fusion events. The third document (18546511) says that detecting gene fusion events across genomes can predict functional associations like physical interactions or complex formation. So the answer should tie together the idea that gene fusion events are a method to infer functional links. The confidence level needs to be a float between 0 and 1. Since two of the three sources mention gene fusion events in this context, and the third supports it as well, I can be fairly confident. Maybe a base_confidence of 0.9? Now, structuring the answer: It should be concise, citing the relevant documents. The answer would state that gene fusion events are used to predict functional associations, citing the third document,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user wants to know how we can infer functional associations from gene fusion events. Looking at the evidence provided, there are three references. First, reference [12519996:12519996_1] and [12519996:12519996_0] both mention that functional links can be inferred from genomic associations. They talk about genes required for the same function showing similar species coverage, proximity in the genome (especially in prokaryotes), and involvement in gene-fusion events. So, gene fusion events are part of these associations. Then, reference [18546511:18546511_0] states that detecting gene fusion events across genomes can predict functional associations, like physical interactions or complex formation. That's a direct point about using gene fusions to infer function. So the answer should combine these points. The main idea is that gene fusion events indicate that two genes are functionally related because they're fused, so their products likely work together. Also, STRING database is", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["10573422", "11178267", "11438739", "11820254", "11864366", "12049665", "12095249", "12429059", "12429063", "12519996", "12952538", "14673105", "15128449", "15215406", "15701682", "15960802", "15980440", "16221304", "16381848", "16571130", "17597916", "17767732", "18025684", "18081932", "18546511", "18629289", "19582169", "20532224", "20851221", "21729286", "22161322", "22267904", "22925561", "23220349", "23365410"], "ideal_answer": "The detection of gene fusion events across genomes can be used for the prediction of functional associations of proteins, based on the observation that related proteins in one organism (including physically interacting proteins/members of complexes, proteins involved in the same pathway) tend to be found in other species as a fused composite gene encoding a single multifunctional protein. For this purpose, gene fusion events may be used as the sole evidence or as independent information combined with other 'genome-aware' or similarity-based methods, and functional association may be predicted at different levels. An advantage of this approach is that it is not necessary to know the function of the composite/components to infer association."}
{"question_id": "514241fcd24251bc05000006", "question": "The protein NONO forms heterodimers. With which proteins?", "retrieved_chunks": [{"doc_id": "22416126", "chunk_id": "22416126_0", "score": 5.8980278968811035, "text": "Structure of the heterodimer of human NONO and paraspeckle protein component 1"}, {"doc_id": "22101825", "chunk_id": "22101825_1", "score": 5.792722225189209, "text": "difficult heterodimeric complex of two human proteins, paraspeckle component 1 (PSPC1) and non-POU domain-containing octamer-binding protein (NONO), that are involved in gene regulation and the structural integrity of nuclear bodies termed paraspeckles is described."}, {"doc_id": "22102035", "chunk_id": "22102035_1", "score": 5.631742477416992, "text": "The paraspeckle component 1 (PSPC1) and non-POU-domain-containing octamer-binding protein (NONO) heterodimer is an essential structural component of paraspeckles,"}], "context": "[22416126:22416126_0] Structure of the heterodimer of human NONO and paraspeckle protein component 1\n[22101825:22101825_1] difficult heterodimeric complex of two human proteins, paraspeckle component 1 (PSPC1) and non-POU domain-containing octamer-binding protein (NONO), that are involved in gene regulation and the structural integrity of nuclear bodies termed paraspeckles is described.\n[22102035:22102035_1] The paraspeckle component 1 (PSPC1) and non-POU-domain-containing octamer-binding protein (NONO) heterodimer is an essential structural component of paraspeckles,", "answer": "<think> Okay, let's tackle this question. The user wants to know which proteins form heterodimers with NONO. The evidence provided has three documents. First, looking at the document IDs and their chunk IDs. The first one, 22416126:22416126_0, mentions the heterodimer of human NONO and paraspeckle protein component 1. So that's PSPC1. The second document, 22101825:22101825_1, talks about a difficult heterodimeric complex between PSPC1 and NONO. The third one, 22102035:22102035_1, again mentions the same pair: PSPC1 and NONO forming a heterodimer. So all three sources point to PSPC1 as the protein that forms a heterodimer with NONO. The answer should be concise, citing the relevant documents. The confidence is high since all three pieces of evidence support this. So base_confidence would be 1.0.", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user wants to know which proteins form heterodimers with NONO. The evidence provided has three documents. First, looking at the document IDs and their chunk IDs. The first one, 22416126:22416126_0, mentions the heterodimer of human NONO and paraspeckle protein component 1. So that's PSPC1. The second document, 22101825:22101825_1, talks about a difficult heterodimeric complex between PSPC1 and NONO. The third one, 22102035:22102035_1, again mentions the same pair: PSPC1 and NONO forming a heterodimer. So all three sources point to PSPC1 as the protein that forms a heterodimer with NONO. The answer should be concise, citing the relevant documents. The confidence is high since all three pieces of evidence support this. So base_confidence would be 1.0.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user wants to know which proteins form heterodimers with NONO. The evidence provided has three references. First, looking at the evidence: - The first document (22416126) mentions a heterodimer of human NONO and paraspeckle protein component 1. So that's PSPC1. - The second document (22101825) talks about a complex involving PSPC1 and NONO, again pointing to the same proteins. - The third document (22102035) confirms the heterodimer between PSPC1 and NONO as part of paraspeckles. All three sources consistently mention that NONO forms a heterodimer with PSPC1. There's no mention of any other proteins in these references. So the answer should be PSPC1. The confidence is high because all three documents support this. I need to make sure the citations are correctly formatted as per the example. The base_confidence can be 1.0 since the evidence is consistent across multiple sources. </think> { \"answer\": \"The", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user wants to know which proteins form heterodimers with NONO. The evidence provided has three documents. First, looking at the document IDs and their chunks. The first one, 22416126:22416126_0, mentions the heterodimer of human NONO and paraspeckle protein component 1. So that's a direct mention of PSPC1. The second document, 22101825:22101825_1, talks about a difficult heterodimeric complex of PSPC1 and NONO. Again, same proteins. The third one, 22102035:22102035_1, also states that the heterodimer is between PSPC1 and NONO. All three sources consistently point to PSPC1 as the protein forming a heterodimer with NONO. There's no mention of any other proteins in these references. The answer should be PSPC1, citing the relevant documents. The confidence is high since all", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["16148043", "18655028", "19423654", "20421735", "22101825", "22102035", "22416126"], "ideal_answer": "The protein NONO forms heterodimers with PSPC1, SFPQ."}
{"question_id": "5709ee36cf1c32585100001e", "question": "Which syndrome is associated with mutant DVL1?", "retrieved_chunks": [{"doc_id": "25817014", "chunk_id": "25817014_1", "score": 6.228790283203125, "text": "Mutations in DVL1 cause an osteosclerotic form of Robinow syndrome."}, {"doc_id": "25817016", "chunk_id": "25817016_0", "score": 5.217873573303223, "text": "DVL1 frameshift mutations clustering in the penultimate exon cause autosomal-dominant Robinow syndrome."}, {"doc_id": "25817014", "chunk_id": "25817014_0", "score": 2.777920722961426, "text": "Here, we identified de novo frameshift mutations in DVL1, a mediator of both canonical and non-canonical Wnt signaling, as the cause of RS-OS, an RS subtype involving osteosclerosis, in three unrelated individuals."}], "context": "[25817014:25817014_1] Mutations in DVL1 cause an osteosclerotic form of Robinow syndrome.\n[25817016:25817016_0] DVL1 frameshift mutations clustering in the penultimate exon cause autosomal-dominant Robinow syndrome.\n[25817014:25817014_0] Here, we identified de novo frameshift mutations in DVL1, a mediator of both canonical and non-canonical Wnt signaling, as the cause of RS-OS, an RS subtype involving osteosclerosis, in three unrelated individuals.", "answer": "<think> Okay, let's tackle this question. The user is asking which syndrome is associated with mutant DVL1. Looking at the evidence provided, there are a few documents mentioning DVL1 and Robinow syndrome. First, document [25817014:25817014_1] states that mutations in DVL1 cause an osteosclerotic form of Robinow syndrome. So that's a direct link between DVL1 mutations and Robinow syndrome, specifically the osteosclerotic type. Another document [25817016:25817016_0] mentions DVL1 frameshift mutations causing autosomal-dominant Robinow syndrome. This reinforces that Robinow syndrome is the syndrome in question here. The third document [25817014:25817014_0] talks about de novo frameshift mutations in DVL1 leading to RS-OS, which is a subtype of Robinow syndrome involving osteosclerosis. All these references point to Robinow syndrome. The answer should be Robinow syndrome, and", "citations": [{"doc_id": "25817014", "chunk_id": "25817014_1"}, {"doc_id": "25817016", "chunk_id": "25817016_0"}, {"doc_id": "25817014", "chunk_id": "25817014_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which syndrome is associated with mutant DVL1. Looking at the evidence provided, there are a few documents mentioning DVL1 and Robinow syndrome. First, document [25817014:25817014_1] states that mutations in DVL1 cause an osteosclerotic form of Robinow syndrome. So that's a direct link between DVL1 mutations and Robinow syndrome, specifically the osteosclerotic type. Another document [25817016:25817016_0] mentions DVL1 frameshift mutations causing autosomal-dominant Robinow syndrome. This reinforces that Robinow syndrome is the syndrome in question here. The third document [25817014:25817014_0] talks about de novo frameshift mutations in DVL1 leading to RS-OS, which is a subtype of Robinow syndrome involving osteosclerosis. All these references point to Robinow syndrome. The answer should be Robinow syndrome, and", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which syndrome is associated with mutant DVL1. Looking at the evidence provided, there are a few documents mentioning DVL1 and Robinow syndrome. First, document 25817014:25817014_1 states that mutations in DVL1 cause an osteosclerotic form of Robinow syndrome. Then, document 25817016:25817016_0 mentions DVL1 frameshift mutations causing autosomal-dominant Robinow syndrome. Another entry from the same document (25817014:25817014_0) talks about de novo frameshift mutations in DVL1 leading to RS-OS, which is an osteosclerotic subtype of Robinow syndrome. So, all these references point to Robinow syndrome. The different parts mention various forms of it, like osteosclerotic (RS-OS) and the autosomal-dominant form. The key here is that DVL1 mutations are linked to Robinow", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which syndrome is associated with mutant DVL1. The evidence provided has three chunks. First, chunk 25817014_1 says mutations in DVL1 cause an osteosclerotic form of Robinow syndrome. So that directly links DVL1 to Robinow syndrome, specifically the osteosclerotic type. Then chunk 25817016_0 mentions DVL1 frameshift mutations causing autosomal-dominant Robinow syndrome. This reinforces that Robinow syndrome is the answer here. The third chunk, 25817014_0, talks about de novo frameshift mutations in DVL1 causing RS-OS, which is an osteosclerosis subtype of Robinow. So all three chunks point to Robinow syndrome. I need to make sure there's no other syndrome mentioned. The answer should be Robinow syndrome. The confidence is high because multiple chunks cite the same syndrome. So base_confidence should be 1.0. </think> { \"answer\": \"Robinow syndrome [25", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["25817014", "25817016"], "ideal_answer": "Mutations in DVL1 cause an osteosclerotic form of Robinow syndrome."}
{"question_id": "517179718ed59a060a00000e", "question": "Are proteasome inhibitors good candidates for treatment of leukemia and solid tumors?", "retrieved_chunks": [{"doc_id": "16258456", "chunk_id": "16258456_1", "score": 8.169944763183594, "text": "Preclinical evidence using bortezomib, the only proteasome inhibitor to enter clinical trials, suggests that proteasome inhibition may be effective in the treatment of hematologic and solid malignancies by promoting apoptosis, retarding angiogenesis, and inhibiting tumor cell adhesion and production of growth factors by acting on molecules such as nuclear factor-kappaB."}, {"doc_id": "22027222", "chunk_id": "22027222_0", "score": 8.061288833618164, "text": "The proteasome inhibitor bortezomib, registered for Multiple Myeloma treatment, is currently explored for activity in solid tumors including non-small cell lung cancer (NSCLC)."}, {"doc_id": "21634429", "chunk_id": "21634429_0", "score": 6.557025909423828, "text": "Bortezomib, a dipeptidyl boronic acid and potent inhibitor of the 26S proteasome, is remarkably effective against multiple myeloma (MM) but not against solid tumors."}], "context": "[16258456:16258456_1] Preclinical evidence using bortezomib, the only proteasome inhibitor to enter clinical trials, suggests that proteasome inhibition may be effective in the treatment of hematologic and solid malignancies by promoting apoptosis, retarding angiogenesis, and inhibiting tumor cell adhesion and production of growth factors by acting on molecules such as nuclear factor-kappaB.\n[22027222:22027222_0] The proteasome inhibitor bortezomib, registered for Multiple Myeloma treatment, is currently explored for activity in solid tumors including non-small cell lung cancer (NSCLC).\n[21634429:21634429_0] Bortezomib, a dipeptidyl boronic acid and potent inhibitor of the 26S proteasome, is remarkably effective against multiple myeloma (MM) but not against solid tumors.", "answer": "<think> Okay, let's tackle this question. The user is asking if proteasome inhibitors are good candidates for treating leukemia and solid tumors. The evidence provided has three chunks. First chunk (16258456:16258456_1) says that bortezomib, a proteasome inhibitor, shows promise in hematologic and solid malignancies by promoting apoptosis, retarding angiogenesis, etc. So this supports the idea that they could be effective. Second chunk (22027222:22027222_0) mentions that bortezomib is used for multiple myeloma and being explored for solid tumors like NSCLC. This also suggests potential in solid tumors. Third chunk (21634429:21634429_0) states that bortezomib is effective against MM but not solid tumors. Wait, this seems contradictory to the previous points. But maybe it's referring to specific cases where it's not effective, but other studies show potential. So, combining these, there's evidence both for", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if proteasome inhibitors are good candidates for treating leukemia and solid tumors. The evidence provided has three chunks. First chunk (16258456:16258456_1) says that bortezomib, a proteasome inhibitor, shows promise in hematologic and solid malignancies by promoting apoptosis, retarding angiogenesis, etc. So this supports the idea that they could be effective. Second chunk (22027222:22027222_0) mentions that bortezomib is used for multiple myeloma and being explored for solid tumors like NSCLC. This also suggests potential in solid tumors. Third chunk (21634429:21634429_0) states that bortezomib is effective against MM but not solid tumors. Wait, this seems contradictory to the previous points. But maybe it's referring to specific cases where it's not effective, but other studies show potential. So, combining these, there's evidence both for", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if proteasome inhibitors are good candidates for treating leukemia and solid tumors. The evidence provided has three chunks. First, chunk 16258456_1 mentions that bortezomib, a proteasome inhibitor, shows effectiveness in hematologic and solid malignancies by promoting apoptosis and other mechanisms. That's a positive sign for both leukemia (hematologic) and solid tumors. Chunk 22027222_0 says bortezomib is used for multiple myeloma and being explored for solid tumors like NSCLC. So, solid tumors are being looked into, but the effectiveness here isn't confirmed yet. Chunk 21634429_0 states that bortezomib is effective against multiple myeloma but not solid tumors. This seems contradictory to the previous chunk. Wait, maybe the difference is between MM and other solid tumors? The first chunk says \"solid malignancies\" in general, while this one says it's not effective against solid tumors. But the second chunk mentions exploration for solid tumors like NSCL", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user wants to know if proteasome inhibitors are good candidates for treating leukemia and solid tumors. The evidence provided has three chunks. First chunk [16258456:16258456_1] says that bortezomib, a proteasome inhibitor, shows promise in hematologic and solid malignancies by promoting apoptosis, etc. So this suggests they might be effective. Second chunk [22027222:22027222_0] mentions that bortezomib is used for multiple myeloma and being explored for solid tumors like NSCLC. This supports the idea that they can be used in solid tumors. Third chunk [21634429:21634429_0] states that bortezomib is effective against MM but not solid tumors. Wait, this seems conflicting with the second chunk. But maybe it's saying that while it works for MM, it's not effective for solid tumors? Or perhaps there's a nuance here. But the question", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["12171876", "15169797", "16135477", "17145882", "17431003", "19712963", "19821999", "20160034", "20219102", "22012631", "22057347", "22134540", "22353937", "22995770", "23181572", "23477519"], "ideal_answer": "Yes, several compounds that inhibit different members of the proteasome pathway (for example Bortezomib) are on trial for treatment of leukemia and solid tumors. It seems that a combination with other drugs may be a useful therapy for solid tumors."}
{"question_id": "553cae13f32186855800000e", "question": "Is there any link between CTF4 and CTF18 during sister chromatid cohesion?", "retrieved_chunks": [{"doc_id": "11287619", "chunk_id": "11287619_0", "score": 8.450674057006836, "text": "CTF4 and CTF18 are required for high-fidelity chromosome segregation. Both exhibit genetic and physical ties to replication fork constituents. We find that absence of either CTF4 or CTF18 causes sister chromatid cohesion failure and leads to a preanaphase accumulation of cells that depends on the spindle assembly checkpoint. The physical and genetic interactions between CTF4, CTF18, and core components of replication fork complexes observed in this study and others suggest that both gene products act in association with the replication fork to facilitate sister chromatid cohesion."}, {"doc_id": "11287619", "chunk_id": "11287619_4", "score": 8.312291145324707, "text": "The physical and genetic interactions between CTF4, CTF18, and core components of replication fork complexes observed in this study and others suggest that both gene products act in association with the replication fork to facilitate sister chromatid cohesion."}, {"doc_id": "11287619", "chunk_id": "11287619_3", "score": 7.9851484298706055, "text": "The physical and genetic interactions between CTF4, CTF18, and core components of replication fork complexes observed in this study and others suggest that both gene products act in association with the replication fork to facilitate sister chromatid cohesion"}], "context": "[11287619:11287619_0] CTF4 and CTF18 are required for high-fidelity chromosome segregation. Both exhibit genetic and physical ties to replication fork constituents. We find that absence of either CTF4 or CTF18 causes sister chromatid cohesion failure and leads to a preanaphase accumulation of cells that depends on the spindle assembly checkpoint. The physical and genetic interactions between CTF4, CTF18, and core components of replication fork complexes observed in this study and others suggest that both gene products act in association with the replication fork to facilitate sister chromatid cohesion.\n[11287619:11287619_4] The physical and genetic interactions between CTF4, CTF18, and core components of replication fork complexes observed in this study and others suggest that both gene products act in association with the replication fork to facilitate sister chromatid cohesion.\n[11287619:11287619_3] The physical and genetic interactions between CTF4, CTF18, and core components of replication fork complexes observed in this study and others suggest that both gene products act in association with the replication fork to facilitate sister chromatid cohesion", "answer": "<think> Okay, let's tackle this question. The user is asking if there's a link between CTF4 and CTF18 during sister chromatid cohesion. First, I need to look at the evidence provided. There are three chunks from the same source, all referencing a study (11287619). Let me read through them carefully. Chunk 1 says that both CTF4 and CTF18 are required for high-fidelity chromosome segregation and have genetic and physical ties to replication fork components. Their absence leads to sister chromatid cohesion failure and preanaphase cell accumulation dependent on the spindle assembly checkpoint. Chunks 2 and 3 repeat the same point about physical and genetic interactions between CTF4, CTF18, and replication fork complexes suggesting both act with the replication fork to facilitate sister chromatid cohesion. So, the key points here are that both genes are involved in sister chromatid cohesion, they interact genetically and physically with replication fork components, and their absence causes cohesion failure. The study indicates they work together in association with replication forks to maintain cohesion. The question is about a link between them during sister chromatid cohesion.", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if there's a link between CTF4 and CTF18 during sister chromatid cohesion. First, I need to look at the evidence provided. There are three chunks from the same source, all referencing a study (11287619). Let me read through them carefully. Chunk 1 says that both CTF4 and CTF18 are required for high-fidelity chromosome segregation and have genetic and physical ties to replication fork components. Their absence leads to sister chromatid cohesion failure and preanaphase cell accumulation dependent on the spindle assembly checkpoint. Chunks 2 and 3 repeat the same point about physical and genetic interactions between CTF4, CTF18, and replication fork complexes suggesting both act with the replication fork to facilitate sister chromatid cohesion. So, the key points here are that both genes are involved in sister chromatid cohesion, they interact genetically and physically with replication fork components, and their absence causes cohesion failure. The study indicates they work together in association with replication forks to maintain cohesion. The question is about a link between them during sister chromatid cohesion.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to answer whether there's a link between CTF4 and CTF18 during sister chromatid cohesion. Let me look at the evidence provided. The first document says that both CTF4 and CTF18 are required for high-fidelity chromosome segregation and have genetic and physical ties to replication fork constituents. It also mentions that their absence leads to sister chromatid cohesion failure. So there's a direct link here. The other chunks (3 and 4) repeat the same point about their interactions suggesting they act with replication forks to facilitate cohesion. So multiple sources are pointing to this connection. The model's confidence should be high because the evidence is consistent across different parts of the same study. So the answer should state that there is a link, citing the first chunk. The base confidence would be 1.0 since all the evidence supports this. </think> { \"answer\": \"Yes, CTF4 and CTF18 are genetically and physically linked to facilitate sister chromatid cohesion, as their absence causes cohesion failure [11287619:11287619_0].\",", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if there's a link between CTF4 and CTF18 during sister chromatid cohesion. First, I need to look at the evidence provided. There are three chunks from the same source (11287619). All of them mention that CTF4 and CTF18 have physical and genetic interactions, especially with replication fork components. They also state that the absence of either gene leads to sister chromatid cohesion failure. The key points here are the genetic and physical ties between CTF4 and CTF18, their role in facilitating sister chromatid cohesion, and the effect of their absence. The answer needs to be concise with citations. The confidence level should be high since multiple chunks support the same conclusion. I should check if all the chunks are saying the same thing. Yes, they all mention the interactions and the role in cohesion. So the answer is that there's a link, citing the relevant chunks. The base confidence can be 1.0 because the evidence consistently supports this. </think> { \"answer\": \"Yes, CTF4 and CTF1", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["11287619", "14742714", "15226378", "16962805", "17483413", "19430531", "23036200", "23334284"], "ideal_answer": "Yes. CTF4 and CTF18 are required for high-fidelity chromosome segregation. Both exhibit genetic and physical ties to replication fork constituents. Absence of either CTF4 or CTF18 causes sister chromatid cohesion failure and leads to a preanaphase accumulation of cells that depends on the spindle assembly checkpoint. The physical and genetic interactions between CTF4, CTF18, and core components of replication fork complexes suggest that both gene products act in association with the replication fork to facilitate sister chromatid cohesion."}
{"question_id": "56a7d5afa17756b72f000002", "question": "What is the Genomic Regions Enrichment of Annotations Tool (GREAT)?", "retrieved_chunks": [{"doc_id": "20436461", "chunk_id": "20436461_4", "score": 9.439291000366211, "text": "We developed the Genomic Regions Enrichment of Annotations Tool (GREAT) to analyze the functional significance of cis-regulatory regions identified by localized measurements of DNA binding events across an entire genome. Whereas previous methods took into account only binding proximal to genes, GREAT is able to properly incorporate distal binding sites and control for false positives using a binomial test over the input genomic regions."}, {"doc_id": "20436461", "chunk_id": "20436461_3", "score": 9.350509643554688, "text": "We developed the Genomic Regions Enrichment of Annotations Tool (GREAT) to analyze the functional significance of cis-regulatory regions identified by localized measurements of DNA binding events across an entire genome. Whereas previous methods took into account only binding proximal to genes, GREAT is able to properly incorporate distal binding sites and control for false positives using a binomial test over the input genomic regions"}, {"doc_id": "20436461", "chunk_id": "20436461_2", "score": 8.946434020996094, "text": "We developed the Genomic Regions Enrichment of Annotations Tool (GREAT) to analyze the functional significance of cis-regulatory regions identified by localized measurements of DNA binding events across an entire genome."}], "context": "[20436461:20436461_4] We developed the Genomic Regions Enrichment of Annotations Tool (GREAT) to analyze the functional significance of cis-regulatory regions identified by localized measurements of DNA binding events across an entire genome. Whereas previous methods took into account only binding proximal to genes, GREAT is able to properly incorporate distal binding sites and control for false positives using a binomial test over the input genomic regions.\n[20436461:20436461_3] We developed the Genomic Regions Enrichment of Annotations Tool (GREAT) to analyze the functional significance of cis-regulatory regions identified by localized measurements of DNA binding events across an entire genome. Whereas previous methods took into account only binding proximal to genes, GREAT is able to properly incorporate distal binding sites and control for false positives using a binomial test over the input genomic regions\n[20436461:20436461_2] We developed the Genomic Regions Enrichment of Annotations Tool (GREAT) to analyze the functional significance of cis-regulatory regions identified by localized measurements of DNA binding events across an entire genome.", "answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. The question is about what the GREAT tool is. Let me look at the evidence provided. The evidence has three chunks, all from the same document ID and different chunk IDs. They all mention that GREAT was developed to analyze the functional significance of cis-regulatory regions identified by DNA binding events across the genome. The key points are that previous methods only considered proximal binding sites, but GREAT incorporates distal ones and uses a binomial test to control for false positives. So the answer should be concise, mentioning that GREAT analyzes the functional significance of cis-regulatory regions using DNA binding data, incorporating both proximal and distal sites, and using a binomial test. The citation would be from the first chunk since it's the first mention. The confidence level is high because all three chunks support the same information. I'll set base_confidence to 1.0. </think> { \"answer\": \"The Genomic Regions Enrichment of Annotations Tool (GREAT) is designed to analyze the functional significance of cis-regulatory regions identified by localized DNA binding events across the genom", "citations": [], "candidates": [{"answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. The question is about what the GREAT tool is. Let me look at the evidence provided. The evidence has three chunks, all from the same document ID and different chunk IDs. They all mention that GREAT was developed to analyze the functional significance of cis-regulatory regions identified by DNA binding events across the genome. The key points are that previous methods only considered proximal binding sites, but GREAT incorporates distal ones and uses a binomial test to control for false positives. So the answer should be concise, mentioning that GREAT analyzes the functional significance of cis-regulatory regions using DNA binding data, incorporating both proximal and distal sites, and using a binomial test. The citation would be from the first chunk since it's the first mention. The confidence level is high because all three chunks support the same information. I'll set base_confidence to 1.0. </think> { \"answer\": \"The Genomic Regions Enrichment of Annotations Tool (GREAT) is designed to analyze the functional significance of cis-regulatory regions identified by localized DNA binding events across the genom", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to generate a JSON answer based on the evidence provided. The question is about what the Genomic Regions Enrichment of Annotations Tool (GREAT) is. Looking at the evidence, there are three chunks from the same document ID. All of them mention that GREAT was developed to analyze the functional significance of cis-regulatory regions identified by DNA binding events across the genome. They also note that previous methods only considered proximal binding sites, while GREAT incorporates distal ones and uses a binomial test to control for false positives. So the answer should be concise, stating that GREAT is used to analyze the functional significance of cis-regulatory regions, incorporating both proximal and distal binding sites, and using a binomial test. The citation would be from the document ID 20436461, but since all chunks are similar, I can pick one. Maybe the first chunk because it's the first occurrence. The confidence level should be high since the information is consistent across all three chunks. Let me set base_confidence to 1.0 as there's no conflicting evidence. </think> { \"answer\": \"The Genomic Regions En", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to generate a JSON answer based on the evidence provided. The question is about what the Genomic Regions Enrichment of Annotations Tool (GREAT) is. Let me look at the evidence. The evidence has three chunks, all from the same document ID 20436461. Each chunk starts by stating that GREAT was developed to analyze the functional significance of cis-regulatory regions identified by DNA binding events across the genome. The first two chunks mention that previous methods only considered proximal binding sites, but GREAT incorporates distal sites and uses a binomial test to control for false positives. So the answer should include the main purpose of GREAT: analyzing functional significance of cis-regulatory regions, mentioning the inclusion of distal binding sites and the binomial test. The citation would be from the first chunk, which is 20436461_4. The confidence level should be high since all evidence points to the same conclusion. Let me structure that into a concise answer with the correct citations and a confidence score between 0 and 1. Maybe 0.95 as it's consistent across multiple chunks. </think>", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["20436461"], "ideal_answer": "Genomic Regions Enrichment of Annotations Tool (GREAT) is a tool to analyse the functional significance of cis-regulatory regions identified by localised measurements of DNA binding events across an entire genome. Whereas previous methods took into account only binding proximal to genes, GREAT is able to properly incorporate distal binding sites and control for false positives using a binomial test over the input genomic regions. GREAT incorporates annotations from 20 ontologies and is available as a web application. Applying GREAT to data sets from chromatin immunoprecipitation coupled with massively parallel sequencing (ChIP-seq) of multiple transcription-associated factors, including SRF, NRSF, GABP, Stat3 and p300 in different developmental contexts, many functions of these factors are recovered that are missed by existing gene-based tools, and testable hypotheses are generated. The utility of GREAT is not limited to ChIP-seq, as it could also be applied to open chromatin, localized epigenomic markers and similar functional data sets, as well as comparative genomics sets."}
{"question_id": "54d649843706e89528000009", "question": "What is the target of the drug Olaparib?", "retrieved_chunks": [{"doc_id": "27317574", "chunk_id": "27317574_0", "score": 3.4074201583862305, "text": "Of note is the recent U.S. Food and Drug Administration breakthrough therapy designation of olaparib for the treatment of BRCA1/2- or ATM-mutated metastatic castration-resistant prostate cancer."}, {"doc_id": "25302833", "chunk_id": "25302833_0", "score": 2.935744285583496, "text": "olaparib, a small molecule inhibitor of the repair enzymes PARP1/2."}, {"doc_id": "29327913", "chunk_id": "29327913_0", "score": 2.263927936553955, "text": "Indeed, three PARP1 inhibitors (Olaparib, Rucaparib, and Niraparib) have recently been approved by the Food and Drug Administration for the treatment of ovarian cancer."}], "context": "[27317574:27317574_0] Of note is the recent U.S. Food and Drug Administration breakthrough therapy designation of olaparib for the treatment of BRCA1/2- or ATM-mutated metastatic castration-resistant prostate cancer.\n[25302833:25302833_0] olaparib, a small molecule inhibitor of the repair enzymes PARP1/2.\n[29327913:29327913_0] Indeed, three PARP1 inhibitors (Olaparib, Rucaparib, and Niraparib) have recently been approved by the Food and Drug Administration for the treatment of ovarian cancer.", "answer": "<think> Okay, let's tackle this question. The user is asking about the target of the drug Olaparib. I need to look at the provided evidence to find the answer. First, looking at the evidence snippets. The first one mentions that olaparib is a breakthrough therapy for BRCA1/2 or ATM-mutated prostate cancer, but that's about its indication, not the target. The second snippet says olaparib is a small molecule inhibitor of PARP1/2 repair enzymes. That seems directly relevant. The third snippet lists PARP1 inhibitors, including Olaparib, approved for ovarian cancer. So the target here is PARP1/2. The answer should be concise and cite the relevant document. The second evidence chunk [25302833:25302833_0] clearly states that it's a PARP1/2 inhibitor. The confidence is high because this is a direct statement from the evidence. So the answer is PARP1/2 with that citation. Base confidence would be 1.0 since the evidence directly states it. </think> { \"answer", "citations": [{"doc_id": "25302833", "chunk_id": "25302833_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking about the target of the drug Olaparib. I need to look at the provided evidence to find the answer. First, looking at the evidence snippets. The first one mentions that olaparib is a breakthrough therapy for BRCA1/2 or ATM-mutated prostate cancer, but that's about its indication, not the target. The second snippet says olaparib is a small molecule inhibitor of PARP1/2 repair enzymes. That seems directly relevant. The third snippet lists PARP1 inhibitors, including Olaparib, approved for ovarian cancer. So the target here is PARP1/2. The answer should be concise and cite the relevant document. The second evidence chunk [25302833:25302833_0] clearly states that it's a PARP1/2 inhibitor. The confidence is high because this is a direct statement from the evidence. So the answer is PARP1/2 with that citation. Base confidence would be 1.0 since the evidence directly states it. </think> { \"answer", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the target of the drug Olaparib. I need to look at the provided evidence to find the answer. First, looking at the evidence documents. The second one says: \"olaparib, a small molecule inhibitor of the repair enzymes PARP1/2.\" That seems directly relevant. So the target here is PARP1/2. The first document mentions BRCA1/2 or ATM-mutated cancers, but that's about the indication, not the target. The third document talks about PARP1 inhibitors being approved for ovarian cancer, which again points to PARP1 as the target. So the answer should be PARP1/2. The confidence is high because two documents explicitly state that Olaparib inhibits PARP1/2. The first document mentions the FDA designation, but doesn't specify the target. The other two clearly state the target. So base confidence would be 0.95 or so. Let me check again. Yes, the second and third documents both mention PARP1/2. The first is about the indication, not", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's see. The user is asking about the target of the drug Olaparib. I need to look at the provided evidence to find the answer. First, checking the evidence documents. The second document [25302833:25302833_0] says that olaparib is a small molecule inhibitor of the repair enzymes PARP1/2. That seems directly relevant. The other documents mention BRCA1/2 and ATM mutations, but they don't specify the target. The third document mentions PARP1 inhibitors, which aligns with the second one. So the target here is PARP1/2. The confidence should be high because it's a direct statement from the evidence. I'll make sure to cite the correct chunk ID. The answer needs to be concise and include the citation. Base confidence is 1.0 since the evidence clearly states that. </think> { \"answer\": \"Olaparib targets the PARP1/2 repair enzymes [25302833:25302833_0]\", \"base_conf", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["25120693", "25127709", "25128455", "25139258", "25144364", "25218906", "25221646", "25275045", "25302833", "25366685", "25374341", "25417706", "25481791", "25483710", "25526472", "25531448"], "ideal_answer": "The drug Olaparib target the protein poly(ADP-ribose) polymerase."}
{"question_id": "52f7c4bd2059c6d71c00002d", "question": "Are thyroid hormone receptor alpha1 mutations implicated in thyroid hormone resistance syndrome?", "retrieved_chunks": [{"doc_id": "23633213", "chunk_id": "23633213_0", "score": 5.744899272918701, "text": "Clinical phenotype of a new type of thyroid hormone resistance caused by a mutation of the TRα1 receptor"}, {"doc_id": "18334584", "chunk_id": "18334584_0", "score": 2.2735002040863037, "text": "When thyroid hormone production was reduced by PTU, high doses of LT(4) (3.7 microg/kg.d) were needed to normalize serum TSH, confirming that mutation of MCT8 is a cause of resistance to thyroid hormone"}, {"doc_id": "21468521", "chunk_id": "21468521_0", "score": 1.8230788707733154, "text": "Novel mutation in MCT8 gene in a Brazilian boy with thyroid hormone resistance and severe neurologic abnormalities."}], "context": "[23633213:23633213_0] Clinical phenotype of a new type of thyroid hormone resistance caused by a mutation of the TRα1 receptor\n[18334584:18334584_0] When thyroid hormone production was reduced by PTU, high doses of LT(4) (3.7 microg/kg.d) were needed to normalize serum TSH, confirming that mutation of MCT8 is a cause of resistance to thyroid hormone\n[21468521:21468521_0] Novel mutation in MCT8 gene in a Brazilian boy with thyroid hormone resistance and severe neurologic abnormalities.", "answer": "<think> Okay, let's tackle this question. The user is asking if thyroid hormone receptor alpha1 mutations are involved in thyroid hormone resistance syndrome. The evidence provided has three documents. First, I need to understand what each document says. The first one, 23633213:23633213_0, mentions a new type of thyroid hormone resistance caused by a mutation in the TRα1 receptor. That directly points to TRα1 mutations being implicated. The second document, 18334584:18334584_0, talks about PTU reducing thyroid hormone production and needing high doses of LT4 to normalize TSH, confirming that MCT8 mutations cause resistance. Wait, MCT8 is a different gene, right? So this might be a different mechanism. But the question is about TRα1, so maybe this is a separate finding. The third document, 21468521:21468521_0, mentions a novel mutation in MCT8 in a Brazilian boy with thyroid hormone resistance. Again, M", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking if thyroid hormone receptor alpha1 mutations are involved in thyroid hormone resistance syndrome. The evidence provided has three documents. First, I need to understand what each document says. The first one, 23633213:23633213_0, mentions a new type of thyroid hormone resistance caused by a mutation in the TRα1 receptor. That directly points to TRα1 mutations being implicated. The second document, 18334584:18334584_0, talks about PTU reducing thyroid hormone production and needing high doses of LT4 to normalize TSH, confirming that MCT8 mutations cause resistance. Wait, MCT8 is a different gene, right? So this might be a different mechanism. But the question is about TRα1, so maybe this is a separate finding. The third document, 21468521:21468521_0, mentions a novel mutation in MCT8 in a Brazilian boy with thyroid hormone resistance. Again, M", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if thyroid hormone receptor alpha1 mutations are involved in thyroid hormone resistance syndrome. The evidence provided includes three documents. First, I need to check each document's content. The first one, 23633213:23633213_0, mentions a new type of thyroid hormone resistance caused by a mutation in the TRα1 receptor. That directly links TRα1 mutations to the syndrome. The second document, 18334584:18334584_0, talks about PTU reducing thyroid hormone production and needing high doses of LT4 to normalize TSH, confirming that MCT8 mutations cause resistance. Wait, MCT8 is a different gene, so this might be a different type of mutation. But the question is about TRα1, so maybe this is a separate finding. The third document, 21468521:21468521_0, mentions a novel mutation in MCT8 in a Brazilian boy with resistance and neurological issues. Again,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking if thyroid hormone receptor alpha1 mutations are involved in thyroid hormone resistance syndrome. The evidence provided includes three documents. First, I need to understand what each document says. The first one, 23633213:23633213_0, mentions a new type of thyroid hormone resistance caused by a mutation in the TRα1 receptor. That directly links TRα1 mutations to the syndrome. The second document, 18334584:18334584_0, talks about PTU reducing thyroid hormone production and needing high doses of LT4 to normalize TSH, confirming that MCT8 mutations cause resistance. Wait, MCT8 is a different gene, right? So this might be another cause, but the question is about TRα1. The third document, 21468521:21468521_0, mentions a novel mutation in MCT8 in a Brazilian boy with resistance and neurological issues. Again, MCT8, not TRα1", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["12356724", "12750454", "15860414", "15913586", "15988389", "17040361", "17906375", "23633213", "7711514", "7913092", "8068885", "8115332", "8384535", "8475937", "8594618", "8954015", "9092799", "9350446", "9685218"], "ideal_answer": "The lack of TR alpha1 exacerbates the manifestation of RTH in TR betaPV mice. Therefore, TR alpha1 could play a compensatory role in mediating the functions of T3 in heterozygous patients with RTH"}
{"question_id": "53188c12b166e2b80600001a", "question": "What is the role of RhoA in bladder cancer?", "retrieved_chunks": [{"doc_id": "21054792", "chunk_id": "21054792_0", "score": 7.008846759796143, "text": "Published reports suggest that elevated RhoA/Rho-kinase signaling plays a role in the development of benign prostatic hyperplasia, erectile dysfunction, kidney failure, ejaculation disorders, prostate and bladder cancer initiation, and eventual metastasis."}, {"doc_id": "19896475", "chunk_id": "19896475_0", "score": 4.328656196594238, "text": "Our results provide evidence that Ras-induced RhoA and NF-kappaB activation was involved in the invasion/migration of bladder cancer."}, {"doc_id": "22006759", "chunk_id": "22006759_0", "score": 3.896911144256592, "text": "Alterations in RhoA, RhoB, RhoC, Rac1 and Cdc42 expression play a significant role in the genesis and progression of UCC of the urinary bladder."}], "context": "[21054792:21054792_0] Published reports suggest that elevated RhoA/Rho-kinase signaling plays a role in the development of benign prostatic hyperplasia, erectile dysfunction, kidney failure, ejaculation disorders, prostate and bladder cancer initiation, and eventual metastasis.\n[19896475:19896475_0] Our results provide evidence that Ras-induced RhoA and NF-kappaB activation was involved in the invasion/migration of bladder cancer.\n[22006759:22006759_0] Alterations in RhoA, RhoB, RhoC, Rac1 and Cdc42 expression play a significant role in the genesis and progression of UCC of the urinary bladder.", "answer": "<think> Okay, let's tackle this question about RhoA's role in bladder cancer. The user provided three evidence snippets, so I need to parse each one and see what they say. First, the evidence from 21054792:21054792_0 mentions that elevated RhoA/Rho-kinase signaling is involved in the development of bladder cancer and its metastasis. That's a direct link between RhoA and bladder cancer. Then, the second snippet (19896475:19896475_0) talks about Ras-induced RhoA and NF-kappaB activation being involved in invasion and migration of bladder cancer cells. So this suggests that RhoA contributes to the aggressive behavior of bladder cancer. The third one (22006759:22006759_0) states that changes in RhoA, RhoB, etc., are significant in the genesis and progression of urinary tract cancers, including bladder cancer. This reinforces that RhoA is part of the molecular mechanisms driving bladder cancer.", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question about RhoA's role in bladder cancer. The user provided three evidence snippets, so I need to parse each one and see what they say. First, the evidence from 21054792:21054792_0 mentions that elevated RhoA/Rho-kinase signaling is involved in the development of bladder cancer and its metastasis. That's a direct link between RhoA and bladder cancer. Then, the second snippet (19896475:19896475_0) talks about Ras-induced RhoA and NF-kappaB activation being involved in invasion and migration of bladder cancer cells. So this suggests that RhoA contributes to the aggressive behavior of bladder cancer. The third one (22006759:22006759_0) states that changes in RhoA, RhoB, etc., are significant in the genesis and progression of urinary tract cancers, including bladder cancer. This reinforces that RhoA is part of the molecular mechanisms driving bladder cancer.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to generate a candidate biomedical answer about the role of RhoA in bladder cancer based on the provided evidence. Let me look at the evidence first. The first document says that elevated RhoA/Rho-kinase signaling is involved in the development of bladder cancer and its metastasis. The second mentions that Ras-induced RhoA and NF-kappaB activation are related to invasion and migration of bladder cancer. The third talks about alterations in RhoA, RhoB, etc., affecting the genesis and progression of urinary tract cancers, including bladder cancer. So, combining these, RhoA seems to be involved in the development, progression, and metastasis of bladder cancer. The answer should mention that RhoA contributes to these processes. I need to cite the relevant documents. The first document [21054792:21054792_0] directly mentions bladder cancer, so that's a good citation. The second [19896475:19896475_0] also relates to invasion and migration, which are part of progression. The third", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question about RhoA's role in bladder cancer. The user provided three evidence snippets, so I need to parse each one and see what they contribute. First, looking at the first evidence: it mentions that elevated RhoA/Rho-kinase signaling is involved in the development of various conditions, including bladder cancer. So that's a direct link between RhoA and bladder cancer. The citation here is [21054792:21054792_0]. The second evidence says Ras-induced RhoA and NF-kappaB activation are involved in the invasion/migration of bladder cancer cells. This suggests that RhoA plays a role in the aggressive aspects of bladder cancer, like spreading. The citation here is [19896475:19896475_0]. Third evidence points out that changes in RhoA, RhoB, etc., are significant in the genesis and progression of urinary tract cancers, including bladder cancer. So this supports RhoA's involvement in both the initial development and progression. The citation is [22", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["12855641", "18190825", "19896475", "21054792", "22006759"], "ideal_answer": "In urinary bladder cancer, RhoA was more commonly found to be activated in the later stages of the disease. This activation was related to poor tumor differentiation, muscle invasion, lymph node metastasis, and shortened disease-free and overall survival."}
{"question_id": "56f802ea09dd18d46b000017", "question": "List human proteins that are subject to a dimer-to-tetramer transition.", "retrieved_chunks": [{"doc_id": "21987805", "chunk_id": "21987805_0", "score": 4.002292633056641, "text": "We conclude that the human Orai1 and Orai3 channels undergo a dimer-to-tetramer transition to form a Ca(2+)-selective pore during store-operated activation and that Orai3 forms a dimeric nonselective cation pore upon activation by 2-APB."}, {"doc_id": "25619277", "chunk_id": "25619277_0", "score": 1.8298176527023315, "text": "while SHMT2 undergoes a dimer-to-tetramer transition upon PLP binding."}, {"doc_id": "25548170", "chunk_id": "25548170_0", "score": 0.11977335810661316, "text": "the ability of GAC to undergo the dimer-to-tetramer transition necessary for enzyme activation."}], "context": "[21987805:21987805_0] We conclude that the human Orai1 and Orai3 channels undergo a dimer-to-tetramer transition to form a Ca(2+)-selective pore during store-operated activation and that Orai3 forms a dimeric nonselective cation pore upon activation by 2-APB.\n[25619277:25619277_0] while SHMT2 undergoes a dimer-to-tetramer transition upon PLP binding.\n[25548170:25548170_0] the ability of GAC to undergo the dimer-to-tetramer transition necessary for enzyme activation.", "answer": "<think> Okay, let's tackle this question. The user is asking for human proteins that undergo a dimer-to-tetramer transition. Looking at the evidence provided, there are three references. First, document 21987805 mentions Orai1 and Orai3 channels in humans. They undergo a dimer-to-tetramer transition during store-operated activation. That's definitely a human protein. The citation is [21987805:21987801_0], but wait, the chunk ID in the evidence is 21987805_0. So the answer should include that. Next, document 25619277 talks about SHMT2 undergoing a dimer-to-tetramer transition upon PLP binding. SHMT2 is a human protein, so that's another one. The citation here is [25619277:25619277_0]. The third document, 25548170, mentions GAC undergoing the transition necessary for enzyme activation. However, GAC might", "citations": [{"doc_id": "21987805", "chunk_id": "21987801_0"}, {"doc_id": "25619277", "chunk_id": "25619277_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking for human proteins that undergo a dimer-to-tetramer transition. Looking at the evidence provided, there are three references. First, document 21987805 mentions Orai1 and Orai3 channels in humans. They undergo a dimer-to-tetramer transition during store-operated activation. That's definitely a human protein. The citation is [21987805:21987801_0], but wait, the chunk ID in the evidence is 21987805_0. So the answer should include that. Next, document 25619277 talks about SHMT2 undergoing a dimer-to-tetramer transition upon PLP binding. SHMT2 is a human protein, so that's another one. The citation here is [25619277:25619277_0]. The third document, 25548170, mentions GAC undergoing the transition necessary for enzyme activation. However, GAC might", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user wants a list of human proteins that undergo a dimer-to-tetramer transition. Looking at the evidence provided, there are three references. First, the reference 21987805 mentions Orai1 and Orai3 channels in humans. So those are two proteins. Then, reference 25619277 talks about SHMT2 undergoing a dimer-to-tetramer transition upon PLP binding. But wait, is SHMT2 a human protein? The question specifies \"human proteins,\" so I need to check if SHMT2 is indeed from humans. The citation doesn't specify the organism, but the first reference does mention human Orai1 and Orai3. Maybe the other references are also about human proteins. However, sometimes citations might not specify, so maybe SHMT2 is a human protein. Alternatively, perhaps it's a different species. But given that the user is asking for human proteins, I should assume that if the citation is from a human study, but the evidence here doesn't explicitly state that. Hmm. Wait, the first reference clearly states \"human", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to generate a JSON answer based on the given evidence. The question is asking for human proteins that undergo a dimer-to-tetramer transition. Let me look at the evidence provided. First evidence: [21987805:21987805_0] mentions Orai1 and Orai3 channels in humans undergoing this transition during store-operated activation. So those are two proteins. Second evidence: [25619277:25619277_0] talks about SHMT2 undergoing the transition upon PLP binding. But wait, is SHMT2 a human protein? The question specifies \"human proteins,\" so I need to check if SHMT2 is from humans. The document ID doesn't specify, but since the user provided it as part of the evidence, maybe it's assumed to be human. However, sometimes gene names can be species-specific. But given that the other examples are Orai1 and Orai3 which are definitely human, perhaps SHMT2 here is also human. I'll include it unless there's a reason to exclude. Third", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["21080238", "21987805", "23739980", "25548170", "25619277"], "ideal_answer": "GAC SHMT2 AMPAR Orai1 Orai3"}
{"question_id": "5335c7f2d6d3ac6a34000051", "question": "Inhibition of which transporter is the mechanism of action of drug Canagliflozin?", "retrieved_chunks": [{"doc_id": "24025022", "chunk_id": "24025022_0", "score": 4.4549360275268555, "text": "Sodium glucose co-transporter 2 (SGLT2) inhibition with canagliflozin in type 2 diabetes mellitus."}, {"doc_id": "23895803", "chunk_id": "23895803_0", "score": 3.698556423187256, "text": "The sodium glucose co-transporter 2 inhibitor canagliflozin lowered blood glucose, blood pressure, and body weight, with increased risk of urogenital infections in Phase 2 studies."}, {"doc_id": "24998153", "chunk_id": "24998153_1", "score": 3.3878092765808105, "text": "Inhibitors of the sodium-glucose co-transporter 2 (SGLT2) promote the excretion of glucose to reduce glycated hemoglobin (HbA1c) levels. Canagliflozin was the first SGLT2 inhibitor to be approved by the US FDA for use in the treatment of type 2 diabetes, and recently dapagliflozin has also been approved."}], "context": "[24025022:24025022_0] Sodium glucose co-transporter 2 (SGLT2) inhibition with canagliflozin in type 2 diabetes mellitus.\n[23895803:23895803_0] The sodium glucose co-transporter 2 inhibitor canagliflozin lowered blood glucose, blood pressure, and body weight, with increased risk of urogenital infections in Phase 2 studies.\n[24998153:24998153_1] Inhibitors of the sodium-glucose co-transporter 2 (SGLT2) promote the excretion of glucose to reduce glycated hemoglobin (HbA1c) levels. Canagliflozin was the first SGLT2 inhibitor to be approved by the US FDA for use in the treatment of type 2 diabetes, and recently dapagliflozin has also been approved.", "answer": "Sodium glucose co-transporter 2 (SGLT2) [24025022:24025022_0]", "citations": [{"doc_id": "24025022", "chunk_id": "24025022_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking about the mechanism of action of Canagliflozin, specifically which transporter it inhibits. First, I need to look at the evidence provided. The first document mentions that Canagliflozin is a sodium glucose co-transporter 2 (SGLT2) inhibitor. That seems directly relevant. The second document also talks about SGLT2 inhibition leading to lower blood glucose, etc. The third document confirms that SGLT2 inhibitors promote glucose excretion and mentions Canagliflozin as an SGLT2 inhibitor. So all three sources point to SGLT2 as the target. The answer should be SGLT2. Now, the citations: the first document is 24025022:24025022_0, which directly states that. The third one also supports this. The second document mentions SGLT2 inhibition but maybe not as directly. However, since the question is about the mechanism, the first and third documents are more direct. For confidence, since all three mention SGLT2", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "Sodium glucose co-transporter 2 (SGLT2) [24025022:24025022_0]", "base_prob": 1.0, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 1.0}, {"answer": "<think> Okay, I need to figure out the answer to the question: \"Inhibition of which transporter is the mechanism of action of drug Canagliflozin?\" The user provided three evidence snippets. Let me go through each one. First evidence: [24025022:24025022_0] says that canagliflozin inhibits SGLT2. That's a direct mention. The second snippet [23895803:23895803_0] also talks about it being an SGLT2 inhibitor, so that's consistent. The third one [24998153:24998153_1] again mentions SGLT2 inhibitors and specifically names canagliflozin as an SGLT2 inhibitor. All three sources point to SGLT2. So the answer should be that Canagliflozin inhibits the sodium glucose co-transporter 2 (SGLT2). The confidence is high because all three pieces of evidence support this. I need to", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 1.0, "gold_docs": ["10481836", "21680987", "22547464", "22621689", "23042029", "23087012", "23326927", "23412078", "23563279", "23590413", "23729000", "23895803", "24025022", "24040872", "24257692"], "ideal_answer": "Inhibition of sodium glucose co-transporter 2 (SGLT2) is the major mechanism of action of canagliflozin. Canagliflozin is the first SGLT2 inhibitor to be approved in the USA for the treatment of type 2 diabetes and is under regulatory review in the EU. Other SGLT2 inhibitors include dapagliflozin and empagliflozin."}
{"question_id": "531b2fc3b166e2b80600003c", "question": "What is the prognostic role of thyroid hormone in patients with heart failure?", "retrieved_chunks": [{"doc_id": "17893267", "chunk_id": "17893267_0", "score": 4.069559097290039, "text": "changes in thyroid hormone were closely correlated to myocardial functional status in patients with heart failure."}, {"doc_id": "18031713", "chunk_id": "18031713_0", "score": 2.0082345008850098, "text": "These data reveal that in human heart failure the reduction of beta-adrenergic receptors is associated with reduced expression of both TRalpha1 and TRalpha2 isoforms of thyroid hormone receptors."}, {"doc_id": "18031713", "chunk_id": "18031713_1", "score": 1.321460485458374, "text": "hese data reveal that in human heart failure the reduction of beta-adrenergic receptors is associated with reduced expression of both TRalpha1 and TRalpha2 isoforms of thyroid hormone receptors."}], "context": "[17893267:17893267_0] changes in thyroid hormone were closely correlated to myocardial functional status in patients with heart failure.\n[18031713:18031713_0] These data reveal that in human heart failure the reduction of beta-adrenergic receptors is associated with reduced expression of both TRalpha1 and TRalpha2 isoforms of thyroid hormone receptors.\n[18031713:18031713_1] hese data reveal that in human heart failure the reduction of beta-adrenergic receptors is associated with reduced expression of both TRalpha1 and TRalpha2 isoforms of thyroid hormone receptors.", "answer": "<think> Okay, let's tackle this question. The user wants to know the prognostic role of thyroid hormone in heart failure patients. The evidence provided has three chunks. First, chunk 17893267_0 says that changes in thyroid hormone are closely correlated with myocardial functional status in heart failure. That suggests thyroid hormone levels might predict how well the heart is functioning. So that's a direct link between thyroid hormone and prognosis. Then, chunks 18031713_0 and 18031713_1 both mention reduced beta-adrenergic receptors in heart failure, which are linked to lower expression of TRalpha1 and TRalpha2 thyroid receptor isoforms. This implies that thyroid hormone receptors are affected, possibly making the body less responsive to thyroid hormones. If the receptors are reduced, maybe the effect of thyroid hormone is diminished, which could impact prognosis. So combining these points: thyroid hormone levels are correlated with heart function (prognosis), and the receptors involved in thyroid hormone action are reduced in heart failure. That suggests that lower thyroid hormone levels or reduced receptor activity might lead to worse outcomes.", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user wants to know the prognostic role of thyroid hormone in heart failure patients. The evidence provided has three chunks. First, chunk 17893267_0 says that changes in thyroid hormone are closely correlated with myocardial functional status in heart failure. That suggests thyroid hormone levels might predict how well the heart is functioning. So that's a direct link between thyroid hormone and prognosis. Then, chunks 18031713_0 and 18031713_1 both mention reduced beta-adrenergic receptors in heart failure, which are linked to lower expression of TRalpha1 and TRalpha2 thyroid receptor isoforms. This implies that thyroid hormone receptors are affected, possibly making the body less responsive to thyroid hormones. If the receptors are reduced, maybe the effect of thyroid hormone is diminished, which could impact prognosis. So combining these points: thyroid hormone levels are correlated with heart function (prognosis), and the receptors involved in thyroid hormone action are reduced in heart failure. That suggests that lower thyroid hormone levels or reduced receptor activity might lead to worse outcomes.", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, I need to generate a candidate biomedical answer based on the provided evidence. The question is about the prognostic role of thyroid hormone in heart failure patients. First, let me look at the evidence given. There are three references here. The first one says that changes in thyroid hormone are closely correlated with myocardial functional status in heart failure patients. That seems directly relevant to the prognostic role because if thyroid hormone levels change, they might indicate how well the heart is functioning. The other two references mention that in heart failure, there's a reduction in beta-adrenergic receptors linked to lower expression of TRalpha1 and TRalpha2 thyroid hormone receptors. This suggests that thyroid hormone receptor expression is affected in heart failure, which could influence prognosis. But these points are more about the mechanism rather than the direct prognostic role. So the main evidence pointing to the prognostic role is the first reference. The answer should mention that thyroid hormone levels correlate with myocardial function, indicating a prognostic role. I need to cite that document. The confidence level should be high because", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the prognostic role of thyroid hormone in heart failure patients. I need to look at the provided evidence to form an answer. First, evidence [17893267:17893267_0] says that changes in thyroid hormone are closely correlated with myocardial functional status in heart failure. That suggests thyroid hormone levels might be a prognostic indicator because they're linked to how well the heart is functioning. Then, the other two pieces of evidence [18031713:18031713_0 and 1] talk about reduced beta-adrenergic receptors in heart failure being associated with lower expression of TRalpha1 and TRalpha2 thyroid hormone receptors. This implies that thyroid hormone receptor levels are affected, which might influence the prognosis. But how does this tie into the prognostic role? Maybe if the receptors are reduced, the body's response to thyroid hormones is impaired, leading to worse outcomes. So combining these points: thyroid hormone levels (or their receptors) are linked to heart function. If there", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["12165115", "12963854", "15259379", "15642542", "15694896", "16499159", "17315395", "17893267", "17923583", "17966446", "18221125", "19006851", "19110971", "19181292", "19917524", "20024637", "20978564", "2189307", "22870736", "23369135", "23435988", "23555069", "2358611", "8333797", "8960429", "9489964"], "ideal_answer": "Altered thyroid profile, particularly sick euthyroid syndrome, is an independent predictor of mortality in patients with chronic heart failure, adding prognostic information to conventional clinical and functional cardiac parameters."}
{"question_id": "531376c8e3eabad021000012", "question": "which mutations of phospholamban gene have been found to cause hypertrophic cardiomyopathy?", "retrieved_chunks": [{"doc_id": "12705874", "chunk_id": "12705874_0", "score": 6.816137790679932, "text": "Using neonatal rat cardiomyocytes, the mutation, -77A-->G, increased the phospholamban promoter activity. No nucleotide change in the phospholamban coding region was found in 99 patients with cardiomyopathy. We suspect that the mutation plays an important role in the development of hypertrophic cardiomyopathy."}, {"doc_id": "18285522", "chunk_id": "18285522_0", "score": 5.734952449798584, "text": "The cardiac troponin C (cTnC) mutation, L29Q, has been found in a patient with familial hypertrophic cardiomyopathy."}, {"doc_id": "15205937", "chunk_id": "15205937_1", "score": 5.487497806549072, "text": "Previous work has shown that mutations in muscle LIM protein (MLP) can cause hypertrophic cardiomyopathy (HCM). In order to gain an insight into the molecular basis of the disease phenotype, we analysed the binding characteristics of wild-type MLP and of the (C58G) mutant MLP that causes hypertrophic cardiomyopathy."}], "context": "[12705874:12705874_0] Using neonatal rat cardiomyocytes, the mutation, -77A-->G, increased the phospholamban promoter activity. No nucleotide change in the phospholamban coding region was found in 99 patients with cardiomyopathy. We suspect that the mutation plays an important role in the development of hypertrophic cardiomyopathy.\n[18285522:18285522_0] The cardiac troponin C (cTnC) mutation, L29Q, has been found in a patient with familial hypertrophic cardiomyopathy.\n[15205937:15205937_1] Previous work has shown that mutations in muscle LIM protein (MLP) can cause hypertrophic cardiomyopathy (HCM). In order to gain an insight into the molecular basis of the disease phenotype, we analysed the binding characteristics of wild-type MLP and of the (C58G) mutant MLP that causes hypertrophic cardiomyopathy.", "answer": "<think> Okay, let's tackle this question. The user is asking which mutations in the phospholamban gene cause hypertrophic cardiomyopathy. Looking at the evidence provided, I need to check each document to see if they mention phospholamban mutations. First, document [12705874:12705874_0] talks about a mutation -77A-->G in the phospholamban promoter. It mentions that this mutation increases promoter activity and that it might play a role in HCM. However, the note says there's no nucleotide change in the coding region of phospholamban in 99 patients. So this mutation is in the promoter, not the coding region. But the question specifically asks about mutations of the phospholamban gene. The promoter is part of the gene, so maybe this counts. But I need to check if the answer should be in the coding region. Wait, the question says \"mutations of phospholamban gene\"—so any mutation in the gene, including promoter regions? Or does it refer only to coding mutations? Then there's [18285", "citations": [{"doc_id": "12705874", "chunk_id": "12705874_0"}], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which mutations in the phospholamban gene cause hypertrophic cardiomyopathy. Looking at the evidence provided, I need to check each document to see if they mention phospholamban mutations. First, document [12705874:12705874_0] talks about a mutation -77A-->G in the phospholamban promoter. It mentions that this mutation increases promoter activity and that it might play a role in HCM. However, the note says there's no nucleotide change in the coding region of phospholamban in 99 patients. So this mutation is in the promoter, not the coding region. But the question specifically asks about mutations of the phospholamban gene. The promoter is part of the gene, so maybe this counts. But I need to check if the answer should be in the coding region. Wait, the question says \"mutations of phospholamban gene\"—so any mutation in the gene, including promoter regions? Or does it refer only to coding mutations? Then there's [18285", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which mutations in the phospholamban gene cause hypertrophic cardiomyopathy. Looking at the evidence provided, I need to check each document to see if they mention phospholamban mutations. First, document [12705874:12705874_0] talks about a mutation -77A-->G in the phospholamban promoter. The text says this mutation increases promoter activity and that it might play a role in HCM. But wait, the question is about mutations in the phospholamban gene. The document mentions a nucleotide change in the coding region but states none were found in 99 patients. However, the mutation discussed here is in the promoter, not the coding region. So maybe this is a regulatory mutation rather than a coding one. But the answer should focus on the mutations mentioned. Next, [18285522:18285522_0] discusses a cTnC mutation, L29Q, which is in cardiac troponin C, not phosphol", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which mutations in the phospholamban gene cause hypertrophic cardiomyopathy. Looking at the evidence provided, I need to check each reference to see if they mention phospholamban mutations. First, reference [12705874:12705874_0] talks about a mutation -77A-->G in the phospholamban promoter. The text says this mutation increases promoter activity and that no coding region changes were found in 99 patients. But it's mentioned as a mutation in the promoter, not the coding region. However, the question is about mutations in the phospholamban gene. Since the promoter is part of the gene, maybe this counts. The study suggests this mutation plays a role in HCM. Next, [18285522:18285522_0] mentions a cTnC mutation L29Q, but that's in cardiac troponin C, not phospholamban. So this is unrelated. The third reference [152059", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["12705874", "16829191", "17655857", "21167350"], "ideal_answer": "The following mutations of the phospholamban gene have been found to be associated with hypertrophic cardiomyopathy: PLN L39X nonsense mutation; PLN Leu39Ter; PLN -42 C>G and PLN -77A-->G"}
{"question_id": "5545186cbf90a13052000002", "question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "retrieved_chunks": [{"doc_id": "17015469", "chunk_id": "17015469_1", "score": 8.785056114196777, "text": "The proficient repair of the nontranscribed strand cannot be explained by the dedicated subpathway of transcription-coupled repair (TCR), which is targeted to the transcribed strand in expressed genes."}, {"doc_id": "17015469", "chunk_id": "17015469_0", "score": 8.618755340576172, "text": "The proficient repair of the nontranscribed strand cannot be explained by the dedicated subpathway of transcription-coupled repair (TCR), which is targeted to the transcribed strand in expressed genes"}, {"doc_id": "20978633", "chunk_id": "20978633_0", "score": 8.365862846374512, "text": "transcription-coupled repair (TCR) since targets for DNA damage are situated on the transcribed or coding strand of DNA"}], "context": "[17015469:17015469_1] The proficient repair of the nontranscribed strand cannot be explained by the dedicated subpathway of transcription-coupled repair (TCR), which is targeted to the transcribed strand in expressed genes.\n[17015469:17015469_0] The proficient repair of the nontranscribed strand cannot be explained by the dedicated subpathway of transcription-coupled repair (TCR), which is targeted to the transcribed strand in expressed genes\n[20978633:20978633_0] transcription-coupled repair (TCR) since targets for DNA damage are situated on the transcribed or coding strand of DNA", "answer": "<think> Okay, let's tackle this question. The user is asking which gene strand is targeted by transcription-coupled repair (TCR). The evidence provided has three chunks. First, looking at chunk 17015469_1: It says that the proficient repair of the nontranscribed strand can't be explained by TCR, which is targeted to the transcribed strand. So here, TCR is targeting the transcribed strand. Chunk 17015469_0 is a duplicate of the first one, so same info. Then chunk 20978633_0 mentions that TCR targets DNA damage on the transcribed or coding strand. Wait, but the question is about which gene strand is targeted. The term \"gene strand\" might refer to the DNA strands. In DNA, there's the transcribed strand (the one being read by RNA polymerase) and the nontranscribed strand. But in the context of TCR, it's known that TCR specifically targets the transcribed strand because when RNA polymerase stalls, it leaves a damage on the transcribed strand, which TCR", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking which gene strand is targeted by transcription-coupled repair (TCR). The evidence provided has three chunks. First, looking at chunk 17015469_1: It says that the proficient repair of the nontranscribed strand can't be explained by TCR, which is targeted to the transcribed strand. So here, TCR is targeting the transcribed strand. Chunk 17015469_0 is a duplicate of the first one, so same info. Then chunk 20978633_0 mentions that TCR targets DNA damage on the transcribed or coding strand. Wait, but the question is about which gene strand is targeted. The term \"gene strand\" might refer to the DNA strands. In DNA, there's the transcribed strand (the one being read by RNA polymerase) and the nontranscribed strand. But in the context of TCR, it's known that TCR specifically targets the transcribed strand because when RNA polymerase stalls, it leaves a damage on the transcribed strand, which TCR", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which gene strand is targeted by transcription-coupled repair (TCR). The evidence provided has three chunks. First, I need to understand what transcription-coupled repair does. From my knowledge, TCR is a mechanism that repairs DNA damage on the transcribed strand of genes. But let me check the evidence. Looking at chunk 17015469_1: It says that TCR is targeted to the transcribed strand in expressed genes. Similarly, chunk 17015469_0 repeats the same point. Then chunk 20978633_0 mentions that TCR targets DNA damage on the transcribed or coding strand. Wait, but the question is about which gene strand is targeted. The answer seems to be the transcribed strand. However, there's a mention of \"coding strand\" in one of the chunks. But in genetics, the coding strand is the one that's complementary to the DNA sequence, and the transcribed strand is the one being read by RNA polymerase. Wait, actually, the coding strand is the same", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking which gene strand is targeted by transcription-coupled repair (TCR). The evidence provided has three chunks. First, looking at chunk 17015469_1: It says that the proficient repair of the nontranscribed strand can't be explained by TCR, which is targeted to the transcribed strand in expressed genes. So here, TCR is targeting the transcribed strand. Chunk 17015469_0 is similar, repeating the same point. So both of these chunks indicate that TCR targets the transcribed strand. Then chunk 20978633_0 mentions that TCR targets DNA damage on the transcribed or coding strand. Wait, so this chunk says \"transcribed or coding strand\". But in the first two chunks, it's specifically the transcribed strand. However, the third chunk adds that it could be either transcribed or coding. But wait, in DNA, the coding strand is the same as the transcriptional strand, right? Because the coding strand is the one that's complementary to the template strand,", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["10637337", "11182543", "11452033", "11821423", "12142466", "12509290", "14599741", "14599769", "14734564", "15186415", "15249207", "15380101", "15913669", "16158195", "16394029", "16978026", "17015469", "17893751", "18291710", "18817898", "19381941", "20463888", "20978633", "21214942", "21466822", "22749141", "22902626", "7957102", "8807287", "8972850", "9065408", "9150262", "9288788", "9637246", "9934845"], "ideal_answer": "Nucleotide Excision Repair (NER) removes a variety of helix-distorting lesions from DNA. It has two sub-pathways, the global genome (gg) NER and the transcription-coupled repair (TCR). TCR is triggered when a RNA polymerase, translocating along the transcribed strand, is arrested at a lesion or unusual structure in the DNA. TCR is dedicated to target and repair the transcribed strand of an active gene."}
{"question_id": "5312280ce3eabad02100000a", "question": "Abnormalities in which chromosomes were linked to the Moyamoya disease?", "retrieved_chunks": [{"doc_id": "10754001", "chunk_id": "10754001_1", "score": 7.0889081954956055, "text": "Linkage of familial moyamoya disease (spontaneous occlusion of the circle of Willis) to chromosome 17q25."}, {"doc_id": "10754001", "chunk_id": "10754001_2", "score": 6.575436115264893, "text": "The characteristic lesions of moyamoya disease are occasionally seen in neurofibromatosis type 1, of which the causative gene (NF1) has been assigned to chromosome 17q11.2."}, {"doc_id": "8898827", "chunk_id": "8898827_0", "score": 6.222747802734375, "text": "We postulate that a protein encoded on chromosome 21 may be related to the pathogenesis of moyamoya disease."}], "context": "[10754001:10754001_1] Linkage of familial moyamoya disease (spontaneous occlusion of the circle of Willis) to chromosome 17q25.\n[10754001:10754001_2] The characteristic lesions of moyamoya disease are occasionally seen in neurofibromatosis type 1, of which the causative gene (NF1) has been assigned to chromosome 17q11.2.\n[8898827:8898827_0] We postulate that a protein encoded on chromosome 21 may be related to the pathogenesis of moyamoya disease.", "answer": "<think> Okay, let's tackle this question. The user is asking about chromosomes linked to Moyamoya disease based on the provided evidence. First, I need to look at the evidence given. There are three references here. Let me go through each one. The first piece of evidence says that familial moyamoya disease is linked to chromosome 17q25. That's a direct mention of chromosome 17. The second reference mentions neurofibromatosis type 1, which is associated with chromosome 17q11.2. However, the question is about Moyamoya disease itself, not neurofibromatosis. But wait, the characteristic lesions in moyamoya can be seen in neurofibromatosis type 1, but that's a different condition. So maybe that's a separate point. The third reference suggests chromosome 21 might be related. So the answer needs to list the chromosomes mentioned in the evidence. The first and second references both mention chromosome 17, but in different locations (q25 and q11.2). However, the question is about abnormalities linked to Moyamoya disease. The first reference", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking about chromosomes linked to Moyamoya disease based on the provided evidence. First, I need to look at the evidence given. There are three references here. Let me go through each one. The first piece of evidence says that familial moyamoya disease is linked to chromosome 17q25. That's a direct mention of chromosome 17. The second reference mentions neurofibromatosis type 1, which is associated with chromosome 17q11.2. However, the question is about Moyamoya disease itself, not neurofibromatosis. But wait, the characteristic lesions in moyamoya can be seen in neurofibromatosis type 1, but that's a different condition. So maybe that's a separate point. The third reference suggests chromosome 21 might be related. So the answer needs to list the chromosomes mentioned in the evidence. The first and second references both mention chromosome 17, but in different locations (q25 and q11.2). However, the question is about abnormalities linked to Moyamoya disease. The first reference", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking about which chromosomes are linked to Moyamoya disease based on the provided evidence. First, I need to look at the evidence given. There are three references here. Let me go through each one. The first piece of evidence [10754001:10754001_1] says that familial moyamoya disease is linked to chromosome 17q25. That's a direct mention of chromosome 17. The second reference [10754001:10754001_2] talks about neurofibromatosis type 1, which is associated with the NF1 gene on chromosome 17q11.2. However, the question is about Moyamoya disease itself, not neurofibromatosis. But it's mentioned that the lesions can be seen in neurofibromatosis type 1, but that doesn't mean the disease is linked to chromosome 17 here. It might be a related condition but not the primary link. The third evidence [8898", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking about chromosomes linked to Moyamoya disease based on the provided evidence. First, I need to look at the evidence given. There are three references here. Let me parse each one. The first one says that familial moyamoya disease is linked to chromosome 17q25. That's a direct mention of chromosome 17. The second reference mentions neurofibromatosis type 1, which is associated with the NF1 gene on chromosome 17q11.2. But the question is about Moyamaya disease itself, not neurofibromatosis. However, it does mention that the characteristic lesions are sometimes seen in neurofibromatosis type 1, which is linked to chromosome 17. The third reference suggests a possible link to chromosome 21. So, the first evidence directly links Moyamoya to 17q25. The second one mentions 17q11.2 but in the context of neurofibromatosis, not directly Moyamoya. The third one is about chromosome 21. However, the question is", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["10754001", "10757474", "11037190", "15340753", "15362573", "15675354", "15675355", "16164190", "16475235", "16723886", "17138018", "17431895", "18174554", "18463369", "18576213", "19335127", "19918425", "20635402", "20644152", "21048783", "21596366", "21631222", "21968521", "22426657", "22436252", "23077562", "23713105", "23966756", "24167642", "8898827", "8937199", "9128751", "9973290"], "ideal_answer": "chromosomes 3, 6, 8, 12, 15, 17, 21, X and Y were implicated in the Moyamoya disease."}
{"question_id": "5357a6d0f1005d6b58000004", "question": "Which is the branch site consensus sequence in U12-dependent introns?", "retrieved_chunks": [{"doc_id": "18824513", "chunk_id": "18824513_0", "score": 8.515624046325684, "text": "Highly conserved sequences at the 5' splice site and branch site of U12-dependent introns are important determinants for splicing by U12-dependent spliceosomes. This study investigates the in vivo splicing phenotypes of mutations in the branch site consensus sequence of the U12-dependent intron F from a human NOL1 (P120) minigene. Intron F contains a fully consensus branch site sequence (UUCCUUAAC)."}, {"doc_id": "18824513", "chunk_id": "18824513_2", "score": 6.467107772827148, "text": "Intron F contains a fully consensus branch site sequence (UUCCUUAAC)."}, {"doc_id": "18824513", "chunk_id": "18824513_1", "score": 6.313333511352539, "text": "Intron F contains a fully consensus branch site sequence (UUCCUUAAC)"}], "context": "[18824513:18824513_0] Highly conserved sequences at the 5' splice site and branch site of U12-dependent introns are important determinants for splicing by U12-dependent spliceosomes. This study investigates the in vivo splicing phenotypes of mutations in the branch site consensus sequence of the U12-dependent intron F from a human NOL1 (P120) minigene. Intron F contains a fully consensus branch site sequence (UUCCUUAAC).\n[18824513:18824513_2] Intron F contains a fully consensus branch site sequence (UUCCUUAAC).\n[18824513:18824513_1] Intron F contains a fully consensus branch site sequence (UUCCUUAAC)", "answer": "<think> Okay, let's tackle this question. The user is asking about the branch site consensus sequence in U12-dependent introns. The evidence provided has three chunks from the same document, all pointing to the sequence UUCCUUAAC in Intron F. First, I need to confirm if the answer is directly stated in the evidence. All three chunks mention that Intron F has a fully consensus branch site sequence of UUCCUUAAC. The first chunk also mentions that this sequence is important for splicing, but the question is specifically about the consensus sequence itself. The answer should be concise and include citations. Since all the evidence points to the same sequence, the answer is straightforward. The confidence level should be high because multiple chunks in the same document support this. The base_confidence can be 1.0 since there's no conflicting information. I need to make sure the JSON structure is correct with the answer and base_confidence keys. The citation should be in the format [doc_id:chunk_id]. Since all three chunks are from the same doc_id, but different chunk_ids, I can use one of them, perhaps the first one as", "citations": [], "candidates": [{"answer": "<think> Okay, let's tackle this question. The user is asking about the branch site consensus sequence in U12-dependent introns. The evidence provided has three chunks from the same document, all pointing to the sequence UUCCUUAAC in Intron F. First, I need to confirm if the answer is directly stated in the evidence. All three chunks mention that Intron F has a fully consensus branch site sequence of UUCCUUAAC. The first chunk also mentions that this sequence is important for splicing, but the question is specifically about the consensus sequence itself. The answer should be concise and include citations. Since all the evidence points to the same sequence, the answer is straightforward. The confidence level should be high because multiple chunks in the same document support this. The base_confidence can be 1.0 since there's no conflicting information. I need to make sure the JSON structure is correct with the answer and base_confidence keys. The citation should be in the format [doc_id:chunk_id]. Since all three chunks are from the same doc_id, but different chunk_ids, I can use one of them, perhaps the first one as", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the branch site consensus sequence in U12-dependent introns. The evidence provided has three chunks from the same document, all pointing to the sequence UUCCUUAAC in Intron F. First, I need to confirm that the answer is indeed UUCCUUAAC. All three chunks mention this exact sequence as the fully consensus branch site for Intron F. The document's title and abstract also talk about studying mutations in the branch site, which supports that this sequence is considered the consensus. The confidence level: since all three chunks explicitly state this sequence without conflicting information, the model can be confident. The citations are from the same source, so there's no contradiction. Therefore, base_confidence should be 1.0. </think> { \"answer\": \"The branch site consensus sequence in U12-dependent introns is UUCCUUAAC [18824513:18824513_0][18824513:18824513_1][188245", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}, {"answer": "<think> Okay, let's tackle this question. The user is asking about the branch site consensus sequence in U12-dependent introns. The evidence provided has three chunks from the same document, all pointing to Intron F having a fully consensus branch site sequence of UUCCUUAAC. First, I need to confirm what the branch site consensus sequence is. From the evidence, multiple chunks mention that Intron F's branch site is fully consensus, specifically UUCCUUAAC. The document references this in chunks 18824513_0, 18824513_1, and 18824513_2. All of them state the same sequence. The question is asking for the consensus sequence, so the answer should be UUCCUUAAC. The citations are all from the same document, so I can reference that. The confidence level here is high because multiple chunks in the same source consistently mention this sequence. So base_confidence would be 1.0 since all evidence points to the same answer without conflicting information. </think> { \"answer\": \"The branch site", "base_prob": 0.5, "critic": {"rel_label": "Irrel", "rel_prob": 0.5, "sup_label": "Partial", "sup_prob": 0.5, "use_score": 3, "use_prob": 0.6, "notes": ""}, "score": 0.5}], "selected_score": 0.5, "gold_docs": ["18824513"], "ideal_answer": "The branch site consensus sequence in U12-dependent introns is UUCCUUAAC."}
